SYSTEMATIC_NAME,VACCINE,PLATFORM,TARGET_PATHOGEN_DISEASE,STANDARD_NAME,MICROBE_TYPE,REGULATION,STUDY_TYPE,STUDY_SUBTYPE,DATE-TIME,DATE,TIME,AGE,AGE_CATEGORY,SAMPLE_SOURCE,MSIGDB_URL,DESCRIPTION_FULL,DESCRIPTION_BRIEF,AUTHORS,PMID,NAMESPACE,GENE_SYMBOLS,SetSize,SOURCE_MEMBERS,COLLECTION,CONTRIBUTOR,CONTRIBUTOR_ORG,EXACT_SOURCE,EXTERNAL_DETAILS_URL,EXTERNAL_NAMES_FOR_SIMILAR_TERMS,FILTERED_BY_SIMILARITY,FOUNDER_NAMES,GEOID
M40932,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_DN,BACTERIUM,DOWN,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_DN,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) (anti-DT antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"A2M,C1QC,C1R,C1S,C2,C3,C7,CCL20,CFH,GPX1,IFNA14,IL1B,IL6,CXCL8,IMPG2,LAMC2,PRL,PTX3,TNR",19,"A2M,C1QC,C1R,C1S,C2,C3,C7,CCL20,CFH,GPX1,IFNA14,IL1B,IL6,IL8,IMPG2,LAMC2,PRL,PTX3,TNR",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068032/table/tbl1/,NA,NA,NA,NA
M40964,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_DN,BACTERIUM,DOWN,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_DN,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) (anti-polysaccharide antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"A2M,AMER2,C7,CFB,CFH,IFNA10,IFNA21,IFNA7,IFNA8,IL1A,IMPG2,ITGB4,MMP12,PRL,STAB1,TNR",16,"A2M,AMER2,C7,CFB,CFH,IFNA10,IFNA21,IFNA7,IFNA8,IL1A,IMPG2,ITGB4,MMP12,PRL,STAB1,TNR",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M40959,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE,BACTERIUM,NEGATIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_NEGATIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes negatively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) (anti-DT antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"BCL3,CCL20,CCL4,CCL5,CD4,CD80,CD83,CD9,CXCL2,CYP1B1,HLA-B,HLA-DMA,HLA-DQA1,ICAM1,IL1B,IL1RN,IL23A,IL4I1,MAP3K8,NFKB2,PCTP,PDE4B,PLAUR,RELB,SERPINB9,STAT4,TNFAIP6",27,"BCL3,CCL20,CCL4,CCL5,CD4,CD80,CD83,CD9,CXCL2,CYP1B1,HLA-B,HLA-DMA,HLA-DQA1,ICAM1,IL1B,IL1RN,IL23A,IL4I1,MAP3K8,NFKB2,PCTP,PDE4B,PLAUR,RELB,SERPINB9,STAT4,TNFAIP6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/figure/f4/,NA,NA,NA,NA
M41037,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_POSITIVE,BACTERIUM,POSITIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_DT_ANTIBODY_3DY_POSITIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes positively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) (anti-DT antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"AGPAT1,ASGR1,ASPH,CD1A,CD1B,CD1C,CD1D,CD74,CD86,CSF1R,CSF2RA,FAR2,FUT7,GCH1,HLA-A,HLA-C,HLA-DMB,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB4,HLA-G,HMOX1,HS3ST3B1,IFNG,IL1R2,METTL7A,NFKBID,PLXDC2,PRKCD,RIN2,RTN1,SAMSN1,SLAMF8,TBXAS1,TLR7,TLR8,TNFSF13B",40,"AGPAT1,ASGR1,ASPH,CD1A,CD1B,CD1C,CD1D,CD74,CD86,CSF1R,CSF2RA,FAR2,FUT7,GCH1,HLA-A,HLA-C,HLA-DMB,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB4,HLA-G,HMOX1,HS3ST3B1,IFNG,IL1R2,METTL7A,NFKBID,PLXDC2,PRKCD,RIN2,RTN1,SAMSN1,SLAMF8,TBXAS1,TLR7,TLR8,TNFSF13B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/figure/f4/,NA,NA,NA,NA
M41038,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_NEGATIVE,BACTERIUM,NEGATIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_NEGATIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes negatively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) (anti-polysaccharide antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"GPAT3,AP1S2,ASPH,BCL3,CD4,CD80,CCN2,HLA-C,HLA-DQB1,HS3ST3B1,IL1R1,IL1R2,IL23A,ITPR3,SLC27A2,SLC40A1,STAT4,VCAM1,WDFY4",19,"AGPAT9,AP1S2,ASPH,BCL3,CD4,CD80,CTGF,HLA-C,HLA-DQB1,HS3ST3B1,IL1R1,IL1R2,IL23A,ITPR3,SLC27A2,SLC40A1,STAT4,VCAM1,WDFY4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Discussion; Fig 4E,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/figure/f4/,NA,NA,NA,NA
M40971,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_POSITIVE,BACTERIUM,POSITIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_CORRELATED_WITH_ANTI_POLYSACCHARIDE_ANTIBODY_3DY_POSITIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes positively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) (anti-polysaccharide antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"ASGR1,ASGR2,BCL6,CCL20,CCL4,CD1A,CD1B,CD1C,CD1D,CD83,CD86,CD9,CSF1R,CSF2RA,CXCL2,CYP1B1,EBI3,FAR2,FUT7,GCH1,HLA-A,HLA-B,HLA-DMA,HLA-DPA1,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB4,HLA-E,HLA-F,HLA-G,HMOX1,ICAM1,IFNG,IL1B,IL1RN,IL4I1,MAP3K8,METTL7A,NFKBID,PCTP,PDE4B,PLAUR,PLXDC2,PRKCD,PTGS2,RELB,RGL1,RIN2,RTN1,SAMSN1,SERPINB9,SLAMF8,TBXAS1,TLR7,TLR8,TNF,TNFAIP6,TNFSF13B",60,"ASGR1,ASGR2,BCL6,CCL20,CCL4,CD1A,CD1B,CD1C,CD1D,CD83,CD86,CD9,CSF1R,CSF2RA,CXCL2,CYP1B1,EBI3,FAR2,FUT7,GCH1,HLA-A,HLA-B,HLA-DMA,HLA-DPA1,HLA-DPB1,HLA-DQA1,HLA-DRA,HLA-DRB1,HLA-DRB4,HLA-E,HLA-F,HLA-G,HMOX1,ICAM1,IFNG,IL1B,IL1RN,IL4I1,MAP3K8,METTL7A,NFKBID,PCTP,PDE4B,PLAUR,PLXDC2,PRKCD,PTGS2,RELB,RGL1,RIN2,RTN1,SAMSN1,SERPINB9,SLAMF8,TBXAS1,TLR7,TLR8,TNF,TNFAIP6,TNFSF13B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F2/,NA,NA,NA,NA
M40970,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_NEGATIVE,BACTERIUM,NEGATIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_NEGATIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes negatively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) after exposure to Menomune A/C/Y/W-135 , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"ANPEP,AP1S2,ASGR1,BCL6,CCL4,CD1D,CD86,CSF1R,CCN2,CYP1B1,FUT7,GPAT3,HLA-DQA1,HLA-F,HS3ST3B1,IL4I1,METTL7A,PRKCD,RGL1,RIN2,SAMSN1,STAT4,TLR7,TLR8,TNFAIP6",25,"ANPEP,AP1S2,ASGR1,BCL6,CCL4,CD1D,CD86,CSF1R,CTGF,CYP1B1,FUT7,GPAT3,HLA-DQA1,HLA-F,HS3ST3B1,IL4I1,METTL7A,PRKCD,RGL1,RIN2,SAMSN1,STAT4,TLR7,TLR8,TNFAIP6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F2/,NA,NA,NA,NA
M41036,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_POSITIVE,BACTERIUM,POSITIVE,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_CORRELATED_WITH_ANTIBODY_RESPONSE_3DY_POSITIVE,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes positively correlated with antibody response in peripheral blood mononuclear cell in adults (18-45) after exposure to Menomune A/C/Y/W-135 , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"ASPH,ATP1B1,BCL3,CCL20,CCL5,CD1B,CD1C,CD4,CD74,CD80,CD83,CD9,CXCL2,EBI3,FAR2,HLA-A,HLA-C,HLA-DMA,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-E,HLA-G,HMOX1,ICAM1,IFNG,IL1B,IL1R2,IL23A,MAP3K8,NFKB2,NFKBID,PCTP,PDE4B,PLAUR,PLXDC2,PTGS2,SLAMF8,SLC27A2,TNF,WDFY4",43,"ASPH,ATP1B1,BCL3,CCL20,CCL5,CD1B,CD1C,CD4,CD74,CD80,CD83,CD9,CXCL2,EBI3,FAR2,HLA-A,HLA-C,HLA-DMA,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA1,HLA-DRB1,HLA-E,HLA-G,HMOX1,ICAM1,IFNG,IL1B,IL1R2,IL23A,MAP3K8,NFKB2,NFKBID,PCTP,PDE4B,PLAUR,PLXDC2,PTGS2,SLAMF8,SLC27A2,TNF,WDFY4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/figure/F2/,NA,NA,NA,NA
M40935,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_UP,BACTERIUM,UP,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_UP,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) (anti-DT antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"ADAMTS20,ARRB2,C3AR1,C5AR1,CARD9,CCRL2,CFB,CFD,CFI,COL8A1,CR1,FCER1G,IFNA10,IFNA16,IFNA2,IFNA21,IFNA5,IFNA7,IFNA8,IL1A,ITGB4,SFN,ST14,STAB1,TBC1D8,TLR4,TYROBP",27,"ADAMTS20,ARRB2,C3AR1,C5AR1,CARD9,CCRL2,CFB,CFD,CFI,COL8A1,CR1,FCER1G,IFNA10,IFNA16,IFNA2,IFNA21,IFNA5,IFNA7,IFNA8,IL1A,ITGB4,SFN,ST14,STAB1,TBC1D8,TLR4,TYROBP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F5/,NA,NA,NA,NA
M40934,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP,BACTERIUM,UP,CORRELATION,ANTIBODY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) (anti-polysaccharide antibody-correlation profile) after exposure to Menactra , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"AIF1,APOBR,C1QA,C1QB,C1R,C2,C3,C3AR1,C5AR1,CARD9,CCL20,CCRL2,CFD,CFI,FCER1G,FGF5,GPX1,IFNA16,IFNA2,IFNA21,IFNA4,IL1B,IL6,CXCL8,LHCGR,PTX3,SERPING1,ST14,TBC1D8,TLR4,TNF,TYROBP",32,"AIF1,APOBR,C1QA,C1QB,C1R,C2,C3,C3AR1,C5AR1,CARD9,CCL20,CCRL2,CFD,CFI,FCER1G,FGF5,GPX1,IFNA16,IFNA2,IFNA21,IFNA4,IL1B,IL6,IL8,LHCGR,PTX3,SERPING1,ST14,TBC1D8,TLR4,TNF,TYROBP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F5/,NA,NA,NA,NA
M41178,MENVEO ACWYVAX,CONJ,MENINGOCOCCUS,OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_DN,BACTERIUM,DOWN,VACCINE,BOOSTER,D7,D,7,30-70,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_DN,"BACKGROUND: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to describe B-cell responses to meningococcal polysaccharide and conjugate vaccines. METHODS: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or conjugate vaccine; one month later all received the conjugate vaccine. Blood samples were taken pre-vaccination and 7, 21 and 28 days after vaccination; B-cell responses were assessed by ELISpot, serum bactericidal assay, flow cytometry and gene expression microarray. RESULTS: Seven days after an initial dose of either vaccine, a gene expression signature characteristic of plasmablasts was detectable. The frequency of newly generated plasma cells (CXCR3<sup>+</sup>HLA-DR<sup>+</sup>) and the expression of transcripts derived from IGKC and IGHG2 correlated with immunogenicity. Notably, using an independent dataset, the expression of glucosamine (N-acetyl)-6-sulfatase was found to reproducibly correlate with the magnitude of immune response. Transcriptomic and flow cytometric data revealed depletion of switched memory B cells following plain-polysaccharide vaccine. CONCLUSIONS: These data describe distinct gene signatures associated with the production of high-avidity antibody and a plain-polysaccharide-specific signature, possibly linked to polysaccharide-induced hyporesponsiveness.","Genes down-regulated in peripheral blood mononuclear cell 7d after second dose vs 7d after first dose in adult (30-70) after exposure to Menveo/ACWYVax , time point 7D. Comment: second dose at 28 days","O'Connor D,Clutterbuck EA,Thompson AJ,Snape MD,Ramasamy MN,Kelly DF,Pollard AJ",28137280,HUMAN_GENE_SYMBOL,"ABHD5,ABITRAM,ABLIM1,PXYLP1,AFF3,AGAP6,AHCTF1,ALDH1A1,ALDH2,ALG13,ANAPC16,ANXA7,ARF4,ARID2,ATG4C,ATMIN,ATP1B3,AXIN2,BANK1,BID,CA2,CAMK2G,CASP8,CEP95,CCDC50,CCT4,CD8A,CD96,CDC14A,CDC5L,CDK2AP1,CDKN1B,FOXN3,CHMP2B,CIAO1,CIPC,CLPX,COPB1,CRTAP,CTSC,CXCR6,DEGS1,DIMT1,DPYD,DSE,ELMO2,ELOVL5,ETFRF1,EVI2B,EXOC1,FAM117B,FAM120A,FAM149B1,ATOSA,FBXO21,FBXO7,FCRL3,FCRLA,FPR2,GBP1,GGPS1,GMPS,GPR160,GSPT2,HERPUD1,HLA-DPB1,HNRNPF,HPRT1,HSD17B11,HSPH1,IDE,IFIH1,IKZF3,IKZF5,INPP4A,IREB2,ITM2B,JAK1,JKAMP,JMJD1C,KCTD6,KHDC4,KHDRBS1,KLF4,KPNB1,KYAT3,LAMP2,LILRB2,ZNF407-AS1,LIPA,LIPT1,LMBRD1,LRRC37B,MAF,MAN2B2,MAP7,MARCKS,MAT2B,MAU2,MAX,MCL1,MFSD14B,MFSD6,MLKL,MORC3,MPPE1,MPZL1,MRI1,MRPS30,MTR,MXI1,NBPF11,NCOA1,NFAT5,NFE2L2,NIP7,NNT,NPTN,NRBF2,NUDT9,OGFRL1,OSBPL10,OSBPL9,PACC1,PAG1,TENT2,CPQ,PGRMC2,PHOSPHO2,PIGB,PKIA,PLEKHB2,PPM1A,PPM1D,PPP2R2D,PPT1,PRDM8,PRKCH,PROSER1,PRPS2,PSIP1,PSMC4,PTEN,PTGDR,PTGER4,PUM1,RAB1A,RAB5A,RBBP4,RBBP5,RBM12,SCAF8,RBM47,RBMS1,RCBTB2,RELCH,RELL1,RESF1,RIN2,RIPK2,RNF13,RSBN1L,RSPH3,RUNDC1,,S100PBP,SCAF11,SDHD,SEC22C,SEC24B,SERPINE2,SGK1,SH2B3,SLC15A4,SLC25A43,SLC35E3,SLC40A1,SMARCA5,SNAP23,SOCS2,SP100,SPPL2A,SRP14,SRP54,SSBP2,ST6GAL1,STK26,SWAP70,SYPL1,TAF2,TARP,TCHP,TCP1,TGFBR2,THEMIS,TIA1,TLR2,TLR6,TMEM192,TMEM248,PIP4P2,TMEM69,TOPBP1,TPK1,TRAK1,TRAPPC11,TRGV3,TRIM23,TRIM24,TRIM33,TRMT1L,TRNAU1AP,TSC22D3,TSEN15,TSNAX,TSPYL1,TTYH2,UBE2E3,UBE2G1,UBTD2,UBXN4,USP24,USP48,VKORC1L1,VPS35,WAC,WDR20,WIPF1,WWP2,YBX1P2,YIPF4,ZC3H14,ZCCHC9,ZFP3,ZFP36L2,ZMIZ1,ZNF207,ZNF23,ZNF274,ZNF567,ZNF586,ZNF621,ZNF654,ZNF700",244,"ABHD5,ABITRAM,ABLIM1,ACPL2,AFF3,AGAP6,AHCTF1,ALDH1A1,ALDH2,ALG13,ANAPC16,ANXA7,ARF4,ARID2,ATG4C,ATMIN,ATP1B3,AXIN2,BANK1,BID,CA2,CAMK2G,CASP8,CCDC45,CCDC50,CCT4,CD8A,CD96,CDC14A,CDC5L,CDK2AP1,CDKN1B,CHES1,CHMP2B,CIAO1,CIPC,CLPX,COPB1,CRTAP,CTSC,CXCR6,DEGS1,DIMT1L,DPYD,DSE,ELMO2,ELOVL5,ETFRF1,EVI2B,EXOC1,FAM117B,FAM120A,FAM149B1,FAM214A,FBXO21,FBXO7,FCRL3,FCRLA,FPR2,GBP1,GGPS1,GMPS,GPR160,GSPT2,HERPUD1,HLA-DPB1,HNRNPF,HPRT1,HSD17B11,HSPH1,IDE,IFIH1,IKZF3,IKZF5,INPP4A,IREB2,ITM2B,JAK1,JKAMP,JMJD1C,KCTD6,KHDC4,KHDRBS1,KLF4,KPNB1,KYAT3,LAMP2,LILRB2,LINC00909,LIPA,LIPT1,LMBRD1,LRRC37B,MAF,MAN2B2,MAP7,MARCKS,MAT2B,MAU2,MAX,MCL1,MFSD14B,MFSD6,MLKL,MORC3,MPPE1,MPZL1,MRI1,MRPS30,MTR,MXI1,NBPF11,NCOA1,NFAT5,NFE2L2,NIP7,NNT,NPTN,NRBF2,NUDT9,OGFRL1,OSBPL10,OSBPL9,PACC1,PAG1,PAPD4,PGCP,PGRMC2,PHOSPHO2,PIGB,PKIA,PLEKHB2,PPM1A,PPM1D,PPP2R2D,PPT1,PRDM8,PRKCH,PROSER1,PRPS2,PSIP1,PSMC4,PTEN,PTGDR,PTGER4,PUM1,RAB1A,RAB5A,RBBP4,RBBP5,RBM12,RBM16,RBM47,RBMS1,RCBTB2,RELCH,RELL1,RESF1,RIN2,RIPK2,RNF13,RSBN1L,RSPH3,RUNDC1,RUNX1-IT1,S100PBP,SCAF11,SDHD,SEC22C,SEC24B,SERPINE2,SGK1,SH2B3,SLC15A4,SLC25A43,SLC35E3,SLC40A1,SMARCA5,SNAP23,SOCS2,SP100,SPPL2A,SRP14,SRP54,SSBP2,ST6GAL1,STK26,SWAP70,SYPL1,TAF2,TARP,TCHP,TCP1,TGFBR2,THEMIS,TIA1,TLR2,TLR6,TMEM192,TMEM248,TMEM55A,TMEM69,TOPBP1,TPK1,TRAK1,TRAPPC11,TRGV3,TRIM23,TRIM24,TRIM33,TRMT1L,TRNAU1AP,TSC22D3,TSEN15,TSNAX,TSPYL1,TTYH2,UBE2E3,UBE2G1,UBTD2,UBXN4,USP24,USP48,VKORC1L1,VPS35,WAC,WDR20,WIPF1,WWP2,YBX1P2,YIPF4,ZC3H14,ZCCHC9,ZFP3,ZFP36L2,ZMIZ1,ZNF207,ZNF23,ZNF274,ZNF567,ZNF586,ZNF621,ZNF654,ZNF700",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T2/,NA,NA,NA,NA
M41190,MENVEO ACWYVAX,CONJ,MENINGOCOCCUS,OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_UP,BACTERIUM,UP,VACCINE,BOOSTER,D7,D,7,30-70,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OCONNOR_PBMC_MENVEO_ACWYVAX_AGE_30_70YO_7DY_AFTER_SECOND_DOSE_VS_7DY_AFTER_FIRST_DOSE_UP,"BACKGROUND: Neisseria meningitidis is a globally important cause of meningitis and septicaemia. Twelve capsular groups of meningococci are known, and quadrivalent vaccines against four of these (A, C, W and Y) are available as plain-polysaccharide and protein-polysaccharide conjugate vaccines. Here we apply contemporary methods to describe B-cell responses to meningococcal polysaccharide and conjugate vaccines. METHODS: Twenty adults were randomly assigned to receive either a meningococcal plain-polysaccharide or conjugate vaccine; one month later all received the conjugate vaccine. Blood samples were taken pre-vaccination and 7, 21 and 28 days after vaccination; B-cell responses were assessed by ELISpot, serum bactericidal assay, flow cytometry and gene expression microarray. RESULTS: Seven days after an initial dose of either vaccine, a gene expression signature characteristic of plasmablasts was detectable. The frequency of newly generated plasma cells (CXCR3<sup>+</sup>HLA-DR<sup>+</sup>) and the expression of transcripts derived from IGKC and IGHG2 correlated with immunogenicity. Notably, using an independent dataset, the expression of glucosamine (N-acetyl)-6-sulfatase was found to reproducibly correlate with the magnitude of immune response. Transcriptomic and flow cytometric data revealed depletion of switched memory B cells following plain-polysaccharide vaccine. CONCLUSIONS: These data describe distinct gene signatures associated with the production of high-avidity antibody and a plain-polysaccharide-specific signature, possibly linked to polysaccharide-induced hyporesponsiveness.","Genes up-regulated in peripheral blood mononuclear cell 7d after second dose vs 7d after first dose in adult (30-70) after exposure to Menveo/ACWYVax , time point 7D. Comment: second dose at 28 days","O'Connor D,Clutterbuck EA,Thompson AJ,Snape MD,Ramasamy MN,Kelly DF,Pollard AJ",28137280,HUMAN_GENE_SYMBOL,"ACAP1,ACIN1,AHCYL1,AIF1,AKAP8L,ANKRD13D,APOBEC3C,APOBEC3D,APOL1,ARL6IP4,ATP2B4,ATP5MF,BATF,BRD3,BRMS1,C7orf50,CARS1,CBX5,CCDC12,CCDC167,CD3E,CEBPE,CHD4,CLASRP,COL6A2,CORO7,CPNE5,CPSF2,CROCC,CSNK2A3,CUX1,CYP4F12,DAXX,DIAPH1,DIS3L2,DYNC1H1,EIF3B,ERC1,ERGIC3,FKBP2,FLNA,FOXP1,GMEB1,GTF2F1,HAPLN3,HDAC7,HMGA1,HNMT,HOMER3,HPS5,HSP90AB1,HUWE1,HYMAI,ILRUN,ITGA2B,KANSL1,KAT6B,KDM2A,KPNA6,LETM1,ZC3H12A-DT,LNPK,ZC3H11C,LONP2,LPCAT4,LSM7,NAA38,MAP4,MARCHF6,MED15,MED24,MICOS13,MRPL41,MRPS16,MYL6,MYO1G,MZT2A,NFKB2,NOSIP,NRBP1,NUDT22,OGDH,PA2G4,PCNX2,PCNX3,PET100,PHKA2,PKN1,PLEC,POLR1B,POLR3A,PPM1B,PPP1R10,PPP2R1A,PROK1,PSMC3,RALGPS2,RDM1,ROMO1,RPL13,RPRD2,RRP7A,RTN4,SAMD4B,SASH3,SIN3B,SIVA1,SLC38A7,SND1,SNTB2,SPOP,SPTBN1,STIP1,STUB1,SUPT5H,SUPT6H,SURF2,SYNJ2BP,TAFAZZIN,TBC1D17,TCEAL9,TFF3,TIMM17B,TM9SF2,TMEM219,TMEM250,TMEM256,TNPO3,TRAPPC10,TRIM4,TRIR,TTC17,TUBGCP2,TYMP,UBE2D2,UBE2Z,UBL5,UGGT1,USF2,USP21,VPS13C,WASF2,WHAMM,YAF2,ZNF512B,ZNF768",146,"ACAP1,ACIN1,AHCYL1,AIF1,AKAP8L,ANKRD13D,APOBEC3C,APOBEC3D,APOL1,ARL6IP4,ATP2B4,ATP5MF,BATF,BRD3,BRMS1,C7orf50,CARS1,CBX5,CCDC12,CCDC167,CD3E,CEBPE,CHD4,CLASRP,COL6A2,CORO7,CPNE5,CPSF2,CROCC,CSNK2A3,CUX1,CYP4F12,DAXX,DIAPH1,DIS3L2,DYNC1H1,EIF3B,ERC1,ERGIC3,FKBP2,FLNA,FOXP1,GMEB1,GTF2F1,HAPLN3,HDAC7,HMGA1,HNMT,HOMER3,HPS5,HSP90AB1,HUWE1,HYMAI,ILRUN,ITGA2B,KANSL1,KAT6B,KDM2A,KPNA6,LETM1,LINC01137,LNPK,LOC441155,LONP2,LPCAT4,LSM7,LSMD1,MAP4,MARCHF6,MED15,MED24,MICOS13,MRPL41,MRPS16,MYL6,MYO1G,MZT2A,NFKB2,NOSIP,NRBP1,NUDT22,OGDH,PA2G4,PCNX2,PCNX3,PET100,PHKA2,PKN1,PLEC,POLR1B,POLR3A,PPM1B,PPP1R10,PPP2R1A,PROK1,PSMC3,RALGPS2,RDM1,ROMO1,RPL13,RPRD2,RRP7A,RTN4,SAMD4B,SASH3,SIN3B,SIVA1,SLC38A7,SND1,SNTB2,SPOP,SPTBN1,STIP1,STUB1,SUPT5H,SUPT6H,SURF2,SYNJ2BP,TAZ,TBC1D17,TCEAL9,TFF3,TIMM17B,TM9SF2,TMEM219,TMEM250,TMEM256,TNPO3,TRAPPC10,TRIM4,TRIR,TTC17,TUBGCP2,TYMP,UBE2D2,UBE2Z,UBL5,UGGT1,USF2,USP21,VPS13C,WASF2,WHAMM,YAF2,ZNF512B,ZNF768",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-mDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40933,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN,BACTERIUM,DOWN,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) after exposure to Menomune A/C/Y/W-135 , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"A2M,ADAMTS20,AIF1,C1S,C3,C3AR1,CFD,COL8A1,CR1,FGF5,IFNA16,IFNA21,IFNA5,IL6,ITGB4,PRL,TBC1D8,TLR4,TNR",19,"A2M,ADAMTS20,AIF1,C1S,C3,C3AR1,CFD,COL8A1,CR1,FGF5,IFNA16,IFNA21,IFNA5,IL6,ITGB4,PRL,TBC1D8,TLR4,TNR",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-6.xlsx,NA,NA,NA,NA
M41150,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_UP,BACTERIUM,UP,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_UP,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) after exposure to Menomune A/C/Y/W-135 , time point 3D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"A2M,AMER2,APOBR,ARRB2,C1QA,C1QB,C1QC,C2,C5AR1,CARD9,CCL20,CFB,CFH,GPX1,IFNA16,IFNA2,IFNA7,IL1A,IL1B,CXCL8,IMPG2,LAMC2,LHCGR,MMP12,PTX3,SERPING1,SFN,ST14,TNF",29,"A2M,AMER2,APOBR,ARRB2,C1QA,C1QB,C1QC,C2,C5AR1,CARD9,CCL20,CFB,CFH,GPX1,IFNA16,IFNA2,IFNA7,IL1A,IL1B,IL8,IMPG2,LAMC2,LHCGR,MMP12,PTX3,SERPING1,SFN,ST14,TNF",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl2.xls,NA,NA,NA,NA
M40999,MENACTRA,CONJ,MENINGOCOCCUS,LI_PBMC_MENACTRA_AGE_18_45YO_7DY_UP,BACTERIUM,UP,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_MENACTRA_AGE_18_45YO_7DY_UP,"Many vaccines induce protective immunity via antibodies. Systems biology approaches have been used to determine signatures that can be used to predict vaccine-induced immunity in humans, but whether there is a 'universal signature' that can be used to predict antibody responses to any vaccine is unknown. Here we did systems analyses of immune responses to the polysaccharide and conjugate vaccines against meningococcus in healthy adults, in the broader context of published studies of vaccines against yellow fever virus and influenza virus. To achieve this, we did a large-scale network integration of publicly available human blood transcriptomes and systems-scale databases in specific biological contexts and deduced a set of transcription modules in blood. Those modules revealed distinct transcriptional signatures of antibody responses to different classes of vaccines, which provided key insights into primary viral, protein recall and anti-polysaccharide responses. Our results elucidate the early transcriptional programs that orchestrate vaccine immunity in humans and demonstrate the power of integrative network modeling.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) after exposure to Menactra , time point 7D","Li S,Rouphael N,Duraisingham S,Romero-Steiner S,Presnell S,Davis C,Schmidt DS,Johnson SE,Milton A,Rajam G,Kasturi S,Carlone GM,Quinn C,Chaussabel D,Palucka AK,Mulligan MJ,Ahmed R,Stephens DS,Nakaya HI,Pulendran B",24336226,HUMAN_GENE_SYMBOL,"FCRL5,HSP90B1,,IGHD,IGHE,IGHG1,IGHG3,IGLL1,IGLV2-14,JCHAIN,PDIA6,TNFRSF13B,TNFRSF17,TXNDC5",14,"FCRL5,HSP90B1,IGH,IGHD,IGHE,IGHG1,IGHG3,IGLL1,IGLV2-14,JCHAIN,PDIA6,TNFRSF13B,TNFRSF17,TXNDC5",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl2.xls,NA,NA,NA,NA
M40892,PREVNAR,CONJ,PNEUMOCOCCUS,VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_8MO_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,M8,M,8,9 mo,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_8MO_UP,"Concerns about the risk of inducing immune deviation-associated neonatal tolerance as described in mice have restricted the widespread adoption of neonatal vaccination. The aim of this study was to demonstrate the immunological feasibility of neonatal pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants in resource poor countries against severe pneumococcal disease and mortality in the early critical period of life. Papua New Guinean infants were randomized to be vaccinated with the 7-valent PCV (7vPCV) at birth, 1 and 2 months (neonatal group, n=104) or at 1, 2 and 3 months of age (infant group, n=105), or to not receive 7vPCV at all (control group, n=109). Analysis of vaccine responses at 3 and 9 months of age demonstrated persistently higher type-1 (IFN-gamma) and type-2 (IL-5 and IL-13) T-cell responses to the protein carrier CRM(197) and IgG antibody titres to 7vPCV serotypes in children vaccinated with 7vPCV according to either schedule as compared to unvaccinated children. In a comprehensive immuno-phenotypic analysis at 9 months of age, no differences in the quantity or quality of vaccine-specific T cell memory responses were found between neonatal vaccinations versus children given their first PCV dose at one month. Hospitalization rates in the first month of life did not differ between children vaccinated with PCV at birth or not. These findings demonstrate that neonatal 7vPCV vaccination is safe and not associated with immunological tolerance. Neonatal immunisation schedules should therefore be considered in high-risk areas where this may result in improved vaccine coverage and the earliest possible protection against pneumococcal disease and death.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (9m) (neonatal) after exposure to Prevnar (USA) , time point 8M","van den Biggelaar AH,Pomat W,Bosco A,Phuanukoonnon S,Devitt CJ,Nadal-Sims MA,Siba PM,Richmond PC,Lehmann D,Holt PG",21645573,HUMAN_GENE_SYMBOL,"AICDA,APOL4,AQP7,ARHGAP11A,ARHGEF39,AURKA,AURKB,BUB1B,C1S,KNL1,CD274,CDK1,CDC45,CDCA2,CENPF,CHAF1B,CIT,CKAP2L,CLSPN,DIAPH3,DUSP4,E2F8,EEF2KMT,ELOA3P,ELOVL6,EXO1,FAM90A1,FGL2,FOXM1,GBP4,GBP5,GBP6,GNLY,H2AC13,H2AC14,H2AC16,H2AC4,H2BC13,H2BC7,H3C12,H3C7,H3C8,HTR1A,IDI2,IFNG,IL12RB2,IL18R1,IL3,IL9,ITGA2,KIF14,KIF15,MCM4,MLC1,MTFR2,NEIL3,NEK2,NUF2,NUSAP1,OR2T8,OR6B3,OSM,PBK,PCLAF,POGLUT2,PRC1,PSG5,RAB19,RAD51,RHO,RP1L1,SERPING1,SHC4,SIX1,SSX4,TEDC2,TICRR,TNFSF4,TRIP13,ZBED2,ZBTB32",81,"AICDA,APOL4,AQP7,ARHGAP11A,ARHGEF39,AURKA,AURKB,BUB1B,C1S,CASC5,CD274,CDC2,CDC45L,CDCA2,CENPF,CHAF1B,CIT,CKAP2L,CLSPN,DIAPH3,DUSP4,E2F8,EEF2KMT,ELOA3P,ELOVL6,EXO1,FAM90A1,FGL2,FOXM1,GBP4,GBP5,GBP6,GNLY,H2AC13,H2AC14,H2AC16,H2AC4,H2BC13,H2BC7,H3C12,H3C7,H3C8,HTR1A,IDI2,IFNG,IL12RB2,IL18R1,IL3,IL9,ITGA2,KIF14,KIF15,MCM4,MLC1,MTFR2,NEIL3,NEK2,NUF2,NUSAP1,OR2T8,OR6B3,OSM,PBK,PCLAF,POGLUT2,PRC1,PSG5,RAB19B,RAD51,RHO,RP1L1,SERPING1,SHC4,SIX1,SSX4,TEDC2,TICRR,TNFSF4,TRIP13,ZBED2,ZBTB32",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/bin/pone.0067922.s004.docx,NA,NA,NA,NA
M40949,PREVNAR,CONJ,PNEUMOCOCCUS,VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_DN,BACTERIUM,DOWN,VACCINE,VAC VS CTRL,M9,M,9,9 mo,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_DN,"Concerns about the risk of inducing immune deviation-associated neonatal tolerance as described in mice have restricted the widespread adoption of neonatal vaccination. The aim of this study was to demonstrate the immunological feasibility of neonatal pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants in resource poor countries against severe pneumococcal disease and mortality in the early critical period of life. Papua New Guinean infants were randomized to be vaccinated with the 7-valent PCV (7vPCV) at birth, 1 and 2 months (neonatal group, n=104) or at 1, 2 and 3 months of age (infant group, n=105), or to not receive 7vPCV at all (control group, n=109). Analysis of vaccine responses at 3 and 9 months of age demonstrated persistently higher type-1 (IFN-gamma) and type-2 (IL-5 and IL-13) T-cell responses to the protein carrier CRM(197) and IgG antibody titres to 7vPCV serotypes in children vaccinated with 7vPCV according to either schedule as compared to unvaccinated children. In a comprehensive immuno-phenotypic analysis at 9 months of age, no differences in the quantity or quality of vaccine-specific T cell memory responses were found between neonatal vaccinations versus children given their first PCV dose at one month. Hospitalization rates in the first month of life did not differ between children vaccinated with PCV at birth or not. These findings demonstrate that neonatal 7vPCV vaccination is safe and not associated with immunological tolerance. Neonatal immunisation schedules should therefore be considered in high-risk areas where this may result in improved vaccine coverage and the earliest possible protection against pneumococcal disease and death.","Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (9m) after exposure to Prevnar (USA) , time point 9M and 8M (identical response signature)","van den Biggelaar AH,Pomat W,Bosco A,Phuanukoonnon S,Devitt CJ,Nadal-Sims MA,Siba PM,Richmond PC,Lehmann D,Holt PG",21645573,HUMAN_GENE_SYMBOL,"CD14,CD163,FABP4,MERTK,MS4A4A",5,"CD14,CD163,FABP4,MERTK,MS4A4A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/,NA,NA,NA,NA
M40952,PREVNAR,CONJ,PNEUMOCOCCUS,VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,M9,M,9,9 mo,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_INFANT_STIMULATED_VS_UNSTIMULATED_9MO_UP,"Concerns about the risk of inducing immune deviation-associated neonatal tolerance as described in mice have restricted the widespread adoption of neonatal vaccination. The aim of this study was to demonstrate the immunological feasibility of neonatal pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants in resource poor countries against severe pneumococcal disease and mortality in the early critical period of life. Papua New Guinean infants were randomized to be vaccinated with the 7-valent PCV (7vPCV) at birth, 1 and 2 months (neonatal group, n=104) or at 1, 2 and 3 months of age (infant group, n=105), or to not receive 7vPCV at all (control group, n=109). Analysis of vaccine responses at 3 and 9 months of age demonstrated persistently higher type-1 (IFN-gamma) and type-2 (IL-5 and IL-13) T-cell responses to the protein carrier CRM(197) and IgG antibody titres to 7vPCV serotypes in children vaccinated with 7vPCV according to either schedule as compared to unvaccinated children. In a comprehensive immuno-phenotypic analysis at 9 months of age, no differences in the quantity or quality of vaccine-specific T cell memory responses were found between neonatal vaccinations versus children given their first PCV dose at one month. Hospitalization rates in the first month of life did not differ between children vaccinated with PCV at birth or not. These findings demonstrate that neonatal 7vPCV vaccination is safe and not associated with immunological tolerance. Neonatal immunisation schedules should therefore be considered in high-risk areas where this may result in improved vaccine coverage and the earliest possible protection against pneumococcal disease and death.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (9m) (infant) after exposure to Prevnar (USA) , time point 9M","van den Biggelaar AH,Pomat W,Bosco A,Phuanukoonnon S,Devitt CJ,Nadal-Sims MA,Siba PM,Richmond PC,Lehmann D,Holt PG",21645573,HUMAN_GENE_SYMBOL,"ANLN,APOL4,AQP7,ASPM,AURKB,BIRC5,BUB1,BUB1B,KNL1,CCNA2,CCNB1,CCNB2,CD274,CDC20,CDC25A,CDCA2,CENPE,CENPF,CEP55,CHAF1B,CHEK1,CISH,CIT,CKAP2L,CLSPN,CSF2,CTSW,CXCL9,DEPDC1B,DLGAP5,DTL,DUX4L9,E2F7,E2F8,EEF2KMT,ELOVL6,ESCO2,ESPL1,EXO1,FAM90A1,FGL2,FOXM1,GBP4,GBP5,GBP6,GTSE1,GZMA,GZMB,H2AC13,H2AC14,H2AC16,H2AC21,H2AC4,H2BC11,H2BC14,H2BC15,H3C10,H3C12,H3C14,H3C2,H3C7,H4C13,H4C6,H4C9,HJURP,HTR1A,IDI2,IFNG,IL12RB2,IL13,IL17F,IL17RB,IL18R1,IL2RA,IL3,IL5,IL9,KIF11,KIF14,KIF18A,KIF23,KIF2C,KIF4A,LIF,LTA,MCM10,MCM4,MELK,MKI67,MLC1,MMP12,NCAPG,NCAPH,NEIL3,ORC1,OSM,PBK,PCDHB2,PHF1,PLK1,PRAMEF8,PRC1,PRR11,RAB19,RAD51,RRM2,SERPING1,SHC4,SIX1,SKA1,SKA3,SLC27A2,SPC25,SSX4,TEDC2,TICRR,TK1,TNFSF4,TOP2A,TPX2,TRIP13,TYMS,UBE2C,USP17L2,WIPF2,ZBED2,ZBTB32",127,"ANLN,APOL4,AQP7,ASPM,AURKB,BIRC5,BUB1,BUB1B,CASC5,CCNA2,CCNB1,CCNB2,CD274,CDC20,CDC25A,CDCA2,CENPE,CENPF,CEP55,CHAF1B,CHEK1,CISH,CIT,CKAP2L,CLSPN,CSF2,CTSW,CXCL9,DEPDC1B,DLGAP5,DTL,DUX4L9,E2F7,E2F8,EEF2KMT,ELOVL6,ESCO2,ESPL1,EXO1,FAM90A1,FGL2,FOXM1,GBP4,GBP5,GBP6,GTSE1,GZMA,GZMB,H2AC13,H2AC14,H2AC16,H2AC21,H2AC4,H2BC11,H2BC14,H2BC15,H3C10,H3C12,H3C14,H3C2,H3C7,H4C13,H4C6,H4C9,HJURP,HTR1A,IDI2,IFNG,IL12RB2,IL13,IL17F,IL17RB,IL18R1,IL2RA,IL3,IL5,IL9,KIF11,KIF14,KIF18A,KIF23,KIF2C,KIF4A,LIF,LTA,MCM10,MCM4,MELK,MKI67,MLC1,MMP12,NCAPG,NCAPH,NEIL3,ORC1,OSM,PBK,PCDHB2,PHF1,PLK1,PRAMEF8,PRC1,PRR11,RAB19,RAD51,RRM2,SERPING1,SHC4,SIX1,SKA1,SKA3,SLC27A2,SPBC25,SSX4,TEDC2,TICRR,TK1,TNFSF4,TOP2A,TPX2,TRIP13,TYMS,UBE2C,USP17L2,WIPF2,ZBED2,ZBTB32",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/table/T3/,NA,NA,NA,NA
M40938,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_DN,VIRUS,DOWN,VACCINE,ADJUVANT,D1,D,1,18-49,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_DN,"BACKGROUND: Adjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood. METHODS: Using ribonucleic acid sequencing on peripheral blood mononuclear cells (PBMCs) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types. RESULTS: AS03-adjuvanted vaccine induced the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, Fcgamma receptor (FcgammaR)-mediated phagocytosis, and antigen processing and presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared with individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMCs, and several pathways identified in individual cell types were absent in PBMCs. CONCLUSIONS: Transcriptomic analysis of PBMCs after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5- to 8-fold upregulation of Fc-gammaR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. Although PBMCs and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.","Genes down-regulated in peripheral blood mononuclear cell vaccinated with AS03 adjuvant vs phosphate-bufferred saline in adults (19-39) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Goll JB,Jensen TL,Hoek KL,Prasad N,Gelber CE,Levy SE,Joyce S,Link AJ,Creech CB,Edwards KM",30566602,HUMAN_GENE_SYMBOL,"ADAMTS7,ATG9B,ATP13A4,KCNJ5-AS1,LINC00612,HEATR9,C2orf27A,CACNA1I,CHD5,COL5A1,COL5A3,CYP4F12,DPEP3,FXYD2,GSDMA,HSPG2,IL23R,LMO7-AS1,MFGE8,MIR635,MMP15,NDRG4,NOG,NRCAM,OCM,SHANK1,SPRY1,SPRY2,STYK1,SYT17,TNNC1,TPBG,TRBJ2-4,TRIM74,ZNF890P",35,"ADAMTS7,ATG9B,ATP13A4,C11orf45,C12orf33,C17orf66,C2orf27A,CACNA1I,CHD5,COL5A1,COL5A3,CYP4F12,DPEP3,FXYD2,GSDMA,HSPG2,IL23R,LMO7-AS1,MFGE8,MIR635,MMP15,NDRG4,NOG,NRCAM,OCM,SHANK1,SPRY1,SPRY2,STYK1,SYT17,TNNC1,TPBG,TRBJ2-4,TRIM74,ZNF890P",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133148/table/T2/,NA,NA,NA,NA
M40997,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_UP,VIRUS,UP,VACCINE,ADJUVANT,D1,D,1,18-49,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_PBMC_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_19_39YO_AS03_ADJUVANT_VS_BUFFER_1DY_UP,"BACKGROUND: Adjuvant System 03 (AS03) markedly enhances responses to influenza A/H5N1 vaccines, but the mechanisms of this enhancement are incompletely understood. METHODS: Using ribonucleic acid sequencing on peripheral blood mononuclear cells (PBMCs) from AS03-adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially expressed genes, enriched pathways, and genes that correlated with serologic responses. We compared bulk PBMC findings with our previously published assessments of flow-sorted immune cell types. RESULTS: AS03-adjuvanted vaccine induced the strongest differential signals on day 1 postvaccination, activating multiple innate immune pathways including interferon and JAK-STAT signaling, Fcgamma receptor (FcgammaR)-mediated phagocytosis, and antigen processing and presentation. Changes in signal transduction and immunoglobulin genes predicted peak hemagglutinin inhibition (HAI) titers. Compared with individual immune cell types, activated PBMC genes and pathways were most similar to innate immune cells. However, several pathways were unique to PBMCs, and several pathways identified in individual cell types were absent in PBMCs. CONCLUSIONS: Transcriptomic analysis of PBMCs after AS03-adjuvanted H5N1 vaccination revealed early activation of innate immune signaling, including a 5- to 8-fold upregulation of Fc-gammaR1A/1B/1C genes. Several early gene responses were correlated with HAI titer, indicating links with the adaptive immune response. Although PBMCs and cell-specific results shared key innate immune signals, unique signals were identified by both approaches.","Genes up-regulated in peripheral blood mononuclear cell vaccinated with AS03 adjuvant vs phosphate-bufferred saline in adults (19-39) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Goll JB,Jensen TL,Hoek KL,Prasad N,Gelber CE,Levy SE,Joyce S,Link AJ,Creech CB,Edwards KM",30566602,HUMAN_GENE_SYMBOL,"AANAT,ACP3,ACSL1,ACVRL1,ADAM9,ADAMTSL4,ADAP2,ADM,ADPRH,AIF1,AIM2,AK4,ALDH1A1,ANKRD22,ANKRD34B,ANO5,APOBEC3A,APOBEC3B,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,BMAL2,ASAP2,ASGR2,ATF3,ATF5,ATP6V1B2,BACH1,BATF2,BATF3,BCL2A1,BCL3,BCL6,BEST1,BLVRA,BST1,SMCO4,SCIMP,MCEMP1,C1DP1,C1QA,C1QB,C2,C3AR1,FAM241A,CARD16,CARD17P,CASP1,CASP5,CASP7,CCDC149,CCR1,CCR2,CCRL2,CD14,CD274,CD300E,CD36,CD38,CDC42EP2,CDCP1,CDHR5,CDKN1A,CES1,CHST15,CLEC4D,CLEC4E,CLEC4G,CLEC5A,CLEC6A,CMPK2,COX17P1,CREB5,CRISPLD2,CTSB,CTSL,CTSS,CXCL10,CXCL16,CXCR2P1,CYP1B1,CYP1B1-AS1,CYP27A1,DDO,DDX60,DHRS9,DMXL2,DOCK4,DPYD,DRAM1,DSC2,DSE,DTX3L,DUSP1,DUSP3,DUSP6,DYSF,EGR2,EGR3,EMILIN2,EPB41L3,EPSTI1,ETV7,EXOC3L1,EXT1,FAM110B,FAM151B,FAM157B,GASK1B,FAM20A,FAM20C,CALHM6,FAM72A,FBXO6,FCAR,FCER1G,FCGR1A,FCGR1BP,FCGR2A,FCGR2C,FCN1,FFAR2,FGD4,FGL2,FOS,FPR1,FPR2,FRMD3,FZD5,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GCA,GCH1,GLT1D1,GLUL,GM2A,GNB4,GNG10,GPBAR1,HCAR2,GPR84,GPRC5C,GRINA,HBEGF,HCK,HERC5,H2BC18,HLA-DQB1-AS1,HLX,HORMAD1,HP,HSPA6,HSPA7,ICAM1,IDO1,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM3,IFNGR2,IGF2BP3,IGSF6,IL15,IL15RA,IL1B,IL1RN,IL27,IL31RA,IL4I1,IRF1,IRF7,ISG15,ITPRIPL2,JAK2,KCNJ15,KCNJ2,KCTD12,SHTN1,KLF4,KREMEN1,KYNU,LACTB,LAMP3,LAP3,LHFPL2,LILRA1,LILRA3,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LILRB5,LINC00482,LIPN,LMNB1,LMO2,LPCAT2,LRG1,LRRC4,LRRK2,LTBR,LYN,LYZ,MAFB,MARCKS,MARCO,MCTP1,MEFV,MEGF9,SLC49A3,MIR22HG,MNDA,MORN2,MPEG1,MPZL2,IRAG1,MS4A4A,MSR1,MT2A,MTHFD2,MUC1,MX1,MYOF,NAMPT,NAMPTP1,NCF1,NCF1B,NCF1C,NEXN,NFAM1,NFIX,NGFR,NHSL1,NLRC4,NLRP3,NMI,NOD2,NPC2,OAS1,OAS2,OAS3,OASL,ODF3B,OPLAH,P2RX7,P2RY12,P2RY13,PARP14,PARP9,PFKFB3,PKHD1L1,PKMYT1,PLA2G4A,PLA2G7,PLBD1,PLEKHG6,PLEKHO1,PLSCR1,PLXDC2,PLXNC1,PRLR,PRRG4,PSMA4,PSMB9,PSME2,PSME2P2,PSTPIP2,NECTIN2,RAB20,RAB31,RAB39A,RASGEF1B,RBM47,RGS1,RHOQP3,RNF217,RSAD2,RTP4,RUFY4,S100A12,S100A8,S100A9,SAMD4A,SAMD9L,SBNO2,SCARB2,SCARF1,SCO2,SDC3,SDSL,SECTM1,SEMA6B,SEPTIN4,MSRB1,SERPINA1,SERPING1,SH3PXD2B,SIGLEC1,SIGLEC11,SIGLEC16,SLAMF8,SLC1A3,SLC22A16,SLC24A4,SLC31A1,SLC31A2,SLC46A2,SLC6A12,SLC8A1,SMAD1,SMTNL1,SNX10,SOCS3,SOD2,SORT1,SQOR,SRC,SRGN,STAT1,STAT2,STEAP4,STK32B,STX11,TAP1,TCN2,TDRD6,TFEC,TGM2,TLR1,TLR2,TLR4,TMEM106A,TMEM150B,TMEM176A,TMEM176B,TMEM51,TMTC1,TNFAIP2,TNFAIP6,TNFSF10,TNFSF13B,TRAFD1,TREM1,TRIB1,TRPV4,TYMP,UBE2D1,UBE2L6,VAMP5,VCAN,VDR,VRK2,WARS1,WDFY3,WDFY3-AS2,WDR49,XAF1,XKR8,ZEB2-AS1,ZMYND15,ZNF702P,ZNF703",377,"AANAT,ACPP,ACSL1,ACVRL1,ADAM9,ADAMTSL4,ADAP2,ADM,ADPRH,AIF1,AIM2,AK4,ALDH1A1,ANKRD22,ANKRD34B,ANO5,APOBEC3A,APOBEC3B,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,ARNTL2,ASAP2,ASGR2,ATF3,ATF5,ATP6V1B2,BACH1,BATF2,BATF3,BCL2A1,BCL3,BCL6,BEST1,BLVRA,BST1,C11orf75,C17orf87,C19orf59,C1DP1,C1QA,C1QB,C2,C3AR1,C4orf32,CARD16,CARD17,CASP1,CASP5,CASP7,CCDC149,CCR1,CCR2,CCRL2,CD14,CD274,CD300E,CD36,CD38,CDC42EP2,CDCP1,CDHR5,CDKN1A,CES1,CHST15,CLEC4D,CLEC4E,CLEC4G,CLEC5A,CLEC6A,CMPK2,COX17P1,CREB5,CRISPLD2,CTSB,CTSL1,CTSS,CXCL10,CXCL16,CXCR2P1,CYP1B1,CYP1B1-AS1,CYP27A1,DDO,DDX60,DHRS9,DMXL2,DOCK4,DPYD,DRAM1,DSC2,DSE,DTX3L,DUSP1,DUSP3,DUSP6,DYSF,EGR2,EGR3,EMILIN2,EPB41L3,EPSTI1,ETV7,EXOC3L1,EXT1,FAM110B,FAM151B,FAM157B,FAM198B,FAM20A,FAM20C,FAM26F,FAM72A,FBXO6,FCAR,FCER1G,FCGR1A,FCGR1B,FCGR2A,FCGR2C,FCN1,FFAR2,FGD4,FGL2,FOS,FPR1,FPR2,FRMD3,FZD5,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GCA,GCH1,GLT1D1,GLUL,GM2A,GNB4,GNG10,GPBAR1,GPR109A,GPR84,GPRC5C,GRINA,HBEGF,HCK,HERC5,HIST2H2BF,HLA-DQB1-AS1,HLX,HORMAD1,HP,HSPA6,HSPA7,ICAM1,IDO1,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM3,IFNGR2,IGF2BP3,IGSF6,IL15,IL15RA,IL1B,IL1RN,IL27,IL31RA,IL4I1,IRF1,IRF7,ISG15,ITPRIPL2,JAK2,KCNJ15,KCNJ2,KCTD12,KIAA1598,KLF4,KREMEN1,KYNU,LACTB,LAMP3,LAP3,LHFPL2,LILRA1,LILRA3,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LILRB5,LINC00482,LIPN,LMNB1,LMO2,LPCAT2,LRG1,LRRC4,LRRK2,LTBR,LYN,LYZ,MAFB,MARCKS,MARCO,MCTP1,MEFV,MEGF9,MFSD7,MIR22HG,MNDA,MORN2,MPEG1,MPZL2,MRVI1,MS4A4A,MSR1,MT2A,MTHFD2,MUC1,MX1,MYOF,NAMPT,NAMPTP1,NCF1,NCF1B,NCF1C,NEXN,NFAM1,NFIX,NGFR,NHSL1,NLRC4,NLRP3,NMI,NOD2,NPC2,OAS1,OAS2,OAS3,OASL,ODF3B,OPLAH,P2RX7,P2RY12,P2RY13,PARP14,PARP9,PFKFB3,PKHD1L1,PKMYT1,PLA2G4A,PLA2G7,PLBD1,PLEKHG6,PLEKHO1,PLSCR1,PLXDC2,PLXNC1,PRLR,PRRG4,PSMA4,PSMB9,PSME2,PSME2P2,PSTPIP2,PVRL2,RAB20,RAB31,RAB39,RASGEF1B,RBM47,RGS1,RHOQP3,RNF217,RSAD2,RTP4,RUFY4,S100A12,S100A8,S100A9,SAMD4A,SAMD9L,SBNO2,SCARB2,SCARF1,SCO2,SDC3,SDSL,SECTM1,SEMA6B,SEPT4,SEPX1,SERPINA1,SERPING1,SH3PXD2B,SIGLEC1,SIGLEC11,SIGLEC16,SLAMF8,SLC1A3,SLC22A16,SLC24A4,SLC31A1,SLC31A2,SLC46A2,SLC6A12,SLC8A1,SMAD1,SMTNL1,SNX10,SOCS3,SOD2,SORT1,SQRDL,SRC,SRGN,STAT1,STAT2,STEAP4,STK32B,STX11,TAP1,TCN2,TDRD6,TFEC,TGM2,TLR1,TLR2,TLR4,TMEM106A,TMEM150B,TMEM176A,TMEM176B,TMEM51,TMTC1,TNFAIP2,TNFAIP6,TNFSF10,TNFSF13B,TRAFD1,TREM1,TRIB1,TRPV4,TYMP,UBE2D1,UBE2L6,VAMP5,VCAN,VDR,VRK2,WARS,WDFY3,WDFY3-AS2,WDR49,XAF1,XKR8,ZEB2-AS1,ZMYND15,ZNF702P,ZNF703",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig S5 (left),http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1519690113/-/DCSupplemental,NA,NA,NA,NA
M41016,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_LOW_VS_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_0DY_DN,VIRUS,DOWN,CORRELATION,ADVERSE EVENT,D0,D,0,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_LOW_VS_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_0DY_DN,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes down-regulated in peripheral blood mononuclear cell -7d vs 0d in adults (18-64) (low AE subjects vs medium/high AE subjects) after exposure to Pandemrix (A/California/7/09 (H1N1)) , time point 0D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"CD163,CLEC4D,GLT1D1,HK2,LYZ,NRG1,SIRPA,TMEM121B",8,"CD163,CLEC4D,GLT1D1,HK2,LYZ,NRG1,SIRPA,TMEM121B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133148/table/T2/,NA,NA,NA,NA
M41007,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_DN,VIRUS,DOWN,CORRELATION,ADVERSE EVENT,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_DN,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes down-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (18-64) (medium-high adverse events score) after exposure to Pandemrix , time point 1D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"GLIPR1,PLB1,SULT1A2,SULT1A4,VIPR1",5,"GLIPR1,PLB1,SULT1A2,SULT1A4,VIPR1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig S2C,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338562/figure/sfig02/,NA,NA,NA,NA
M41137,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_1DY_UP,VIRUS,UP,CORRELATION,ADVERSE EVENT,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_MEDIUM_HIGH_ADVERSE_EVENT_SUBJECTS_1DY_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in peripheral blood mononuclear cell -7d vs 1d in adults (18-64) (medium/high AE subjects) after exposure to Pandemrix (A/California/7/09 (H1N1)) , time point 1D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"BANK1,C8G,CD19,CD22,CD72,CD79A,CD79B,CFH,CNR2,CXCR5,DENND5B,DOK7,EBF1,FAM30A,FCER2,FCRL1,FCRL2,FCRL5,FCRLA,GPR20,L1TD1,LARGE1,LINC00926,MEG3,MOXD1,MS4A1,MTSS1,NIBAN3,P2RX5,PAWR,PCDH9,PPP1R17,RPS26,RUBCNL,SETBP1,SYT17,TNFRSF13C,TSPAN13,VMO1",39,"BANK1,C8G,CD19,CD22,CD72,CD79A,CD79B,CFH,CNR2,CXCR5,DENND5B,DOK7,EBF1,FAM30A,FCER2,FCRL1,FCRL2,FCRL5,FCRLA,GPR20,L1TD1,LARGE,LINC00926,MEG3,MOXD1,MS4A1,MTSS1,NIBAN3,P2RX5,PAWR,PCDH9,PPP1R17,RPS26,RUBCNL,SETBP1,SYT17,TNFRSF13C,TSPAN13,VMO1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-Bcells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41201,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP,VIRUS,UP,CORRELATION,ADVERSE EVENT,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_CORRELATED_WITH_TRANSITIONAL_B_CELLS_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in peripheral blood mononuclear cell high vs low responders in adults (18-64) (medium-high adverse events score) after exposure to Pandemrix , time point 1D. Comment: Pre-vaccine transitional B cell levels and increased auto-antibodies correlate with post-vaccination AE. (a) Genes expressed differentially in low AE vs medium/high AE study subjects, both pre-vaccination and on post-vaccine days +1 and +7","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"BANK1,CD19,CD22,CD72,CD79B,CNR2,EBF1,FCER2,FCRL1,FCRL2,FCRLA,LARGE1,MS4A1,NIBAN3,P2RX5,PAWR,PCDH9,RUBCNL,SETBP1,TSPAN13,VMO1",21,"BANK1,CD19,CD22,CD72,CD79B,CNR2,EBF1,FCER2,FCRL1,FCRL2,FCRLA,LARGE1,MS4A1,NIBAN3,P2RX5,PAWR,PCDH9,RUBCNL,SETBP1,TSPAN13,VMO1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-mDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41060,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_TRANSIENT_UP,VIRUS,UP,CORRELATION,ADVERSE EVENT,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_HIGH_VS_LOW_RESPONDERS_MEDIUM_HIGH_ADVERSE_EVENTS_SCORE_1DY_TRANSIENT_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in peripheral blood mononuclear cell high vs low responders in adults (18-64) (medium-high adverse events score) after exposure to Pandemrix , time point 1D. Comment: High AE individuals show day +1 and pre-vaccine differences to asymptomatic study subjects. (e) Genes expressed differentially in low AE vs medium/high AE study subjects on post-vaccine day +1","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"BCL2L14,CNDP2,IDO1,KRT9,LNX2,LRRC75B,METTL6,PLAAT4,RMI2,TGM2",10,"BCL2L14,CNDP2,IDO1,KRT9,LNX2,LRRC75B,METTL6,PLAAT4,RMI2,TGM2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-Bcells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41011,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_CORRELATED_WITH_AGE_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,AGE,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_CORRELATED_WITH_AGE_1DY_POSITIVE,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes positively correlated with age in peripheral blood mononuclear cell in adults (18-64) after exposure to Pandemrix , time point 1D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"AK1,C1D,CACNA1I,CACNA2D2,CARD16,CD28,CD38,DOCK4,EEF2,ENO2,FGFBP2,HDAC4,IGFBP3,IL11RA,KIF21B,LIM2,LOC100505915,LPAR1,MCOLN2,MXI1,NETO2,NLRP1,OPTN,PRSS23,PYCR1,SYNE1,SYNM,TBX21,TNFRSF1A,VPS37A",30,"AK1,C1D,CACNA1I,CACNA2D2,CARD16,CD28,CD38,DOCK4,EEF2,ENO2,FGFBP2,HDAC4,IGFBP3,IL11RA,KIF21B,LIM2,LOC100505915,LPAR1,MCOLN2,MXI1,NETO2,NLRP1,OPTN,PRSS23,PYCR1,SYNE1,SYNM,TBX21,TNFRSF1A,VPS37A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/table/pone.0160970.t001/,NA,NA,NA,NA
M40867,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_VS_70PLS_0DY_UP,VIRUS,UP,CORRELATION,AGE,D0,D,0,21-30 vs 70+,ADULT VS ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_VS_70PLS_0DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell young adults vs seniors in young adults (21-30), seniors (70+) after exposure to Inactivated influenza vaccine , time point 0D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"AAK1,AGAP4,ALDOB,ARRDC5,CD248,CSAD,EP300,FCGBP,GTPBP3,IQSEC1,LINC01089,,LRRN3,NAA16,NPIPA1,NPIPB15,NSUN5P1,PDE7A,PPTC7,RAI1,SNORD4A,SREBF1,TUT4",23,"AAK1,AGAP4,ALDOB,ARRDC5,CD248,CSAD,EP300,FCGBP,GTPBP3,IQSEC1,LINC01089,LOC100190986,LRRN3,NARG1L,NPIP,NPIPB15,NSUN5B,PDE7A,PPTC7,RAI1,SNORD4A,SREBF1,ZCCHC11",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-Monocytes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41012,FLUAD,IN,INFLUENZA,NAKAYA_PBMC_FLUAD_IMUVAC_MALE_AGE_14_27YO_CORRELATED_WITH_HAI_RESPONSE_MF59_ADJUVANTED_AND_NON_1DY_GENES_IN_BTM_M75_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D1,D,1,14-27,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUAD_IMUVAC_MALE_AGE_14_27YO_CORRELATED_WITH_HAI_RESPONSE_MF59_ADJUVANTED_AND_NON_1DY_GENES_IN_BTM_M75_POSITIVE,"The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4(+) T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.","Genes positively correlated with HAI response in peripheral blood mononuclear cell in children (14-27m) (MF59-adjuvanted and non-adjuvanted) after exposure to Fluad/Imuvac , time point 1D. Comment: Genes in BTM M75","Nakaya HI,Clutterbuck E,Kazmin D,Wang L,Cortese M,Bosinger SE,Patel NB,Zak DE,Aderem A,Dong T,Del Giudice G,Rappuoli R,Cerundolo V,Pollard AJ,Pulendran B,Siegrist CA",26755593,HUMAN_GENE_SYMBOL,"ANXA3,BCL3,C1QB,CARD9,CXCL10,RIGI,DDX60,DHX58,HERC5,IFIH1,IFIT1,IL1B,IRF7,OAS1,OAS3,PML,RARA,RSAD2,SERPING1",19,"ANXA3,BCL3,C1QB,CARD9,CXCL10,DDX58,DDX60,DHX58,HERC5,IFIH1,IFIT1,IL1B,IRF7,OAS1,OAS3,PML,RARA,RSAD2,SERPING1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Fig 6a, Fig 4C",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F4/,NA,NA,NA,NA
M40902,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,D0,D,0,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_NEGATIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes negatively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 0D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"ACTG1,ADIPOR1,AP3D1,ARPC2,CAMK1G,CAMK2A,SPICE1,FBXO7,FBXO9,FSTL4,GNA12,IL17REL,MCRS1,NINJ2",14,"ACTG1,ADIPOR1,AP3D1,ARPC2,CAMK1G,CAMK2A,CCDC52,FBXO7,FBXO9,FSTL4,GNA12,IL17REL,MCRS1,NINJ2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 4a,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/#S1,NA,NA,NA,NA
M41051,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D0,D,0,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_0DY_POSITIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes positively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 0D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"GCNA,AHSA2P,BLK,BST2,SNRNP25,CD79B,DHX35,FCRLA,GABBR1,KCNG1,LMTK3,LTB,LYRM4,MED22,MIR600HG,PAOX,PIBF1,RINL,SAT2,SUSD3,TCL1A,UBE2Z",22,"ACRC,AHSA2,BLK,BST2,C16orf33,CD79B,DHX35,FCRLA,GABBR1,KCNG1,LMTK3,LTB,LYRM4,MED22,MIR600HG,PAOX,PIBF1,RINL,SAT2,SUSD3,TCL1A,UBE2Z",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Results: Early BTM Signatures Induced in Whole Blood Post Vaccination Correlate with Later Serum Antibody Responses,NA,NA,NA,NA,NA
M40993,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,D1,D,1,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_NEGATIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes negatively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 1D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"ANKRD33,CARHSP1,KYAT1,CCDC92,CXCR6,DEFA1B,EML3,FADD,STRIP2,FKBP11,GLS,GMCL1,HSD17B12,KLHL22,MEF2D,MXD4,NCALD,NMNAT3,PIK3IP1,PRKDC,TOX2",21,"ANKRD33,CARHSP1,CCBL1,CCDC92,CXCR6,DEFA1B,EML3,FADD,FAM40B,FKBP11,GLS,GMCL1,HSD17B12,KLHL22,MEF2D,MXD4,NCALD,NMNAT3,PIK3IP1,PRKDC,TOX2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/table/T2/,NA,NA,NA,NA
M41110,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D1,D,1,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_1DY_POSITIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes positively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 1D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"ACOT9,AIM2,ANKRD22,APOL3,ATF3,ATF5,BATF2,BLVRA,SCIMP,C1GALT1C1,C3AR1,CASP1,CASP4,CASP5,CCR1,CD300A,CD74,CEACAM1,CMPK2,CREG1,CTSL,CUL1,RIGI,DDX60,DHX58,DRAP1,DYNLT1,TYMP,EIF2AK2,EPSTI1,FAM225A,FBXO6,FCER1G,FGL2,FRMD3,FZD2,GAS6,GBP1,GBP2,GBP4,GBP5,GCH1,HERC6,IFI16,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT3,IFITM1,IL15,IL1RN,IRF7,ISG15,ISG20,JAK2,KARS1,LAMP3,LAP3,LHFPL2,LMO2,LPGAT1,LY6E,LYSMD2,MLKL,MOV10,MT2A,MX1,MX2,MYOF,NCOA7,OAS1,OAS2,OAS3,OASL,OTOF,P2RY14,PANK2,PARP10,PARP12,PARP14,PARP9,PHF11,PLSCR1,PPCDC,HELZ2,PSMB9,PSME1,PTPRO,RGL1,RIPK2,RPAP3,RPS6KC1,RSAD2,SAMD4A,SAT1,SBNO2,SCARB2,SCO2,SLC6A12,SP110,SP140,STAT1,STAT2,STX11,TAP1,TCN2,TDRD7,TLR7,TMEM123,TMEM208,TNFSF13B,TOR1A,TRAFD1,TRIM22,TRIM5,TRIM56,TRIM6,UBE2L6,UNC93B1,WARS1,XAF1,ZBP1,ZC3HAV1,ZNF684,ZNFX1",129,"ACOT9,AIM2,ANKRD22,APOL3,ATF3,ATF5,BATF2,BLVRA,C17orf87,C1GALT1C1,C3AR1,CASP1,CASP4,CASP5,CCR1,CD300A,CD74,CEACAM1,CMPK2,CREG1,CTSL1,CUL1,DDX58,DDX60,DHX58,DRAP1,DYNLT1,ECGF1,EIF2AK2,EPSTI1,FAM225A,FBXO6,FCER1G,FGL2,FRMD3,FZD2,GAS6,GBP1,GBP2,GBP4,GBP5,GCH1,HERC6,IFI16,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT3,IFITM1,IL15,IL1RN,IRF7,ISG15,ISG20,JAK2,KARS,LAMP3,LAP3,LHFPL2,LMO2,LPGAT1,LY6E,LYSMD2,MLKL,MOV10,MT2A,MX1,MX2,MYOF,NCOA7,OAS1,OAS2,OAS3,OASL,OTOF,P2RY14,PANK2,PARP10,PARP12,PARP14,PARP9,PHF11,PLSCR1,PPCDC,PRIC285,PSMB9,PSME1,PTPRO,RGL1,RIPK2,RPAP3,RPS6KC1,RSAD2,SAMD4A,SAT1,SBNO2,SCARB2,SCO2,SLC6A12,SP110,SP140,STAT1,STAT2,STX11,TAP1,TCN2,TDRD7,TLR7,TMEM123,TMEM208,TNFSF13B,TOR1A,TRAFD1,TRIM22,TRIM5,TRIM56,TRIM6,UBE2L6,UNC93B1,WARS,XAF1,ZBP1,ZC3HAV1,ZNF684,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/table/T3/,NA,NA,NA,NA
M41168,FLUARIX FLUVIRIN,IN,INFLUENZA,BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_3DY_POSITIVE_PREDICTIVE_OF_TITER,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D1-D3,D,1-3,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_3DY_POSITIVE_PREDICTIVE_OF_TITER,"BACKGROUND: Annual vaccination is the primary means for preventing influenza. However, great interindividual variability exists in vaccine responses, the cellular events that take place in vivo after vaccination are poorly understood, and appropriate biomarkers for vaccine responsiveness have not been developed. METHODS: We immunized a cohort of healthy male adults with a licensed trivalent influenza vaccine and performed a timed assessment of global gene expression before and after vaccination. We analyzed the relationship between gene expression patterns and the humoral immune response to vaccination. RESULTS: Marked up regulation of expression of genes involved in interferon signaling, positive IL-6 regulation, and antigen processing and presentation, were detected within 24 hours of immunization. The late vaccine response showed a transcriptional pattern suggestive of increased protein biosynthesis and cellular proliferation. Integrative analyses revealed a 494-gene expression signature--including STAT1, CD74, and E2F2--which strongly correlates with the magnitude of the antibody response. High vaccine responder status correlates with increased early expression of interferon signaling and antigen processing and presentation genes. CONCLUSIONS: The results highlight the role of a systems biology approach in understanding the molecular events that take place in vivo after influenza vaccination and in the development of better predictors of vaccine responsiveness.","Genes positively correlated with titer response index in peripheral blood mononuclear cell in Caucasian male adults (18-40) (high responders) after exposure to Fluarix/Fluvirin , time point 1D and 3DY. Comment: Signature predictive of titer response index (TRI). Day 1 and day 3 values averaged.","Bucasas KL,Franco LM,Shaw CA,Bray MS,Wells JM,Nio D,Arden N,Quarles JM,Couch RB,Belmont JW",21357945,HUMAN_GENE_SYMBOL,"CD74,HLA-E,IRF9,SPI1,STAT1,TNFSF13B",6,"CD74,HLA-E,IRF9,SPI1,STAT1,TNFSF13B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M41090,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,D14,D,14,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_NEGATIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes negatively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 14D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"AKAP7,BANF2,BDKRB1,PRR14L,VSX2,DNASE1L1,DUSP5,EPPK1,FARP2,GPBAR1,IRX1,ITPRIPL2,KCMF1,KDM2B,MUC6,NAPA,NEXN,NPC2,PGLYRP4,PTPN6,RBMX2,RTF1,RXRG,SERPINA13P,SPATA13,STAC2,TIPRL,ZNF146",28,"AKAP7,BANF2,BDKRB1,C22orf30,CHX10,DNASE1L1,DUSP5,EPPK1,FARP2,GPBAR1,IRX1,ITPRIPL2,KCMF1,KDM2B,MUC6,NAPA,NEXN,NPC2,PGLYRP4,PTPN6,RBMX2,RTF1,RXRG,SERPINA13,SPATA13,STAC2,TIPRL,ZNF146",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Results: Early BTM Signatures Induced in Whole Blood Post Vaccination Correlate with Later Serum Antibody Responses,NA,NA,NA,NA,NA
M40940,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D14,D,14,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_14DY_POSITIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes positively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 14D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"ABCF2,ANAPC5,ANKRD10,UBR7,SWSAP1,CARMIL2,CCDC24,CD19,CD79A,CDR2,CXCR3,DHCR7,ECHDC2,HERC2,CCDC191,LRP5L,MCM7,MLH1,MRPL49,PNKD,PRKAB2,TRMT10B,ZNF514,ZNF558",24,"ABCF2,ANAPC5,ANKRD10,C14orf130,C19orf39,CARMIL2,CCDC24,CD19,CD79A,CDR2,CXCR3,DHCR7,ECHDC2,HERC2,KIAA1407,LRP5L,MCM7,MLH1,MRPL49,PNKD,PRKAB2,RG9MTD3,ZNF514,ZNF558",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400991/table/T2/,NA,NA,NA,NA
M41103,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE,VIRUS,UP,CORRELATION,ANTIBODY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_NEGATIVE,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes negatively correlated with HAI response at 28d in peripheral blood mononuclear cell in adults (18-50) after exposure to Fluarix/Fluvirin , time point 3D. Comment: Supplementary Table 5: All genes whose expression (d3/d0 or d7/d0) correlates to the fold increase in HAI titers (d28/d0).","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AFF3,AFF4,AHCTF1,AK3,AMD1,ANK3,ANKRD12,ANKRD36,APBA2,AQP3,ARHGAP24,ARL4C,ATF7IP2,ATP2B1,ATRX,ATXN7,B3GNT7,BACH2,BANK1,BBX,BCL11B,BCLAF1,BEX2,BEX4,BOLA2,BPGM,BRD1,C11orf58,TMEM263,C12orf29,C12orf57,C12orf75,RGCC,ADPRM,CTC1,URI1,ARMH1,ADTRP,TMEM243,SMIM19,CAMK4,CBLB,CBX5,CFAP36,CEP95,CCDC50,TRMT13,CCND2,CCNT1,CD28,CD3D,CD3G,CDC14B,CDC42SE2,CDK12,CDK17,CDR2,CEBPZ,CEP57,CEPT1,CETN2,CHD1,CHD2,CHIC1,CHORDC1,CIR1,UTP4,CLASP1,CLDND1,CLK4,CNOT6L,CNST,COX11,CREBRF,CTLA4,CWF19L2,DANCR,DBF4,DCAF16,DDHD1,DDX11L2,DDX47,DENND11,DHX36,DIS3,DLST,DNAJB1,DNAJB14,DNAJC2,DNTTIP2,DUSP11,DUSP4,EAPP,EBLN2,ECD,ELP2,EML4,ENDOD1,EPB41L4A-AS1,EPB42,ESCO1,EWSR1,EZR,FAM133B,FAM153A,,FAM162A,FAM169A,FAM20B,ATOSA,TENT5C,SINHCAF,FAM76B,FAM98B,FBXL3,FHL1,FNBP4,FOXO1,FOXP1,FUS,GAS5,GCOM1,GGNBP2,GGTA1,GKAP1,GNAS,GNB5,GNE,GOLGA8A,GOLGA8B,GON4L,GPAM,GPR183,GPRASP1,H2AZ2,HBP1,HEATR1,HGD,H1-3,HMGB1,HNRNPD,HSF2,IL6ST,ISCA1,ITGA6,ITGB3BP,ITK,ITM2A,ITPKB,ITPR1,IVNS1ABP,JAK1,KDM7A,JMY,JUND,KCNA3,KDM3A,KDM6A,ATG13,KIAA1143,VIRMA,KLF12,KLF9,KLHL24,KLRB1,KPNA3,KPNA5,KRR1,PPFIBP1,LCOR,LEF1,LINC02076,LMO7,LSG1,LUC7L2,LY9,MALAT1,MAML2,MAN1C1,MAP3K4,MATR3,MED21,MED23,MED30,METAP2,METTL16,METTL8,MEX3C,MFSD14A,MGAT4A,MLH3,MPHOSPH8,MSI2,MTF2,KAT6B,N4BP2,NAA25,NAE1,NAP1L5,NDFIP2,NEDD1,NGDN,NKTR,NOL11,NOL7,NOSIP,NR1D2,NUCB2,NUCKS1,NUFIP1,OCIAD2,OXNAD1,P2RY10,TENT4B,PASK,PCBP2,PDE4D,PDE4DIP,PHF20L1,PHF5A,PIK3CA,PIK3IP1,PIK3R1,PLA2G12A,PNISR,PNN,POLR2M,POLR3E,PPIG,PPM1A,PPP1CB,PPP1R16B,PPP1R2,PPP4R3A,PRKACB,PRKCQ,PRKRA,PRORP,PRRC2C,PSPC1,PTCD3,PTPN2,PTPN4,PTS,PURB,RAB30,RALGAPA1,RANBP2,RAPGEF6,RBM25,RBM38,RBM39,RC3H2,RCAN3,RGPD5,RHOH,RICTOR,RNF138,RNMT,RORA,RPL37,RSBN1,RSL24D1,RSRC2,RUNX3,RYK,SAR1A,SBDS,SCML1,CAVIN2,SECISBP2L,SEPSECS,SEPTIN2,SETD2,SF1,SFPQ,SRSF11,SRSF3,SRSF6,SFXN1,SGTB,SH2D1A,SH3YL1,SLC16A7,SLC25A36,SLC38A1,SLC4A7,SMC3,SMN1,SMN2,SNCA,SNHG1,SNHG8,SNRK,SNRPN,SOS2,SPTY2D1,SSBP1,STAT4,STK17A,STK4,STMN3,STT3B,SUPV3L1,SVIP,SYNCRIP,SYNE2,TAF4B,TAF9B,TBC1D15,TC2N,TGFBR2,THEMIS,THOC2,TIPARP,TM9SF3,TMEM106B,TMEM220,TNIK,TNKS,TNPO1,TOMM20,TPP2,TRAC,TRAPPC10,TRAT1,TRIM13,TSPYL1,TTC3,TTC32,TUBB1,TUBB6,TWF1,UFL1,USP12,USP16,USP36,USP47,USPL1,WASF2,WDR89,WTAP,YTHDC1,ZBTB25,ZBTB38,ZC3H11A,ZCCHC10,ZEB1,ZFR,ZMYM2,ZNF101,ZNF12,ZNF131,ZNF136,ZNF22,ZNF26,ZNF274,ZNF277,ZNF292,ZNF331,ZNF395,ZNF512B,ZNF814,ZNF92",364,"AFF3,AFF4,AHCTF1,AK3,AMD1,ANK3,ANKRD12,ANKRD36,APBA2,AQP3,ARHGAP24,ARL4C,ATF7IP2,ATP2B1,ATRX,ATXN7,B3GNT7,BACH2,BANK1,BBX,BCL11B,BCLAF1,BEX2,BEX4,BOLA2,BPGM,BRD1,C11orf58,C12orf23,C12orf29,C12orf57,C12orf75,C13orf15,C17orf48,C17orf68,C19orf2,C1orf228,C6orf105,C7orf23,C8orf40,CAMK4,CBLB,CBX5,CCDC104,CCDC45,CCDC50,CCDC76,CCND2,CCNT1,CD28,CD3D,CD3G,CDC14B,CDC42SE2,CDK12,CDK17,CDR2,CEBPZ,CEP57,CEPT1,CETN2,CHD1,CHD2,CHIC1,CHORDC1,CIR1,CIRH1A,CLASP1,CLDND1,CLK4,CNOT6L,CNST,COX11,CREBRF,CTLA4,CWF19L2,DANCR,DBF4,DCAF16,DDHD1,DDX11L2,DDX47,DENND11,DHX36,DIS3,DLST,DNAJB1,DNAJB14,DNAJC2,DNTTIP2,DUSP11,DUSP4,EAPP,EBLN2,ECD,ELP2,EML4,ENDOD1,EPB41L4A-AS1,EPB42,ESCO1,EWSR1,EZR,FAM133B,FAM153A,FAM153B,FAM162A,FAM169A,FAM20B,FAM214A,FAM46C,FAM60A,FAM76B,FAM98B,FBXL3,FHL1,FNBP4,FOXO1,FOXP1,FUS,GAS5,GCOM1,GGNBP2,GGTA1,GKAP1,GNAS,GNB5,GNE,GOLGA8A,GOLGA8B,GON4L,GPAM,GPR183,GPRASP1,H2AFV,HBP1,HEATR1,HGD,HIST1H1D,HMGB1,HNRNPD,HSF2,IL6ST,ISCA1,ITGA6,ITGB3BP,ITK,ITM2A,ITPKB,ITPR1,IVNS1ABP,JAK1,JHDM1D,JMY,JUND,KCNA3,KDM3A,KDM6A,KIAA0652,KIAA1143,KIAA1429,KLF12,KLF9,KLHL24,KLRB1,KPNA3,KPNA5,KRR1,L2,LCOR,LEF1,LINC02076,LMO7,LSG1,LUC7L2,LY9,MALAT1,MAML2,MAN1C1,MAP3K4,MATR3,MED21,MED23,MED30,METAP2,METTL16,METTL8,MEX3C,MFSD14A,MGAT4A,MLH3,MPHOSPH8,MSI2,MTF2,MYST4,N4BP2,NAA25,NAE1,NAP1L5,NDFIP2,NEDD1,NGDN,NKTR,NOL11,NOL7,NOSIP,NR1D2,NUCB2,NUCKS1,NUFIP1,OCIAD2,OXNAD1,P2RY10,PAPD5,PASK,PCBP2,PDE4D,PDE4DIP,PHF20L1,PHF5A,PIK3CA,PIK3IP1,PIK3R1,PLA2G12A,PNISR,PNN,POLR2M,POLR3E,PPIG,PPM1A,PPP1CB,PPP1R16B,PPP1R2,PPP4R3A,PRKACB,PRKCQ,PRKRA,PRORP,PRRC2C,PSPC1,PTCD3,PTPN2,PTPN4,PTS,PURB,RAB30,RALGAPA1,RANBP2,RAPGEF6,RBM25,RBM38,RBM39,RC3H2,RCAN3,RGPD5,RHOH,RICTOR,RNF138,RNMT,RORA,RPL37,RSBN1,RSL24D1,RSRC2,RUNX3,RYK,SAR1A,SBDS,SCML1,SDPR,SECISBP2L,SEPSECS,SEPT2,SETD2,SF1,SFPQ,SFRS11,SFRS3,SFRS6,SFXN1,SGTB,SH2D1A,SH3YL1,SLC16A7,SLC25A36,SLC38A1,SLC4A7,SMC3,SMN1,SMN2,SNCA,SNHG1,SNHG8,SNRK,SNRPN,SOS2,SPTY2D1,SSBP1,STAT4,STK17A,STK4,STMN3,STT3B,SUPV3L1,SVIP,SYNCRIP,SYNE2,TAF4B,TAF9B,TBC1D15,TC2N,TGFBR2,THEMIS,THOC2,TIPARP,TM9SF3,TMEM106B,TMEM220,TNIK,TNKS,TNPO1,TOMM20,TPP2,TRAC,TRAPPC10,TRAT1,TRIM13,TSPYL1,TTC3,TTC32,TUBB1,TUBB6,TWF1,UFL1,USP12,USP16,USP36,USP47,USPL1,WASF2,WDR89,WTAP,YTHDC1,ZBTB25,ZBTB38,ZC3H11A,ZCCHC10,ZEB1,ZFR,ZMYM2,ZNF101,ZNF12,ZNF131,ZNF136,ZNF22,ZNF26,ZNF274,ZNF277,ZNF292,ZNF331,ZNF395,ZNF512B,ZNF814,ZNF92",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41019,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_POSITIVE,VIRUS,UP,CORRELATION,ANTIBODY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_3DY_POSITIVE,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes positively correlated with HAI response at 28d in peripheral blood mononuclear cell in adults (18-50) after exposure to Fluarix/Fluvirin , time point 3D. Comment: Supplementary Table 5: All genes whose expression (d3/d0 or d7/d0) correlates to the fold increase in HAI titers (d28/d0).","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA7,ABHD2,ACLY,ACTR3,ADCY7,ADIPOR2,AGPS,AGTRAP,AHCYL1,AKR1A1,JAML,ANPEP,AP3S2,APAF1,APBB1IP,APEH,APH1B,APLP2,APOBR,APTX,AQP9,ARAP1,ARAP3,ARF3,ARHGAP9,ARPC1B,ARSD,ASGR2,ASH2L,ASRGL1,ATG7,ATP10D,ATP6AP1,ATP6V0A1,ATP6V0D1,ATP6V1A,ATP6V1B2,BEST1,BRI3,BTK,WBP1L,SMCO4,SPTSSA,DGLUCY,HYPK,USB1,MILR1,C1orf162,KIAA0930,ABHD18,C4orf48,CYREN,TRIQK,C9orf72,CALML4,CAMSAP1,CAP1,CAPG,CAPNS1,CAPZB,CARD8,CASP1,CASP10,COA3,CCPG1,CCR5,CD300A,CD36,CD4,CD53,CD58,CD93,ADA2,CFD,CHST15,CHURC1,CIDEB,CKLF,CLDN6,CLEC4E,CLMN,CLTA,CNIH4,CORO1A,CORO1B,COX15,CPPED1,CR1,CREB5,CRLS1,CSF1R,CSF2RB,CSF3R,CSK,CSTB,CTBP2,CTSD,CX3CR1,CYFIP1,DAGLB,DAPK1,DAXX,DBT,DCAF7,DCUN1D1,DDB2,RIGI,DENR,DFFA,DGAT2,DHRS9,DMXL2,DPYSL2,DRAM1,VPS26C,DUSP18,EEFSEC,EFHD2,AGO4,EIF4E2,ENTPD1,ENTPD4,ERICH1,HYCC1,RTL8C,FAM193A,DENND10,RIPOR2,FAR2,FBXL5,FGD2,FGD4,FGL2,FKBP15,,FNDC3B,FPGT,FPR2,FRAT1,FRAT2,GAA,GALNT2,GALNT7,GAPT,GBA1,GCA,GCNT1,GCNT2,SLX1B,GK,GLRX,GLT1D1,GNS,GPBAR1,GRAMD4,GRN,GSN,HAL,HCK,HDAC5,PUDP,HDLBP,HK1,HK3,HMBS,JPT1,HNRNPAB,HS1BP3,HSPA6,IDH1,IFI30,IFITM2,IFITM3,IFNAR1,IFNGR2,IL10RB,IL17RA,ILK,IMPA2,IQGAP1,IRF2,ITGAX,JAGN1,JUP,KCNE3,KCNJ15,KCNJ2,KCNK6,KCNMB1,KDELR1,KDELR2,KIAA0513,KIAA2013,KIR2DL2,KIR3DL1,KIR3DL2,LAIR1,LAMP2,LARP4B,LAT2,LILRA1,LILRA2,LILRA3,LILRA6,LILRB1,LILRB2,LILRB3,ANXA2R-AS1,,LRP1,LRRK2,LST1,LYL1,LYST,M6PR,MAP2K3,MAP2K4,MAPK1,MAPKAPK3,MBOAT1,MBOAT7,MCCC2,MEGF9,MGST2,MGST3,MICU1,MIR21,MNDA,MOB3A,MOGS,MOSPD2,MPEG1,IRAG1,MS4A7,MSL1,MSRB2,NAAA,NADK,NAGA,NAGK,NAIP,NCF1,NCF1B,NCF1C,NCF2,NCF4,NDUFB3,NEK9,NLRP12,NME6,NOD2,NOL12,NPL,NQO2,NUDT16,OGDH,ORAI3,ORMDL2,OS9,OSBPL11,OSTM1,P2RY13,PACSIN2,PADI2,PAK1,PANK2,PCGF6,PCID2,PECAM1,PEPD,PHKA2,PIK3AP1,PILRA,PLXNC1,PMVK,POLR1D,POU2F2,PPARGC1A,PPCDC,PPID,PPM1L,PPP1R11,PPP1R18,PPP2CB,PRAM1,PRCP,PRDX1,PRDX3,PRELID1,PRKACA,PRKAR1A,PRKCD,PRMT5,PLPBP,PRRC2A,PRRG4,PSEN1,PTAFR,PTPN6,PTPRJ,PYCARD,QPCT,RAB10,RAB1B,RAB27A,RAB4B,RAB7A,RAB8A,RALBP1,RASSF2,RBM19,RBM47,RBP1,RCBTB2,REEP4,RGS14,RNF135,RNF149,RNF24,RNF31,RPS6KA1,RRAGD,RTN1,RXRA,S100A11,SASH1,SEC23B,SEC23IP,SECTM1,SELPLG,SEMA4A,MSRB1,SERF2,SERPINA1,SERPINB1,SREK1,SFT2D1,SGCD,SH3BP2,SIGLEC10,SIGLEC12,SIGLEC5,SIGLEC7,SIL1,SIRPA,SIRPB1,SIRPB2,SKAP2,SLAMF7,SLC11A1,SLC12A6,SLC22A15,SLC25A11,SLC27A3,SLC38A10,SLC6A6,SLC8A1,SLX1A,SMC1A,SNX1,SNX27,SORT1,SPTLC2,ST8SIA4,STAM2,STEAP4,STX3,STX6,STYXL1,SULT1A1,SULT1A3,SULT1A4,SUSD1,SYK,SYT11,TAF4,TBCE,TBXAS1,TCF7L2,TCIRG1,TET2,TFEB,THOC2,TIMP2,TLR5,TM9SF1,TMEFF2,TMEM107,TMEM179B,TMEM208,TMEM218,VMP1,TMEM80,TNFAIP2,TNFRSF1A,TNFSF12-TNFSF13,TNFSF13,TOR1A,TPI1,TPPP3,TRIM14,TRIOBP,TRPS1,TYMP,UBA1,UBASH3B,UBE2R2,UBE3C,UBR2,UBTD2,UEVLD,UVSSA,VAV1,VDR,VIPAS39,VNN2,VPS35,VRK3,WASHC5,WDFY3,WSB1,YWHAE,TUT7,ZMYM6,ZNF143,ZNF641,ZSWIM6,ZYX",428,"ABCA7,ABHD2,ACLY,ACTR3,ADCY7,ADIPOR2,AGPS,AGTRAP,AHCYL1,AKR1A1,AMICA1,ANPEP,AP3S2,APAF1,APBB1IP,APEH,APH1B,APLP2,APOB48R,APTX,AQP9,ARAP1,ARAP3,ARF3,ARHGAP9,ARPC1B,ARSD,ASGR2,ASH2L,ASRGL1,ATG7,ATP10D,ATP6AP1,ATP6V0A1,ATP6V0D1,ATP6V1A,ATP6V1B2,BEST1,BRI3,BTK,C10orf26,C11orf75,C14orf147,C14orf159,C15orf63,C16orf57,C17orf60,C1orf162,C22orf9,C4orf29,C4orf48,C7orf49,C8orf83,C9orf72,CALML4,CAMSAP1,CAP1,CAPG,CAPNS1,CAPZB,CARD8,CASP1,CASP10,CCDC56,CCPG1,CCR5,CD300A,CD36,CD4,CD53,CD58,CD93,CECR1,CFD,CHST15,CHURC1,CIDEB,CKLF,CLDN6,CLEC4E,CLMN,CLTA,CNIH4,CORO1A,CORO1B,COX15,CPPED1,CR1,CREB5,CRLS1,CSF1R,CSF2RB,CSF3R,CSK,CSTB,CTBP2,CTSD,CX3CR1,CYFIP1,DAGLB,DAPK1,DAXX,DBT,DCAF7,DCUN1D1,DDB2,DDX58,DENR,DFFA,DGAT2,DHRS9,DMXL2,DPYSL2,DRAM1,DSCR3,DUSP18,EEFSEC,EFHD2,EIF2C4,EIF4E2,ENTPD1,ENTPD4,ERICH1,FAM126A,FAM127A,FAM193A,FAM45A,FAM65B,FAR2,FBXL5,FGD2,FGD4,FGL2,FKBP15,FLJ45340,FNDC3B,FPGT,FPR2,FRAT1,FRAT2,GAA,GALNT2,GALNT7,GAPT,GBA,GCA,GCNT1,GCNT2,GIYD2,GK,GLRX,GLT1D1,GNS,GPBAR1,GRAMD4,GRN,GSN,HAL,HCK,HDAC5,HDHD1A,HDLBP,HK1,HK3,HMBS,HN1,HNRNPAB,HS1BP3,HSPA6,IDH1,IFI30,IFITM2,IFITM3,IFNAR1,IFNGR2,IL10RB,IL17RA,ILK,IMPA2,IQGAP1,IRF2,ITGAX,JAGN1,JUP,KCNE3,KCNJ15,KCNJ2,KCNK6,KCNMB1,KDELR1,KDELR2,KIAA0513,KIAA2013,KIR2DL2,KIR3DL1,KIR3DL2,LAIR1,LAMP2,LARP4B,LAT2,LILRA1,LILRA2,LILRA3,LILRA6,LILRB1,LILRB2,LILRB3,LOC153684,LOC729737,LRP1,LRRK2,LST1,LYL1,LYST,M6PR,MAP2K3,MAP2K4,MAPK1,MAPKAPK3,MBOAT1,MBOAT7,MCCC2,MEGF9,MGST2,MGST3,MICU1,MIR21,MNDA,MOBKL2A,MOGS,MOSPD2,MPEG1,MRVI1,MS4A7,MSL1,MSRB2,NAAA,NADK,NAGA,NAGK,NAIP,NCF1,NCF1B,NCF1C,NCF2,NCF4,NDUFB3,NEK9,NLRP12,NME6,NOD2,NOL12,NPL,NQO2,NUDT16,OGDH,ORAI3,ORMDL2,OS9,OSBPL11,OSTM1,P2RY13,PACSIN2,PADI2,PAK1,PANK2,PCGF6,PCID2,PECAM1,PEPD,PHKA2,PIK3AP1,PILRA,PLXNC1,PMVK,POLR1D,POU2F2,PPARGC1A,PPCDC,PPID,PPM1L,PPP1R11,PPP1R18,PPP2CB,PRAM1,PRCP,PRDX1,PRDX3,PRELID1,PRKACA,PRKAR1A,PRKCD,PRMT5,PROSC,PRRC2A,PRRG4,PSEN1,PTAFR,PTPN6,PTPRJ,PYCARD,QPCT,RAB10,RAB1B,RAB27A,RAB4B,RAB7A,RAB8A,RALBP1,RASSF2,RBM19,RBM47,RBP1,RCBTB2,REEP4,RGS14,RNF135,RNF149,RNF24,RNF31,RPS6KA1,RRAGD,RTN1,RXRA,S100A11,SASH1,SEC23B,SEC23IP,SECTM1,SELPLG,SEMA4A,SEPX1,SERF2,SERPINA1,SERPINB1,SFRS12,SFT2D1,SGCD,SH3BP2,SIGLEC10,SIGLEC12,SIGLEC5,SIGLEC7,SIL1,SIRPA,SIRPB1,SIRPB2,SKAP2,SLAMF7,SLC11A1,SLC12A6,SLC22A15,SLC25A11,SLC27A3,SLC38A10,SLC6A6,SLC8A1,SLX1A,SMC1A,SNX1,SNX27,SORT1,SPTLC2,ST8SIA4,STAM2,STEAP4,STX3,STX6,STYXL1,SULT1A1,SULT1A3,SULT1A4,SUSD1,SYK,SYT11,TAF4,TBCE,TBXAS1,TCF7L2,TCIRG1,TET2,TFEB,THOC2,TIMP2,TLR5,TM9SF1,TMEFF2,TMEM107,TMEM179B,TMEM208,TMEM218,TMEM49,TMEM80,TNFAIP2,TNFRSF1A,TNFSF12-TNFSF13,TNFSF13,TOR1A,TPI1,TPPP3,TRIM14,TRIOBP,TRPS1,TYMP,UBA1,UBASH3B,UBE2R2,UBE3C,UBR2,UBTD2,UEVLD,UVSSA,VAV1,VDR,VIPAR,VNN2,VPS35,VRK3,WASHC5,WDFY3,WSB1,YWHAE,ZCCHC6,ZMYM6,ZNF143,ZNF641,ZSWIM6,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41040,SANOFI INFLUENZA,IN,INFLUENZA,FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_3DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D3,D,3,18-40,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FRANCO_BLOOD_SANOFI_PASTEUR_SA_INACTIVATED_INFLUENZA_VACCINE_CORRELATED_WITH_ANTIBODY_RESPONSE_AGE_18_40YO_3DY_POSITIVE,"Identification of the host genetic factors that contribute to variation in vaccine responsiveness may uncover important mechanisms affecting vaccine efficacy. We carried out an integrative, longitudinal study combining genetic, transcriptional, and immunologic data in humans given seasonal influenza vaccine. We identified 20 genes exhibiting a transcriptional response to vaccination, significant genotype effects on gene expression, and correlation between the transcriptional and antibody responses. The results show that variation at the level of genes involved in membrane trafficking and antigen processing significantly influences the human response to influenza vaccination. More broadly, we demonstrate that an integrative study design is an efficient alternative to existing methods for the identification of genes involved in complex traits. DOI:http://dx.doi.org/10.7554/eLife.00299.001.","Genes positively correlated with antibody response in blood in adults (18-40) after exposure to Sanofi Pasteur, SA, Inactivated influenza vaccine , time point 3D","Franco LM,Bucasas KL,Wells JM,Nio D,Wang X,Zapata GE,Arden N,Renwick A,Yu P,Quarles JM,Bray MS,Couch RB,Belmont JW,Shaw CA",23878721,HUMAN_GENE_SYMBOL,"ATXN7L2,CDK5RAP2,CEACAM1,CYFIP1,EMILIN2,HIPK2,IL4R,JUP,LUC7L,MERTK,CCL18,PATL1,PPP1R16A,PTPRA,RRBP1,,SNX29,TBC1D2,TIMM44",19,"ATXN7L2,CDK5RAP2,CEACAM1,CYFIP1,EMILIN2,HIPK2,IL4R,JUP,LUC7L,MERTK,PARC,PATL1,PPP1R16A,PTPRA,RRBP1,RYDEN,SNX29,TBC1D2,TIMM44",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/table/T5/,NA,NA,NA,NA
M40991,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE,VIRUS,UP,CORRELATION,ANTIBODY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_NEGATIVE,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes negatively correlated with HAI response at 28d in peripheral blood mononuclear cell in adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D. Comment: Supplementary Table 5: All genes whose expression (d3/d0 or d7/d0) correlates to the fold increase in HAI titers (d28/d0).","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ACBD6,ADAM28,AFF3,AFF4,AHCTF1,AIMP1,AIMP2,AKT3,AMD1,ANK3,ANKLE2,ANKRD44,ANKZF1,AP1G1,APOOL,ARF1,ARHGEF7,ARID2,ARIH1,ARL4C,ARPP19,ASCC3,ASXL1,ATAD2B,ATF2,ATF6B,ATG13,ATG14,ATG16L1,ATP11B,ATP1B1,ATP9B,ATXN2L,AZI2,B4GALT1,BACH2,BAG4,BANK1,BAX,BBX,BCL11B,BCLAF1,BLK,BOD1,BRD1,CFAP68,C11orf58,RGCC,VCPKMT,CFAP20,CTC1,URI1,ZSWIM9,ARMH1,RSRP1,C2orf49,CALM1,CAMK2G,CAMK4,CBX5,CCAR1,CEP95,CCDC50,CCDC66,TRMT13,CCNL1,CCNT1,CCNYL1,CD44,CD6,CD69,CD8B,CD96,CDC42,CDC42SE1,CDC5L,CEP68,CHD1,CHERP,CLASP1,CLEC2D,CLINT1,CLK1,CNOT4,CNOT6L,CREBZF,CSNK1A1,CSRNP1,CTLA4,CTNNB1,CUL4B,CWF19L2,CXorf65,CYB5R3,CYCS,CYLD,DBR1,DCK,DDX24,INTS6L,DDX3X,DENND11,DGKA,DHX30,DHX40,DHX9,DIS3L2,DLST,DNAH1,DNAJB1,DOCK9,DUSP10,DUSP4,DYNC1LI2,DYRK2,E4F1,ECPAS,EHBP1,EHMT1,EIF1,EIF4A2,ELF1,EML4,ENDOD1,ENOSF1,EPC1,EZR,FAM117B,FAM120AOS,PABIR3,NIBAN3,FAM153A,,FAM153CP,COX20,SINHCAF,,FAM85B,FAM98B,FBXL17,FBXO16,FBXO28,FCRL1,FCRL2,FGD3,FHIT,KLF3-AS1,FLT3LG,FNBP4,FOXP1,FUS,FYTTD1,G3BP2,GADD45GIP1,GALNT3,GAS5,GATA3,GFM1,GIGYF2,GKAP1,GNAS,GNE,GOLGA8A,GOLGA8B,GON4L,GOPC,GPR18,GPRASP1,GPS1,GRAMD1B,GTF3A,HBP1,HEATR1,HECA,HECTD1,HELB,HELQ,HERC2P3,HINT1,HIPK1,H2BC8,HLA-DQA1,HNRNPA1,HNRNPH1,HNRNPL,HNRNPM,HOXA7,HP1BP3,HPCAL1,IFT80,IGF1R,IKBKE,IFNLR1,IL6ST,PATJ,INPP5B,INPP5D,IPO11,ITPKB,IVD,JMY,JUN,JUND,KBTBD8,KCTD9,KDM6A,VIRMA,EPG5,KLF12,KLF3,KLF6,KLF9,KLHL24,KLHL28,KPNA4,KPNA5,KRR1,PPFIBP1,LCOR,LEF1,LINS1,,LONP2,LPP,LRRC70,LRRFIP1,LUZP1,LY9,MALAT1,MAP2K7,MAP3K1,MAP3K2,MBD4,MBNL1,MCOLN2,MDM4,MED1,MED14,MED17,MED21,MED30,MED6,METTL14,METTL3,METTL8,MIAT,MIER3,MKLN1,MPHOSPH9,MPZL3,MS4A1,MSI2,MTMR14,MYLIP,KAT6B,NAA25,NAP1L5,BBIP1,NGDN,NGRN,NKTR,NMT2,NOMO1,NOMO2,NOMO3,NR1D2,NR4A2,NR4A3,NRIP1,NSFL1C,NT5E,NUFIP2,NUMA1,NUP54,NUP58,OCLN,OGT,P2RX4,P2RY10,PABPC1,TENT4B,PCBP2,PCYOX1L,PDAP1,PDE7A,PDP1,PDXDC1,PHACTR2,PHC3,PHF20L1,PHF3,PHF5A,PHKB,PIAS2,PIGA,PIGL,PIK3R1,PLA2G12A,PLXDC1,PMAIP1,PNO1,POLR1C,PPIA,PPM1A,PPM1K,PPP1R15A,PPP1R2,PPP2R5C,PPP4R3A,PRPF3,PRPF4B,PSIP1,PSMB7,PSME4,PTCD3,PTK2,PTP4A1,PTS,PVALB,QRSL1,RAB11FIP2,RAB3IP,RAB5A,RAB5B,RAB8B,RALGAPB,RANBP2,RAP2A,RAP2B,RBBP6,RBM14,RBM18,RBM25,RBM34,RBM39,RBM4,RBM8A,RBSN,RFX7,RGPD1,RGPD2,RGPD3,RGPD4,RGPD5,RGPD6,RGPD8,RGS1,RHBDD1,RICTOR,RIF1,RIMKLB,RNF138,RNMT,RORA,RPL37,RPRD1B,RPS27,RPS6KB1,RUFY3,SAMHD1,SBDS,SBNO2,MSMO1,SEPTIN6,SERPINF1,SF1,SFI1,SFPQ,SUGP2,SCAF4,SRSF3,SRSF5,SRSF6,SRSF7,SFSWAP,SFXN3,SGTB,SIN3A,SLAMF1,SLC11A2,SLC16A7,SLC25A36,SLC5A6,SLC7A6,SLFN12,SMCR8,SMG1,SNX9,SPG7,SPOCK2,SPTBN1,SSB,SSBP2,STAG3L1,STAG3L2,STAG3L4,STAMBPL1,STAP1,STAT3,STAT4,STAT5B,STK17A,STK4,STRAP,SUMO1,SUPV3L1,SYS1,TAF15,TAGAP,TBC1D4,TCP11L2,TESPA1,TFAM,TGFBR2,TGIF1,THEMIS,TIGD1,TLE4,TM2D3,TMED5,TMEM170A,PIP4P1,TMEM63A,TNFRSF25,TNKS2,TOPORS,TRA2B,TRAF3IP3,TRAF5,TRAPPC10,TRAT1,TRIB2,TRPM7,TSC22D3,TSPYL1,TSPYL2,TWF1,POLR1F,UBE2B,UBE2D3,UBE2G2,UBE3A,UBXN7,UHMK1,UNK,UROS,USF3,USP36,USP48,UXS1,WDR75,YPEL5,YRDC,YTHDC1,YTHDC2,ZBTB10,ZBTB11,ZEB1,ZFP90,ZFR,ZFX,ZMYM2,ZMYM5,ZNF12,ZNF136,ZNF195,ZNF202,ZNF274,ZBTB21,ZNF317,ZNF318,ZNF395,ZNF430,ZNF451,ZNF507,ZNF655,ZNF814",477,"ACBD6,ADAM28,AFF3,AFF4,AHCTF1,AIMP1,AIMP2,AKT3,AMD1,ANK3,ANKLE2,ANKRD44,ANKZF1,AP1G1,APOOL,ARF1,ARHGEF7,ARID2,ARIH1,ARL4C,ARPP19,ASCC3,ASXL1,ATAD2B,ATF2,ATF6B,ATG13,ATG14,ATG16L1,ATP11B,ATP1B1,ATP9B,ATXN2L,AZI2,B4GALT1,BACH2,BAG4,BANK1,BAX,BBX,BCL11B,BCLAF1,BLK,BOD1,BRD1,C11orf1,C11orf58,C13orf15,C14orf138,C16orf80,C17orf68,C19orf2,C19orf68,C1orf228,C1orf63,C2orf49,CALM1,CAMK2G,CAMK4,CBX5,CCAR1,CCDC45,CCDC50,CCDC66,CCDC76,CCNL1,CCNT1,CCNYL1,CD44,CD6,CD69,CD8B,CD96,CDC42,CDC42SE1,CDC5L,CEP68,CHD1,CHERP,CLASP1,CLEC2D,CLINT1,CLK1,CNOT4,CNOT6L,CREBZF,CSNK1A1,CSRNP1,CTLA4,CTNNB1,CUL4B,CWF19L2,CXorf65,CYB5R3,CYCS,CYLD,DBR1,DCK,DDX24,DDX26B,DDX3X,DENND11,DGKA,DHX30,DHX40,DHX9,DIS3L2,DLST,DNAH1,DNAJB1,DOCK9,DUSP10,DUSP4,DYNC1LI2,DYRK2,E4F1,ECPAS,EHBP1,EHMT1,EIF1,EIF4A2,ELF1,EML4,ENDOD1,ENOSF1,EPC1,EZR,FAM117B,FAM120AOS,FAM122C,FAM129C,FAM153A,FAM153B,FAM153C,FAM36A,FAM60A,FAM85A,FAM85B,FAM98B,FBXL17,FBXO16,FBXO28,FCRL1,FCRL2,FGD3,FHIT,FLJ13197,FLT3LG,FNBP4,FOXP1,FUS,FYTTD1,G3BP2,GADD45GIP1,GALNT3,GAS5,GATA3,GFM1,GIGYF2,GKAP1,GNAS,GNE,GOLGA8A,GOLGA8B,GON4L,GOPC,GPR18,GPRASP1,GPS1,GRAMD1B,GTF3A,HBP1,HEATR1,HECA,HECTD1,HELB,HELQ,HERC2P3,HINT1,HIPK1,HIST1H2BG,HLA-DQA1,HNRNPA1,HNRNPH1,HNRNPL,HNRNPM,HOXA7,HP1BP3,HPCAL1,IFT80,IGF1R,IKBKE,IL28RA,IL6ST,INADL,INPP5B,INPP5D,IPO11,ITPKB,IVD,JMY,JUN,JUND,KBTBD8,KCTD9,KDM6A,KIAA1429,KIAA1632,KLF12,KLF3,KLF6,KLF9,KLHL24,KLHL28,KPNA4,KPNA5,KRR1,L2,LCOR,LEF1,LINS1,LOC114224,LONP2,LPP,LRRC70,LRRFIP1,LUZP1,LY9,MALAT1,MAP2K7,MAP3K1,MAP3K2,MBD4,MBNL1,MCOLN2,MDM4,MED1,MED14,MED17,MED21,MED30,MED6,METTL14,METTL3,METTL8,MIAT,MIER3,MKLN1,MPHOSPH9,MPZL3,MS4A1,MSI2,MTMR14,MYLIP,MYST4,NAA25,NAP1L5,NCRNA00081,NGDN,NGRN,NKTR,NMT2,NOMO1,NOMO2,NOMO3,NR1D2,NR4A2,NR4A3,NRIP1,NSFL1C,NT5E,NUFIP2,NUMA1,NUP54,NUPL1,OCLN,OGT,P2RX4,P2RY10,PABPC1,PAPD5,PCBP2,PCYOX1L,PDAP1,PDE7A,PDP1,PDXDC1,PHACTR2,PHC3,PHF20L1,PHF3,PHF5A,PHKB,PIAS2,PIGA,PIGL,PIK3R1,PLA2G12A,PLXDC1,PMAIP1,PNO1,POLR1C,PPIA,PPM1A,PPM1K,PPP1R15A,PPP1R2,PPP2R5C,PPP4R3A,PRPF3,PRPF4B,PSIP1,PSMB7,PSME4,PTCD3,PTK2,PTP4A1,PTS,PVALB,QRSL1,RAB11FIP2,RAB3IP,RAB5A,RAB5B,RAB8B,RALGAPB,RANBP2,RAP2A,RAP2B,RBBP6,RBM14,RBM18,RBM25,RBM34,RBM39,RBM4,RBM8A,RBSN,RFX7,RGPD1,RGPD2,RGPD3,RGPD4,RGPD5,RGPD6,RGPD8,RGS1,RHBDD1,RICTOR,RIF1,RIMKLB,RNF138,RNMT,RORA,RPL37,RPRD1B,RPS27,RPS6KB1,RUFY3,SAMHD1,SBDS,SBNO2,SC4MOL,SEPT6,SERPINF1,SF1,SFI1,SFPQ,SFRS14,SFRS15,SFRS3,SFRS5,SFRS6,SFRS7,SFRS8,SFXN3,SGTB,SIN3A,SLAMF1,SLC11A2,SLC16A7,SLC25A36,SLC5A6,SLC7A6,SLFN12,SMCR8,SMG1,SNX9,SPG7,SPOCK2,SPTBN1,SSB,SSBP2,STAG3L1,STAG3L2,STAG3L4,STAMBPL1,STAP1,STAT3,STAT4,STAT5B,STK17A,STK4,STRAP,SUMO1,SUPV3L1,SYS1,TAF15,TAGAP,TBC1D4,TCP11L2,TESPA1,TFAM,TGFBR2,TGIF1,THEMIS,TIGD1,TLE4,TM2D3,TMED5,TMEM170A,TMEM55B,TMEM63A,TNFRSF25,TNKS2,TOPORS,TRA2B,TRAF3IP3,TRAF5,TRAPPC10,TRAT1,TRIB2,TRPM7,TSC22D3,TSPYL1,TSPYL2,TWF1,TWISTNB,UBE2B,UBE2D3,UBE2G2,UBE3A,UBXN7,UHMK1,UNK,UROS,USF3,USP36,USP48,UXS1,WDR75,YPEL5,YRDC,YTHDC1,YTHDC2,ZBTB10,ZBTB11,ZEB1,ZFP90,ZFR,ZFX,ZMYM2,ZMYM5,ZNF12,ZNF136,ZNF195,ZNF202,ZNF274,ZNF295,ZNF317,ZNF318,ZNF395,ZNF430,ZNF451,ZNF507,ZNF655,ZNF814",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41204,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_POSITIVE,VIRUS,UP,CORRELATION,ANTIBODY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_POSITIVE,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes positively correlated with HAI response at 28d in peripheral blood mononuclear cell in adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D. Comment: Supplementary Table 5: All genes whose expression (d3/d0 or d7/d0) correlates to the fold increase in HAI titers (d28/d0).","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ACO2,AP3S2,APOBEC3B,ARAP3,ATP1B3,ATP6V1A,AURKAIP1,BTK,TMEM258,MFSD12,CALML4,CARHSP1,CAV1,CCDC18,CCNA2,CCPG1,CD38,CD59,CD93,CENPW,CHCHD1,CHERP,CIDEB,CKLF,CLC,CLMN,CLPTM1L,CR1,CREB3L2,CRELD2,CSF1R,CTNNA1,CXCR1,,DAPK1,DGAT2,DNAH1,EAF2,EMSY,ENTPD1,ERLEC1,EYA3,INKA2,FGD4,FLOT1,FNDC3B,GEMIN7,GGH,SLX1B,GP1BB,HDLBP,HSP90B1,HYOU1,,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHG4,IGHM,IGHV4-31,,IGKC,IGKV1D-33,IGKV3-20,,IGLC1,IGLL1,IGLL5,IGLV1-44,IGLV3-16,IGLV3-25,ITPK1,KCNJ2,KDELR2,EMC1,KIAA2013,LRP10,MAN1A1,MANEA,MANF,MAP2K4,MCCC2,MESD,METTL7A,MLEC,MORN1,MRPL51,BLOC1S5,MYDGF,MZB1,NDUFB3,NDUFB6,NFIB,NIPSNAP1,NOMO1,NOMO2,NOMO3,OPCML,ORMDL2,P4HB,PALLD,PDIA4,PDIA6,PDXK,PECAM1,PITPNA,PLCG2,PNOC,POU2AF1,PLPP5,PPCDC,PRDX1,PRDX3,PLPBP,PSMD14,RBM26,RHOG,RNF31,RPN1,RPN2,RPS27L,RRM2,RUNX1,S100A11,SCAMP2,SEC11C,SEC24D,SEMA4A,SFT2D1,SHMT2,SIGLEC10,SIGLEC12,SLAMF7,SLC17A9,SLC30A1,SLC35B1,SLC38A10,SLC44A1,SLX1A,SNRNP25,SPCS2,SRPK1,SRPRA,SSR1,STOX2,TIMM8B,TMEM165,TMEM176A,TNFRSF17,TP53INP1,TRAC,TXNDC15,TXNDC5,TYMS,UBE2C,UBE2J1,UBXN2B,UGGT1,UQCC3,UQCRQ,VRK3,WNK2,ZNF124,ZWINT",166,"ACO2,AP3S2,APOBEC3B,ARAP3,ATP1B3,ATP6V1A,AURKAIP1,BTK,C11orf10,C19orf28,CALML4,CARHSP1,CAV1,CCDC18,CCNA2,CCPG1,CD38,CD59,CD93,CENPW,CHCHD1,CHERP,CIDEB,CKLF,CLC,CLMN,CLPTM1L,CR1,CREB3L2,CRELD2,CSF1R,CTNNA1,CXCR1,CYAT1,DAPK1,DGAT2,DNAH1,EAF2,EMSY,ENTPD1,ERLEC1,EYA3,FAM212B,FGD4,FLOT1,FNDC3B,GEMIN7,GGH,GIYD2,GP1BB,HDLBP,HSP90B1,HYOU1,IGH,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHG4,IGHM,IGHV4-31,IGK,IGKC,IGKV1D-33,IGKV3-20,IGL,IGLC1,IGLL1,IGLL5,IGLV1-44,IGLV3-16,IGLV3-25,ITPK1,KCNJ2,KDELR2,KIAA0090,KIAA2013,LRP10,MAN1A1,MANEA,MANF,MAP2K4,MCCC2,MESDC2,METTL7A,MLEC,MORN1,MRPL51,MUTED,MYDGF,MZB1,NDUFB3,NDUFB6,NFIB,NIPSNAP1,NOMO1,NOMO2,NOMO3,OPCML,ORMDL2,P4HB,PALLD,PDIA4,PDIA6,PDXK,PECAM1,PITPNA,PLCG2,PNOC,POU2AF1,PPAPDC1B,PPCDC,PRDX1,PRDX3,PROSC,PSMD14,RBM26,RHOG,RNF31,RPN1,RPN2,RPS27L,RRM2,RUNX1,S100A11,SCAMP2,SEC11C,SEC24D,SEMA4A,SFT2D1,SHMT2,SIGLEC10,SIGLEC12,SLAMF7,SLC17A9,SLC30A1,SLC35B1,SLC38A10,SLC44A1,SLX1A,SNRNP25,SPCS2,SRPK1,SRPR,SSR1,STOX2,TIMM8B,TMEM165,TMEM176A,TNFRSF17,TP53INP1,TRAC,TXNDC15,TXNDC5,TYMS,UBE2C,UBE2J1,UBXN2B,UGGT1,UQCC3,UQCRQ,VRK3,WNK2,ZNF124,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711596/figure/F1/,NA,NA,NA,NA
M41115,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,D0,D,0,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 0D","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"ABCB7,ACO2,ADAM17,AHNAK2,AJAP1,ALDH2,ANO10,ANO8,AOAH,AP3B1,APOM,APP,ARF1,ARHGAP24,ARID3A,ARL8A,ASAH1,ASAP1,ASCC2,ATP11C,ATP1B1,ATP6V0B,ATP6V0C,ATP6V1F,AZU1,BACH1,BAHCC1,BCL2L2-PABPN1,BCL6,BMI1,BNIP2,BNIP3L,BOP1,BRI3BP,CCDC186,ANAPC15,GPATCH2L,IGBP1P1,ST20-AS1,NATD1,,C19orf38,RHEX,C2orf49,XXYLT1,PXDC1,GINM1,LINC02908,ABITRAM,CADM4,CAMK1D,CBX6,CCDC47,CCDC50,CCDC6,CCDC86,CCDC88A,CCNYL1,CD300C,CDA,CDC40,CDC42EP1,CDK8,CDKN1A,CEBPB,CEBPD,CEP170,CERS6,CHML,CHPT1,CIDEB,CIITA,CLDN23,CLEC4C,CLEC6A,CLPB,CREB5,CRISPLD2,YBX3P1,CSDE1,CSNK1A1L,CSNK1A1P1,CTAGE7P,CUX2,CXXC5,DACH1,DCUN1D1,DENND1A,DENND5A,DERA,DHX40,AP5B1,DNAJC11,DOCK4,DSG2,DTX2P1-UPK3BP1-PMS2P11,DYM,DYSF,EIF2AK2,EIF4E2,EIF4H,ELOF1,EME2,ENPP2,EPHA2,EPHX1,ERC1,ERCC5,FAAH,FAM151B,FAM168A,WASHC2A,WASHC2C,FCHSD2,FRRS1,FSCN1,FUT4,G0S2,GAB2,GALNS,GANC,GAS2L3,GAS7,GATAD1,NIPSNAP2,GLIS3,GLUD2,GMEB1,GMFB,GNA11,GNA15,GNAQ,GNL2,GOLIM4,GPM6B,ADGRA2,GPR157,GRAMD1B,GRIK5,GRINA,GTF3C4,GUCY2D,MROH1,HINT3,HLA-DMA,HLA-DMB,HLA-DRA,HNRNPH2,HSF1,HTR7P1,IDH3A,IER2,IFT20,IL18,CXCL8,INCENP,INO80B,IRF8,JAG1,JUN,KAT5,KCNC3,KCNK17,KCNQ1,KCTD3,KHSRP,MACF1,SOGA1,RIC1,MAP3K21,KIAA1958,KIF13A,KLF10,KLF4,KLF7,KLHL8,KPNA3,KRT23,KSR1,LDLRAD3,LENG9,P3H2,LGALS8,LGR4,LILRA4,LIN7A,,,ENSG00000272447,ENSG00000280852,,LRG1,NRROS,LRRC4,LRRC58,LRRC59,LRRK1,LTA4H,LTB4R2,LYZ,MAML3,MAN2A1,MAP1LC3B2,MAP2K7,MAP3K3,MAPK6,MAPK7,MAPRE1,MARVELD1,MBD6,MED13L,MED25,MEF2A,MEMO1,TLNRD1,MICAL2,MID1IP1,MKNK2,MKRN9P,MLX,MLXIP,MME,MOB1A,MOB3A,MPP7,MRPS22,MTMR14,MTX1,N4BP2,NAB1,NAB2,NCF1,NCOR2,NEK6,NETO2,NEU3,NFIC,NFIL3,NINJ1,NKIRAS2,NPEPL1,NRIP1,NRP1,NUBP1,NUDT17,NUDT3,NUP58,OAF,OCRL,OGFRL1,OLIG1,OPN3,P2RY11,PABPC1P2,PABPC3,PAK1IP1,PANK3,PANX2,PAPLN,PCDHGC3,PEAK1,PELI2,PEMT,PGAM2,PHKA2,PI4KA,PI4KAP2,PIAS4,PIK3CB,PIP5K1B,PISD,PJA2,PLAGL1,PLBD1,PLEK,PLEKHM2,PLEKHM3,PLXDC2,PNPLA2,POM121,PPM1J,PPP2R5B,PPP4R2,PPTC7,PRKACG,PRKAR2A,PSMB7,PSMD3,PTENP1,PTGS2,PXK,RAB11FIP2,RAB20,RAB5C,RARA,RASSF4,RDH14,REL,RELB,RFX2,RIN3,RIPK2,RNASE2,RNASEK,RNF130,RNF217,RNF24,RNF6,RNPEP,ROGDI,RPL7L1,RPS6KC1,RRAGC,RREB1,RRM2B,RSC1A1,RSRC1,SNX29,S1PR3,SAMD1,SCAMP2,SCAMP5,SCARB1,SCML2,SCN9A,SCPEP1,SCT,SDCBP,SDCCAG8,COA7,SERINC1,SERPINF1,SERTAD2,SETD7,SFT2D2,SGK3,SH3BP4,SHANK1,SIGLEC6,SLC12A6,SLC15A3,SLC16A5,SLC22A4,SLC2A9,SLC30A1,SLC36A4,SLC38A7,SLC9A7,SMAP2,SMARCB1,SMARCD3,SNX12,SNX2,SPEN,SPI1,SPOPL,SPRED2,SRGAP2B,SRRM2,ITPRID2,ST6GALNAC3,STRN4,STS,STX10,SULT1B1,SUMO1P3,SYK,SYS1-DBNDD2,TBC1D12,TBC1D14,TBC1D9,TCF4,TECPR1,TET3,TFE3,TIFAB,TM9SF2,TMED7,TMED7-TICAM2,TMEM144,TMEM150B,TMEM170B,TMEM183A,TMEM39B,TMEM86A,TMTC1,TMTC2,TNFRSF10B,TNFRSF21,TOR1AIP1,TPCN1,TRAM2,TRIM8,TRIO,TSNARE1,TSPAN16,TTC3P1,TTC7A,TUBGCP3,TXNDC5,TYROBP,UBE2MP1,UCHL3,UGCG,UGGT2,BLTP3A,BLTP3B,USP6NL,VEGFA,VENTXP7,VIM,VRK2,WBP11P1,WDFY4,WDR17,WLS,YPEL2,ZBED3,ZDHHC7,ZFAND3,ZFAT,ZFP36,ZFP91,ZFP91-CNTF,ZFP92,ZMIZ1,ZNF281,ZNF385A,ZNF426,ZNF487,ZNF496,ZNF503,ZNF511,ZNF689,ZNF697,ZNF703,ZNF768,ZNF791,ZNF844",439,"ABCB7,ACO2,ADAM17,AHNAK2,AJAP1,ALDH2,ANO10,ANO8,AOAH,AP3B1,APOM,APP,ARF1,ARHGAP24,ARID3A,ARL8A,ASAH1,ASAP1,ASCC2,ATP11C,ATP1B1,ATP6V0B,ATP6V0C,ATP6V1F,AZU1,BACH1,BAHCC1,BCL2L2-PABPN1,BCL6,BMI1,BNIP2,BNIP3L,BOP1,BRI3BP,C10orf118,C11orf51,C14orf118,C14orf19,C15orf37,C17orf103,C17orf61-PLSCR3,C19orf38,C1orf186,C2orf49,C3orf21,C6orf145,C6orf72,C9orf139,C9orf6,CADM4,CAMK1D,CBX6,CCDC47,CCDC50,CCDC6,CCDC86,CCDC88A,CCNYL1,CD300C,CDA,CDC40,CDC42EP1,CDK8,CDKN1A,CEBPB,CEBPD,CEP170,CERS6,CHML,CHPT1,CIDEB,CIITA,CLDN23,CLEC4C,CLEC6A,CLPB,CREB5,CRISPLD2,CSDAP1,CSDE1,CSNK1A1L,CSNK1A1P1,CTAGE7P,CUX2,CXXC5,DACH1,DCUN1D1,DENND1A,DENND5A,DERA,DHX40,DKFZp761E198,DNAJC11,DOCK4,DSG2,DTX2P1-UPK3BP1-PMS2P11,DYM,DYSF,EIF2AK2,EIF4E2,EIF4H,ELOF1,EME2,ENPP2,EPHA2,EPHX1,ERC1,ERCC5,FAAH,FAM151B,FAM168A,FAM21A,FAM21C,FCHSD2,FRRS1,FSCN1,FUT4,G0S2,GAB2,GALNS,GANC,GAS2L3,GAS7,GATAD1,GBAS,GLIS3,GLUD2,GMEB1,GMFB,GNA11,GNA15,GNAQ,GNL2,GOLIM4,GPM6B,GPR124,GPR157,GRAMD1B,GRIK5,GRINA,GTF3C4,GUCY2D,HEATR7A,HINT3,HLA-DMA,HLA-DMB,HLA-DRA,HNRNPH2,HSF1,HTR7P1,IDH3A,IER2,IFT20,IL18,IL8,INCENP,INO80B,IRF8,JAG1,JUN,KAT5,KCNC3,KCNK17,KCNQ1,KCTD3,KHSRP,KIAA0754,KIAA0889,KIAA1432,KIAA1804,KIAA1958,KIF13A,KLF10,KLF4,KLF7,KLHL8,KPNA3,KRT23,KSR1,LDLRAD3,LENG9,LEPREL1,LGALS8,LGR4,LILRA4,LIN7A,LOC401127,LOC441455,LOC642361,LOC653653,LOC728024,LRG1,LRRC33,LRRC4,LRRC58,LRRC59,LRRK1,LTA4H,LTB4R2,LYZ,MAML3,MAN2A1,MAP1LC3B2,MAP2K7,MAP3K3,MAPK6,MAPK7,MAPRE1,MARVELD1,MBD6,MED13L,MED25,MEF2A,MEMO1,MESDC1,MICALCL,MID1IP1,MKNK2,MKRN9P,MLX,MLXIP,MME,MOBKL1B,MOBKL2A,MPP7,MRPS22,MTMR14,MTX1,N4BP2,NAB1,NAB2,NCF1,NCOR2,NEK6,NETO2,NEU3,NFIC,NFIL3,NINJ1,NKIRAS2,NPEPL1,NRIP1,NRP1,NUBP1,NUDT17,NUDT3,NUPL1,OAF,OCRL,OGFRL1,OLIG1,OPN3,P2RY11,PABPC1P2,PABPC3,PAK1IP1,PANK3,PANX2,PAPLN,PCDHGC3,PEAK1,PELI2,PEMT,PGAM2,PHKA2,PI4KA,PI4KAP2,PIAS4,PIK3CB,PIP5K1B,PISD,PJA2,PLAGL1,PLBD1,PLEK,PLEKHM2,PLEKHM3,PLXDC2,PNPLA2,POM121,PPM1J,PPP2R5B,PPP4R2,PPTC7,PRKACG,PRKAR2A,PSMB7,PSMD3,PTENP1,PTGS2,PXK,RAB11FIP2,RAB20,RAB5C,RARA,RASSF4,RDH14,REL,RELB,RFX2,RIN3,RIPK2,RNASE2,RNASEK,RNF130,RNF217,RNF24,RNF6,RNPEP,ROGDI,RPL7L1,RPS6KC1,RRAGC,RREB1,RRM2B,RSC1A1,RSRC1,RUNDC2A,S1PR3,SAMD1,SCAMP2,SCAMP5,SCARB1,SCML2,SCN9A,SCPEP1,SCT,SDCBP,SDCCAG8,SELRC1,SERINC1,SERPINF1,SERTAD2,SETD7,SFT2D2,SGK3,SH3BP4,SHANK1,SIGLEC6,SLC12A6,SLC15A3,SLC16A5,SLC22A4,SLC2A9,SLC30A1,SLC36A4,SLC38A7,SLC9A7,SMAP2,SMARCB1,SMARCD3,SNX12,SNX2,SPEN,SPI1,SPOPL,SPRED2,SRGAP2P2,SRRM2,SSFA2,ST6GALNAC3,STRN4,STS,STX10,SULT1B1,SUMO1P3,SYK,SYS1-DBNDD2,TBC1D12,TBC1D14,TBC1D9,TCF4,TECPR1,TET3,TFE3,TIFAB,TM9SF2,TMED7,TMED7-TICAM2,TMEM144,TMEM150B,TMEM170B,TMEM183A,TMEM39B,TMEM86A,TMTC1,TMTC2,TNFRSF10B,TNFRSF21,TOR1AIP1,TPCN1,TRAM2,TRIM8,TRIO,TSNARE1,TSPAN16,TTC3P1,TTC7A,TUBGCP3,TXNDC5,TYROBP,UBE2MP1,UCHL3,UGCG,UGGT2,UHRF1BP1,UHRF1BP1L,USP6NL,VEGFA,VENTXP7,VIM,VRK2,WBP11P1,WDFY4,WDR17,WLS,YPEL2,ZBED3,ZDHHC7,ZFAND3,ZFAT,ZFP36,ZFP91,ZFP91-CNTF,ZFP92,ZMIZ1,ZNF281,ZNF385A,ZNF426,ZNF487P,ZNF496,ZNF503,ZNF511,ZNF689,ZNF697,ZNF703,ZNF768,ZNF791,ZNF844",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Results: Modulation of gene expression by HIV-LIPO-5,https://www.ncbi.nlm.nih.gov/pubmed/?term=23759749,NA,NA,NA,NA
M41171,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP,VIRUS,UP,CORRELATION,ANTIBODY,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP,"This study aimed to identify gene expression markers shared between both influenza hemagglutination inhibition (HAI) and virus-neutralization antibody (VNA) responses. We enrolled 158 older subjects who received the 2010-2011 trivalent inactivated influenza vaccine. Influenza-specific HAI and VNA titers and mRNA-sequencing were performed using blood samples obtained at Days 0, 3 and 28 post vaccination. For antibody response at Day 28 versus Day 0, several gene sets were identified as significant in predictive models for HAI (n=7) and VNA (n=35) responses. Five gene sets (comprising the genes MAZ, TTF, GSTM, RABGGTA, SMS, CA, IFNG and DOPEY) were in common for both HAI and VNA. For response at Day 28 versus Day 3, many gene sets were identified in predictive models for HAI (n=13) and VNA (n=41). Ten gene sets (comprising biologically related genes, such as MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3, TLR7 and others) were shared between HAI and VNA. These identified gene sets demonstrated a high degree of network interactions and likelihood for functional relationships. Influenza-specific HAI and VNA responses demonstrated a remarkable degree of similarity. Although unique gene set signatures were identified for each humoral outcome, several gene sets were determined to be in common with both HAI and VNA response to influenza vaccine.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 0d in adults (50-74) (in common with both HAI and VNA) after exposure to Fluarix , time point 28D , administered i.m.. Comment: Common Genesets with genes entering regression models for HAI and VNA Responses with the log2 Day 28 vs Day 0 fold-change in gene expression as the explanatory variables.","Ovsyannikova IG,Salk HM,Kennedy RB,Haralambieva IH,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27534615,HUMAN_GENE_SYMBOL,"CA8,DOP1B,IFNG,MAT2A,RABGGTA,SUPT16H,UPF1",7,"CA8,DOPEY2,IFNG,MAT2A,RABGGTA,SUPT16H,UPF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M41066,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,D28 VS D3,D,NA,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN,"This study aimed to identify gene expression markers shared between both influenza hemagglutination inhibition (HAI) and virus-neutralization antibody (VNA) responses. We enrolled 158 older subjects who received the 2010-2011 trivalent inactivated influenza vaccine. Influenza-specific HAI and VNA titers and mRNA-sequencing were performed using blood samples obtained at Days 0, 3 and 28 post vaccination. For antibody response at Day 28 versus Day 0, several gene sets were identified as significant in predictive models for HAI (n=7) and VNA (n=35) responses. Five gene sets (comprising the genes MAZ, TTF, GSTM, RABGGTA, SMS, CA, IFNG and DOPEY) were in common for both HAI and VNA. For response at Day 28 versus Day 3, many gene sets were identified in predictive models for HAI (n=13) and VNA (n=41). Ten gene sets (comprising biologically related genes, such as MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3, TLR7 and others) were shared between HAI and VNA. These identified gene sets demonstrated a high degree of network interactions and likelihood for functional relationships. Influenza-specific HAI and VNA responses demonstrated a remarkable degree of similarity. Although unique gene set signatures were identified for each humoral outcome, several gene sets were determined to be in common with both HAI and VNA response to influenza vaccine.","Genes down-regulated in peripheral blood mononuclear cell 28d vs 3d in adults (50-74) (in common with both HAI and VNA) after exposure to Fluarix , time point 28D , administered i.m.. Comment: Common Genesets with genes entering regression models for HAI and VNA Responses, withlog2 Day 28 vs Day 3 fold-change in gene expression as the explanatory variables","Ovsyannikova IG,Salk HM,Kennedy RB,Haralambieva IH,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27534615,HUMAN_GENE_SYMBOL,"ADGRB1,CEBPG,CRHBP,CS,DLG4,ELOVL7,FOXP3,GSTM3,IL12A,MAN1B1,NEIL1,PARP2,POLL,RAD51B,RAD54B,REC8,STAG3,TAPT1",18,"BAI1,CEBPG,CRHBP,CS,DLG4,ELOVL7,FOXP3,GSTM3,IL12A,MAN1B1,NEIL1,PARP2,POLL,RAD51B,RAD54B,REC8,STAG3,TAPT1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133148/table/T1/,NA,NA,NA,NA
M40987,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP,VIRUS,UP,CORRELATION,ANTIBODY,D28 VS D3,D,NA,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_3DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_UP,"This study aimed to identify gene expression markers shared between both influenza hemagglutination inhibition (HAI) and virus-neutralization antibody (VNA) responses. We enrolled 158 older subjects who received the 2010-2011 trivalent inactivated influenza vaccine. Influenza-specific HAI and VNA titers and mRNA-sequencing were performed using blood samples obtained at Days 0, 3 and 28 post vaccination. For antibody response at Day 28 versus Day 0, several gene sets were identified as significant in predictive models for HAI (n=7) and VNA (n=35) responses. Five gene sets (comprising the genes MAZ, TTF, GSTM, RABGGTA, SMS, CA, IFNG and DOPEY) were in common for both HAI and VNA. For response at Day 28 versus Day 3, many gene sets were identified in predictive models for HAI (n=13) and VNA (n=41). Ten gene sets (comprising biologically related genes, such as MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3, TLR7 and others) were shared between HAI and VNA. These identified gene sets demonstrated a high degree of network interactions and likelihood for functional relationships. Influenza-specific HAI and VNA responses demonstrated a remarkable degree of similarity. Although unique gene set signatures were identified for each humoral outcome, several gene sets were determined to be in common with both HAI and VNA response to influenza vaccine.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 3d in adults (50-74) (in common with both HAI and VNA) after exposure to Fluarix , time point 28D , administered i.m.. Comment: Common Genesets with genes entering regression models for HAI and VNA Responses, withlog2 Day 28 vs Day 3 fold-change in gene expression as the explanatory variables","Ovsyannikova IG,Salk HM,Kennedy RB,Haralambieva IH,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27534615,HUMAN_GENE_SYMBOL,"ACO2,ACSL1,ACSL4,ACSL5,EBI3,FASN,FH,FYN,GALR2,HSD17B12,IDH2,INHBA,LIG3,NF1,OGDH,S100B,SDHA,SLC25A1,SMUG1,SUCLA2,TLR3,TLR7,TLR9,TUBG1,VLDLR",25,"ACO2,ACSL1,ACSL4,ACSL5,EBI3,FASN,FH,FYN,GALR2,HSD17B12,IDH2,INHBA,LIG3,NF1,OGDH,S100B,SDHA,SLC25A1,SMUG1,SUCLA2,TLR3,TLR7,TLR9,TUBG1,VLDLR",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40896,IMUVAC,IN,INFLUENZA,NAKAYA_PBMC_IMUVAC_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0DY_PREIMM_TIV_UP,VIRUS,UP,VACCINE,BOOSTER,D1,D,1,14-27,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_IMUVAC_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0DY_PREIMM_TIV_UP,"The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4(+) T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.","Genes up-regulated in peripheral blood mononuclear cell 1d postboost vs 0d pre-imm in children (14-27m) after exposure to Imuvac , time point 1D. Comment: TIV","Nakaya HI,Clutterbuck E,Kazmin D,Wang L,Cortese M,Bosinger SE,Patel NB,Zak DE,Aderem A,Dong T,Del Giudice G,Rappuoli R,Cerundolo V,Pollard AJ,Pulendran B,Siegrist CA",26755593,HUMAN_GENE_SYMBOL,"ADORA3,ANKRD22,ATP6V0C,BATF2,CCR3,CD274,CTSW,ETV7,FAS,FCGR1A,FCGR1BP,FKBP5,GBP1,GBP4,GBP5,GK,GK3,ICAM1,IDO1,IGLV4-60,IRF1,KREMEN1,LPCAT2,MS4A3,NOD2,P2RY14,PI3,PRRG4,PRSS33,PSMF1,PSTPIP2,PTGDR2,RAB20,RAPGEF2,SERPING1,SIRPB1,SLC4A1,SNX27,TMOD1,TNFAIP2,TSPAN5,UCP2,VSTM1,WARS1",44,"ADORA3,ANKRD22,ATP6V0C,BATF2,CCR3,CD274,CTSW,ETV7,FAS,FCGR1A,FCGR1B,FKBP5,GBP1,GBP4,GBP5,GK,GK3P,ICAM1,IDO1,IGLV4-60,IRF1,KREMEN1,LPCAT2,MS4A3,NOD2,P2RY14,PI3,PRRG4,PRSS33,PSMF1,PSTPIP2,PTGDR2,RAB20,RAPGEF2,SERPING1,SIRPB1,SLC4A1,SNX27,TMOD1,TNFAIP2,TSPAN5,UCP2,VSTM1,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-Monocytes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40897,FLUAD,IN,INFLUENZA,NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP,VIRUS,UP,VACCINE,BOOSTER,D1,D,1,14-27,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_ATIV_UP,"The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4(+) T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.","Genes up-regulated in peripheral blood mononuclear cell 1d postboost vs 0d pre-imm in children (14-27m) (MF59-adjuvanted) after exposure to Fluad , time point 1D. Comment: ATIV","Nakaya HI,Clutterbuck E,Kazmin D,Wang L,Cortese M,Bosinger SE,Patel NB,Zak DE,Aderem A,Dong T,Del Giudice G,Rappuoli R,Cerundolo V,Pollard AJ,Pulendran B,Siegrist CA",26755593,HUMAN_GENE_SYMBOL,"ANKRD22,ATF3,BATF2,CALHM6,CD274,CEACAM1,CXCL10,EFCAB2,EPSTI1,ETV7,FBXO6,FCGR1A,FCGR1BP,GBP1,GBP4,GBP5,GK,ICAM1,IDO1,IFI35,IFI44L,IL15,KREMEN1,LAMP3,LAP3,LHFPL2,MYOF,OAS3,P2RY14,PSTPIP2,RSAD2,SCARF1,SERPING1,SMCO4,SORT1,STAT1,TFEC,TYMP,VAMP5,WARS1",40,"ANKRD22,ATF3,BATF2,CALHM6,CD274,CEACAM1,CXCL10,EFCAB2,EPSTI1,ETV7,FBXO6,FCGR1A,FCGR1B,GBP1,GBP4,GBP5,GK,ICAM1,IDO1,IFI35,IFI44L,IL15,KREMEN1,LAMP3,LAP3,LHFPL2,MYOF,OAS3,P2RY14,PSTPIP2,RSAD2,SCARF1,SERPING1,SMCO4,SORT1,STAT1,TFEC,TYMP,VAMP5,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41196,FLUVIRIN PANDEMRIX,IN,INFLUENZA,TSANG_PBMC_FLUVIRIN_PANDEMRIX_ADULT_CORR_WITH_CELL_FREQ_CD27HI_CD38HI_CD20_NEG_PLASMABLASTS_AND_CD38PLUS_OF_IGD_CD27PLUS_MEM_B_CELLS_7DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D7,D,7,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/TSANG_PBMC_FLUVIRIN_PANDEMRIX_ADULT_CORR_WITH_CELL_FREQ_CD27HI_CD38HI_CD20_NEG_PLASMABLASTS_AND_CD38PLUS_OF_IGD_CD27PLUS_MEM_B_CELLS_7DY_POSITIVE,"A major goal of systems biology is the development of models that accurately predict responses to perturbation. Constructing such models requires the collection of dense measurements of system states, yet transformation of data into predictive constructs remains a challenge. To begin to model human immunity, we analyzed immune parameters in depth both at baseline and in response to influenza vaccination. Peripheral blood mononuclear cell transcriptomes, serum titers, cell subpopulation frequencies, and B cell responses were assessed in 63 individuals before and after vaccination and were used to develop a systematic framework to dissect inter- and intra-individual variation and build predictive models of postvaccination antibody responses. Strikingly, independent of age and pre-existing antibody titers, accurate models could be constructed using pre-perturbation cell populations alone, which were validated using independent baseline time points. Most of the parameters contributing to prediction delineated temporally stable baseline differences across individuals, raising the prospect of immune monitoring before intervention.","Genes positively correlated with cell frequency CD27hi CD38hi of CD20- B cells (Plasmablasts) and CD38+ of IgD-CD27+ memory B cells in peripheral blood mononuclear cell in adults after exposure to Fluvirin/Pandemrix , time point 7D","Tsang JS,Schwartzberg PL,Kotliarov Y,Biancotto A,Xie Z,Germain RN,Wang E,Olnes MJ,Narayanan M,Golding H,Moir S,Dickler HB,Perl S,Cheung F,Baylor HIPC Center,CHI Consortium",24725414,HUMAN_GENE_SYMBOL,"APOBEC3B,ARHGAP42,B4GALT3,BHLHE41,BUB1,CAV1,CCNA2,CCNB2,CD38,CDK1,CHAC2,CHEK1,DENND5B,DIPK1A,DLGAP5,DTL,ELL2,ERLEC1,FBXO16,FBH1,FBXO5,GLCCI1,GPRC5D,H1-5,H2BC14,H3C12,HSP90B1,HSPA13,HSPA5,IGHV4OR15-8,JCHAIN,IGKC,IGKV4-1,IRF4,ITM2C,KCNN3,KIF11,KLHL14,LMAN1,MAGED1,MAN1A1,MANEA,MEI1,MKI67,MTDH,MYO1D,NT5DC2,PARM1,PBK,PCLAF,PDIA4,PHGDH,PIM2,PLAAT2,PLK1,PLPP5,RAB30,RGS13,RRM2,SEC11C,SEC24A,SEL1L3,SHCBP1,SLC44A1,SPATS2,SPCS3,SUB1,TNFRSF17,TOP2A,TP53INP1,TPD52,TRAM2,TSHR,TYMS,UAP1,UBE2J1,XBP1,ZBP1",78,"APOBEC3B,ARHGAP42,B4GALT3,BHLHE41,BUB1,CAV1,CCNA2,CCNB2,CD38,CDK1,CHAC2,CHEK1,DENND5B,DIPK1A,DLGAP5,DTL,ELL2,ERLEC1,FBXO16,FBXO18,FBXO5,GLCCI1,GPRC5D,H1-5,H2BC14,H3C12,HSP90B1,HSPA13,HSPA5,IGHV4OR15-8,IGJ,IGKC,IGKV4-1,IRF4,ITM2C,KCNN3,KIF11,KLHL14,LMAN1,MAGED1,MAN1A1,MANEA,MEI1,MKI67,MTDH,MYO1D,NT5DC2,PARM1,PBK,PCLAF,PDIA4,PHGDH,PIM2,PLAAT2,PLK1,PLPP5,RAB30,RGS13,RRM2,SEC11C,SEC24A,SEL1L3,SHCBP1,SLC44A1,SPATS2,SPCS3,SUB1,TNFRSF17,TOP2A,TP53INP1,TPD52,TRAM2,TSHR,TYMS,UAP1,UBE2J1,XBP1,ZBP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/table/pone.0160970.t001/,NA,NA,NA,NA
M41185,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D0,D,0,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_0DY_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors(50-74) after exposure to Fluarix , time point 0D","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"AAGAB,AARSD1,ABCC5,ACTR3B,ACVR2A,ADARB1,AFAP1-AS1,AGFG2,AIRE,AKAP12,ALKBH3,AMZ2,ANAPC7,ANGPT2,AP2B1,AP5Z1,APOBEC3D,APOBEC3F,APOBEC3H,APOL2,APTX,ARFRP1,ARHGEF39,ARL6IP4,ARMH3,ASB1,ASTN2,ATAD3C,ATAT1,ATG13,ATG5,ATP5F1D,ATP5MK,ATP5MG,ATP6V0E2,ATPAF1,ATP5IF1,B3GAT3,BATF,BAX,BCL7C,BDH2,BLCAP,BRD7,BRWD1,BTBD6,BUB3,C11orf58,C11orf80,UQCC6,C14orf132,C19orf12,C1orf56,CAAP1,CACNA1C,CACNB1,CACNB2,CAMTA1,CARD8,CCDC57,CCDC65,CCDC85B,CCM2,CD27-AS1,CD2BP2,CD3D,CD47,CD99,CDADC1,CDKN2A,CDKN2B-AS1,CDRT4,CEP250,CERK,CERS4,CERS5,CHMP4A,CHMP6,CHN1,CIAO2B,CLEC2D,CLIC5,CNPY2,COG2,COMMD4,COMMD6,COMMD7,COMTD1,COPS9,COX14,COX6C,CPNE7,CROT,CRYBG2,CSMD3,CSTF3,CWF19L2,CXCR6,CYP20A1,CYTOR,DCAF8,DGKZ,DGUOK,DHRS13,DIAPH1,DLG3,DNAJC19,DOK6,DUT,EBAG9,EEF1D,EIF5B,ELAVL1,ENSA,ERG28,ETFB,ETV2,EVA1C,EYA3,FAHD2B,FAIM,FAM219B,FANK1,FAT2,FDXR,NHSL2,FPGS,FTSJ1,FTX,FUT2,FXYD1,GALM,GFER,GLE1,GLG1,GNL1,GOLGA7B,GPI,GSDMD,GTF2IRD2B,GTF3C1,GTPBP8,GTSE1-DT,GUK1,HCFC2,HCN2,HCST,HDDC3,HDHD3,HENMT1,HIKESHI,HINT1,HMOX2,HNRNPA3,HOXC4,HRH4,HSPBP1,HTT,IFITM1,IGSF22,IL2RG,IL32,ILRUN,IMMP1L,INPP5B,INSIG2,IPO11,IPP,IQCH,ITGB1BP1,ITPRIPL1,JAKMIP1,JTB,KATNAL1,KDM5A,KIF3A,KIFAP3,KLHDC4,KLHL35,KLRB1,KLRG1,KMT5B,KPNA1,LACTB2-AS1,LAGE3,LBHD1,LCMT1,LIME1,LIN54,LINC00426,LINC00892,LINC01011,LINC02591,,LOXL1,LOXL1-AS1,LRFN2,LRRC1,LRTOMT,LTBP4,LY75,LYAR,LYPLA2,LYSMD1,MADD,MAF,MAP4,MAPK11,MAPT,MAVS,MAX,MBD3,MBP,MCOLN3,MCRIP1,MDH1,MEAK7,MECR,MED4,MEI1,METRN,MFF,MICOS10,MIF-AS1,MLH1,MLH3,MMAB,MMP24,MOB2,MPRIP,MRPL11,MRPL48,MRPL52,MRPL57,MRPS25,MRTO4,MTLN,MUC6,MVD,MVK,MYL6,N6AMT1,NAA38,NAALADL1,NAP1L4,NAXE,NDFIP2,NDUFA2,NDUFA4,NDUFA9,NDUFB11,NDUFB2,NDUFB9,NDUFC2,NECAB1,NEDD8,NEFL,NEIL2,NENF,NFATC3,NIFK-AS1,NOP14-AS1,NOTCH2NLA,NSMCE1,NSUN5,,NUDCD3,OPTN,OSBPL3,OSER1-DT,PAFAH2,PAPOLG,PARP1,PBXIP1,PCED1B-AS1,PCID2,PCNX3,PCYT2,PDAP1,PDCD10,PDP2,PDZD11,PECR,PEF1,PEX16,PGAP3,PHF19,PHKG2,PHTF2,PI16,PIGU,PIN4,PKNOX1,PLAAT4,PLCD1,PMVK,POLH,POLR2F,POLR3A,POLR3GL,PPIA,PPIE,PPP1R12B,PPP2R5C,PRMT2,PRR13,PRR5,PRR5L,PRSS27,PSMB8,PSMC5,PSMD13,PSMD9,PSME1,PTGER2,PTPN7,PUM3,PYCR3,RAB22A,RAB25,RAB29,RAI14,RANGAP1,RANGRF,RBIS,RBMX2,RCN2,RDH16,RECQL5,RETREG3,RFC4,RINL,RNASEH2C,RNF167,RNF187,RNF220,RNF8,RPA1,RPA3,RPL13A,RPL14,RPL23A,RPL27A,RPL32,RPL37,RPL39,RPS19,,RPS23,RPS27A,RPS29,RPS6,RPS7,RUVBL1,RWDD1,SAMM50,SARS1,SCAMP3,SELENOH,SELENOW,SEMA4F,SERF2,SERGEF,SERPINI1,SETD4,SF3B3,SH2D1A,SH2D2A,SIGIRR,SIRT5,SKP1,SLC25A12,SLC25A15,SLC25A26,SLC25A51,SLC39A8,,SMAD4,SMIM27,SMIM29,SNAP47,SNF8,SNHG20,SNORD34,SNORD35A,SNORD38A,SNORD4A,,SNORD54,SNRPC,SNRPE,SNRPN,SOD1,SP140,SPATA5,SPEF2,SPN,SRI,SRPRB,SSNA1,ST6GALNAC6,STK24,STOM,STX8,STXBP4,SYNJ2BP-COX16,SYNRG,SYTL1,TADA3,TARBP2,TBC1D24,TBX19,TEDC2,TEX264,TGDS,THAP3,THOC3,THYN1,TINF2,TLE5,TMEM106C,TMEM14A,TMEM161A,TMEM171,TMEM178B,TMEM191A,TMEM222,TMEM50B,KRT10-AS1,TNFRSF4,TNNC1,TOMM5,TRADD,TRAPPC2,TRAPPC4,TRAPPC6B,TRIM2,TRIM65,TRNAU1AP,TRPV2,TSPAN15,TSPAN5,TSPOAP1-AS1,TTC39C,TTLL1,TXNL4A,UBA52,UBAC2-AS1,UBE2D2,UBE2F,UBE2L3,UBL5,UBL7-DT,UFD1,UGGT1,UGP2,UNC13D,UNC45B,UNG,UQCR10,UQCR11,UQCRB,UQCRQ,USP31,USP37,USP46,USP5,UTS2,VAPB,VBP1,VPS4A,VRK3,WDR4,WDR83OS,YAF2,ZC3HC1,ZCRB1,ZDHHC13,ZFAND2B,ZGPAT,ZMYM5,ZNF133,ZNF233,ZNF428,ZNF530,ZNF585A,ZNF621,ZNF670,ZNF674,ZNF688,ZNF701,KRBOX5,ZNF738,ZNF763,ZNF780A,ZNF780B,ZNHIT6",497,"AAGAB,AARSD1,ABCC5,ACTR3B,ACVR2A,ADARB1,AFAP1-AS1,AGFG2,AIRE,AKAP12,ALKBH3,AMZ2,ANAPC7,ANGPT2,AP2B1,AP5Z1,APOBEC3D,APOBEC3F,APOBEC3H,APOL2,APTX,ARFRP1,ARHGEF39,ARL6IP4,ARMH3,ASB1,ASTN2,ATAD3C,ATAT1,ATG13,ATG5,ATP5F1D,ATP5MD,ATP5MG,ATP6V0E2,ATPAF1,ATPIF1,B3GAT3,BATF,BAX,BCL7C,BDH2,BLCAP,BRD7,BRWD1,BTBD6,BUB3,C11orf58,C11orf80,C12orf73,C14orf132,C19orf12,C1orf56,CAAP1,CACNA1C,CACNB1,CACNB2,CAMTA1,CARD8,CCDC57,CCDC65,CCDC85B,CCM2,CD27-AS1,CD2BP2,CD3D,CD47,CD99,CDADC1,CDKN2A,CDKN2B-AS1,CDRT4,CEP250,CERK,CERS4,CERS5,CHMP4A,CHMP6,CHN1,CIAO2B,CLEC2D,CLIC5,CNPY2,COG2,COMMD4,COMMD6,COMMD7,COMTD1,COPS9,COX14,COX6C,CPNE7,CROT,CRYBG2,CSMD3,CSTF3,CWF19L2,CXCR6,CYP20A1,CYTOR,DCAF8,DGKZ,DGUOK,DHRS13,DIAPH1,DLG3,DNAJC19,DOK6,DUT,EBAG9,EEF1D,EIF5B,ELAVL1,ENSA,ERG28,ETFB,ETV2,EVA1C,EYA3,FAHD2B,FAIM,FAM219B,FANK1,FAT2,FDXR,FLJ44635,FPGS,FTSJ1,FTX,FUT2,FXYD1,GALM,GFER,GLE1,GLG1,GNL1,GOLGA7B,GPI,GSDMD,GTF2IRD2B,GTF3C1,GTPBP8,GTSE1-DT,GUK1,HCFC2,HCN2,HCST,HDDC3,HDHD3,HENMT1,HIKESHI,HINT1,HMOX2,HNRNPA3,HOXC4,HRH4,HSPBP1,HTT,IFITM1,IGSF22,IL2RG,IL32,ILRUN,IMMP1L,INPP5B,INSIG2,IPO11,IPP,IQCH,ITGB1BP1,ITPRIPL1,JAKMIP1,JTB,KATNAL1,KDM5A,KIF3A,KIFAP3,KLHDC4,KLHL35,KLRB1,KLRG1,KMT5B,KPNA1,LACTB2-AS1,LAGE3,LBHD1,LCMT1,LIME1,LIN54,LINC00426,LINC00892,LINC01011,LINC02591,LOC100506990,LOXL1,LOXL1-AS1,LRFN2,LRRC1,LRTOMT,LTBP4,LY75,LYAR,LYPLA2,LYSMD1,MADD,MAF,MAP4,MAPK11,MAPT,MAVS,MAX,MBD3,MBP,MCOLN3,MCRIP1,MDH1,MEAK7,MECR,MED4,MEI1,METRN,MFF,MICOS10,MIF-AS1,MLH1,MLH3,MMAB,MMP24,MOB2,MPRIP,MRPL11,MRPL48,MRPL52,MRPL57,MRPS25,MRTO4,MTLN,MUC6,MVD,MVK,MYL6,N6AMT1,NAA38,NAALADL1,NAP1L4,NAXE,NDFIP2,NDUFA2,NDUFA4,NDUFA9,NDUFB11,NDUFB2,NDUFB9,NDUFC2,NECAB1,NEDD8,NEFL,NEIL2,NENF,NFATC3,NIFK-AS1,NOP14-AS1,NOTCH2NLA,NSMCE1,NSUN5,NT5C3AA,NUDCD3,OPTN,OSBPL3,OSER1-DT,PAFAH2,PAPOLG,PARP1,PBXIP1,PCED1B-AS1,PCID2,PCNX3,PCYT2,PDAP1,PDCD10,PDP2,PDZD11,PECR,PEF1,PEX16,PGAP3,PHF19,PHKG2,PHTF2,PI16,PIGU,PIN4,PKNOX1,PLAAT4,PLCD1,PMVK,POLH,POLR2F,POLR3A,POLR3GL,PPIA,PPIE,PPP1R12B,PPP2R5C,PRMT2,PRR13,PRR5,PRR5L,PRSS27,PSMB8,PSMC5,PSMD13,PSMD9,PSME1,PTGER2,PTPN7,PUM3,PYCR3,RAB22A,RAB25,RAB29,RAI14,RANGAP1,RANGRF,RBIS,RBMX2,RCN2,RDH16,RECQL5,RETREG3,RFC4,RINL,RNASEH2C,RNF167,RNF187,RNF220,RNF8,RPA1,RPA3,RPL13A,RPL14,RPL23A,RPL27A,RPL32,RPL37,RPL39,RPS19,RPS21.1,RPS23,RPS27A,RPS29,RPS6,RPS7,RUVBL1,RWDD1,SAMM50,SARS1,SCAMP3,SELENOH,SELENOW,SEMA4F,SERF2,SERGEF,SERPINI1,SETD4,SF3B3,SH2D1A,SH2D2A,SIGIRR,SIRT5,SKP1,SLC25A12,SLC25A15,SLC25A26,SLC25A51,SLC39A8,SLMO2-ATP5E,SMAD4,SMIM27,SMIM29,SNAP47,SNF8,SNHG20,SNORD34,SNORD35A,SNORD38A,SNORD4A,SNORD50A,SNORD54,SNRPC,SNRPE,SNRPN,SOD1,SP140,SPATA5,SPEF2,SPN,SRI,SRPRB,SSNA1,ST6GALNAC6,STK24,STOM,STX8,STXBP4,SYNJ2BP-COX16,SYNRG,SYTL1,TADA3,TARBP2,TBC1D24,TBX19,TEDC2,TEX264,TGDS,THAP3,THOC3,THYN1,TINF2,TLE5,TMEM106C,TMEM14A,TMEM161A,TMEM171,TMEM178B,TMEM191A,TMEM222,TMEM50B,TMEM99,TNFRSF4,TNNC1,TOMM5,TRADD,TRAPPC2,TRAPPC4,TRAPPC6B,TRIM2,TRIM65,TRNAU1AP,TRPV2,TSPAN15,TSPAN5,TSPOAP1-AS1,TTC39C,TTLL1,TXNL4A,UBA52,UBAC2-AS1,UBE2D2,UBE2F,UBE2L3,UBL5,UBL7-AS1,UFD1,UGGT1,UGP2,UNC13D,UNC45B,UNG,UQCR10,UQCR11,UQCRB,UQCRQ,USP31,USP37,USP46,USP5,UTS2,VAPB,VBP1,VPS4A,VRK3,WDR4,WDR83OS,YAF2,ZC3HC1,ZCRB1,ZDHHC13,ZFAND2B,ZGPAT,ZMYM5,ZNF133,ZNF233,ZNF428,ZNF530,ZNF585A,ZNF621,ZNF670,ZNF674,ZNF688,ZNF701,ZNF720,ZNF738,ZNF763,ZNF780A,ZNF780B,ZNHIT6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/bin/jiy420_suppl_supplementary_table_2.docx,NA,NA,NA,NA
M41069,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN,VIRUS,DOWN,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_50_74YO_COMMON_WITH_BOTH_HAI_AND_VNA_28DY_VS_0DY_USED_IN_HAI_AND_VNA_RESPONSE_MODELS_DN,"This study aimed to identify gene expression markers shared between both influenza hemagglutination inhibition (HAI) and virus-neutralization antibody (VNA) responses. We enrolled 158 older subjects who received the 2010-2011 trivalent inactivated influenza vaccine. Influenza-specific HAI and VNA titers and mRNA-sequencing were performed using blood samples obtained at Days 0, 3 and 28 post vaccination. For antibody response at Day 28 versus Day 0, several gene sets were identified as significant in predictive models for HAI (n=7) and VNA (n=35) responses. Five gene sets (comprising the genes MAZ, TTF, GSTM, RABGGTA, SMS, CA, IFNG and DOPEY) were in common for both HAI and VNA. For response at Day 28 versus Day 3, many gene sets were identified in predictive models for HAI (n=13) and VNA (n=41). Ten gene sets (comprising biologically related genes, such as MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3, TLR7 and others) were shared between HAI and VNA. These identified gene sets demonstrated a high degree of network interactions and likelihood for functional relationships. Influenza-specific HAI and VNA responses demonstrated a remarkable degree of similarity. Although unique gene set signatures were identified for each humoral outcome, several gene sets were determined to be in common with both HAI and VNA response to influenza vaccine.","Genes down-regulated in peripheral blood mononuclear cell 28d vs 0d in adults (50-74) (in common with both HAI and VNA) after exposure to Fluarix , time point 28D , administered i.m.. Comment: Common Genesets with genes entering regression models for HAI and VNA Responses with the log2 Day 28 vs Day 0 fold-change in gene expression as the explanatory variables.","Ovsyannikova IG,Salk HM,Kennedy RB,Haralambieva IH,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27534615,HUMAN_GENE_SYMBOL,"CA11,CA14,CA2,CA6,GSTM1,GSTM2,MAZ,SMS,TTF2",9,"CA11,CA14,CA2,CA6,GSTM1,GSTM2,MAZ,SMS,TTF2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 9,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M41091,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 28D. Comment: D: Late gene expression individual gene models (predicting peak B cell ELISPOT response) for module 11 (D, MSE=2.062)","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"A1BG,CRB2,DAB2,IGSF10,NFE2L3,RAI1,SNORA3B,SNORD102,SYNJ1,ZNF682",10,"A1BG,CRB2,DAB2,IGSF10,NFE2L3,RAI1,SNORA45,SNORD102,SYNJ1,ZNF682",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,NA,NA,NA,NA,NA,NA
M41154,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LATE_GENE_EXPR_INDIVID_GENE_MODELS_PRED_PEAK_B_CELL_ELISPOT_RESP_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 28D. Comment: D: Late gene expression individual gene models (predicting peak B cell ELISPOT response) for module 11 (D, MSE=2.062)","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"AJAP1,ANXA1,C1QC,DSG2,IFNAR2,LRRC58,MKNK2,RASSF8,SCML2,SEZ6,SH3RF3,SIGLEC6,TIGD3,XPR1,ZC3H10,ZNF746",16,"AJAP1,ANXA1,C1QC,DSG2,IFNAR2,LRRC58,MKNK2,RASSF8,SCML2,SEZ6,SH3RF3,SIGLEC6,TIGD3,XPR1,ZC3H10,ZNF746",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Table 2, NFKB1 and NFKB2 mentioned in text",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583508/table/tbl2/,NA,NA,NA,NA
M40893,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 28D. Comment: selected pathways: leukocyte migration, MAP kinase activity, cytokine signaling, diabetes of the young","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"AIMP1,CCR2,CKLF,COMMD7,DUOX1,HNF1A,MAPK1,MAPK11,MAPK9,PAX6,ZNF675",11,"AIMP1,CCR2,CKLF,COMMD7,DUOX1,HNF1A,MAPK1,MAPK11,MAPK9,PAX6,ZNF675",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41177,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_LEUK_MIGR_MAPK_ACT_CYTOK_SIG_DIAB_OF_THE_YNG_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 28D. Comment: selected pathways: leukocyte migration, MAP kinase activity, cytokine signaling, diabetes of the young","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"BHLHA15,CD34,DOCK2,EREG,HES1,IL10,CXCL8,MAPK12,MAPK14,MAPK7,PF4,SFTPD,SOCS5,TGFB2",14,"BHLHA15,CD34,DOCK2,EREG,HES1,IL10,IL8,MAPK12,MAPK14,MAPK7,PF4,SFTPD,SOCS5,TGFB2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41099,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_28DY_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 28D","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"ABAT,ABCA1,ABCA6,ABCD1,ABHD5,ABTB2,ACAD9,ACBD3,ACO2,ACP5,ACSL1,ACSL4,ACVR1B,ADAM17,ADAM9,ADAMTSL4,ADGRE2,ADIPOR1,ADM,GRK3,ADRM1,ADSS1,AFF3,AHNAK2,AHR,AIMP2,AKIRIN2,AKT1S1,ALAS1,ALDH1A1,ALDH2,ALDH3B1,ALDH3B2,ALOX5,ANGPT1,ANKLE1,ANKRD36BP1,SOWAHC,ANO8,ANP32D,ANXA1,AP1B1,AP2A1,AP3B1,APLP2,APOM,APP,ARF1,ARF4,ARG2,ARHGAP1,ARHGAP23,ARHGAP24,ARHGAP42,ARHGEF40,ARID3A,ARL4A,ARL5B,ARL6IP1,ARL8A,ARL8B,BMAL2,ARRDC4,ARSG,ASAH1,ASAP1,ATF3,ATF5,ATOX1,ATP11A,ATP1B1,ATP2A2,ATP5F1B,ATP5F1C,ATP6V0B,ATP6V0C,ATP6V1F,ATPAF2,AZI2,AZU1,B3GNT5,B9D2,BACH1,BAG6,BAHCC1,BAK1,BAMBI,BANK1,BASP1,BAZ2B,BCAT1,BCL10,BCL2A1,BCL2L11,BCL2L2,BCL2L2-PABPN1,BCL3,BCL6,BHLHA15,BHLHE40,BHLHE41,BLVRB,BMF,BMP8B,BNIP2,BNIP3L,BOP1,BORCS8-MEF2B,BPI,BRI3BP,BRWD3,BTBD3,BTK,BZW1,C11orf24,SMCO4,ZFTA,C11orf96,FAM222A,TMEM52B,MIDEAS,C15orf39,C15orf48,PHAF1,NATD1,C17orf107,SCIMP,C19orf38,FAAP24,ACTMAP,TEKTIP1,SPRTN,RHEX,CCSAP,GUCD1,C2orf49,XXYLT1,DIPK2A,C4orf46,C5AR1,PXDC1,GINM1,LINC02908,SAPCD2,PRXL2C,DOCK8-AS1,C9orf72,CA5BP1,CADM4,CAPZA1,CARM1,CASP3,CASP9,CAT,CBFA2T3,CBX2,CBX6,CBX8,CCDC103,CCDC13,CCDC43,CCDC47,CCDC50,CCDC6,CCDC86,CCDC88A,YJU2,CCL20,CCNK,CCNYL1,CCPG1,CCR1,CCRL2,NOCT,CD300E,CD302,CD34,CD38,CD46,CD55,CD68,CD80,CD83,CD86,CDA,CDC40,CDC42BPB,CDC42EP1,CDC42EP2,CDC42EP4,CDC5L,CDK14,CDKN1A,CEACAM4,CEBPB,CEBPD,CENPW,CEP170,CERS6,CHKA,CHML,CHMP1B,CHMP2B,CHRAC1,CHRNE,CHST15,CIDEB,CIITA,CKAP2,CKAP4,CKS2,CLDN23,CLEC12A,CLEC4C,CLEC4D,CLEC4F,CLIC4,CLIP2,CLMN,CLN6,CLPB,CLPTM1,CMIP,CMTM6,CNIH4,CNNM4,CNTLN,COBL,COBLL1,COL24A1,CERT1,COL9A2,COQ8A,CORO1C,CORO7-PAM16,COTL1,COX5B,CPA3,CPEB4,CREB5,CRISPLD2,CRK,YBX3,CSF1R,CSF2RB,CSF3R,CSGALNACT2,CSNK1A1L,CST3,CTIF,CTSZ,CUEDC1,CUX2,CWC25,CXCL16,CXXC5,TASL,CYB5R4,CYBB,CYC1,CYP51A1,DACH1,DAPK1,DCTN4,DCUN1D1,DCUN1D3,DDO,DDX21,DDX3X,DDX49,DENND1A,DENND3,DENND5B,DERA,DHTKD1,DHX8,DIAPH2,DICER1,SLC49A4,AP5B1,DLC1,DLX2,DNAJC11,DNAJC3,DNASE1L1,DNM2,DNMBP,DOCK1,DOCK2,DOCK4,DOCK5,DOK3,DOT1L,DPP3,DPPA4,DSC2,DSE,DSG2,DUSP10,DUSP6,DVL3,DYM,DYSF,EAF1,ECHDC3,EFCAB11,CRACR2B,EIF3A,EIF3C,EIF4A1,EIF4A3,EIF4E2,EIF4EBP1,EIF4EBP3,EIF4G2,EIF4H,ELF1,ELF4,ELL,ELL2,ELOF1,EME2,EMP1,ENTPD7,EPB41L2,EPHA2,EPHX3,EPN1,ERCC5,EREG,ERF,ERG,ESRRA,ETF1,ETS2,EVI2B,EXT1,F3,UBALD1,EEIG2,FAM110B,FAM117B,FAM124B,HYCC1,RTL8C,FAM151B,ABRAXAS2,GASK1B,INKA2,ATOSB,FAM43A,DENND10,TENT5A,TENT5B,CYRIA,FAM53C,RIPOR1,TMEM255B,FAM91A1,FAM98B,FBN1,FBXO30,FCAR,FCGR2C,FCGR3B,FCHSD2,FCN1,FEM1A,FEM1C,FEZ2,FFAR2,FGD2,FGD6,FILIP1L,FKBP9,FLII,FNDC3B,FOLR3,FOSB,FOSL1,FOSL2,FOXO3,FPR2,FRAT1,FRMD4B,FRRS1,FSCN1,FTH1,FTL,G0S2,GAB1,GAB2,GABARAPL1,GABARAPL3,GALNT2,GALNT3,GALR2,GANC,GAPDH,GAS2L3,GAS6,GAS7,NIPSNAP2,GBGT1,GEM,GEN1,GGN,GJB2,GLA,GLTPD2,GLUL,GMEB1,GMFB,GNA11,GNA15,GNAI2,GNAQ,GNB4,GNG5,GNL2,GOLIM4,GPER1,GPM6B,ADGRA2,GPR141,GPR18,GPR27,C5AR2,GPR84,GPRC5A,GPX3,GRAMD1B,GRAMD4,GRINA,GRN,GSTP1,GTF2B,GUCY2D,GUSB,GZF1,H3-5,HAAO,HAL,HBEGF,HBP1,HCAR2,HCAR3,HDAC6,HDC,HERPUD1,HES1,HES4,HEYL,HIC1,HIC2,HIF1A,HINT3,HIP1,HLA-DMA,HLA-DMB,HLA-DRA,HLA-DRB1,HLA-DRB5,HLX,HMGCR,HMGCS1,HMGXB4,HMOX1,HNRNPAB,HNRNPH2,HRH2,HS6ST1,HSP90AA4P,HSPA13,HSPA4,HSPG2,ICAM1,ICOSLG,ID1,ID2,ID2B,IDH3A,IDI1,IER2,IER3,IER5,IFI30,IFIT2,IFNGR1,IFNGR2,IFT20,IGF2BP2,IGF2BP3,IGSF6,IKBKG,IL17RC,IL1B,IL1R1,IL1RAP,IL6,CXCL8,IMPA2,INCENP,ING3,INO80B,INSR,IPMK,IQGAP2,IQSEC1,IQSEC2,IRF4,IRF8,IRS2,ISG20L2,ITFG1,FAM234A,ITGA9,ITGAX,ITPRIP,ITPRIPL2,JAG1,JAK2,JARID2,JDP2,JMJD1C,JUN,JUND,KANK2,KAT5,KATNIP,KBTBD7,KBTBD8,KCNA5,KCNC3,KCNJ15,KCNJ2,KCNJ2-AS1,KCNQ1,KCTD3,KCTD5,KDM4B,KDM6B,KHSRP,KIAA0513,KIAA1522,KIF13A,KIF5B,KLF10,KLF2,KLF4,KLF6,KLHL15,KLHL2,KLHL8,KLK1,KPNA2,KPNA3,KREMEN1,KRT23,KSR1,KYNU,LACTB,LAMB3,LASP1,LATS2,LDHD,LDLR,LDLRAD3,LENG9,LGALS8,LGR4,LHFPL2,LILRA1,LILRA4,LILRB1,LILRB4,LIN7A,LIPN,ZNF594-DT,LONRF1,LOXL3,LPCAT3,PLPPR2,LRG1,IRAG2,NRROS,LRRC4,LRRC58,LRRC59,LRRK1,LRRK2,LTB4R2,,LY86,LYN,LYNX1,LYSMD3,LYST,LYZ,MACC1,MAFB,MAFG,MAFK,MAML3,MAN1A1,MAN2B1,MAP1LC3B2,MAP2K3,MAP2K7,MAP3K11,MAP3K2,MAP3K20-AS1,MAP3K3,MAP3K8,MAPK12,MAPK6,MAPK7,MAPK8,MAPRE1,MAPRE3,MARVELD1,MAT2A,MBTPS2,MCL1,MCM5,MCTP1,MCU,MDM2,MED12L,MED13L,MED14,MED25,MED26,MED29,MEF2A,MEF2C,MERTK,TLNRD1,METRNL,MEX3B,MFAP1,MFAP3,MFAP4,MFSD2A,SLC49A3,MGRN1,MICAL2,MID1IP1,MIDN,MIER2,MILR1,MIR23A,MIR24-2,MIR27A,MIR3064,MIR650,MIS18BP1,MITF,MKNK2,MKRN9P,MLX,MME,MMP9,MNT,MOB1A,MOB3A,MON1B,MPEG1,MPO,MPP7,MPV17L2,MROH1,MRPS17,MRPS22,MS4A14,MTHFD2,MTMR10,MTMR14,MTMR3,MTMR6,MTX1,MUL1,MXD1,MYADM,MYD88,MYO1E,MYO1F,MYO5A,MYO9B,NAB1,NAB2,NADK,NADSYN1,NAMPT,NANS,NAT1,NAT8L,NBPF10,NCF1,NCF1C,NCF2,NCF4,NCKAP1L,NCOA4,NCOR2,NDEL1,NDST1,NEDD9,NETO2,NFE2L2,NFIC,NFIL3,NFKBIA,NFKBIB,NFKBID,NFKBIE,NFKBIZ,NHLRC3,NHS,NINJ1,NIPAL2,NKIRAS2,NLRP3,NOTCH3,NPEPL1,NPR3,NR1H2,NR4A1,NR4A2,NR4A3,NR6A1,NRARP,NRAS,NRBF2,NRIP1,NRP1,NSUN7,NT5DC2,NUBP1,NUDT17,NUDT3,NUMB,NUP58,OAF,OASL,OAT,OCRL,ODF3B,ODF3L1,OGFRL1,OLIG1,OLR1,OPN3,OR2B11,OSGIN1,OSGIN2,OSM,OSR2,OTUD1,OXER1,P2RX1,P2RX7,P2RY1,P2RY11,P2RY13,P3H2,PAK1IP1,PAK4,PALD1,PANX2,PCCA,PCDHGC3,PDLIM7,PEAK1,PELI1,PELI2,PFKFB2,PFKFB3,PGAM2,PGD,PGM5,PHACTR1,JADE3,PHLDA2,PI4K2A,PIAS4,PICALM,PIGS,PIK3CG,PIK3R5,PILRA,PIM3,PIP5K1B,PISD,PJA2,PLAGL1,PLAGL2,PLAUR,PLBD1,PLCG2,PLD2,PLD4,PLEK,PLEKHM1,PLEKHM2,PLEKHO2,PLK2,PLVAP,PLXDC2,PLXNC1,PLXND1,PMAIP1,PNO1,PNOC,PNPLA1,PNPLA2,PNPLA8,POU2F2,PLPP3,PPIF,PPIP5K2,PPM1J,PPM1L,PPP1R15A,PPP1R15B,PPP2CA,PPP2R5B,PRC1,PRICKLE4,PRKACA,PRKACG,CAVIN3,PRLR,PRMT3,PROSER1,PSMB7,PSMD11,PSMD3,PTGES,PTGS2,PTP4A1,PTPRE,PTPRS,PTTG1IP,PTX3,PXK,PYCARD,QTRT2,RAB11FIP1,RAB18,RAB1A,RAB20,RAB21,RAB35,RAB39A,RAB5A,RAB5C,RAB8A,RABGEF1,RAD23B,RAD51AP1,RAD9B,RAF1,RAP2C,RAPGEF2,RARA,RASD1,RASGEF1B,RASGRP4,RASL10A,RASL11A,RASSF8,RB1CC1,RBBP8,RBM47,RCOR1,RDX,REEP4,REL,RELB,RELT,COP1,RFX1,RGS2,RGS7,RHBDF2,RHOB,RHOQ,RIC1,RILPL2,RIN3,RIOK3,RIPK2,RIT1,RMND5A,RNASE6,RNASEK,RNASET2,RNF122,RNF13,RNF130,RNF24,ROCK1,RP2,RPH3A,RPL7L1,RPP21,RPS6KC1,RRAGC,RRBP1,RREB1,RRM2B,RRP12,RSC1A1,RSRC1,SNX29,RUSC2,RYBP,S100Z,S1PR3,SAMD4B,SAP130,SAP30,SAT1,SBF2,SCAMP2,SCAMP4,SCAMP5,SCARB1,SCARB2,SCARF1,SCN9A,SCPEP1,SCRN1,SDCBP,SEC14L1,SEL1L,COA7,SEMA4A,SEMA6B,SEMA7A,SERINC1,SERPINB1,SERPINB2,SERPINB8,SERPINB9,SERPINE1,SERPINF1,SESN2,SESTD1,SETD7,SFPQ,SFT2D2,SFXN3,SGK1,SGK3,SGMS2,SH2B2,SH3BP4,SH3PXD2B,SH3RF1,SHANK1,SHD,SHKBP1,SIDT2,SIGLEC10,SIGLEC14,SIGLEC15,SIGLEC6,SIK1,SIN3B,SIPA1L1,SIPA1L2,SIPA1L3,SIRPB2,SIRT1,SKAP2,SKIL,MTREX,SLC12A3,SLC12A6,SLC15A3,SLC16A5,SLC17A9,SLC19A1,SLC19A2,SLC1A5,SLC22A18,SLC22A18AS,SLC22A4,SLC25A34,SLC25A37,SLC29A1,SLC2A3,SLC2A6,SLC30A1,SLC30A9,SLC31A1,SLC31A2,SLC35B1,SLC35E3,SLC35E4,SLC36A1,SLC36A4,SLC38A7,SLC38A9,SLC39A9,SLC43A2,SLC6A6,SLC7A11,SLC7A5,SLC8A1,SLC9A7,SLX4,SMAD1,SMARCB1,SMARCD3,SMPD3,SMTN,SNAI1,SNIP1,SNX10,SNX12,SNX13,SNX2,SOAT1,SOCS4,SOD2,SOGA1,SOX15,SOX4,SOX5,SPATA2L,SPHK1,SPI1,SPIB,SPOPL,SPRY2,SPTY2D1,SQSTM1,SRC,SRGAP2B,SRGN,SRSF9,ITPRID2,SSPN,SSPOP,ST14,ST20-AS1,ST6GALNAC2,STEAP3,STK17B,STK32B,STRN4,STS,STX10,STX11,STX12,STX16-NPEPL1,SULF2,SUSD6,SWAP70,SYK,SYS1-DBNDD2,SYT1,TAF13,TAS1R3,TBC1D12,TBC1D2,TBC1D23,TBC1D8,TBC1D9,TBC1D9B,TBXAS1,TCF4,TDG,TESK2,TET2,TET3,TFE3,TFEC,TFIP11,TGFBI,TGIF1,THAP9,THBD,THEMIS2,THG1L,TIAM2,TICAM1,TICAM2,TIFAB,TIGD3,TIMP2,TKT,TLE3,TLR1,TLR4,TLR6,TLR9,TM9SF2,TMED7,TMED7-TICAM2,TMEM104,TMEM127,TMEM144,TMEM150B,TMEM154,TMEM167A,TMEM167B,TMEM170B,TMEM175,TMEM38A,TMEM39A,TMEM39B,TMEM86A,TMEM88,EMC6,TMTC2,TNFAIP2,TNFAIP6,TNFRSF10B,TNFRSF10C,TNFRSF12A,TNFRSF13C,TNFRSF1B,TNFRSF21,TNFSF12-TNFSF13,TNFSF13,TNFSF15,TNRC18,TNS3,TOP1,TOR1AIP1,TP53INP2,TPK1,TRAF7,TRAK1,TRAM2,TREM1,TREML4,TRIB1,TRIM26,TRIM8,TRIO,TRIP12,TSC22D2,TSG101,TSPAN13,TSPYL5,TTC4,TTC7A,TTLL4,TTYH3,TUBB4B,TUBB3,TUBB6,TUBGCP2,TUBGCP3,TXNDC16,TXNDC5,TXNRD1,TYROBP,UAP1L1,UBC,UBE2D1,UBE2E2,UBE2J1,UBE2W,UCHL3,UGCG,UGGT2,BLTP3A,BLTP3B,ULK1,UNC93B1,USP16,USP3,USP32,USP38,USP6NL,USP8,UVSSA,VAMP3,VAV2,VEGFA,VIM,VMP1,VNN1,VNN3P,VPS25,VPS26A,VPS37C,VRK2,VSIG10L,WARS1,WASF1,WASHC2A,WASHC2C,WDFY4,WDR17,WDR45B,WDR47,WIPI1,YIF1A,YPEL2,YPEL5,YTHDF3,YWHAE,YWHAG,MAP3K20,ZBTB33,ZBTB34,ZBTB43,ZBTB7A,ZC3H12A,ZC3H12C,ZDHHC7,ZFAND3,ZFAND5,ZFAT,ZFHX3,ZFP36,ZFP92,ZFR,ZMIZ1,ZMYND15,ZNF100,ZNF124,ZNF184,ZNF267,ZNF281,ZBTB21,ZNF330,ZNF385A,ZNF426,ZNF503,ZNF503-AS2,ZNF516,ZNF521,ZNF532,ZNF593,ZNF614,ZNF689,ZNF697,ZNF703,ZNF710,ZNF746,ZNF768,ZNF791,ZNF844",1251,"ABAT,ABCA1,ABCA6,ABCD1,ABHD5,ABTB2,ACAD9,ACBD3,ACO2,ACP5,ACSL1,ACSL4,ACVR1B,ADAM17,ADAM9,ADAMTSL4,ADGRE2,ADIPOR1,ADM,ADRBK2,ADRM1,ADSSL1,AFF3,AHNAK2,AHR,AIMP2,AKIRIN2,AKT1S1,ALAS1,ALDH1A1,ALDH2,ALDH3B1,ALDH3B2,ALOX5,ANGPT1,ANKLE1,ANKRD36BP1,ANKRD57,ANO8,ANP32D,ANXA1,AP1B1,AP2A1,AP3B1,APLP2,APOM,APP,ARF1,ARF4,ARG2,ARHGAP1,ARHGAP23,ARHGAP24,ARHGAP42,ARHGEF40,ARID3A,ARL4A,ARL5B,ARL6IP1,ARL8A,ARL8B,ARNTL2,ARRDC4,ARSG,ASAH1,ASAP1,ATF3,ATF5,ATOX1,ATP11A,ATP1B1,ATP2A2,ATP5B,ATP5C1,ATP6V0B,ATP6V0C,ATP6V1F,ATPAF2,AZI2,AZU1,B3GNT5,B9D2,BACH1,BAG6,BAHCC1,BAK1,BAMBI,BANK1,BASP1,BAZ2B,BCAT1,BCL10,BCL2A1,BCL2L11,BCL2L2,BCL2L2-PABPN1,BCL3,BCL6,BHLHA15,BHLHE40,BHLHE41,BLVRB,BMF,BMP8B,BNIP2,BNIP3L,BOP1,BORCS8-MEF2B,BPI,BRI3BP,BRWD3,BTBD3,BTK,BZW1,C11orf24,C11orf75,C11orf95,C11orf96,C12orf34,C12orf59,C14orf43,C15orf39,C15orf48,C16orf70,C17orf103,C17orf107,C17orf87,C19orf38,C19orf40,C19orf54,C19orf71,C1orf124,C1orf186,C1orf96,C22orf13,C2orf49,C3orf21,C3orf58,C4orf46,C5AR1,C6orf145,C6orf72,C9orf139,C9orf140,C9orf21,C9orf66,C9orf72,CA5BP1,CADM4,CAPZA1,CARM1,CASP3,CASP9,CAT,CBFA2T3,CBX2,CBX6,CBX8,CCDC103,CCDC13,CCDC43,CCDC47,CCDC50,CCDC6,CCDC86,CCDC88A,CCDC94,CCL20,CCNK,CCNYL1,CCPG1,CCR1,CCRL2,CCRN4L,CD300E,CD302,CD34,CD38,CD46,CD55,CD68,CD80,CD83,CD86,CDA,CDC40,CDC42BPB,CDC42EP1,CDC42EP2,CDC42EP4,CDC5L,CDK14,CDKN1A,CEACAM4,CEBPB,CEBPD,CENPW,CEP170,CERS6,CHKA,CHML,CHMP1B,CHMP2B,CHRAC1,CHRNE,CHST15,CIDEB,CIITA,CKAP2,CKAP4,CKS2,CLDN23,CLEC12A,CLEC4C,CLEC4D,CLEC4F,CLIC4,CLIP2,CLMN,CLN6,CLPB,CLPTM1,CMIP,CMTM6,CNIH4,CNNM4,CNTLN,COBL,COBLL1,COL24A1,COL4A3BP,COL9A2,COQ8A,CORO1C,CORO7-PAM16,COTL1,COX5B,CPA3,CPEB4,CREB5,CRISPLD2,CRK,CSDA,CSF1R,CSF2RB,CSF3R,CSGALNACT2,CSNK1A1L,CST3,CTIF,CTSZ,CUEDC1,CUX2,CWC25,CXCL16,CXorf21,CXXC5,CYB5R4,CYBB,CYC1,CYP51A1,DACH1,DAPK1,DCTN4,DCUN1D1,DCUN1D3,DDO,DDX21,DDX3X,DDX49,DENND1A,DENND3,DENND5B,DERA,DHTKD1,DHX8,DIAPH2,DICER1,DIRC2,DKFZp761E198,DLC1,DLX2,DNAJC11,DNAJC3,DNASE1L1,DNM2,DNMBP,DOCK1,DOCK2,DOCK4,DOCK5,DOK3,DOT1L,DPP3,DPPA4,DSC2,DSE,DSG2,DUSP10,DUSP6,DVL3,DYM,DYSF,EAF1,ECHDC3,EFCAB11,EFCAB4A,EIF3A,EIF3C,EIF4A1,EIF4A3,EIF4E2,EIF4EBP1,EIF4EBP3,EIF4G2,EIF4H,ELF1,ELF4,ELL,ELL2,ELOF1,EME2,EMP1,ENTPD7,EPB41L2,EPHA2,EPHX3,EPN1,ERCC5,EREG,ERF,ERG,ESRRA,ETF1,ETS2,EVI2B,EXT1,F3,FAM100A,FAM102B,FAM110B,FAM117B,FAM124B,FAM126A,FAM127A,FAM151B,FAM175B,FAM198B,FAM212B,FAM214B,FAM43A,FAM45A,FAM46A,FAM46B,FAM49A,FAM53C,FAM65A,FAM70B,FAM91A1,FAM98B,FBN1,FBXO30,FCAR,FCGR2C,FCGR3B,FCHSD2,FCN1,FEM1A,FEM1C,FEZ2,FFAR2,FGD2,FGD6,FILIP1L,FKBP9,FLII,FNDC3B,FOLR3,FOSB,FOSL1,FOSL2,FOXO3,FPR2,FRAT1,FRMD4B,FRRS1,FSCN1,FTH1,FTL,G0S2,GAB1,GAB2,GABARAPL1,GABARAPL3,GALNT2,GALNT3,GALR2,GANC,GAPDH,GAS2L3,GAS6,GAS7,GBAS,GBGT1,GEM,GEN1,GGN,GJB2,GLA,GLTPD2,GLUL,GMEB1,GMFB,GNA11,GNA15,GNAI2,GNAQ,GNB4,GNG5,GNL2,GOLIM4,GPER1,GPM6B,GPR124,GPR141,GPR18,GPR27,GPR77,GPR84,GPRC5A,GPX3,GRAMD1B,GRAMD4,GRINA,GRN,GSTP1,GTF2B,GUCY2D,GUSB,GZF1,H3F3C,HAAO,HAL,HBEGF,HBP1,HCAR2,HCAR3,HDAC6,HDC,HERPUD1,HES1,HES4,HEYL,HIC1,HIC2,HIF1A,HINT3,HIP1,HLA-DMA,HLA-DMB,HLA-DRA,HLA-DRB1,HLA-DRB5,HLX,HMGCR,HMGCS1,HMGXB4,HMOX1,HNRNPAB,HNRNPH2,HRH2,HS6ST1,HSP90AA4P,HSPA13,HSPA4,HSPG2,ICAM1,ICOSLG,ID1,ID2,ID2B,IDH3A,IDI1,IER2,IER3,IER5,IFI30,IFIT2,IFNGR1,IFNGR2,IFT20,IGF2BP2,IGF2BP3,IGSF6,IKBKG,IL17RC,IL1B,IL1R1,IL1RAP,IL6,IL8,IMPA2,INCENP,ING3,INO80B,INSR,IPMK,IQGAP2,IQSEC1,IQSEC2,IRF4,IRF8,IRS2,ISG20L2,ITFG1,ITFG3,ITGA9,ITGAX,ITPRIP,ITPRIPL2,JAG1,JAK2,JARID2,JDP2,JMJD1C,JUN,JUND,KANK2,KAT5,KATNIP,KBTBD7,KBTBD8,KCNA5,KCNC3,KCNJ15,KCNJ2,KCNJ2-AS1,KCNQ1,KCTD3,KCTD5,KDM4B,KDM6B,KHSRP,KIAA0513,KIAA1522,KIF13A,KIF5B,KLF10,KLF2,KLF4,KLF6,KLHL15,KLHL2,KLHL8,KLK1,KPNA2,KPNA3,KREMEN1,KRT23,KSR1,KYNU,LACTB,LAMB3,LASP1,LATS2,LDHD,LDLR,LDLRAD3,LENG9,LGALS8,LGR4,LHFPL2,LILRA1,LILRA4,LILRB1,LILRB4,LIN7A,LIPN,LOC100130950,LONRF1,LOXL3,LPCAT3,LPPR2,LRG1,LRMP,LRRC33,LRRC4,LRRC58,LRRC59,LRRK1,LRRK2,LTB4R2,LUZP6,LY86,LYN,LYNX1,LYSMD3,LYST,LYZ,MACC1,MAFB,MAFG,MAFK,MAML3,MAN1A1,MAN2B1,MAP1LC3B2,MAP2K3,MAP2K7,MAP3K11,MAP3K2,MAP3K20-AS1,MAP3K3,MAP3K8,MAPK12,MAPK6,MAPK7,MAPK8,MAPRE1,MAPRE3,MARVELD1,MAT2A,MBTPS2,MCL1,MCM5,MCTP1,MCU,MDM2,MED12L,MED13L,MED14,MED25,MED26,MED29,MEF2A,MEF2C,MERTK,MESDC1,METRNL,MEX3B,MFAP1,MFAP3,MFAP4,MFSD2A,MFSD7,MGRN1,MICALCL,MID1IP1,MIDN,MIER2,MILR1,MIR23A,MIR24-2,MIR27A,MIR3064,MIR650,MIS18BP1,MITF,MKNK2,MKRN9P,MLX,MME,MMP9,MNT,MOBKL1B,MOBKL2A,MON1B,MPEG1,MPO,MPP7,MPV17L2,MROH1,MRPS17,MRPS22,MS4A14,MTHFD2,MTMR10,MTMR14,MTMR3,MTMR6,MTX1,MUL1,MXD1,MYADM,MYD88,MYO1E,MYO1F,MYO5A,MYO9B,NAB1,NAB2,NADK,NADSYN1,NAMPT,NANS,NAT1,NAT8L,NBPF10,NCF1,NCF1C,NCF2,NCF4,NCKAP1L,NCOA4,NCOR2,NDEL1,NDST1,NEDD9,NETO2,NFE2L2,NFIC,NFIL3,NFKBIA,NFKBIB,NFKBID,NFKBIE,NFKBIZ,NHLRC3,NHS,NINJ1,NIPAL2,NKIRAS2,NLRP3,NOTCH3,NPEPL1,NPR3,NR1H2,NR4A1,NR4A2,NR4A3,NR6A1,NRARP,NRAS,NRBF2,NRIP1,NRP1,NSUN7,NT5DC2,NUBP1,NUDT17,NUDT3,NUMB,NUPL1,OAF,OASL,OAT,OCRL,ODF3B,ODF3L1,OGFRL1,OLIG1,OLR1,OPN3,OR2B11,OSGIN1,OSGIN2,OSM,OSR2,OTUD1,OXER1,P2RX1,P2RX7,P2RY1,P2RY11,P2RY13,P3H2,PAK1IP1,PAK4,PALD1,PANX2,PCCA,PCDHGC3,PDLIM7,PEAK1,PELI1,PELI2,PFKFB2,PFKFB3,PGAM2,PGD,PGM5,PHACTR1,PHF16,PHLDA2,PI4K2A,PIAS4,PICALM,PIGS,PIK3CG,PIK3R5,PILRA,PIM3,PIP5K1B,PISD,PJA2,PLAGL1,PLAGL2,PLAUR,PLBD1,PLCG2,PLD2,PLD4,PLEK,PLEKHM1,PLEKHM2,PLEKHO2,PLK2,PLVAP,PLXDC2,PLXNC1,PLXND1,PMAIP1,PNO1,PNOC,PNPLA1,PNPLA2,PNPLA8,POU2F2,PPAP2B,PPIF,PPIP5K2,PPM1J,PPM1L,PPP1R15A,PPP1R15B,PPP2CA,PPP2R5B,PRC1,PRICKLE4,PRKACA,PRKACG,PRKCDBP,PRLR,PRMT3,PROSER1,PSMB7,PSMD11,PSMD3,PTGES,PTGS2,PTP4A1,PTPRE,PTPRS,PTTG1IP,PTX3,PXK,PYCARD,QTRTD1,RAB11FIP1,RAB18,RAB1A,RAB20,RAB21,RAB35,RAB39,RAB5A,RAB5C,RAB8A,RABGEF1,RAD23B,RAD51AP1,RAD9B,RAF1,RAP2C,RAPGEF2,RARA,RASD1,RASGEF1B,RASGRP4,RASL10A,RASL11A,RASSF8,RB1CC1,RBBP8,RBM47,RCOR1,RDX,REEP4,REL,RELB,RELT,RFWD2,RFX1,RGS2,RGS7,RHBDF2,RHOB,RHOQ,RIC1,RILPL2,RIN3,RIOK3,RIPK2,RIT1,RMND5A,RNASE6,RNASEK,RNASET2,RNF122,RNF13,RNF130,RNF24,ROCK1,RP2,RPH3A,RPL7L1,RPP21,RPS6KC1,RRAGC,RRBP1,RREB1,RRM2B,RRP12,RSC1A1,RSRC1,RUNDC2A,RUSC2,RYBP,S100Z,S1PR3,SAMD4B,SAP130,SAP30,SAT1,SBF2,SCAMP2,SCAMP4,SCAMP5,SCARB1,SCARB2,SCARF1,SCN9A,SCPEP1,SCRN1,SDCBP,SEC14L1,SEL1L,SELRC1,SEMA4A,SEMA6B,SEMA7A,SERINC1,SERPINB1,SERPINB2,SERPINB8,SERPINB9,SERPINE1,SERPINF1,SESN2,SESTD1,SETD7,SFPQ,SFT2D2,SFXN3,SGK1,SGK3,SGMS2,SH2B2,SH3BP4,SH3PXD2B,SH3RF1,SHANK1,SHD,SHKBP1,SIDT2,SIGLEC10,SIGLEC14,SIGLEC15,SIGLEC6,SIK1,SIN3B,SIPA1L1,SIPA1L2,SIPA1L3,SIRPB2,SIRT1,SKAP2,SKIL,SKIV2L2,SLC12A3,SLC12A6,SLC15A3,SLC16A5,SLC17A9,SLC19A1,SLC19A2,SLC1A5,SLC22A18,SLC22A18AS,SLC22A4,SLC25A34,SLC25A37,SLC29A1,SLC2A3,SLC2A6,SLC30A1,SLC30A9,SLC31A1,SLC31A2,SLC35B1,SLC35E3,SLC35E4,SLC36A1,SLC36A4,SLC38A7,SLC38A9,SLC39A9,SLC43A2,SLC6A6,SLC7A11,SLC7A5,SLC8A1,SLC9A7,SLX4,SMAD1,SMARCB1,SMARCD3,SMPD3,SMTN,SNAI1,SNIP1,SNX10,SNX12,SNX13,SNX2,SOAT1,SOCS4,SOD2,SOGA1,SOX15,SOX4,SOX5,SPATA2L,SPHK1,SPI1,SPIB,SPOPL,SPRY2,SPTY2D1,SQSTM1,SRC,SRGAP2P2,SRGN,SRSF9,SSFA2,SSPN,SSPO,ST14,ST20-AS1,ST6GALNAC2,STEAP3,STK17B,STK32B,STRN4,STS,STX10,STX11,STX12,STX16-NPEPL1,SULF2,SUSD6,SWAP70,SYK,SYS1-DBNDD2,SYT1,TAF13,TAS1R3,TBC1D12,TBC1D2,TBC1D23,TBC1D8,TBC1D9,TBC1D9B,TBXAS1,TCF4,TDG,TESK2,TET2,TET3,TFE3,TFEC,TFIP11,TGFBI,TGIF1,THAP9,THBD,THEMIS2,THG1L,TIAM2,TICAM1,TICAM2,TIFAB,TIGD3,TIMP2,TKT,TLE3,TLR1,TLR4,TLR6,TLR9,TM9SF2,TMED7,TMED7-TICAM2,TMEM104,TMEM127,TMEM144,TMEM150B,TMEM154,TMEM167A,TMEM167B,TMEM170B,TMEM175,TMEM38A,TMEM39A,TMEM39B,TMEM86A,TMEM88,TMEM93,TMTC2,TNFAIP2,TNFAIP6,TNFRSF10B,TNFRSF10C,TNFRSF12A,TNFRSF13C,TNFRSF1B,TNFRSF21,TNFSF12-TNFSF13,TNFSF13,TNFSF15,TNRC18,TNS3,TOP1,TOR1AIP1,TP53INP2,TPK1,TRAF7,TRAK1,TRAM2,TREM1,TREML4,TRIB1,TRIM26,TRIM8,TRIO,TRIP12,TSC22D2,TSG101,TSPAN13,TSPYL5,TTC4,TTC7A,TTLL4,TTYH3,TUBB2C,TUBB3,TUBB6,TUBGCP2,TUBGCP3,TXNDC16,TXNDC5,TXNRD1,TYROBP,UAP1L1,UBC,UBE2D1,UBE2E2,UBE2J1,UBE2W,UCHL3,UGCG,UGGT2,UHRF1BP1,UHRF1BP1L,ULK1,UNC93B1,USP16,USP3,USP32,USP38,USP6NL,USP8,UVSSA,VAMP3,VAV2,VEGFA,VIM,VMP1,VNN1,VNN3,VPS25,VPS26A,VPS37C,VRK2,VSIG10L,WARS,WASF1,WASHC2A,WASHC2C,WDFY4,WDR17,WDR45L,WDR47,WIPI1,YIF1A,YPEL2,YPEL5,YTHDF3,YWHAE,YWHAG,ZAK,ZBTB33,ZBTB34,ZBTB43,ZBTB7A,ZC3H12A,ZC3H12C,ZDHHC7,ZFAND3,ZFAND5,ZFAT,ZFHX3,ZFP36,ZFP92,ZFR,ZMIZ1,ZMYND15,ZNF100,ZNF124,ZNF184,ZNF267,ZNF281,ZNF295,ZNF330,ZNF385A,ZNF426,ZNF503,ZNF503-AS2,ZNF516,ZNF521,ZNF532,ZNF593,ZNF614,ZNF689,ZNF697,ZNF703,ZNF710,ZNF746,ZNF768,ZNF791,ZNF844",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M40966,INFLUENZA,IN,INFLUENZA,HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_28DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_28DY_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response in peripheral blood mononuclear cell in adults (50-74) after exposure to trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). , time point 28D. Comment: Association of baseline, early and late gene expression changes with peak memory B cell ELISPOT response (Day 28 - Day 0) in older individuals","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"BLCAP,CFH,CHMP4A,CMBL,CNPY4,DHRS13,ERG28,GOLGA7B,ITGB1BP1,KIAA0408,KRT1,LINC02591,MCRIP1,IGSF9B,MSX2P1,NDFIP2,NECTIN3-AS1,PECR,SELENOW,SERGEF,STX8,TRIM2,TTLL1,UGP2,ZNF32",25,"BLCAP,CFH,CHMP4A,CMBL,CNPY4,DHRS13,ERG28,GOLGA7B,ITGB1BP1,KIAA0408,KRT1,LINC02591,MCRIP1,MIR4697HG,MSX2P1,NDFIP2,NECTIN3-AS1,PECR,SELENOW,SERGEF,STX8,TRIM2,TTLL1,UGP2,ZNF32",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41118,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D3,D,3,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 3D","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"AAGAB,ABCC5,ACBD4,ACTR10,ACTR6,ADAL,AFAP1-AS1,AGFG2,AGL,AHSA1,AKAP12,AKTIP,ALDH5A1,ALDH9A1,ALG6,AMACR,ANAPC7,ANGEL2,ANGPT2,AP2A2,AP2B1,APC2,APEH,API5,APOBEC3D,APOBEC3F,APOBEC3H,ARFRP1,ARHGAP30,ARHGEF19,ARHGEF4,ARL17A,ARMC7,ASB1,ASB2,ASTN2,ATAT1,ATG10,ATP5F1D,ATP5F1EP2,ATP5MC2,ATPAF1,ATP5IF1,ATRIP,B3GNT2,BCAP31,BDH2,BLCAP,BMS1,BOD1,BOLA3,BORCS5,BPNT1,BTBD10,BUB3,BUD13,TMEM258,C11orf68,HIKESHI,INTS13,ERG28,C14orf132,COA8,PAGR1,C17orf100,OGFOD3,C17orf75,C18orf54,C19orf25,WDR83OS,MICOS10,C1orf216,C1orf56,ACTL10,GATD3,C21orf62-AS1,C22orf39,CDPF1,CLHC1,RTP5,C4orf3,TMA16,SMIM20,SMIM29,ABRACL,MTRES1,SAYSD1,RNF32-DT,TMEM248,RBIS,AOPEP,C9orf43,CAAP1,CABIN1,CACNA1C,CARD8,CBR4,CBX3,KYAT1,CCDC167,CCDC34,CCDC61,CCDC81,CCM2,CCT4,CD2BP2,CDADC1,CDK4,CDKL3,CDRT4,CEMP1,CEP250,CEP44,CEP89,CERK,CERS5,CHMP4A,CHMP6,CHRNB1,CIPC,CISD1,CLIC5,CLNS1A,CLYBL,CMBL,CNPY2,CNPY4,COA5,COG6,COMMD6,COPS4,COPS5,COPZ1,COQ4,COX15,CPNE1,CPNE7,CRTC1,CSTF3,CTU1,CWF19L2,CXCR6,CYB561D1,CYB5B,ZFTRAF1,CYP20A1,DBT,DCAF8,DCP2,DCTN5,DCTPP1,DDB1,DGUOK,DHDDS,DHRS13,DIAPH1,LINC01011,DLGAP4,DMAC1,DNAJC19,DNAJC24,DNAJC8,DNAL4,DOCK7,DTYMK,DUSP19,DUT,EARS2,,EEF2KMT,EIF2B3,EIF2B4,EIF2S2,EIF5B,ELAC1,ELAVL1,ENTPD3-AS1,ERP29,EXOSC7,EYA3,FAHD2B,FAIM,PABIR1,RETREG3,SLF2,PSME3IP1,TAFA1,FARSB,FAT2,FBLN5,FBXO22,FBXW2,FCF1,FCRLB,FDFT1,FDXR,FKBP3,FKBP4,FLAD1,FLVCR1-DT,FOCAD,FRA10AC1,FUT2,GFOD2,GGPS1,GIMAP1,GIMAP1-GIMAP5,GIN1,GLE1,GLG1,GNL1,GNPNAT1,GOLGA7B,GOSR2,GOT1,GOT2,GPATCH4,GPD1L,GTF3C1,GTPBP10,MACROH2A2,HCFC2,HCST,HDDC3,HDHD3,HENMT1,HHLA3,HIF1AN,HIRIP3,HLTF,HMGCL,HMOX2,JPT2,HNF1A,HNRNPA3,HNRNPU,HOXB2,HSPA1L,HSPBP1,HTRA2,HTT,ICE2,IFT27,IGFBP4,IGSF8,IL16,ING4,INPP5B,INSIG2,ITGB1BP1,JMJD4,JRK,KBTBD3,KCTD7,KDM5A,KIF3A,KIFAP3,KLHDC3,KLHL22,KLHL9,KLRG1,KMT5B,PRKRIP1,KRIT1,KRT1,L3MBTL2,LAGE3,LBHD1,LCMT1,LEO1,ZC3H12A-DT,LMAN2,LMAN2L,,,C2orf74-DT,ANXA2R-OT1,LRP11,LRPPRC,LRRC45,LRTOMT,LSM2,LSM4,LSM5,LYAR,LYPLA2,LYRM7,LYSMD1,LYSMD2,MADD,MAEA,MAF,MAGOHB,MAP4,MAP7D3,MAPT,MAVS,MBP,MCRIP1,MCTS1,MDH1,MDM1,MDP1,MED22,MED4,MESD,EEF1AKMT3,METTL23,METTL2A,METTL6,MFF,RIOX2,MIPEP,MKS1,MLH1,MLH3,MMAB,MOB2,MPPED2,MRC2,MROH7-TTC4,MRPL57,MRPL19,MRPL30,MRPL35,MRPL48,MRPL51,MRPS12,MRPS14,MRPS16,MRPS18B,MRPS25,MRPS33,MRPS5,MRPS7,MRPS9,MTHFSD,MVK,MYL6,N6AMT1,NAA38,NAALADL1,NAP1L4,NAPEPLD,NBAS,NCBP1,MTLN,LINC00324,NDFIP2,NDUFA2,NDUFA6,NDUFB2,NDUFS2,NDUFS5,NEDD8,NEIL2,NFATC1,NFATC3,NFS1,NFU1,NHLRC4,SNU13,NIF3L1,NME7,NMRAL1,NOM1,NOP14-AS1,NPDC1,NSMCE1,NTHL1,NUDCD3,ORMDL2,OSGEP,OXSM,PAAF1,PAQR8,PARG,PARP1,PCID2,PCNX3,PCYT2,PDCD10,PDCD11,PDK2,PDLIM2,PDP2,PDZD11,PEF1,PFDN5,PFKL,PGAP3,PHB1,PHF19,PHF20,PHTF2,PIGP,PIGU,PIN4,PKNOX1,PLEKHH1,PMVK,POLH,POLR3K,POT1,PPA2,PPIE,PPIP5K1,PPP1R12B,PPP2R1A,PPP2R5C,PPP2R5D,PREPL,PRMT2,PRPSAP2,PRR13,PRR5,PSMC6,PSMD13,PSMD4,PSMG3-AS1,PTGES3,PTPRN2,PURA,PWWP2A,PXMP4,PYGO2,QDPR,RAB22A,RABEPK,RAD51C,RAI14,RALA,RANGAP1,RANGRF,RBM14,RBM4B,RBMX2,RDH16,RECQL5,RER1,RFC4,RFESD,RFPL2,RFT1,RIC8B,RINL,RNASEH2B,RNASEH2C,RNF14,RNF167,RNF220,RNF25,RNF8,RPA1,RPA2,RPL15,RPL23A,RPL32,RPL39,RPL39L,RPS24,RRP1,RTCA,RTN4RL1,S1PR4,SAP30L,SARNP,SARS1,SCAMP3,SCAND2P,SCAP,SCOC,SDAD1,SEMA4F,SEMA4G,SERF2,SERGEF,SETD4,SETDB2,SF3A3,SF3B3,SHF,SEM1,SIRT4,SIRT5,SKA2,SLC30A7,SLC39A8,,SMARCC2,MIEF2,SNORD34,SNORD36C,SNORD50B,SNRPC,SNRPD3,SNUPN,SNX5,SPAG16,SPEF2,SPN,SPOP,SPRN,SPRYD3,SPSB2,SRI,SRPRB,SRSF1,ST20,ST7L,ST8SIA1,STAT5A,STBD1,STRADA,SUCLG1,SUGT1,SURF4,SV2A,SYNRG,SYTL2,TADA3,TAF1,TAF15,TBC1D24,TBCD,TDRKH,TEX264,TFB1M,TGDS,THAP3,THOC3,THOC7,THYN1,MYO18A,TIGD7,TINF2,TIPRL,TLN2,TMCO1,TMEM107,TMEM120B,TMEM186,TMEM203,TMEM216,TMEM50B,TMEM67,TMEM79,KRT10-AS1,TMX2,TNFAIP8L1,TNNC1,TOMM5,TPRG1,TRAPPC2,TRAPPC4,TRAPPC6B,TRIM2,TRIM65,TRIP4,TRNAU1AP,TRPV2,EIPR1,TTC1,TTC9,TTLL1,UBAC2,UBAC2-AS1,UBE2D2,UBE2I,UBE2L3,UBE2Q2,UBL5,UGGT1,UGP2,UNC13D,UNC45B,UNG,UPF3B,UQCR10,UQCR11,UQCRB,ATP5MK,USP37,USP40,USP5,VAPB,VBP1,VEZT,VPS72,VRK3,WDR35,WDR77,PYM1,XPO1,YAF2,YY1AP1,ZC3H6,ZDHHC13,ZFP14,ZFP2,ZFP62,ZFR2,ZMAT2,ZMYM5,ZNF12,ZNF197,ZNF226,ZNF232,ZNF233,ZNF260,ZNF28,ZNF302,ZNF320,ZNF404,ZNF445,ZNF48,ZNF480,ZNF500,ZNF506,ZNF527,ZNF559,ZNF568,ZNF584,ZNF585A,ZNF610,ZNF619,ZNF621,ZNF626,ZNF674,ZNF696,ZNF701,KRBOX5,ZNF737,ZNF738,ZNF75D,ZNF763,ZNF780A,ZNF780B,ZNF84,ZNF850,ZNHIT6,ZSWIM7",642,"AAGAB,ABCC5,ACBD4,ACTR10,ACTR6,ADAL,AFAP1-AS1,AGFG2,AGL,AHSA1,AKAP12,AKTIP,ALDH5A1,ALDH9A1,ALG6,AMACR,ANAPC7,ANGEL2,ANGPT2,AP2A2,AP2B1,APC2,APEH,API5,APOBEC3D,APOBEC3F,APOBEC3H,ARFRP1,ARHGAP30,ARHGEF19,ARHGEF4,ARL17A,ARMC7,ASB1,ASB2,ASTN2,ATAT1,ATG10,ATP5D,ATP5EP2,ATP5G2,ATPAF1,ATPIF1,ATRIP,B3GNT1,BCAP31,BDH2,BLCAP,BMS1,BOD1,BOLA3,BORCS5,BPNT1,BTBD10,BUB3,BUD13,C11orf10,C11orf68,C11orf73,C12orf11,C14orf1,C14orf132,C14orf153,C16orf53,C17orf100,C17orf101,C17orf75,C18orf54,C19orf25,C19orf56,C1orf151,C1orf216,C1orf56,C20orf134,C21orf33,C21orf62-AS1,C22orf39,C22orf40,C2orf63,C2orf85,C4orf3,C4orf43,C4orf52,C6orf1,C6orf115,C6orf203,C6orf64,C7orf13,C7orf42,C8orf59,C9orf3,C9orf43,C9orf82,CABIN1,CACNA1C,CARD8,CBR4,CBX3,CCBL1,CCDC167,CCDC34,CCDC61,CCDC81,CCM2,CCT4,CD2BP2,CDADC1,CDK4,CDKL3,CDRT4,CEMP1,CEP250,CEP44,CEP89,CERK,CERS5,CHMP4A,CHMP6,CHRNB1,CIPC,CISD1,CLIC5,CLNS1A,CLYBL,CMBL,CNPY2,CNPY4,COA5,COG6,COMMD6,COPS4,COPS5,COPZ1,COQ4,COX15,CPNE1,CPNE7,CRTC1,CSTF3,CTU1,CWF19L2,CXCR6,CYB561D1,CYB5B,CYHR1,CYP20A1,DBT,DCAF8,DCP2,DCTN5,DCTPP1,DDB1,DGUOK,DHDDS,DHRS13,DIAPH1,DKFZP686I15217,DLGAP4,DMAC1,DNAJC19,DNAJC24,DNAJC8,DNAL4,DOCK7,DTYMK,DUSP19,DUT,EARS2,EEF1E1-MUTED,EEF2KMT,EIF2B3,EIF2B4,EIF2S2,EIF5B,ELAC1,ELAVL1,ENTPD3-AS1,ERP29,EXOSC7,EYA3,FAHD2B,FAIM,FAM122A,FAM134C,FAM178A,FAM192A,FAM19A1,FARSB,FAT2,FBLN5,FBXO22,FBXW2,FCF1,FCRLB,FDFT1,FDXR,FKBP3,FKBP4,FLAD1,FLVCR1-AS1,FOCAD,FRA10AC1,FUT2,GFOD2,GGPS1,GIMAP1,GIMAP1-GIMAP5,GIN1,GLE1,GLG1,GNL1,GNPNAT1,GOLGA7B,GOSR2,GOT1,GOT2,GPATCH4,GPD1L,GTF3C1,GTPBP10,H2AFY2,HCFC2,HCST,HDDC3,HDHD3,HENMT1,HHLA3,HIF1AN,HIRIP3,HLTF,HMGCL,HMOX2,HN1L,HNF1A,HNRNPA3,HNRNPU,HOXB2,HSPA1L,HSPBP1,HTRA2,HTT,ICE2,IFT27,IGFBP4,IGSF8,IL16,ING4,INPP5B,INSIG2,ITGB1BP1,JMJD4,JRK,KBTBD3,KCTD7,KDM5A,KIF3A,KIFAP3,KLHDC3,KLHL22,KLHL9,KLRG1,KMT5B,KRBOX3,KRIT1,KRT1,L3MBTL2,LAGE3,LBHD1,LCMT1,LEO1,LINC01137,LMAN2,LMAN2L,LOC100506990,LOC143666,LOC339803,LOC648987,LRP11,LRPPRC,LRRC45,LRTOMT,LSM2,LSM4,LSM5,LYAR,LYPLA2,LYRM7,LYSMD1,LYSMD2,MADD,MAEA,MAF,MAGOHB,MAP4,MAP7D3,MAPT,MAVS,MBP,MCRIP1,MCTS1,MDH1,MDM1,MDP1,MED22,MED4,MESDC2,METTL21B,METTL23,METTL2A,METTL6,MFF,MINA,MIPEP,MKS1,MLH1,MLH3,MMAB,MOB2,MPPED2,MRC2,MROH7-TTC4,MRP63,MRPL19,MRPL30,MRPL35,MRPL48,MRPL51,MRPS12,MRPS14,MRPS16,MRPS18B,MRPS25,MRPS33,MRPS5,MRPS7,MRPS9,MTHFSD,MVK,MYL6,N6AMT1,NAA38,NAALADL1,NAP1L4,NAPEPLD,NBAS,NCBP1,NCRNA00116,NCRNA00324,NDFIP2,NDUFA2,NDUFA6,NDUFB2,NDUFS2,NDUFS5,NEDD8,NEIL2,NFATC1,NFATC3,NFS1,NFU1,NHLRC4,NHP2L1,NIF3L1,NME7,NMRAL1,NOM1,NOP14-AS1,NPDC1,NSMCE1,NTHL1,NUDCD3,ORMDL2,OSGEP,OXSM,PAAF1,PAQR8,PARG,PARP1,PCID2,PCNXL3,PCYT2,PDCD10,PDCD11,PDK2,PDLIM2,PDP2,PDZD11,PEF1,PFDN5,PFKL,PGAP3,PHB,PHF19,PHF20,PHTF2,PIGP,PIGU,PIN4,PKNOX1,PLEKHH1,PMVK,POLH,POLR3K,POT1,PPA2,PPIE,PPIP5K1,PPP1R12B,PPP2R1A,PPP2R5C,PPP2R5D,PREPL,PRMT2,PRPSAP2,PRR13,PRR5,PSMC6,PSMD13,PSMD4,PSMG3-AS1,PTGES3,PTPRN2,PURA,PWWP2A,PXMP4,PYGO2,QDPR,RAB22A,RABEPK,RAD51C,RAI14,RALA,RANGAP1,RANGRF,RBM14,RBM4B,RBMX2,RDH16,RECQL5,RER1,RFC4,RFESD,RFPL2,RFT1,RIC8B,RINL,RNASEH2B,RNASEH2C,RNF14,RNF167,RNF220,RNF25,RNF8,RPA1,RPA2,RPL15,RPL23A,RPL32,RPL39,RPL39L,RPS24,RRP1,RTCD1,RTN4RL1,S1PR4,SAP30L,SARNP,SARS,SCAMP3,SCAND2,SCAP,SCOC,SDAD1,SEMA4F,SEMA4G,SERF2,SERGEF,SETD4,SETDB2,SF3A3,SF3B3,SHF,SHFM1,SIRT4,SIRT5,SKA2,SLC30A7,SLC39A8,SLMO2-ATP5E,SMARCC2,SMCR7,SNORD34,SNORD36C,SNORD50B,SNRPC,SNRPD3,SNUPN,SNX5,SPAG16,SPEF2,SPN,SPOP,SPRN,SPRYD3,SPSB2,SRI,SRPRB,SRSF1,ST20,ST7L,ST8SIA1,STAT5A,STBD1,STRADA,SUCLG1,SUGT1,SURF4,SV2A,SYNRG,SYTL2,TADA3,TAF1,TAF15,TBC1D24,TBCD,TDRKH,TEX264,TFB1M,TGDS,THAP3,THOC3,THOC7,THYN1,TIAF1,TIGD7,TINF2,TIPRL,TLN2,TMCO1,TMEM107,TMEM120B,TMEM186,TMEM203,TMEM216,TMEM50B,TMEM67,TMEM79,TMEM99,TMX2,TNFAIP8L1,TNNC1,TOMM5,TPRG1,TRAPPC2,TRAPPC4,TRAPPC6B,TRIM2,TRIM65,TRIP4,TRNAU1AP,TRPV2,TSSC1,TTC1,TTC9,TTLL1,UBAC2,UBAC2-AS1,UBE2D2,UBE2I,UBE2L3,UBE2Q2,UBL5,UGGT1,UGP2,UNC13D,UNC45B,UNG,UPF3B,UQCR10,UQCR11,UQCRB,USMG5,USP37,USP40,USP5,VAPB,VBP1,VEZT,VPS72,VRK3,WDR35,WDR77,WIBG,XPO1,YAF2,YY1AP1,ZC3H6,ZDHHC13,ZFP14,ZFP2,ZFP62,ZFR2,ZMAT2,ZMYM5,ZNF12,ZNF197,ZNF226,ZNF232,ZNF233,ZNF260,ZNF28,ZNF302,ZNF320,ZNF404,ZNF445,ZNF48,ZNF480,ZNF500,ZNF506,ZNF527,ZNF559,ZNF568,ZNF584,ZNF585A,ZNF610,ZNF619,ZNF621,ZNF626,ZNF674,ZNF696,ZNF701,ZNF720,ZNF737,ZNF738,ZNF75D,ZNF763,ZNF780A,ZNF780B,ZNF84,ZNF850,ZNHIT6,ZSWIM7",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41100,FLUARIX,IN,INFLUENZA,HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D3,D,3,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_FLUARIX_AGE_50_74YO_CORR_WITH_28D_MEM_B_CELL_RESPONSE_AT_3DY_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response at 28d in peripheral blood mononuclear cell in seniors (50-74) after exposure to Fluarix , time point 3D","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"ACO2,ACSL1,ADAM17,ADM,AHR,ANO8,AP3B1,AP5B1,APP,ARF1,ARL15,ARL5B,ARL8A,BMAL2,ARSG,ASAP1,ASTL,ATP11C,ATP2A2,ATP6V0C,BCL2L2-PABPN1,BCL3,BCL6,BHLHE40,BNIP2,BOP1,BPI,ANAPC15,C11orf96,NATD1,C17orf107,GUCD1,C2orf49,C2orf69,XXYLT1,PXDC1,GINM1,SAPCD2,PRXL2C,CARD19,ZNG1B,CBX6,CCDC186,CCDC6,CCDC69,CCDC86,YJU2,CCNK,NOCT,CDC40,CDK14,CDK8,CDKN1A,CEBPB,CERS6,CHPT1,CHRM4,CIC,CIITA,COIL,CSGALNACT2,CWC25,CXXC5,CYC1,DCTN4,DCUN1D1,DDX21,DDX3X,DHX8,DIP2B,DNAJC11,DUSP10,DYM,EAF1,EGR1,EIF2AK2,EIF3A,EIF3C,EIF4H,ELF1,EME2,EPS15L1,ETS2,ETV3,EXT1,FAF2,FAM117B,ABRAXAS2,FAM53C,FCHSD2,FEM1A,FEM1C,FNDC3B,FOSL1,FOSL2,FOXN3,FOXO4,FRMD8P1,G0S2,GALNS,GANC,GEM,GGN,GLUD2,GMEB1,GMFB,GNA11,GNA12,GNAQ,GPM6B,GPR84,GRAMD1B,GRIK5,GRPEL1,GTF3C4,H3-5,HBEGF,HBP1,HIC2,HIF1A,HINT3,H2AC25,HOXA5,HSF1,HSPA13,ICAM1,ICOSLG,ID2,ID2B,IDI2-AS1,IER2,IER3,IKBKG,IKZF5,IL1A,IL1B,IL1RAP,IL6,INCENP,INO80B,IRAK1,IRF4,IRS2,ISG20L2,ITPRIP,JARID2,JMJD1C,KAT5,KCNC3,KCNQ1,KCTD3,KDM6A,KHSRP,KIAA1958,KLF10,KLF4,KLF5,KLF7,KLHL15,KPNA2,KPNA3,KREMEN1,KRR1,KSR1,LCOR,LGALS8,LMTK2,,ENSG00000272447,NRROS,LRRC4,LRRC59,LRRK1,MAP1LC3B2,MAP2,MAP3K3,MAPK6,MAPK7,MAPK8,MAPRE1,MED13L,MED21,MED26,MEMO1,METTL14,MEX3B,MFSD14A,MICAL2,MIDN,MIER3,MKRN9P,MLX,MLXIP,MOB1A,MROH1,MRPS22,MTM1,MUL1,MYLIP,NAB1,NBPF10,NBPF9,NCF1C,NFIC,NFIL3,NFKBIA,NFKBID,NFKBIZ,NIPAL2,NPEPL1,NR4A3,NRIP1,NUBP1,NUDT3,OLR1,OPN3,PANK3,PCDHGC3,PDZD8,PELI1,PELI2,PER1,PFKFB3,PGAM2,PGK2,PHLDA2,PIM3,PIP5K1C,PJA2,PLEKHM2,PLEKHM3,PNO1,PNPLA2,PNPLA8,POLR2M,POM121,PPM1L,PPP1R15A,PPP1R15B,PPP1R2B,PPP2R5E,PPP4R1L,PPP4R2,PPTC7,PRKCE,PSMB7,PTP4A1,PXK,QTRT2,RAB11FIP2,RAB30,RAB33B,RAB5C,RAF1,RASGEF1B,REL,RGS7,RIPK2,RPL7L1,RREB1,RSRC1,SNX29,,SCML1,SEC24B,SENP2,SERINC1,SERTAD2,SFT2D2,SHANK1,SIK1,SIPA1L3,SIRT1,SKIL,SLC25A30,SLC25A34,SLC2A3,SLC38A7,SLC7A5,SLC9A7,SLK,SMARCB1,SMPD4,SMURF1,SNAI1,SNIP1,SNTB1,SNX12,SNX13,SOCS1,SOCS3,SOCS4,SPTY2D1,SRGAP2B,SRRD,STARD4,STK17B,STRN4,STX10,SULT1B1,SYNE3,TAF13,TBC1D14,TBC1D9B,TESK2,TGFBRAP1,TMED7,TMED7-TICAM2,TMEM167B,TMEM183A,TMEM199,TMEM38A,EMC6,TNFAIP3,TNFAIP6,TNFRSF10B,TNFRSF12A,TNFRSF13C,TNFRSF21,TOR1AIP1,TRAM1L1,TREML4,TSC22D2,TSNARE1,TWF1,POLR1F,TXNDC5,UAP1L1,UGCG,BLTP3B,USP3,USP38,USP6NL,UVRAG,UVSSA,VEGFA,VRK2,VTI1A,VTI1B,WASHC2A,WASHC2C,YPEL2,YTHDF3,ZBED4,ZBTB10,ZBTB43,ZC3H12A,ZCCHC2,ZDHHC20,ZFAT,ZFP36,ZFP91,ZFP91-CNTF,ZFP92,ZFR,ZNF124,ZNF184,ZNF281,ZBTB21,ZNF304,ZNF324,ZNF487,ZNF496,ZNF511,ZNF551,ZNF614,ZNF689,ZNF791,ZNF844,ZNF93",370,"ACO2,ACSL1,ADAM17,ADM,AHR,ANO8,AP3B1,AP5B1,APP,ARF1,ARL15,ARL5B,ARL8A,ARNTL2,ARSG,ASAP1,ASTL,ATP11C,ATP2A2,ATP6V0C,BCL2L2-PABPN1,BCL3,BCL6,BHLHE40,BNIP2,BOP1,BPI,C11orf51,C11orf96,C17orf103,C17orf107,C22orf13,C2orf49,C2orf69,C3orf21,C6orf145,C6orf72,C9orf140,C9orf21,C9orf89,CBWD2,CBX6,CCDC186,CCDC6,CCDC69,CCDC86,CCDC94,CCNK,CCRN4L,CDC40,CDK14,CDK8,CDKN1A,CEBPB,CERS6,CHPT1,CHRM4,CIC,CIITA,COIL,CSGALNACT2,CWC25,CXXC5,CYC1,DCTN4,DCUN1D1,DDX21,DDX3X,DHX8,DIP2B,DNAJC11,DUSP10,DYM,EAF1,EGR1,EIF2AK2,EIF3A,EIF3C,EIF4H,ELF1,EME2,EPS15L1,ETS2,ETV3,EXT1,FAF2,FAM117B,FAM175B,FAM53C,FCHSD2,FEM1A,FEM1C,FNDC3B,FOSL1,FOSL2,FOXN3,FOXO4,FRMD8P1,G0S2,GALNS,GANC,GEM,GGN,GLUD2,GMEB1,GMFB,GNA11,GNA12,GNAQ,GPM6B,GPR84,GRAMD1B,GRIK5,GRPEL1,GTF3C4,H3F3C,HBEGF,HBP1,HIC2,HIF1A,HINT3,HIST3H2A,HOXA5,HSF1,HSPA13,ICAM1,ICOSLG,ID2,ID2B,IDI2-AS1,IER2,IER3,IKBKG,IKZF5,IL1A,IL1B,IL1RAP,IL6,INCENP,INO80B,IRAK1,IRF4,IRS2,ISG20L2,ITPRIP,JARID2,JMJD1C,KAT5,KCNC3,KCNQ1,KCTD3,KDM6A,KHSRP,KIAA1958,KLF10,KLF4,KLF5,KLF7,KLHL15,KPNA2,KPNA3,KREMEN1,KRR1,KSR1,LCOR,LGALS8,LMTK2,LOC100288123,LOC642361,LRRC33,LRRC4,LRRC59,LRRK1,MAP1LC3B2,MAP2,MAP3K3,MAPK6,MAPK7,MAPK8,MAPRE1,MED13L,MED21,MED26,MEMO1,METTL14,MEX3B,MFSD14A,MICALCL,MIDN,MIER3,MKRN9P,MLX,MLXIP,MOBKL1B,MROH1,MRPS22,MTM1,MUL1,MYLIP,NAB1,NBPF10,NBPF9,NCF1C,NFIC,NFIL3,NFKBIA,NFKBID,NFKBIZ,NIPAL2,NPEPL1,NR4A3,NRIP1,NUBP1,NUDT3,OLR1,OPN3,PANK3,PCDHGC3,PDZD8,PELI1,PELI2,PER1,PFKFB3,PGAM2,PGK2,PHLDA2,PIM3,PIP5K1C,PJA2,PLEKHM2,PLEKHM3,PNO1,PNPLA2,PNPLA8,POLR2M,POM121,PPM1L,PPP1R15A,PPP1R15B,PPP1R2P3,PPP2R5E,PPP4R1L,PPP4R2,PPTC7,PRKCE,PSMB7,PTP4A1,PXK,QTRTD1,RAB11FIP2,RAB30,RAB33B,RAB5C,RAF1,RASGEF1B,REL,RGS7,RIPK2,RPL7L1,RREB1,RSRC1,RUNDC2A,S,SCML1,SEC24B,SENP2,SERINC1,SERTAD2,SFT2D2,SHANK1,SIK1,SIPA1L3,SIRT1,SKIL,SLC25A30,SLC25A34,SLC2A3,SLC38A7,SLC7A5,SLC9A7,SLK,SMARCB1,SMPD4,SMURF1,SNAI1,SNIP1,SNTB1,SNX12,SNX13,SOCS1,SOCS3,SOCS4,SPTY2D1,SRGAP2P2,SRRD,STARD4,STK17B,STRN4,STX10,SULT1B1,SYNE3,TAF13,TBC1D14,TBC1D9B,TESK2,TGFBRAP1,TMED7,TMED7-TICAM2,TMEM167B,TMEM183A,TMEM199,TMEM38A,TMEM93,TNFAIP3,TNFAIP6,TNFRSF10B,TNFRSF12A,TNFRSF13C,TNFRSF21,TOR1AIP1,TRAM1L1,TREML4,TSC22D2,TSNARE1,TWF1,TWISTNB,TXNDC5,UAP1L1,UGCG,UHRF1BP1L,USP3,USP38,USP6NL,UVRAG,UVSSA,VEGFA,VRK2,VTI1A,VTI1B,WASHC2A,WASHC2C,YPEL2,YTHDF3,ZBED4,ZBTB10,ZBTB43,ZC3H12A,ZCCHC2,ZDHHC20,ZFAT,ZFP36,ZFP91,ZFP91-CNTF,ZFP92,ZFR,ZNF124,ZNF184,ZNF281,ZNF295,ZNF304,ZNF324,ZNF487,ZNF496,ZNF511,ZNF551,ZNF614,ZNF689,ZNF791,ZNF844,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41208,INFLUENZA,IN,INFLUENZA,HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D3,D,3,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_NEGATIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes negatively correlated with memory B cell response in peripheral blood mononuclear cell in adults (50-74) after exposure to trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). , time point 3D. Comment: Association of baseline, early and late gene expression changes with peak memory B cell ELISPOT response (Day 28 - Day 0) in older individuals","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"ACTL10,BLCAP,CDK4,CHMP4A,DHRS13,EEF1E1-BLOC1S5,LRP11,MAP4,PMVK,RAD51C,THAP3,KRT10-AS1,TTLL1,ZNF233,ZNF780B",15,"ACTL10,BLCAP,CDK4,CHMP4A,DHRS13,EEF1E1-BLOC1S5,LRP11,MAP4,PMVK,RAD51C,THAP3,TMEM99,TTLL1,ZNF233,ZNF780B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41169,INFLUENZA,IN,INFLUENZA,HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D3,D,3,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_TIV_AGE_50_74YO_CORRELATED_WITH_MEMORY_B_CELL_RESPONSE_3DY_POSITIVE,"BACKGROUND: Studies suggest that the recall-based humoral immune responses to influenza A/H1N1 originates from activated memory B cells. The aim of this study was to identify baseline, early and late blood transcriptional signatures (in peripheral blood mononuclear cells/PBMCs) associated with memory B cell response following influenza vaccination. METHODS: We used pre- and post-vaccination mRNA-Seq transcriptional profiling on samples from 159 subjects (50-74years old) following receipt of seasonal trivalent influenza vaccine containing the A/California/7/2009/H1N1-like virus, and penalized regression modeling to identify associations with influenza A/H1N1-specific memory B cell ELISPOT response after vaccination. RESULTS: Genesets and genes (p-value range 7.92E(-08) to 0.00018, q-value range 0.00019-0.039) demonstrating significant associations (of gene expression levels) with memory B cell response suggest the importance of metabolic (cholesterol and lipid metabolism-related), cell migration/adhesion, MAP kinase, NF-kB cell signaling (chemokine/cytokine signaling) and transcriptional regulation gene signatures in the development of memory B cell response after influenza vaccination. CONCLUSION: Through an unbiased transcriptome-wide profiling approach, our study identified signatures of memory B cell response following influenza vaccination, highlighting the underappreciated role of metabolic changes (among the other immune function-related events) in the regulation of influenza vaccine-induced immune memory.","Genes positively correlated with memory B cell response in peripheral blood mononuclear cell in adults (50-74) after exposure to trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). , time point 3D. Comment: Association of baseline, early and late gene expression changes with peak memory B cell ELISPOT response (Day 28 - Day 0) in older individuals","Haralambieva IH,Ovsyannikova IG,Kennedy RB,Zimmermann MT,Grill DE,Oberg AL,Poland GA",27317456,HUMAN_GENE_SYMBOL,"ANO8,CCDC6,ELF1,FCHSD2,GMEB1,H3-5,MAP1LC3B2,NFKBIA,PELI1,PLEKHM2,SOCS3,STK17B,TESK2,USP6NL,WASHC2C",15,"ANO8,CCDC6,ELF1,FCHSD2,GMEB1,H3F3C,MAP1LC3B2,NFKBIA,PELI1,PLEKHM2,SOCS3,STK17B,TESK2,USP6NL,WASHC2C",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1986836/figure/F6/,NA,NA,NA,NA
M41097,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_CORRELATED_WITH_H3N1_HI_TITER_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D1,D,1,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_CORRELATED_WITH_H3N1_HI_TITER_1DY_POSITIVE,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes positively correlated with H3N1 HI titer in blood in children (0.5-14y) after exposure to Fluzone , time point 1D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"GBP1,IFI44L,IFIT1,IFIT3,ISG15,OASL",6,"GBP1,IFI44L,IFIT1,IFIT3,ISG15,OASL",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 4a,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729923/#S1,NA,NA,NA,NA
M41125,INFLUENZA,IN,INFLUENZA,HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_DOWN,VIRUS,DOWN,VACCINE,COMPARISON,D0,D,0,21-35,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_DOWN,"Annual influenza vaccinations are currently recommended for all individuals 6 months and older. Antibodies induced by vaccination are an important mechanism of protection against infection. Despite the overall public health success of influenza vaccination, many individuals fail to induce a substantial antibody response. Systems-level immune profiling studies have discerned associations between transcriptional and cell subset signatures with the success of antibody responses. However, existing signatures have relied on small cohorts and have not been validated in large independent studies. We leveraged multiple influenza vaccination cohorts spanning distinct geographical locations and seasons from the Human Immunology Project Consortium (HIPC) and the Center for Human Immunology (CHI) to identify baseline (i.e., before vaccination) predictive transcriptional signatures of influenza vaccination responses. Our multicohort analysis of HIPC data identified nine genes (<i>RAB24</i>, <i>GRB2</i>, <i>DPP3</i>, <i>ACTB</i>, <i>MVP</i>, <i>DPP7</i>, <i>ARPC4</i>, <i>PLEKHB2</i>, and <i>ARRB1</i>) and three gene modules that were significantly associated with the magnitude of the antibody response, and these associations were validated in the independent CHI cohort. These signatures were specific to young individuals, suggesting that distinct mechanisms underlie the lower vaccine response in older individuals. We found an inverse correlation between the effect size of signatures in young and older individuals. Although the presence of an inflammatory gene signature, for example, was associated with better antibody responses in young individuals, it was associated with worse responses in older individuals. These results point to the prospect of predicting antibody responses before vaccination and provide insights into the biological mechanisms underlying successful vaccination responses.","Genes down-regulated in peripheral blood mononuclear cell high responders vs low responders in younger adults (21-35) (high responders) after exposure to trivalent influenza vaccine (TIV) , time point 0D. Comment: data from six different cohorts, trivalent vaccine year not specified","HIPC-CHI Signatures Project Team,HIPC-I Consortium",28842433,HUMAN_GENE_SYMBOL,"CASP6,NUDCD2,PPIB,PTPN22,PURA,SP4",6,"CASP6,NUDCD2,PPIB,PTPN22,PURA,SP4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table, see also Fig 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712333/bin/aging-07-1077-s001.xlsx,NA,NA,NA,NA
M41127,INFLUENZA,IN,INFLUENZA,HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP,VIRUS,UP,VACCINE,COMPARISON,D0,D,0,21-35,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HIPC_SIGNATURES_PROJECT_PBMC_TRIVALENT_INFLUENZA_VACCINE_HIGH_RESPONDERS_VS_LOW_RESPONDERS_YOUNGER_ADULTS_21_35_HIGH_RESPONDERS_0D_UP,"Annual influenza vaccinations are currently recommended for all individuals 6 months and older. Antibodies induced by vaccination are an important mechanism of protection against infection. Despite the overall public health success of influenza vaccination, many individuals fail to induce a substantial antibody response. Systems-level immune profiling studies have discerned associations between transcriptional and cell subset signatures with the success of antibody responses. However, existing signatures have relied on small cohorts and have not been validated in large independent studies. We leveraged multiple influenza vaccination cohorts spanning distinct geographical locations and seasons from the Human Immunology Project Consortium (HIPC) and the Center for Human Immunology (CHI) to identify baseline (i.e., before vaccination) predictive transcriptional signatures of influenza vaccination responses. Our multicohort analysis of HIPC data identified nine genes (<i>RAB24</i>, <i>GRB2</i>, <i>DPP3</i>, <i>ACTB</i>, <i>MVP</i>, <i>DPP7</i>, <i>ARPC4</i>, <i>PLEKHB2</i>, and <i>ARRB1</i>) and three gene modules that were significantly associated with the magnitude of the antibody response, and these associations were validated in the independent CHI cohort. These signatures were specific to young individuals, suggesting that distinct mechanisms underlie the lower vaccine response in older individuals. We found an inverse correlation between the effect size of signatures in young and older individuals. Although the presence of an inflammatory gene signature, for example, was associated with better antibody responses in young individuals, it was associated with worse responses in older individuals. These results point to the prospect of predicting antibody responses before vaccination and provide insights into the biological mechanisms underlying successful vaccination responses.","Genes up-regulated in peripheral blood mononuclear cell high responders vs low responders in younger adults (21-35) (high responders) after exposure to trivalent influenza vaccine (TIV) , time point 0D. Comment: data from six different cohorts, trivalent vaccine year not specified","HIPC-CHI Signatures Project Team,HIPC-I Consortium",28842433,HUMAN_GENE_SYMBOL,"ACTB,ARPC4,ARRB1,DPP3,DPP7,GRB2,MVP,PLEKHB2,RAB24",9,"ACTB,ARPC4,ARRB1,DPP3,DPP7,GRB2,MVP,PLEKHB2,RAB24",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/bin/aging-07-38-s002.doc,NA,NA,NA,NA
M41032,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_RESPONDERS_VS_NONRESPONDERS_7DY_UP,VIRUS,UP,VACCINE,COMPARISON,D7,D,7,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_RESPONDERS_VS_NONRESPONDERS_7DY_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in peripheral blood mononuclear cell responders vs nonresponders in adults (18-64) after exposure to Pandemrix , time point 7D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"CD38,ELL2,ERLEC1,FKBP11,GGH,GLDC,IGHV1-69,IGHV3-48,,IGKC,IGKV1D-8,IGLL1,ITM2C,JCHAIN,KRT81,MANF,MZB1,,SDC1,SEC11C,TNFRSF17,TRAM2,TXNDC5,UCHL1",24,"CD38,ELL2,ERLEC1,FKBP11,GGH,GLDC,IGHV1-69,IGHV3-48,IGK,IGKC,IGKV1D-8,IGLL1,ITM2C,JCHAIN,KRT81,MANF,MZB1,SCFV,SDC1,SEC11C,TNFRSF17,TRAM2,TXNDC5,UCHL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41079,FLUARIX,IN,INFLUENZA,VOIGT_PBMC_FLUARIX_AGE_50_74YO_FEMALES_VS_MALES_0DY_TO_28D_UP,VIRUS,UP,VACCINE,COMPARISON,D28,D,28,50-74,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/VOIGT_PBMC_FLUARIX_AGE_50_74YO_FEMALES_VS_MALES_0DY_TO_28D_UP,"<b>Background:</b> Sex differences in immune responses to influenza vaccine may impact efficacy across populations. <b>Methods:</b> In a cohort of 138 older adults (50-74 years old), we measured influenza A/H1N1 antibody titers, B-cell ELISPOT response, PBMC transcriptomics, and PBMC cell compositions at 0, 3, and 28 days post-immunization with the 2010/11 seasonal inactivated influenza vaccine. <b>Results:</b> We identified higher B-cell ELISPOT responses in females than males. Potential mechanisms for sex effects were identified in four gene clusters related to T, NK, and B cells. Mediation analysis indicated that sex-dependent expression in T and NK cell genes can be partially attributed to higher CD4+ T cell and lower NK cell fractions in females. We identified strong sex effects in 135 B cell genes whose expression correlates with ELISPOT measures, and found that cell subset differences did not explain the effect of sex on these genes' expression. Post-vaccination expression of these genes, however, mediated 41% of the sex effect on ELISPOT responses. <b>Conclusions:</b> These results improve our understanding of sexual dimorphism in immunity and influenza vaccine response.","Genes up-regulated in peripheral blood mononuclear cell females vs males in adults (50-74) (females) after exposure to Fluarix , time point 0D, 3DY, 28D. Comment: Caucasian adults (50-74); See Suppl Table 6 for full DE gene list, time point 0D, 3DY, 28D combined (identical signatures)","Voigt EA,Ovsyannikova IG,Kennedy RB,Grill DE,Goergen KM,Schaid DJ,Poland GA",30873150,HUMAN_GENE_SYMBOL,"ADD2,BLNK,CD19,CD22,CD40,CDCA7L,DPF3,NIBAN3,FCRL2,FCRL5,KHDRBS2,MOXD1,NXPH4,PAWR,PTPRK,RALGPS2,SPIB,STAP1,TCL6,TSPAN13",20,"ADD2,BLNK,CD19,CD22,CD40,CDCA7L,DPF3,FAM129C,FCRL2,FCRL5,KHDRBS2,MOXD1,NXPH4,PAWR,PTPRK,RALGPS2,SPIB,STAP1,TCL6,TSPAN13",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40888,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_UP,VIRUS,UP,VACCINE,NON RESPONDER,D28,D,28,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 0d in young adults (21-30) (nonresponder) after exposure to Inactivated influenza vaccine , time point 28D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ABCC4,ABHD10,ABI1,ACBD3,ADO,AFTPH,AGL,ARHGAP24,ARL5A,ARL8B,ARMC1,ARMCX3,ASNSD1,BAZ2B,BCL11A,BET1,BIRC2,BLCAP,BTLA,C12orf76,HAPSTR1,DIPK2A,C5orf15,IGIP,C6orf62,CAND1,CCDC117,CD52,CEPT1,CGGBP1,CHCHD4,CHD9,CLIC4,CLK4,CLN5,CNOT6,COBLL1,CUL4B,CWF19L2,DARS1,DCP2,DDX1,DMAC1,DNAJA2,DNAJC10,DNAJC15,DOCK11,EFR3A,EIF2S1,EIF4G2,RAMAC,FAM104A,FAM104B,FAM117B,FAM13B,CMTR2,GART,GCC1,GEMIN6,GGPS1,GLUD1,HDAC2,HLTF,HMGCS1,HSDL2,IFRD1,IPO11,IRF2BP2,IVNS1ABP,KBTBD8,MSANTD4,KIF20B,KLHL9,KRCC1,LARP4,CERS6,LPAR5,LRRC8D,LYPLAL1,LAMTOR3,MAP3K1,MAP3K7,MED7,MEF2C,MIS18BP1,MKKS,MOB3C,MOSPD2,MRPL50,MTMR10,BLOC1S5,NAP1L1,NCOA3,NGLY1,NIN,NIPBL,NOC3L,PNP,NUDT21,NUP54,RPRD1A,PAK2,PARM1,PCM1,PCMTD1,PDS5A,PIGN,PJA2,PPAT,PPM1B,PPP1R14A,PPP4R3A,PTK2,PUM2,RAB33B,RAB8B,RB1CC1,RBM15,RBPMS2,RFX7,RMI1,RNF149,RNF20,RNGTT,RSBN1,SAMD9,SCYL2,SEC23IP,SERBP1,SH3BP5L,SIRT1,SLC38A2,SLMAP,SMCHD1,MIEF1,SNRPG,SP3,ST8SIA4,STAP1,STAT5A,UBASH3B,TAPT1,TBC1D9,TBL1XR1,TCAIM,TCF12,TMEM60,TOMM70,TOP2B,TRAK2,TXNDC9,UPF2,USP1,USP38,VPS26A,VPS36,VPS37A,VPS41,XRN1,YTHDF3,ZBTB33,ZNF146,ZNF189,ZNF26,ZNF263,ZNF302,ZNF322,ZNF451,ZNF480,ZNF518A,ZNF613,ZNF615,ZNF816,ZNF845",174,"ABCC4,ABHD10,ABI1,ACBD3,ADO,AFTPH,AGL,ARHGAP24,ARL5A,ARL8B,ARMC1,ARMCX3,ASNSD1,BAZ2B,BCL11A,BET1,BIRC2,BLCAP,BTLA,C12orf76,C16orf72,C3orf58,C5orf15,C5orf53,C6orf62,CAND1,CCDC117,CD52,CEPT1,CGGBP1,CHCHD4,CHD9,CLIC4,CLK4,CLN5,CNOT6,COBLL1,CUL4B,CWF19L2,DARS,DCP2,DDX1,DMAC1,DNAJA2,DNAJC10,DNAJC15,DOCK11,EFR3A,EIF2S1,EIF4G2,FAM103A1,FAM104A,FAM104B,FAM117B,FAM13B,FTSJD1,GART,GCC1,GEMIN6,GGPS1,GLUD1,HDAC2,HLTF,HMGCS1,HSDL2,IFRD1,IPO11,IRF2BP2,IVNS1ABP,KBTBD8,KIAA1826,KIF20B,KLHL9,KRCC1,LARP4,LASS6,LPAR5,LRRC8D,LYPLAL1,MAP2K1IP1,MAP3K1,MAP3K7,MED7,MEF2C,MIS18BP1,MKKS,MOBKL2C,MOSPD2,MRPL50,MTMR10,MUTED,NAP1L1,NCOA3,NGLY1,NIN,NIPBL,NOC3L,NP,NUDT21,NUP54,P15RS,PAK2,PARM1,PCM1,PCMTD1,PDS5A,PIGN,PJA2,PPAT,PPM1B,PPP1R14A,PPP4R3A,PTK2,PUM2,RAB33B,RAB8B,RB1CC1,RBM15,RBPMS2,RFX7,RMI1,RNF149,RNF20,RNGTT,RSBN1,SAMD9,SCYL2,SEC23IP,SERBP1,SH3BP5L,SIRT1,SLC38A2,SLMAP,SMCHD1,SMCR7L,SNRPG,SP3,ST8SIA4,STAP1,STAT5A,STS-1,TAPT1,TBC1D9,TBL1XR1,TCAIM,TCF12,TMEM60,TOMM70A,TOP2B,TRAK2,TXNDC9,UPF2,USP1,USP38,VPS26A,VPS36,VPS37A,VPS41,XRN1,YTHDF3,ZBTB33,ZNF146,ZNF189,ZNF26,ZNF263,ZNF302,ZNF322A,ZNF451,ZNF480,ZNF518A,ZNF613,ZNF615,ZNF816A,ZNF845",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-Monocytes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40914,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_DN,VIRUS,DOWN,VACCINE,NON RESPONDER,D28,D,28,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_28DY_DN,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes down-regulated in peripheral blood mononuclear cell 28d vs 0d in young adults (21-30) (nonresponder) after exposure to Inactivated influenza vaccine , time point 28D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ADGRL1,ATG4B,ATP2A2,BHLHE40,CBX4,CES2,CIDEB,COMT,CSAD,RPL10,EIF4H,ENTPD4,ENTPD6,EXOSC2,TOGARAM2,FLII,FUBP3,FYN,RAP1GAP2,GTF3C1,GUSB,HLA-C,IL32,ITGAL,ITGB2,MAF,MIAT,NDUFB4,NPIPA1,NXF1,OSBPL7,PITPNM1,PLOD3,PNKP,PNPLA6,RANBP3,RHOT2,RNASEH1,S100A10,SCAND1,SDE2,SDF4,SF1,SLC35B2,SLC3A2,SLCO3A1,SLFN13,SNORA64,SNORD35B,SNORD4A,SNORD68,SRPK2,STAT6,TM9SF4,TNFSF12,TTLL3,VPS52,WDFY2,DCAF7,WWP2,YPEL2,ZFHX3,ZNF362,ZYX",64,"ADGRL1,ATG4B,ATP2A2,BHLHB2,CBX4,CES2,CIDEB,COMT,CSAD,DXS648E,EIF4H,ENTPD4,ENTPD6,EXOSC2,FAM179A,FLII,FUBP3,FYN,GARNL4,GTF3C1,GUSB,HLA-C,IL32,ITGAL,ITGB2,MAF,MIAT,NDUFB4,NPIP,NXF1,OSBPL7,PITPNM1,PLOD3,PNKP,PNPLA6,RANBP3,RHOT2,RNASEH1,S100A10,SCAND1,SDE2,SDF4,SF1,SLC35B2,SLC3A2,SLCO3A1,SLFN13,SNORA64,SNORD35B,SNORD4A,SNORD68,SRPK2,STAT6,TM9SF4,TNFSF12,TTLL3,VPS52,WDFY2,WDR68,WWP2,YPEL2,ZFHX3,ZNF362,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5e,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F5/,NA,NA,NA,NA
M40882,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_DN,VIRUS,DOWN,VACCINE,NON RESPONDER,D7,D,7,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_DN,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in young adults (21-30) (nonresponder) after exposure to Inactivated influenza vaccine , time point 7D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ACO2,ACVR1B,ADGRL1,ALDOA,ARPC3,ATG4B,ATP2A2,ATXN1L,B4GALT5,BHLHE40,BRPF1,CAMK2N1,CD99,CIDEB,CLOCK,CLSTN1,CSAD,CSTB,CUX1,DNASE1L1,DUSP18,ECH1,EIF4H,ELF4,ENTPD4,EP300,FLII,FYN,RAP1GAP2,HERPUD1,IL32,ITFG2,ITGAL,ITGB2,KLF13,KMT2A,LAG3,MAF,MBD2,MIAT,MIDEAS,NLRC5,NPIPA1,OSBPL7,PITPNM1,PPP1CA,PRKCSH,PSMC4,PTGER2,RAI1,RANBP3,RHOT2,RMDN3,SDE2,SDF4,SEC22C,SIGMAR1,SLCO3A1,SLFN13,SMARCC2,SMPDL3A,SRPK2,STAT6,TBC1D9B,TM9SF4,TNFSF12,TUBA1C,DCAF7,YPEL2,ZFHX3,ZFPM1,ZYX",72,"ACO2,ACVR1B,ADGRL1,ALDOA,ARPC3,ATG4B,ATP2A2,ATXN1L,B4GALT5,BHLHB2,BRPF1,CAMK2N1,CD99,CIDEB,CLOCK,CLSTN1,CSAD,CSTB,CUX1,DNASE1L1,DUSP18,ECH1,EIF4H,ELF4,ENTPD4,EP300,FLII,FYN,GARNL4,HERPUD1,IL32,ITFG2,ITGAL,ITGB2,KLF13,KMT2A,LAG3,MAF,MBD2,MIAT,MIDEAS,NLRC5,NPIP,OSBPL7,PITPNM1,PPP1CA,PRKCSH,PSMC4,PTGER2,RAI1,RANBP3,RHOT2,RMDN3,SDE2,SDF4,SEC22C,SIGMAR1,SLCO3A1,SLFN13,SMARCC2,SMPDL3A,SRPK2,STAT6,TBC1D9B,TM9SF4,TNFSF12,TUBA1C,WDR68,YPEL2,ZFHX3,ZFPM1,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl. Fig 8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf,NA,NA,NA,NA
M40905,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_UP,VIRUS,UP,VACCINE,NON RESPONDER,D7,D,7,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_NONRESPONDER_7DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in young adults (21-30) (nonresponder) after exposure to Inactivated influenza vaccine , time point 7D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ABHD10,ACBD3,AGL,AKAP8L,ALCAM,ALG6,ARHGAP24,ARMC1,ATG101,BAZ2B,BCL11A,BCLAF1,BIRC2,BLCAP,BST2,BTLA,HAPSTR1,C5orf15,C6orf62,CEPT1,CERS6,CHCHD4,CHD9,CHSY1,CLN5,CMTR2,CNOT6,COBLL1,COX15,CPED1,CPSF3,CUL4B,DCP2,DDX1,DMAC1,DNAJA2,DNAJC10,DNAJC15,DOCK11,EFR3A,EIF2S1,EIF4G2,EMG1,EXOC6,FAM104A,FAM117B,FAM13B,FAR1,FOXN2,GANAB,GFM1,GLE1,GLUD1,HDAC2,HMGCS1,HSDL2,ICAM3,KRCC1,LPAR1,LRPPRC,MAP3K1,MAP3K7,MAT2A,MATR3,MKKS,MOSPD2,MRPL27,MSL3,MSL3,MTMR10,NECAP2,NIN,NIPBL,NOC3L,RPRD1A,PAK2,PAPOLA,PDS5A,PFDN5,PIGN,PJA2,PPM1B,PPP2R5A,PPP4R3A,PPP6R3,PSMC1,PUM2,RAB10,RAB33B,RAB8B,RABGAP1,RB1CC1,RCN1,RFX7,RMI1,RNF20,SCYL2,SERBP1,SLC18B1,SLC38A2,SLC43A3,SLMAP,SRPRB,ST8SIA4,STAT5A,TDG,TMEM123,TOP2B,TRAK2,TXNDC9,UPF2,USF1,USP38,USP7,VPS13C,VPS41,WDFY1,XRN1,YTHDF3,ZBTB33,TUT7,ZNF146,ZNF26,ZNF263,ZNF322,ZNF451,ZNF480,ZNF518A",128,"ABHD10,ACBD3,AGL,AKAP8L,ALCAM,ALG6,ARHGAP24,ARMC1,ATG101,BAZ2B,BCL11A,BCLAF1,BIRC2,BLCAP,BST2,BTLA,C16orf72,C5orf15,C6orf62,CEPT1,CERS6,CHCHD4,CHD9,CHSY1,CLN5,CMTR2,CNOT6,COBLL1,COX15,CPED1,CPSF3,CUL4B,DCP2,DDX1,DMAC1,DNAJA2,DNAJC10,DNAJC15,DOCK11,EFR3A,EIF2S1,EIF4G2,EMG1,EXOC6,FAM104A,FAM117B,FAM13B,FAR1,FOXN2,GANAB,GFM1,GLE1,GLUD1,HDAC2,HMGCS1,HSDL2,ICAM3,KRCC1,LPAR1,LRPPRC,MAP3K1,MAP3K7,MAT2A,MATR3,MKKS,MOSPD2,MRPL27,MSL3,MSL3L1,MTMR10,NECAP2,NIN,NIPBL,NOC3L,P15RS,PAK2,PAPOLA,PDS5A,PFDN5,PIGN,PJA2,PPM1B,PPP2R5A,PPP4R3A,PPP6R3,PSMC1,PUM2,RAB10,RAB33B,RAB8B,RABGAP1,RB1CC1,RCN1,RFX7,RMI1,RNF20,SCYL2,SERBP1,SLC18B1,SLC38A2,SLC43A3,SLMAP,SRPRB,ST8SIA4,STAT5A,TDG,TMEM123,TOP2B,TRAK2,TXNDC9,UPF2,USF1,USP38,USP7,VPS13C,VPS41,WDFY1,XRN1,YTHDF3,ZBTB33,ZCCHC6,ZNF146,ZNF26,ZNF263,ZNF322A,ZNF451,ZNF480,ZNF518A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-mDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40921,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_DN,VIRUS,DOWN,VACCINE,NON RESPONDER,D2,D,2,70+,ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_DN,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes down-regulated in peripheral blood mononuclear cell 2d vs 0d in seniors (70+) (nonresponder) after exposure to Inactivated influenza vaccine , time point 2D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ABR,ACSS2,ADAM15,ADAP2,ALAD,ALDH1A1,ALDH2,ALDOA,ALOX5,ANXA5,AP1S2,ARRDC3,ATF5,ATP6AP1,ATP6V0A1,BCKDK,BCL3,BHLHE40,BICRA,BTBD2,C15orf39,C1orf162,C9orf72,CALM3,CARM1,CBX4,CCNY,CD300C,CD33,CD86,CDC37,CDC42EP3,CENPB,ADAP1,CES2,CHST13,CIRBP,CLCN7,CLEC16A,CMIP,CNPY3,CREG1,CRTAP,CSF1R,CTNNA1,CUEDC1,CXCL16,DAZAP2,DENND5A,DMXL2,DOCK2,FAAP100,FAM156A,ENTREP3,FBP1,FGR,FUT4,GADD45B,GAS7,GMEB2,GNAQ,GRAMD4,GRN,MACROH2A1,H3-5,H3-3B,HCFC1,HLA-DRB4,HNRNPH2,IMPDH1,IRF1,ITGB2,JARID2,JMJD8,KATNIP,KDM2B,KHSRP,KLF10,KLF11,LGALS9,LILRA3,LILRA6,LRP3,LZTR1,MAPKAPK3,MILR1,MPEG1,MYH9,MYOF,NACC2,NAPRT,NCLN,NCSTN,NIBAN2,NINJ1,NSMF,NUAK2,OAF,PFKFB3,PIEZO1,PIM3,PLSCR1,PNPLA6,PPM1F,SLC66A2,PSAP,RAB40C,RAB44,RAPGEF1,RCC2,RFNG,RHOG,RIPOR1,RNASET2,RNPEP,RUNX3,SEPTIN9,SHFL,SLC25A28,SLC26A6,SLC2A6,SLC3A2,SLC43A2,SLC9A1,SNX27,SPG21,SRF,STK25,TBC1D2,TGOLN2,TNFRSF1B,TNS3,TOM1,TPD52L2,TRIM8,TSPO,TYK2,ULK1,VSIR,WWP2,MAP3K20,ZDHHC7,ZMIZ1,ZNF296,ZNF362,ZNF467,ZNF598,ZYX",148,"ABR,ACSS2,ADAM15,ADAP2,ALAD,ALDH1A1,ALDH2,ALDOA,ALOX5,ANXA5,AP1S2,ARRDC3,ATF5,ATP6AP1,ATP6V0A1,BCKDK,BCL3,BHLHB2,BICRA,BTBD2,C15orf39,C1orf162,C9orf72,CALM3,CARM1,CBX4,CCNY,CD300C,CD33,CD86,CDC37,CDC42EP3,CENPB,CENTA1,CES2,CHST13,CIRBP,CLCN7,CLEC16A,CMIP,CNPY3,CREG1,CRTAP,CSF1R,CTNNA1,CUEDC1,CXCL16,DAZAP2,DENND5A,DMXL2,DOCK2,FAAP100,FAM156A,FAM189B,FBP1,FGR,FUT4,GADD45B,GAS7,GMEB2,GNAQ,GRAMD4,GRN,H2AFY,H3-5,H3F3B,HCFC1,HLA-DRB4,HNRNPH2,IMPDH1,IRF1,ITGB2,JARID2,JMJD8,KATNIP,KDM2B,KHSRP,KLF10,KLF11,LGALS9,LILRA3,LILRA6,LRP3,LZTR1,MAPKAPK3,MILR1,MPEG1,MYH9,MYOF,NACC2,NAPRT1,NCLN,NCSTN,NIBAN2,NINJ1,NSMF,NUAK2,OAF,PFKFB3,PIEZO1,PIM3,PLSCR1,PNPLA6,PPM1F,PQLC1,PSAP,RAB40C,RAB44,RAPGEF1,RCC2,RFNG,RHOG,RIPOR1,RNASET2,RNPEP,RUNX3,SEPTIN9,SHFL,SLC25A28,SLC26A6,SLC2A6,SLC3A2,SLC43A2,SLC9A1,SNX27,SPG21,SRF,STK25,TBC1D2,TGOLN2,TNFRSF1B,TNS3,TOM1,TPD52L2,TRIM8,TSPO,TYK2,ULK1,VSIR,WWP2,ZAK,ZDHHC7,ZMIZ1,ZNF296,ZNF362,ZNF467,ZNF598,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl. Fig 8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf,NA,NA,NA,NA
M40928,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_UP,VIRUS,UP,VACCINE,NON RESPONDER,D2,D,2,70+,ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_NONRESPONDER_2DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell 2d vs 0d in seniors (70+) (nonresponder) after exposure to Inactivated influenza vaccine , time point 2D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ACTR6,AGL,AIDA,ASF1A,BOLA3,BTLA,C12orf29,C12orf57,GON7,ROMO1,CCDC167,CCDC32,CCDC34,MIX23,CCNB1IP1,CD160,CD24,CDC42SE2,CEBPZ,CISD1,CKS2,COBLL1,DENND1B,DNAJB14,DYNLL1,DPY30,DYNLT3,ECI2,ERGIC2,FAM107B,FAM133B,DIPK1A,FAM98A,FKBP5,FYTTD1,GART,HACD3,IFT74,LARP4,LDHB,LEMD3,LEPROTL1,LSM5,LYRM7,MCM6,MED31,MTF2,BLOC1S5,NOSIP,PNP,NRBF2,NTRK1,NUP43,NUP54,OCIAD2,PCMTD1,PPM1B,PRKAA1,PTPN4,PURA,PUS3,RBM34,RNGTT,RPL14,RPL23,RPP40,RPS6KA5,RRM1,PPP6R2,SAR1A,SAR1B,MSMO1,SCOC,SDHAF3,SEC62,SEPTIN7,TRA2B,SLC38A2,SMARCA5,PPP4R3B,SOCS2,SP4,SRPRB,STAP1,STK26,SYTL2,TAPT1,TARS1,TBPL1,TC2N,TEX30,THEMIS,THNSL1,TMCO1,TMEM14B,TRAK2,TSC22D2,UBE2Q2,UBLCP1,UGCG,USO1,USP1,USP38,VBP1,VPS26A,VPS37A,YEATS4,ZNF146,ZNF260,ZNF654,ZNF91",111,"ACTR6,AGL,AIDA,ASF1A,BOLA3,BTLA,C12orf29,C12orf57,C14orf142,C20orf52,C6orf129,CCDC32,CCDC34,CCDC58,CCNB1IP1,CD160,CD24,CDC42SE2,CEBPZ,CISD1,CKS2,COBLL1,DENND1B,DNAJB14,DNCL1,DPY30,DYNLT3,ECI2,ERGIC2,FAM107B,FAM133B,FAM69A,FAM98A,FKBP5,FYTTD1,GART,HACD3,IFT74,LARP4,LDHB,LEMD3,LEPROTL1,LSM5,LYRM7,MCM6,MED31,MTF2,MUTED,NOSIP,NP,NRBF2,NTRK1,NUP43,NUP54,OCIAD2,PCMTD1,PPM1B,PRKAA1,PTPN4,PURA,PUS3,RBM34,RNGTT,RPL14,RPL23,RPP40,RPS6KA5,RRM1,SAPS2,SAR1A,SAR1B,SC4MOL,SCOC,SDHAF3,SEC62,SEPT7,SFRS10,SLC38A2,SMARCA5,SMEK2,SOCS2,SP4,SRPRB,STAP1,STK26,SYTL2,TAPT1,TARS,TBPL1,TC2N,TEX30,THEMIS,THNSL1,TMCO1,TMEM14B,TRAK2,TSC22D2,UBE2Q2,UBLCP1,UGCG,USO1,USP1,USP38,VBP1,VPS26A,VPS37A,YEATS4,ZNF146,ZNF260,ZNF654,ZNF91",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-mDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40986,FLUARIX FLUVIRIN,IN,INFLUENZA,BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_LOW_RESPONDERS_1DY_POSITIVE_PREDICTIVE_OF_TITER,VIRUS,POSITIVE,CORRELATION,RESPONDER,D1,D,1,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_LOW_RESPONDERS_1DY_POSITIVE_PREDICTIVE_OF_TITER,"BACKGROUND: Annual vaccination is the primary means for preventing influenza. However, great interindividual variability exists in vaccine responses, the cellular events that take place in vivo after vaccination are poorly understood, and appropriate biomarkers for vaccine responsiveness have not been developed. METHODS: We immunized a cohort of healthy male adults with a licensed trivalent influenza vaccine and performed a timed assessment of global gene expression before and after vaccination. We analyzed the relationship between gene expression patterns and the humoral immune response to vaccination. RESULTS: Marked up regulation of expression of genes involved in interferon signaling, positive IL-6 regulation, and antigen processing and presentation, were detected within 24 hours of immunization. The late vaccine response showed a transcriptional pattern suggestive of increased protein biosynthesis and cellular proliferation. Integrative analyses revealed a 494-gene expression signature--including STAT1, CD74, and E2F2--which strongly correlates with the magnitude of the antibody response. High vaccine responder status correlates with increased early expression of interferon signaling and antigen processing and presentation genes. CONCLUSIONS: The results highlight the role of a systems biology approach in understanding the molecular events that take place in vivo after influenza vaccination and in the development of better predictors of vaccine responsiveness.","Genes positively correlated with titer response index in peripheral blood mononuclear cell in Caucasian male adults (18-40) (low responders) after exposure to Fluarix/Fluvirin , time point 1D. Comment: Signature predictive of titer response index (TRI). Day 1 and day 3 values averaged.","Bucasas KL,Franco LM,Shaw CA,Bray MS,Wells JM,Nio D,Arden N,Quarles JM,Couch RB,Belmont JW",21357945,HUMAN_GENE_SYMBOL,"E2F2,ITGB1,PRDX2,PRDX3,PTEN",5,"E2F2,ITGB1,PRDX2,PRDX3,PTEN",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M40865,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN,VIRUS,DOWN,VACCINE,RESPONDER,D28,D,28,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_DN,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes down-regulated in peripheral blood mononuclear cell 28d vs 0d in young adults (21-30) (responders) after exposure to Inactivated influenza vaccine , time point 28D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"AAK1,ABHD18,ABHD3,ABL1,ABR,ACAD11,ACADVL,ACCS,ACSS2,ACVR1B,ADAM15,ADAM19,ADAM8,ADCY7,ADGRG1,ADHFE1,GRK2,AGAP4,AGAP6,AHR,AIRE,AKAP13,AKR1D1,AKT1,ALAD,ALDH2,ALDOA,ALG9,ALKBH6,ALOX5,AMT,AMY2A,ANKDD1A,ANKMY1,ANKRD11,ANKRD30B,ANKRD36,ANKRD36B,ANKS1A,,ANXA11,AP1G2,AP1M1,AP3D1,AP4B1,APBB3,APOBR,APOL3,ARAF,ARFGAP2,ARHGAP1,ARHGAP27,ARHGAP4,ARID3B,ARL16,ARL17A,ARL17B,BMAL1,ARRDC3,ARRDC5,ASAH1,ASCC2,ASPSCR1,ATG2A,ATG4B,ATP13A1,ATP2A2,ATP6AP1,ATP6V0A1,CARNS1,ATXN1L,AXIN1,CEP131,B4GALT5,BCKDK,BCL3,BCS1L,BHLHE40,BRAT1,BRD9,BRI3,BTBD2,BTN2A1,BTN3A1,VSIR,C11orf21,DGLUCY,C15orf39,VPS9D1,CTC1,FAAP100,TMEM259,C1orf162,ADISSP,C21orf58,KIAA0930,C2orf69,C6orf136,PPP1R35,CFAP418,PAXX,C9orf72,INIP,CACNA1I,CACNA2D4,CAPS,CARD9,CARM1,CASP8,CASZ1,CAT,CBLB,CBX6,YJU2B,CWC25,CENATAC,CCL3,CCL3L1,CCM2,CCNL1,CCR6,CD1C,CD300C,CD302,CD33,CD74,ADGRE5,CDAN1,CDC37,CDC42EP3,CDC42EP4,CDH23,CDK10,CDK11B,CDK5RAP1,CDK5RAP3,CDK9,CDKN1C,CEBPB,ADA2,CELF2,ADAP1,CEP192,HAUS2,CERK,CES2,CFD,CFL1,CHFR,CHKB,CHN2,CIDEB,CLCN6,CLCN7,CLDN15,CLDND2,CLEC16A,CLEC7A,CLIP4,CLK3,CLN3,CLSTN1,CMIP,CMTM4,CMTM7,CNDP2,CNN2,CNNM3,COMT,COPE,COPS7B,COQ10A,COTL1,COX19,COX8A,CPNE1,CPSF1,CRCP,CREB1,CREBBP,CREBZF,CRTAP,CSAD,CSF1R,CSF2RA,CSF3R,CSGALNACT2,CSNK1D,CSNK1E,CSNK1G2,CST3,AGAP6,CTRL,CTSB,CUEDC1,CUX1,CXCL16,CXXC1,CXorf65,CYB561,CYBA,CYC1,CYTH2,,D2HGDH,DAGLB,DAPP1,DDX56,DEF8,DENND1C,DENND3,DGKA,DGKQ,DHRS1,DICER1,DIDO1,DIP2A,DLL1,DMAP1,DNAAF5,DNAH1,DNAJC28,DNASE1L1,DNMT1,DOCK2,DOP1B,DPAGT1,DPEP2,DUS1L,DUS3L,DUSP18,DVL3,RPL10,DYSF,E2F4,E4F1,EBLN2,ECHDC2,EFHD2,EHBP1L1,EIF1,EIF4E2,EIF4H,ELF4,ELMO2,EMD,EML3,ENG,ENGASE,ENO3,ENTPD4,ENTPD6,EP300,EPM2AIP1,EPN1,ERAL1,ETV3,EVL,EXOSC10,OTULINL,PCED1A,PCED1B,TCAF1,DENND6B,NIBAN2,,FAM156A,FAM156B,TOGARAM2,PIEZO1,WASH3P,WASHC1,STRIP2,RIPOR1,RIPOR2,FARSB,FBP1,FBXL6,FBXW9,FCER1G,FCGR2A,FCGRT,FCN1,FES,FGD3,FGR,FKBP15,FKTN,FLII,YJU2,FN3KRP,FNIP1,FOXJ2,FRAT2,FRS3,FTL,FUBP3,FUT4,FXYD5,GAB2,GABPB2,GAK,GAL3ST4,GALT,RAP1GAP2,GARRE1,GAS7,GFOD1,GGA3,GHDC,GIT2,GJC1,BICRA,GMDS,GMEB2,GMIP,GNG7,GOLGA8B,GON4L,GPR137,GPR162,GPS1,GPS2,GRAMD1A,GRAMD4,GRN,GSDMB,GSE1,GSTK1,GSTM1,GSTM2,GTPBP3,GTPBP6,GUSB,H3-5,HCFC1,HCG27,HERPUD1,HES4,HEXD,HGS,HIC2,HINT3,HK3,HLA-DMA,HLA-DQA1,HLA-DRB1,HLA-DRB4,HNMT,HNRNPM,HOXB2,HPS1,HPS4,HSH2D,HSPA7,ICA1,IDH3G,IDUA,IER5,IFFO1,IFI44L,IFITM2,IFITM3,IKBKB,IKBKG,IL10,IL10RA,IL11RA,IL18,IL18BP,IL18RAP,IL2RB,IMPDH1,PATJ,INTS1,INTS3,INTS4,IP6K1,IQSEC1,IRF1,IRF7,IRF9,ITFG2,ITGA5,ITGAL,ITGAX,ITGB2,ITIH4,ITIH5,ITPR3,JAK1,KDM5D,JARID2,JMJD8,KAT2A,KATNB1,KATNIP,KCNMB1,KCTD13,KDELR1,KDM2A,KHNYN,KIAA0319L,IQCN,KIF21B,KIF22,KIR2DL3,KLF10,KLF13,KLF6,KLHL3,KRBA1,KRT72,KRT73,KXD1,LAG3,LILRA3,LILRA6,LILRB1,LILRB3,LINC00954,LMTK3,,,,LPCAT3,LPIN1,LRCH4,LRP10,LRP5L,LRRC14,NRROS,LRSAM1,LSS,LST1,LTBP4,LUC7L,LYN,LYZ,LZTR1,MAEA,MAN1B1,MAN2A2,MAN2B1,MAN2C1,TRAPPC14,MAP3K8,MAP4K1,MAPK8IP3,MARCHF1,MAST3,MAU2,MBD1,MBD2,MBD6,MCM3AP,MCM7,MCM8,MCOLN2,MDC1,MED16,MED25,MEF2D,MEGF6,METTL17,METTL3,MFSD10,MFSD3,NOL12,MICAL1,MIDEAS,MIDN,MIIP,MILR1,MKNK1,MKNK2,MMP23B,MMS19,MNDA,MNT,MOB3A,MOGS,MPEG1,MTCH1,IRF4,MUTYH,MX1,MXD1,MXD4,MYADM,MYO9B,MYOF,MZF1,N4BP1,NADSYN1,NAGK,NAGPA,NAPRT,NAA16,NBPF10,NBPF11,NBPF14,NBPF3,NCF1,NCF4,NCLN,NCSTN,NDE1,NDST2,NDUFB4,NDUFV1,NECAP1,NFATC2IP,NFIC,NINJ1,NISCH,NKTR,,NLRC5,NLRP1,NLRP2,NME3,NMRAL1,NOL12,NOL6,NOP2,NOTCH1,NPEPL1,NPIPA1,NPIPB15,NPRL3,NR2C1,NRBP2,NSMF,NSUN5,NSUN5P1,NSUN5P2,NUAK2,NUCB1,NUP62,NXF1,OCEL1,OCIAD1,ODF3B,LTO1,ORC6,OSBPL7,OXA1L,P2RX7,P4HTM,PABPC1,PABPC1L,PAN2,PARP10,PARVG,PATL2,PBX4,PCNT,PCSK7,PDE4C,PDPR,PDXDC1,PEMT,PFKFB3,PFKL,PGAM1,PGAP3,PGS1,PHACTR4,PHF19,PI4KA,PI4KAP1,PI4KAP2,PIAS4,PIGQ,PIGT,PIK3R2,PI4KA,PILRA,PILRB,PITPNM1,PLA2G4B,PLAGL1,PLAGL2,PLAUR,PLCB2,PLCH2,PLCXD1,PLD3,PLEKHM1,PLEKHM2,PLSCR1,PLSCR3,PLXNB2,PNISR,PNMA3,PNPLA6,PNPT1,POFUT2,POLG,POLM,POLR1C,POLR2J2,POLR2J3,PPOX,PPP1CA,PPP1R12C,PPP1R15A,PPP1R18,PPP1R3E,PPTC7,PRAM1,PRDX2,HELZ2,PRKCD,PRKCSH,PRKRIP1,PRKY,PRR14,PRSS53,PRXL2A,PSAP,CYTH1,CYTH4,PSMC4,PSMD12,PSTPIP1,PTCD1,PTPRE,QPCT,QRICH1,QSOX2,QTRT2,RAB11FIP1,RAB12,RAB24,RAB27A,RAB40C,RABL2B,RAD54L2,RAF1,RAI1,RALGPS1,RANBP3,RAPGEF1,RARA,RASAL3,RASGRP4,RAX2,RBCK1,RBM14,RBM23,RBM33,RDH5,REC8,RELCH,RENBP,REPIN1,REXO1,RHBDF2,RHOG,RHOT2,RNASEH1,RNASET2,RNF115,RNF126,RNF165,RNF216,RNF44,RNFT1,ROCK2,RPL7L1,MAP7D1,RSRP1,RUNX3,RUSC1,RUSF1,S100A10,S100A11,S100A4,S100Z,SAFB2,SBF1,SCAP,SCNM1,SCO2,SCPEP1,SDE2,SEC14L1,SEC22C,SEC24C,SEPTIN7P2,SEPTIN9,SERPINA1,SETDB1,SF1,SF3B1,SF3B4,SUGP1,SUGP2,AKAP17A,SRSF2,SRSF4,SGSM2,SH3GLB2,SHCBP1,SHFL,SIK3,SKIC2,SLC11A1,SLC12A9,SLC15A3,SLC16A12,SLC16A5,SLC22A18,SLC25A22,SLC25A28,SLC25A42,SLC26A11,SLC26A6,SLC27A3,SLC2A3,SLC2A8,SLC2A9,SLC3A2,SLC44A4,SLC4A5,SLC7A6,SLC8B1,SLCO3A1,SLFN13,SMAP2,SMARCA4,SMARCC2,SMARCD1,SMCR5,SMG5,SMPDL3A,SND1-IT1,SNORA61,SNORA67,SNORD10,,SNORD35B,SNORD36C,SNORD4A,SNRNP70,SNX1,ARHGAP33,SNX27,SNX29,SPATA20,SPEN,SPG21,SPG7,SPHK2,SPI1,SPNS1,SPOCK2,SPSB3,SPTAN1,SREBF1,SRRM2,SRRT,SSH3,STAG3L1,STAG3L2,STAG3L3,STAT2,STAT6,STK10,STK25,STK36,STK40,STRADA,STX16,STX4,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,SUSD6,SYNJ2BP,SYVN1,TAF1C,TAF6L,TAGLN,TBC1D2,TBC1D3G,TCEA2,TCF25,TCIRG1,TEPSIN,TGOLN2,THOC6,MYO18A,TICAM1,TINF2,TJAP1,TLR6,TM9SF4,TMEM131,TMEM131L,TMEM138,TMEM150A,TMEM164,STING1,TMEM175,TMEM176A,TMEM179B,TNF,TNFRSF10B,TNFRSF14,TNFRSF1B,TNFRSF25,TNFSF12,TNK2,TNNI2,TOM1,TOP3A,TOP3B,TP53I13,TPCN2,TPM2,TRABD,TRAF1,TRIM22,TRIM44,TRIM5,TRIM66,TRIM8,TRMT1,TRPC4AP,TRPT1,TRRAP,TSPAN32,TTC31,TTF2,TTLL3,TUBG2,TUBGCP5,TUBGCP6,TXNRD2,TYK2,TYROBP,U2AF1L4,UBA7,UBR4,UBXN11,UCKL1,ULK1,UNC119,UPK3BL1,USP3,USP32,USP36,USP4,UTRN,UVRAG,VAMP1,VASH1,VIPR1,VPS16,VPS52,WAS,WDFY2,WDR37,WDR54,WDR59,WDR6,WDR73,WRAP73,WWP2,XPO6,YPEL2,ZBTB40,ZBTB48,ZC3H12A,ZC3H3,UNK,TUT4,ZDHHC1,ZDHHC8,ZFHX3,ZFP36,ZFP36L2,ZFYVE26,ZMIZ1,ZMIZ2,ZMYND15,ZNF142,ZNF223,ZNF275,ZNF296,ZNF346,ZNF362,ZNF430,ZNF467,ZNF486,ZNF493,ZNF503,ZNF513,ZNF526,ZNF548,ZNF573,ZNF598,ZNF669,ZNF674,ZNF746,ZNF786,ZNF827,ZNF839,ZSCAN18,ZXDC,ZYX,ZZEF1",917,"AAK1,ABHD18,ABHD3,ABL1,ABR,ACAD11,ACADVL,ACCS,ACSS2,ACVR1B,ADAM15,ADAM19,ADAM8,ADCY7,ADGRG1,ADHFE1,ADRBK1,AGAP4,AGAP6,AHR,AIRE,AKAP13,AKR1D1,AKT1,ALAD,ALDH2,ALDOA,ALG9,ALKBH6,ALOX5,AMT,AMY2A,ANKDD1A,ANKMY1,ANKRD11,ANKRD30B,ANKRD36,ANKRD36B,ANKS1A,ANP32A-IT1,ANXA11,AP1G2,AP1M1,AP3D1,AP4B1,APBB3,APOB48R,APOL3,ARAF,ARFGAP2,ARHGAP1,ARHGAP27,ARHGAP4,ARID3B,ARL16,ARL17A,ARL17B,ARNTL,ARRDC3,ARRDC5,ASAH1,ASCC2,ASPSCR1,ATG2A,ATG4B,ATP13A1,ATP2A2,ATP6AP1,ATP6V0A1,ATPGD1,ATXN1L,AXIN1,AZI1,B4GALT5,BCKDK,BCL3,BCS1L,BHLHB2,BRAT1,BRD9,BRI3,BTBD2,BTN2A1,BTN3A1,C10orf54,C11orf21,C14orf159,C15orf39,C16orf7,C17orf68,C17orf70,C19orf6,C1orf162,C20orf27,C21orf58,C22orf9,C2orf69,C6orf136,C7orf47,C8orf37,C9orf142,C9orf72,C9orf80,CACNA1I,CACNA2D4,CAPS,CARD9,CARM1,CASP8,CASZ1,CAT,CBLB,CBX6,CCDC130,CCDC49,CCDC84,CCL3,CCL3L1,CCM2,CCNL1,CCR6,CD1C,CD300C,CD302,CD33,CD74,CD97,CDAN1,CDC37,CDC42EP3,CDC42EP4,CDH23,CDK10,CDK11B,CDK5RAP1,CDK5RAP3,CDK9,CDKN1C,CEBPB,CECR1,CELF2,CENTA1,CEP192,CEP27,CERK,CES2,CFD,CFL1,CHFR,CHKB,CHN2,CIDEB,CLCN6,CLCN7,CLDN15,CLDND2,CLEC16A,CLEC7A,CLIP4,CLK3,CLN3,CLSTN1,CMIP,CMTM4,CMTM7,CNDP2,CNN2,CNNM3,COMT,COPE,COPS7B,COQ10A,COTL1,COX19,COX8A,CPNE1,CPSF1,CRCP,CREB1,CREBBP,CREBZF,CRTAP,CSAD,CSF1R,CSF2RA,CSF3R,CSGALNACT2,CSNK1D,CSNK1E,CSNK1G2,CST3,CTGLF3,CTRL,CTSB,CUEDC1,CUX1,CXCL16,CXorf65,CXXC1,CYB561,CYBA,CYC1,CYTH2,CZ1P-ASNS,D2HGDH,DAGLB,DAPP1,DDX56,DEF8,DENND1C,DENND3,DGKA,DGKQ,DHRS1,DICER1,DIDO1,DIP2A,DLL1,DMAP1,DNAAF5,DNAH1,DNAJC28,DNASE1L1,DNMT1,DOCK2,DOPEY2,DPAGT1,DPEP2,DUS1L,DUS3L,DUSP18,DVL3,DXS648E,DYSF,E2F4,E4F1,EBLN2,ECHDC2,EFHD2,EHBP1L1,EIF1,EIF4E2,EIF4H,ELF4,ELMO2,EMD,EML3,ENG,ENGASE,ENO3,ENTPD4,ENTPD6,EP300,EPM2AIP1,EPN1,ERAL1,ETV3,EVL,EXOSC10,FAM105A,FAM113A,FAM113B,FAM115A,FAM116B,FAM129B,FAM153B,FAM156A,FAM156B,FAM179A,FAM38A,FAM39DP,FAM39E,FAM40B,FAM65A,FAM65B,FARSLB,FBP1,FBXL6,FBXW9,FCER1G,FCGR2A,FCGRT,FCN1,FES,FGD3,FGR,FKBP15,FKTN,FLII,FLJ10374,FN3KRP,FNIP1,FOXJ2,FRAT2,FRS3,FTL,FUBP3,FUT4,FXYD5,GAB2,GABPB2,GAK,GAL3ST4,GALT,GARNL4,GARRE1,GAS7,GFOD1,GGA3,GHDC,GIT2,GJC1,GLTSCR1,GMDS,GMEB2,GMIP,GNG7,GOLGA8B,GON4L,GPR137,GPR162,GPS1,GPS2,GRAMD1A,GRAMD4,GRN,GSDMB,GSE1,GSTK1,GSTM1,GSTM2,GTPBP3,GTPBP6,GUSB,H3-5,HCFC1,HCG27,HERPUD1,HES4,HEXDC,HGS,HIC2,HINT3,HK3,HLA-DMA,HLA-DQA1,HLA-DRB1,HLA-DRB4,HNMT,HNRPM,HOXB2,HPS1,HPS4,HSH2D,HSPA7,ICA1,IDH3G,IDUA,IER5,IFFO1,IFI44L,IFITM2,IFITM3,IKBKB,IKBKG,IL10,IL10RA,IL11RA,IL18,IL18BP,IL18RAP,IL2RB,IMPDH1,INADL,INTS1,INTS3,INTS4,IP6K1,IQSEC1,IRF1,IRF7,IRF9,ITFG2,ITGA5,ITGAL,ITGAX,ITGB2,ITIH4,ITIH5,ITPR3,JAK1,JARID1D,JARID2,JMJD8,KAT2A,KATNB1,KATNIP,KCNMB1,KCTD13,KDELR1,KDM2A,KHNYN,KIAA0319L,KIAA1683,KIF21B,KIF22,KIR2DL3,KLF10,KLF13,KLF6,KLHL3,KRBA1,KRT72,KRT73,KXD1,LAG3,LILRA3,LILRA6,LILRB1,LILRB3,LINC00954,LMTK3,LOC100190986,LOC401357,LOC730234,LPCAT3,LPIN1,LRCH4,LRP10,LRP5L,LRRC14,LRRC33,LRSAM1,LSS,LST1,LTBP4,LUC7L,LYN,LYZ,LZTR1,MAEA,MAN1B1,MAN2A2,MAN2B1,MAN2C1,MAP11,MAP3K8,MAP4K1,MAPK8IP3,MARCH1,MAST3,MAU2,MBD1,MBD2,MBD6,MCM3AP,MCM7,MCM8,MCOLN2,MDC1,MED16,MED25,MEF2D,MEGF6,METT11D1,METTL3,MFSD10,MFSD3,MGC3731,MICAL1,MIDEAS,MIDN,MIIP,MILR1,MKNK1,MKNK2,MMP23B,MMS19,MNDA,MNT,MOBKL2A,MOGS,MPEG1,MTCH1,MUM1,MUTYH,MX1,MXD1,MXD4,MYADM,MYO9B,MYOF,MZF1,N4BP1,NADSYN1,NAGK,NAGPA,NAPRT1,NARG1L,NBPF10,NBPF11,NBPF14,NBPF3,NCF1,NCF4,NCLN,NCSTN,NDE1,NDST2,NDUFB4,NDUFV1,NECAP1,NFATC2IP,NFIC,NINJ1,NISCH,NKTR,NLPR1,NLRC5,NLRP1,NLRP2,NME3,NMRAL1,NOL12,NOL6,NOP2,NOTCH1,NPEPL1,NPIP,NPIPB15,NPRL3,NR2C1,NRBP2,NSMF,NSUN5,NSUN5B,NSUN5C,NUAK2,NUCB1,NUP62,NXF1,OCEL1,OCIAD1,ODF3B,ORAOV1,ORC6L,OSBPL7,OXA1L,P2RX7,P4HTM,PABPC1,PABPC1L,PAN2,PARP10,PARVG,PATL2,PBX4,PCNT,PCSK7,PDE4C,PDPR,PDXDC1,PEMT,PFKFB3,PFKL,PGAM1,PGAP3,PGS1,PHACTR4,PHF19,PI4KA,PI4KAP1,PI4KAP2,PIAS4,PIGQ,PIGT,PIK3R2,PIK4CA,PILRA,PILRB,PITPNM1,PLA2G4B,PLAGL1,PLAGL2,PLAUR,PLCB2,PLCH2,PLCXD1,PLD3,PLEKHM1,PLEKHM2,PLSCR1,PLSCR3,PLXNB2,PNISR,PNMA3,PNPLA6,PNPT1,POFUT2,POLG,POLM,POLR1C,POLR2J2,POLR2J3,PPOX,PPP1CA,PPP1R12C,PPP1R15A,PPP1R18,PPP1R3E,PPTC7,PRAM1,PRDX2,PRIC285,PRKCD,PRKCSH,PRKRIP1,PRKY,PRR14,PRSS53,PRXL2A,PSAP,PSCD1,PSCD4,PSMC4,PSMD12,PSTPIP1,PTCD1,PTPRE,QPCT,QRICH1,QSOX2,QTRTD1,RAB11FIP1,RAB12,RAB24,RAB27A,RAB40C,RABL2B,RAD54L2,RAF1,RAI1,RALGPS1,RANBP3,RAPGEF1,RARA,RASAL3,RASGRP4,RAXL1,RBCK1,RBM14,RBM23,RBM33,RDH5,REC8,RELCH,RENBP,REPIN1,REXO1,RHBDF2,RHOG,RHOT2,RNASEH1,RNASET2,RNF115,RNF126,RNF165,RNF216,RNF44,RNFT1,ROCK2,RPL7L1,RPRC1,RSRP1,RUNX3,RUSC1,RUSF1,S100A10,S100A11,S100A4,S100Z,SAFB2,SBF1,SCAP,SCNM1,SCO2,SCPEP1,SDE2,SEC14L1,SEC22C,SEC24C,SEPT13,SEPT9,SERPINA1,SETDB1,SF1,SF3B1,SF3B4,SF4,SFRS14,SFRS17A,SFRS2,SFRS4,SGSM2,SH3GLB2,SHCBP1,SHFL,SIK3,SKIV2L,SLC11A1,SLC12A9,SLC15A3,SLC16A12,SLC16A5,SLC22A18,SLC25A22,SLC25A28,SLC25A42,SLC26A11,SLC26A6,SLC27A3,SLC2A3,SLC2A8,SLC2A9,SLC3A2,SLC44A4,SLC4A5,SLC7A6,SLC8B1,SLCO3A1,SLFN13,SMAP2,SMARCA4,SMARCC2,SMARCD1,SMCR5,SMG5,SMPDL3A,SND1-IT1,SNORA61,SNORA67,SNORD10,SNORD31,SNORD35B,SNORD36C,SNORD4A,SNRNP70,SNX1,SNX26,SNX27,SNX29,SPATA20,SPEN,SPG21,SPG7,SPHK2,SPI1,SPNS1,SPOCK2,SPSB3,SPTAN1,SREBF1,SRRM2,SRRT,SSH3,STAG3L1,STAG3L2,STAG3L3,STAT2,STAT6,STK10,STK25,STK36,STK40,STRADA,STX16,STX4,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,SUSD6,SYNJ2BP,SYVN1,TAF1C,TAF6L,TAGLN,TBC1D2,TBC1D3G,TCEA2,TCF25,TCIRG1,TEPSIN,TGOLN2,THOC6,TIAF1,TICAM1,TINF2,TJAP1,TLR6,TM9SF4,TMEM131,TMEM131L,TMEM138,TMEM150A,TMEM164,TMEM173,TMEM175,TMEM176A,TMEM179B,TNF,TNFRSF10B,TNFRSF14,TNFRSF1B,TNFRSF25,TNFSF12,TNK2,TNNI2,TOM1,TOP3A,TOP3B,TP53I13,TPCN2,TPM2,TRABD,TRAF1,TRIM22,TRIM44,TRIM5,TRIM66,TRIM8,TRMT1,TRPC4AP,TRPT1,TRRAP,TSPAN32,TTC31,TTF2,TTLL3,TUBG2,TUBGCP5,TUBGCP6,TXNRD2,TYK2,TYROBP,U2AF1L4,UBA7,UBR4,UBXN11,UCKL1,ULK1,UNC119,UPLP,USP3,USP32,USP36,USP4,UTRN,UVRAG,VAMP1,VASH1,VIPR1,VPS16,VPS52,WAS,WDFY2,WDR37,WDR54,WDR59,WDR6,WDR73,WDR8,WWP2,XPO6,YPEL2,ZBTB40,ZBTB48,ZC3H12A,ZC3H3,ZC3H5,ZCCHC11,ZDHHC1,ZDHHC8,ZFHX3,ZFP36,ZFP36L2,ZFYVE26,ZMIZ1,ZMIZ2,ZMYND15,ZNF142,ZNF223,ZNF275,ZNF296,ZNF346,ZNF362,ZNF430,ZNF467,ZNF486,ZNF493,ZNF503,ZNF513,ZNF526,ZNF548,ZNF573,ZNF598,ZNF669,ZNF674,ZNF746,ZNF786,ZNF827,ZNF839,ZSCAN18,ZXDC,ZYX,ZZEF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 8 in additional file 9,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282650/bin/13073_2017_400_MOESM9_ESM.xls,NA,NA,NA,NA
M40866,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN,VIRUS,DOWN,VACCINE,RESPONDER,D7,D,7,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in young adults (21-30) (responders) after exposure to Inactivated influenza vaccine , time point 7D. Comment: most (70-80%) of cohort were white","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"AAK1,ABHD18,ABHD3,ABR,ACAD11,ACADVL,ACSS2,ACVR1B,ADA2,ADAM19,ADAM8,ADCY7,ADHFE1,AGAP4,AGAP6,AHR,AIRE,AK1,AKAP13,AKAP17A,AKT1,ALAD,ALDOA,ALKBH6,ALOX5,AMT,AMY2A,ANKMY1,ANKRD11,ANKRD36,ANKRD36B,ANXA11,AP1G2,AP4B1,APBB3,ARAF,ARHGAP1,ARHGAP27,ARHGAP33,ARHGAP4,ARHGAP9,ARID3B,BMAL1,ARRB2,ARRDC3,ARRDC5,ASCC2,ASPSCR1,ATG2A,ATG4B,ATP2A2,ATP6V0A1,ATXN1L,AXIN1,B4GALT5,BCL3,BHLHE40,BICRA,BRD9,BTBD2,BTG2,BTN2A1,C11orf21,C1QTNF6,C1orf162,C6orf136,C9orf72,CACNA1I,CACNA2D4,CAMK2G,CAPS,CARM1,CARNS1,CASP8,CASZ1,CBLB,CBX4,CBX6,YJU2B,CWC25,CENATAC,CCL28,CCL3,CCL3L1,CCL3L3,CCNL1,CD302,ADGRE5,CDAN1,CDC37,CDC42EP3,CDH23,CDK11B,CDK5RAP1,CDK5RAP3,CDK9,CEBPB,CEBPD,CELF2,CERK,CES2,CHKB,CHMP1B,CHN2,CIDEB,CLCN6,CLCN7,CLDN15,CLEC7A,CLIP4,CLK3,CMIP,CMTM4,CMTM7,CNN2,CNPY3,COG1,COPS7B,CPSF1,CREBBP,CREBZF,CRTAP,CSAD,CSF3R,CSGALNACT2,CSNK1A1P1,CSNK1D,CSNK1G2,CTRL,CUEDC1,CUX1,CXCL16,CXCR4,CXorf65,CYB561,CYTH2,D2HGDH,DAGLB,DAPP1,DDX56,DEF8,DGKA,DGKQ,DHRS1,DICER1,DIDO1,DIP2A,DMAP1,DMXL2,DNAH1,DNAJC28,DNASE1L1,DNMT1,DPEP2,DUS1L,DUS3L,DUSP1,DUSP18,DVL3,E2F4,E4F1,ECHDC2,EFHD2,EIF1,EIF3CL,EIF4H,ELF4,ELMO2,EMD,EML3,ENGASE,ENO3,ENTPD4,EP300,EPN1,ETV3,EVL,FAM156A,FARSB,FBXL6,FCGR2A,FGD3,FLII,FN3KRP,FNIP1,FOXJ2,FRS3,FUBP3,FUT4,GABPB2,GAK,GALT,GARRE1,GGA3,GIT2,GK5,GMEB2,GNAQ,GPR137,GPS2,GPSM3,GRAMD1A,GRAMD4,GRB2,GRK2,GRN,GSDMB,GSTM1,GSTM2,GTPBP3,GUSB,HCFC1,HECTD4,HERPUD1,HEXD,HGS,HIC2,HLA-C,HLA-DMA,HNRNPM,HPS1,HPS4,IDUA,IER5,IFFO1,IKBKB,IKZF5,IL11RA,IL18,IMPDH1,INAFM1,INTS1,IP6K1,IQSEC1,IRF9,ITFG2,ITGAL,ITGB2,ITPR3,ITPRIP,JAK1,JARID2,JMJD8,JUND,KATNIP,KCNMB1,KDM2A,KHNYN,KIF21B,KLF10,KLF2,KLF6,KLHL3,KRBA1,KRT73,KXD1,LAG3,LILRA3,LILRA6,LILRB3,LINC00294,LINC01089,LINC01205,LMTK3,,,,LPCAT3,LPIN1,LRCH3,LRCH4,LRP5L,LRRC14,NRROS,LRSAM1,LTBP4,LUC7L,LYN,LYPLA1,LZTR1,MAEA,MAN2C1,TRAPPC14,MAP3K8,MAP4K1,MAPK8IP3,MARCHF1,MAU2,MBD2,MBD6,MCM7,MCM8,MCOLN2,MDC1,MED25,MEF2A,MEF2D,METTL17,METTL3,MFSD10,MFSD14A,MICAL1,MIDEAS,MILR1,MIR22HG,MKNK1,MKNK2,MMS19,MNDA,MNT,MOGS,MPEG1,MRI1,MTCH1,MTX3,MXD1,MYADM,MZF1,N4BP1,NAA16,NBPF10,NBPF11,NBPF14,NBPF3,NCF1,NCOR1P1,NCSTN,NDE1,NDUFB4,NDUFV1,NECAP1,NFATC2IP,NFKBIA,NFKBIZ,NIBAN2,NINJ1,NISCH,NKTR,,NLRC5,NLRP1,NOL12,NOL6,NOP2,NOTCH1,NPEPL1,NPIPA1,NPIPB15,NPRL3,NR2C1,NRBP2,NSMF,NSUN5,NUCB1,NUP62,NXF1,LTO1,ORC6,OSBPL7,OSER1,OSM,P4HTM,PABPC1,PABPC1L,PAN2,PATL1,PBX4,PCBP1,PCED1A,PCSK7,PDCD4-AS1,PDE4C,PFKFB3,PFKL,PGAP3,PGS1,PHACTR4,PHF19,PI4KA,PIAS4,PIEZO1,PIK3R2,PI4KA,PILRA,PILRB,PITPNM1,PLA2G4B,PLAUR,PLCB2,PLCH2,PLD3,PLSCR1,PLSCR3,PLXNB2,PNISR,PNMA3,PNN,PNPLA6,PNPT1,POFUT2,POLG,POLM,POLR1C,POLR2J2,PPP1R15A,PPP1R18,PPP1R3E,PPTC7,PRKAG2,PRKCD,PRKCSH,PSAP,CYTH1,CYTH4,PSMC4,PTPRE,PUM1,QPCT,QRICH1,QSOX2,QTRT2,RAB12,RAB27A,RAB40C,RABL2B,RAD54L2,RAF1,RAI1,RALGDS,RALGPS1,RANBP3,RAP1GAP2,RARA,RASAL3,RASGRP4,RAX2,RBCK1,RBM33,REC8,RELCH,REPIN1,REXO1,RFX1,RHBDF2,RHOG,RHOT2,RIOK3,RIPOR2,RNASEH1,RNASET2,RNF126,RNF216,RNFT1,RP2,RPL10,MAP7D1,RSKR,RSRP1,RUSF1,S100A10,S100A4,S100Z,SAFB2,SCAP,SCNM1,SDE2,SEC22C,SERPINA1,SESTD1,SETD1B,SF1,SF3B1,SF3B4,SRSF2,SRSF4,SGK1,SGSM2,SH3GLB2,SHCBP1,SHFL,SIK3,SKIC2,SLC11A1,SLC16A12,SLC16A5,SLC16A6,SLC22A18,SLC25A25-AS1,SLC25A28,SLC25A42,SLC26A11,SLC26A6,SLC27A3,SLC2A3,SLC2A9,SLC3A2,SLC44A4,SLC8B1,SLFN13,SMAP2,SMARCA4,SMARCC2,SMARCD1,SMCR5,SMPDL3A,SNORA3B,SNORA6,SNORA61,SNORA67,SNORD10,SNORD21,,SNORD35B,SNORD36C,SNORD38A,SNORD4A,SNORD68,SNORD89,SNRNP70,SNX1,SORBS3,SP2,SPATA20,SPEN,SPG21,SPG7,SPHK2,SPNS1,SPOCK2,SPSB3,SREBF1,SRRM2,SRRT,SSH3,STAT6,STK25,STMN3,STRADA,STX11,STX16,STX4,SUGP2,SULT1A1,SULT1A2,SUN1,SUSD6,SYNJ2BP,TAF15,TAF1C,TAF6L,TAGLN,TBC1D2,TBC1D9B,TCEA2,TCIRG1,TEPSIN,TGOLN2,TJAP1,TM9SF4,TMEM131,TMEM131L,TMEM138,TMEM150A,STING1,TMEM175,TMEM86B,TNFRSF10B,TNFRSF25,TNFSF12,TNK2,TNNI2,TOGARAM2,TP53I13,TPM2,TRA2A,TRABD,TRIM22,TRMT1,TRPC4AP,TRPT1,TSPAN32,TTC31,TTF2,TTLL3,TUBG2,TUBGCP5,TUBGCP6,TXK,TYK2,U2AF1L4,UBA7,UBE2D3,UBXN11,UFM1,ULK1,UNC119,UPK3BL1,USP3,USP32,USP36,VAMP1,VIPR1,VPS52,WAS,WASHC1,WDFY2,WDR37,WDR59,WDR73,WHAMM,WWP2,XPO6,YPEL2,ZBTB40,ZC3H12A,ZC3H3,UNK,TUT4,ZDHHC1,ZDHHC8,ZFHX3,ZFP36,ZFP36L2,ZMIZ1,ZMIZ2,ZMYND15,ZNF274,ZNF275,ZNF486,ZNF493,ZNF514,ZNF526,ZNF548,ZNF598,ZNF674,ZNF827,ZNF839,ZSCAN18,ZXDC,ZYX,ZZEF1",641,"AAK1,ABHD18,ABHD3,ABR,ACAD11,ACADVL,ACSS2,ACVR1B,ADA2,ADAM19,ADAM8,ADCY7,ADHFE1,AGAP4,AGAP6,AHR,AIRE,AK1,AKAP13,AKAP17A,AKT1,ALAD,ALDOA,ALKBH6,ALOX5,AMT,AMY2A,ANKMY1,ANKRD11,ANKRD36,ANKRD36B,ANXA11,AP1G2,AP4B1,APBB3,ARAF,ARHGAP1,ARHGAP27,ARHGAP33,ARHGAP4,ARHGAP9,ARID3B,ARNTL,ARRB2,ARRDC3,ARRDC5,ASCC2,ASPSCR1,ATG2A,ATG4B,ATP2A2,ATP6V0A1,ATXN1L,AXIN1,B4GALT5,BCL3,BHLHE40,BICRA,BRD9,BTBD2,BTG2,BTN2A1,C11orf21,C1orf162,C1QTNF6,C6orf136,C9orf72,CACNA1I,CACNA2D4,CAMK2G,CAPS,CARM1,CARNS1,CASP8,CASZ1,CBLB,CBX4,CBX6,CCDC130,CCDC49,CCDC84,CCL28,CCL3,CCL3L1,CCL3L3,CCNL1,CD302,CD97,CDAN1,CDC37,CDC42EP3,CDH23,CDK11B,CDK5RAP1,CDK5RAP3,CDK9,CEBPB,CEBPD,CELF2,CERK,CES2,CHKB,CHMP1B,CHN2,CIDEB,CLCN6,CLCN7,CLDN15,CLEC7A,CLIP4,CLK3,CMIP,CMTM4,CMTM7,CNN2,CNPY3,COG1,COPS7B,CPSF1,CREBBP,CREBZF,CRTAP,CSAD,CSF3R,CSGALNACT2,CSNK1A1P1,CSNK1D,CSNK1G2,CTRL,CUEDC1,CUX1,CXCL16,CXCR4,CXorf65,CYB561,CYTH2,D2HGDH,DAGLB,DAPP1,DDX56,DEF8,DGKA,DGKQ,DHRS1,DICER1,DIDO1,DIP2A,DMAP1,DMXL2,DNAH1,DNAJC28,DNASE1L1,DNMT1,DPEP2,DUS1L,DUS3L,DUSP1,DUSP18,DVL3,E2F4,E4F1,ECHDC2,EFHD2,EIF1,EIF3CL,EIF4H,ELF4,ELMO2,EMD,EML3,ENGASE,ENO3,ENTPD4,EP300,EPN1,ETV3,EVL,FAM156A,FARSLB,FBXL6,FCGR2A,FGD3,FLII,FN3KRP,FNIP1,FOXJ2,FRS3,FUBP3,FUT4,GABPB2,GAK,GALT,GARRE1,GGA3,GIT2,GK5,GMEB2,GNAQ,GPR137,GPS2,GPSM3,GRAMD1A,GRAMD4,GRB2,GRK2,GRN,GSDMB,GSTM1,GSTM2,GTPBP3,GUSB,HCFC1,HECTD4,HERPUD1,HEXDC,HGS,HIC2,HLA-C,HLA-DMA,HNRPM,HPS1,HPS4,IDUA,IER5,IFFO1,IKBKB,IKZF5,IL11RA,IL18,IMPDH1,INAFM1,INTS1,IP6K1,IQSEC1,IRF9,ITFG2,ITGAL,ITGB2,ITPR3,ITPRIP,JAK1,JARID2,JMJD8,JUND,KATNIP,KCNMB1,KDM2A,KHNYN,KIF21B,KLF10,KLF2,KLF6,KLHL3,KRBA1,KRT73,KXD1,LAG3,LILRA3,LILRA6,LILRB3,LINC00294,LINC01089,LINC01205,LMTK3,LOC100190986,LOC401357,LOC730234,LPCAT3,LPIN1,LRCH3,LRCH4,LRP5L,LRRC14,LRRC33,LRSAM1,LTBP4,LUC7L,LYN,LYPLA1,LZTR1,MAEA,MAN2C1,MAP11,MAP3K8,MAP4K1,MAPK8IP3,MARCH1,MAU2,MBD2,MBD6,MCM7,MCM8,MCOLN2,MDC1,MED25,MEF2A,MEF2D,METT11D1,METTL3,MFSD10,MFSD14A,MICAL1,MIDEAS,MILR1,MIR22HG,MKNK1,MKNK2,MMS19,MNDA,MNT,MOGS,MPEG1,MRI1,MTCH1,MTX3,MXD1,MYADM,MZF1,N4BP1,NAA16,NBPF10,NBPF11,NBPF14,NBPF3,NCF1,NCOR1P1,NCSTN,NDE1,NDUFB4,NDUFV1,NECAP1,NFATC2IP,NFKBIA,NFKBIZ,NIBAN2,NINJ1,NISCH,NKTR,NLPR1,NLRC5,NLRP1,NOL12,NOL6,NOP2,NOTCH1,NPEPL1,NPIP,NPIPB15,NPRL3,NR2C1,NRBP2,NSMF,NSUN5,NUCB1,NUP62,NXF1,ORAOV1,ORC6L,OSBPL7,OSER1,OSM,P4HTM,PABPC1,PABPC1L,PAN2,PATL1,PBX4,PCBP1,PCED1A,PCSK7,PDCD4-AS1,PDE4C,PFKFB3,PFKL,PGAP3,PGS1,PHACTR4,PHF19,PI4KA,PIAS4,PIEZO1,PIK3R2,PIK4CA,PILRA,PILRB,PITPNM1,PLA2G4B,PLAUR,PLCB2,PLCH2,PLD3,PLSCR1,PLSCR3,PLXNB2,PNISR,PNMA3,PNN,PNPLA6,PNPT1,POFUT2,POLG,POLM,POLR1C,POLR2J2,PPP1R15A,PPP1R18,PPP1R3E,PPTC7,PRKAG2,PRKCD,PRKCSH,PSAP,PSCD1,PSCD4,PSMC4,PTPRE,PUM1,QPCT,QRICH1,QSOX2,QTRTD1,RAB12,RAB27A,RAB40C,RABL2B,RAD54L2,RAF1,RAI1,RALGDS,RALGPS1,RANBP3,RAP1GAP2,RARA,RASAL3,RASGRP4,RAXL1,RBCK1,RBM33,REC8,RELCH,REPIN1,REXO1,RFX1,RHBDF2,RHOG,RHOT2,RIOK3,RIPOR2,RNASEH1,RNASET2,RNF126,RNF216,RNFT1,RP2,RPL10,RPRC1,RSKR,RSRP1,RUSF1,S100A10,S100A4,S100Z,SAFB2,SCAP,SCNM1,SDE2,SEC22C,SERPINA1,SESTD1,SETD1B,SF1,SF3B1,SF3B4,SFRS2,SFRS4,SGK1,SGSM2,SH3GLB2,SHCBP1,SHFL,SIK3,SKIV2L,SLC11A1,SLC16A12,SLC16A5,SLC16A6,SLC22A18,SLC25A25-AS1,SLC25A28,SLC25A42,SLC26A11,SLC26A6,SLC27A3,SLC2A3,SLC2A9,SLC3A2,SLC44A4,SLC8B1,SLFN13,SMAP2,SMARCA4,SMARCC2,SMARCD1,SMCR5,SMPDL3A,SNORA3B,SNORA6,SNORA61,SNORA67,SNORD10,SNORD21,SNORD31,SNORD35B,SNORD36C,SNORD38A,SNORD4A,SNORD68,SNORD89,SNRNP70,SNX1,SORBS3,SP2,SPATA20,SPEN,SPG21,SPG7,SPHK2,SPNS1,SPOCK2,SPSB3,SREBF1,SRRM2,SRRT,SSH3,STAT6,STK25,STMN3,STRADA,STX11,STX16,STX4,SUGP2,SULT1A1,SULT1A2,SUN1,SUSD6,SYNJ2BP,TAF15,TAF1C,TAF6L,TAGLN,TBC1D2,TBC1D9B,TCEA2,TCIRG1,TEPSIN,TGOLN2,TJAP1,TM9SF4,TMEM131,TMEM131L,TMEM138,TMEM150A,TMEM173,TMEM175,TMEM86B,TNFRSF10B,TNFRSF25,TNFSF12,TNK2,TNNI2,TOGARAM2,TP53I13,TPM2,TRA2A,TRABD,TRIM22,TRMT1,TRPC4AP,TRPT1,TSPAN32,TTC31,TTF2,TTLL3,TUBG2,TUBGCP5,TUBGCP6,TXK,TYK2,U2AF1L4,UBA7,UBE2D3,UBXN11,UFM1,ULK1,UNC119,UPLP,USP3,USP32,USP36,VAMP1,VIPR1,VPS52,WAS,WASHC1,WDFY2,WDR37,WDR59,WDR73,WHAMM,WWP2,XPO6,YPEL2,ZBTB40,ZC3H12A,ZC3H3,ZC3H5,ZCCHC11,ZDHHC1,ZDHHC8,ZFHX3,ZFP36,ZFP36L2,ZMIZ1,ZMIZ2,ZMYND15,ZNF274,ZNF275,ZNF486,ZNF493,ZNF514,ZNF526,ZNF548,ZNF598,ZNF674,ZNF827,ZNF839,ZSCAN18,ZXDC,ZYX,ZZEF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 8 in additional file 9,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282650/bin/13073_2017_400_MOESM9_ESM.xls,NA,NA,NA,NA
M40870,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_UP,VIRUS,UP,VACCINE,RESPONDER,D7,D,7,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_28DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 0d in young adults (21-30) (responders) after exposure to Inactivated influenza vaccine , time point 28D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ABCC3,ABCE1,ABLIM3,ACRBP,ACSBG1,ACVR1,ADD3,ADK,AGFG1,AHCTF1,AKAP11,AKAP7,ALG5,ALG6,ALOX12,AMD1,ANAPC10,ANKRD12,ANKRD13A,ANKRD46,ANTXR2,AQP10,ARFIP1,ARL6IP5,ARL8B,ARPC5,ASAP2,ASB8,ATG5,ATP6V1G1,ATP9A,BAX,BAZ2B,BCL2,BCL2L1,BCLAF1,BMI1,BMP6,BMPR2,STAP1,ANAPC16,C12orf76,RTRAF,IRF2BPL,BBOF1,CEP20,ADPRM,C1GALT1,C1GALT1C1,C1orf198,YBEY,MAP3K7CL,MMADHC,C2orf88,DIPK2A,GASK1B,HPF1,FAM172A,FAXDC2,RIMOC1,C6orf62,MTURN,MSANTD3,CABP5,CALD1,CAMLG,CAST,CBFB,CFAP36,CCDC34,CCDC6,CCDC65,CCDC90B,CCDC91,CCNB1IP1,CCNG1,CD226,CD3G,CD8B,CDC23,CDKN2AIP,CDV3,CENPK,CGRRF1,CHD9,FOXN3,CHM,CHSY1,CLDN5,CLEC1B,CLEC2D,CLIC4,CLK4,CNOT7,COPB1,COPG2,COPS8,CORO1C,COX7A2L,CPD,CREBRF,CTDSPL,CYP4V2,DAB2,DCAF12,DEK,DENR,DHX29,DIAPH2,LINC01011,DLEU1,DNAJB9,DNAJC15,DYNLL1,DNM3,DOCK11,DPY30,EBAG9,ECHDC1,EEF1B2,EIF1AX,EIF4G2,CELA1,ENSA,DMTN,EPC1,ERGIC2,ERH,ESAM,ETF1,F13A1,RETREG1,FAM172A,CCSER2,SINHCAF,FBXO33,FEZ2,FHL1,FHL2,FKBP3,FLI1,FRMD3,FRYL,FUNDC1,G3BP1,GALNT1,GFM1,GIMAP2,GIN1,GLRX,GMPR,GNA12,GNB5,GOPC,GPBP1,GPR160,GPR183,GRB14,GTF2F2,GTF3A,GTSCR1,GUCY1A1,GYPC,HBA1,HBA2,HBD,HBG2,HECA,HIGD1A,H2AC6,H2AC11,H2BC5,H2BC9,H2BC11,H3C7,H3C10,H4C8,H2BC21,H3C14,HMGB1,HMGN4,HPGD,HSD17B12,IDI1,IFRD1,IGF2BP2,ING3,INPP4B,INTS6,INTS8,IRF2BP2,ISCA1,ITGAE,ITGB3,ITGB5,IVNS1ABP,JKAMP,KIF2A,KIFC3,KLHL28,KLHL9,KLRC2,LAMP2,LAPTM4B,LARP7,LAX1,LCLAT1,LEPROT,LEPROTL1,LIMS1,CAPN1-AS1,LRBA,MAP3K1,MAP3K7,MARCHF7,MAST4,MAT2B,MAX,MEIS1,METTL23,METTL7A,MEX3C,MFAP1,MFHAS1,MFSD1,MFSD6,MGLL,MMADHC,MMD,MORF4L1,MPL,MRPL13,MRPL21,MRPL3,MRPL42,MRPL47,MRPS28,MRPS35,MTDH,MTF2,MTMR6,MTPN,MTX2,MYL4,MYLK,N4BP2L2,NACA4P,NAP1L1,NCK1,NCK2,NDUFAB1,NDUFV2,NELL2,NFIB,NGDN,BEX3,NKRF,NMD3,NOSIP,NPTN,NRGN,NSA2,NT5C3A,NT5M,NUCB2,NUCKS1,NUDT21,NUP54,NUP88,NXT2,OPTN,ORC3,OSBP2,OSBPL11,OSBPL8,OSTM1,PAIP2,PAQR8,PCDHGB6,PCMT1,PCMTD1,PDCD10,PDLIM1,PGRMC1,PHAX,PHIP,PI4K2B,PIGY,PIK3R1,PIM1,PLCL2,PLEKHA8P1,PPP1R14A,PPP1R2,PRDX6,PRKAB2,PRNP,PRORP,PROS1,PRPF18,PSMA2,PSMA3,PSMA4,PSMC6,PSMD14,PTCRA,PTEN,PTGER4,PTGES3,PTGS1,PTMA,PTPN12,PTPN22,PURA,RAB10,RAB11A,RAB21,RAD21,RB1CC1,RBBP7,RBM27,RBM34,RCAN1,RDH11,RGS10,RGS18,RIOK2,RIT1,,RNA5S9,RNASEH2B,RNF11,RNF138,RNY1,RPA1,RPL15,RPL34,RPS3A,RPS6KB1,RYBP,SAMD14,SAP18,SCGB1C1,SDHAF3,CAVIN2,SEC62,SELENOT,SERINC1,SERP1,SRSF1,SRSF3,SH3BGRL2,SLC35B3,SLC39A8,SLITRK4,SMC2,PPP4R3B,SMOX,SNCA,SNORA12,SNORD32A,SNORD33,SNORD48,SNORD62B,SNORD8,SOD1,SOX4,SP3,SPARC,SPAST,SPC25,SRBD1,SRP72,SSBP1,ST8SIA4,STAG2,STAP1,STOM,STRADB,SUZ12,TAPT1,TAX1BP1,TBC1D15,TBCA,TBK1,TBPL1,TC2N,TCF12,THOC7,TIMM9,NSA2,TLK1,TM9SF2,TMED5,EMC3,TMEM123,TMEM126A,TMEM140,TMEM14A,TMEM14B,TMEM158,TMEM30A,PIP4P2,TNFSF4,TNNC2,TNPO1,TOMM7,TP53INP1,TPM1,TREML1,TSC22D1,TSC22D2,TSPAN9,TSTD1,TUBA3D,UBE2D2,UBE2E1,UBE2Q2,UBE2V2,UBLCP1,UBP1,UBQLN1,UBQLN2,UCHL3,UGCG,VAMP7,VASP,VDAC3,VRK1,VWF,POC1B,WTAP,XK,YEATS4,YIPF4,YPEL5,YWHAH,ZBTB4,ZBTB8OS,ZC3H11B,ZC3H15,ZCCHC7,ZFAND1,ZFAS1,ZNF17,ZNF189,ZNF318,ZNF559",448,"ABCC3,ABCE1,ABLIM3,ACRBP,ACSBG1,ACVR1,ADD3,ADK,AGFG1,AHCTF1,AKAP11,AKAP7,ALG5,ALG6,ALOX12,AMD1,ANAPC10,ANKRD12,ANKRD13A,ANKRD46,ANTXR2,AQP10,ARFIP1,ARL6IP5,ARL8B,ARPC5,ASAP2,ASB8,ATG5,ATP6V1G1,ATP9A,BAX,BAZ2B,BCL2,BCL2L1,BCLAF1,BMI1,BMP6,BMPR2,BRDG1,C10orf104,C12orf76,C14orf166,C14orf4,C14orf45,C16orf63,C17orf48,C1GALT1,C1GALT1C1,C1orf198,C21orf57,C21orf7,C2orf25,C2orf88,C3orf58,C4orf18,C4orf27,C5orf21,C5orf4,C5orf51,C6orf62,C7orf41,C9orf30,CABP5,CALD1,CAMLG,CAST,CBFB,CCDC104,CCDC34,CCDC6,CCDC65,CCDC90B,CCDC91,CCNB1IP1,CCNG1,CD226,CD3G,CD8B,CDC23,CDKN2AIP,CDV3,CENPK,CGRRF1,CHD9,CHES1,CHM,CHSY1,CLDN5,CLEC1B,CLEC2D,CLIC4,CLK4,CNOT7,COPB1,COPG2,COPS8,CORO1C,COX7A2L,CPD,CREBRF,CTDSPL,CYP4V2,DAB2,DCAF12,DEK,DENR,DHX29,DIAPH2,DKFZp686I15217,DLEU1,DNAJB9,DNAJC15,DNCL1,DNM3,DOCK11,DPY30,EBAG9,ECHDC1,EEF1B2,EIF1AX,EIF4G2,ELA1,ENSA,EPB49,EPC1,ERGIC2,ERH,ESAM,ETF1,F13A1,FAM134B,FAM172A,FAM190B,FAM60A,FBXO33,FEZ2,FHL1,FHL2,FKBP3,FLI1,FRMD3,FRYL,FUNDC1,G3BP1,GALNT1,GFM1,GIMAP2,GIN1,GLRX,GMPR,GNA12,GNB5,GOPC,GPBP1,GPR160,GPR183,GRB14,GTF2F2,GTF3A,GTSCR1,GUCY1A3,GYPC,HBA1,HBA2,HBD,HBG2,HECA,HIGD1A,HIST1H2AC,HIST1H2AG,HIST1H2BD,HIST1H2BH,HIST1H2BJ,HIST1H3F,HIST1H3H,HIST1H4H,HIST2H2BE,HIST2H3C,HMGB1,HMGN4,HPGD,HSD17B12,IDI1,IFRD1,IGF2BP2,ING3,INPP4B,INTS6,INTS8,IRF2BP2,ISCA1,ITGAE,ITGB3,ITGB5,IVNS1ABP,JKAMP,KIF2A,KIFC3,KLHL28,KLHL9,KLRC2,LAMP2,LAPTM4B,LARP7,LAX1,LCLAT1,LEPROT,LEPROTL1,LIMS1,LOC728975,LRBA,MAP3K1,MAP3K7,MARCH7,MAST4,MAT2B,MAX,MEIS1,METTL23,METTL7A,MEX3C,MFAP1,MFHAS1,MFSD1,MFSD6,MGLL,MMADHC,MMD,MORF4L1,MPL,MRPL13,MRPL21,MRPL3,MRPL42,MRPL47,MRPS28,MRPS35,MTDH,MTF2,MTMR6,MTPN,MTX2,MYL4,MYLK,N4BP2L2,NACAP1,NAP1L1,NCK1,NCK2,NDUFAB1,NDUFV2,NELL2,NFIB,NGDN,NGFRAP1,NKRF,NMD3,NOSIP,NPTN,NRGN,NSA2,NT5C3A,NT5M,NUCB2,NUCKS1,NUDT21,NUP54,NUP88,NXT2,OPTN,ORC3,OSBP2,OSBPL11,OSBPL8,OSTM1,PAIP2,PAQR8,PCDHGB6,PCMT1,PCMTD1,PDCD10,PDLIM1,PGRMC1,PHAX,PHIP,PI4K2B,PIGY,PIK3R1,PIM1,PLCL2,PLEKHA9,PPP1R14A,PPP1R2,PRDX6,PRKAB2,PRNP,PRORP,PROS1,PRPF18,PSMA2,PSMA3,PSMA4,PSMC6,PSMD14,PTCRA,PTEN,PTGER4,PTGES3,PTGS1,PTMA,PTPN12,PTPN22,PURA,RAB10,RAB11A,RAB21,RAD21,RB1CC1,RBBP7,RBM27,RBM34,RCAN1,RDH11,RGS10,RGS18,RIOK2,RIT1,RN18S1,RNA5S9,RNASEH2B,RNF11,RNF138,RNY1,RPA1,RPL15,RPL34,RPS3A,RPS6KB1,RYBP,SAMD14,SAP18,SCGB1C1,SDHAF3,SDPR,SEC62,SELT,SERINC1,SERP1,SFRS1,SFRS3,SH3BGRL2,SLC35B3,SLC39A8,SLITRK4,SMC2,SMEK2,SMOX,SNCA,SNORA12,SNORD32A,SNORD33,SNORD48,SNORD62B,SNORD8,SOD1,SOX4,SP3,SPARC,SPAST,SPC25,SRBD1,SRP72,SSBP1,ST8SIA4,STAG2,STAP1,STOM,STRADB,SUZ12,TAPT1,TAX1BP1,TBC1D15,TBCA,TBK1,TBPL1,TC2N,TCF12,THOC7,TIMM9,TINP1,TLK1,TM9SF2,TMED5,TMEM111,TMEM123,TMEM126A,TMEM140,TMEM14A,TMEM14B,TMEM158,TMEM30A,TMEM55A,TNFSF4,TNNC2,TNPO1,TOMM7,TP53INP1,TPM1,TREML1,TSC22D1,TSC22D2,TSPAN9,TSTD1,TUBA3D,UBE2D2,UBE2E1,UBE2Q2,UBE2V2,UBLCP1,UBP1,UBQLN1,UBQLN2,UCHL3,UGCG,VAMP7,VASP,VDAC3,VRK1,VWF,WDR51B,WTAP,XK,YEATS4,YIPF4,YPEL5,YWHAH,ZBTB4,ZBTB8OS,ZC3H11B,ZC3H15,ZCCHC7,ZFAND1,ZFAS1,ZNF17,ZNF189,ZNF318,ZNF559",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M40871,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_UP,VIRUS,UP,VACCINE,RESPONDER,D7,D,7,21-30,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in young adults (21-30) (responders) after exposure to Inactivated influenza vaccine , time point 7D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ABCC4,ABHD10,ABI1,ACADM,ACAT1,ACBD3,ACTR6,ADORA2A,AFTPH,AGL,AGPAT1,AHCY,AIDA,AK2,AKAP8L,ALCAM,AP1S1,AP2B1,APTX,ARCN1,ARF5,ARHGAP15,ARL5A,ARL6IP1,ARL6IP4,ARMC1,ARMC7,MANF,ARPP19,ASF1A,ASNSD1,ATG101,ATP11B,ATP5F1E,ATP5MC1,ATP5ME,ATP6V1D,ATP8B4,BAK1,BIRC2,BLCAP,BLOC1S1,BNIP3,BOLA2,BOLA3,BPNT1,BST2,BTLA,CFAP68,C12orf29,HAPSTR1,C1orf43,C2orf74,C6orf47,CALR,CALU,CANT1,CANX,CAPZA2,CASP3,CAV1,CCDC117,CCDC167,CCDC32,MIX23,CCT2,CCT3,CCT6A,CCT8,CD160,CD244,CD38,CD52,CDC26,CDC42,CDC42SE2,CDK4,CDKN2C,CEBPZ,CEP350,CEPT1,CES1,CETN3,CFDP1,CGGBP1,CHCHD4,CHCHD7,CHI3L2,SARNP,CISD1,CISD2,CISH,CKS2,CLCN3,CLN5,CLPTM1L,CMC2,CMPK1,CMSS1,CMTM5,CNOT6,CNPY2,COBLL1,COIL,CERT1,COPS4,COPS5,COQ5,COX14,COX16,COX17,COX6C,COX7B,COX7C,CPEB3,CPNE3,CPSF3,CRBN,CRYZ,CSE1L,CTTN,CUL4B,CWF19L2,CXCL5,BEND2,DAD1,DANCR,DBI,DCP2,DCTPP1,DCUN1D4,DDX1,DDX18,DDX50,DENND1B,DERL1,DMAC1,DNAJA2,DNAJB11,DNAJB14,DNAJC10,DNAJC3,DNAJC7,DNPH1,DPH5,DR1,DSTN,DYNLT3,DYRK4,EDEM3,EEF1E1,EFR3A,EIF2S1,EIF3A,EIF3D,EIF3E,ELL2,ELP6,EMG1,ENDOD1,EPRS1,ERCC6L2,ETFA,EXOC6,RAMAC,FAM104A,FAM107B,FAM117B,FAM133B,FAM13B,ABRAXAS2,DIPK1A,FAM98A,FAR1,FBXO4,FEN1,FGFR1OP2,FH,FIS1,FKBP2,FOXN2,FRG1,CMTR2,FXR1,FXR2,FYTTD1,GANAB,GART,GATD3,GCC1,GDI2,GGCT,GGPS1,GIMAP5,GIMAP7,GLO1,GLUD1,GM2A,GMFB,GNAI3,GNB2,GNL3,GOLGB1,GON7,GORASP2,GP1BA,GPN1,GPR65,GPX7,GRAP2,GRSF1,GRWD1,GSKIP,GTF2E2,GTF2H5,GZMA,GZMH,GZMK,GZMM,HACD2,HACD3,HAT1,HAX1,HBB,HBQ1,HDAC2,HDDC2,HDHD2,HGD,HIKESHI,HINT1,H2BC12,H4C3,HLTF,HMGB1P1,HMGCR,HMGCS1,HOPX,HSD17B8,HSDL2,HSP90AA1,HSP90B1,HSPA8,HSPD1,HSPE1,HSPH1,IAH1,ICMT,ICOS,MRPL58,IDH2,IER3IP1,IFI27L1,IFI27L2,IFNAR1,JCHAIN,IGLL1,IMPA1,IPO11,IPO8,ITGA2B,ITGB1,ITGB3BP,ITM2A,ITM2C,KBTBD8,KDELR2,KDM1A,KIAA2013,KLRB1,KLRD1,KLRF1,KPNA3,KRCC1,LARP4,CERS6,LDHB,LEMD3,LEPR,LMAN2L,LMO4,LRPPRC,LRRN3,LSM1,LSM10,LSM3,LSM5,NAA38,LY6G6F,MAD2L1,MAGEH1,MAN2A1,MARCHF6,MATR3,MBNL1,MBNL2,MCTS1,MCUR1,MDH1,MDP1,MEA1,MED31,MEF2C,METAP2,MGAT1,MGAT2,MIS18BP1,MKKS,MKRN2,MLEC,MOB4,MPDU1,MRPL1,MRPL11,MRPL12,MRPL14,MRPL15,MRPL24,MRPL27,MRPL35,MRPL36,MRPL46,MRPL48,MRPL50,MRPL51,MRPL54,MRPS17,MRPS18C,MRPS23,MRPS31,MRPS33,MSH6,MSL3,MSL3,BLOC1S5,MYB,MYCBP2,MYDGF,MYL9,MYNN,MZB1,NAPSA,NARS1,NAT8B,NCOA3,NDUFA10,NDUFA13,NDUFA4,NDUFA6,NDUFA8,NDUFAF2,NDUFB2,NDUFB3,NDUFB7,NDUFS4,NDUFS5,NECAP2,NET1,NFE2L1,NIN,NIPBL,NME1,NOC3L,NOMO2,NRIP1,NT5DC2,NUDT1,NUDT2,NUDT5,OCIAD2,ODC1,OGDH,ORAI1,OST4,OCA2,RPRD1A,PAICS,PANK2,PAPOLA,PARP1,PARVB,PCNA,PDE12,PDE5A,PDIA4,PDIA6,PDS5A,PDS5B,PDZK1IP1,PEBP1,PEF1,PFDN5,PHF14,PHF5A,PIGF,PIGK,PIGN,PITHD1,PKIA,PLEKHO2,PLRG1,PMVK,PNPLA8,POLR3K,POMP,PPAT,PPIG,PPIH,PPIL1,PPIL3,LRR1,PPM1B,PPP2R5A,PPP4R3A,PRDX4,PRDX5,PREB,PRIM1,THAP12,PRMT1,PRMT5,PRPF40A,PRUNE1,CYTIP,PSIP1,PSMB5,PSMC1,PSMC2,PSMD10,PSMD8,PSMG4,PTPN11,PTPN4,PTTG3P,PUM2,PUS3,RAB33B,RAB5A,RAB5C,RAB8B,RABAC1,RABGAP1L,IFT27,RALA,RAP1B,RAP2A,RBIS,RBM39,RBX1,RDH14,REEP5,RESF1,RFX7,RMI1,RNF14,RNF181,RNF20,RNGTT,RNY4,,ROMO1,RPA2,RPA3,RPAP3,RPF2,RPL13,RPL14,RPL23,RPL23A,RPL26L1,RPL39L,RPL7,RPN1,RPP40,RPS19BP1,RPS27L,RRM1,RSBN1,RSL24D1,RWDD1,S1PR4,SAC3D1,SAMD9,SASH3,SCAMP1,SCARNA16,SCARNA18,SCOC,SDF2L1,SDHAF1,SEC11C,SEC61A1,SEC61B,SEL1L3,SELENOS,SEPTIN7,SERBP1,SETDB2,SF3B5,TRA2B,SH2D1A,SH3BP5L,SEM1,SHOC2,SIRT1,SIVA1,MTREX,SLA,SLAIN1,SLAMF7,SLC25A26,SLC25A4,SLC30A7,SLC30A9,SLC35A5,SLC35C1,SLC38A2,SLC40A1,SLC43A3,SLMAP,SMAP1,SMARCA5,SMARCD2,SMC4,MIEF1,SMIM19,SNHG5,SNRPG,SNX14,SPCS2,SPCS3,SPNS3,SRP19,SRP68,SRPRB,SS18L2,SSR1,SSR4,ST13,STAT5A,STIP1,STK26,STK38,UBASH3B,STT3A,STYX,SUB1,SUPT16H,SUPT3H,SURF4,SWI5,SYS1,TAF7,TAGLN2,TARS1,TATDN2,TCAIM,TCEAL8,DYNLT2B,TDG,TEX30,ACOT13,THEMIS,THOC2,TICAM2,TIMM8B,TM9SF3,TMED2,TMED3,TMED9,TMEM101,TMEM106C,TMEM141,TMEM208,LYSET,CNPY2,EMC6,TMX1,TNFRSF13B,TNFRSF17,TOMM5,TOMM6,TOMM70,TOP2B,TOR1A,TOR3A,TP53RK,TRAK2,TRAM1,TRAT1,TRIAP1,TRIP12,TRIR,TRMT12,RO60,TTC1,TTC19,TUBA4A,TXNDC11,TMX2,TXNDC17,TXNDC5,TXNDC9,TXNRD1,UAP1,UBE2C,UBE2J1,UBE2T,UBE2Z,UBE3A,UBL5,UPF2,UQCC2,UQCC3,UQCRB,UQCRC2,UQCRHL,USO1,USP1,USP38,USP7,UTP14A,VBP1,VCPIP1,VEZF1,VMA21,VPS35,VPS37A,VPS41,WASHC3,TCEAL9,WDFY1,WDR33,WDR7,PYM1,XRCC6,XRN1,YTHDF2,YTHDF3,YWHAG,ZBTB33,ZCCHC17,ZFR,ZFYVE21,ZMPSTE24,ZNF146,ZNF148,ZPR1,ZNF263,ZNF281,ZNF32,ZNF322,ZNF428,ZNF451,ZNF480,ZNF586,ZNF613,ZNF816,ZNF845,ZNF91,POLR1H",661,"ABCC4,ABHD10,ABI1,ACADM,ACAT1,ACBD3,ACTR6,ADORA2A,AFTPH,AGL,AGPAT1,AHCY,AIDA,AK2,AKAP8L,ALCAM,AP1S1,AP2B1,APTX,ARCN1,ARF5,ARHGAP15,ARL5A,ARL6IP1,ARL6IP4,ARMC1,ARMC7,ARMET,ARPP19,ASF1A,ASNSD1,ATG101,ATP11B,ATP5E,ATP5G1,ATP5I,ATP6V1D,ATP8B4,BAK1,BIRC2,BLCAP,BLOC1S1,BNIP3,BOLA2,BOLA3,BPNT1,BST2,BTLA,C11orf1,C12orf29,C16orf72,C1orf43,C2orf74,C6orf47,CALR,CALU,CANT1,CANX,CAPZA2,CASP3,CAV1,CCDC117,CCDC167,CCDC32,CCDC58,CCT2,CCT3,CCT6A,CCT8,CD160,CD244,CD38,CD52,CDC26,CDC42,CDC42SE2,CDK4,CDKN2C,CEBPZ,CEP350,CEPT1,CES1,CETN3,CFDP1,CGGBP1,CHCHD4,CHCHD7,CHI3L2,CIP29,CISD1,CISD2,CISH,CKS2,CLCN3,CLN5,CLPTM1L,CMC2,CMPK1,CMSS1,CMTM5,CNOT6,CNPY2,COBLL1,COIL,COL4A3BP,COPS4,COPS5,COQ5,COX14,COX16,COX17,COX6C,COX7B,COX7C,CPEB3,CPNE3,CPSF3,CRBN,CRYZ,CSE1L,CTTN,CUL4B,CWF19L2,CXCL5,CXorf20,DAD1,DANCR,DBI,DCP2,DCTPP1,DCUN1D4,DDX1,DDX18,DDX50,DENND1B,DERL1,DMAC1,DNAJA2,DNAJB11,DNAJB14,DNAJC10,DNAJC3,DNAJC7,DNPH1,DPH5,DR1,DSTN,DYNLT3,DYRK4,EDEM3,EEF1E1,EFR3A,EIF2S1,EIF3A,EIF3D,EIF3E,ELL2,ELP6,EMG1,ENDOD1,EPRS,ERCC6L2,ETFA,EXOC6,FAM103A1,FAM104A,FAM107B,FAM117B,FAM133B,FAM13B,FAM175B,FAM69A,FAM98A,FAR1,FBXO4,FEN1,FGFR1OP2,FH,FIS1,FKBP2,FOXN2,FRG1,FTSJD1,FXR1,FXR2,FYTTD1,GANAB,GART,GATD3A,GCC1,GDI2,GGCT,GGPS1,GIMAP5,GIMAP7,GLO1,GLUD1,GM2A,GMFB,GNAI3,GNB2,GNL3,GOLGB1,GON7,GORASP2,GP1BA,GPN1,GPR65,GPX7,GRAP2,GRSF1,GRWD1,GSKIP,GTF2E2,GTF2H5,GZMA,GZMH,GZMK,GZMM,HACD2,HACD3,HAT1,HAX1,HBB,HBQ1,HDAC2,HDDC2,HDHD2,HGD,HIKESHI,HINT1,HIST1H2BK,HIST1H4C,HLTF,HMGB1L1,HMGCR,HMGCS1,HOPX,HSD17B8,HSDL2,HSP90AA1,HSP90B1,HSPA8,HSPD1,HSPE1,HSPH1,IAH1,ICMT,ICOS,ICT1,IDH2,IER3IP1,IFI27L1,IFI27L2,IFNAR1,IGJ,IGLL1,IMPA1,IPO11,IPO8,ITGA2B,ITGB1,ITGB3BP,ITM2A,ITM2C,KBTBD8,KDELR2,KDM1A,KIAA2013,KLRB1,KLRD1,KLRF1,KPNA3,KRCC1,LARP4,LASS6,LDHB,LEMD3,LEPR,LMAN2L,LMO4,LRPPRC,LRRN3,LSM1,LSM10,LSM3,LSM5,LSMD1,LY6G6F,MAD2L1,MAGEH1,MAN2A1,MARCH6,MATR3,MBNL1,MBNL2,MCTS1,MCUR1,MDH1,MDP1,MEA1,MED31,MEF2C,METAP2,MGAT1,MGAT2,MIS18BP1,MKKS,MKRN2,MLEC,MOBKL3,MPDU1,MRPL1,MRPL11,MRPL12,MRPL14,MRPL15,MRPL24,MRPL27,MRPL35,MRPL36,MRPL46,MRPL48,MRPL50,MRPL51,MRPL54,MRPS17,MRPS18C,MRPS23,MRPS31,MRPS33,MSH6,MSL3,MSL3L1,MUTED,MYB,MYCBP2,MYDGF,MYL9,MYNN,MZB1,NAPSA,NARS,NAT8B,NCOA3,NDUFA10,NDUFA13,NDUFA4,NDUFA6,NDUFA8,NDUFAF2,NDUFB2,NDUFB3,NDUFB7,NDUFS4,NDUFS5,NECAP2,NET1,NFE2L1,NIN,NIPBL,NME1,NOC3L,NOMO2,NRIP1,NT5DC2,NUDT1,NUDT2,NUDT5,OCIAD2,ODC1,OGDH,ORAI1,OST4,P,P15RS,PAICS,PANK2,PAPOLA,PARP1,PARVB,PCNA,PDE12,PDE5A,PDIA4,PDIA6,PDS5A,PDS5B,PDZK1IP1,PEBP1,PEF1,PFDN5,PHF14,PHF5A,PIGF,PIGK,PIGN,PITHD1,PKIA,PLEKHO2,PLRG1,PMVK,PNPLA8,POLR3K,POMP,PPAT,PPIG,PPIH,PPIL1,PPIL3,PPIL5,PPM1B,PPP2R5A,PPP4R3A,PRDX4,PRDX5,PREB,PRIM1,PRKRIR,PRMT1,PRMT5,PRPF40A,PRUNE,PSCDBP,PSIP1,PSMB5,PSMC1,PSMC2,PSMD10,PSMD8,PSMG4,PTPN11,PTPN4,PTTG3P,PUM2,PUS3,RAB33B,RAB5A,RAB5C,RAB8B,RABAC1,RABGAP1L,RABL4,RALA,RAP1B,RAP2A,RBIS,RBM39,RBX1,RDH14,REEP5,RESF1,RFX7,RMI1,RNF14,RNF181,RNF20,RNGTT,RNY4,RNY5,ROMO1,RPA2,RPA3,RPAP3,RPF2,RPL13,RPL14,RPL23,RPL23A,RPL26L1,RPL39L,RPL7,RPN1,RPP40,RPS19BP1,RPS27L,RRM1,RSBN1,RSL24D1,RWDD1,S1PR4,SAC3D1,SAMD9,SASH3,SCAMP1,SCARNA16,SCARNA18,SCOC,SDF2L1,SDHAF1,SEC11C,SEC61A1,SEC61B,SEL1L3,SELS,SEPT7,SERBP1,SETDB2,SF3B5,SFRS10,SH2D1A,SH3BP5L,SHFM1,SHOC2,SIRT1,SIVA1,SKIV2L2,SLA,SLAIN1,SLAMF7,SLC25A26,SLC25A4,SLC30A7,SLC30A9,SLC35A5,SLC35C1,SLC38A2,SLC40A1,SLC43A3,SLMAP,SMAP1,SMARCA5,SMARCD2,SMC4,SMCR7L,SMIM19,SNHG5,SNRPG,SNX14,SPCS2,SPCS3,SPNS3,SRP19,SRP68,SRPRB,SS18L2,SSR1,SSR4,ST13,STAT5A,STIP1,STK26,STK38,STS-1,STT3A,STYX,SUB1,SUPT16H,SUPT3H,SURF4,SWI5,SYS1,TAF7,TAGLN2,TARS,TATDN2,TCAIM,TCEAL8,TCTEX1D2,TDG,TEX30,THEM2,THEMIS,THOC2,TICAM2,TIMM8B,TM9SF3,TMED2,TMED3,TMED9,TMEM101,TMEM106C,TMEM141,TMEM208,TMEM251,TMEM4,TMEM93,TMX1,TNFRSF13B,TNFRSF17,TOMM5,TOMM6,TOMM70A,TOP2B,TOR1A,TOR3A,TP53RK,TRAK2,TRAM1,TRAT1,TRIAP1,TRIP12,TRIR,TRMT12,TROVE2,TTC1,TTC19,TUBA4A,TXNDC11,TXNDC14,TXNDC17,TXNDC5,TXNDC9,TXNRD1,UAP1,UBE2C,UBE2J1,UBE2T,UBE2Z,UBE3A,UBL5,UPF2,UQCC2,UQCC3,UQCRB,UQCRC2,UQCRHL,USO1,USP1,USP38,USP7,UTP14A,VBP1,VCPIP1,VEZF1,VMA21,VPS35,VPS37A,VPS41,WASHC3,WBP5,WDFY1,WDR33,WDR7,WIBG,XRCC6,XRN1,YTHDF2,YTHDF3,YWHAG,ZBTB33,ZCCHC17,ZFR,ZFYVE21,ZMPSTE24,ZNF146,ZNF148,ZNF259,ZNF263,ZNF281,ZNF32,ZNF322A,ZNF428,ZNF451,ZNF480,ZNF586,ZNF613,ZNF816A,ZNF845,ZNF91,ZNRD1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41156,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_DN,VIRUS,DOWN,VACCINE,RESPONDER VS NON RESPONDER,D0,D,0,55-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_DN,"To assess gene signatures related to humoral response among healthy older subjects following seasonal influenza vaccination, we studied 94 healthy adults (50-74 years old) who received one documented dose of licensed trivalent influenza vaccine containing the A/California/7/2009 (H1N1)-like virus strain. Influenza-specific antibody (HAI) titer in serum samples and next-generation sequencing on PBMCs were performed using blood samples collected prior to (Day 0) and at two timepoints after (Days 3 and 28) vaccination. We identified a number of uncharacterized genes (ZNF300, NUP1333, KLK1 and others) and confirmed previous studies demonstrating specific genes/genesets that are important mediators of host immune responses and that displayed associations with antibody response to influenza A/H1N1 vaccine. These included interferon-regulatory transcription factors (IRF1/IRF2/IRF6/IRF7/IRF9), chemokine/chemokine receptors (CCR5/CCR9/CCL5), cytokine/cytokine receptors (IFNG/IL10RA/TNFRSF1A), protein kinases (MAP2K4/MAPK3), growth factor receptor (TGFBR1). The identification of gene signatures associated with antibody response represents an early stage in the science for which further research is needed. Such research may assist in the design of better vaccines to facilitate improved defenses against new influenza virus strains, as well as better understanding the genetic drivers of immune responses.","Genes down-regulated in peripheral blood mononuclear cell responders vs nonresponders in adults (55-64) after exposure to Fluarix , time point 0D. Comment: Gene expression related to HAI response","Ovsyannikova IG,Oberg AL,Kennedy RB,Zimmermann MT,Haralambieva IH,Goergen KM,Grill DE,Poland GA",27441275,HUMAN_GENE_SYMBOL,"AP3S1,DUSP18,FBXL18,GET3,HPRT1,INIP,ISL2,MIA2-AS1,PCBD1,RDX,SFXN3,SHISA4,SLC66A3,SPIRE1,TMED5,TNNT1,ZFAND6",17,"AP3S1,DUSP18,FBXL18,GET3,HPRT1,INIP,ISL2,LOC100288846,PCBD1,RDX,SFXN3,SHISA4,SLC66A3,SPIRE1,TMED5,TNNT1,ZFAND6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/bin/aging-07-38-s002.doc,NA,NA,NA,NA
M40907,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_UP,VIRUS,UP,VACCINE,RESPONDER VS NON RESPONDER,D0,D,0,55-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_0DY_UP,"To assess gene signatures related to humoral response among healthy older subjects following seasonal influenza vaccination, we studied 94 healthy adults (50-74 years old) who received one documented dose of licensed trivalent influenza vaccine containing the A/California/7/2009 (H1N1)-like virus strain. Influenza-specific antibody (HAI) titer in serum samples and next-generation sequencing on PBMCs were performed using blood samples collected prior to (Day 0) and at two timepoints after (Days 3 and 28) vaccination. We identified a number of uncharacterized genes (ZNF300, NUP1333, KLK1 and others) and confirmed previous studies demonstrating specific genes/genesets that are important mediators of host immune responses and that displayed associations with antibody response to influenza A/H1N1 vaccine. These included interferon-regulatory transcription factors (IRF1/IRF2/IRF6/IRF7/IRF9), chemokine/chemokine receptors (CCR5/CCR9/CCL5), cytokine/cytokine receptors (IFNG/IL10RA/TNFRSF1A), protein kinases (MAP2K4/MAPK3), growth factor receptor (TGFBR1). The identification of gene signatures associated with antibody response represents an early stage in the science for which further research is needed. Such research may assist in the design of better vaccines to facilitate improved defenses against new influenza virus strains, as well as better understanding the genetic drivers of immune responses.","Genes up-regulated in peripheral blood mononuclear cell responders vs nonresponders in adults (55-64) after exposure to Fluarix , time point 0D. Comment: Gene expression related to HAI response","Ovsyannikova IG,Oberg AL,Kennedy RB,Zimmermann MT,Haralambieva IH,Goergen KM,Grill DE,Poland GA",27441275,HUMAN_GENE_SYMBOL,"ACSF3,AHRR,ARHGEF10,ATP13A4,CACTIN,CCDC106,CD22,CENPV,CEP295,DVL1,FAM177B,FAM24B,,FAM30A,GADD45GIP1,GTF2H4,KRI1,LIG1,LRWD1,METTL26,MLST8,MRPL38,MTA1,NEK8,PKIG,SNX22,TTC27,VPREB3,ZIK1,ZNF502,ZNF608,ZNF880",32,"ACSF3,AHRR,ARHGEF10,ATP13A4,CACTIN,CCDC106,CD22,CENPV,CEP295,DVL1,FAM177B,FAM24B,FAM24B-CUZD1,FAM30A,GADD45GIP1,GTF2H4,KRI1,LIG1,LRWD1,METTL26,MLST8,MRPL38,MTA1,NEK8,PKIG,SNX22,TTC27,VPREB3,ZIK1,ZNF502,ZNF608,ZNF880",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1B, Tab DEGs_LAIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M40929,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_DN,VIRUS,DOWN,VACCINE,RESPONDER VS NON RESPONDER,D28,D,28,55-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_DN,"To assess gene signatures related to humoral response among healthy older subjects following seasonal influenza vaccination, we studied 94 healthy adults (50-74 years old) who received one documented dose of licensed trivalent influenza vaccine containing the A/California/7/2009 (H1N1)-like virus strain. Influenza-specific antibody (HAI) titer in serum samples and next-generation sequencing on PBMCs were performed using blood samples collected prior to (Day 0) and at two timepoints after (Days 3 and 28) vaccination. We identified a number of uncharacterized genes (ZNF300, NUP1333, KLK1 and others) and confirmed previous studies demonstrating specific genes/genesets that are important mediators of host immune responses and that displayed associations with antibody response to influenza A/H1N1 vaccine. These included interferon-regulatory transcription factors (IRF1/IRF2/IRF6/IRF7/IRF9), chemokine/chemokine receptors (CCR5/CCR9/CCL5), cytokine/cytokine receptors (IFNG/IL10RA/TNFRSF1A), protein kinases (MAP2K4/MAPK3), growth factor receptor (TGFBR1). The identification of gene signatures associated with antibody response represents an early stage in the science for which further research is needed. Such research may assist in the design of better vaccines to facilitate improved defenses against new influenza virus strains, as well as better understanding the genetic drivers of immune responses.","Genes down-regulated in peripheral blood mononuclear cell responders vs nonresponders in adults (55-64) after exposure to Fluarix , time point 28D. Comment: Gene expression related to HAI response","Ovsyannikova IG,Oberg AL,Kennedy RB,Zimmermann MT,Haralambieva IH,Goergen KM,Grill DE,Poland GA",27441275,HUMAN_GENE_SYMBOL,"AP1M2,B3GNTL1,C17orf97,NCKIPSD,PEF1,SLC38A9,TMEM104",7,"AP1M2,B3GNTL1,C17orf97,NCKIPSD,PEF1,SLC38A9,TMEM104",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig S5 (right),http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1519690113/-/DCSupplemental,NA,NA,NA,NA
M40906,FLUARIX,IN,INFLUENZA,OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_UP,VIRUS,UP,VACCINE,RESPONDER VS NON RESPONDER,D28,D,28,55-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OVSYANNIKOVA_PBMC_FLUARIX_AGE_55_64YO_RESPONDERS_VS_NONRESPONDERS_28DY_UP,"To assess gene signatures related to humoral response among healthy older subjects following seasonal influenza vaccination, we studied 94 healthy adults (50-74 years old) who received one documented dose of licensed trivalent influenza vaccine containing the A/California/7/2009 (H1N1)-like virus strain. Influenza-specific antibody (HAI) titer in serum samples and next-generation sequencing on PBMCs were performed using blood samples collected prior to (Day 0) and at two timepoints after (Days 3 and 28) vaccination. We identified a number of uncharacterized genes (ZNF300, NUP1333, KLK1 and others) and confirmed previous studies demonstrating specific genes/genesets that are important mediators of host immune responses and that displayed associations with antibody response to influenza A/H1N1 vaccine. These included interferon-regulatory transcription factors (IRF1/IRF2/IRF6/IRF7/IRF9), chemokine/chemokine receptors (CCR5/CCR9/CCL5), cytokine/cytokine receptors (IFNG/IL10RA/TNFRSF1A), protein kinases (MAP2K4/MAPK3), growth factor receptor (TGFBR1). The identification of gene signatures associated with antibody response represents an early stage in the science for which further research is needed. Such research may assist in the design of better vaccines to facilitate improved defenses against new influenza virus strains, as well as better understanding the genetic drivers of immune responses.","Genes up-regulated in peripheral blood mononuclear cell responders vs nonresponders in adults (55-64) after exposure to Fluarix , time point 28D. Comment: Gene expression related to HAI response","Ovsyannikova IG,Oberg AL,Kennedy RB,Zimmermann MT,Haralambieva IH,Goergen KM,Grill DE,Poland GA",27441275,HUMAN_GENE_SYMBOL,"ARHGEF10,ATP13A4,CUL1,GRPEL2,KAT2B,MBTPS1,MIR155HG,PHF2,SCRIB",9,"ARHGEF10,ATP13A4,CUL1,GRPEL2,KAT2B,MBTPS1,MIR155HG,PHF2,SCRIB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-pDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41054,FLUARIX FLUVIRIN,IN,INFLUENZA,BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_TOP_FUNCTIONAL_NETWORK_POSITIVE,VIRUS,UP,CORRELATION,SIGNATURE,D1,D,1,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/BUCASAS_PBMC_FLUARIX_FLUVIRIN_CAUCASIAN_MALE_AGE_18_40YO_HIGH_RESPONDERS_1DY_TOP_FUNCTIONAL_NETWORK_POSITIVE,"BACKGROUND: Annual vaccination is the primary means for preventing influenza. However, great interindividual variability exists in vaccine responses, the cellular events that take place in vivo after vaccination are poorly understood, and appropriate biomarkers for vaccine responsiveness have not been developed. METHODS: We immunized a cohort of healthy male adults with a licensed trivalent influenza vaccine and performed a timed assessment of global gene expression before and after vaccination. We analyzed the relationship between gene expression patterns and the humoral immune response to vaccination. RESULTS: Marked up regulation of expression of genes involved in interferon signaling, positive IL-6 regulation, and antigen processing and presentation, were detected within 24 hours of immunization. The late vaccine response showed a transcriptional pattern suggestive of increased protein biosynthesis and cellular proliferation. Integrative analyses revealed a 494-gene expression signature--including STAT1, CD74, and E2F2--which strongly correlates with the magnitude of the antibody response. High vaccine responder status correlates with increased early expression of interferon signaling and antigen processing and presentation genes. CONCLUSIONS: The results highlight the role of a systems biology approach in understanding the molecular events that take place in vivo after influenza vaccination and in the development of better predictors of vaccine responsiveness.","Genes positively correlated with a functional network in peripheral blood mononuclear cell in Caucasian male adults (18-40) (high responders) after exposure to Fluarix/Fluvirin , time point 1D. Comment: Top functional network for genes preferentially upregulated in the high responder group","Bucasas KL,Franco LM,Shaw CA,Bray MS,Wells JM,Nio D,Arden N,Quarles JM,Couch RB,Belmont JW",21357945,HUMAN_GENE_SYMBOL,"CD27,CORO1A,CSF2RA,DAPP1,FCGR1A,HLA-G,IRF9,ISG15,LILRB1,LILRB3,PIGR,PNPT1,PRKD2,RBCK1,SNRNP70,STAT1,STAT2,TAPBP,TNFSF14",19,"CD27,CORO1A,CSF2RA,DAPP1,FCGR1A,HLA-G,IRF9,ISG15,LILRB1,LILRB3,PIGR,PNPT1,PRKD2,RBCK1,SNRNP70,STAT1,STAT2,TAPBP,TNFSF14",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-pDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41107,FLUAD,IN,INFLUENZA,NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_DN,VIRUS,DOWN,SUBSET,SIGNATURE,D1,D,1,14-27,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_DN,"The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4(+) T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.","Genes down-regulated in peripheral blood mononuclear cell 1d postboost vs 0d pre-imm in children (14-27m) (MF59-adjuvanted) after exposure to Fluad , time point 1D. Comment: (B) Genes in BTM M7.0; (D) Genes in BTM M53","Nakaya HI,Clutterbuck E,Kazmin D,Wang L,Cortese M,Bosinger SE,Patel NB,Zak DE,Aderem A,Dong T,Del Giudice G,Rappuoli R,Cerundolo V,Pollard AJ,Pulendran B,Siegrist CA",26755593,HUMAN_GENE_SYMBOL,"BCL11B,BIRC3,CCL5,CD2,CD247,CD27,CD28,CD3D,CD3E,CD3G,CD6,CD96,EOMES,ETS1,GATA3,GIMAP6,GIMAP7,GNLY,GPR171,GZMA,GZMB,GZMH,GZMK,GZMM,HLA-DQB1,ICOS,IL32,IL7R,ITK,ITM2A,KLRB1,LAT,LCK,LEF1,MAL,NELL2,NKG7,NLRC3,PAK1,PRKCH,PRKCQ,RASGRP1,RORA,SAMD3,SH2D1A,SIRPG,SIT1,TIGIT,TRAC,TRAJ17,TRAT1,TRAV20,TRBC1,UBASH3A,XCL2,ZAP70",56,"BCL11B,BIRC3,CCL5,CD2,CD247,CD27,CD28,CD3D,CD3E,CD3G,CD6,CD96,EOMES,ETS1,GATA3,GIMAP6,GIMAP7,GNLY,GPR171,GZMA,GZMB,GZMH,GZMK,GZMM,HLA-DQB1,ICOS,IL32,IL7R,ITK,ITM2A,KLRB1,LAT,LCK,LEF1,MAL,NELL2,NKG7,NLRC3,PAK1,PRKCH,PRKCQ,RASGRP1,RORA,SAMD3,SH2D1A,SIRPG,SIT1,TIGIT,TRAC,TRAJ17,TRAT1,TRAV20,TRBC1,UBASH3A,XCL2,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4 & Suppl Table 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/bin/NIHMS593578-supplement-01.pdf,NA,NA,NA,NA
M40956,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_UP,VIRUS,UP,SUBSET,SIGNATURE,D1,D,1,14-27,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUAD_MALE_AGE_14_27YO_1D_POSTBOOST_VS_0D_PREIMM_MF59_ADJUVANTED_1DY_GENES_IN_BTM_M40_AND_M53_UP,"The dynamics and molecular mechanisms underlying vaccine immunity in early childhood remain poorly understood. Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in 90 14- to 24-mo-old healthy children. MF59 enhanced the magnitude and kinetics of serum antibody titers following vaccination, and induced a greater frequency of vaccine specific, multicytokine-producing CD4(+) T cells. Compared with transcriptional responses to TIV vaccination previously reported in adults, responses to TIV in infants were markedly attenuated, limited to genes regulating antiviral and antigen presentation pathways, and observed only in a subset of vaccinees. In contrast, transcriptional responses to ATIV boost were more homogenous and robust. Interestingly, a day 1 gene signature characteristic of the innate response (antiviral IFN genes, dendritic cell, and monocyte responses) correlated with hemagglutination at day 28. These findings demonstrate that MF59 enhances the magnitude, kinetics, and consistency of the innate and adaptive response to vaccination with the seasonal influenza vaccine during early childhood, and identify potential molecular correlates of antibody responses.","Genes up-regulated in peripheral blood mononuclear cell 1d postboost vs 0d pre-imm in children (14-27m) (MF59-adjuvanted) after exposure to Fluad , time point 1D. Comment: (C) Genes in BTM M40; (D) Genes in BTM M53","Nakaya HI,Clutterbuck E,Kazmin D,Wang L,Cortese M,Bosinger SE,Patel NB,Zak DE,Aderem A,Dong T,Del Giudice G,Rappuoli R,Cerundolo V,Pollard AJ,Pulendran B,Siegrist CA",26755593,HUMAN_GENE_SYMBOL,"C1QA,C1QB,C1QC,CD58,CD86,HLA-DQA1,LY96,NFKBIA,NLRC4,NLRP3,NOD2,RIPK2,RXRA,SIRPA,TLR4,TNFAIP3,TYROBP",17,"C1QA,C1QB,C1QC,CD58,CD86,HLA-DQA1,LY96,NFKBIA,NLRC4,NLRP3,NOD2,RIPK2,RXRA,SIRPA,TLR4,TNFAIP3,TYROBP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M40931,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in monocyte 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ACTL10,AZU1,C2orf74,C3orf86P,CDH26,CDKN1C,CLEC3B,FLNB,GOLGA8N,LRRC3,PLD4,PMP22,PRR22,RETN,RNU6-1,TTLL1",16,"ACTL10,AZU1,C2orf74,C3orf86,CDH26,CDKN1C,CLEC3B,FLNB,GOLGA8N,LRRC3,PLD4,PMP22,PRR22,RETN,RNU6-1,TTLL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41153,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in myeloid dendritic cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"GFI1B,NOTCH3,NRXN2,PPP1R35,SH3RF3,ZBTB7C",6,"GFI1B,NOTCH3,NRXN2,PPP1R35,SH3RF3,ZBTB7C",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supplemental_Information.docx,NA,NA,NA,NA
M41106,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in neutrophil 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ABCC5,ACAD9,ACBD6,ADAM19,ADK,ARIH2OS,AUH,BEND7,BBLN,CD1D,CD68,CEBPZOS,CMTM8,COA6,COA6-AS1,CRISP3,CTSD,DGKG,DPP7,EBP,EDARADD,FLT1,GALNT14,GPAT4,GRAMD4,HOMER3,HSPE1,ITPKB-IT1,LRP3,LRRC75A,MRPL21,NAA40,CIAO3,NDUFA7,NRIP1,NT5DC1,OPLAH,PADI4,PF4V1,PLCB3,PLD3,PNPLA1,PPDPF,PTPN22,NECTIN1,REX1BD,RSU1,RUBCNL,SAP30,SEPTIN5,SH3RF3,SIGMAR1,SNRNP25,SYCP2,SYTL3,TBC1D3B,TCN1,TESC,TFDP1,TM7SF3,TMEM39B,TSR2,TTC38",63,"ABCC5,ACAD9,ACBD6,ADAM19,ADK,ARIH2OS,AUH,BEND7,C9orf16,CD1D,CD68,CEBPZOS,CMTM8,COA6,COA6-AS1,CRISP3,CTSD,DGKG,DPP7,EBP,EDARADD,FLT1,GALNT14,GPAT4,GRAMD4,HOMER3,HSPE1,ITPKB-IT1,LRP3,LRRC75A,MRPL21,NAA40,NARFL,NDUFA7,NRIP1,NT5DC1,OPLAH,PADI4,PF4V1,PLCB3,PLD3,PNPLA1,PPDPF,PTPN22,PVRL1,REX1BD,RSU1,RUBCNL,SAP30,SEPTIN5,SH3RF3,SIGMAR1,SNRNP25,SYCP2,SYTL3,TBC1D3B,TCN1,TESC,TFDP1,TM7SF3,TMEM39B,TSR2,TTC38",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2C-F; Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/table/T2/,NA,NA,NA,NA
M41198,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_1D_VS_0DY_ADULT_1D_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_1D_VS_0DY_ADULT_1D_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in natural killer cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADAT3,AJM1,ALKBH7,ASB13,AVPI1,AXIN2,C4orf48,CENPM,COL18A1,DIPK1B,DNPH1,ENHO,EVA1B,FBXW9,FRS3,FXYD7,GOLGA8R,HLA-DQA1,IGFBP7,IQSEC2,JSRP1,KIF19,KLF3-AS1,LILRA4,LILRA5,LTK,LYL1,MAPK8IP1,MIR3648-1,MIR4665,MRPL23-AS1,MYCL,NCF4,PCSK4,PDCD4-AS1,PDXP,PLA2G7,PRSS36,RN7SL2,RTN4R,SLC15A3,SLX1A,SOX12,ST14,SUSD3,TIGD5,TMEM150B,TMEM238,TNNI2,TRIM46,TTC24,TTLL10,UPK2,ZNF467",54,"ADAT3,AJM1,ALKBH7,ASB13,AVPI1,AXIN2,C4orf48,CENPM,COL18A1,DIPK1B,DNPH1,ENHO,EVA1B,FBXW9,FRS3,FXYD7,GOLGA8R,HLA-DQA1,IGFBP7,IQSEC2,JSRP1,KIF19,KLF3-AS1,LILRA4,LILRA5,LTK,LYL1,MAPK8IP1,MIR3648-1,MIR4665,MRPL23-AS1,MYCL1,NCF4,PCSK4,PDCD4-AS1,PDXP,PLA2G7,PRSS36,RN7SL2,RTN4R,SLC15A3,SLX1A,SOX12,ST14,SUSD3,TIGD5,TMEM150B,TMEM238,TNNI2,TRIM46,TTC24,TTLL10,UPK2,ZNF467",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supplemental_Information.docx,NA,NA,NA,NA
M41064,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in peripheral blood mononuclear cell 1d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"BOLA2B,GDF9,IGHV3-74,IGLV8-61,LGALS12,LYG1,ROPN1L,RPL39L,SERPINB2,TMEM169,TPPP,TRAV16,UBAC2-AS1",13,"BOLA2B,GDF9,IGHV3-74,IGLV8-61,LGALS12,LYG1,ROPN1L,RPL39L,SERPINB2,TMEM169,TPPP,TRAV16,UBAC2-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1: Early gene expression (Day 3 - Day 0),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/table/T1/,NA,NA,NA,NA
M41077,INFLUENZA,IN,INFLUENZA,HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in T cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"C4orf48,CCR9,MORN1,NTSR1,TOB1-AS1,TRIM74,UPK2",7,"C4orf48,CCR9,MORN1,NTSR1,TOB1-AS1,TRIM74,UPK2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 11,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M41088,INFLUENZA,IN,INFLUENZA,HOEK_B_CELL_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_B_CELL_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in B cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ATP6V0C,DUSP5,FCN1,IGLV10-54,LINC00943,NCAPH,NPIPB8,PDXP,RN7SK,RNU6-1,SULT1A4",11,"ATP6V0C,DUSP5,FCN1,IGLV10-54,LINC00943,NCAPH,NPIPB8,PDXP,RN7SK,RNU6-1,SULT1A4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3: Adjuvanted,https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig3,NA,NA,NA,NA
M40916,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in monocyte 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"APLF,AUNIP,CD83,H3P16,KDM4A-AS1,LINC01001,P2RY12,S100P,SLX1B-SULT1A4,SYNJ2BP-COX16,ZNF485",11,"APLF,AUNIP,CD83,H3P16,KDM4A-AS1,LINC01001,P2RY12,S100P,SLX1B-SULT1A4,SYNJ2BP-COX16,ZNF485",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig2c,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F2/,NA,NA,NA,NA
M41020,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in myeloid dendritic cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ALOX5AP,CCL3,CD163,CD69,CPED1,DEPTOR,EMB,EPHB3,F13A1,FCGR1A,FUNDC1,GNAI1,GZMM,HDGFL3,H2AC20,ID3,KIF1C-AS1,MIR17HG,NBPF15,P2RY12,PEDS1-UBE2V1,PPP1R35-AS1,PRR34-AS1,RARG,RNASE2,S100A12,STAB1,VCAN-AS1,ZNF253",29,"ALOX5AP,CCL3,CD163,CD69,CPED1,DEPTOR,EMB,EPHB3,F13A1,FCGR1A,FUNDC1,GNAI1,GZMM,HDGFL3,HIST2H2AC,ID3,KIF1C-AS1,MIR17HG,NBPF15,P2RY12,PEDS1-UBE2V1,PPP1R35-AS1,PRR34-AS1,RARG,RNASE2,S100A12,STAB1,VCAN-AS1,ZNF253",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S1 Table,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443534/bin/pntd.0005527.s002.xls,NA,NA,NA,NA
M41013,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in neutrophil 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"APOL3,ATF3,C12orf60,,CPT1B,DDX60,DOCK4-AS1,ECE1-AS1,EGR2,EPSTI1,FANCL,FRMD3,GBP6,GCH1,H1-4,HES4,HLA-DMA,HLA-DMB,HLA-DRA,IFI44,IFI44L,LINC02471,LINC02555,LRRK2-DT,MT2A,NRIR,NXT2,OAS1,OAS2,OAS3,P2RY14,PDCD1LG2,PRKX,RSAD2,SESTD1,SGPP1,SNORA11,TFEC,XAF1",39,"APOL3,ATF3,C12orf60,CCL4L1,CPT1B,DDX60,DOCK4-AS1,ECE1-AS1,EGR2,EPSTI1,FANCL,FRMD3,GBP6,GCH1,H1-4,HES4,HLA-DMA,HLA-DMB,HLA-DRA,IFI44,IFI44L,LINC02471,LINC02555,LRRK2-DT,MT2A,NRIR,NXT2,OAS1,OAS2,OAS3,P2RY14,PDCD1LG2,PRKX,RSAD2,SESTD1,SGPP1,SNORA11,TFEC,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F4/,NA,NA,NA,NA
M41030,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in natural killer cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ARL17A,BET1-AS1,CALB1,DSE,FNDC9,IFIT1,IGFBP7-AS1,IGLV5-52,LINC00707,NPIPB11,PSMA8,SLC2A14,TPH1,TRGVB",14,"ARL17A,BET1-AS1,CALB1,DSE,FNDC9,IFIT1,IGFBP7-AS1,IGLV5-52,LINC00707,NPIPB11,PSMA8,SLC2A14,TPH1,TRGVB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M41033,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"CLEC6A,GEMIN7-AS1,HYAL3,ICAM5,IGKV1-9,IGKV1D-12,IGKV2-30,IGKV2D-30,IGLV1-47,IGLV3-25,IGLV6-57,IGLV7-43,SLX1B",13,"CLEC6A,GEMIN7-AS1,HYAL3,ICAM5,IGKV1-9,IGKV1D-12,IGKV2-30,IGKV2D-30,IGLV1-47,IGLV3-25,IGLV6-57,IGLV7-43,SLX1B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M41087,INFLUENZA,IN,INFLUENZA,HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,ADULT,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_T_CELL_2011_2012_TIV_ADULT_1DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in T cell 1d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 1D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ANKRD30BL,GINS3,GPLD1,NBPF15,NPIPB12,RHEBL1,RN7SK,RPP40,RTP4,SIGLEC17P,UBE2E2,XRCC4,ZC2HC1A",13,"ANKRD30BL,GINS3,GPLD1,NBPF15,NPIPB12,RHEBL1,RN7SK,RPP40,RTP4,SIGLEC17P,UBE2E2,XRCC4,ZC2HC1A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T3/,NA,NA,NA,NA
M41210,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes down-regulated in dendritic cell 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ACY3,ANGPT1,TBATA,BMERB1,LKAAEAR1,CBX2,CDK5R1,CEBPA,CES3,CSGALNACT1,FAM167A,FCRL5,FIBCD1,FOXO6,ADGRD1,PTGDR2,GPRC5B,IGFBP6,IL1R1,IL1R2,LRP3,MAP2K6,MIR4771-1,MN1,MYO10,NOTCH3,OLIG1,PDGFC,PITPNM2,PPP1R3G,PRPF31,RANBP17,RASL10A,RPH3A,SLC28A3,SLC5A10,SMAD6,SOX12,TNNT3,ZNF443,ZNF704",41,"ACY3,ANGPT1,C10orf27,C16orf45,C20orf201,CBX2,CDK5R1,CEBPA,CES3,CSGALNACT1,FAM167A,FCRL5,FIBCD1,FOXO6,GPR133,GPR44,GPRC5B,IGFBP6,IL1R1,IL1R2,LRP3,MAP2K6,MIR4771-1,MN1,MYO10,NOTCH3,OLIG1,PDGFC,PITPNM2,PPP1R3G,PRPF31,RANBP17,RASL10A,RPH3A,SLC28A3,SLC5A10,SMAD6,SOX12,TNNT3,ZNF443,ZNF704",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 14,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M41058,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes down-regulated in monocyte 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"AFF3,AZU1,KCNJ5-AS1,C16orf74,C1orf127,CD2,CDCA7,CKB,COL9A2,COLEC12,CTSF,DTNA,ESAM,FCER1A,FCGBP,GATM,HSPG2,IL1R1,ITGA9,KLHL30,LGI4,LPL,MYB,PCGF2,PLD4,PRPF31,PRRT4,QPRT,SIDT1,SNAI1,SNORA66,SPNS3,SRGAP3,STARD13,SYT17,WFS1,ZNF519",37,"AFF3,AZU1,C11orf45,C16orf74,C1orf127,CD2,CDCA7,CKB,COL9A2,COLEC12,CTSF,DTNA,ESAM,FCER1A,FCGBP,GATM,HSPG2,IL1R1,ITGA9,KLHL30,LGI4,LPL,MYB,PCGF2,PLD4,PRPF31,PRRT4,QPRT,SIDT1,SNAI1,SNORA66,SPNS3,SRGAP3,STARD13,SYT17,WFS1,ZNF519",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338562/figure/fig05/,NA,NA,NA,NA
M41010,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_DN,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes down-regulated in neutrophil 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ABCC5,ABHD12,ACACB,ACBD6,ADAM15,ADRB2,ALDOC,ANGPT1,ANGPT4,APOLD1,ARHGEF4,ATG4C,BIK,ABTB3,ARPIN,C16orf74,PRIMPOL,CCND2,CD101,CD9,CEP85L,CHST13,CRTC3,CTNNBIP1,CX3CR1,CXCL6,DCST1,DDX28,DGKG,DTX4,EHMT2,EIF4EBP1,EPN2,FADS2,FCMR,RFLNB,EEIG2,MVB12B,FDXR,FLT1,FLYWCH1,GPR162,H2AX,HDAC11,HEATR3,MROH1,HIVEP3,HMOX1,HOMER3,ICMT,IER5L,IGSF23,CXCL8,IL9RP3,IRF2BP2,KBTBD11,KIT,LLGL2,LPCAT4,MAST4,MAT2A,MEAF6,MIF4GD,MXI1,NRROS,OLIG1,OSBPL5,PAQR4,PDK4,PHACTR1,PLCB1,PLCB3,PNKD,POLR3K,PPFIA4,PPM1H,PUS7,RASA3,RELL1,REX1BD,RNF125,RUBCNL,SAMD1,SCCPDH,SEMA6C,SHISA4,SLC25A36,SLC25A40,SMYD3,SNRNP25,SOX13,SPINT1,SPNS2,SPP1,SYNE3,SYTL3,TAB1,TEF,TESC,TEX2,THRA,TPP2,TRAPPC2L,TSPAN13,UPB1,VWF,XYLT1,XYLT2,ZMYND10,ZNF697",110,"ABCC5,ABHD12,ACACB,ACBD6,ADAM15,ADRB2,ALDOC,ANGPT1,ANGPT4,APOLD1,ARHGEF4,ATG4C,BIK,BTBD11,C15orf38,C16orf74,CCDC111,CCND2,CD101,CD9,CEP85L,CHST13,CRTC3,CTNNBIP1,CX3CR1,CXCL6,DCST1,DDX28,DGKG,DTX4,EHMT2,EIF4EBP1,EPN2,FADS2,FAIM3,FAM101B,FAM102B,FAM125B,FDXR,FLT1,FLYWCH1,GPR162,H2AFX,HDAC11,HEATR3,HEATR7A,HIVEP3,HMOX1,HOMER3,ICMT,IER5L,IGSF23,IL8,IL9RP3,IRF2BP2,KBTBD11,KIT,LLGL2,LPCAT4,MAST4,MAT2A,MEAF6,MIF4GD,MXI1,NRROS,OLIG1,OSBPL5,PAQR4,PDK4,PHACTR1,PLCB1,PLCB3,PNKD,POLR3K,PPFIA4,PPM1H,PUS7,RASA3,RELL1,REX1BD,RNF125,RUBCNL,SAMD1,SCCPDH,SEMA6C,SHISA4,SLC25A36,SLC25A40,SMYD3,SNRNP25,SOX13,SPINT1,SPNS2,SPP1,SYNE3,SYTL3,TAB1,TEF,TESC,TEX2,THRA,TPP2,TRAPPC2L,TSPAN13,UPB1,VWF,XYLT1,XYLT2,ZMYND10,ZNF697",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338562/figure/fig05/,NA,NA,NA,NA
M41166,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_B_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_B_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in B cell 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"APOL6,EPSTI1,FBXO6,GBP1,GBP2,GBP4,GBP5,HAPLN3,INPP1,IRF1,PARP9,STAT1,TRIM69,UBE2L6",14,"APOL6,EPSTI1,FBXO6,GBP1,GBP2,GBP4,GBP5,HAPLN3,INPP1,IRF1,PARP9,STAT1,TRIM69,UBE2L6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6A (PO),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M40998,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in dendritic cell 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"AANAT,ADAM19,AIM2,AK4,ALDH1A1,AMIGO2,ANKRD22,APOL1,APOL2,APOL3,APOL4,APOL6,ASAP2,ATF3,BATF,BATF2,MCEMP1,C1QB,C1QC,ARMH1,C2,IRF1-AS1,C5orf58,GSN-AS1,CACNA1A,CASP7,CCND1,CCR1,CD226,CD274,CD38,CD40,CD7,CDCP1,CEACAM21,CFB,CMPK2,CUL1,CXCL10,CXCR2P1,DDX60,DLL1,DTX3L,DYSF,EGR3,EID3,EIF4E3,ENPP2,EPSTI1,ETV7,EXOC3L1,FAM225A,FBXO6,FCGR1A,FCGR1BP,FCRL6,FFAR2,FRMD3,GAS6,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,HAPLN3,HERC5,HLX,IDO1,IFI35,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFITM1,IGHEP2,IRF1,IRF7,ISG15,ISG20,KIAA0040,KIR3DX1,KLHDC7B,KREMEN1,L3MBTL4,LAP3,LDLR,LGALS3BP,LHFPL2,LINC00189,LMNB1,MSR1,MT2A,MUC1,MYO7B,NCF1,NCF1B,NCF1C,NEXN,NGFR,NLRC5,OAS3,ODF3B,PARP14,PARP9,PFKP,PIM1,PLAC8,PLCXD2,PLEKHH1,PLSCR1,PRRT2,PSMB9,PSME2,PSME2P2,PTK2,PLAAT4,RASGRP3,RHOBTB3,RNF213,RUFY4,S100A8,SAMD4A,SAMD9L,SCO2,SDC3,SERPING1,SIGLEC11,SIGLEC16,SLAMF7,SLAMF8,SLC12A8,SLC2A3,SLC31A2,SLC6A12,SMTNL1,SOCS3,STAB1,STAMBPL1,STAT1,STOM,SUCNR1,TAP1,TAP2,TFEC,TGM2,TIFA,TMPRSS3,TNFSF10,TYMP,UBE2L6,USP18,VAMP5,WARS1,XAF1,XKR8,ZBP1",159,"AANAT,ADAM19,AIM2,AK4,ALDH1A1,AMIGO2,ANKRD22,APOL1,APOL2,APOL3,APOL4,APOL6,ASAP2,ATF3,BATF,BATF2,C19orf59,C1orf228,C1QB,C1QC,C2,C5orf56,C5orf58,C9orf31,CACNA1A,CASP7,CCND1,CCR1,CD226,CD274,CD38,CD40,CD7,CDCP1,CEACAM21,CFB,CMPK2,CUL1,CXCL10,CXCR2P1,DDX60,DLL1,DTX3L,DYSF,EGR3,EID3,EIF4E3,ENPP2,EPSTI1,ETV7,EXOC3L1,FAM225A,FBXO6,FCGR1A,FCGR1B,FCRL6,FFAR2,FRMD3,GAS6,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,HAPLN3,HERC5,HLX,IDO1,IFI35,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFITM1,IGHEP2,IRF1,IRF7,ISG15,ISG20,KIAA0040,KIR3DX1,KLHDC7B,KREMEN1,L3MBTL4,LAP3,LDLR,LGALS3BP,LHFPL2,LINC00189,LMNB1,MSR1,MT2A,MUC1,MYO7B,NCF1,NCF1B,NCF1C,NEXN,NGFR,NLRC5,OAS3,ODF3B,PARP14,PARP9,PFKP,PIM1,PLAC8,PLCXD2,PLEKHH1,PLSCR1,PRRT2,PSMB9,PSME2,PSME2P2,PTK2,RARRES3,RASGRP3,RHOBTB3,RNF213,RUFY4,S100A8,SAMD4A,SAMD9L,SCO2,SDC3,SERPING1,SIGLEC11,SIGLEC16,SLAMF7,SLAMF8,SLC12A8,SLC2A3,SLC31A2,SLC6A12,SMTNL1,SOCS3,STAB1,STAMBPL1,STAT1,STOM,SUCNR1,TAP1,TAP2,TFEC,TGM2,TIFA,TMPRSS3,TNFSF10,TYMP,UBE2L6,USP18,VAMP5,WARS,XAF1,XKR8,ZBP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/figure/pone-0067922-g001/,NA,NA,NA,NA
M40995,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_MONOCYTE_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in monocyte 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"AANAT,ACSL1,ADAMTS10,ADAMTSL4-AS1,ADARB1,ADCY3,ADM,AIM2,ALOX15B,AMIGO2,ANKRD22,ANXA9,APOBEC3A,APOBEC3B,APOBEC3F,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,ARID5B,BMAL2,ASAP2,ATP1B2,AVPI1,BATF2,BCL2A1,BRCA2,VPS9D1,C2,C21orf58,MAP3K7CL,IRF1-AS1,CAMK2D,CARD17P,CASP5,CASP7,CCL2,CD1E,CD274,CD38,CD40,CD69,CD7,CD9,CDCP1,CDHR5,CDK5R1,CETP,CFB,CLEC17A,CLU,CMPK2,CTSL,CUL1,CXCL10,CXCR2P1,CYP4F22,DDX60,DES,DOC2A,DTX3L,DUSP5,DYSF,ENPP2,EPSTI1,ETV7,EXOC3L1,PCED1B,FAM157A,FAM20A,FAM225A,CALHM6,FAM89A,FANCL,FBXO24,FBXO6,FCGR1A,FCGR1BP,FCGR2B,FCRL6,FFAR2,FILIP1L,FPR2,FRMD3,GAS6,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GCH1,GFRA2,GNG10,GPC2,GPR84,ADGRV1,GVINP1,HAPLN3,HERC5,HIC1,H2BC18,HIVEP2,HLA-DOB,HP,HSPA6,IDO1,IFI35,IFI44,IFI44L,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGF2BP3,IGHEP2,IL12RB1,IL15RA,IL27,IL31RA,IRF1,IRF7,ISG15,ISG20,JAK3,KCNJ15,KIFC3,KLHDC7B,KREMEN1,KRT80,LAP3,LGALS3BP,LIMK2,LMNA,LMNB1,LMTK2,METAP1D,MIR21,MRPS18AP1,MT2A,MTND6P5,MUC1,MYOF,NAMPT,NEXN,NLRC5,NR1D1,OAS2,OAS3,OASL,ODF3B,OLIG1,OPTN,ORC6,OXR1,P2RY12,PARP14,PARP9,PFKFB3,PIM1,PITPNM2,PLAC8,PLEKHG6,PML,PPARGC1A,PRDM11,PRICKLE1,PROS1,PRR5L,PRRT2,PRSS21,PSMB9,PSME2,PSME2P2,PSTPIP2,RAB20,PLAAT4,RASL11A,RHOBTB3,RIMKLB,RNF213,RNU7-40P,RSAD2,RTP4,SAMD4A,SAMD9,SAMD9L,SCO2,SDC3,SECTM1,SEMA6B,SEPTIN14,SEPTIN4,SERPINF1,SERPING1,SLAMF7,SLAMF8,SLC39A8,SLC6A12,SMTNL1,SOCS3,SOX12,SP140,STAMBPL1,STAT1,STAT2,STOM,STX11,TAP1,TAP2,TCN2,TGM2,TIFA,TNFAIP6,TNFSF10,TRANK1,TRPC2,TYMP,UBE2L6,VAMP5,VSIG2,WARS1,XAF1,XKR8,XRN1,ZBP1,ZNF702P",231,"AANAT,ACSL1,ADAMTS10,ADAMTSL4-AS1,ADARB1,ADCY3,ADM,AIM2,ALOX15B,AMIGO2,ANKRD22,ANXA9,APOBEC3A,APOBEC3B,APOBEC3F,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,ARID5B,ARNTL2,ASAP2,ATP1B2,AVPI1,BATF2,BCL2A1,BRCA2,C16orf7,C2,C21orf58,C21orf7,C5orf56,CAMK2D,CARD17,CASP5,CASP7,CCL2,CD1E,CD274,CD38,CD40,CD69,CD7,CD9,CDCP1,CDHR5,CDK5R1,CETP,CFB,CLEC17A,CLU,CMPK2,CTSL1,CUL1,CXCL10,CXCR2P1,CYP4F22,DDX60,DES,DOC2A,DTX3L,DUSP5,DYSF,ENPP2,EPSTI1,ETV7,EXOC3L1,FAM113B,FAM157A,FAM20A,FAM225A,FAM26F,FAM89A,FANCL,FBXO24,FBXO6,FCGR1A,FCGR1B,FCGR2B,FCRL6,FFAR2,FILIP1L,FPR2,FRMD3,GAS6,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GCH1,GFRA2,GNG10,GPC2,GPR84,GPR98,GVINP1,HAPLN3,HERC5,HIC1,HIST2H2BF,HIVEP2,HLA-DOB,HP,HSPA6,IDO1,IFI35,IFI44,IFI44L,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGF2BP3,IGHEP2,IL12RB1,IL15RA,IL27,IL31RA,IRF1,IRF7,ISG15,ISG20,JAK3,KCNJ15,KIFC3,KLHDC7B,KREMEN1,KRT80,LAP3,LGALS3BP,LIMK2,LMNA,LMNB1,LMTK2,METAP1D,MIR21,MRPS18AP1,MT2A,MTND6P5,MUC1,MYOF,NAMPT,NEXN,NLRC5,NR1D1,OAS2,OAS3,OASL,ODF3B,OLIG1,OPTN,ORC6,OXR1,P2RY12,PARP14,PARP9,PFKFB3,PIM1,PITPNM2,PLAC8,PLEKHG6,PML,PPARGC1A,PRDM11,PRICKLE1,PROS1,PRR5L,PRRT2,PRSS21,PSMB9,PSME2,PSME2P2,PSTPIP2,RAB20,RARRES3,RASL11A,RHOBTB3,RIMKLB,RNF213,RNU7-40P,RSAD2,RTP4,SAMD4A,SAMD9,SAMD9L,SCO2,SDC3,SECTM1,SEMA6B,SEPT14,SEPT4,SERPINF1,SERPING1,SLAMF7,SLAMF8,SLC39A8,SLC6A12,SMTNL1,SOCS3,SOX12,SP140,STAMBPL1,STAT1,STAT2,STOM,STX11,TAP1,TAP2,TCN2,TGM2,TIFA,TNFAIP6,TNFSF10,TRANK1,TRPC2,TYMP,UBE2L6,VAMP5,VSIG2,WARS,XAF1,XKR8,XRN1,ZBP1,ZNF702P",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M40996,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in neutrophil 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"AANAT,ACO1,ACSL5,AFF1,AGPAT3,AIM2,ANKRD22,ANO6,ANXA3,AP1AR,APOBEC3C,APOBEC3D,APOBEC3F,APOBEC3G,APOL1,APOL2,APOL3,APOL4,APOL6,ARHGAP5,ARL2,ASPHD2,ATF3,ATP10D,ATP1B3,ATR,BAK1,BAK1P1,BATF,BATF2,BPI,BPNT1,BRCA2,BST2,BTLA,BTN3A3,SMCO4,DDIAS,C12orf4,SPTSSA,CMC2,VPS9D1,RMI2,C19orf12,ARMH1,CFAP410,C22orf23,C3AR1,C4BPA,FAM241A,C5,ANXA2R,IRF1-AS1,TMEM268,CACNA1A,CACNA1E,CAPNS2,CARD16,CARD17P,CASP5,CASP7,CASZ1,CCRL2,CD22,CD274,CD2AP,CD59,CD69,CD7,CD74,CEACAM1,CNTRL,CETP,CIITA,CISH,CLEC5A,CMAHP,CMPK2,CNDP2,CNIH4,CPNE5,CREB3L2,CREG1,CTRL,CTSA,DDX21,DDX51,RIGI,DDX60,DDX60L,DENND1A,DEXI,WHRN,DHX58,DNAJC1,DNPEP,DOCK4,DTNBP1,DTX3L,DUSP5,ECHS1,EFCAB2,EIF2AK2,EIF4G3,ENTPD6,EPB41L5,EPG5,EPSTI1,SELENOI,ERAP2,ERI1,ERLIN1,ETV7,EXOC3L1,EZH2,FAM111A,PCED1B,MVB12A,FAM135A,EMC9,CALHM6,FANCA,FANCL,FBXO6,FCER2,FCGR1A,FCGR1BP,FCRL2,FLT3LG,FRMD3,FRMD4B,CMTR1,FZD5,GADD45B,GADD45G,GALM,GAS8,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GBP6,GCH1,GIMAP1,GIMAP2,GLS,GPR65,GRAMD1B,GRINA,GRIP1,GSDMD,GSTK1,GSTO1,GVINP1,GYPC,HEBP1,HELB,HERC5,HERC6,H2BC18,HLA-DMA,HLA-DMB,HLA-DOB,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB5,HLA-K,ICAM1,ID3,IDO1,IFI16,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGF2BP3,IGFLR1,IKZF4,IL12RB1,IL15RA,IL18R1,IRAK2,IRF1,IRF7,IRF9,ISG15,ISG20,ITPRIPL2,KARS1,KCNJ15,KDSR,MATCAP1,KIAA0930,KIF24,KLF4,KLF5,KLHDC7B,KPTN,KREMEN1,LACTB,LAMP3,LAP3,LHFPL2,LIMK1,LIPA,LIPM,LMTK2,LOXL1,LPCAT2,LY6E,MAFF,CGAS,MDK,MED12L,MICALL1,MICB,MITD1,MOV10,MR1,MRPL44,MSRB2,MT2A,MTHFD2,MX1,N4BP2L1,NAA15,NAPA,NASP,NCOA7,NDUFA9,NLRC5,NOD1,NOD2,NOL10,NPC2,NRADDP,NRN1,NT5C3A,NUB1,NUCB1,NUP205,OAS1,OAS2,OAS3,OASL,STN1,ODF3B,P2RY14,PAN2,PARP10,PARP11,PARP12,PARP14,PARP9,PCGF5,PCK2,PDCD1LG2,PDE4B,PI4K2B,PIK3AP1,BLOC1S6,PLSCR1,PLSCR2,PML,POLB,PPM1K,PPP1R2P1,PPP2R5B,PRR5L,PRRG4,PSMB10,PSMB8,PSMB9,PSME1,PSME2,PSME2P2,PSTPIP2,PUS3,RAB20,RANGAP1,PLAAT4,RASGRP3,RBCK1,RBM43,RCVRN,REC8,RFX5,RHBDF2,RHOC,RHOH,RILP,RIPK2,RNASEH2B,RNF144A,RNF213,RNF43,RPS2P5,RSAD2,RSPH9,RTP4,SAMD9L,SAMHD1,SCARF1,SCO2,SCRN1,SECTM1,SEPHS2,SEPTIN4,SERPINB6,SERPINB9,SERPING1,SESTD1,SH3PXD2A,SIAH2,SLAMF7,SLC25A22,SLC25A28,SLC26A8,SLC43A3,SLFN5,SLK,SMTNL1,SNX20,SOCS1,SORT1,SP140,SPATS2L,SPHK1,SRBD1,SSB,STAMBPL1,STAT1,STAT2,STK3,STOM,STOML1,STX11,STX17,TAP1,TAP2,TARBP1,TARS1,TBC1D8,TFEC,TIFA,TIMM10,TLDC2,TLR5,TMEM229B,TMEM272,TMEM62,TMSB10,TNFAIP6,TNFSF13B,TRAFD1,TRIM21,TRIM22,TRIM38,TRIM5,TRIM6,TRIM69,TSPAN17,TTC26,TTC39B,TYMP,UBE2L6,UBR1,USP30,USP42,VAMP5,VAT1,VPS13C,VRK2,WARS1,WDFY1,WDR86,XAF1,XRN1,ZBP1,ZC3H7B,ZC3HAV1,ZCCHC2,ZNF496",394,"AANAT,ACO1,ACSL5,AFF1,AGPAT3,AIM2,ANKRD22,ANO6,ANXA3,AP1AR,APOBEC3C,APOBEC3D,APOBEC3F,APOBEC3G,APOL1,APOL2,APOL3,APOL4,APOL6,ARHGAP5,ARL2,ASPHD2,ATF3,ATP10D,ATP1B3,ATR,BAK1,BAK1P1,BATF,BATF2,BPI,BPNT1,BRCA2,BST2,BTLA,BTN3A3,C11orf75,C11orf82,C12orf4,C14orf147,C16orf61,C16orf7,C16orf75,C19orf12,C1orf228,C21orf2,C22orf23,C3AR1,C4BPA,C4orf32,C5,C5orf39,C5orf56,C9orf91,CACNA1A,CACNA1E,CAPNS2,CARD16,CARD17,CASP5,CASP7,CASZ1,CCRL2,CD22,CD274,CD2AP,CD59,CD69,CD7,CD74,CEACAM1,CEP110,CETP,CIITA,CISH,CLEC5A,CMAHP,CMPK2,CNDP2,CNIH4,CPNE5,CREB3L2,CREG1,CTRL,CTSA,DDX21,DDX51,DDX58,DDX60,DDX60L,DENND1A,DEXI,DFNB31,DHX58,DNAJC1,DNPEP,DOCK4,DTNBP1,DTX3L,DUSP5,ECHS1,EFCAB2,EIF2AK2,EIF4G3,ENTPD6,EPB41L5,EPG5,EPSTI1,EPT1,ERAP2,ERI1,ERLIN1,ETV7,EXOC3L1,EZH2,FAM111A,FAM113B,FAM125A,FAM135A,FAM158A,FAM26F,FANCA,FANCL,FBXO6,FCER2,FCGR1A,FCGR1B,FCRL2,FLT3LG,FRMD3,FRMD4B,FTSJD2,FZD5,GADD45B,GADD45G,GALM,GAS8,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GBP6,GCH1,GIMAP1,GIMAP2,GLS,GPR65,GRAMD1B,GRINA,GRIP1,GSDMD,GSTK1,GSTO1,GVINP1,GYPC,HEBP1,HELB,HERC5,HERC6,HIST2H2BF,HLA-DMA,HLA-DMB,HLA-DOB,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB5,HLA-K,ICAM1,ID3,IDO1,IFI16,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGF2BP3,IGFLR1,IKZF4,IL12RB1,IL15RA,IL18R1,IRAK2,IRF1,IRF7,IRF9,ISG15,ISG20,ITPRIPL2,KARS,KCNJ15,KDSR,KIAA0895L,KIAA0930,KIF24,KLF4,KLF5,KLHDC7B,KPTN,KREMEN1,LACTB,LAMP3,LAP3,LHFPL2,LIMK1,LIPA,LIPM,LMTK2,LOXL1,LPCAT2,LY6E,MAFF,MB21D1,MDK,MED12L,MICALL1,MICB,MITD1,MOV10,MR1,MRPL44,MSRB2,MT2A,MTHFD2,MX1,N4BP2L1,NAA15,NAPA,NASP,NCOA7,NDUFA9,NLRC5,NOD1,NOD2,NOL10,NPC2,NRADDP,NRN1,NT5C3,NUB1,NUCB1,NUP205,OAS1,OAS2,OAS3,OASL,OBFC1,ODF3B,P2RY14,PAN2,PARP10,PARP11,PARP12,PARP14,PARP9,PCGF5,PCK2,PDCD1LG2,PDE4B,PI4K2B,PIK3AP1,PLDN,PLSCR1,PLSCR2,PML,POLB,PPM1K,PPP1R2P1,PPP2R5B,PRR5L,PRRG4,PSMB10,PSMB8,PSMB9,PSME1,PSME2,PSME2P2,PSTPIP2,PUS3,RAB20,RANGAP1,RARRES3,RASGRP3,RBCK1,RBM43,RCVRN,REC8,RFX5,RHBDF2,RHOC,RHOH,RILP,RIPK2,RNASEH2B,RNF144A,RNF213,RNF43,RPS2P5,RSAD2,RSPH9,RTP4,SAMD9L,SAMHD1,SCARF1,SCO2,SCRN1,SECTM1,SEPHS2,SEPT4,SERPINB6,SERPINB9,SERPING1,SESTD1,SH3PXD2A,SIAH2,SLAMF7,SLC25A22,SLC25A28,SLC26A8,SLC43A3,SLFN5,SLK,SMTNL1,SNX20,SOCS1,SORT1,SP140,SPATS2L,SPHK1,SRBD1,SSB,STAMBPL1,STAT1,STAT2,STK3,STOM,STOML1,STX11,STX17,TAP1,TAP2,TARBP1,TARS,TBC1D8,TFEC,TIFA,TIMM10,TLDC2,TLR5,TMEM229B,TMEM272,TMEM62,TMSB10,TNFAIP6,TNFSF13B,TRAFD1,TRIM21,TRIM22,TRIM38,TRIM5,TRIM6,TRIM69,TSPAN17,TTC26,TTC39B,TYMP,UBE2L6,UBR1,USP30,USP42,VAMP5,VAT1,VPS13C,VRK2,WARS,WDFY1,WDR86,XAF1,XRN1,ZBP1,ZC3H7B,ZC3HAV1,ZCCHC2,ZNF496",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M40967,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in natural killer cell 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"MIR9-1HG,CCR3,CETP,CMPK2,CSF1,DERL3,EPAS1,EPSTI1,ETV7,GBP1,HAPLN3,IFI44L,IFIT3,IRF1,MTHFD1L,OAS3,ODF3B,PARP9,PRPF31,STAT1,TYMP",21,"C1orf61,CCR3,CETP,CMPK2,CSF1,DERL3,EPAS1,EPSTI1,ETV7,GBP1,HAPLN3,IFI44L,IFIT3,IRF1,MTHFD1L,OAS3,ODF3B,PARP9,PRPF31,STAT1,TYMP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41024,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_T_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-49,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_T_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_1DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in T cell 1d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 1D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ACOT7,APOL6,BCL3,CD38,CEACAM1,CETP,CMPK2,CSF1,DTX3L,EPSTI1,ETV7,FBXO6,GBP1,GBP2,GBP4,GBP5,ICAM1,IFI30,IFI35,IFI44,IFI44L,IFIT3,IRF1,IRF8,MUC1,NFIX,OAS1,ODF3B,PARP9,PRPF31,RGS1,RSAD2,SAMD4A,SAMD9L,SMTNL1,SOCS3,STAT1,TNFSF13B,TRAFD1,TYMP,UBE2L6,XAF1",42,"ACOT7,APOL6,BCL3,CD38,CEACAM1,CETP,CMPK2,CSF1,DTX3L,EPSTI1,ETV7,FBXO6,GBP1,GBP2,GBP4,GBP5,ICAM1,IFI30,IFI35,IFI44,IFI44L,IFIT3,IRF1,IRF8,MUC1,NFIX,OAS1,ODF3B,PARP9,PRPF31,RGS1,RSAD2,SAMD4A,SAMD9L,SMTNL1,SOCS3,STAT1,TNFSF13B,TRAFD1,TYMP,UBE2L6,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41167,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_1DY_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (18-64) after exposure to Pandemrix , time point 1D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"CD40,CD86,HLA-DRA,HLA-DRB1,HLA-DRB3,HLA-DRB4,HLA-DRB5,IRF1,IRF2,IRF7,IRF9,MYD88,NOD2,STAT1,TAP1,TLR1,TLR2,TLR4,TLR6,TLR7,TLR8",21,"CD40,CD86,HLA-DRA,HLA-DRB1,HLA-DRB3,HLA-DRB4,HLA-DRB5,IRF1,IRF2,IRF7,IRF9,MYD88,NOD2,STAT1,TAP1,TLR1,TLR2,TLR4,TLR6,TLR7,TLR8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41207,PANDEMRIX,IN,INFLUENZA,SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-64,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_1DY_UP,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes up-regulated in T cell 1d vs 0d in adults (18-64) after exposure to Pandemrix (A/California/7/09 (H1N1)) , time point 1D. Comment: - roughly 60/40 female:male ratio, over 70% were Causasian","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"CD247,CD3D,CD3E,CD3G,CD8A,CD8B,CXCL10,CXCL9,FYN,LAT,LCK,MAP4K1,NFATC1,NFATC2,NFATC3,PAG1,PLCG1,PRF1,PRKCQ,RASGRP1,RASGRP2,SLA2,ZAP70",23,"CD247,CD3D,CD3E,CD3G,CD8A,CD8B,CXCL10,CXCL9,FYN,LAT,LCK,MAP4K1,NFATC1,NFATC2,NFATC3,PAG1,PLCG1,PRF1,PRKCQ,RASGRP1,RASGRP2,SLA2,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41112,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D28,D,28,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in B cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA1,ACIN1,ACTR1A,AFF3,AGRN,AKAP13,AMT,ANAPC1,ANGEL2,ANKMY1,ANKRD11,APOL5,APPBP2,ARHGAP19,ARHGEF9,ARID1A,ASS1,ATN1,BACE2,BACH2,BCL7B,BHLHE40,BTBD7,BTN2A1,BTN3A1,ACTMAP,MIS18A,CFAP298,CACYBP,CCDC25,CD164,CD302,CDADC1,CDC42EP3,CENPM,CFLAR,CLEC7A,CLMN,CLN8,COBLL1,COPS7A,CORO2B,CREM,CROCCP2,CUBN,CXCR5,CYFIP1,DAAM1,DCAF11,DCLRE1C,DDX18,DENND2D,DGCR8,DGKQ,DHX29,DHX9,DIAPH2,DICER1,DIDO1,DKC1,DMXL1,DNAJC8,DUOX1,DYRK2,AGO1,AGO4,EIF4G2,ELMO1,EPS15L1,ETF1,EVI5,F11,FADS1,FASTKD3,FBXO28,FEM1B,FGF18,FGFR2,FKBP4,FMO5,FOXO3,FYCO1,GALNT11,GALNT7,GNA12,GNB1,GPD2,GTF2E2,GTF2IRD2,GTF2IRD2B,HERC1,HES1,HGFAC,HIPK2,HOPX,HR,HUS1,ID2,ID2B,IFI35,ELP1,IL6,ING2,INPP5F,IPO7,,ITM2A,JAM3,KCTD20,KHSRP,KIAA1614,KLHL20,KMO,KPNA4,KRT3,LAMA5,LAMC1,LANCL1,LETM1,LRRC37A3,LSM1,LYST,MAN2A2,MAPK13,MAPK8IP1,MCM3AP-AS1,MCTS1,MED31,MEF2D,MGMT,MICALL1,MKRN2,MPDU1,PALS1,MRM2,MRPS18C,MTF2,MTMR3,MTSS1,MYO7A,N4BP2L2,NAA50,NCLN,NCOA2,NDRG2,NECAP1,NEU1,NF1,NFATC2IP,NFATC3,NFIB,NFYC,NHP2,NIPSNAP3B,NOD1,NOX1,NPAT,NR3C2,NR4A2,NUP43,OAS2,OGT,OLFML2A,OXR1,PALB2,PANX1,PAPOLA,PARM1,PAX3,PCMT1,PCNT,PDAP1,PDZK1,PER2,PEX11A,PFKM,PGLS,PHB1,PHLPP1,PMS2,PMS2CL,PNKP,PNN,PPM1B,PPP1R13L,PPP2R1B,PRUNE1,PSD3,PSEN1,CAVIN1,RAB28,RAPGEF3,RBBP9,RBFOX2,RBM12B,SCAF8,RBM26,RBM41,RBPJ,RBPMS,RCAN1,RING1,RNF187,RNH1,RPL28,RRAS2,RXRB,SAFB,SC5D,SCUBE3,SDHD,SELENOW,SEPTIN9,SFT2D2,SGPP1,SHMT2,SIGIRR,SKIL,SLC19A2,SLC1A4,SLC25A12,SLC31A1,SLC35A1,SLC35E3,SLC35F2,SLC8B1,SMAD3,SMPD1,SNED1,SNRK,SNX24,SORL1,SOX4,SPEN,SPON1,SPTBN1,SSBP3,STK10,STK19,SUV39H1,TAF6L,TBC1D1,TBL1XR1,TBPL1,TCP11L1,TDG,TFDP2,TGFB1,TGM4,PAM16,TIMM23,TIMM23B,TLE1,TMEM127,TMEM222,TMOD1,TMSB15B,TNFRSF4,TNS3,TOR3A,TPD52,TRIM33,TRPC1,TTBK2,TUBGCP3,TUBGCP4,UBE2H,UBE2O,UBE3A,USE1,USP10,USP34,USP36,USP39,USP9X,UTP14C,VGLL4,VPS37B,WASL,WIPF2,WIPI1,WNT16,WSB1,WWP1,YIPF5,YLPM1,ZBTB20,ZDHHC14,ZMAT3,ZNF107,ZNF264,ZNF35,ZNF576,ZNF692,ZNF81",295,"ABCA1,ACIN1,ACTR1A,AFF3,AGRN,AKAP13,AMT,ANAPC1,ANGEL2,ANKMY1,ANKRD11,APOL5,APPBP2,ARHGAP19,ARHGEF9,ARID1A,ASS1,ATN1,BACE2,BACH2,BCL7B,BHLHE40,BTBD7,BTN2A1,BTN3A1,C19orf54,C21orf45,C21orf59,CACYBP,CCDC25,CD164,CD302,CDADC1,CDC42EP3,CENPM,CFLAR,CLEC7A,CLMN,CLN8,COBLL1,COPS7A,CORO2B,CREM,CROCCL1,CUBN,CXCR5,CYFIP1,DAAM1,DCAF11,DCLRE1C,DDX18,DENND2D,DGCR8,DGKQ,DHX29,DHX9,DIAPH2,DICER1,DIDO1,DKC1,DMXL1,DNAJC8,DUOX1,DYRK2,EIF2C1,EIF2C4,EIF4G2,ELMO1,EPS15L1,ETF1,EVI5,F11,FADS1,FASTKD3,FBXO28,FEM1B,FGF18,FGFR2,FKBP4,FMO5,FOXO3,FYCO1,GALNT11,GALNT7,GNA12,GNB1,GPD2,GTF2E2,GTF2IRD2,GTF2IRD2B,HERC1,HES1,HGFAC,HIPK2,HOPX,HR,HUS1,ID2,ID2B,IFI35,IKBKAP,IL6,ING2,INPP5F,IPO7,IPW,ITM2A,JAM3,KCTD20,KHSRP,KIAA1614,KLHL20,KMO,KPNA4,KRT3,LAMA5,LAMC1,LANCL1,LETM1,LRRC37A3,LSM1,LYST,MAN2A2,MAPK13,MAPK8IP1,MCM3AP-AS1,MCTS1,MED31,MEF2D,MGMT,MICALL1,MKRN2,MPDU1,MPP5,MRM2,MRPS18C,MTF2,MTMR3,MTSS1,MYO7A,N4BP2L2,NAA50,NCLN,NCOA2,NDRG2,NECAP1,NEU1,NF1,NFATC2IP,NFATC3,NFIB,NFYC,NHP2,NIPSNAP3B,NOD1,NOX1,NPAT,NR3C2,NR4A2,NUP43,OAS2,OGT,OLFML2A,OXR1,PALB2,PANX1,PAPOLA,PARM1,PAX3,PCMT1,PCNT,PDAP1,PDZK1,PER2,PEX11A,PFKM,PGLS,PHB,PHLPP1,PMS2,PMS2CL,PNKP,PNN,PPM1B,PPP1R13L,PPP2R1B,PRUNE,PSD3,PSEN1,PTRF,RAB28,RAPGEF3,RBBP9,RBFOX2,RBM12B,RBM16,RBM26,RBM41,RBPJ,RBPMS,RCAN1,RING1,RNF187,RNH1,RPL28,RRAS2,RXRB,SAFB,SC5DL,SCUBE3,SDHD,SELENOW,SEPT9,SFT2D2,SGPP1,SHMT2,SIGIRR,SKIL,SLC19A2,SLC1A4,SLC25A12,SLC31A1,SLC35A1,SLC35E3,SLC35F2,SLC8B1,SMAD3,SMPD1,SNED1,SNRK,SNX24,SORL1,SOX4,SPEN,SPON1,SPTBN1,SSBP3,STK10,STK19,SUV39H1,TAF6L,TBC1D1,TBL1XR1,TBPL1,TCP11L1,TDG,TFDP2,TGFB1,TGM4,TIMM16,TIMM23,TIMM23B,TLE1,TMEM127,TMEM222,TMOD1,TMSB15B,TNFRSF4,TNS3,TOR3A,TPD52,TRIM33,TRPC1,TTBK2,TUBGCP3,TUBGCP4,UBE2H,UBE2O,UBE3A,USE1,USP10,USP34,USP36,USP39,USP9X,UTP14C,VGLL4,VPS37B,WASL,WIPF2,WIPI1,WNT16,WSB1,WWP1,YIPF5,YLPM1,ZBTB20,ZDHHC14,ZMAT3,ZNF107,ZNF264,ZNF35,ZNF576,ZNF692,ZNF81",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s008.docx,NA,NA,NA,NA
M40989,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_28DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D28,D,28,18-49,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_28DY_DN,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes down-regulated in natural killer cell 28d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 28D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ACP3,AHR,ALCAM,JAML,ANXA5,ARHGEF11,ARHGEF40,ATP6V0A1,BMF,C19orf38,CACNA2D3,CARD9,CD1C,CD33,CIITA,CLEC4A,CST3,CTSH,CYP2S1,EMILIN2,EMP1,ENHO,NIBAN2,FAM20C,FCER1A,FGD2,GABBR1,GAPT,GCA,ADGRD1,GRN,HLA-DMB,HLA-DPA1,HLA-DQB1,HLA-DRA,HLA-DRB1,HPSE,IFI30,IFNGR2,IGSF6,JUP,KCNC3,KCNMB1,LILRA2,LRRK1,LY86,MARCHF1,MYOF,NOD2,OSCAR,PRPF31,RAB34,SEMA3C,SEMA4A,SIGLEC5,SLC15A3,SLC37A2,SLC8A1,SULF2,TIMP2,TNFAIP2,ZNF385A",62,"ACPP,AHR,ALCAM,AMICA1,ANXA5,ARHGEF11,ARHGEF40,ATP6V0A1,BMF,C19orf38,CACNA2D3,CARD9,CD1C,CD33,CIITA,CLEC4A,CST3,CTSH,CYP2S1,EMILIN2,EMP1,ENHO,FAM129B,FAM20C,FCER1A,FGD2,GABBR1,GAPT,GCA,GPR133,GRN,HLA-DMB,HLA-DPA1,HLA-DQB1,HLA-DRA,HLA-DRB1,HPSE,IFI30,IFNGR2,IGSF6,JUP,KCNC3,KCNMB1,LILRA2,LRRK1,LY86,MARCH1,MYOF,NOD2,OSCAR,PRPF31,RAB34,SEMA3C,SEMA4A,SIGLEC5,SLC15A3,SLC37A2,SLC8A1,SULF2,TIMP2,TNFAIP2,ZNF385A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4B,https://www.ncbi.nlm.nih.gov/pubmed/?term=23759749,NA,NA,NA,NA
M41149,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-50) after exposure to Fluarix/Fluvirin , time point 3D. Comment: Supplementary Table 1a: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AAK1,ACAP1,AFF4,AGFG1,AKAP8,AKT2,AMY1A,AMY1B,AMY1C,AMY2A,ANAPC1,ANKRD10,ANKRD11,AP1G1,AP3M2,APBA2,ARID3B,ARID5A,BMAL1,ASXL1,ATG16L1,ATG2A,ATL2,ATP2B1,ATXN1L,ATXN7,AXIN2,BANP,BBX,BCL3,BCLAF1,BEX2,BHLHE40,BRD7,BTG1,BTG3,KANSL2,RGCC,VCPKMT,SPRTN,ARMH1,C1orf52,SDE2,OSER1,NOL4L,HMCES,MALSU1,CAPRIN1,CBX3,CCDC186,CEP95,CENATAC,CCNL1,CCNL2,CCNT2,CD6,CDC14A,CDC42,CDK11A,CDK11B,CDK12,CDKN1B,CDR2,CHD2,CHD7,CIRBP,CLDND1,CLK1,CLK4,CNOT2,COPA,COQ10B,COX4I1,CTDSPL2,CWC25,CXCR4,CXorf65,CYLD,CYTIP,DCAF16,DCP1A,DDIT3,DDX21,DDX24,DDX47,DDX50,DDX51,DDX52,DGKA,DIP2B,DNAJB1,DNAJB9,DNAJC7,DUSP2,DYNC1LI2,EBLN2,EIF1,EIF1AD,EIF2AK3,EIF3B,ELF2,ENTPD4,EXOC3,UBALD2,EEIG1,FAM153A,,FAM153CP,FHIP2A,TASOR2,,FAM8A1,FASTKD2,FBXO3,FBXO33,GABPB1-IT1,PSMA3-AS1,LINC-PINT,FNIP1,FOXJ3,FUS,G0S2,GAS5,GATA3,GGNBP2,GMEB2,GNE,GNL1,GOLGA4,GOLGA6L9,GOLGA8A,GOLGA8B,GORAB,GPR183,GPRASP1,GSPT1,GTF2B,H2AZ2,H3-3B,HABP4,HAUS3,HBP1,HECA,HERC3,HERPUD1,HIF1A,HINT1,HIP1R,HMGB1,HNRNPA1,HNRNPA3,HNRNPD,HNRNPH3,HNRNPM,HPS4,HSF2,ICOS,IFRD1,IGF1R,IKZF5,IL11RA,IL6ST,ILF3,ILKAP,IP6K2,IST1,ITCH,ITPKB,ITPR1,IVNS1ABP,JADE1,JAK1,KDM7A,JMJD1C,JMY,JOSD1,KDM2A,KDM3A,KIZ,KLF9,KLHDC2,KLHL20,KRAS,LENG8,,LPIN1,LRP10,LSG1,LUC7L2,MAFF,MAP4K1,MAPK1IP1L,MAPK8,MARCHF6,MBD4,MDH1,MDM4,MDN1,MED10,MED23,MED26,MED6,MEF2D,MFSD14A,MGAT5,OGA,MIR22HG,MOAP1,MPHOSPH8,MSI2,MTAP,MTCH1,MTX3,MYLIP,KAT6B,NAA16,NAP1L4,NDEL1,NDUFAF5,NDUFB8,NECAP1,NGDN,NKTR,NLRP1,NOL11,NOP58,NUP153,NUP58,NXT1,OFD1,OGT,OSBP,OSM,PABPC1,TENT4A,PAPOLA,PARP8,PBX4,PCBP2,PCNP,PCNX1,PDCD4,PDE4B,PDE4D,PDE7A,PDZD8,PELI1,PER1,PGGHG,PGM2L1,PHF1,PHF10,PHF3,PIDD1,PIGA,PIK3IP1,PIM3,PLK3,PNISR,PNN,POLR1C,POLR3E,PPIA,PPIL4,PPM1A,PPM1B,PPP1R16B,PPP2CA,PPP2R5C,PPTC7,PRDM2,PRKCZ,PRPF4B,PSMA3,PSMD12,PTBP2,PTPN1,PTS,PURB,QRICH1,QSOX2,RAB11FIP2,RABGGTB,RACK1,RAD23B,RANBP2,RAPGEF2,RBBP6,RBM14,RBM19,RBM25,RBM33,RBM39,RBM8A,RBSN,RCAN3,RELL1,RGPD5,RGPD6,RGPD8,RHOH,RICTOR,RLIM,RNF10,RNF103,RNF216,RORA,RPAIN,RPL10,RPRD1B,RRN3P1,RRP1B,RSRC2,RUNX2,RYK,SAR1A,SBDS,SEC31A,SEC31B,SELENOK,SEMA4D,SENP1,SENP3,SEPTIN2,SERINC1,SETD1B,SF3A1,SFI1,SFPQ,SREK1,AKAP17A,SCAF11,SGSM2,SGTB,SIAH1,SIVA1,SLC25A16,SLC25A28,SLC25A36,SLC2A14,SLC2A3,SLC6A6,SLCO3A1,SMC4,SMPD4,SMURF1,SNHG1,SNORD89,SNRK,SNRNP200,SNRPA1,SON,SORL1,SOX6,SPG7,SPOCK2,SPTAN1,SPTY2D1,U2SURP,SRSF1,SRSF10,SSBP1,STAM,STK35,STMN3,SUB1,SUPV3L1,SYNCRIP,SYTL3,TAF11,TFRC,THBD,THSD1,TIPARP,TLE3,TM2D3,TMEM41B,TMEM50B,TMEM59,TNFAIP3,TNFRSF25,TPM2,TRA2A,TRAPPC10,TRIM13,TSEN54,TSPYL2,TUFT1,U2AF1,UBAP2L,UBE2A,UBE2B,UHRF2,UNKL,USP15,USP16,USP21,USP3,USP36,USPL1,VEGFA,WDR20,WDR26,WDR33,WHAMM,WTAP,YRDC,YTHDC1,YTHDF1,ZBTB10,ZBTB11,ZBTB25,ZBTB43,ZBTB5,ZBTB7A,ZC3H12A,ZC3H12D,TUT4,ZDBF2,ZEB1,ZFAND6,ZFAS1,ZFYVE27,ZNF14,ZNF274,ZNF430,ZNF512B,ZNF529,ZNF609,ZNF639,ZNF655,ZNF746,ZNF880,ZRANB1,ZSCAN25",435,"AAK1,ACAP1,AFF4,AGFG1,AKAP8,AKT2,AMY1A,AMY1B,AMY1C,AMY2A,ANAPC1,ANKRD10,ANKRD11,AP1G1,AP3M2,APBA2,ARID3B,ARID5A,ARNTL,ASXL1,ATG16L1,ATG2A,ATL2,ATP2B1,ATXN1L,ATXN7,AXIN2,BANP,BBX,BCL3,BCLAF1,BEX2,BHLHE40,BRD7,BTG1,BTG3,C12orf41,C13orf15,C14orf138,C1orf124,C1orf228,C1orf52,C1orf55,C20orf111,C20orf112,C3orf37,C7orf30,CAPRIN1,CBX3,CCDC186,CCDC45,CCDC84,CCNL1,CCNL2,CCNT2,CD6,CDC14A,CDC42,CDK11A,CDK11B,CDK12,CDKN1B,CDR2,CHD2,CHD7,CIRBP,CLDND1,CLK1,CLK4,CNOT2,COPA,COQ10B,COX4I1,CTDSPL2,CWC25,CXCR4,CXorf65,CYLD,CYTIP,DCAF16,DCP1A,DDIT3,DDX21,DDX24,DDX47,DDX50,DDX51,DDX52,DGKA,DIP2B,DNAJB1,DNAJB9,DNAJC7,DUSP2,DYNC1LI2,EBLN2,EIF1,EIF1AD,EIF2AK3,EIF3B,ELF2,ENTPD4,EXOC3,FAM100B,FAM102A,FAM153A,FAM153B,FAM153C,FAM160B1,FAM208B,FAM85A,FAM8A1,FASTKD2,FBXO3,FBXO33,FLJ10038,FLJ31306,FLJ43663,FNIP1,FOXJ3,FUS,G0S2,GAS5,GATA3,GGNBP2,GMEB2,GNE,GNL1,GOLGA4,GOLGA6L9,GOLGA8A,GOLGA8B,GORAB,GPR183,GPRASP1,GSPT1,GTF2B,H2AFV,H3F3B,HABP4,HAUS3,HBP1,HECA,HERC3,HERPUD1,HIF1A,HINT1,HIP1R,HMGB1,HNRNPA1,HNRNPA3,HNRNPD,HNRNPH3,HNRNPM,HPS4,HSF2,ICOS,IFRD1,IGF1R,IKZF5,IL11RA,IL6ST,ILF3,ILKAP,IP6K2,IST1,ITCH,ITPKB,ITPR1,IVNS1ABP,JADE1,JAK1,JHDM1D,JMJD1C,JMY,JOSD1,KDM2A,KDM3A,KIZ,KLF9,KLHDC2,KLHL20,KRAS,LENG8,LOC114224,LPIN1,LRP10,LSG1,LUC7L2,MAFF,MAP4K1,MAPK1IP1L,MAPK8,MARCH6,MBD4,MDH1,MDM4,MDN1,MED10,MED23,MED26,MED6,MEF2D,MFSD14A,MGAT5,MGEA5,MIR22HG,MOAP1,MPHOSPH8,MSI2,MTAP,MTCH1,MTX3,MYLIP,MYST4,NAA16,NAP1L4,NDEL1,NDUFAF5,NDUFB8,NECAP1,NGDN,NKTR,NLRP1,NOL11,NOP58,NUP153,NUPL1,NXT1,OFD1,OGT,OSBP,OSM,PABPC1,PAPD7,PAPOLA,PARP8,PBX4,PCBP2,PCNP,PCNX,PDCD4,PDE4B,PDE4D,PDE7A,PDZD8,PELI1,PER1,PGGHG,PGM2L1,PHF1,PHF10,PHF3,PIDD1,PIGA,PIK3IP1,PIM3,PLK3,PNISR,PNN,POLR1C,POLR3E,PPIA,PPIL4,PPM1A,PPM1B,PPP1R16B,PPP2CA,PPP2R5C,PPTC7,PRDM2,PRKCZ,PRPF4B,PSMA3,PSMD12,PTBP2,PTPN1,PTS,PURB,QRICH1,QSOX2,RAB11FIP2,RABGGTB,RACK1,RAD23B,RANBP2,RAPGEF2,RBBP6,RBM14,RBM19,RBM25,RBM33,RBM39,RBM8A,RBSN,RCAN3,RELL1,RGPD5,RGPD6,RGPD8,RHOH,RICTOR,RLIM,RNF10,RNF103,RNF216,RORA,RPAIN,RPL10,RPRD1B,RRN3P1,RRP1B,RSRC2,RUNX2,RYK,SAR1A,SBDS,SEC31A,SEC31B,SELK,SEMA4D,SENP1,SENP3,SEPT2,SERINC1,SETD1B,SF3A1,SFI1,SFPQ,SFRS12,SFRS17A,SFRS2IP,SGSM2,SGTB,SIAH1,SIVA1,SLC25A16,SLC25A28,SLC25A36,SLC2A14,SLC2A3,SLC6A6,SLCO3A1,SMC4,SMPD4,SMURF1,SNHG1,SNORD89,SNRK,SNRNP200,SNRPA1,SON,SORL1,SOX6,SPG7,SPOCK2,SPTAN1,SPTY2D1,SR140,SRSF1,SRSF10,SSBP1,STAM,STK35,STMN3,SUB1,SUPV3L1,SYNCRIP,SYTL3,TAF11,TFRC,THBD,THSD1,TIPARP,TLE3,TM2D3,TMEM41B,TMEM50B,TMEM59,TNFAIP3,TNFRSF25,TPM2,TRA2A,TRAPPC10,TRIM13,TSEN54,TSPYL2,TUFT1,U2AF1,UBAP2L,UBE2A,UBE2B,UHRF2,UNKL,USP15,USP16,USP21,USP3,USP36,USPL1,VEGFA,WDR20,WDR26,WDR33,WHAMM,WTAP,YRDC,YTHDC1,YTHDF1,ZBTB10,ZBTB11,ZBTB25,ZBTB43,ZBTB5,ZBTB7A,ZC3H12A,ZC3H12D,ZCCHC11,ZDBF2,ZEB1,ZFAND6,ZFAS1,ZFYVE27,ZNF14,ZNF274,ZNF430,ZNF512B,ZNF529,ZNF609,ZNF639,ZNF655,ZNF746,ZNF880,ZRANB1,ZSCAN25",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41067,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_3DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-50) after exposure to Fluarix/Fluvirin , time point 3D. Comment: Supplementary Table 1a: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCD3,ABI3,ACAA2,ACER3,ACP3,ACTR1A,ADA,ADAP2,ADGRE1,ADGRE2,ADGRG1,AFTPH,AGFG1,AGPS,AHCYL1,AHSA1,AIDA,AIF1,AK2,AKAP10,AKR1C3,AKR7A2,ALDH3A2,ALDH9A1,ANAPC13,ANKMY2,ANKRD17,ANXA4,AP1S2,AP2A1,AP2B1,AP2S1,AP3B1,APAF1,APOBEC3F,APOBEC3G,ARF3,ARF5,ARF6,ARFIP1,ARHGAP18,ARL5A,ARMC1,ARNT,ARRB1,ARSD,ARV1,ASH2L,ASXL2,ATP2B4,ATP6V0E1,ATP6V1B2,ATP6V1C1,ATP6V1D,B3GALT4,B3GALT6,BANF1,BARD1,BCAT1,BICD2,BID,BLVRA,BMPR2,BSG,BTBD7,C11orf71,HIKESHI,LACC1,C14orf119,GON7,SPTSSA,SLIRP,C15orf39,HYPK,USB1,MIEN1,MILR1,LRIF1,C1orf162,COA6,HENMT1,GATD3,CFAP298,KIAA0930,C2orf74,C3AR1,C3orf14,TCAIM,HPF1,ABRACL,UQCC2,MPLKIP,TRIQK,INIP,CALHM2,CALML4,CAP1,CAPN1,CASP1,CAT,CBL,CBX1,CCDC115,CCDC126,COA3,CCDC90B,CCR2,CCR5,CCT3,CCT5,CD160,CD244,CD300A,CD300C,CD300LF,CD36,CD53,CD86,CDK2AP1,CDK4,CDKN1C,CNTRL,CHCHD1,CHMP4A,CHST2,CHURC1,CKLF,CLCN3,CLEC12A,CLEC12B,CLIC3,CLN5,CLTA,CLTC,CNIH4,COG5,CERT1,COMMD8,COPS5,COPS7A,COPZ1,COQ2,COQ5,CORO1A,CORO1C,COX15,CPSF2,CREBL2,CRIPT,CSF1R,CSRP1,CST7,CSTB,CTBP2,CTNND1,CTSA,CTSC,CTSL,CUX1,CWC27,CX3CR1,CYB561D2,CYB5A,CYB5B,CYBRD1,CYFIP1,CYSLTR1,DAPK1,DBI,DBNL,DCAF10,DDRGK1,DECR1,DHRS4,DHRS4L2,DICER1,DISC1,DLEC1,DNAJB6,DNAJC16,DNAJC7,DNAJC8,DOK2,DPP8,DPY30,DPYSL2,DRG1,VPS26C,DYNC1I2,DYNLL1,ECH1,ECHDC1,EDEM3,EEA1,EFCAB14,EIF2B3,EIF2S1,ELAVL1,ELP3,EPB41L3,ERMP1,ESPN,C21orf91,EXOC5,EXOSC1,FAHD1,TASOR,CALHM6,FAM32A,DENND10,CYRIA,RMDN1,FAR1,FASTKD3,FBP1,FBXW11,FCER1G,FEM1B,FEZ2,FGD4,FIBP,FIG4,FKBP15,FKBP1A,FLI1,FMNL2,FNIP2,FUCA1,FUCA2,FZD1,G3BP1,G6PC3,GALC,GALNT1,GAPT,GART,GBA1,GIMAP1,GIMAP2,GIMAP4,GIMAP6,GIMAP8,SLX1B,GLB1,GLIPR1,GLRX,GMPR2,GNGT2,GNPDA1,GNS,GOLPH3,GPALPP1,GPBAR1,GPKOW,GPN3,GRSF1,GTF2H1,GTF2H5,GTF3C6,GZMA,HADH,HAUS1,HAVCR2,HCST,PUDP,HDHD2,HIGD1A,HMGN4,HMOX1,HMOX2,HNMT,HPS3,HPS5,HSBP1,HSD17B4,HTATIP2,HVCN1,ICAM2,ICMT,IDE,IDH1,IER3IP1,IFI16,IGFBP7,IL10RB,IL17RA,IL27RA,ILK,ING4,INTS6,IPO7,IPO8,IQGAP1,IRAK3,JAGN1,KCNE3,KCNK3,KDELR2,KDM1B,KIF3B,KLRD1,KLRF1,KMT5B,KRCC1,LAIR1,LFNG,LILRB2,LINC00324,LINC01560,LIPA,LPCAT3,LRRC8D,LSM10,NAA38,LST1,LTA4H,LY86,LY96,LYAR,LYPLA1,LYST,M6PR,MAP3K7,MAPK1,MAPKAPK3,MARCHF1,MAT2B,MCTS1,ME2,MEA1,MED13,MERTK,MESD,METTL5,METTL7A,MGAT2,MGLL,MGST2,MGST3,MIB1,MICU1,MKKS,MLX,MOSPD2,MPDU1,MPV17,MRM2,MRPL15,MRPL18,MRPL19,MRPL20,MRPL30,MRPL35,MRPL36,MRPL51,MRPS11,MRPS12,MRPS14,MRPS18C,MRPS28,MRPS6,MS4A4A,MS4A6A,MS4A7,MTCH2,MTF2,MTIF2,MTMR11,MTMR12,MTSS1,MYCBP,MYCL,NAAA,NACC2,NAGA,NBR1,NDUFA8,NDUFAF1,NDUFB3,NDUFB5,NDUFB7,NDUFS1,NDUFV3,NEDD8,NEK7,NFATC3,NLRC4,NSL1,NUDT22,NXT2,OAZ2,OGFOD1,OPN3,ORMDL2,OSBPL11,OSTF1,OSTM1,OXR1,OCA2,PAK1,PAPSS1,PARP4,PBRM1,PCMT1,PCNA,PDCD6IP,PDE6D,PDGFD,PDHB,PDHX,PDLIM5,PDZD11,PECAM1,PFDN6,PGLS,PGM2,PIGF,PIK3AP1,PIN4,GSAP,PLAC8,PLRG1,PMVK,PNPO,POLR1D,POLR3K,POP4,POU2F2,PPA2,PPID,PPM1G,PPP1CA,PPP1R7,PPP2CB,PPP3CA,PPP3CB,PRAM1,PRCP,PRDX1,PRF1,PLPBP,PRSS23,PSEN1,PSMB2,PSMC2,PSMD1,PSMD10,PSMD14,PSMD4,PTER,PTGDR,PTPRJ,PURA,QKI,RAB10,RAB1B,RAB27A,RAB7A,RAB8A,RABGAP1L,RALA,RAP2A,RASSF4,RCAN1,RCBTB2,RDH11,REEP5,RHOC,RNASE2,RNASE6,RNF14,RNF20,RNF5,LAMTOR2,RPA2,RPE,RPS27L,RPS6KA1,RRAGA,RRAS,RWDD2B,SASH1,SCAMP1,SCOC,SCYL2,SDAD1,SDHAF2,SDHC,SEC22B,SEC23IP,SEC62,SELENOW,SELPLG,SERF2,SERPINB6,SETD3,SCAF11,SFT2D1,SGO2,SGPL1,SH2D1B,SHQ1,SIGLEC7,SKA2,SLC25A11,SLC25A12,SLC25A20,SLC25A46,SLC26A2,SLC35A5,SLC43A3,SLC7A7,SLC8A1,SLK,SLX1A,SNAPC5,SNAPIN,SNX11,SNX19,SNX27,SNX5,SORT1,SP1,SPON2,SPTLC2,STAM2,STARD3NL,STOM,STX6,STX7,STX8,STYXL1,SUCLG1,SULT1A3,SULT1A4,SUPT4H1,SYK,TADA3,TAOK1,TAPBPL,TARS1,TBC1D1,TBXAS1,TCF7L2,TFCP2,THYN1,TIMM8B,TIMP1,TINF2,TIPRL,TK2,TLR5,TLR8,TM2D1,TMBIM4,TMCO1,TMCO3,TMED9,TMEM107,TMEM126B,TMEM167A,TMEM185A,TMEM19,TMEM218,TMEM87B,TMPO,TMX1,TMX2,TMX3,TNFAIP8L2,TOMM5,TOR1A,TPI1,TPST2,TRAC,TRAPPC1,TRAPPC3,,TRIM27,TRIM69,TRPS1,TSNAX,TTC9C,TTF1,TUBB,TXN2,TXNDC15,TXNDC17,TXNDC9,UBE2E2,UBE2K,UBE2L3,UBE2V2,UBE4A,UBN2,UBR7,UCHL3,UQCC3,UQCR10,VAMP8,VDAC1,VIPAS39,VKORC1L1,VPS35,VPS41,VPS45,VPS72,VRK2,VTI1B,WASHC4,WIPI2,WSB2,YIF1B,YIPF1,YIPF6,ZCCHC17,ZCRB1,ZEB2,ZMAT3,ZMPSTE24,ZMYM6,ZNF146,ZNF25,ZNF641,POLR1H,ZSWIM6",626,"ABCD3,ABI3,ACAA2,ACER3,ACPP,ACTR1A,ADA,ADAP2,ADGRE1,ADGRE2,ADGRG1,AFTPH,AGFG1,AGPS,AHCYL1,AHSA1,AIDA,AIF1,AK2,AKAP10,AKR1C3,AKR7A2,ALDH3A2,ALDH9A1,ANAPC13,ANKMY2,ANKRD17,ANXA4,AP1S2,AP2A1,AP2B1,AP2S1,AP3B1,APAF1,APOBEC3F,APOBEC3G,ARF3,ARF5,ARF6,ARFIP1,ARHGAP18,ARL5A,ARMC1,ARNT,ARRB1,ARSD,ARV1,ASH2L,ASXL2,ATP2B4,ATP6V0E1,ATP6V1B2,ATP6V1C1,ATP6V1D,B3GALT4,B3GALT6,BANF1,BARD1,BCAT1,BICD2,BID,BLVRA,BMPR2,BSG,BTBD7,C11orf71,C11orf73,C13orf31,C14orf119,C14orf142,C14orf147,C14orf156,C15orf39,C15orf63,C16orf57,C17orf37,C17orf60,C1orf103,C1orf162,C1orf31,C1orf59,C21orf33,C21orf59,C22orf9,C2orf74,C3AR1,C3orf14,C3orf23,C4orf27,C6orf115,C6orf125,C7orf11,C8orf83,C9orf80,CALHM2,CALML4,CAP1,CAPN1,CASP1,CAT,CBL,CBX1,CCDC115,CCDC126,CCDC56,CCDC90B,CCR2,CCR5,CCT3,CCT5,CD160,CD244,CD300A,CD300C,CD300LF,CD36,CD53,CD86,CDK2AP1,CDK4,CDKN1C,CEP110,CHCHD1,CHMP4A,CHST2,CHURC1,CKLF,CLCN3,CLEC12A,CLEC12B,CLIC3,CLN5,CLTA,CLTC,CNIH4,COG5,COL4A3BP,COMMD8,COPS5,COPS7A,COPZ1,COQ2,COQ5,CORO1A,CORO1C,COX15,CPSF2,CREBL2,CRIPT,CSF1R,CSRP1,CST7,CSTB,CTBP2,CTNND1,CTSA,CTSC,CTSL1,CUX1,CWC27,CX3CR1,CYB561D2,CYB5A,CYB5B,CYBRD1,CYFIP1,CYSLTR1,DAPK1,DBI,DBNL,DCAF10,DDRGK1,DECR1,DHRS4,DHRS4L2,DICER1,DISC1,DLEC1,DNAJB6,DNAJC16,DNAJC7,DNAJC8,DOK2,DPP8,DPY30,DPYSL2,DRG1,DSCR3,DYNC1I2,DYNLL1,ECH1,ECHDC1,EDEM3,EEA1,EFCAB14,EIF2B3,EIF2S1,ELAVL1,ELP3,EPB41L3,ERMP1,ESPN,EURL,EXOC5,EXOSC1,FAHD1,FAM208A,FAM26F,FAM32A,FAM45A,FAM49A,FAM82B,FAR1,FASTKD3,FBP1,FBXW11,FCER1G,FEM1B,FEZ2,FGD4,FIBP,FIG4,FKBP15,FKBP1A,FLI1,FMNL2,FNIP2,FUCA1,FUCA2,FZD1,G3BP1,G6PC3,GALC,GALNT1,GAPT,GART,GBA,GIMAP1,GIMAP2,GIMAP4,GIMAP6,GIMAP8,GIYD2,GLB1,GLIPR1,GLRX,GMPR2,GNGT2,GNPDA1,GNS,GOLPH3,GPALPP1,GPBAR1,GPKOW,GPN3,GRSF1,GTF2H1,GTF2H5,GTF3C6,GZMA,HADH,HAUS1,HAVCR2,HCST,HDHD1A,HDHD2,HIGD1A,HMGN4,HMOX1,HMOX2,HNMT,HPS3,HPS5,HSBP1,HSD17B4,HTATIP2,HVCN1,ICAM2,ICMT,IDE,IDH1,IER3IP1,IFI16,IGFBP7,IL10RB,IL17RA,IL27RA,ILK,ING4,INTS6,IPO7,IPO8,IQGAP1,IRAK3,JAGN1,KCNE3,KCNK3,KDELR2,KDM1B,KIF3B,KLRD1,KLRF1,KMT5B,KRCC1,LAIR1,LFNG,LILRB2,LINC00324,LINC01560,LIPA,LPCAT3,LRRC8D,LSM10,LSMD1,LST1,LTA4H,LY86,LY96,LYAR,LYPLA1,LYST,M6PR,MAP3K7,MAPK1,MAPKAPK3,MARCH1,MAT2B,MCTS1,ME2,MEA1,MED13,MERTK,MESDC2,METTL5,METTL7A,MGAT2,MGLL,MGST2,MGST3,MIB1,MICU1,MKKS,MLX,MOSPD2,MPDU1,MPV17,MRM2,MRPL15,MRPL18,MRPL19,MRPL20,MRPL30,MRPL35,MRPL36,MRPL51,MRPS11,MRPS12,MRPS14,MRPS18C,MRPS28,MRPS6,MS4A4A,MS4A6A,MS4A7,MTCH2,MTF2,MTIF2,MTMR11,MTMR12,MTSS1,MYCBP,MYCL1,NAAA,NACC2,NAGA,NBR1,NDUFA8,NDUFAF1,NDUFB3,NDUFB5,NDUFB7,NDUFS1,NDUFV3,NEDD8,NEK7,NFATC3,NLRC4,NSL1,NUDT22,NXT2,OAZ2,OGFOD1,OPN3,ORMDL2,OSBPL11,OSTF1,OSTM1,OXR1,P,PAK1,PAPSS1,PARP4,PBRM1,PCMT1,PCNA,PDCD6IP,PDE6D,PDGFD,PDHB,PDHX,PDLIM5,PDZD11,PECAM1,PFDN6,PGLS,PGM2,PIGF,PIK3AP1,PIN4,PION,PLAC8,PLRG1,PMVK,PNPO,POLR1D,POLR3K,POP4,POU2F2,PPA2,PPID,PPM1G,PPP1CA,PPP1R7,PPP2CB,PPP3CA,PPP3CB,PRAM1,PRCP,PRDX1,PRF1,PROSC,PRSS23,PSEN1,PSMB2,PSMC2,PSMD1,PSMD10,PSMD14,PSMD4,PTER,PTGDR,PTPRJ,PURA,QKI,RAB10,RAB1B,RAB27A,RAB7A,RAB8A,RABGAP1L,RALA,RAP2A,RASSF4,RCAN1,RCBTB2,RDH11,REEP5,RHOC,RNASE2,RNASE6,RNF14,RNF20,RNF5,ROBLD3,RPA2,RPE,RPS27L,RPS6KA1,RRAGA,RRAS,RWDD2B,SASH1,SCAMP1,SCOC,SCYL2,SDAD1,SDHAF2,SDHC,SEC22B,SEC23IP,SEC62,SELENOW,SELPLG,SERF2,SERPINB6,SETD3,SFRS2IP,SFT2D1,SGOL2,SGPL1,SH2D1B,SHQ1,SIGLEC7,SKA2,SLC25A11,SLC25A12,SLC25A20,SLC25A46,SLC26A2,SLC35A5,SLC43A3,SLC7A7,SLC8A1,SLK,SLX1A,SNAPC5,SNAPIN,SNX11,SNX19,SNX27,SNX5,SORT1,SP1,SPON2,SPTLC2,STAM2,STARD3NL,STOM,STX6,STX7,STX8,STYXL1,SUCLG1,SULT1A3,SULT1A4,SUPT4H1,SYK,TADA3,TAOK1,TAPBPL,TARS,TBC1D1,TBXAS1,TCF7L2,TFCP2,THYN1,TIMM8B,TIMP1,TINF2,TIPRL,TK2,TLR5,TLR8,TM2D1,TMBIM4,TMCO1,TMCO3,TMED9,TMEM107,TMEM126B,TMEM167A,TMEM185A,TMEM19,TMEM218,TMEM87B,TMPO,TMX1,TMX2,TMX3,TNFAIP8L2,TOMM5,TOR1A,TPI1,TPST2,TRAC,TRAPPC1,TRAPPC3,TRD,TRIM27,TRIM69,TRPS1,TSNAX,TTC9C,TTF1,TUBB,TXN2,TXNDC15,TXNDC17,TXNDC9,UBE2E2,UBE2K,UBE2L3,UBE2V2,UBE4A,UBN2,UBR7,UCHL3,UQCC3,UQCR10,VAMP8,VDAC1,VIPAR,VKORC1L1,VPS35,VPS41,VPS45,VPS72,VRK2,VTI1B,WASHC4,WIPI2,WSB2,YIF1B,YIPF1,YIPF6,ZCCHC17,ZCRB1,ZEB2,ZMAT3,ZMPSTE24,ZMYM6,ZNF146,ZNF25,ZNF641,ZNRD1,ZSWIM6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41181,INFLUENZA,IN,INFLUENZA,GIAROLA_SILVA_BLOOD_INFLUENZA_A_AGE_21_51YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,21-51,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GIAROLA_SILVA_BLOOD_INFLUENZA_A_AGE_21_51YO_3DY_UP,"The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4<sup>+</sup>, CD8<sup>+</sup> T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tlr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,IL-6,IL-1beta,IL-12,IL-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells along with promiscuous production of IL-4/IL-5/IL-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8<sup>+</sup> T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4<sup>+</sup>/CD8<sup>+</sup> T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity.","Genes up-regulated in blood 3d vs 0d in adults (21-51) after exposure to Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur) , time point 3D , administered i.m.","Giarola-Silva S,Coelho-Dos-Reis JGA,Mouro MM,Campi-Azevedo AC,Nakagaki Silva EE,Luiza-Silva M,Martins MA,Silveira-Cassette ACO,Batista MA,Peruhype-Magalhes V,Antonelli LRDV,Leite Ribeiro JG,Eli-Santos SM,Machado AV,Teixeira-Carvalho A,Martins-Filho OA,Arajo MSS",28549970,HUMAN_GENE_SYMBOL,"IFNG,TLR3,TLR4,TLR7,TLR9",5,"IFNG,TLR3,TLR4,TLR7,TLR9",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3: Adjuvanted,https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig3,NA,NA,NA,NA
M41143,INFLUENZA,IN,INFLUENZA,HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in B cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"CIDEB,IL10RB-DT,KDM4A-AS1,MDP1,RSC1A1",5,"CIDEB,IL10RB-DT,KDM4A-AS1,MDP1,RSC1A1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41092,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in monocyte 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ABCA11P,C3orf86P,EREG,FAM110B,NR1I3,TUBE1",6,"ABCA11P,C3orf86,EREG,FAM110B,NR1I3,TUBE1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41158,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in myeloid dendritic cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"B3GNT9,CARS1-AS1,CC2D2B,CCDC106,CCNE2,DLG2,DLGAP4-AS1,DPEP3,EGR1,GAS8,GATC,IDI2,LINC00920,LINC02631,MAFF,MIR3648-1,MSMP,NME8,PKMYT1,RN7SK,RNU6-1,RO60,RXFP4,SLC7A5,SNORA40,SNORA73A,SNORA8,SNORD5,,TAB3-AS1,TAB3-AS2,TMEM120B,TMOD4,ZMYM4-AS1",34,"B3GNT9,CARS-AS1,CC2D2B,CCDC106,CCNE2,DLG2,DLGAP4-AS1,DPEP3,EGR1,GAS8,GATC,IDI2,LINC00920,LINC02631,MAFF,MIR3648-1,MSMP,NME8,PKMYT1,RN7SK,RNU6-1,RO60,RXFP4,SLC7A5,SNORA40,SNORA73A,SNORA8,SNORD5,SNORD76,TAB3-AS1,TAB3-AS2,TMEM120B,TMOD4,ZMYM4-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 1D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supp_Fig_1.tiff,NA,NA,NA,NA
M41000,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in neutrophil 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"DNAJC25-GNG10,EGR2,FGGY,HBEGF,MIR221,PDK4,PHACTR1,SNORA3A,SNORA64,TBC1D7",10,"DNAJC25-GNG10,EGR2,FGGY,HBEGF,MIR221,PDK4,PHACTR1,SNORA3A,SNORA64,TBC1D7",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2C-F; Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/table/T2/,NA,NA,NA,NA
M41144,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_3D_VS_0DY_ADULT_3D_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_3D_VS_0DY_ADULT_3D_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in natural killer cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"AATBC,ADAMTSL4,ADGRE2,AIF1,ALDH2,ALOX5,ANKRD30BL,ANKRD9,ANPEP,APOBEC3A,ARHGEF11,ARHGEF40,ARMH1,ASB13,ASGR2,ATF7-NPFF,ATP4A,AVPI1,BST1,BTK,C19orf38,C5AR1,CARS1-AS1,CBFA2T3,CD101,CD14,CD163,CD1D,CD300E,CD300LF,CD33,CD36,CD4,CD5,CD86,CDKN1A,CEACAM4,CEBPB,CES1,CFAP206,CFD,CFP,CHADL,CHST15,CIITA,CLEC10A,CLEC4A,CLEC7A,CPVL,CREB5,CSF1R,CSF2RA,CSF2RB,CSF3R,CST3,CSTA,CTRL,CTSH,CXCL16,CYBB,CYP2S1,DLG2,DMXL2,DNPH1,DOK3,DPYD-AS1,DUSP1,EGR1,ELOA-AS1,F13A1,FAM20C,FCER1A,FCN1,FGD2,FOSB,FPR1,FRS3,GABBR1,GASK1B,GCA,GCC2-AS1,GNA15,GPSM1,GRK3,HCK,HFM1,HK3,HLA-DOA,HLA-DQA1,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB5,HRH2,IDI2,IFI30,IFNGR2,IGSF6,IL13RA1,IL6R,IRS2,JAML,JUN,JUNB,JUP,KCNC3,KCNE3,KCNMB1,KCNQ1,KCTD12,KLF4,LHFPL5,LILRA1,LILRA2,LILRA3,LILRA5,LILRA6,LILRB2,LILRB3,LILRB4,LMO2,LNX1,LRP1,LRRC24,LRRC25,LRRK1,LRRK2,LTBR,LY86,LYL1,LYZ,MAFB,MARCKS,MARVELD1,MEFV,MIR2110,MIR3198-2,MIR3648-1,MIR571,MNDA,MPEG1,MS4A6A,MS4A7,MTMR11,MYCL,MYOF,NCF1,NCF2,NCF4,NFAM1,NFE2,NIBAN2,NID1,NLRP12,NLRP3,NPB,NR4A1,NR4A2,NT5C1B-RDH14,OAF,ODF3B,OSCAR,OSM,P2RX1,P2RY13,PADI2,PDE3A,PDK4,PEDS1-UBE2V1,PER1,PFKFB4,PID1,PLA2G4B,PLA2G7,PLAUR,PLBD1,PLXNB2,PRAM1,PTAFR,PYGL,RAB32,RAB34,RABGEF1,RASGRP4,RBP7,RETN,,,RNASE2,RNU1-1,RTN1,S100A12,S100A8,S100A9,SAMD11,SCARF1,SECTM1,SEMA4A,SERPINA1,SETD7,SIGLEC14,SIRPA,SIRPB1,SIRPB2,SLC11A1,SLC15A3,SLC2A6,SLC37A2,SLC43A2,SLC7A7,SLCO5A1,PELATON,SNORA25,SNORA27,SNORA40,SNORA73B,SNORA8,SNORC,SNORD102,SNORD4A,SNORD5,SOCS1,SORT1,SPI1,SPINT1,SPINT2,MISFA,STAB1,SULF2,SYNJ2BP-COX16,TAMALIN,TBC1D9,TFEC,TGFBI,TIMP2,TLR2,TLR4,TLR5,TLR8,TMED7-TICAM2,TMEM150B,TMEM88,TNFAIP2,TNFSF12-TNFSF13,TNFSF13B,TRIB1,TUBB2A,TYMP,UNC45B,VAV2,VCAN,VCAN-AS1,VENTX,VIPR1,WAKMAR2,YBX3,ZFP36,ZMYM4-AS1,ZNF385A,ZNF703",260,"AATBC,ADAMTSL4,ADGRE2,AIF1,ALDH2,ALOX5,ANKRD30BL,ANKRD9,ANPEP,APOBEC3A,ARHGEF11,ARHGEF40,ARMH1,ASB13,ASGR2,ATF7-NPFF,ATP4A,AVPI1,BST1,BTK,C19orf38,C5AR1,CARS-AS1,CBFA2T3,CD101,CD14,CD163,CD1D,CD300E,CD300LF,CD33,CD36,CD4,CD5,CD86,CDKN1A,CEACAM4,CEBPB,CES1,CFAP206,CFD,CFP,CHADL,CHST15,CIITA,CLEC10A,CLEC4A,CLEC7A,CPVL,CREB5,CSF1R,CSF2RA,CSF2RB,CSF3R,CST3,CSTA,CTRL,CTSH,CXCL16,CYBB,CYP2S1,DLG2,DMXL2,DNPH1,DOK3,DPYD-AS1,DUSP1,EGR1,ELOA-AS1,F13A1,FAM20C,FCER1A,FCN1,FGD2,FOSB,FPR1,FRS3,GABBR1,GASK1B,GCA,GCC2-AS1,GNA15,GPSM1,GRK3,HCK,HFM1,HK3,HLA-DOA,HLA-DQA1,HLA-DQB1,HLA-DRA,HLA-DRB1,HLA-DRB5,HRH2,IDI2,IFI30,IFNGR2,IGSF6,IL13RA1,IL6R,IRS2,JAML,JUN,JUNB,JUP,KCNC3,KCNE3,KCNMB1,KCNQ1,KCTD12,KLF4,LHFPL5,LILRA1,LILRA2,LILRA3,LILRA5,LILRA6,LILRB2,LILRB3,LILRB4,LMO2,LNX1,LRP1,LRRC24,LRRC25,LRRK1,LRRK2,LTBR,LY86,LYL1,LYZ,MAFB,MARCKS,MARVELD1,MEFV,MIR2110,MIR3198-2,MIR3648-1,MIR571,MNDA,MPEG1,MS4A6A,MS4A7,MTMR11,MYCL1,MYOF,NCF1,NCF2,NCF4,NFAM1,NFE2,NIBAN2,NID1,NLRP12,NLRP3,NPB,NR4A1,NR4A2,NT5C1B-RDH14,OAF,ODF3B,OSCAR,OSM,P2RX1,P2RY13,PADI2,PDE3A,PDK4,PEDS1-UBE2V1,PER1,PFKFB4,PID1,PLA2G4B,PLA2G7,PLAUR,PLBD1,PLXNB2,PRAM1,PTAFR,PYGL,RAB32,RAB34,RABGEF1,RASGRP4,RBP7,RETN,RNA18S5,RNA28S5,RNASE2,RNU1-1,RTN1,S100A12,S100A8,S100A9,SAMD11,SCARF1,SECTM1,SEMA4A,SERPINA1,SETD7,SIGLEC14,SIRPA,SIRPB1,SIRPB2,SLC11A1,SLC15A3,SLC2A6,SLC37A2,SLC43A2,SLC7A7,SLCO5A1,SMIM25,SNORA25,SNORA27,SNORA40,SNORA73B,SNORA8,SNORC,SNORD102,SNORD4A,SNORD5,SOCS1,SORT1,SPI1,SPINT1,SPINT2,SPTY2D1OS,STAB1,SULF2,SYNJ2BP-COX16,TAMALIN,TBC1D9,TFEC,TGFBI,TIMP2,TLR2,TLR4,TLR5,TLR8,TMED7-TICAM2,TMEM150B,TMEM88,TNFAIP2,TNFSF12-TNFSF13,TNFSF13B,TRIB1,TUBB2A,TYMP,UNC45B,VAV2,VCAN,VCAN-AS1,VENTX,VIPR1,WAKMAR2,YBX3,ZFP36,ZMYM4-AS1,ZNF385A,ZNF703",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supplemental_Information.docx,NA,NA,NA,NA
M41015,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADAMTSL4-AS1,ADM,CXCL8,EREG,FCGR3B,FNDC11,FPR3,G0S2,GK3,HBEGF,HHLA3,IGKV1-16,IGLV2-11,KNDC1,NME7,PER1,PI3,TRBV5-7,TRGJP1",19,"ADAMTSL4-AS1,ADM,CXCL8,EREG,FCGR3B,FNDC11,FPR3,G0S2,GK3P,HBEGF,HHLA3,IGKV1-16,IGLV2-11,KNDC1,NME7,PER1,PI3,TRBV5-7,TRGJP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1: Early gene expression (Day 3 - Day 0),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/table/T1/,NA,NA,NA,NA
M40878,INFLUENZA,IN,INFLUENZA,HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in T cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ACBD3-AS1,ATP6V0C,C4orf48,DUSP2,ENC1,FOSL2,LINC02870,MAP3K8,MIR22HG,MIR564,NKPD1,NT5C1B-RDH14,PHLPP1,ZBED2",14,"ACBD3-AS1,ATP6V0C,C4orf48,DUSP2,ENC1,FOSL2,LINC02870,MAP3K8,MIR22HG,MIR564,NKPD1,NT5C1B-RDH14,PHLPP1,ZBED2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 14,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40961,INFLUENZA,IN,INFLUENZA,HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_B_CELL_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in B cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"AQP3,BIK,CAV1,CCNA2,CDC20,CENPM,CHEK1,CHPF,FCN1,FNDC3B,HASPIN,HBA2,HBB,IGKV1-17,IGKV2D-30,IGKV3D-20,LGALS3,LINC00899,MAN1A1,MIR3652,MIXL1,MKI67,NBPF11,NCAPH,NRGN,NT5DC2,PLAAT2,PLEKHG7,PSAT1,PYCR1,RRM2,S100A9,SDC1,SLAMF7,SPN,SULT1A4,TNFRSF17,TRIB1,TYMS",39,"AQP3,BIK,CAV1,CCNA2,CDC20,CENPM,CHEK1,CHPF,FCN1,FNDC3B,HASPIN,HBA2,HBB,IGKV1-17,IGKV2D-30,IGKV3D-20,LGALS3,LINC00899,MAN1A1,MIR3652,MIXL1,MKI67,NBPF11,NCAPH,NRGN,NT5DC2,PLAAT2,PLEKHG7,PSAT1,PYCR1,RRM2,S100A9,SDC1,SLAMF7,SPN,SULT1A4,TNFRSF17,TRIB1,TYMS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 2e,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf,NA,NA,NA,NA
M41074,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in monocyte 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"CD180,LILRA4,MIR374B,MIR4787,RN7SL2,SLX1B",6,"CD180,LILRA4,MIR374B,MIR4787,RN7SL2,SLX1B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig2c,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F2/,NA,NA,NA,NA
M41200,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in myeloid dendritic cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"IL2RB,INTS6-AS1,LRRC70,SH3RF3,SLX1B,TMEM156,UBE2Q1-AS1",7,"IL2RB,INTS6-AS1,LRRC70,SH3RF3,SLX1B,TMEM156,UBE2Q1-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 4,NA,NA,NA,NA,NA
M41073,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in neutrophil 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"DDIAS,C12orf60,GGT5,HMGN5,MIR4477A,NAA35,NME4,NXT2,PLAU,ZBTB3",10,"C11orf82,C12orf60,GGT5,HMGN5,MIR4477A,NAA35,NME4,NXT2,PLAU,ZBTB3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F5/,NA,NA,NA,NA
M41056,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in natural killer cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ARL17A,ATG10,C1D,CAVIN2,CCDC39,CCNB1,CLHC1,CNMD,ALKAL2,GPR82,HNRNPU,HOXA9,IGLV5-52,LINC00623,NPIPA7,PEDS1,PHOSPHO2,RGS17,RNU4-2,SFRP4,TBXT,TPH1,WBP4",23,"ARL17A,ATG10,C1D,CAVIN2,CCDC39,CCNB1,CLHC1,CNMD,FAM150B,GPR82,HNRNPU-AS1,HOXA9,IGLV5-52,LINC00623,NPIPA7,PEDS1,PHOSPHO2,RGS17,RNU4-2,SFRP4,TBXT,TPH1,WBP4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M41101,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ALAS2,ZNG1E,EAF1-AS1,HFM1,HYAL3,IGKV2D-29,IGLV4-69,MEF2C-AS2,MIR3671,NPIPB8,ORC1,SLCO5A1,SULT1A3,TIMM23B,TRAV8-2,TRBV30",16,"ALAS2,CBWD5,EAF1-AS1,HFM1,HYAL3,IGKV2D-29,IGLV4-69,MEF2C-AS2,MIR3671,NPIPB8,ORC1,SLCO5A1,SULT1A3,TIMM23B,TRAV8-2,TRBV30",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M41114,INFLUENZA,IN,INFLUENZA,HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,ADULT,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_T_CELL_2011_2012_TIV_ADULT_3DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in T cell 3d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 3D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"BRWD1-AS2,ZNG1E,CCNB2,CDCA8,EFNA1,HBB,INAFM2,LINC00544,LINC01063,LINC02802,NRGN,PIK3CD-AS2,RN7SK,RRM2,TCEAL9,TOP2A,UBE2E2",17,"BRWD1-AS2,CBWD5,CCNB2,CDCA8,EFNA1,HBB,INAFM2,LINC00544,LINC01063,LINC02802,NRGN,PIK3CD-AS2,RN7SK,RRM2,TCEAL9,TOP2A,UBE2E2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T3/,NA,NA,NA,NA
M40992,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,18-49,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_DN,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes down-regulated in neutrophil 3d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 3D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ANKRD37,YBX3,DDX21,TVP23A,MAP6,RAVER2,TSPAN13,TTYH2",8,"ANKRD37,CSDA,DDX21,FAM18A,MAP6,RAVER2,TSPAN13,TTYH2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Results: Modulation of gene expression by HIV-LIPO-5,https://www.ncbi.nlm.nih.gov/pubmed/?term=23759749,NA,NA,NA,NA
M40947,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-49,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_DENDRITIC_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in dendritic cell 3d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 3D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"AIM2,ALDH1A1,CCR1,LGALS3BP,MARCO,NCF1,NCF1C,SDC3,SERPING1,SIGLEC1,TCN2",11,"AIM2,ALDH1A1,CCR1,LGALS3BP,MARCO,NCF1,NCF1C,SDC3,SERPING1,SIGLEC1,TCN2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S2 Table,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s002.docx,NA,NA,NA,NA
M41109,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-49,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NEUTROPHIL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in neutrophil 3d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 3D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ACO1,AGRN,AIM2,APOBEC3D,APOL3,BATF2,BST2,BTN2A3P,BTN3A3,TMEM268,CARD17P,CATSPER2,CD274,CD2AP,CLMP,CMAHP,CMPK2,CREB3L2,CYB561,DDX60,DHX58,ECHDC2,EIF2AK2,EPSTI1,ETV7,EVL,EXOC3L1,EXOSC9,FCGR1A,FRMD3,CMTR1,GALM,GBP1,GBP3,GBP4,GBP5,GBP6,GCH1,GIMAP1,GIMAP2,GRAMD1B,HERC5,HERC6,HLA-DRA,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM3,ISG15,MATCAP1,KIAA1958,KLHDC7B,LAMP3,LAP3,LHFPL2,LIPA,LPAR6,LY6E,MDN1,MOV10,MT2A,MX1,OAS1,OAS2,OAS3,OASL,P2RY14,PARP10,PARP12,PARP14,PCK2,PLSCR1,PNPT1,PLPP6,PPM1K,PRPF31,RHOC,RHPN1,RNF144A,RSAD2,RTP4,SAMD9L,SAMHD1,SCARB2,SERPING1,SESTD1,SIGLEC1,SLFN13,SLFN5,SMTNL1,SP140,SPATS2L,STOML1,TFEC,TIMM10,TLDC2,TMEM62,TNIK,TREX1,TRIB2,TRIM14,TRIM22,TRIM5,TRIM6,USP18,VAMP5,WDR86,XAF1,ZBP1,ZCCHC2,ZNF496,ZNF680,ZSWIM3",119,"ACO1,AGRN,AIM2,APOBEC3D,APOL3,BATF2,BST2,BTN2A3,BTN3A3,C9orf91,CARD17,CATSPER2,CD274,CD2AP,CLMP,CMAHP,CMPK2,CREB3L2,CYB561,DDX60,DHX58,ECHDC2,EIF2AK2,EPSTI1,ETV7,EVL,EXOC3L1,EXOSC9,FCGR1A,FRMD3,FTSJD2,GALM,GBP1,GBP3,GBP4,GBP5,GBP6,GCH1,GIMAP1,GIMAP2,GRAMD1B,HERC5,HERC6,HLA-DRA,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM3,ISG15,KIAA0895L,KIAA1958,KLHDC7B,LAMP3,LAP3,LHFPL2,LIPA,LPAR6,LY6E,MDN1,MOV10,MT2A,MX1,OAS1,OAS2,OAS3,OASL,P2RY14,PARP10,PARP12,PARP14,PCK2,PLSCR1,PNPT1,PPAPDC2,PPM1K,PRPF31,RHOC,RHPN1,RNF144,RSAD2,RTP4,SAMD9L,SAMHD1,SCARB2,SERPING1,SESTD1,SIGLEC1,SLFN13,SLFN5,SMTNL1,SP140,SPATS2L,STOML1,TFEC,TIMM10,TLDC2,TMEM62,TNIK,TREX1,TRIB2,TRIM14,TRIM22,TRIM5,TRIM6,USP18,VAMP5,WDR86,XAF1,ZBP1,ZCCHC2,ZNF496,ZNF680,ZSWIM3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41108,MONOV INFLUENZA A,IN,INFLUENZA,HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-49,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOWARD_NK_CELL_INACT_MONOV_INFLUENZA_A_INDONESIA_05_2005_H5N1_AGE_18_49YO_3DY_UP,"BACKGROUND: Vaccine development for influenza A/H5N1 is an important public health priority, but H5N1 vaccines are less immunogenic than seasonal influenza vaccines. Adjuvant System 03 (AS03) markedly enhances immune responses to H5N1 vaccine antigens, but the underlying molecular mechanisms are incompletely understood. OBJECTIVE: We compared the safety (primary endpoint), immunogenicity (secondary), gene expression (tertiary) and cytokine responses (exploratory) between AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 influenza vaccines. In a double-blinded clinical trial, we randomized twenty adults aged 18-49 to receive two doses of either AS03-adjuvanted (n = 10) or unadjuvanted (n = 10) H5N1 vaccine 28 days apart. We used a systems biology approach to characterize and correlate changes in serum cytokines, antibody titers, and gene expression levels in six immune cell types at 1, 3, 7, and 28 days after the first vaccination. RESULTS: Both vaccines were well-tolerated. Nine of 10 subjects in the adjuvanted group and 0/10 in the unadjuvanted group exhibited seroprotection (hemagglutination inhibition antibody titer > 1:40) at day 56. Within 24 hours of AS03-adjuvanted vaccination, increased serum levels of IL-6 and IP-10 were noted. Interferon signaling and antigen processing and presentation-related gene responses were induced in dendritic cells, monocytes, and neutrophils. Upregulation of MHC class II antigen presentation-related genes was seen in neutrophils. Three days after AS03-adjuvanted vaccine, upregulation of genes involved in cell cycle and division was detected in NK cells and correlated with serum levels of IP-10. Early upregulation of interferon signaling-related genes was also found to predict seroprotection 56 days after first vaccination. CONCLUSIONS: Using this cell-based systems approach, novel mechanisms of action for AS03-adjuvanted pandemic influenza vaccination were observed. TRIAL: ClinicalTrials.gov NCT01573312.","Genes up-regulated in natural killer cell 3d vs 0d in adults (18-49) after exposure to inactivated monovalent influenza A/Indonesia/05/2005 H5N1 split-virus vaccine , time point 3D , administered i.m.","Howard LM,Hoek KL,Goll JB,Samir P,Galassie A,Allos TM,Niu X,Gordy LE,Creech CB,Prasad N,Jensen TL,Hill H,Levy SE,Joyce S,Link AJ,Edwards KM",28099485,HUMAN_GENE_SYMBOL,"ANLN,APOBEC3B,ASF1B,ASPM,AURKB,BIRC5,BRCA2,BUB1,BUB1B,TICRR,SAPCD2,KNL1,CCNA2,CCNE1,CDC20,CDC25A,CDCA2,CDCA5,CDCA8,CDK1,CENPE,CENPF,CENPM,CKAP2L,DLGAP5,DTL,E2F1,E2F2,E2F7,E2F8,ESCO2,ESPL1,FAM111B,GTSE1,HJURP,KIF14,KIF15,KIF18A,KIF18B,KIF20A,KIF23,KIF2C,KIFC1,MCM10,MCM4,MKI67,CENPU,MYBL2,NCAPG,NCAPH,NUSAP1,PAQR4,PIMREG,PKMYT1,POLQ,PRPF31,PRR11,RRM2,SKA3,STMN1,TK1,TOP2A,TPX2,TROAP,TYMS,UBE2C,UBE2T,ZWINT",68,"ANLN,APOBEC3B,ASF1B,ASPM,AURKB,BIRC5,BRCA2,BUB1,BUB1B,C15orf42,C9orf140,CASC5,CCNA2,CCNE1,CDC20,CDC25A,CDCA2,CDCA5,CDCA8,CDK1,CENPE,CENPF,CENPM,CKAP2L,DLGAP5,DTL,E2F1,E2F2,E2F7,E2F8,ESCO2,ESPL1,FAM111B,GTSE1,HJURP,KIF14,KIF15,KIF18A,KIF18B,KIF20A,KIF23,KIF2C,KIFC1,MCM10,MCM4,MKI67,MLF1IP,MYBL2,NCAPG,NCAPH,NUSAP1,PAQR4,PIMREG,PKMYT1,POLQ,PRPF31,PRR11,RRM2,SKA3,STMN1,TK1,TOP2A,TPX2,TROAP,TYMS,UBE2C,UBE2T,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41182,PANDEMRIX,IN,INFLUENZA,GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,21-51,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_3DY_UP,"The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4<sup>+</sup>, CD8<sup>+</sup> T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tlr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,IL-6,IL-1beta,IL-12,IL-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells along with promiscuous production of IL-4/IL-5/IL-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8<sup>+</sup> T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4<sup>+</sup>/CD8<sup>+</sup> T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity.","Genes up-regulated in blood 3d vs 0d in adults (21-51) after exposure to Pandemrix , time point 3D , administered i.m.","Giarola-Silva S,Coelho-Dos-Reis JGA,Mouro MM,Campi-Azevedo AC,Nakagaki Silva EE,Luiza-Silva M,Martins MA,Silveira-Cassette ACO,Batista MA,Peruhype-Magalhes V,Antonelli LRDV,Leite Ribeiro JG,Eli-Santos SM,Machado AV,Teixeira-Carvalho A,Martins-Filho OA,Arajo MSS",28549970,HUMAN_GENE_SYMBOL,"CCL5,CXCL8,CXCL9,TLR3,TLR7",5,"CCL5,CXCL8,CXCL9,TLR3,TLR7",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41183,PANDEMRIX,IN,INFLUENZA,GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_30DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D30,D,30,21-51,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GIAROLA_SILVA_BLOOD_PANDEMRIX_AGE_21_51YO_30DY_UP,"The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4<sup>+</sup>, CD8<sup>+</sup> T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tlr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,IL-6,IL-1beta,IL-12,IL-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells along with promiscuous production of IL-4/IL-5/IL-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8<sup>+</sup> T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4<sup>+</sup>/CD8<sup>+</sup> T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity.","Genes up-regulated in blood 30d vs 0d in adults (21-51) after exposure to Pandemrix , time point 30D , administered i.m.","Giarola-Silva S,Coelho-Dos-Reis JGA,Mouro MM,Campi-Azevedo AC,Nakagaki Silva EE,Luiza-Silva M,Martins MA,Silveira-Cassette ACO,Batista MA,Peruhype-Magalhes V,Antonelli LRDV,Leite Ribeiro JG,Eli-Santos SM,Machado AV,Teixeira-Carvalho A,Martins-Filho OA,Arajo MSS",28549970,HUMAN_GENE_SYMBOL,"CCL5,CXCL8,CXCL9,IFNG,TLR7,TLR9",6,"CCL5,CXCL8,CXCL9,IFNG,TLR7,TLR9",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41174,FLUAD,IN,INFLUENZA,NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in myeloid dendritic cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AATF,ABCF2,ACACB,ACADVL,ACAP1,ACSF2,ACTN1,ADGRG6,ADSL,AGL,AKAP10,AKT3,ALDH3A2,ALDOC,ANAPC10,ANG,ANKLE2,ANKRD12,ANKRD40,ANKS1A,AOAH,AP3S2,AREG,ARFIP1,ARHGAP25,ARHGEF2,ASCC3,ASH2L,ASNSD1,ATP6V1C1,ATP8B4,AXL,BAG2,BEST1,BPTF,BRD4,BUB1,RTRAF,CZIB,C1orf56,IBA57,ADISSP,C2CD2L,C2CD3,C2orf49,DNPH1,BBLN,CALM1,CAPN7,CASP2,CEP112,CCND3,CCNG1,CD101,CD151,CD36,ADGRE5,CD99,CDC5L,CDK11A,CDK11B,CDK16,FBXW10B,CDS2,CEBPD,CELF1,CNTRL,CEP192,CEP350,CHN2,CLK3,CLTB,CMAHP,CNOT4,COG8,COQ6,CORO1B,CREBL2,CRIP1,CRK,CRYL1,CSF2RA,CSNK2A1,CTSW,CUEDC2,EOLA1,EOLA2,CYP51A1,CYTH1,NSG1,DCLRE1C,DDOST,DDX27,DENND4B,DEXI,DGKA,DISC1,DLX4,DNAJC13,DNM2,DOK2,DVL2,ECH1,EFNA4,EGR1,EGR3,EHBP1,EIF2B3,AGO1,AGO2,EIF3J,ELP3,ENGASE,ERMAP,ETNK1,ETS2,EVI5,EXOC7,F13A1,TCAF1,FAM124B,RETREG2,CCSER2,DENND10,SUPT20H,FKBP5,FLII,FOS,FOSB,FOXJ3,FOXN2,FOXP1,FRAT1,FTSJ1,FYB1,GABBR1,GAPVD1,GCDH,GLG1,GLYR1,GNAL,GNL3L,GORASP2,GPD1L,GPD2,GPI,GRAMD2B,GSK3B,GTF2A1,GTF2H5,HAX1,HDAC4,HEBP2,HEXIM1,HIP1,HIPK2,HNRNPA0,HPS1,HTR7,HUS1,IDI2-AS1,IDS,IFNAR1,IFRD1,IKBKB,IL13RA1,IL18R1,ILVBL,ISG20L2,IVNS1ABP,JUN,KANSL3,KDM4B,KHNYN,KLF12,KLF6,KLF9,KLHDC10,LDLRAD4,LIAS,LILRA6,LILRB1,LILRB3,LMO4,LRIG1,LRP5L,LRRC41,LRRC47,LSM5,LUC7L,MACF1,MAFF,MAGOH,MAP1LC3B,MAP3K2,MAPK1,MAPK9,MAPKAPK5-AS1,MARCHF1,MCCC2,MCM3AP,ME3,MED6,MEF2A,MFN1,MIA3,MICU1,MKI67,MOSPD3,MPZL1,MRPL15,MRPS18B,MSR1,MTDH,MTF1,MUS81,NIPAL2,NOL8,NR4A2,NUMA1,NUP155,NUP205,NABP1,PAPSS2,PAQR3,PCGF2,PDCD6,PDE4DIP,PDF,PDS5B,PDSS1,JADE2,PI4KB,PIGB,PIGP,PLAUR,PLCB2,PLN,PLXND1,PMVK,POLR2H,POLR3C,PON2,POP5,PLPP1,PPIA,PPIE,PQBP1,PRDM2,PRDM4,PRKCA,PRKCI,PSD4,PSMD5,PSPH,PTAFR,PTCD1,PTEN,PTGER4,PTGS2,RAB29,RABL2A,RABL2B,RAD50,RAD51B,RAD51C,RAP2A,RAP2B,RASA1,RASA2,RCBTB2,RECQL,RFXAP,RGS1,RHOC,RIC8A,RNF24,RNFT1,ROBO3,RPL26L1,RRP9,RTN1,RUNX1,RUSC1,RXRB,SAFB2,SCAMP1,SCAND2P,SCN9A,SDHC,SEZ6L,SUGP2,SH3BP4,SH3TC1,SHQ1,SIGLEC7,SKIL,SLC24A1,SLC35A3,SLC39A9,SLC4A7,SLCO3A1,SMYD2,SNAPC3,SOCS3,SOD2,SOS2,SPATA20,SPATA6,SPTLC2,SS18,ST6GAL1,ST8SIA4,STAU2,STK3,STK38L,STX16,STX17,STX6,SUPT7L,SUV39H1,SYMPK,SYNC,TACO1,TAF12,TAF4,TBL1XR1,TBRG4,ELOB,TCF20,TESC,TGFBR2,TIMM9,TLR8,TMPO,TMX4,TNNI2,TNPO1,TOR1AIP1,TRABD,TRAM2,TRAPPC4,TRIM14,TRIO,TRIP11,TRNAU1AP,TSC22D3,TSNAX-DISC1,TTC3,TUBB,TUBB4B,TUG1,TWF1,TXLNA,TXNL4A,UBE2Q1,UBE3A,UBE3B,ULK2,USP4,USP7,UTP14A,VAMP1,VCAN,VEZF1,DCAF1,VPS4A,VWA8,WASHC4,WDR45,TUT7,ZFP36L2,ZNF142,ZNF175,ZNF331,ZNF408,ZNF419,ZNF518A",378,"AATF,ABCF2,ACACB,ACADVL,ACAP1,ACSF2,ACTN1,ADGRG6,ADSL,AGL,AKAP10,AKT3,ALDH3A2,ALDOC,ANAPC10,ANG,ANKLE2,ANKRD12,ANKRD40,ANKS1A,AOAH,AP3S2,AREG,ARFIP1,ARHGAP25,ARHGEF2,ASCC3,ASH2L,ASNSD1,ATP6V1C1,ATP8B4,AXL,BAG2,BEST1,BPTF,BRD4,BUB1,C14orf166,C1orf123,C1orf56,C1orf69,C20orf27,C2CD2L,C2CD3,C2orf49,C6orf108,C9orf16,CALM1,CAPN7,CASP2,CCDC46,CCND3,CCNG1,CD101,CD151,CD36,CD97,CD99,CDC5L,CDK11A,CDK11B,CDK16,CDRT1,CDS2,CEBPD,CELF1,CEP110,CEP192,CEP350,CHN2,CLK3,CLTB,CMAH,CNOT4,COG8,COQ6,CORO1B,CREBL2,CRIP1,CRK,CRYL1,CSF2RA,CSNK2A1,CTSW,CUEDC2,CXorf40A,CXorf40B,CYP51A1,CYTH1,D4S234E,DCLRE1C,DDOST,DDX27,DENND4B,DEXI,DGKA,DISC1,DLX4,DNAJC13,DNM2,DOK2,DVL2,ECH1,EFNA4,EGR1,EGR3,EHBP1,EIF2B3,EIF2C1,EIF2C2,EIF3J,ELP3,ENGASE,ERMAP,ETNK1,ETS2,EVI5,EXOC7,F13A1,FAM115A,FAM124B,FAM134A,FAM190B,FAM45A,FAM48A,FKBP5,FLII,FOS,FOSB,FOXJ3,FOXN2,FOXP1,FRAT1,FTSJ1,FYB,GABBR1,GAPVD1,GCDH,GLG1,GLYR1,GNAL,GNL3L,GORASP2,GPD1L,GPD2,GPI,GRAMD3,GSK3B,GTF2A1,GTF2H5,HAX1,HDAC4,HEBP2,HEXIM1,HIP1,HIPK2,HNRNPA0,HPS1,HTR7,HUS1,IDI2-AS1,IDS,IFNAR1,IFRD1,IKBKB,IL13RA1,IL18R1,ILVBL,ISG20L2,IVNS1ABP,JUN,KANSL3,KDM4B,KHNYN,KLF12,KLF6,KLF9,KLHDC10,LDLRAD4,LIAS,LILRA6,LILRB1,LILRB3,LMO4,LRIG1,LRP5L,LRRC41,LRRC47,LSM5,LUC7L,MACF1,MAFF,MAGOH,MAP1LC3B,MAP3K2,MAPK1,MAPK9,MAPKAPK5-AS1,MARCH1,MCCC2,MCM3AP,ME3,MED6,MEF2A,MFN1,MIA3,MICU1,MKI67,MOSPD3,MPZL1,MRPL15,MRPS18B,MSR1,MTDH,MTF1,MUS81,NIPAL2,NOL8,NR4A2,NUMA1,NUP155,NUP205,OBFC2A,PAPSS2,PAQR3,PCGF2,PDCD6,PDE4DIP,PDF,PDS5B,PDSS1,PHF15,PI4KB,PIGB,PIGP,PLAUR,PLCB2,PLN,PLXND1,PMVK,POLR2H,POLR3C,PON2,POP5,PPAP2A,PPIA,PPIE,PQBP1,PRDM2,PRDM4,PRKCA,PRKCI,PSD4,PSMD5,PSPH,PTAFR,PTCD1,PTEN,PTGER4,PTGS2,RAB7L1,RABL2A,RABL2B,RAD50,RAD51B,RAD51C,RAP2A,RAP2B,RASA1,RASA2,RCBTB2,RECQL,RFXAP,RGS1,RHOC,RIC8A,RNF24,RNFT1,ROBO3,RPL26L1,RRP9,RTN1,RUNX1,RUSC1,RXRB,SAFB2,SCAMP1,SCAND2,SCN9A,SDHC,SEZ6L,SFRS14,SH3BP4,SH3TC1,SHQ1,SIGLEC7,SKIL,SLC24A1,SLC35A3,SLC39A9,SLC4A7,SLCO3A1,SMYD2,SNAPC3,SOCS3,SOD2,SOS2,SPATA20,SPATA6,SPTLC2,SS18,ST6GAL1,ST8SIA4,STAU2,STK3,STK38L,STX16,STX17,STX6,SUPT7L,SUV39H1,SYMPK,SYNC,TACO1,TAF12,TAF4,TBL1XR1,TBRG4,TCEB2,TCF20,TESC,TGFBR2,TIMM9,TLR8,TMPO,TMX4,TNNI2,TNPO1,TOR1AIP1,TRABD,TRAM2,TRAPPC4,TRIM14,TRIO,TRIP11,TRNAU1AP,TSC22D3,TSNAX-DISC1,TTC3,TUBB,TUBB2C,TUG1,TWF1,TXLNA,TXNL4A,UBE2Q1,UBE3A,UBE3B,ULK2,USP4,USP7,UTP14A,VAMP1,VCAN,VEZF1,VPRBP,VPS4A,VWA8,WASHC4,WDR45,ZCCHC6,ZFP36L2,ZNF142,ZNF175,ZNF331,ZNF408,ZNF419,ZNF518A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41179,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in monocyte 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA1,ABCC1,ADNP2,ARG2,ARNT,BIN3,C5AR1,CAMSAP1,CCPG1,NOCT,CD44,CDC42EP4,CFLAR,CHMP1B,CLEC4A,CREM,CUL5,CXCR4,DCLRE1B,DMXL2,DOCK5,EGR3,EPB42,ERAP2,ESYT1,EXOC5,FAM110B,NXPE3,FCAR,GABARAPL1,GALC,GIT2,GLYR1,GNA13,HBEGF,VPS37A,HOXA2,IL15RA,IRS2,KBTBD11,KDM4B,KLF7,KLHL7,KSR1,LAS1L,PLPPR2,NAMPT,NID1,PCSK5,PDE4B,PER1,PEX6,PIN4,PLAGL2,PLCB1,PLK2,PMVK,POLG,PPARD,DESI2,PRDM1,RASA1,RDX,RFC5,RFWD3,RNF41,RUSC1,SAT1,SGPL1,SIK1,SLC22A4,SLC2A14,SLC2A3,SLC44A1,SLFN12,SPATA6,SPRY1,TAF4,TCF7L2,TGIF1,THBS1,TMCC1,TMEM97,TNFSF12-TNFSF13,TNFSF13,TRAF3IP3,TRAM2,UBE3B,VEGFA,VNN1,VRK2,WDR59,XRCC1,YRDC,ZNF331",95,"ABCA1,ABCC1,ADNP2,ARG2,ARNT,BIN3,C5AR1,CAMSAP1,CCPG1,CCRN4L,CD44,CDC42EP4,CFLAR,CHMP1B,CLEC4A,CREM,CUL5,CXCR4,DCLRE1B,DMXL2,DOCK5,EGR3,EPB42,ERAP2,ESYT1,EXOC5,FAM110B,FAM55C,FCAR,GABARAPL1,GALC,GIT2,GLYR1,GNA13,HBEGF,HCRP1,HOXA2,IL15RA,IRS2,KBTBD11,KDM4B,KLF7,KLHL7,KSR1,LAS1L,LPPR2,NAMPT,NID1,PCSK5,PDE4B,PER1,PEX6,PIN4,PLAGL2,PLCB1,PLK2,PMVK,POLG,PPARD,PPPDE1,PRDM1,RASA1,RDX,RFC5,RFWD3,RNF41,RUSC1,SAT1,SGPL1,SIK1,SLC22A4,SLC2A14,SLC2A3,SLC44A1,SLFN12,SPATA6,SPRY1,TAF4,TCF7L2,TGIF1,THBS1,TMCC1,TMEM97,TNFSF12-TNFSF13,TNFSF13,TRAF3IP3,TRAM2,UBE3B,VEGFA,VNN1,VRK2,WDR59,XRCC1,YRDC,ZNF331",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table III,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc,NA,NA,NA,NA
M41203,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in myeloid dendritic cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AFF4,AGPAT3,AKAP8L,AMMECR1,ANKRD17,AQP3,ARHGAP26,ARHGEF7,ARHGEF9,ARL3,ARL4C,ARNT,ATF7IP,ATP2B4,DMAC2L,ATP6V0A1,ATP8A1,AUTS2,BCL2,BIRC5,BLNK,BRWD1,BTN2A3P,NKAPD1,USB1,PRR14L,C2CD3,CAMSAP1,CASK,CBFA2T2,CBL,CC2D1A,YJU2,CCND2,CCNJ,CD164,CD47,CDC42BPA,CDHR5,CDK4,CDYL,CEBPD,CENPF,CENPN,CES2,CHD4,CHD8,CHST10,CKS1B,CLN8,COPS2,COX11,CTSA,CTSB,CXCR4,DAB2,DBN1,DHX29,DHX9,DIAPH2,DIAPH2-AS1,DLAT,DLG1,DMD,DMXL2,DUS1L,DVL1,EHBP1L1,EIF2S1,EIF5B,ENOX2,EPS15,EXT2,EZR,FAS,FNBP1,FOXN3,GAS7,GLS,GLTP,GNA13,GNB5,GPD1L,GPN1,GTPBP8,HADH,HAUS5,HBB,HES1,HIF1AN,HIGD1B,H2BC13,HK1,HNRNPC,HUWE1,ICOSLG,IDH3G,IDS,IGHM,,IGKC,IL13RA1,IL1RAP,ING3,INO80D,INSIG1,IPO8,ITGB1,ITGB3,JUP,KCNE1,KDM5A,KHDC4,KIF2A,KLHL22,KLHL7,KRT5,LAMP1,LDLR,LILRA5,LRBA,LRRFIP2,MAN1A2,MAP4K5,MAP9,MAPKAPK2,MAU2,MDM2,MEF2D,MFNG,MFSD6,MGMT,MLX,MORC3,MPHOSPH9,PALS2,MRPS18B,MSL1,MTMR1,MTMR10,MXRA7,N4BP2L2,NCKIPSD,NEK1,NF2,NIF3L1,NME6,NOP14,NR3C1,NUP88,OPA1,ORC5,OTUB1,OTUD3,OTUD4,PAK2,PANK3,PARVB,PDHB,PDLIM5,PEPD,PFAS,PHC1,PHEX,JADE3,PHKB,PHTF1,PIGC,PIK3C3,PIK3R4,PJA2,PKP2,PLCB1,POLG,POP5,PPIL6,PPP2R1B,PPP2R5D,PRCC,PRDM2,PRDX1,PRKACA,PSMD11,PTGIR,PTPN11,PTPN12,PUS3,QTRT1,RAB11B,RAB11FIP2,RCOR3,RIOK3,RNF146,RNF24,RPP25,RPS6KA4,RRBP1,RRM2,RTF1,RUBCNL,SAR1A,SCARB1,SCCPDH,SEMA4D,SF3A2,SFRP1,SIDT1,SIRT5,SIT1,SLC14A2,SLC26A2,SLC35D1,SLC39A8,SLC44A1,SLC7A1,SLCO3A1,SMAD3,SMARCA4,SMC6,SNRPN,SNURF,SNX1,SORD,SRGAP3,SRP72,SSBP2,SSRP1,ST20,STX6,SUMO3,SWAP70,TAB1,TAF6,TBC1D13,TBK1,TCF20,TCF4,TCP11L1,TEX28,TFDP2,TGOLN2,TINF2,TK2,TLR6,TMCO6,TOMM22,TOX4,TRAF3IP3,TRAF5,TRGV5,TTC3,TXLNG,TXNL4A,U2AF2,UBE2G1,UBXN1,UBXN8,UCHL3,VEZF1,WDR1,YLPM1,ZBTB25,ZC3H14,ZC3H15,ZFC3H1,ZNF3,ZNF331,ZNF589,ZNF609,ZNF93",270,"AFF4,AGPAT3,AKAP8L,AMMECR1,ANKRD17,AQP3,ARHGAP26,ARHGEF7,ARHGEF9,ARL3,ARL4C,ARNT,ATF7IP,ATP2B4,ATP5S,ATP6V0A1,ATP8A1,AUTS2,BCL2,BIRC5,BLNK,BRWD1,BTN2A3,C11orf57,C16orf57,C22orf30,C2CD3,CAMSAP1,CASK,CBFA2T2,CBL,CC2D1A,CCDC94,CCND2,CCNJ,CD164,CD47,CDC42BPA,CDHR5,CDK4,CDYL,CEBPD,CENPF,CENPN,CES2,CHD4,CHD8,CHST10,CKS1B,CLN8,COPS2,COX11,CTSA,CTSB,CXCR4,DAB2,DBN1,DHX29,DHX9,DIAPH2,DIAPH2-AS1,DLAT,DLG1,DMD,DMXL2,DUS1L,DVL1,EHBP1L1,EIF2S1,EIF5B,ENOX2,EPS15,EXT2,EZR,FAS,FNBP1,FOXN3,GAS7,GLS,GLTP,GNA13,GNB5,GPD1L,GPN1,GTPBP8,HADH,HAUS5,HBB,HES1,HIF1AN,HIGD1B,HIST1H2BL,HK1,HNRNPC,HUWE1,ICOSLG,IDH3G,IDS,IGHM,IGK,IGKC,IL13RA1,IL1RAP,ING3,INO80D,INSIG1,IPO8,ITGB1,ITGB3,JUP,KCNE1,KDM5A,KHDC4,KIF2A,KLHL22,KLHL7,KRT5,LAMP1,LDLR,LILRA5,LRBA,LRRFIP2,MAN1A2,MAP4K5,MAP9,MAPKAPK2,MAU2,MDM2,MEF2D,MFNG,MFSD6,MGMT,MLX,MORC3,MPHOSPH9,MPP6,MRPS18B,MSL1,MTMR1,MTMR10,MXRA7,N4BP2L2,NCKIPSD,NEK1,NF2,NIF3L1,NME6,NOP14,NR3C1,NUP88,OPA1,ORC5L,OTUB1,OTUD3,OTUD4,PAK2,PANK3,PARVB,PDHB,PDLIM5,PEPD,PFAS,PHC1,PHEX,PHF16,PHKB,PHTF1,PIGC,PIK3C3,PIK3R4,PJA2,PKP2,PLCB1,POLG,POP5,PPIL6,PPP2R1B,PPP2R5D,PRCC,PRDM2,PRDX1,PRKACA,PSMD11,PTGIR,PTPN11,PTPN12,PUS3,QTRT1,RAB11B,RAB11FIP2,RCOR3,RIOK3,RNF146,RNF24,RPP25,RPS6KA4,RRBP1,RRM2,RTF1,RUBCNL,SAR1A,SCARB1,SCCPDH,SEMA4D,SF3A2,SFRP1,SIDT1,SIRT5,SIT1,SLC14A2,SLC26A2,SLC35D1,SLC39A8,SLC44A1,SLC7A1,SLCO3A1,SMAD3,SMARCA4,SMC6,SNRPN,SNURF,SNX1,SORD,SRGAP3,SRP72,SSBP2,SSRP1,ST20,STX6,SUMO3,SWAP70,TAB1,TAF6,TBC1D13,TBK1,TCF20,TCF4,TCP11L1,TEX28,TFDP2,TGOLN2,TINF2,TK2,TLR6,TMCO6,TOMM22,TOX4,TRAF3IP3,TRAF5,TRGV5,TTC3,TXLNG,TXNL4A,U2AF2,UBE2G1,UBXN1,UBXN8,UCHL3,VEZF1,WDR1,YLPM1,ZBTB25,ZC3H14,ZC3H15,ZFC3H1,ZNF3,ZNF331,ZNF589,ZNF609,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table III,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc,NA,NA,NA,NA
M41105,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in plasmacytoid dendritic cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"GRK3,AKAP11,ALG13,AMIGO2,ANKFY1,API5,CENPS,ARMCX5,ARSB,ASNS,ATP5MG,B3GALT2,BCAT1,BCS1L,BDH1,BRCC3,BTBD3,BTN2A2,METTL22,KNOP1,CACFD1,CCNL2,CD84,CDC23,CDK17,CEP63,CES2,CFP,CIB2,CKAP5,COPS6,COQ10B,CPSF4,CPT1A,CREBZF,CSAD,CSTF1,CUL5,CXCL2,DBNDD2,DCTN4,DDX49,DNAJB6,DNAJC24,DPP4,DSE,DUS4L,EGR2,EIF4ENIF1,ELMO2,EML2,ENTPD7,EPHA2,ERGIC2,ESR2,EWSR1,FAM131A,RETREG2,FASTKD3,FBXL5,FBXO38,FDX1,FH,FRAS1,GAS1,PAXBP1,GIPC1,GK,GLMN,GMPR2,GNA11,GNG10,GNL3L,GNMT,GPX3,GSTZ1,H1-0,HERC1,HSPA13,HSPA1L,ICAM2,IFI44,IL11RA,IL13RA1,JAG1,KLC2,KLF11,KMT2A,LILRB4,LONP2,LRFN4,LRP10,LUC7L2,MADD,MAP4K5,MAPK14,MAPRE2,MEF2D,MID2,MORC2,MORC4,MPIG6B,MRPL9,MTERF3,MTF2,MTMR6,MYCL,N4BP1,NAIP,NANOG,NCOR2,NDST2,NDUFA5,NFATC2IP,NOP14,NR3C1,NUP133,NUP98,NABP1,OSBPL2,P2RY1,P4HB,PDE4B,PHLPP1,PIK3R1,PIP5K1B,PNPLA2,POMZP3,PPP2R2A,PRC1,PRDX6,PRKCI,PRPF4,PTEN,PTPN11,RAB11A,RAE1,RASA4,RASA4B,RBM12B-AS1,RFC4,RGS14,RHEB,RNF138,RPA1,RPL37A,RRP1B,RXRB,SACS,SAT1,SCN3B,SDAD1,SEC23B,SEPTIN9,SGCB,SH3BGRL,SLC12A7,SLC38A4,SLC8A2,SLC9A6,SMG6,SOCS5,SPATA20,SPIN2A,SPRED2,STXBP6,SYS1,SYS1-DBNDD2,TAF6L,TCTA,THBD,TLK1,TLR6,TPM2,TPRKB,TRIM36,TTC4,UBE2K,UEVLD,UQCRFS1,USP3,USP46,USP9X,WDR13,WDR43,WWC3,YBX2,YOD1,YPEL1,ZBTB43,ZFP64,ZKSCAN5,ZKSCAN7,ZNF212,ZNF3,ZNF589",196,"ADRBK2,AKAP11,ALG13,AMIGO2,ANKFY1,API5,APITD1,ARMCX5,ARSB,ASNS,ATP5L,B3GALT2,BCAT1,BCS1L,BDH1,BRCC3,BTBD3,BTN2A2,C16orf68,C16orf88,C9orf7,CCNL2,CD84,CDC23,CDK17,CEP63,CES2,CFP,CIB2,CKAP5,COPS6,COQ10B,CPSF4,CPT1A,CREBZF,CSAD,CSTF1,CUL5,CXCL2,DBNDD2,DCTN4,DDX49,DNAJB6,DNAJC24,DPP4,DSE,DUS4L,EGR2,EIF4ENIF1,ELMO2,EML2,ENTPD7,EPHA2,ERGIC2,ESR2,EWSR1,FAM131A,FAM134A,FASTKD3,FBXL5,FBXO38,FDX1,FH,FRAS1,GAS1,GCFC1,GIPC1,GK,GLMN,GMPR2,GNA11,GNG10,GNL3L,GNMT,GPX3,GSTZ1,H1F0,HERC1,HSPA13,HSPA1L,ICAM2,IFI44,IL11RA,IL13RA1,JAG1,KLC2,KLF11,KMT2A,LILRB4,LONP2,LRFN4,LRP10,LUC7L2,MADD,MAP4K5,MAPK14,MAPRE2,MEF2D,MID2,MORC2,MORC4,MPIG6B,MRPL9,MTERFD1,MTF2,MTMR6,MYCL1,N4BP1,NAIP,NANOG,NCOR2,NDST2,NDUFA5,NFATC2IP,NOP14,NR3C1,NUP133,NUP98,OBFC2A,OSBPL2,P2RY1,P4HB,PDE4B,PHLPP1,PIK3R1,PIP5K1B,PNPLA2,POMZP3,PPP2R2A,PRC1,PRDX6,PRKCI,PRPF4,PTEN,PTPN11,RAB11A,RAE1,RASA4,RASA4B,RBM12B-AS1,RFC4,RGS14,RHEB,RNF138,RPA1,RPL37A,RRP1B,RXRB,SACS,SAT1,SCN3B,SDAD1,SEC23B,SEPT9,SGCB,SH3BGRL,SLC12A7,SLC38A4,SLC8A2,SLC9A6,SMG6,SOCS5,SPATA20,SPIN2A,SPRED2,STXBP6,SYS1,SYS1-DBNDD2,TAF6L,TCTA,THBD,TLK1,TLR6,TPM2,TPRKB,TRIM36,TTC4,UBE2K,UEVLD,UQCRFS1,USP3,USP46,USP9X,WDR13,WDR43,WWC3,YBX2,YOD1,YPEL1,ZBTB43,ZFP64,ZKSCAN5,ZNF167,ZNF212,ZNF3,ZNF589",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table III,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc,NA,NA,NA,NA
M41159,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_B_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in B cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AASDHPPT,AGPS,AHR,AIMP1,AIMP2,AMPD3,ANKFY1,ANKMY1,ANXA2,ANXA4,ANXA6,AP5Z1,APOBEC3G,ARF3,ARF4,ARFIP2,ARMC8,ASPH,ATF6B,ATF7IP2,ATP1A1,ATP5MG,DMAC2,ATP6AP2,ATP6V1C1,BAX,BAZ1A,BAZ2B,BBX,BCL2L1,BECN1,BLMH,BLOC1S1,BLVRB,BTN2A2,C10orf88,AAMDC,TIGAR,TMEM260,SPTSSA,LYRM9,MILR1,C1QBP,RAB5IF,SAPCD1,CALM3,CBX5,COA3,CCNB1IP1,CCNG1,CCNG2,CD247,CD36,CD58,CDC14A,CDC16,CDK2AP2,CEBPG,CELSR1,CHKB-CPT1B,CHST11,CIAO1,CLCN3,CLTB,CNIH1,CNTNAP2,COPB2,COPS5,COPS6,COPS8,COX6A1,CPNE3,CPT1B,CRELD2,CSNK2A1,CTRL,CYB5R3,CYFIP2,CYLD,DCAF8,DCTN2,DDX60,DECR1,DENND4A,DET1,DGUOK,DHX16,DNAJB12,DNAJC10,DNM1L,DYNLT1,DYNLT3,EIF2S1,EIF4E,EIF4E2,ELMO2,EPHA4,ERAP1,ERCC1,ERP44,ETFDH,FABP5,FAHD2A,TASOR,TENT5A,FBXO22,FBXO38,FEN1,FGR,FLOT1,FTSJ1,FUBP3,FUCA1,GABBR1,GALNT10,GART,GCOM1,GK,GLRX,GLYR1,GM2A,GNB1,GOLGB1,GPD1L,GPM6B,GPX1,GSTM4,GTF2A2,GTF2H5,GTPBP8,GYG1,HDAC2,HECTD3,HEG1,HHEX,HRK,ICMT,IDI2-AS1,IFIT1,,IGHA1,IGHA2,IGHD,IGHG1,IGHG2,IGHG3,IGHM,IGHV1-69,IGHV3-23,IGHV4-31,IKZF1,IL21R,IL6R,IMP4,IPO5,IPO9,ISG15,ITCH,ITFG1,ITGA4,ITGAL,KCTD9,KDELR1,TTI1,KIDINS220,KIN,KLHDC10,KRT86,LARP4B,LIMS1,,LRRFIP2,LTN1,M6PR,MAK16,MAML1,MAP3K8,MAST2,MBNL2,MCCC2,MDC1,ME2,MED1,MED6,MED8,MICAL3,MIR22HG,MNDA,MT1X,MT2A,MTHFR,MYO5A,MYO9B,NAB1,NADK,NANS,NCOA4,NDC80,NDUFC1,NET1,NFYA,NFYB,NPRL2,NUCB2,NUP50,NUP58,STN1,OGFOD1,ORC5,OTUB1,OTUD4,PAICS,PAIP1,PAK1,PAK1IP1,PASK,PBX2,PCBP2,PCMT1,PDE5A,PDIA4,PDIA6,PELI2,PEX5,PEX7,PFDN4,PGAP3,PHF20,PHKB,PIP4K2B,PLEKHJ1,PLIN3,PLN,PLXNC1,PMVK,POLE3,POLR2M,PPFIBP1,PPP1R7,PPP2CA,PPP4C,DESI2,PRDX2,PRKAG2,PRKCD,PRPF4B,PSEN1,PSMA6,PSMB1,PSMD14,PTPN2,PTPN9,PYROXD1,QKI,R3HDM1,RABEP2,RAD50,RANBP2,RANBP9,RAP2A,RAP2B,RARA,RASA4,RASA4B,RBM19,RCN2,RELA,RHEB,RIOK3,RNASE6,RNF11,RNF113A,RNF19B,RPF1,RPN2,RPRD1A,RPS6KC1,RRM2,RRS1,SAMHD1,SAP30L-AS1,SEC31A,SEC31B,SERPINB1,SF3B3,SGCB,SHC1,SIGLEC6,SLAMF7,SLC20A1,SLC35D1,SLC39A9,SLC7A7,SLFN12,SMAD2,SNAP29,SNAPC5,SNRNP200,SNRNP27,SNRPC,SOD2,SPATA1,SPIN1,ST13,STK38L,SUPT7L,SYNCRIP,SYNJ2,TAF9B,TALDO1,TBC1D10B,TBC1D3,TBC1D3C,TBC1D3F,TBC1D3H,TBC1D9B,TBK1,TCF3,TERF1,TERF2,THOC7,THSD1,TIMM17A,TM7SF3,TM9SF2,TMCO1,TMCO6,TMEM131L,NEMP1,TNXB,TOP1,TOP3A,TOR1A,TOR1B,TPD52L2,TTF1,TXLNA,TYMP,U2AF2,UBE2B,UBE2J1,UBR5,UBXN2B,UQCRQ,USP4,UTP14A,UTP14C,DCAF1,VPS33B,WAPL,WASHC2A,WASHC2C,WDR74,WNK1,WSB2,XBP1,YARS1,YLPM1,YWHAQ,ZCCHC8,ZNF117,ZNF207,ZNF226,ZNF236,ZNF32,ZNF451,ZNF780A,ZNF780B,ZNF83",369,"AASDHPPT,AGPS,AHR,AIMP1,AIMP2,AMPD3,ANKFY1,ANKMY1,ANXA2,ANXA4,ANXA6,AP5Z1,APOBEC3G,ARF3,ARF4,ARFIP2,ARMC8,ASPH,ATF6B,ATF7IP2,ATP1A1,ATP5L,ATP5SL,ATP6AP2,ATP6V1C1,BAX,BAZ1A,BAZ2B,BBX,BCL2L1,BECN1,BLMH,BLOC1S1,BLVRB,BTN2A2,C10orf88,C11orf67,C12orf5,C14orf101,C14orf147,C17orf108,C17orf60,C1QBP,C20orf24,C6orf26,CALM3,CBX5,CCDC56,CCNB1IP1,CCNG1,CCNG2,CD247,CD36,CD58,CDC14A,CDC16,CDK2AP2,CEBPG,CELSR1,CHKB-CPT1B,CHST11,CIAO1,CLCN3,CLTB,CNIH,CNTNAP2,COPB2,COPS5,COPS6,COPS8,COX6A1,CPNE3,CPT1B,CRELD2,CSNK2A1,CTRL,CYB5R3,CYFIP2,CYLD,DCAF8,DCTN2,DDX60,DECR1,DENND4A,DET1,DGUOK,DHX16,DNAJB12,DNAJC10,DNM1L,DYNLT1,DYNLT3,EIF2S1,EIF4E,EIF4E2,ELMO2,EPHA4,ERAP1,ERCC1,ERP44,ETFDH,FABP5,FAHD2A,FAM208A,FAM46A,FBXO22,FBXO38,FEN1,FGR,FLOT1,FTSJ1,FUBP3,FUCA1,GABBR1,GALNT10,GART,GCOM1,GK,GLRX,GLYR1,GM2A,GNB1,GOLGB1,GPD1L,GPM6B,GPX1,GSTM4,GTF2A2,GTF2H5,GTPBP8,GYG1,HDAC2,HECTD3,HEG1,HHEX,HRK,ICMT,IDI2-AS1,IFIT1,IGH,IGHA1,IGHA2,IGHD,IGHG1,IGHG2,IGHG3,IGHM,IGHV1-69,IGHV3-23,IGHV4-31,IKZF1,IL21R,IL6R,IMP4,IPO5,IPO9,ISG15,ITCH,ITFG1,ITGA4,ITGAL,KCTD9,KDELR1,KIAA0406,KIDINS220,KIN,KLHDC10,KRT86,LARP4B,LIMS1,LOC100290036,LRRFIP2,LTN1,M6PR,MAK16,MAML1,MAP3K8,MAST2,MBNL2,MCCC2,MDC1,ME2,MED1,MED6,MED8,MICAL3,MIR22HG,MNDA,MT1X,MT2A,MTHFR,MYO5A,MYO9B,NAB1,NADK,NANS,NCOA4,NDC80,NDUFC1,NET1,NFYA,NFYB,NPRL2,NUCB2,NUP50,NUPL1,OBFC1,OGFOD1,ORC5L,OTUB1,OTUD4,PAICS,PAIP1,PAK1,PAK1IP1,PASK,PBX2,PCBP2,PCMT1,PDE5A,PDIA4,PDIA6,PELI2,PEX5,PEX7,PFDN4,PGAP3,PHF20,PHKB,PIP4K2B,PLEKHJ1,PLIN3,PLN,PLXNC1,PMVK,POLE3,POLR2M,PPFIBP1,PPP1R7,PPP2CA,PPP4C,PPPDE1,PRDX2,PRKAG2,PRKCD,PRPF4B,PSEN1,PSMA6,PSMB1,PSMD14,PTPN2,PTPN9,PYROXD1,QKI,R3HDM1,RABEP2,RAD50,RANBP2,RANBP9,RAP2A,RAP2B,RARA,RASA4,RASA4B,RBM19,RCN2,RELA,RHEB,RIOK3,RNASE6,RNF11,RNF113A,RNF19B,RPF1,RPN2,RPRD1A,RPS6KC1,RRM2,RRS1,SAMHD1,SAP30L-AS1,SEC31A,SEC31B,SERPINB1,SF3B3,SGCB,SHC1,SIGLEC6,SLAMF7,SLC20A1,SLC35D1,SLC39A9,SLC7A7,SLFN12,SMAD2,SNAP29,SNAPC5,SNRNP200,SNRNP27,SNRPC,SOD2,SPATA1,SPIN1,ST13,STK38L,SUPT7L,SYNCRIP,SYNJ2,TAF9B,TALDO1,TBC1D10B,TBC1D3,TBC1D3C,TBC1D3F,TBC1D3H,TBC1D9B,TBK1,TCF3,TERF1,TERF2,THOC7,THSD1,TIMM17A,TM7SF3,TM9SF2,TMCO1,TMCO6,TMEM131L,TMEM194A,TNXB,TOP1,TOP3A,TOR1A,TOR1B,TPD52L2,TTF1,TXLNA,TYMP,U2AF2,UBE2B,UBE2J1,UBR5,UBXN2B,UQCRQ,USP4,UTP14A,UTP14C,VPRBP,VPS33B,WAPAL,WASHC2A,WASHC2C,WDR74,WNK1,WSB2,XBP1,YARS,YLPM1,YWHAQ,ZCCHC8,ZNF117,ZNF207,ZNF226,ZNF236,ZNF32,ZNF451,ZNF780A,ZNF780B,ZNF83",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40930,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in monocyte 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCB7,ABHD2,ACACB,ACO1,ADAMTSL4,ADNP,AK2,AKAP13,ALDH3A2,ALG13,ANAPC5,ANG,ANKLE2,ANKRD17,ANKS1A,APAF1,APOOL,APPBP2,ARAP3,AREG,ARFGEF2,ARFIP1,ARHGAP19,ARMC8,ASB13,ASF1A,ASPH,ASRGL1,ATF2,ATG4A,ATM,ATP6V1B2,ATP6V1C1,ATR,AZI2,BAZ1A,BBS9,BCAP29,BCCIP,BCL2,BMP2K,BRCC3,BTD,WBP1L,SMCO4,RESF1,BORA,DNAAF2,OGFOD3,ELP5,C1QBP,C1orf50,RTCB,NOP14-AS1,HPF1,C5AR1,DNPH1,C6orf120,SPOUT1,CAND1,CAP1,CAPN3,CASP2,CCDC25,CCDC88C,CCL3,CCL3L1,CCL3L3,CCL4,CCND3,CCR2,CCT2,CD163,CD1E,CD33,CD86,CD9,CD93,CDC73,CEP57,CEPT1,CHUK,CIITA,CLEC2D,CLIP1,CLN5,CNOT1,CNOT3,CNOT6,CPD,CPM,CPPED1,CPT1A,CREBL2,CRISPLD2,CRTAP,YBX3,CSF2RA,CSPP1,CTDSP1,CTPS2,CX3CR1,CXCL1,CXCL3,CYB5R1,CYBRD1,DCAF10,DCAF13,DCLRE1B,DDX18,DEGS1,DERA,DEXI,DHX16,DICER1,DLG1,DMXL1,DNAJB1,DNAJB2,DPP8,DUSP2,DUSP6,DYNLL1,EBAG9,EFHC1,EGR1,EGR2,EGR3,EIF1AX,EIF2B4,ENC1,ENGASE,ENOX2,ENTPD1,EPM2A,EPRS1,EREG,ERI2,ERLIN2,ERMP1,ESYT1,ETNK1,ETS2,EXOC5,EXOSC10,F5,OTULINL,RETREG2,FAM13A,CCSER2,TASOR,COX20,RIPOR2,FASTKD1,FASTKD3,FBXL12,FBXL14,FBXO28,FBXW2,FCAR,FCF1,FKBP1A,FKBP5,FLI1,GABPB1-IT1,FPR3,FUCA1,FYN,GAA,GADD45A,GALC,GALNT2,GAS2L1,GCSH,,GEMIN4,GGA3,GIMAP4,GIMAP5,GIMAP6,GLO1,GNL3L,GNPDA1,GNPTAB,GORASP2,GOSR2,GPATCH1,GPATCH4,ADGRA2,HACD2,HAL,,PUDP,HEATR3,HECTD4,HERC2,HIP1,HIPK2,HIPK3,HNMT,HNRNPUL2,HOXA7,HSD17B12,HSPA1A,HSPA1B,IARS1,IBTK,IDS,IER2,IFFO1,IFNGR1,IFRD1,IFT74,IL10RB,IL13RA1,IL27RA,IL4R,IL6,CXCL8,INPP5A,IPCEF1,IPO5,IPO7,IRAK1,IRAK3,IRS2,ITGA6,ITPR2,IVNS1ABP,JADE1,JUN,KDM2A,KDM3B,TRAPPC8,KIDINS220,KLF2,KLF6,KLHL11,KLHL18,KRT10,LAIR1,LCMT1,LIMK2,LIMS1,LPAR1,LRRC8D,LYRM4,LYST,MAFF,MAN2A1,MAN2C1,MAP3K12,MAPK1IP1L,MAPKAPK5-AS1,MAU2,MBNL1,MBNL2,MBP,MCM3AP-AS1,MCTP1,MDM2,MEAF6,MED20,MEF2C,MERTK,METTL7A,MGAT2,MICAL2,MID1IP1,MINK1,MLX,MLXIP,MMS19,MNDA,MON2,MRPL15,MRPL24,MRPL3,MRPS14,MRPS30,MRPS31,MRS2,MS4A4A,MSL2,MTDH,MTERF3,MTR,MTRR,MTSS1,IRF4,MYCBP,NAALAD2,NAIP,NCOR1,NDUFA6,NDUFB6,NEU1,NEU3,NID1,NME1,NOLC1,NPAT,NR4A2,NR4A3,NRBF2,NRG1,NUDT15,OAZ2,NABP1,OGFOD1,OLFM1,OXR1,PAFAH1B1,PBXIP1,PCF11,PDGFC,PFAS,PHF20,PHLDA2,PIBF1,PID1,PIK3C2A,PKNOX1,PKP4,PLAUR,PLXNC1,PNMA1,PPP1R10,PREB,PREPL,PRKAG1,PRPF40A,PRPSAP1,PSMD14,PTEN,PTGER4,PTGS1,PTGS2,PTPN12,PTPN22,PTX3,PURA,PUS7,RAB33B,RAB3GAP2,RAB4A,RAB9A,RABEP1,TERF2IP,RAP1GDS1,RASA4,RASSF4,RCAN1,RCHY1,RGL2,RHOT1,RNASE2,RNASE4,RNF111,RNF146,RPE,RTN1,SAP30,SDAD1,SEC23B,SEC24A,SEC63,SERP1,SETX,SIGLEC7,SIKE1,GEMIN2,SLA,SLC15A2,SLC16A1,SLC16A3,SLC25A24,SLC25A40,SLC35A5,SMARCC2,SMC5,SMG1,SMPD4,SNAPC3,SRPK2,SRPRB,SS18L2,ST6GAL1,STAM2,STK3,STK38L,SULT1A2,SWAP70,TAF12,TAX1BP1,TBC1D22A,TBC1D5,TBC1D8,TBL1X,TCF3,TCP1,TCP11L1,TCTN3,TGFBRAP1,THOC7,TIA1,TJAP1,TLR6,TLR8,TM2D1,TMBIM1,TMCO1,TMEM184C,TMPO,TNF,TNFAIP1,TNFAIP3,TNFRSF1A,TNFSF10,TOB2,TOPBP1,TOR1A,TOR1AIP1,TP73-AS1,TPM1,TRAPPC10,TRIM5,TRIT1,RO60,TRPS1,TRRAP,TSC22D3,TSNAX,TTBK2,TTC17,TTC27,TTC3,TTC9,UBE2I,UBE2V2,UBE3B,UBE4B,UBL3,UBR4,UGDH,UGGT2,USP32,VAMP4,VAT1,VBP1,VNN1,VPS54,WBP4,WDR12,WDR7,WIPF1,WWP1,XRCC4,ZBTB10,ZBTB11,ZBTB40,ZFAND5,ZFP36L2,ZFP64,ZMPSTE24,ZMYM6,ZNF106,ZNF146,ZNF202,ZNF224,ZNF225,ZNF226,ZNF277,ZNF32,ZNF329,ZNF354A,ZNF45,ZNF580,ZNF780A,ZNF780B",480,"ABCB7,ABHD2,ACACB,ACO1,ADAMTSL4,ADNP,AK2,AKAP13,ALDH3A2,ALG13,ANAPC5,ANG,ANKLE2,ANKRD17,ANKS1A,APAF1,APOOL,APPBP2,ARAP3,AREG,ARFGEF2,ARFIP1,ARHGAP19,ARMC8,ASB13,ASF1A,ASPH,ASRGL1,ATF2,ATG4A,ATM,ATP6V1B2,ATP6V1C1,ATR,AZI2,BAZ1A,BBS9,BCAP29,BCCIP,BCL2,BMP2K,BRCC3,BTD,C10orf26,C11orf75,C12orf35,C13orf34,C14orf104,C17orf101,C17orf81,C1orf50,C1QBP,C22orf28,C4orf10,C4orf27,C5AR1,C6orf108,C6orf120,C9orf114,CAND1,CAP1,CAPN3,CASP2,CCDC25,CCDC88C,CCL3,CCL3L1,CCL3L3,CCL4,CCND3,CCR2,CCT2,CD163,CD1E,CD33,CD86,CD9,CD93,CDC73,CEP57,CEPT1,CHUK,CIITA,CLEC2D,CLIP1,CLN5,CNOT1,CNOT3,CNOT6,CPD,CPM,CPPED1,CPT1A,CREBL2,CRISPLD2,CRTAP,CSDA,CSF2RA,CSPP1,CTDSP1,CTPS2,CX3CR1,CXCL1,CXCL3,CYB5R1,CYBRD1,DCAF10,DCAF13,DCLRE1B,DDX18,DEGS1,DERA,DEXI,DHX16,DICER1,DLG1,DMXL1,DNAJB1,DNAJB2,DPP8,DUSP2,DUSP6,DYNLL1,EBAG9,EFHC1,EGR1,EGR2,EGR3,EIF1AX,EIF2B4,ENC1,ENGASE,ENOX2,ENTPD1,EPM2A,EPRS,EREG,ERI2,ERLIN2,ERMP1,ESYT1,ETNK1,ETS2,EXOC5,EXOSC10,F5,FAM105A,FAM134A,FAM13A,FAM190B,FAM208A,FAM36A,FAM65B,FASTKD1,FASTKD3,FBXL12,FBXL14,FBXO28,FBXW2,FCAR,FCF1,FKBP1A,FKBP5,FLI1,FLJ10038,FPR3,FUCA1,FYN,GAA,GADD45A,GALC,GALNT2,GAS2L1,GCSH,GDS1,GEMIN4,GGA3,GIMAP4,GIMAP5,GIMAP6,GLO1,GNL3L,GNPDA1,GNPTAB,GORASP2,GOSR2,GPATCH1,GPATCH4,GPR124,HACD2,HAL,HDGFRP3,HDHD1A,HEATR3,HECTD4,HERC2,HIP1,HIPK2,HIPK3,HNMT,HNRNPUL2,HOXA7,HSD17B12,HSPA1A,HSPA1B,IARS,IBTK,IDS,IER2,IFFO1,IFNGR1,IFRD1,IFT74,IL10RB,IL13RA1,IL27RA,IL4R,IL6,IL8,INPP5A,IPCEF1,IPO5,IPO7,IRAK1,IRAK3,IRS2,ITGA6,ITPR2,IVNS1ABP,JADE1,JUN,KDM2A,KDM3B,KIAA1012,KIDINS220,KLF2,KLF6,KLHL11,KLHL18,KRT10,LAIR1,LCMT1,LIMK2,LIMS1,LPAR1,LRRC8D,LYRM4,LYST,MAFF,MAN2A1,MAN2C1,MAP3K12,MAPK1IP1L,MAPKAPK5-AS1,MAU2,MBNL1,MBNL2,MBP,MCM3AP-AS1,MCTP1,MDM2,MEAF6,MED20,MEF2C,MERTK,METTL7A,MGAT2,MICAL2,MID1IP1,MINK1,MLX,MLXIP,MMS19,MNDA,MON2,MRPL15,MRPL24,MRPL3,MRPS14,MRPS30,MRPS31,MRS2,MS4A4A,MSL2,MTDH,MTERFD1,MTR,MTRR,MTSS1,MUM1,MYCBP,NAALAD2,NAIP,NCOR1,NDUFA6,NDUFB6,NEU1,NEU3,NID1,NME1,NOLC1,NPAT,NR4A2,NR4A3,NRBF2,NRG1,NUDT15,OAZ2,OBFC2A,OGFOD1,OLFM1,OXR1,PAFAH1B1,PBXIP1,PCF11,PDGFC,PFAS,PHF20,PHLDA2,PIBF1,PID1,PIK3C2A,PKNOX1,PKP4,PLAUR,PLXNC1,PNMA1,PPP1R10,PREB,PREPL,PRKAG1,PRPF40A,PRPSAP1,PSMD14,PTEN,PTGER4,PTGS1,PTGS2,PTPN12,PTPN22,PTX3,PURA,PUS7,RAB33B,RAB3GAP2,RAB4A,RAB9A,RABEP1,RAP1,RAP1GDS1,RASA4,RASSF4,RCAN1,RCHY1,RGL2,RHOT1,RNASE2,RNASE4,RNF111,RNF146,RPE,RTN1,SAP30,SDAD1,SEC23B,SEC24A,SEC63,SERP1,SETX,SIGLEC7,SIKE1,SIP1,SLA,SLC15A2,SLC16A1,SLC16A3,SLC25A24,SLC25A40,SLC35A5,SMARCC2,SMC5,SMG1,SMPD4,SNAPC3,SRPK2,SRPRB,SS18L2,ST6GAL1,STAM2,STK3,STK38L,SULT1A2,SWAP70,TAF12,TAX1BP1,TBC1D22A,TBC1D5,TBC1D8,TBL1X,TCF3,TCP1,TCP11L1,TCTN3,TGFBRAP1,THOC7,TIA1,TJAP1,TLR6,TLR8,TM2D1,TMBIM1,TMCO1,TMEM184C,TMPO,TNF,TNFAIP1,TNFAIP3,TNFRSF1A,TNFSF10,TOB2,TOPBP1,TOR1A,TOR1AIP1,TP73-AS1,TPM1,TRAPPC10,TRIM5,TRIT1,TROVE2,TRPS1,TRRAP,TSC22D3,TSNAX,TTBK2,TTC17,TTC27,TTC3,TTC9,UBE2I,UBE2V2,UBE3B,UBE4B,UBL3,UBR4,UGDH,UGGT2,USP32,VAMP4,VAT1,VBP1,VNN1,VPS54,WBP4,WDR12,WDR7,WIPF1,WWP1,XRCC4,ZBTB10,ZBTB11,ZBTB40,ZFAND5,ZFP36L2,ZFP64,ZMPSTE24,ZMYM6,ZNF106,ZNF146,ZNF202,ZNF224,ZNF225,ZNF226,ZNF277,ZNF32,ZNF329,ZNF354A,ZNF45,ZNF580,ZNF780A,ZNF780B",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41128,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D. Comment: Supplementary Table 1a: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABHD13,ADO,AREG,ARIH2,ARL4A,ARL4C,ARMC8,ASCC3,ASH1L,ATF3,ATP1B1,ATXN7,B3GNT5,BAG5,BCL10,BCL2A1,BCL6,BCOR,BTG2,CACUL1,C11orf58,TIGAR,GPATCH2L,C15orf39,C2orf49,C5AR1,C9orf72,C9orf78,CALCOCO2,CCDC59,CCL3,CCL3L1,CCL3L3,CD55,CD6,CD83,CDADC1,CDK17,CDKN1A,CFL2,CHD1,CHMP1B,CHMP2B,CHORDC1,CLEC2B,CLK4,COX17,CPEB2,CREBRF,CREM,CRY1,CSRNP1,CTNNB1,CXCL16,CXCL2,CYLD,DDX21,DICER1,DNAJB9,DUSP1,DUSP5,DYNLL2,EGR1,EGR2,EGR3,EIF5,ELF1,ELK4,ENC1,ENPP4,EPS8,ESCO1,ETF1,ETNK1,ETV3,EXOC8,FAM117B,TENT5A,FAM53C,FBXL3,FEM1C,FGFR1,FKBP15,FOS,FOSB,FOSL2,FTH1,GABARAPL1,GABARAPL3,GADD45B,GCC1,HCAR3,GPR18,GZF1,HAVCR2,HBEGF,HEG1,HERC4,HLA-F,HNRNPC,HSPA14,ICAM1,IDI1,IFNGR1,IL1B,CXCL8,INSIG1,IRF2BP2,ITPRIP,IVNS1ABP,JARID2,KDM7A,JMJD1C,JMJD6,JUNB,JUND,KBTBD2,KBTBD8,KCNS2,SPIDR,EPG5,KLF11,KLF4,KLHL15,L3MBTL3,LATS2,LCOR,MIR23AHG,LONRF1,LRRFIP1,LYN,MAD2L1BP,MAFB,MAFF,MAFK,MALAT1,MAP3K8,MAPK1IP1L,MCL1,MCM9,MED21,MED30,MEF2D,METRNL,MEX3C,MNT,MSL2,MTMR6,MUL1,KAT7,NAMPT,NCAM1,NFE2L2,NFIL3,NFKBIE,NGRN,NLRP3,NR4A1,NR4A2,NR4A3,NSF,NUB1,NUDT15,OSM,OTUD1,TENT4B,PCGF5,PDE4D,PDP1,PDZD8,PFKFB3,PGGT1B,PHACTR1,PLAUR,PMAIP1,PPM1A,PPM1D,PPP1R15A,PPP1R15B,PPP2R2A,PRKAR1A,PRPF4B,PTGER4,PTGS2,PTP4A1,PTPRE,PTX3,PWWP2B,QKI,RAB11FIP4,RAB12,RAB18,RAB20,RAB8B,RAP2C,RASGEF1B,RBBP6,RBM15,RBM18,RBM33,RBM38,RBM7,RELT,RGS1,RGS2,RHOB,RICTOR,RIPK2,RLIM,RNF138,RNF139,RNF19A,RPS24,SAMD8,SAMSN1,SAT1,SERTAD1,SERTAD2,SERTAD3,SCAF11,SRSF3,SIK1,SLC16A6,SLC25A30,SMAD4,SNHG15,SNIP1,SNX13,SOCS1,SOCS3,SP100,SP3,SPOPL,SPTY2D1,SRGAP2,STK39,TGIF1,THBS1,TNFRSF21,TPM3,TRAF6,TRIB1,TSC22D2,TSPYL1,UQCRC2,USF3,USP30,USP42,UTRN,VEGFA,WASL,WDR48,WTAP,XPR1,YES1,YPEL5,YTHDF3,ZBTB1,ZBTB10,ZBTB33,ZBTB43,ZC3HAV1,ZCCHC2,ZFAND5,ZFC3H1,ZFP36,ZNF267,ZNF281,ZNF282,ZBTB21,ZNF326,ZNF350,ZNF506,ZNF644,ZNF703,ZNF92,ZXDA",277,"ABHD13,ADO,AREG,ARIH2,ARL4A,ARL4C,ARMC8,ASCC3,ASH1L,ATF3,ATP1B1,ATXN7,B3GNT5,BAG5,BCL10,BCL2A1,BCL6,BCOR,BTG2,C10orf46,C11orf58,C12orf5,C14orf118,C15orf39,C2orf49,C5AR1,C9orf72,C9orf78,CALCOCO2,CCDC59,CCL3,CCL3L1,CCL3L3,CD55,CD6,CD83,CDADC1,CDK17,CDKN1A,CFL2,CHD1,CHMP1B,CHMP2B,CHORDC1,CLEC2B,CLK4,COX17,CPEB2,CREBRF,CREM,CRY1,CSRNP1,CTNNB1,CXCL16,CXCL2,CYLD,DDX21,DICER1,DNAJB9,DUSP1,DUSP5,DYNLL2,EGR1,EGR2,EGR3,EIF5,ELF1,ELK4,ENC1,ENPP4,EPS8,ESCO1,ETF1,ETNK1,ETV3,EXOC8,FAM117B,FAM46A,FAM53C,FBXL3,FEM1C,FGFR1,FKBP15,FOS,FOSB,FOSL2,FTH1,GABARAPL1,GABARAPL3,GADD45B,GCC1,GPR109B,GPR18,GZF1,HAVCR2,HBEGF,HEG1,HERC4,HLA-F,HNRNPC,HSPA14,ICAM1,IDI1,IFNGR1,IL1B,IL8,INSIG1,IRF2BP2,ITPRIP,IVNS1ABP,JARID2,JHDM1D,JMJD1C,JMJD6,JUNB,JUND,KBTBD2,KBTBD8,KCNS2,KIAA0146,KIAA1632,KLF11,KLF4,KLHL15,L3MBTL3,LATS2,LCOR,LOC284454,LONRF1,LRRFIP1,LYN,MAD2L1BP,MAFB,MAFF,MAFK,MALAT1,MAP3K8,MAPK1IP1L,MCL1,MCM9,MED21,MED30,MEF2D,METRNL,MEX3C,MNT,MSL2,MTMR6,MUL1,MYST2,NAMPT,NCAM1,NFE2L2,NFIL3,NFKBIE,NGRN,NLRP3,NR4A1,NR4A2,NR4A3,NSF,NUB1,NUDT15,OSM,OTUD1,PAPD5,PCGF5,PDE4D,PDP1,PDZD8,PFKFB3,PGGT1B,PHACTR1,PLAUR,PMAIP1,PPM1A,PPM1D,PPP1R15A,PPP1R15B,PPP2R2A,PRKAR1A,PRPF4B,PTGER4,PTGS2,PTP4A1,PTPRE,PTX3,PWWP2B,QKI,RAB11FIP4,RAB12,RAB18,RAB20,RAB8B,RAP2C,RASGEF1B,RBBP6,RBM15,RBM18,RBM33,RBM38,RBM7,RELT,RGS1,RGS2,RHOB,RICTOR,RIPK2,RLIM,RNF138,RNF139,RNF19A,RPS24,SAMD8,SAMSN1,SAT1,SERTAD1,SERTAD2,SERTAD3,SFRS2IP,SFRS3,SIK1,SLC16A6,SLC25A30,SMAD4,SNHG15,SNIP1,SNX13,SOCS1,SOCS3,SP100,SP3,SPOPL,SPTY2D1,SRGAP2,STK39,TGIF1,THBS1,TNFRSF21,TPM3,TRAF6,TRIB1,TSC22D2,TSPYL1,UQCRC2,USF3,USP30,USP42,UTRN,VEGFA,WASL,WDR48,WTAP,XPR1,YES1,YPEL5,YTHDF3,ZBTB1,ZBTB10,ZBTB33,ZBTB43,ZC3HAV1,ZCCHC2,ZFAND5,ZFC3H1,ZFP36,ZNF267,ZNF281,ZNF282,ZNF295,ZNF326,ZNF350,ZNF506,ZNF644,ZNF703,ZNF92,ZXDA",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41006,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D. Comment: Supplementary Table 1b: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AARS1,AARSD1,ACADM,ACAT1,ACSL5,ACSS1,ADAM19,ADK,ADSL,AIFM1,AK2,ALG14,ALG5,ALG8,ANAPC7,ANG,ANKRD17,ANKRD36B,ANKZF1,ANTXR2,ANXA6,APEH,APOBEC3B,AQP3,ARF1,ARF4,ARIH2,ASB3,ATF6,ATG7,ATIC,ATP6V0A2,ATP8B2,ATXN2,AURKAIP1,BATF,BCAT2,BET1,BLNK,BRCC3,TMEM258,C11orf24,C11orf54,HIKESHI,METTL25,TMEM260,DTD2,C17orf80,ELP5,C1GALT1C1,C1orf56,COA5,C2orf68,TIMMDC1,C6orf89,C9orf85,NMRK1,CALU,CAMK2G,CASP2,CASP6,CAV1,CBFA2T2,PRIMPOL,CD27,CD38,CD59,CD79A,CD79B,CDC16,CDC25B,CDK13,CEP350,CHCHD7,COA4,CLCC1,CLK2,CLN5,CLPTM1,CLPTM1L,CNOT1,CNOT6,CNPY2,COBLL1,COG8,COMMD1,COMMD3,COPB2,COPE,COPG1,COPS6,COPZ1,COX18,CPSF2,CREB3,CREB3L2,CREBZF,CRLS1,CSTF3,CUTC,,DCPS,DDOST,DENND2D,DGUOK,DHPS,DHRS4-AS1,DLG1,DNAJB11,DNAJC1,DPEP2,DPM3,DPP3,DZIP3,EAF2,EBNA1BP2,ECE1,ECHDC1,ECHDC2,EDEM1,EDEM3,EDF1,EEF1A1,EIF2B4,EIF3J,EIF3M,ELP3,EMSY,ENTPD1,EPRS1,ERGIC2,ERLEC1,ESYT1,FAHD2A,FCMR,PCED1B,FAM120AOS,FAM120B,PSME3IP1,FAM200B,FAM30A,FAM3C,SUPT20H,,FAM85B,FARSB,FASTKD1,FBXL16,FBH1,FBXO9,FBXW7,FCRL5,FDPS,FKBP11,FKBP14,FKBP2,FLAD1,FLI1,FUS,G3BP1,GALM,GART,GATAD1,GCN1,GEMIN7,GGH,GIMAP1,GLCCI1,GLT8D1,GMDS,GMPPB,GNPAT,GOLGA5,GOT1,GPAA1,GPATCH1,GPR75,GRAP,GTF2A2,GTF2H1,GTF2H2,GTPBP3,HACD3,HAX1,HBS1L,HDDC2,HDDC3,HDLBP,HECA,HERC2,HERC2P3,HERC4,HEXA,HFE,HIBCH,HINT2,HIPK2,HIRIP3,H1-3,H4C11,H4C12,HM13,HMG20B,JPT2,HS2ST1,HSP90B1,HYOU1,IARS1,IDH2,IFFO1,,IGHA1,IGHA2,IGHD,IGHG1,IGHG2,IGHG3,IGHG4,IGHM,IGHV1-69,IGHV3-23,IGHV3-48,IGHV4-31,JCHAIN,,IGKC,IGKV1D-33,IGKV3-20,,IGLC1,IGLL1,IGLL5,IGLV1-44,IGLV2-23,IGLV3-16,IGLV3-19,IGLV3-25,IKBKB,IL2RA,IL6R,IMMT,INPP4A,INPP5B,IPO9,IPP,ISG20,ITGB7,ITM2C,KCNK6,KDELR1,KDELR2,KDSR,KHDC4,BLTP2,KIAA1143,KIF3B,KLHDC10,KLHL14,KRI1,KRIT1,KRTCAP2,L3MBTL2,LARP4B,LDAH,LDLRAP1,,ERCC6L2-AS1,LINC01138,LMAN1,LMAN2,,,PGM5-AS1,ENSG00000272447,,LPXN,LRCH3,LRIG2,LSM4,LUC7L,LXN,MAD1L1,MAN1A1,MANF,MAP3K7,MARK2,MCCC2,MCM3,MCM7,MCTS1,MDS2,MED16,MED17,MEGF6,METTL2A,METTL2B,METTL3,METTL8,MFF,MFNG,MFSD8,MIAT,MID1,MITD1,MLEC,MON2,MPHOSPH9,MRI1,MRPL23,MRPL24,MRPL34,MRPL37,MRPL41,MRPS16,MRPS18A,MRPS18B,MRPS31,MRPS33,MRPS7,MRTO4,MS4A1,MTAP,MTDH,MTHFD1,MTIF3,MTMR4,MTRF1,BLOC1S5,MYDGF,MZB1,NAA20,NAIP,NBPF1,NCL,NCOA3,FTX,NDOR1,NDST1,NDUFAF3,NDUFC1,NFATC2IP,NIPAL3,NIPSNAP1,NIT1,NMRAL1,NMT1,NNT,NOMO1,NOMO2,NPAT,NPHP3,NSD2,NSUN5,NSUN5P1,NSUN5P2,NT5C2,NT5DC1,NUDT5,NUDT9,NUP210,NUP37,NUP43,NVL,OCIAD1,OGDH,OGFOD1,OGT,ORC3,ORMDL1,OSBPL10,OSTC,P2RX5,P4HB,PAAF1,PABPC1L,PAICS,PAQR8,PBRM1,PCID2,PCLAF,PDCD11,PDF,PDHA1,PDIA4,PDIA5,PDIA6,PFDN6,PHB1,PHKB,PI4KB,PIGF,PIGP,PIGU,PIK3C2A,PILRB,PLA2G6,PMS1,PMS2P2,PNOC,POC5,POLR2H,POLR2J2,POLR2L,POLR3A,POP5,POU2AF1,PLPP5,PPIB,PPP1R21,PPP1R3E,PPP6R3,PRDM15,PRDX4,PREB,PRIM1,PRKCI,PRKDC,PRMT1,PLPBP,PRPSAP1,PSMB5,PSMC3,PSME3,PTPRCAP,PYCR2,QRSL1,QSOX1,RAB3GAP1,RAB3GAP2,RABAC1,RAD17,RAI1,RALGAPB,RBM41,RBM5,RBM6,RER1,REXO2,RNF34,RPA3,RPN1,RPN2,RPRD1A,RPS27A,RRM2,S100PBP,SAMM50,SAR1B,SDF2L1,SEC11C,SEC23B,SEC24A,SEC61A1,SEL1L,SEL1L3,SETD5,SETDB2,,SRSF1,SHMT2,SIRPG,SLAMF1,SLAMF6,SLAMF7,SLC26A2,SLC30A5,SLC30A6,SLC30A7,SLC33A1,SLC35B3,SLC35E2A,SLC44A1,SMC4,SNAPC5,SNORA28,SNORD104,SNRNP25,SNX19,SP3,SPATS2,SPCS2,SPCS3,SPIN3,SPOP,SPTBN1,SRM,SRP54,SRPRB,SSR1,SSR3,ST6GAL1,STAT5B,STK38,STT3A,STYX,SUB1,SYNRG,TAF12,TAPBPL,TBC1D14,TBCE,TCF12,TCF7,TCTN2,TERF2,TFB1M,THEM4,TIMM13,TMBIM4,TMC6,TMED9,TMEM156,TMEM165,STING1,TMEM19,TMEM204,TMEM214,TMEM223,TNFRSF13B,TNFRSF17,TNIP1,TOR3A,TPD52,TRAF5,TRAM2,TRIB2,TRIM52,TRIM73,TRRAP,TRUB2,TSC1,TTC1,TRAPPC12,TTC17,TUBD1,TXNDC15,TXNDC5,TYMS,UBA5,UBAP2,UBASH3A,UBE2G1,UBE2J1,UBE4B,UBXN8,UCP2,UGGT1,UPF3A,UQCRQ,USO1,USP28,USP45,USP48,UXS1,VAMP1,VAPA,VPS29,VPS8,VRK3,WASHC3,WDR46,DNAAF10,WIPI1,YIF1A,ZBTB8OS,ZDHHC13,ZFX,ZKSCAN1,ZMYM5,MSS51,ZNF207,ZNF318,ZNF512,ZNF514,ZNF573,ZNF585B,ZNF638,ZNF692,ZNF717,KRBOX5,ZNF818P,ZNHIT1,ZWINT",583,"AARS,AARSD1,ACADM,ACAT1,ACSL5,ACSS1,ADAM19,ADK,ADSL,AIFM1,AK2,ALG14,ALG5,ALG8,ANAPC7,ANG,ANKRD17,ANKRD36B,ANKZF1,ANTXR2,ANXA6,APEH,APOBEC3B,AQP3,ARF1,ARF4,ARIH2,ASB3,ATF6,ATG7,ATIC,ATP6V0A2,ATP8B2,ATXN2,AURKAIP1,BATF,BCAT2,BET1,BLNK,BRCC3,C11orf10,C11orf24,C11orf54,C11orf73,C12orf26,C14orf101,C14orf126,C17orf80,C17orf81,C1GALT1C1,C1orf56,C2orf64,C2orf68,C3orf1,C6orf89,C9orf85,C9orf95,CALU,CAMK2G,CASP2,CASP6,CAV1,CBFA2T2,CCDC111,CD27,CD38,CD59,CD79A,CD79B,CDC16,CDC25B,CDK13,CEP350,CHCHD7,CHCHD8,CLCC1,CLK2,CLN5,CLPTM1,CLPTM1L,CNOT1,CNOT6,CNPY2,COBLL1,COG8,COMMD1,COMMD3,COPB2,COPE,COPG,COPS6,COPZ1,COX18,CPSF2,CREB3,CREB3L2,CREBZF,CRLS1,CSTF3,CUTC,CYAT1,DCPS,DDOST,DENND2D,DGUOK,DHPS,DHRS4-AS1,DLG1,DNAJB11,DNAJC1,DPEP2,DPM3,DPP3,DZIP3,EAF2,EBNA1BP2,ECE1,ECHDC1,ECHDC2,EDEM1,EDEM3,EDF1,EEF1A1,EIF2B4,EIF3J,EIF3M,ELP3,EMSY,ENTPD1,EPRS,ERGIC2,ERLEC1,ESYT1,FAHD2A,FAIM3,FAM113B,FAM120AOS,FAM120B,FAM192A,FAM200B,FAM30A,FAM3C,FAM48A,FAM85A,FAM85B,FARSB,FASTKD1,FBXL16,FBXO18,FBXO9,FBXW7,FCRL5,FDPS,FKBP11,FKBP14,FKBP2,FLAD1,FLI1,FUS,G3BP1,GALM,GART,GATAD1,GCN1,GEMIN7,GGH,GIMAP1,GLCCI1,GLT8D1,GMDS,GMPPB,GNPAT,GOLGA5,GOT1,GPAA1,GPATCH1,GPR75,GRAP,GTF2A2,GTF2H1,GTF2H2,GTPBP3,HACD3,HAX1,HBS1L,HDDC2,HDDC3,HDLBP,HECA,HERC2,HERC2P3,HERC4,HEXA,HFE,HIBCH,HINT2,HIPK2,HIRIP3,HIST1H1D,HIST1H4J,HIST1H4K,HM13,HMG20B,HN1L,HS2ST1,HSP90B1,HYOU1,IARS,IDH2,IFFO1,IGH,IGHA1,IGHA2,IGHD,IGHG1,IGHG2,IGHG3,IGHG4,IGHM,IGHV1-69,IGHV3-23,IGHV3-48,IGHV4-31,IGJ,IGK,IGKC,IGKV1D-33,IGKV3-20,IGL,IGLC1,IGLL1,IGLL5,IGLV1-44,IGLV2-23,IGLV3-16,IGLV3-19,IGLV3-25,IKBKB,IL2RA,IL6R,IMMT,INPP4A,INPP5B,IPO9,IPP,ISG20,ITGB7,ITM2C,KCNK6,KDELR1,KDELR2,KDSR,KHDC4,KIAA0100,KIAA1143,KIF3B,KLHDC10,KLHL14,KRI1,KRIT1,KRTCAP2,L3MBTL2,LARP4B,LDAH,LDLRAP1,LINC00260,LINC00476,LINC01138,LMAN1,LMAN2,LOC100132741,LOC100290036,LOC572558,LOC642361,LOC729683,LPXN,LRCH3,LRIG2,LSM4,LUC7L,LXN,MAD1L1,MAN1A1,MANF,MAP3K7,MARK2,MCCC2,MCM3,MCM7,MCTS1,MDS2,MED16,MED17,MEGF6,METTL2A,METTL2B,METTL3,METTL8,MFF,MFNG,MFSD8,MIAT,MID1,MITD1,MLEC,MON2,MPHOSPH9,MRI1,MRPL23,MRPL24,MRPL34,MRPL37,MRPL41,MRPS16,MRPS18A,MRPS18B,MRPS31,MRPS33,MRPS7,MRTO4,MS4A1,MTAP,MTDH,MTHFD1,MTIF3,MTMR4,MTRF1,MUTED,MYDGF,MZB1,NAA20,NAIP,NBPF1,NCL,NCOA3,NCRNA00182,NDOR1,NDST1,NDUFAF3,NDUFC1,NFATC2IP,NIPAL3,NIPSNAP1,NIT1,NMRAL1,NMT1,NNT,NOMO1,NOMO2,NPAT,NPHP3,NSD2,NSUN5,NSUN5P1,NSUN5P2,NT5C2,NT5DC1,NUDT5,NUDT9,NUP210,NUP37,NUP43,NVL,OCIAD1,OGDH,OGFOD1,OGT,ORC3,ORMDL1,OSBPL10,OSTC,P2RX5,P4HB,PAAF1,PABPC1L,PAICS,PAQR8,PBRM1,PCID2,PCLAF,PDCD11,PDF,PDHA1,PDIA4,PDIA5,PDIA6,PFDN6,PHB,PHKB,PI4KB,PIGF,PIGP,PIGU,PIK3C2A,PILRB,PLA2G6,PMS1,PMS2L2,PNOC,POC5,POLR2H,POLR2J2,POLR2L,POLR3A,POP5,POU2AF1,PPAPDC1B,PPIB,PPP1R21,PPP1R3E,PPP6R3,PRDM15,PRDX4,PREB,PRIM1,PRKCI,PRKDC,PRMT1,PROSC,PRPSAP1,PSMB5,PSMC3,PSME3,PTPRCAP,PYCR2,QRSL1,QSOX1,RAB3GAP1,RAB3GAP2,RABAC1,RAD17,RAI1,RALGAPB,RBM41,RBM5,RBM6,RER1,REXO2,RNF34,RPA3,RPN1,RPN2,RPRD1A,RPS27A,RRM2,S100PBP,SAMM50,SAR1B,SDF2L1,SEC11C,SEC23B,SEC24A,SEC61A1,SEL1L,SEL1L3,SETD5,SETDB2,SF3B14,SFRS1,SHMT2,SIRPG,SLAMF1,SLAMF6,SLAMF7,SLC26A2,SLC30A5,SLC30A6,SLC30A7,SLC33A1,SLC35B3,SLC35E2,SLC44A1,SMC4,SNAPC5,SNORA28,SNORD104,SNRNP25,SNX19,SP3,SPATS2,SPCS2,SPCS3,SPIN3,SPOP,SPTBN1,SRM,SRP54,SRPRB,SSR1,SSR3,ST6GAL1,STAT5B,STK38,STT3A,STYX,SUB1,SYNRG,TAF12,TAPBPL,TBC1D14,TBCE,TCF12,TCF7,TCTN2,TERF2,TFB1M,THEM4,TIMM13,TMBIM4,TMC6,TMED9,TMEM156,TMEM165,TMEM173,TMEM19,TMEM204,TMEM214,TMEM223,TNFRSF13B,TNFRSF17,TNIP1,TOR3A,TPD52,TRAF5,TRAM2,TRIB2,TRIM52,TRIM73,TRRAP,TRUB2,TSC1,TTC1,TTC15,TTC17,TUBD1,TXNDC15,TXNDC5,TYMS,UBA5,UBAP2,UBASH3A,UBE2G1,UBE2J1,UBE4B,UBXN8,UCP2,UGGT1,UPF3A,UQCRQ,USO1,USP28,USP45,USP48,UXS1,VAMP1,VAPA,VPS29,VPS8,VRK3,WASHC3,WDR46,WDR92,WIPI1,YIF1A,ZBTB8OS,ZDHHC13,ZFX,ZKSCAN1,ZMYM5,ZMYND17,ZNF207,ZNF318,ZNF512,ZNF514,ZNF573,ZNF585B,ZNF638,ZNF692,ZNF717,ZNF720,ZNF818P,ZNHIT1,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41199,FLUARIX FLUVIRIN,IN,INFLUENZA,NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in plasmacytoid dendritic cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ADAM28,ADCK2,TLE5,AIFM1,,AKAP6,ALDH5A1,AMMECR1,APAF1,APEX2,APLP2,ARIH1,ARNT,ARRB2,ATF7IP,ATP10A,ATP5MC2,BACH1,BAX,BLVRA,BRD3OS,TMEM260,SZRD1,CALML4,CAMSAP1,CARD8,CBLB,CCNA2,CD180,CD22,CD40,CD69,CD86,CDC25A,CDC42EP3,CDHR5,CENPO,CEP135,CFLAR,CLUAP1,CNOT4,COL9A3,COTL1,CRABP2,CRIM1,CTSO,CTSZ,DEDD,DHX34,DHX40,DLG1,DNAJB6,DPP4,VPS26C,EEA1,EGR1,EIF4A1,ELP4,EPB41L3,EYA3,F11R,TASOR,DENND10,FAR2,FEM1B,FOXO3,TIMM10B,GABBR1,GABPB1,GADD45B,GGPS1,GLO1,GNL3L,GOLGA2,GPR52,HBS1L,HECTD3,HEXIM1,HGSNAT,HIPK3,H2AC18,H2AC19,HSD17B8,,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHG4,IGHM,IGHV3-23,IL10RB,IL6R,IPCEF1,IPO5,IQGAP1,IRF3,ISG20L2,ITSN2,JUN,KDM5B,KIF2A,KLF9,KLHL28,KPNA6,KRAS,KRT86,KYNU,LAIR1,LGALS8,LILRA1,LIMK2,LPIN1,LRRC37A2,MAP3K7,MARCKS,MEF2C,MRPS18C,MTAP,MTSS1,MYC,NCOR1,NEAT1,NIPBL,NMB,NOLC1,NRP1,NTM,OAS3,PAK2,PALM2AKAP2,PCBP2,PDE4DIP,PFN2,PIH1D1,PLBD1,PMAIP1,POLR2A,POM121,POM121C,PPIA,PRKCA,PRPF4B,PSEN1,PSME3,PTGS2,PTK2,PTPN12,RABGGTB,RAD21,RALBP1,RALGAPB,RASA2,RBM12B,RBMX,RGPD5,RGPD6,RGPD8,RHOB,RHOQ,RRP9,S100A2,SAR1A,SCO2,SEC14L1,SF1,SRSF11,SCAF11,SFSWAP,SIGLEC6,SIK3,SLC12A3,SLC17A5,SLC2A14,SLC2A3,SLC35D1,SLC4A7,SMAD2,SNX27,SP4,SPEN,SRRT,STX11,STX16,STX17,STX5,SULT1A1,SULT1A3,SULT1A4,TAOK3,TCOF1,TFDP2,THBS1,TIMP2,TLE4,TMCC1,TMEM135,TMPO,TMUB2,TNFRSF10B,TNFSF12-TNFSF13,TNFSF13,TNIP1,TNPO2,TP53I3,TRIM33,TRPS1,UBA7,UBXN4,WASHC4,WDFY3,WSB1,ZBED4,ZFP36L1,ZGPAT,ZMAT3,ZMYND8,ZNF148,ZPR1,ZNF593",221,"ADAM28,ADCK2,AES,AIFM1,AKAP2,AKAP6,ALDH5A1,AMMECR1,APAF1,APEX2,APLP2,ARIH1,ARNT,ARRB2,ATF7IP,ATP10A,ATP5G2,BACH1,BAX,BLVRA,BRD3OS,C14orf101,C1orf144,CALML4,CAMSAP1,CARD8,CBLB,CCNA2,CD180,CD22,CD40,CD69,CD86,CDC25A,CDC42EP3,CDHR5,CENPO,CEP135,CFLAR,CLUAP1,CNOT4,COL9A3,COTL1,CRABP2,CRIM1,CTSO,CTSZ,DEDD,DHX34,DHX40,DLG1,DNAJB6,DPP4,DSCR3,EEA1,EGR1,EIF4A1,ELP4,EPB41L3,EYA3,F11R,FAM208A,FAM45A,FAR2,FEM1B,FOXO3,FXC1,GABBR1,GABPB1,GADD45B,GGPS1,GLO1,GNL3L,GOLGA2,GPR52,HBS1L,HECTD3,HEXIM1,HGSNAT,HIPK3,HIST2H2AA3,HIST2H2AA4,HSD17B8,IGH,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHG4,IGHM,IGHV3-23,IL10RB,IL6R,IPCEF1,IPO5,IQGAP1,IRF3,ISG20L2,ITSN2,JUN,KDM5B,KIF2A,KLF9,KLHL28,KPNA6,KRAS,KRT86,KYNU,LAIR1,LGALS8,LILRA1,LIMK2,LPIN1,LRRC37A2,MAP3K7,MARCKS,MEF2C,MRPS18C,MTAP,MTSS1,MYC,NCOR1,NEAT1,NIPBL,NMB,NOLC1,NRP1,NTM,OAS3,PAK2,PALM2-AKAP2,PCBP2,PDE4DIP,PFN2,PIH1D1,PLBD1,PMAIP1,POLR2A,POM121,POM121C,PPIA,PRKCA,PRPF4B,PSEN1,PSME3,PTGS2,PTK2,PTPN12,RABGGTB,RAD21,RALBP1,RALGAPB,RASA2,RBM12B,RBMX,RGPD5,RGPD6,RGPD8,RHOB,RHOQ,RRP9,S100A2,SAR1A,SCO2,SEC14L1,SF1,SFRS11,SFRS2IP,SFRS8,SIGLEC6,SIK3,SLC12A3,SLC17A5,SLC2A14,SLC2A3,SLC35D1,SLC4A7,SMAD2,SNX27,SP4,SPEN,SRRT,STX11,STX16,STX17,STX5,SULT1A1,SULT1A3,SULT1A4,TAOK3,TCOF1,TFDP2,THBS1,TIMP2,TLE4,TMCC1,TMEM135,TMPO,TMUB2,TNFRSF10B,TNFSF12-TNFSF13,TNFSF13,TNIP1,TNPO2,TP53I3,TRIM33,TRPS1,UBA7,UBXN4,WASHC4,WDFY3,WSB1,ZBED4,ZFP36L1,ZGPAT,ZMAT3,ZMYND8,ZNF148,ZNF259,ZNF593",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40950,INFLUENZA,IN,INFLUENZA,HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in B cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ARRDC3,CD1A,DACT1,HAVCR2,IGKV1-6,PEAK3,PEX11G,PRRT2,SRP54-AS1",9,"ARRDC3,CD1A,DACT1,HAVCR2,IGKV1-6,PEAK3,PEX11G,PRRT2,SRP54-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41186,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in monocyte 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"CD40,EREG,ETV7,G0S2,GOLGA8N,TAMALIN,KLHDC7B,LINC01888,OSM,P2RY6,SIK1,TMOD4,TTLL1,ZBTB11-AS1",14,"CD40,EREG,ETV7,G0S2,GOLGA8N,GRASP,KLHDC7B,LINC01888,OSM,P2RY6,SIK1,TMOD4,TTLL1,ZBTB11-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supplemental_Information.docx,NA,NA,NA,NA
M41145,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in myeloid dendritic cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"DND1,GBP5,LINC00920,NLGN3,PFKFB3,RN7SK,SDC3,SMTNL1,TMEM88",9,"DND1,GBP5,LINC00920,NLGN3,PFKFB3,RN7SK,SDC3,SMTNL1,TMEM88",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 1D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supp_Fig_1.tiff,NA,NA,NA,NA
M41049,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in neutrophil 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"AP1M2,APEX2,APOBEC3D,APOL3,ATF3,BATF2,CCDC85B,CMPK2,COA6,DIMT1,EPSTI1,ETV7,FRMD3,GBP5,GBP6,H2BC11,HEBP1,IFI44,IFI44L,IFI6,IFITM3,IFT52,ISG15,LILRA4,LIMK1,LY6E,NASP,NRIR,NUP54,OAS1,OAS2,OAS3,OSM,PNPT1,PPDPF,RILP,RSAD2,RTP4,SERPING1,SRXN1",40,"AP1M2,APEX2,APOBEC3D,APOL3,ATF3,BATF2,CCDC85B,CMPK2,COA6,DIMT1,EPSTI1,ETV7,FRMD3,GBP5,GBP6,H2BC11,HEBP1,IFI44,IFI44L,IFI6,IFITM3,IFT52,ISG15,LILRA4,LIMK1,LY6E,NASP,NRIR,NUP54,OAS1,OAS2,OAS3,OSM,PNPT1,PPDPF,RILP,RSAD2,RTP4,SERPING1,SRXN1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/bin/NIHMS880612-supplement-Supplemental_Information.docx,NA,NA,NA,NA
M41078,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_7D_VS_0DY_ADULT_7D_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_7D_VS_0DY_ADULT_7D_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in natural killer cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"AVPR2,CFAP68,CDC45,DTL,FOSB,GINS2,GOLGA8R,JUN,KIF15,MCM10,MORN1,OAF,ODC1-DT,PKMYT1,PNMT,PODXL,RAD51,RAD54L,RNU1-1",19,"AVPR2,C11orf1,CDC45,DTL,FOSB,GINS2,GOLGA8R,JUN,KIF15,MCM10,MORN1,OAF,ODC1-DT,PKMYT1,PNMT,PODXL,RAD51,RAD54L,RNU1-1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1: Late gene expression (Day 28 - Day 0),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520794/table/T1/,NA,NA,NA,NA
M41146,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_DN,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 7D. Comment: Down-regulated DE RNA transcripts (down >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADM,ANKRD22,BATF2,C2,CABP5,CDKN1A,EPB41L4A,EREG,H2BC11,HBEGF,IGHV3-13,IGKV1-27,KCNJ15,LIPN,MXD1,OSM,RAB20,RNU6-1,SDC3,THBD,,VNN3P,ZMYND15",23,"ADM,ANKRD22,BATF2,C2,CABP5,CDKN1A,EPB41L4A,EREG,H2BC11,HBEGF,IGHV3-13,IGKV1-27,KCNJ15,LIPN,MXD1,OSM,RAB20,RNU6-1,SDC3,THBD,TMX2-CTNND1,VNN3,ZMYND15",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 11,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40963,INFLUENZA,IN,INFLUENZA,HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,B CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_B_CELL_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in B cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADHFE1,AICDA,AQP3,BHLHA15,BLOC1S5-TXNDC5,BMP6,CAV1,CDKN2C,CHPF,CXCR3,DCAF12,DHRS9,FNDC3B,FOS,GOLGA8O,HBA2,HBB,IGHG1,IGHJ2,IGHV3-20,IGKV3-7,IGKV3D-20,IGLC2,IGLV3-19,IGLV3-21,MYDGF,NBPF11,NBPF15,NRGN,NT5DC2,NUCB2,PIF1,POU4F1,RCBTB2,RFLNB,RRM2,S100A9,SCAMP5,SDC1,SDF2L1,SLAMF7,TGM2,TNFRSF17,TPX2,TXNDC5,VDR,XBP1,ZWINT",48,"ADHFE1,AICDA,AQP3,BHLHA15,BLOC1S5-TXNDC5,BMP6,CAV1,CDKN2C,CHPF,CXCR3,DCAF12,DHRS9,FNDC3B,FOS,GOLGA8O,HBA2,HBB,IGHG1,IGHJ2,IGHV3-20,IGKV3-7,IGKV3D-20,IGLC2,IGLV3-19,IGLV3-21,MYDGF,NBPF11,NBPF15,NRGN,NT5DC2,NUCB2,PIF1,POU4F1,RCBTB2,RFLNB,RRM2,S100A9,SCAMP5,SDC1,SDF2L1,SLAMF7,TGM2,TNFRSF17,TPX2,TXNDC5,VDR,XBP1,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 2e,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F2/,NA,NA,NA,NA
M40946,INFLUENZA,IN,INFLUENZA,HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,MONOCYTE,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MONOCYTE_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in monocyte 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"CCNE2,FCMR,GPHN,HBB,MIR374B,N6AMT1,SLX1B,TRBC2,DNAAF10",9,"CCNE2,FCMR,GPHN,HBB,MIR374B,N6AMT1,SLX1B,TRBC2,WDR92",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S1 Table,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443534/bin/pntd.0005527.s002.xls,NA,NA,NA,NA
M41009,INFLUENZA,IN,INFLUENZA,HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_MYELOID_DENDRITIC_CELL_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in myeloid dendritic cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADAMTS10,ADORA1,B3GNT7,BOLA2B,BTLA,CARD11,CCDC65,CCR5AS,CD2,CLEC9A,DPP4,GPX7,IDO1,KIT,KLRB1,LPL,MACORIS,MATK,MSLN,PRKCH,PTX3,S100A12,SEPTIN1,SEPTIN3,SIGLEC6,TLE1,TRBV7-3",27,"ADAMTS10,ADORA1,B3GNT7,BOLA2B,BTLA,CARD11,CCDC65,CCR5AS,CD2,CLEC9A,DPP4,GPX7,IDO1,KIT,KLRB1,LPL,MACORIS,MATK,MSLN,PRKCH,PTX3,S100A12,SEPTIN1,SEPTIN3,SIGLEC6,TLE1,TRBV7-3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,NA,NA,NA,NA,NA
M40955,INFLUENZA,IN,INFLUENZA,HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,NEUTROPHIL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NEUTROPHIL_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in neutrophil 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ADORA3,ALOX15,C12orf60,CD52,CLC,CYSLTR2,DDB2,DOK2,,INSYN2B,KLF9,MIAT,NCR1,NPIPB3,PRSS33,PTGDR2,,SAYSD1,SEMG1,SIGLEC8,SLC29A1,SMPD3",22,"ADORA3,ALOX15,C12orf60,CD52,CLC,CYSLTR2,DDB2,DOK2,EURL-OT1,INSYN2B,KLF9,MIAT,NCR1,NPIPB3,PRSS33,PTGDR2,RNA18S5,SAYSD1,SEMG1,SIGLEC8,SLC29A1,SMPD3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F5/,NA,NA,NA,NA
M41014,INFLUENZA,IN,INFLUENZA,HOEK_NK_CELL_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,NK CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_NK_CELL_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in natural killer cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ANKRD30BL,ANXA9,ATP4A,C1D,CLHC1,DLG2,EIF3C,HFM1,IGHA1,IGHM,JCHAIN,PPBP,PRSS33,RYR2,CAVIN2,SIAH1,SIRPG,SLCO5A1",18,"ANKRD30BL,ANXA9,ATP4A,C1D,CLHC1,DLG2,EIF3C,HFM1,IGHA1,IGHM,IGJ,PPBP,PRSS33,RYR2,SDPR,SIAH1,SIRPG,SLCO5A1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M41093,INFLUENZA,IN,INFLUENZA,HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_PBMC_INACTIVATED_INFLUENZA_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in adults after exposure to Inactivated influenza vaccine , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ALAS2,BHLHA15,C22orf15,CPXM1,CTSG,CXCR3,DEPTOR,DNAI2,GTF2H2C,HBA1,HERC2P3,HSD11B1L,IGHG1,IGHG2,IGHG3,IGHG4,IGHJ2,IGHV1-46,IGHV1-58,IGHV1-69,IGHV2-26,IGHV3-20,IGHV3-7,IGHV4-39,IGHV6-1,IGLC1,IGLC2,IGLC3,IGLJ3,IGLL5,IGLV1-36,IGLV1-44,IGLV1-51,IGLV2-14,IGLV2-18,IGLV3-1,IGLV3-19,IGLV3-21,MEF2C-AS2,NT5DC2,OLMALINC,SFRP5,SLX1A,STX1B,SULT1A3,TMEM121,TRAV38-1,TRBV30,UPK2",49,"ALAS2,BHLHA15,C22orf15,CPXM1,CTSG,CXCR3,DEPTOR,DNAI2,GTF2H2C,HBA1,HERC2P3,HSD11B1L,IGHG1,IGHG2,IGHG3,IGHG4,IGHJ2,IGHV1-46,IGHV1-58,IGHV1-69,IGHV2-26,IGHV3-20,IGHV3-7,IGHV4-39,IGHV6-1,IGLC1,IGLC2,IGLC3,IGLJ3,IGLL5,IGLV1-36,IGLV1-44,IGLV1-51,IGLV2-14,IGLV2-18,IGLV3-1,IGLV3-19,IGLV3-21,MEF2C-AS2,NT5DC2,OLMALINC,SFRP5,SLX1A,STX1B,SULT1A3,TMEM121,TRAV38-1,TRBV30,UPK2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/bin/NIHMS29119-supplement-sup_tbl1.xls,NA,NA,NA,NA
M40898,INFLUENZA,IN,INFLUENZA,HOEK_T_CELL_2011_2012_TIV_ADULT_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,ADULT,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOEK_T_CELL_2011_2012_TIV_ADULT_7DY_UP,"Systems biology is an approach to comprehensively study complex interactions within a biological system. Most published systems vaccinology studies have utilized whole blood or peripheral blood mononuclear cells (PBMC) to monitor the immune response after vaccination. Because human blood is comprised of multiple hematopoietic cell types, the potential for masking responses of under-represented cell populations is increased when analyzing whole blood or PBMC. To investigate the contribution of individual cell types to the immune response after vaccination, we established a rapid and efficient method to purify human T and B cells, natural killer (NK) cells, myeloid dendritic cells (mDC), monocytes, and neutrophils from fresh venous blood. Purified cells were fractionated and processed in a single day. RNA-Seq and quantitative shotgun proteomics were performed to determine expression profiles for each cell type prior to and after inactivated seasonal influenza vaccination. Our results show that transcriptomic and proteomic profiles generated from purified immune cells differ significantly from PBMC. Differential expression analysis for each immune cell type also shows unique transcriptomic and proteomic expression profiles as well as changing biological networks at early time points after vaccination. This cell type-specific information provides a more comprehensive approach to monitor vaccine responses.","Genes up-regulated in T cell 7d vs 0d in adults after exposure to 2011-2012 trivalent inactivated vaccine (A/California/7/09 (H1N1), A/Perth /16/2009 (H3N2), B/Brisbane/60/2008) , time point 7D. Comment: Up-regulated DE RNA transcripts (up >= 1.5x) shared between both TIV-vaccinated donors","Hoek KL,Samir P,Howard LM,Niu X,Prasad N,Galassie A,Liu Q,Allos TM,Floyd KA,Guo Y,Shyr Y,Levy SE,Joyce S,Edwards KM,Link AJ",25706537,HUMAN_GENE_SYMBOL,"ANKRD30BL,CASP5,CCDC34,H3C1,LINC01063,NPIPB12,PI4KAP2,SIGLEC17P",8,"ANKRD30BL,CASP5,CCDC34,H3C1,LINC01063,NPIPB12,PI4KAP2,SIGLEC17P",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6A (PO),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M41194,PANDEMRIX,IN,INFLUENZA,SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-64,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_PBMC_PANDEMRIX_AGE_18_64YO_7DY_DN,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 1d in adults (18-64) after exposure to Pandemrix , time point 7D","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"APOBEC3A,APOBEC3B,CXCL10,CXCL9,GBP1,GBP2,GBP4,GBP5,IDO1,IFI27,IFI30,IFI35,IFI44,IFIT1,IFIT2,IFIT3,IFITM1,IFITM2,IFNAR1,IFNAR2,IFNGR1,IFNGR2,MX1,MX2,OAS1,OAS2,OAS3,OASL,PSMB8,SERPINA1,SERPING1,TRIM22,WARS1",33,"APOBEC3A,APOBEC3B,CXCL10,CXCL9,GBP1,GBP2,GBP4,GBP5,IDO1,IFI27,IFI30,IFI35,IFI44,IFIT1,IFIT2,IFIT3,IFITM1,IFITM2,IFNAR1,IFNAR2,IFNGR1,IFNGR2,MX1,MX2,OAS1,OAS2,OAS3,OASL,PSMB8,SERPINA1,SERPING1,TRIM22,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 6,http://links.lww.com/QAD/A314,NA,NA,NA,NA
M41206,PANDEMRIX,IN,INFLUENZA,SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-64,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SOBOLEV_T_CELL_PANDEMRIX_AGE_18_64YO_7DY_DN,"Adjuvanted vaccines afford invaluable protection against disease, and the molecular and cellular changes they induce offer direct insight into human immunobiology. Here we show that within 24 h of receiving adjuvanted swine flu vaccine, healthy individuals made expansive, complex molecular and cellular responses that included overt lymphoid as well as myeloid contributions. Unexpectedly, this early response was subtly but significantly different in people older than ~35 years. Wide-ranging adverse clinical events can seriously confound vaccine adoption, but whether there are immunological correlates of these is unknown. Here we identify a molecular signature of adverse events that was commonly associated with an existing B cell phenotype. Thus immunophenotypic variation among healthy humans may be manifest in complex pathophysiological responses.","Genes down-regulated in T cell 7d vs 1d in adults (18-64) after exposure to Pandemrix (A/California/7/09 (H1N1)) , time point 7D. Comment: - roughly 60/40 female:male ratio, over 70% were Causasian","Sobolev O,Binda E,O'Farrell S,Lorenc A,Pradines J,Huang Y,Duffner J,Schulz R,Cason J,Zambon M,Malim MH,Peakman M,Cope A,Capila I,Kaundinya GV,Hayday AC",26726811,HUMAN_GENE_SYMBOL,"CD247,CD3D,CD3E,CD3G,CD8A,CD8B,FYN,LAT,LCK,MAP4K1,NFATC1,NFATC2,NFATC3,PAG1,PLCG1,PRF1,PRKCQ,RASGRP1,RASGRP2,SLA2,ZAP70",21,"CD247,CD3D,CD3E,CD3G,CD8A,CD8B,FYN,LAT,LCK,MAP4K1,NFATC1,NFATC2,NFATC3,PAG1,PLCG1,PRF1,PRKCQ,RASGRP1,RASGRP2,SLA2,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4B-D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/fig04/,NA,NA,NA,NA
M40910,INACTIVATED INFLUENZA,IN,INFLUENZA,THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_VS_21_30YO_0DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D0,D,0,70+,ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_70PLS_VS_21_30YO_0DY_UP,"To elucidate gene expression pathways underlying age-associated impairment in influenza vaccine response, we screened young (age 21-30) and older (age >= 65) adults receiving influenza vaccine in two consecutive seasons and identified those with strong or absent response to vaccine, including a subset of older adults meeting criteria for frailty. PBMCs obtained prior to vaccination (Day 0) and at day 2 or 4, day 7 and day 28 post-vaccine were subjected to gene expression microarray analysis. We defined a response signature and also detected induction of a type I interferon response at day 2 and a plasma cell signature at day 7 post-vaccine in young responders. The response signature was dysregulated in older adults, with the plasma cell signature induced at day 2, and was never induced in frail subjects (who were all non-responders). We also identified a mitochondrial signature in young vaccine responders containing genes mediating mitochondrial biogenesis and oxidative phosphorylation that was consistent in two different vaccine seasons and verified by analyses of mitochondrial content and protein expression. These results represent the first genome-wide transcriptional profiling analysis of age-associated dynamics following influenza vaccination, and implicate changes in mitochondrial biogenesis and function as a critical factor in human vaccine responsiveness.","Genes up-regulated in peripheral blood mononuclear cell seniors vs young adults in seniors (70+), young adults (21-30) after exposure to Inactivated influenza vaccine , time point 0D","Thakar J,Mohanty S,West AP,Joshi SR,Ueda I,Wilson J,Meng H,Blevins TP,Tsang S,Trentalange M,Siconolfi B,Park K,Gill TM,Belshe RB,Kaech SM,Shadel GS,Kleinstein SH,Shaw AC",25596819,HUMAN_GENE_SYMBOL,"ARL6IP1,GBP5,ITGB1,LPAR6,REEP5",5,"ARL6IP1,GBP5,ITGB1,LPAR6,REEP5",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_tcl_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41102,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 1d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 1D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"CACNA2D2,FAM209B,ORM1,PGM3,PHOSPHO2,TGM3",6,"CACNA2D2,FAM209B,ORM1,PGM3,PHOSPHO2,TGM3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41151,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_1DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 1d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 1D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"BATF2,FCGR1A,FCGR1BP,IDO1,IFIT3,IDO1,SERPING1",7,"BATF2,FCGR1A,FCGR1B,IDO1,IFIT3,INDO,SERPING1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_nkc_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41104,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D30,D,30,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 30d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 30D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"AIFM1,CCDC51,CTDSP1,P2RY14,PHOSPHO2,TMEM106A,TMEM229B,USP1",8,"AIFM1,CCDC51,CTDSP1,P2RY14,PHOSPHO2,TMEM106A,TMEM229B,USP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41197,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D30,D,30,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_30DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 30d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 30D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"ADCK5,ALG3,BTRC,DUSP10,METTL2A,SALL2,SPRING1,TSHZ2",8,"ADCK5,ALG3,BTRC,DUSP10,METTL2A,SALL2,SPRING1,TSHZ2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_nkc_d28,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41039,FLUZONE,IN,INFLUENZA,COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,03-17,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/COLE_BLOOD_FLUZONE_FLUARIX_AGE_03_17YO_7DY_DN,"BACKGROUND: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV). To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV. METHODS: Children 3-17years of age receiving quadrivalent influenza vaccine were enrolled. Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10days) following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log<sub>2</sub> transformed and compared between the two vaccine groups. RESULTS: Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in both groups. CONCLUSIONS: Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients. These results help to elucidate the immune response to influenza vaccines and may be related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.","Genes down-regulated in blood 7d vs 0d in children (3-17) after exposure to Fluzone/Fluarix (IIV) , time point 7D. Comment: IIV (inactivated influenza vaccine)","Cole KS,Martin JM,Horne WT,Lin CJ,Nowalk MP,Alcorn JF,Zimmerman RK",29132989,HUMAN_GENE_SYMBOL,"CCL2,CCL7,CXCR4,IFNA1,IL12B,IL4,CXCL8",7,"CCL2,CCL7,CXCR4,IFNA1,IL12B,IL4,IL8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41061,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 7d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 7D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"CTBP2,FCAR,H3C13,IRAG1,KAZN,LRRK2,P2RY14,PLAUR",8,"CTBP2,FCAR,H3C13,IRAG1,KAZN,LRRK2,P2RY14,PLAUR",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M40983,FLUZONE,IN,INFLUENZA,CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUZONE_AGE_05_14YO_7DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 7d vs 0d in children (0.5-14y) after exposure to Fluzone , time point 7D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"CEACAM8,DEFA1B,PDIA4,SNORD3C,SPRING1,TNFRSF17,WFS1,ZFP30",8,"CEACAM8,DEFA1B,PDIA4,SNORD3C,SPRING1,TNFRSF17,WFS1,ZFP30",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_nkc_d3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41098,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_CORRELATED_WITH_H3N2_VN_TITER_7DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D7,D,7,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_CORRELATED_WITH_H3N2_VN_TITER_7DY_POSITIVE,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes positively correlated with H3N2 VN titer in blood in children (0.5-14y) after exposure to FluMist , time point 7D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"GBP1,GBP5,IFIT1,IFIT3,IFITM3,OAS1,OAS2,OASL,RSAD2",9,"GBP1,GBP5,IFIT1,IFIT3,IFITM3,OAS1,OAS2,OASL,RSAD2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M40943,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_HIGH_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,Y7,W,7,11-22,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_HIGH_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN,"BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.","Genes down-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) (high antibody responders to treatment) after exposure to M-M-R II , time point 7Y","Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA",27529750,HUMAN_GENE_SYMBOL,"CCL24,CD33,CD93,CYP3A5,FPR2,HTR7,PID1,SGCD,VEGFA,VNN1",10,"CCL24,CD33,CD93,CYP3A5,FPR2,HTR7,PID1,SGCD,VEGFA,VNN1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/table/T3/,NA,NA,NA,NA
M41113,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,Y7,W,7,11-22,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_DN,"BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.","Genes down-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) (low antibody responders to treatment) after exposure to M-M-R II , time point 7Y","Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA",27529750,HUMAN_GENE_SYMBOL,"ADGRA2,CCL24,CD33,CD93,G0S2,HTR7,LAMB3,PID1,SGCD,SIGLEC15,VNN1",11,"ADGRA2,CCL24,CD33,CD93,G0S2,HTR7,LAMB3,PID1,SGCD,SIGLEC15,VNN1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table, see also Fig 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712333/bin/aging-07-1077-s001.xlsx,NA,NA,NA,NA
M40920,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP,VIRUS,UP,CORRELATION,ANTIBODY,Y7,W,7,11-22,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_LOW_ANTIBODY_RESPONDERS_TO_TREATMENT_7YR_UP,"BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.","Genes up-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) (low antibody responders to treatment) after exposure to M-M-R II , time point 7Y","Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA",27529750,HUMAN_GENE_SYMBOL,"AK4,BCL2A1,CHST7,CYP1A1,IL36RN,IL6,ITGB8,LIF,MET,MSC,NAMPT,OR52N4,RFX8,TRPA1",14,"AK4,BCL2A1,CHST7,CYP1A1,IL36RN,IL6,ITGB8,LIF,MET,MSC,NAMPT,OR52N4,RFX8,TRPA1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41034,TICE BGC RBCG,LA,TUBERCULOSIS,HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE,BACTERIUM,NEGATIVE,CORRELATION,ANTIMICROBIAL ACTIVITY,D14,D,14,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_PBMC_TICE_BCG_RBCG_AG85A_AG85B_AGE_18_40YO_CORRELATED_WITH_WHOLE_BLOOD_BACTERICIDAL_ACTIVITY_NEGATIVE,"BACKGROUND: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. METHODS: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy adult, BCG-nave volunteers, negative for prior exposure to Mtb, at one US clinical site. Volunteers were randomized 2:1 at each dose level to receive a single intradermal dose of AERAS-422 ( > 10(5)- < 10(6)CFU=low dose, 10(6)- < 10(7)CFU=high dose) or non-recombinant Tice BCG (1-810(5)CFU). Randomization used an independently prepared randomly generated sequence of treatment assignments. The primary and secondary outcomes were safety and immunogenicity, respectively, assessed in all participants through 182days post-vaccination. ClinicalTrials.gov registration number: NCT01340820. FINDINGS: Between Nov 2010 and Aug 2011, 24 volunteers were enrolled (AERAS-422 high dose, n=8; AERAS-422 low dose, n=8; Tice BCG, n=8); all were included in the safety and immunogenicity analyses. All 24 subjects had at least one adverse event, primarily expected local reactions. High dose AERAS-422 vaccination induced Ag85A- and Ag85B-specific lymphoproliferative responses and marked anti-mycobacterial activity in a whole blood bactericidal activity culture assay (WBA), but was associated with varicella zoster virus (VZV) reactivation in two vaccinees. These volunteers displayed high BCG-specific IFN- responses pre- and post-vaccination possibly predisposing them to autocrine/paracrine negative regulation of immune control of latent VZV. A systems biology transcriptomal approach identified positive correlations between post-vaccination T cell expression modules and WBA, and negative correlations between post-vaccination monocyte expression modules and WBA. The expression of one key macrophage marker (F4/80) was constitutively elevated in the two volunteers with zoster. INTERPRETATION: The unexpected development of VZV in two of eight healthy adult vaccine recipients resulted in discontinuation of AERAS-422 vaccine development. Immunological and transcriptomal data identified correlations with the development of TB immunity and VZV that require further investigation. FUNDING: Aeras, FDA, Bill and Melinda Gates Foundation.","Genes negatively correlated with whole blood bactericidal activity in peripheral blood mononuclear cell in adults (18-40) after exposure to Tice BCG/rBCG-Ag85A/Ag85B , time point 14D","Hoft DF,Blazevic A,Selimovic A,Turan A,Tennant J,Abate G,Fulkerson J,Zak DE,Walker R,McClain B,Sadoff J,Scott J,Shepherd B,Ishmukhamedov J,Hokey DA,Dheenadhayalan V,Shankar S,Amon L,Navarro G,Podyminogin R,Aderem A,Barker L,Brennan M,Wallis RS,Gershon AA,Gershon MD,Steinberg S",27322481,HUMAN_GENE_SYMBOL,"ADCY9,AGAP1,ATP2B4,CACNA2D2,CCL5,CD247,COLQ,CST7,ELOVL6,FCRL6,FGFBP2,FRMPD3,GNLY,GZMB,GZMH,HOPX,IGFBP3,IL12RB2,IL2RB,KIR3DL1,KLRB1,KLRF1,MCTP2,NCR1,NKG7,NMUR1,PDGFD,PHLDB2,PRF1,PRR5L,PRSS23,RASGEF1A,RNF165,SH2D1B,SIGLEC17P,SLC4A4,SPIRE1,SYNE1,TGFBR3,YPEL1",40,"ADCY9,AGAP1,ATP2B4,CACNA2D2,CCL5,CD247,COLQ,CST7,ELOVL6,FCRL6,FGFBP2,FRMPD3,GNLY,GZMB,GZMH,HOPX,IGFBP3,IL12RB2,IL2RB,KIR3DL1,KLRB1,KLRF1,MCTP2,NCR1,NKG7,NMUR1,PDGFD,PHLDB2,PRF1,PRR5L,PRSS23,RASGEF1A,RNF165,SH2D1B,SIGLEC17P,SLC4A4,SPIRE1,SYNE1,TGFBR3,YPEL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/table/pone.0160970.t001/,NA,NA,NA,NA
M40911,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN,BACTERIUM,DOWN,CORRELATION,CELL,D56,D,56,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes down-regulated in CD4-positive, alpha-beta memory T cell 56d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 56D , administered PO (oral). Comment: top 100 most differentially expressed genes comparing Day 0 and Day 56 responses after in vitro re-stimulation with BCG-infected autologous dendritic cells","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ABCC1,ADCY1,AP2A1,ARAP1,ARHGAP17,ARHGEF11,ARMC6,BMP2K,CNOT3,CREG1,CXCL1,CXCR5,EIF3B,ERC1,GBF1,HDAC7,HDGFL3,IFIT1,IFIT3,INTS5,IRF2BP1,JUP,KIF11,MFHAS1,MFSD12,MGAT4B,MYO1C,NFATC3,NOC2L,OASL,PLXNA1,PTGIR,PYGO2,RPRD2,RUBCNL,SAMD4B,SLC29A1,TAF1,THBS1,TLE3,TMEM94,TRAF7,TRANK1,VCAN,WASF2,ZNF184,ZNF763",47,"ABCC1,ADCY1,AP2A1,ARAP1,ARHGAP17,ARHGEF11,ARMC6,BMP2K,CNOT3,CREG1,CXCL1,CXCR5,EIF3B,ERC1,GBF1,HDAC7,HDGFL3,IFIT1,IFIT3,INTS5,IRF2BP1,JUP,KIF11,MFHAS1,MFSD12,MGAT4B,MYO1C,NFATC3,NOC2L,OASL,PLXNA1,PTGIR,PYGO2,RPRD2,RUBCNL,SAMD4B,SLC29A1,TAF1,THBS1,TLE3,TMEM94,TRAF7,TRANK1,VCAN,WASF2,ZNF184,ZNF763",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500554/bin/jiy721_suppl_supplementary_table_1a.xlsx,NA,NA,NA,NA
M41184,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN,BACTERIUM,DOWN,CORRELATION,CELL,D56,D,56,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_DN,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes down-regulated in CD4-positive, alpha-beta memory T cell 56d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 56D , administered ID (intradermal). Comment: top 100 most differentially expressed genes comparing Day 0 and Day 56 responses after in vitro re-stimulation with BCG-infected autologous dendritic cells","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ACKR3,ARAP1,ARAP2,ARID4A,BAIAP2L1,C19orf25,CLIC3,DCLRE1C,ERLIN1,FOXO3B,GNB5,CMKLR2,GTPBP6,HBB,IL17RD,LZTFL1,MTFR1,MTRF1,MYO3B,NFAT5,NOL8,OSBPL8,PABPC1,RAB33B,RGS18,SLC36A4,SPATA13,SPDYE6,SPIN1,SSH1,TAOK1,THAP1,TMEM106B,TMEM191A,TMEM267,TTC33,TUBD1,UHMK1,ZBTB20,ZFP91,ZNF140",41,"ACKR3,ARAP1,ARAP2,ARID4A,BAIAP2L1,C19orf25,CLIC3,DCLRE1C,ERLIN1,FOXO3B,GNB5,GPR1,GTPBP6,HBB,IL17RD,LZTFL1,MTFR1,MTRF1,MYO3B,NFAT5,NOL8,OSBPL8,PABPC1,RAB33B,RGS18,SLC36A4,SPATA13,SPDYE6,SPIN1,SSH1,TAOK1,THAP1,TMEM106B,TMEM191A,TMEM267,TTC33,TUBD1,UHMK1,ZBTB20,ZFP91,ZNF140",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Fig 6a, Suppl Fig 8a",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-1.pdf|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F6/,NA,NA,NA,NA
M41160,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP,BACTERIUM,UP,CORRELATION,CELL,D56,D,56,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes up-regulated in CD4-positive, alpha-beta memory T cell 56d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 56D , administered PO (oral). Comment: top 100 most differentially expressed genes comparing Day 0 and Day 56 responses after in vitro re-stimulation with BCG-infected autologous dendritic cells","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ANKRD36C,CA5B,COPS2,DAPP1,GPKOW,IFT20,LUC7L3,LYPLA2P1,METTL17,PHF20L1,PI16,PTMA,RNU1-4,RNY1,RPL12P6,SBDS,SNORD38A,SNRNP25,TMEM70,TNFAIP8L1,TUBD1,UBE2Z,ZDHHC11,ZNF93",24,"ANKRD36C,CA5B,COPS2,DAPP1,GPKOW,IFT20,LUC7L3,LYPLA2P1,METTL17,PHF20L1,PI16,PTMA,RNU1-4,RNY1,RPL12P6,SBDS,SNORD38A,SNRNP25,TMEM70,TNFAIP8L1,TUBD1,UBE2Z,ZDHHC11,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-Bcells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M41180,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP,BACTERIUM,UP,CORRELATION,CELL,D56,D,56,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_56D_TOP_100_DEG_AFTER_IN_VITRO_RE_STIMULATION_UP,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes up-regulated in CD4-positive, alpha-beta memory T cell 56d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 56D , administered ID (intradermal). Comment: top 100 most differentially expressed genes comparing Day 0 and Day 56 responses after in vitro re-stimulation with BCG-infected autologous dendritic cells","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ABCA1,AGRN,ANAPC15,C4BPB,CHPF,COG5,CPSF2,FAM219A,GGT1,GNL3L,HAMP,HSD11B1L,HYAL2,HYOU1,IL9,LIMK1,METRNL,MOGS,MRPL11,NOC4L,OGFOD3,PAFAH1B3,PALD1,PLEKHN1,PNPLA7,PXMP2,RAI1,RPL10A,SLC39A3,SLC39A4,SLC43A3,SNU13,SREBF1,ZNRD2-DT,TAF6,TBC1D17,TICAM1,TMEM160,TMEM63B,UQCC3,YDJC,ZGPAT",42,"ABCA1,AGRN,ANAPC15,C4BPB,CHPF,COG5,CPSF2,FAM219A,GGT1,GNL3L,HAMP,HSD11B1L,HYAL2,HYOU1,IL9,LIMK1,METRNL,MOGS,MRPL11,NOC4L,OGFOD3,PAFAH1B3,PALD1,PLEKHN1,PNPLA7,PXMP2,RAI1,RPL10A,SLC39A3,SLC39A4,SLC43A3,SNU13,SREBF1,SSSCA1-AS1,TAF6,TBC1D17,TICAM1,TMEM160,TMEM63B,UQCC3,YDJC,ZGPAT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-Monocytes,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40913,YF17D,LA,YF,QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45_7DY_PREDICTIVE,VIRUS,UP,CORRELATION,CELL,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45_7DY_PREDICTIVE,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4-an orchestrator of the integrated stress response-that correlated with and predicted YF-17D CD8(+) T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.","Genes that are components of a model predictive of response in peripheral blood mononuclear cell 7d vs 0d in adults (18-45) after exposure to YF-17D vaccine , time point 7D. Comment: Suppl Table 4: genes validated by ClaNC as being predictive of CD8+ T cell responses from Fig. 4.","Querec TD,Akondy RS,Lee EK,Cao W,Nakaya HI,Teuwen D,Pirani A,Gernert K,Deng J,Marzolf B,Kennedy K,Wu H,Bennouna S,Oluoch H,Miller J,Vencio RZ,Mulligan M,Aderem A,Ahmed R,Pulendran B",19029902,HUMAN_GENE_SYMBOL,"ADSS1,ALDH16A1,ASGR2,BIRC3,BNIP3L,C8orf82,CPEB3,CTBP1,ACKR3,DEFA4,EIF2AK4,EIF4G3,EMILIN2,FBXO15,SLC47A1,GPR18,HBA1,HBB,HBZ,HEATR3,ITGAL,MEF2A,MYL4,NANS,NAPRT,NDRG2,PRAM1,SAT2,SLC25A13,SLC2A6,SLC39A11,SLC47A1,SPON2,TMOD1,ULK2,DCAF12,ZEB1,ZSWIM5",38,"ADSSL1,ALDH16A1,ASGR2,BIRC3,BNIP3L,C8orf82,CPEB3,CTBP1,CXCR7,DEFA4,EIF2AK4,EIF4G3,EMILIN2,FBXO15,FLJ10847,GPR18,HBA1,HBB,HBZ,HEATR3,ITGAL,MEF2A,MYL4,NANS,NAPRT1,NDRG2,PRAM1,SAT2,SLC25A13,SLC2A6,SLC39A11,SLC47A1,SPON2,TMOD1,ULK2,WDR40A,ZEB1,ZSWIM5",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Table III, see also Suppl Table III",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/table/T3/,NA,NA,NA,NA
M41133,YF17D,LA,YF,QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_PREDICTIVE,VIRUS,UP,CORRELATION,CELL,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QUEREC_MODEL_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_PREDICTIVE,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4-an orchestrator of the integrated stress response-that correlated with and predicted YF-17D CD8(+) T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.","Genes that are components of a model predictive of response in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) after exposure to YF-17D vaccine , time point 3D. Comment: Suppl Table 4: genes validated by ClaNC as being predictive of CD8+ T cell responses from Fig. 4.","Querec TD,Akondy RS,Lee EK,Cao W,Nakaya HI,Teuwen D,Pirani A,Gernert K,Deng J,Marzolf B,Kennedy K,Wu H,Bennouna S,Oluoch H,Miller J,Vencio RZ,Mulligan M,Aderem A,Ahmed R,Pulendran B",19029902,HUMAN_GENE_SYMBOL,"ALDH3B1,ASGR2,ATP6V1E1,BCKDK,BIRC3,BNIP3L,C1QB,CALR,CAMKK2,CD69,CENPB,CRAT,CTSB,CXCR6,ACKR3,EIF4G3,ETV3,FBXO15,FERMT3,GAA,GAS2L1,GBGT1,GPR18,HBB,HTRA4,IMPDH1,JUN,NAPRT,NRGN,PNPLA6,PRAM1,RAB8B,RGS1,SAT2,SLC16A5,SLC2A6,SMARCD3,STK17A,TBC1D7,TCEAL4,TEP1,TMEM176A,TMEM176B,TNFSF14,TUFM,ZFP82,ZNF606,ZYX",48,"ALDH3B1,ASGR2,ATP6V1E1,BCKDK,BIRC3,BNIP3L,C1QB,CALR,CAMKK2,CD69,CENPB,CRAT,CTSB,CXCR6,CXCR7,EIF4G3,ETV3,FBXO15,FERMT3,GAA,GAS2L1,GBGT1,GPR18,HBB,HTRA4,IMPDH1,JUN,NAPRT1,NRGN,PNPLA6,PRAM1,RAB8B,RGS1,SAT2,SLC16A5,SLC2A6,SMARCD3,STK17A,TBC1D7,TCEAL4,TEP1,TMEM176A,TMEM176B,TNFSF14,TUFM,ZFP82,ZNF606,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Table III, see also Suppl Table III",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/table/T3/,NA,NA,NA,NA
M41116,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_DN,BACTERIUM,DOWN,CORRELATION,CELL,D7,D,7,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_DN,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes down-regulated in CD4-positive, alpha-beta memory T cell 7d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 7D , administered ID (intradermal). Comment: top 100 most significantly altered genes comparing Day 0 and Day 7 responses directly ex vivo","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"AMY1B,CAPZA1,COPS2,DENND4C,FABP5,HBA1,HBA2,HBB,HSPE1,LUC7L3,MAFF,OBI1,PIM3,PMAIP1,SAMSN1,UBE2Z",16,"AMY1B,CAPZA1,COPS2,DENND4C,FABP5,HBA1,HBA2,HBB,HSPE1,LUC7L3,MAFF,OBI1,PIM3,PMAIP1,SAMSN1,UBE2Z",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500554/bin/jiy721_suppl_supplementary_table_1a.xlsx,NA,NA,NA,NA
M40994,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_UP,BACTERIUM,UP,CORRELATION,CELL,D7,D,7,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_ID_7DY_TOP_100_DEG_EX_VIVO_UP,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes up-regulated in CD4-positive, alpha-beta memory T cell 7d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 7D , administered ID (intradermal). Comment: top 100 most significantly altered genes comparing Day 0 and Day 7 responses directly ex vivo","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ACSL3,AGMAT,APBB3,ATG16L2,AVL9,CHST15,CLIC5,CPXM1,CTSF,DPEP2,DRC7,FAM8A1,FXYD1,GRAMD4,LDLRAP1,MAP3K20,MAP6D1,MEOX1,METTL2A,MIR99AHG,P3H4,PI16,RASA3,TECPR1,THG1L,TSC22D3,USP33,ZDHHC14",28,"ACSL3,AGMAT,APBB3,ATG16L2,AVL9,CHST15,CLIC5,CPXM1,CTSF,DPEP2,DRC7,FAM8A1,FXYD1,GRAMD4,LDLRAP1,MAP3K20,MAP6D1,MEOX1,METTL2A,MIR99AHG,P3H4,PI16,RASA3,TECPR1,THG1L,TSC22D3,USP33,ZDHHC14",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: LAIV-Bcells,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40899,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D1,D,1,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_NEGATIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes negatively correlated with expansion of VZV specific T cells (0d to peak) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"ANKRD35,AP2S1,APOBEC3D,ARID4B,ARMH1,ASS1,ATP5PF,ATRAID,BNIP3L,BOLA2,C12orf57,C1QBP,C7orf50,CA1,CARD14,CD200,CD52,CD79B,CDK11A,CHRNB3,CLC,CLTB,CLUHP3,COMMD6,COPZ1,COX6C,CXorf38,DAB2,DHX29,DPM2,DPP9,DRAP1,DTYMK,DYRK2,EEF1B2,EEF1D,ELMOD3,EVI5,FAM72B,FBXL15,FUCA2,GIMAP5,GNL3L,GPX4,GTF3A,GZMA,H2AC18,H4C3,HDAC7,HINT1,HMGCR,HMGN1,ITM2A,LILRA5,,,MARCHF6,MCOLN1,MRPL14,MRPL20,MRPL23,MRPL36,MRPL41,MRPL51,MRPL54,MRPS24,MRPS33,MSL3,MT1E,NAA20,NBPF20,NDUFA1,NDUFA13,NDUFB2,NDUFB3,NFAT5,NSUN5,NUDT1,OCIAD2,PASK,PCYOX1,PLEKHB2,PQBP1,PSMA3,PSMA4,PSMA6,PSMC3,PVALB,RAB27A,RAD23A,RBM12B,RHOC,RINL,RNASE2,RO60,RPL11,RPL27,RPL4,RPL6,RPL7L1,RPS17,RPS27,RPS27L,RPS5,RRAS,SEC22C,SEPTIN6,SERF2,SF1,SF3B5,SH2D2A,SIVA1,SNHG5,STAG3L2,TMA7,TMC6,TMEM238,TOMM6,TOMM7,TPT1,TRIM25,TRIM38,TXNDC17,TYMP,U2AF1,UBE2H,UBE2Z,UQCRHL,UQCRQ,USP48,VPREB3,VPS25,VTI1B,WASH3P,YBX1,ZNF160,ZNF511,ZSWIM8",138,"ANKRD35,AP2S1,APOBEC3D,ARID4B,ARMH1,ASS1,ATP5PF,ATRAID,BNIP3L,BOLA2,C12orf57,C1QBP,C7orf50,CA1,CARD14,CD200,CD52,CD79B,CDK11A,CHRNB3,CLC,CLTB,CLUHP3,COMMD6,COPZ1,COX6C,CXorf38,DAB2,DHX29,DPM2,DPP9,DRAP1,DTYMK,DYRK2,EEF1B2,EEF1D,ELMOD3,EVI5,FAM72B,FBXL15,FUCA2,GIMAP5,GNL3L,GPX4,GTF3A,GZMA,H2AC18,H4C3,HDAC7,HINT1,HMGCR,HMGN1,ITM2A,LILRA5,LOC100505502,LOC401261,MARCHF6,MCOLN1,MRPL14,MRPL20,MRPL23,MRPL36,MRPL41,MRPL51,MRPL54,MRPS24,MRPS33,MSL3,MT1E,NAA20,NBPF20,NDUFA1,NDUFA13,NDUFB2,NDUFB3,NFAT5,NSUN5,NUDT1,OCIAD2,PASK,PCYOX1,PLEKHB2,PQBP1,PSMA3,PSMA4,PSMA6,PSMC3,PVALB,RAB27A,RAD23A,RBM12B,RHOC,RINL,RNASE2,RO60,RPL11,RPL27,RPL4,RPL6,RPL7L1,RPS17,RPS27,RPS27L,RPS5,RRAS,SEC22C,SEPTIN6,SERF2,SF1,SF3B5,SH2D2A,SIVA1,SNHG5,STAG3L2,TMA7,TMC6,TMEM238,TOMM6,TOMM7,TPT1,TRIM25,TRIM38,TXNDC17,TYMP,U2AF1,UBE2H,UBE2Z,UQCRHL,UQCRQ,USP48,VPREB3,VPS25,VTI1B,WASH3P,YBX1,ZNF160,ZNF511,ZSWIM8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Figure 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800877/figure/F4/,NA,NA,NA,NA
M40874,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D1,D,1,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_EXPANSION_OF_VZV_SPECIFIC_T_CELLS_TO_PEAK_AT_1DY_POSITIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes positively correlated with expansion of VZV specific T cells (0d to peak) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"ABHD5,ACAP2,ADD1,ADGRE3,ADGRG1,ADPRS,AKIRIN2,ALDH2,ALOX5,ALOX5AP,AMY2A,ANTXR2,AP1M1,ARAP3,ARHGAP25,ARHGAP30,ARHGDIB,ARPC5,ATP8B2,B4GALT5,B9D2,BANP,BTG1,BTN2A1,C5AR1,CAB39,CALM2,CALML4,CAMK2G,CAST,CCND3,CCR2,CD14,CDK5R1,CHD1,CHST15,CITED2,CLEC16A,CLEC2D,CMIP,CPQ,CSF2RA,CTDSP1,CTDSP2,CTNNB1,CTSS,CXCR2,CXCR4,CYRIB,CYSLTR1,CYTIP,DDX3X,DENND5A,DHRS9,DHX38,DPEP2,DPYD,EFHD2,EIF3L,EIF4G2,ERICH1,EVI2B,EXO5,FADD,FAM8A1,FBXO33,FBXO7,FEZ2,FGD3,FLI1,FNBP1,FNDC3B,FOXN3,FPR1,FRAT1,GAB2,GABARAP,GALM,GLB1,GPR162,GPR65,HERPUD1,HLA-B,HLA-F,HLA-H,HNRNPH3,HSPA1A,HSPA6,ICAM3,IL1R2,IRF2BPL,IST1,ITGB2,IWS1,JAK1,JARID2,KDM2B,KDM3B,KIAA0319L,KIF5B,KLHL22,KLHL24,L3MBTL2,LAMP2,LILRB2,LILRB3,LMBRD1,,LPAR2,LPIN2,LRG1,LRP10,LRRC25,LRRC47,LRRK2,LSP1,MAN2B2,MANSC1,MAP3K14,MAP4K4,MBP,MED16,MED6,MFSD1,MKNK1,MLKL,MME,MMP25,MOB1A,MPPE1,MTMR14,MTMR3,MTMR6,MXD1,MYADM,MYH9,N4BP2L2,NABP1,NFE2,NPL,OSBPL2,PAM,PANX2,PARP1,PCBP1,PDE7A,PDLIM7,PECAM1,PELI1,PFN1,PGAM1,PGAM4,PGD,PGRMC2,PLCG2,PLOD1,PNISR,POGK,POTEKP,PPP1R18,PPP1R21,PPT1,PRR13,PRRC2C,PRSS23,PSAP,PTBP3,PTOV1,QPCT,RAB11FIP1,RAB35,RASSF2,RASSF5,RB1CC1,RBL2,RBM33,RCBTB2,REPS2,RESF1,RHOG,RIPOR1,RNF130,RNF145,RNF149,RNF19A,RNF38,RNPEP,RUNX2,RXRA,SARAF,SCYL1,SDHD,SEC14L1,SELL,SERPINA1,SGK1,SGSM2,SH3KBP1,SIGLEC10,SIGLEC14,SIPA1,SIRPA,SKIC2,SLC11A1,SLC40A1,SLC6A6,SLCO3A1,SMAD4,SMAP2,SNRK,SOD2,SPAG9,SPG21,SPI1,STAT3,STK26,STX4,TACC1,TAGLN2,TALDO1,TCN1,TGFBR2,TGOLN2,TM2D3,TMED7,TNFRSF10B,TNFRSF1B,TOMM20,TRIM8,TSC22D3,TST,TTC27,TUBA1A,TUBB,TXK,TXNIP,UBAP1,UBE3C,UBXN4,UPF2,VNN3P,VRK3,VSIR,WAS,WLS,YWHAH,ZMIZ1,ZNF106,ZNF586",249,"ABHD5,ACAP2,ADD1,ADGRE3,ADGRG1,ADPRS,AKIRIN2,ALDH2,ALOX5,ALOX5AP,AMY2A,ANTXR2,AP1M1,ARAP3,ARHGAP25,ARHGAP30,ARHGDIB,ARPC5,ATP8B2,B4GALT5,B9D2,BANP,BTG1,BTN2A1,C5AR1,CAB39,CALM2,CALML4,CAMK2G,CAST,CCND3,CCR2,CD14,CDK5R1,CHD1,CHST15,CITED2,CLEC16A,CLEC2D,CMIP,CPQ,CSF2RA,CTDSP1,CTDSP2,CTNNB1,CTSS,CXCR2,CXCR4,CYRIB,CYSLTR1,CYTIP,DDX3X,DENND5A,DHRS9,DHX38,DPEP2,DPYD,EFHD2,EIF3L,EIF4G2,ERICH1,EVI2B,EXO5,FADD,FAM8A1,FBXO33,FBXO7,FEZ2,FGD3,FLI1,FNBP1,FNDC3B,FOXN3,FPR1,FRAT1,GAB2,GABARAP,GALM,GLB1,GPR162,GPR65,HERPUD1,HLA-B,HLA-F,HLA-H,HNRNPH3,HSPA1A,HSPA6,ICAM3,IL1R2,IRF2BPL,IST1,ITGB2,IWS1,JAK1,JARID2,KDM2B,KDM3B,KIAA0319L,KIF5B,KLHL22,KLHL24,L3MBTL2,LAMP2,LILRB2,LILRB3,LMBRD1,LOC100129034,LPAR2,LPIN2,LRG1,LRP10,LRRC25,LRRC47,LRRK2,LSP1,MAN2B2,MANSC1,MAP3K14,MAP4K4,MBP,MED16,MED6,MFSD1,MKNK1,MLKL,MME,MMP25,MOB1A,MPPE1,MTMR14,MTMR3,MTMR6,MXD1,MYADM,MYH9,N4BP2L2,NABP1,NFE2,NPL,OSBPL2,PAM,PANX2,PARP1,PCBP1,PDE7A,PDLIM7,PECAM1,PELI1,PFN1,PGAM1,PGAM4,PGD,PGRMC2,PLCG2,PLOD1,PNISR,POGK,POTEKP,PPP1R18,PPP1R21,PPT1,PRR13,PRRC2C,PRSS23,PSAP,PTBP3,PTOV1,QPCT,RAB11FIP1,RAB35,RASSF2,RASSF5,RB1CC1,RBL2,RBM33,RCBTB2,REPS2,RESF1,RHOG,RIPOR1,RNF130,RNF145,RNF149,RNF19A,RNF38,RNPEP,RUNX2,RXRA,SARAF,SCYL1,SDHD,SEC14L1,SELL,SERPINA1,SGK1,SGSM2,SH3KBP1,SIGLEC10,SIGLEC14,SIPA1,SIRPA,SKIV2L,SLC11A1,SLC40A1,SLC6A6,SLCO3A1,SMAD4,SMAP2,SNRK,SOD2,SPAG9,SPG21,SPI1,STAT3,STK26,STX4,TACC1,TAGLN2,TALDO1,TCN1,TGFBR2,TGOLN2,TM2D3,TMED7,TNFRSF10B,TNFRSF1B,TOMM20,TRIM8,TSC22D3,TST,TTC27,TUBA1A,TUBB,TXK,TXNIP,UBAP1,UBE3C,UBXN4,UPF2,VNN3,VRK3,VSIR,WAS,WLS,YWHAH,ZMIZ1,ZNF106,ZNF586",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Figure 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800877/figure/F4/,NA,NA,NA,NA
M41132,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_28D_PEAK_T_CELL_RESPONSE_14DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D14,D,14,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_28D_PEAK_T_CELL_RESPONSE_14DY_NEGATIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes negatively correlated with peak T cell response 28d in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax, time point 14D. Comment: negative correlation coefficients between gene expression level at day 14 after vaccination and peak to day 28 T cell responses","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"ATR,BIRC5,BRCA1,CDC25A,CDK1,CDKN1B,CENPM,CENPS,CHEK1,ERCC6L,EXO1,FANCD2,GINS2,GMNN,HDAC2,MAD2L1,MCM2,MCM5,MCM7,MND1,MSH2,MSH6,PCNA,PRIM1,PTTG1,RACGAP1,RAD21,RFC2,RFC3,RFC4,RMI1,RPA3,SMC2,SMC3,SUV39H2,TDP1,ZWINT",37,"ATR,BIRC5,BRCA1,CDC25A,CDK1,CDKN1B,CENPM,CENPS,CHEK1,ERCC6L,EXO1,FANCD2,GINS2,GMNN,HDAC2,MAD2L1,MCM2,MCM5,MCM7,MND1,MSH2,MSH6,PCNA,PRIM1,PTTG1,RACGAP1,RAD21,RFC2,RFC3,RFC4,RMI1,RPA3,SMC2,SMC3,SUV39H2,TDP1,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641062/table/pone-0062149-t002/,NA,NA,NA,NA
M40988,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_1D_INFORMATIVE_OF_LONG_TERM_RESPONSES_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D14,D,14,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_1D_INFORMATIVE_OF_LONG_TERM_RESPONSES_NEGATIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes negatively correlated with T cell responses (long term) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D. Comment: (B) Network of genes informative of long-term responses.","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"ANXA1,CAMK1D,CCR2,EEF1A1,ENO1,FTL,GAPDH,IL6ST,KLF2,LGALS1,LILRA5,MRPL41,RPS27",13,"ANXA1,CAMK1D,CCR2,EEF1A1,ENO1,FTL,GAPDH,IL6ST,KLF2,LGALS1,LILRA5,MRPL41,RPS27",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3C,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/figure/f0003/,NA,NA,NA,NA
M40978,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_EXPANSION_AND_CONTRACTION_1D_NOT_INFORMATIVE_OF_LONG_TERM_RESPONSES_POSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D14,D,14,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_T_CELL_RESPONSES_EXPANSION_AND_CONTRACTION_1D_NOT_INFORMATIVE_OF_LONG_TERM_RESPONSES_POSITIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes positively correlated with T cell responses (expansion and contraction, not long term) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D. Comment: (A) Network of genes for which the change in expression correlated with both expansion and contraction and therefore not with long-term outcome","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"APOBEC3G,CCL5,CCR2,CD14,CX3CR1,CXCR2,CYSLTR1,HLA-G,ITGB2,JAK1,RXRA,SELL,SIGLEC10,STAT3,TSC22D3,WAS",16,"APOBEC3G,CCL5,CCR2,CD14,CX3CR1,CXCR2,CYSLTR1,HLA-G,ITGB2,JAK1,RXRA,SELL,SIGLEC10,STAT3,TSC22D3,WAS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M40873,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DY_AT_1DYPOSITIVE,VIRUS,POSITIVE,CORRELATION,CELL,D28,D,28,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DY_AT_1DYPOSITIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes positively correlated with contraction of VZV specific T cells (peak to 28d) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"ABHD5,ACAP2,ADAR,ADD1,ADGRE2,ADGRE3,ADGRE5,ADPRS,AKIRIN2,ALDH2,ALOX5,AMY2A,ANTXR2,AP1M1,ARAP3,ARF1,ARHGAP25,ARHGAP30,ARHGDIB,ARID1A,ARPC5,ATP6V1B2,B4GALT5,BANP,BNIP3L,BTF3,BTN2A1,CAB39,CALM2,CAMK2G,CAP1,CAPNS1,CCR2,CD14,CD300A,CD300LF,CDC42,CFAP58,CHD1,CHST15,CITED2,CLEC16A,CLIC4,CLINT1,CLNS1A,CMIP,CPQ,CPSF1,CPVL,CREBBP,CTDSP2,CTNNA1,CYBA,CYBB,CYSLTR1,CYTIP,DCAF12,DCAF7,EXO5,DENND5A,DERL1,DIP2B,DNAJB6,DPYD,EFTUD2,EIF3L,EIF4A3,EIF4E3,ELF2,EMILIN2,ERGIC1,ERICH1,ESS2,FBXO33,FBXO7,FCGR3B,FGR,FNBP1,FNDC3B,FOS,FOXO3,FRAT1,GAB2,GAB3,GABARAPL2,GAS7,GATD3,GDI2,GIMAP8,GLB1,GNAI2,GRN,GTPBP4,HARS2,HCFC1,HDAC1,HERPUD1,HHEX,HLA-B,HLA-DRA,HLA-DRB3,HMGB2,HNRNPA2B1,HSPA1A,IFIH1,IGF2BP2,IK,CXCR2,IRF2BP2,IST1,ITGB1BP1,ITGB2,IWS1,JAK1,JARID2,KDM2B,KDM3B,KHDC4,KIF5B,L3MBTL2,LCP1,LILRA6,LIMS1,LMO2,GPC1-AS1,LPAR2,LRP10,LRRK2,MAN2B2,MARCKS,MED16,MLKL,MMP25,MORC2-AS1,MORF4L1,MTMR14,MTMR3,MYADM,MYH9,NAAA,NABP1,NACA,NARF,NCF1C,NCOA1,NCOA4,NCOA6,NFE2,NIBAN1,NKTR,NOMO1,NOTCH1,NPL,NUCB1,NUP93,PARP1,PCBP1,PCBP2,PCMTD1,PDE7A,PDLIM7,PGAM1,PGAM4,PGRMC2,PHIP,PLCG2,PLSCR1,POGK,POTEF,PPP1R21,PPP4R1,PPT1,PRKCB,PRKCD,PRR13,PSAP,PSMB10,PSME4,PTBP1,PTBP3,RAB11FIP1,RAB24,RAC2,RAF1,RALBP1,RB1CC1,RBL2,RBM33,RBM47,RERE,RESF1,RFTN1,RHOG,RIPOR1,RNASET2,RNF103,RNF114,RNF13,RNF130,RNF145,RNF149,RNF19A,RNF34,RNF40,ROCK2,RRBP1,RTF2,RUNDC1,RXRA,SARAF,SCAF11,SDE2,SDF4,SEC14L1,SELENOS,SELL,SERF1B,SERPINA1,SGK1,SH3GLB1,SH3KBP1,SHCBP1,SIGLEC10,SIGLEC14,SLA,SLC6A6,SLC7A5,SLCO3A1,SMAP2,SMNDC1,SNCA,SNRK,SOD2,SON,SP3,SPAG9,SPEN,SRSF5,ST13P4,ST6GAL1,STAT3,STX4,SYPL1,TACC1,TAGLN2,TALDO1,TCN1,TFDP1,TGFBR2,THUMPD1,TIPARP,TLR1,TLR4,TM2D3,TMBIM1,TMED7,TMEM140,TMEM158,TMEM179B,TMEM87A,TNFAIP6,TNFRSF1A,TNFRSF1B,TOMM20,TRIM58,TRIP12,TRMT5,TSC22D3,TTC27,TUBB,TXK,UBA7,UBAP1,UBC,UBE3C,UVSSA,VPS26B,VSIR,WAC,WAS,WBP2,WDR1,WDR37,WLS,YBX3,YIPF6,YWHAB,ZC3H4,ZC3H7A,ZC3HAV1,ZFAND5,ZHX2,ZMIZ1,ZNF217",294,"ABHD5,ACAP2,ADAR,ADD1,ADGRE2,ADGRE3,ADGRE5,ADPRHL2,AKIRIN2,ALDH2,ALOX5,AMY2A,ANTXR2,AP1M1,ARAP3,ARF1,ARHGAP25,ARHGAP30,ARHGDIB,ARID1A,ARPC5,ATP6V1B2,B4GALT5,BANP,BNIP3L,BTF3,BTN2A1,CAB39,CALM2,CAMK2G,CAP1,CAPNS1,CCR2,CD14,CD300A,CD300LF,CDC42,CFAP58,CHD1,CHST15,CITED2,CLEC16A,CLIC4,CLINT1,CLNS1A,CMIP,CPQ,CPSF1,CPVL,CREBBP,CTDSP2,CTNNA1,CYBA,CYBB,CYSLTR1,CYTIP,DCAF12,DCAF7,DEM1,DENND5A,DERL1,DIP2B,DNAJB6,DPYD,EFTUD2,EIF3L,EIF4A3,EIF4E3,ELF2,EMILIN2,ERGIC1,ERICH1,ESS2,FBXO33,FBXO7,FCGR3B,FGR,FNBP1,FNDC3B,FOS,FOXO3,FRAT1,GAB2,GAB3,GABARAPL2,GAS7,GATD3A,GDI2,GIMAP8,GLB1,GNAI2,GRN,GTPBP4,HARS2,HCFC1,HDAC1,HERPUD1,HHEX,HLA-B,HLA-DRA,HLA-DRB3,HMGB2,HNRPA2B1,HSPA1A,IFIH1,IGF2BP2,IK,IL8RB,IRF2BP2,IST1,ITGB1BP1,ITGB2,IWS1,JAK1,JARID2,KDM2B,KDM3B,KHDC4,KIF5B,L3MBTL2,LCP1,LILRA6,LIMS1,LMO2,LOC100130449,LPAR2,LRP10,LRRK2,MAN2B2,MARCKS,MED16,MLKL,MMP25,MORC2-AS1,MORF4L1,MTMR14,MTMR3,MYADM,MYH9,NAAA,NABP1,NACA,NARF,NCF1C,NCOA1,NCOA4,NCOA6,NFE2,NIBAN1,NKTR,NOMO1,NOTCH1,NPL,NUCB1,NUP93,PARP1,PCBP1,PCBP2,PCMTD1,PDE7A,PDLIM7,PGAM1,PGAM4,PGRMC2,PHIP,PLCG2,PLSCR1,POGK,POTEF,PPP1R21,PPP4R1,PPT1,PRKCB,PRKCD,PRR13,PSAP,PSMB10,PSME4,PTBP1,PTBP3,RAB11FIP1,RAB24,RAC2,RAF1,RALBP1,RB1CC1,RBL2,RBM33,RBM47,RERE,RESF1,RFTN1,RHOG,RIPOR1,RNASET2,RNF103,RNF114,RNF13,RNF130,RNF145,RNF149,RNF19A,RNF34,RNF40,ROCK2,RRBP1,RTF2,RUNDC1,RXRA,SARAF,SCAF11,SDE2,SDF4,SEC14L1,SELENOS,SELL,SERF1B,SERPINA1,SGK1,SH3GLB1,SH3KBP1,SHCBP1,SIGLEC10,SIGLEC14,SLA,SLC6A6,SLC7A5,SLCO3A1,SMAP2,SMNDC1,SNCA,SNRK,SOD2,SON,SP3,SPAG9,SPEN,SRSF5,ST13P4,ST6GAL1,STAT3,STX4,SYPL1,TACC1,TAGLN2,TALDO1,TCN1,TFDP1,TGFBR2,THUMPD1,TIPARP,TLR1,TLR4,TM2D3,TMBIM1,TMED7,TMEM140,TMEM158,TMEM179B,TMEM87A,TNFAIP6,TNFRSF1A,TNFRSF1B,TOMM20,TRIM58,TRIP12,TRMT5,TSC22D3,TTC27,TUBB,TXK,UBA7,UBAP1,UBC,UBE3C,UVSSA,VPS26B,VSIR,WAC,WAS,WBP2,WDR1,WDR37,WLS,YBX3,YIPF6,YWHAB,ZC3H4,ZC3H7A,ZC3HAV1,ZFAND5,ZHX2,ZMIZ1,ZNF217",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/figure/pone-0067922-g003/,NA,NA,NA,NA
M40904,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,CELL,D28,D,28,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_CORRELATED_WITH_CONTRACTION_OF_VZV_SPECIFIC_T_CELLS_PEAK_TO_28DYAT_1DY_NEGATIVE,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes negatively correlated with contraction of VZV specific T cells (peak to 28d) in peripheral blood mononuclear cell in seniors (50-75) after exposure to Zostavax , time point 1D","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"AGAP6,ANXA2R,APEH,APOBEC3G,ARHGAP9,ARHGEF1,ARID4B,ATP2B1-AS1,ATP5PD,ATP5PF,BLZF1,BOLA2,C12orf57,C1QBP,C4orf3,C7orf50,CAMKK2,CARD14,CASP1,CCDC93,CD79B,CD8A,CDK13,CDK2AP2,CLTB,COMMD3,COMMD6,COX7B,CUTA,CXCR3,DAB2,DDX17,DPP9,DRAP1,DTYMK,DUSP1,DUSP19,DUSP23,DYNLRB1,DYRK2,EEF1B2,EEF1D,,EIF3M,ELMOD3,ERH,EEIG1,FAM238B,FAM72B,FAU,FCAR,FUT6,GALNT3,GDPD1,GNG11,GNL3L,GRK5,GTF2E2,GZMA,HMGN1,HTATIP2,IFI27L2,ISY1,ITM2A,KCNH6,KLHL28,KLRB1,KLRF1,LILRA5,,,LRPPRC,M6PR,MAFF,MARCHF6,MBD4,MBP,MBTD1,METTL26,MICOS13,MIF,MRPL14,MRPL20,MRPL41,MRPL51,MRPL54,MRPS33,MSL3,MT1E,MTHFS,NAA20,NCK1,NDUFA12,NDUFA13,NDUFB5,NDUFS5,NFAT5,NFATC2IP,NME1-NME2,NSUN5,NT5C3A,OCIAD2,PCYOX1,PDPK1,PLEKHA1,PNPT1,POLE4,PPIAL4A,PPP1R16B,PRDX1,PRMT2,PSMB1,PTPRC,PTPRCAP,PVALB,PYCARD,RAB27A,RBM12B,RETREG2,RHOC,RNASE2,RPL11,RPL13P5,RPL14,RPL17,RPL18A,RPL23,RPL26,RPL27,RPL35,RPL36,RPL4,RPS17,RPS26,RPS27,RPS27A,RPS27L,RPS29,RPS3A,RPS5,RPS6KA4,RRAGA,RTEL1,S100P,SAMD4B,SEPTIN6,SF1,SF3A3,SF3B5,SRSF7,SH2D2A,SIVA1,SLC31A1,SLC39A1,SMIM26,SNHG5,SNRPD2,SPINT1,SS18L2,STAG3L2,STMN3,TAF12,TCP1,TDRD1,TMA7,TMEM160,TMEM218,TMEM238,TMEM256,TMEM9B,TNFSF15,TOMM22,TOMM6,TOMM7,TPT1,TRAPPC1,TRAPPC4,TRIM38,TRIR,RO60,TUFM,TXNDC17,TYMP,U2AF1,UBE2Z,UGP2,UNC50,UPP1,UQCR10,USF2,VPREB3,VPS25,WASH3P,ZBP1,ZBTB40,ZNF483,ZNF598,ZNF69,ZNF91,ZSWIM8",200,"AGAP6,ANXA2R,APEH,APOBEC3G,ARHGAP9,ARHGEF1,ARID4B,ATP2B1-AS1,ATP5H,ATP5PF,BLZF1,BOLA2,C12orf57,C1QBP,C4orf3,C7orf50,CAMKK2,CARD14,CASP1,CCDC93,CD79B,CD8A,CDK13,CDK2AP2,CLTB,COMMD3,COMMD6,COX7B,CUTA,CXCR3,DAB2,DDX17,DPP9,DRAP1,DTYMK,DUSP1,DUSP19,DUSP23,DYNLRB1,DYRK2,EEF1B2,EEF1D,EIF3FP2,EIF3M,ELMOD3,ERH,FAM102A,FAM238B,FAM72B,FAU,FCAR,FUT6,GALNT3,GDPD1,GNG11,GNL3L,GRK5,GTF2E2,GZMA,HMGN1,HTATIP2,IFI27L2,ISY1,ITM2A,KCNH6,KLHL28,KLRB1,KLRF1,LILRA5,LOC100505502,LOC401261,LRPPRC,M6PR,MAFF,MARCHF6,MBD4,MBP,MBTD1,METTL26,MICOS13,MIF,MRPL14,MRPL20,MRPL41,MRPL51,MRPL54,MRPS33,MSL3,MT1E,MTHFS,NAA20,NCK1,NDUFA12,NDUFA13,NDUFB5,NDUFS5,NFAT5,NFATC2IP,NME1-NME2,NSUN5,NT5C3A,OCIAD2,PCYOX1,PDPK1,PLEKHA1,PNPT1,POLE4,PPIAL4A,PPP1R16B,PRDX1,PRMT2,PSMB1,PTPRC,PTPRCAP,PVALB,PYCARD,RAB27A,RBM12B,RETREG2,RHOC,RNASE2,RPL11,RPL13P5,RPL14,RPL17,RPL18A,RPL23,RPL26,RPL27,RPL35,RPL36,RPL4,RPS17,RPS26,RPS27,RPS27A,RPS27L,RPS29,RPS3A,RPS5,RPS6KA4,RRAGA,RTEL1,S100P,SAMD4B,SEPTIN6,SF1,SF3A3,SF3B5,SFRS7,SH2D2A,SIVA1,SLC31A1,SLC39A1,SMIM26,SNHG5,SNRPD2,SPINT1,SS18L2,STAG3L2,STMN3,TAF12,TCP1,TDRD1,TMA7,TMEM160,TMEM218,TMEM238,TMEM256,TMEM9B,TNFSF15,TOMM22,TOMM6,TOMM7,TPT1,TRAPPC1,TRAPPC4,TRIM38,TRIR,TROVE2,TUFM,TXNDC17,TYMP,U2AF1,UBE2Z,UGP2,UNC50,UPP1,UQCR10,USF2,VPREB3,VPS25,WASH3P,ZBP1,ZBTB40,ZNF483,ZNF598,ZNF69,ZNF91,ZSWIM8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/table/tab2/,NA,NA,NA,NA
M41192,ZOSTAVAX,LA,VZV,QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN,VIRUS,DOWN,VACCINE,CELL,D9,D,9,52-75,"ADULT, ELDER",OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN,"Diversity and size of the antigen-specific T cell receptor (TCR) repertoire are two critical determinants for successful control of chronic infection. Varicella zoster virus (VZV) that establishes latency during childhood can escape control mechanisms, in particular with increasing age. We examined the TCR diversity of VZV-reactive CD4 T cells in individuals older than 50 years by studying three identical twin pairs and three unrelated individuals before and after vaccination with live attenuated VZV. Although all individuals had a small number of dominant T cell clones, the breadth of the VZV-specific repertoire differed markedly. A genetic influence was seen for the sharing of individual TCR sequences from antigen-reactive cells but not for repertoire richness or the selection of dominant clones. VZV vaccination favored the expansion of infrequent VZV antigen-reactive TCRs, including those from naive T cells with lesser boosting of dominant T cell clones. Thus, vaccination does not reinforce the in vivo selection that occurred during chronic infection but leads to a diversification of the VZV-reactive T cell repertoire. However, a single-booster immunization seems insufficient to establish new clonal dominance. Our results suggest that repertoire analysis of antigen-specific TCRs can be an important readout to assess whether a vaccination was able to generate memory cells in clonal sizes that are necessary for immune protection.","Genes down-regulated in naive T cell CD4-positive T cell vs naive CD4-positive T cell in seniors (52-75) after exposure to Zostavax , time point 7 to 9D. Comment: Table S3. BV and BJ gene segment usage in VZV-reactive CD4 T cells compared to naive and memory CD4 T cells (FDR <= 0.1).","Qi Q,Cavanagh MM,Le Saux S,NamKoong H,Kim C,Turgano E,Liu Y,Wang C,Mackey S,Swan GE,Dekker CL,Olshen RA,Boyd SD,Weyand CM,Tian L,Goronzy JJ",27030598,HUMAN_GENE_SYMBOL,"TRBJ2-1,TRBV10-3,TRBV14,TRBV15,TRBV19,TRBV20-1,,TRBV5-3",8,"TRBJ2-1,TRBV10-3,TRBV14,TRBV15,TRBV19,TRBV20-1,TRBV4-3,TRBV5-3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3C,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068032/figure/fig3/,NA,NA,NA,NA
M41193,ZOSTAVAX,LA,VZV,QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_UP,VIRUS,UP,VACCINE,CELL,D9,D,9,52-75,"ADULT, ELDER",OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_NAIVE_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_UP,"Diversity and size of the antigen-specific T cell receptor (TCR) repertoire are two critical determinants for successful control of chronic infection. Varicella zoster virus (VZV) that establishes latency during childhood can escape control mechanisms, in particular with increasing age. We examined the TCR diversity of VZV-reactive CD4 T cells in individuals older than 50 years by studying three identical twin pairs and three unrelated individuals before and after vaccination with live attenuated VZV. Although all individuals had a small number of dominant T cell clones, the breadth of the VZV-specific repertoire differed markedly. A genetic influence was seen for the sharing of individual TCR sequences from antigen-reactive cells but not for repertoire richness or the selection of dominant clones. VZV vaccination favored the expansion of infrequent VZV antigen-reactive TCRs, including those from naive T cells with lesser boosting of dominant T cell clones. Thus, vaccination does not reinforce the in vivo selection that occurred during chronic infection but leads to a diversification of the VZV-reactive T cell repertoire. However, a single-booster immunization seems insufficient to establish new clonal dominance. Our results suggest that repertoire analysis of antigen-specific TCRs can be an important readout to assess whether a vaccination was able to generate memory cells in clonal sizes that are necessary for immune protection.","Genes up-regulated in naive T cell CD4-positive T cell vs naive CD4-positive T cell in seniors (52-75) after exposure to Zostavax , time point 7 to 9D. Comment: Table S3. BV and BJ gene segment usage in VZV-reactive CD4 T cells compared to naive and memory CD4 T cells (FDR <= 0.1).","Qi Q,Cavanagh MM,Le Saux S,NamKoong H,Kim C,Turgano E,Liu Y,Wang C,Mackey S,Swan GE,Dekker CL,Olshen RA,Boyd SD,Weyand CM,Tian L,Goronzy JJ",27030598,HUMAN_GENE_SYMBOL,"TRBV12-4,TRBV5-4,TRBV5-5,,TRBV6-1,TRBV7-3,TRBV7-4",7,"TRBV12-4,TRBV5-4,TRBV5-5,TRBV5-8,TRBV6-1,TRBV7-3,TRBV7-4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Fig 13,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/bin/NIHMS540680-supplement-13.jpg,NA,NA,NA,NA
M41191,ZOSTAVAX,LA,VZV,QI_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN,VIRUS,DOWN,VACCINE,CELL,H72,H,72,52-75,"ADULT, ELDER",OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_ZOSTAVAX_AGE_52_75YO_CD4_T_CELL_VS_NAIVE_CD4_T_CELL_7_TO_9DY_DN,"Diversity and size of the antigen-specific T cell receptor (TCR) repertoire are two critical determinants for successful control of chronic infection. Varicella zoster virus (VZV) that establishes latency during childhood can escape control mechanisms, in particular with increasing age. We examined the TCR diversity of VZV-reactive CD4 T cells in individuals older than 50 years by studying three identical twin pairs and three unrelated individuals before and after vaccination with live attenuated VZV. Although all individuals had a small number of dominant T cell clones, the breadth of the VZV-specific repertoire differed markedly. A genetic influence was seen for the sharing of individual TCR sequences from antigen-reactive cells but not for repertoire richness or the selection of dominant clones. VZV vaccination favored the expansion of infrequent VZV antigen-reactive TCRs, including those from naive T cells with lesser boosting of dominant T cell clones. Thus, vaccination does not reinforce the in vivo selection that occurred during chronic infection but leads to a diversification of the VZV-reactive T cell repertoire. However, a single-booster immunization seems insufficient to establish new clonal dominance. Our results suggest that repertoire analysis of antigen-specific TCRs can be an important readout to assess whether a vaccination was able to generate memory cells in clonal sizes that are necessary for immune protection.","Genes down-regulated in CD4-positive, alpha-beta memory T cell CD4-positive T cell vs naive CD4-positive T cell in seniors (52-75) after exposure to Zostavax , time point 7 to 9D. Comment: Table S3. BV and BJ gene segment usage in VZV-reactive CD4 T cells compared to naive and memory CD4 T cells (FDR <= 0.1).","Qi Q,Cavanagh MM,Le Saux S,NamKoong H,Kim C,Turgano E,Liu Y,Wang C,Mackey S,Swan GE,Dekker CL,Olshen RA,Boyd SD,Weyand CM,Tian L,Goronzy JJ",27030598,HUMAN_GENE_SYMBOL,"TRBJ1-4,TRBJ1-5,TRBJ2-1,TRBV10-3,TRBV14,TRBV15,TRBV19,TRBV20-1,,TRBV5-3",10,"TRBJ1-4,TRBJ1-5,TRBJ2-1,TRBV10-3,TRBV14,TRBV15,TRBV19,TRBV20-1,TRBV4-3,TRBV5-3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068032/table/tbl1/,NA,NA,NA,NA
M41055,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_DN,VIRUS,DOWN,CHALLENGE,CHALLENGE,D3,D,3,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_DN,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes down-regulated in skin of body 3d vs 0hr in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 3D","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"AKAP1,ANKRD13D,AQP11,ARIH1,CD200,CEP41,COQ9,DCBLD1,ECPAS,EDN3,ERC1,FIGN,ADGRF2,LEXM,LINC00113,LUC7L3,MAP6,MDM2,MGA,MIR30C2,MIR646,MYEOV,NF1,NFATC2IP,NHLH1,PAX6,PCNP,PPP2R2B,PTCSC1,RAB30-DT,RBM19,SCGB2B2,SF1,SLC22A3,SLC25A15,SLC44A5,SLC52A1,SRY,TTC14,WDR72,WNT3,YLPM1",42,"AKAP1,ANKRD13D,AQP11,ARIH1,CD200,CEP41,COQ9,DCBLD1,ECPAS,EDN3,ERC1,FIGN,GPR111,LEXM,LINC00113,LUC7L3,MAP6,MDM2,MGA,MIR30C2,MIR646,MYEOV,NF1,NFATC2IP,NHLH1,PAX6,PCNP,PPP2R2B,PTCSC1,RAB30-DT,RBM19,SCGB2B2,SF1,SLC22A3,SLC25A15,SLC44A5,SLC52A1,SRY,TTC14,WDR72,WNT3,YLPM1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T2/,NA,NA,NA,NA
M41176,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_UP,VIRUS,UP,CHALLENGE,CHALLENGE,D3,D,3,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_3DY_UP,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes up-regulated in skin of body 3d vs 0hr in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 3D","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"ABI3BP,ACP5,AIF1,AOX1,AP1S2,ARHGAP18,ARPC1B,ATP11A,B3GNT7,BCAT1,C16orf54,C1RL,C3AR1,CACNA2D3,CALU,CAPRIN1,CCL2,CCR1,CD163,CD180,CD33,CD84,CD86,CENPH,CLEC12A,CLEC7A,CLIC2,CLU,COLEC12,CPVL,CTSB,CTSS,CTSZ,CX3CR1,CYBB,DAB2,DCLK1,DDOST,EFEMP1,EPB41L3,EVI2A,EVI2B,CALHM6,FCER1G,FKBP1A,FPR3,GLIPR1,GPSM3,GZMK,HAVCR2,HGF,HMOX1,IGF2BP3,IGSF6,IKBIP,IKZF1,IL13RA1,INHBC,ITGAM,LCP1,LGMN,LILRB2,LIPA,LIPC,LY86,LYZ,MARCKS,MPEG1,MS4A6A,MYO5A,NAGA,NID1,NPL,OSTC,PAPSS2,PIK3AP1,PIP4K2A,PLA2G2A,PLXDC1,POLR1D,PTGER4,PTP4A2,NECTIN3,RAB32,RHOJ,SAMSN1,SASH3,SDC2,SERPINA1,SERPINA3,SH2B3,SLC15A3,SLC38A6,SLC7A7,SMC2,SRGN,SRSF11,SSR2,TACC1,TDRD12,TFEC,THY1,TIMP1,TLR7,TLR8,TPK1,TYROBP,VSIG4,ZFP36L2,ZNF567",110,"ABI3BP,ACP5,AIF1,AOX1,AP1S2,ARHGAP18,ARPC1B,ATP11A,B3GNT7,BCAT1,C16orf54,C1RL,C3AR1,CACNA2D3,CALU,CAPRIN1,CCL2,CCR1,CD163,CD180,CD33,CD84,CD86,CENPH,CLEC12A,CLEC7A,CLIC2,CLU,COLEC12,CPVL,CTSB,CTSS,CTSZ,CX3CR1,CYBB,DAB2,DCLK1,DDOST,EFEMP1,EPB41L3,EVI2A,EVI2B,FAM26F,FCER1G,FKBP1A,FPR3,GLIPR1,GPSM3,GZMK,HAVCR2,HGF,HMOX1,IGF2BP3,IGSF6,IKBIP,IKZF1,IL13RA1,INHBC,ITGAM,LCP1,LGMN,LILRB2,LIPA,LIPC,LY86,LYZ,MARCKS,MPEG1,MS4A6A,MYO5A,NAGA,NID1,NPL,OSTC,PAPSS2,PIK3AP1,PIP4K2A,PLA2G2A,PLXDC1,POLR1D,PTGER4,PTP4A2,PVRL3,RAB32,RHOJ,SAMSN1,SASH3,SDC2,SERPINA1,SERPINA3,SH2B3,SLC15A3,SLC38A6,SLC7A7,SMC2,SRGN,SRSF11,SSR2,TACC1,TDRD12,TFEC,THY1,TIMP1,TLR7,TLR8,TPK1,TYROBP,VSIG4,ZFP36L2,ZNF567",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1A, Tab DEGs_TIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M40894,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_DN,VIRUS,DOWN,CHALLENGE,CHALLENGE,H6,H,6,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_DN,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes down-regulated in skin of body 6hr vs 0hr in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 6H","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"ACOT13,AFDN-DT,AIG1,AKAP1,ALDH4A1,ALS2CL,ANKRD13D,ANKS6,AQP11,ARHGEF9,ATG16L2,BABAM1,BTNL9,C5orf63,DMAC1,CAPN3,CARS2,CCS,CDK5RAP3,CEP152,CEP41,COQ9,COX4I1,CUL9,DCBLD1,DHX16,DUT,EDN3,ELP4,ERC1,ERICH1,FAHD2A,FIGN,FLJ20021,GGCX,HHAT,HSPB3,INTS8,IRX5,KANK1,LDAH,LEXM,LINC00113,LINC00310,LINC01550,LRRC28,MAP3K4,MAP6,MED12L,MIR30C2,MMAB,MORF4L2-AS1,MRPS16,MRPS6,NDUFA8,NDUFV1,NECAB3,NHLH1,NIT1,NUDT22,PCCA,PCGF1,PER1,PEX6,PIGG,PIN4,PLEKHJ1,PRCD,PRMT7,PTCSC1,RBM19,RFXANK,RPL32P3,RPUSD3,RUFY3,RUSC1-AS1,SAMD1,SAMM50,SCARB1,SDCCAG8,SEC16B,SHOX2,SIRT5,SLC52A1,SLC9A9,SPAG8,SRY,STX16,SUGP1,TARBP2,TBX5,TCTA,TET1,TFCP2,THADA,TMEM184A,TMEM254-AS1,TMEM63A,TRPM4,TTC28-AS1,ULK2,USP40,VILL,VPS26B,VPS45,DYNC2I2,ZBTB16,ZNF300P1,ZNF32,ZNF341",110,"ACOT13,AFDN-DT,AIG1,AKAP1,ALDH4A1,ALS2CL,ANKRD13D,ANKS6,AQP11,ARHGEF9,ATG16L2,BABAM1,BTNL9,C5orf63,C9orf123,CAPN3,CARS2,CCS,CDK5RAP3,CEP152,CEP41,COQ9,COX4I1,CUL9,DCBLD1,DHX16,DUT,EDN3,ELP4,ERC1,ERICH1,FAHD2A,FIGN,FLJ20021,GGCX,HHAT,HSPB3,INTS8,IRX5,KANK1,LDAH,LEXM,LINC00113,LINC00310,LINC01550,LRRC28,MAP3K4,MAP6,MED12L,MIR30C2,MMAB,MORF4L2-AS1,MRPS16,MRPS6,NDUFA8,NDUFV1,NECAB3,NHLH1,NIT1,NUDT22,PCCA,PCGF1,PER1,PEX6,PIGG,PIN4,PLEKHJ1,PRCD,PRMT7,PTCSC1,RBM19,RFXANK,RPL32P3,RPUSD3,RUFY3,RUSC1-AS1,SAMD1,SAMM50,SCARB1,SDCCAG8,SEC16B,SHOX2,SIRT5,SLC52A1,SLC9A9,SPAG8,SRY,STX16,SUGP1,TARBP2,TBX5,TCTA,TET1,TFCP2,THADA,TMEM184A,TMEM254-AS1,TMEM63A,TRPM4,TTC28-AS1,ULK2,USP40,VILL,VPS26B,VPS45,WDR34,ZBTB16,ZNF300P1,ZNF32,ZNF341",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4 & Suppl Table 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/bin/NIHMS593578-supplement-01.pdf,NA,NA,NA,NA
M41002,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_UP,VIRUS,UP,CHALLENGE,CHALLENGE,H6,H,6,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_UP,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes up-regulated in skin of body 6hr vs 0hr in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 6H","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"ABCA1,ACSL4,ADAM19,AHR,AKAP12,ANKRD28,APOL2,APOL3,APOL6,ARFGAP3,ARHGAP18,ARHGAP31,ARL13B,ASAP1,ATAD1,ATF1,ATP11A,ATP11C,ATP13A3,ATP2B1,B4GALT5,BASP1,BATF3,BCL2A1,BCL3,BIRC3,BLOC1S6,BZW1,C16orf54,C2orf69,C3AR1,CCDC50,CCDC71L,CCL2,CCL8,CCNJ,CCNT1,CCR1,CD44,CD83,CDC27,CDC42EP2,CDC42EP3,CDC42EP4,CDK12,CDK17,CH25H,CHD1,CHST15,CHSY1,CHSY3,CHUK,CLEC7A,CNN3,COL15A1,COQ10B,CRY1,CSF2RB,CSGALNACT2,CTDSP2,CTSL,CXCL1,CXCL10,CXCL2,CXCL3,CCN1,DAB2,ACKR1,DDX21,DDX3X,DERL1,DHX33,DIMT1,DNAJB9,DOK5,DUSP6,ECPAS,EFHD2,EIF1AX,EIF4E,ELK4,EML4,ETS1,HYCC1,GASK1B,TASOR2,FAM20A,CALHM6,FAM3C,FAM76B,FCGR1BP,FCGR2A,FCGR3B,FEM1B,FGD6,FGL2,FGR,FOSL1,FOSL2,FPR1,FTH1P5,FZD5,G3BP2,GABPB1,GBP1,GCA,GFPT2,GNAQ,GOLPH3,GOLT1B,ADGRF2,GPR183,GPR65,GREM1,HAPLN3,HDC,,HGF,MFSD14A,HPRT1,ICAM1,IFI16,IFNGR1,IFNGR2,IFT57,IKZF1,IL13RA1,IL1B,IL1RL1,IL4R,IL6,IL6R,IL6ST,CXCL8,INTS6,IRF1,IRGQ,IRX2,ITGAX,JAK3,KCNJ15,KLF10,KPNA4,LARP4,LEXM,LIFR,LILRB2,,LYN,LYZ,MARCKS,MCTP1,MECP2,MED13L,MEDAG,MGAT2,MIDN,MIER1,MRPL44,MT1E,MT1M,MT2A,MTMR9,MTSS2,MYB,MYLIP,MYO1B,NABP1,NADK2,NAMPT,NAP1L1,NCOA7,NEK6,NFIL3,NMD3,NNMT,NR4A3,NRIP3,OSMR,PAK2,PATL1,PCGF5,PDPN,PHACTR2,PIP4K2A,PITPNB,PLAUR,PLEK,PLSCR1,POTEKP,PPP1R15B,PPP3R1,PPP4R2,PPTC7,PRRC2C,PRRX1,PTCSC1,PTGER4,PTP4A2,PTPRC,PTX3,QTRT2,RAB23,RAB27A,RAB3IL1,RBPJ,RGS16,RHEB,RHOU,RIT1,RNF145,RNF19A,RP2,RPS6KB1,RRN3,RRP1B,RUBCNL,RYBP,SAMD4A,SAMSN1,SCAF8,SDCBP,SEC24A,SEC24D,SECTM1,SELE,SELL,SERPINA1,SERPINA3,SERPINB1,SERPINB9,SERPINE1,SH2B3,SIN3A,SIPA1L1,SLC20A1,SLC25A37,SLC2A3,SLC39A14,SLC41A2,SLC4A7,SMARCA1,SOCS3,SPRED1,SRFBP1,SRGAP1,SRGN,SRSF11,SSR1,STAU1,STEAP4,STK3,STOM,STX12,SULF1,SV2B,SYNJ2,TAF2,TGFBR1,THBS1,TJP2,TLR4,TM4SF1,CEMIP2,TMEM200A,TMEM70,TNFAIP2,TNFAIP6,TNFRSF1A,TPBG,TSHZ3,TXLNG,UAP1,UBE2D1,UBE2W,UGCG,UGDH,BLTP3B,VCAM1,VCAN,VEZF1,VMP1,WTAP,YWHAG,ZBTB2,ZEB2,ZFP36L1,ZFX,ZNF217,ZPR1,ZNF267,ZNF436,ZNF567",293,"ABCA1,ACSL4,ADAM19,AHR,AKAP12,ANKRD28,APOL2,APOL3,APOL6,ARFGAP3,ARHGAP18,ARHGAP31,ARL13B,ASAP1,ATAD1,ATF1,ATP11A,ATP11C,ATP13A3,ATP2B1,B4GALT5,BASP1,BATF3,BCL2A1,BCL3,BIRC3,BLOC1S6,BZW1,C16orf54,C2orf69,C3AR1,CCDC50,CCDC71L,CCL2,CCL8,CCNJ,CCNT1,CCR1,CD44,CD83,CDC27,CDC42EP2,CDC42EP3,CDC42EP4,CDK12,CDK17,CH25H,CHD1,CHST15,CHSY1,CHSY3,CHUK,CLEC7A,CNN3,COL15A1,COQ10B,CRY1,CSF2RB,CSGALNACT2,CTDSP2,CTSL1,CXCL1,CXCL10,CXCL2,CXCL3,CYR61,DAB2,DARC,DDX21,DDX3X,DERL1,DHX33,DIMT1,DNAJB9,DOK5,DUSP6,ECPAS,EFHD2,EIF1AX,EIF4E,ELK4,EML4,ETS1,FAM126A,FAM198B,FAM208B,FAM20A,FAM26F,FAM3C,FAM76B,FCGR1B,FCGR2A,FCGR3B,FEM1B,FGD6,FGL2,FGR,FOSL1,FOSL2,FPR1,FTH1P5,FZD5,G3BP2,GABPB1,GBP1,GCA,GFPT2,GNAQ,GOLPH3,GOLT1B,GPR111,GPR183,GPR65,GREM1,HAPLN3,HDC,HDGFRP3,HGF,HIAT1,HPRT1,ICAM1,IFI16,IFNGR1,IFNGR2,IFT57,IKZF1,IL13RA1,IL1B,IL1RL1,IL4R,IL6,IL6R,IL6ST,IL8,INTS6,IRF1,IRGQ,IRX2,ITGAX,JAK3,KCNJ15,KLF10,KPNA4,LARP4,LEXM,LIFR,LILRB2,LOC114224,LYN,LYZ,MARCKS,MCTP1,MECP2,MED13L,MEDAG,MGAT2,MIDN,MIER1,MRPL44,MT1E,MT1M,MT2A,MTMR9,MTSS1L,MYB,MYLIP,MYO1B,NABP1,NADKD1,NAMPT,NAP1L1,NCOA7,NEK6,NFIL3,NMD3,NNMT,NR4A3,NRIP3,OSMR,PAK2,PATL1,PCGF5,PDPN,PHACTR2,PIP4K2A,PITPNB,PLAUR,PLEK,PLSCR1,POTEKP,PPP1R15B,PPP3R1,PPP4R2,PPTC7,PRRC2C,PRRX1,PTCSC1,PTGER4,PTP4A2,PTPRC,PTX3,QTRTD1,RAB23,RAB27A,RAB3IL1,RBPJ,RGS16,RHEB,RHOU,RIT1,RNF145,RNF19A,RP2,RPS6KB1,RRN3,RRP1B,RUBCNL,RYBP,SAMD4A,SAMSN1,SCAF8,SDCBP,SEC24A,SEC24D,SECTM1,SELE,SELL,SERPINA1,SERPINA3,SERPINB1,SERPINB9,SERPINE1,SH2B3,SIN3A,SIPA1L1,SLC20A1,SLC25A37,SLC2A3,SLC39A14,SLC41A2,SLC4A7,SMARCA1,SOCS3,SPRED1,SRFBP1,SRGAP1,SRGN,SRSF11,SSR1,STAU1,STEAP4,STK3,STOM,STX12,SULF1,SV2B,SYNJ2,TAF2,TGFBR1,THBS1,TJP2,TLR4,TM4SF1,TMEM2,TMEM200A,TMEM70,TNFAIP2,TNFAIP6,TNFRSF1A,TPBG,TSHZ3,TXLNG,UAP1,UBE2D1,UBE2W,UGCG,UGDH,UHRF1BP1L,VCAM1,VCAN,VEZF1,VMP1,WTAP,YWHAG,ZBTB2,ZEB2,ZFP36L1,ZFX,ZNF217,ZNF259,ZNF267,ZNF436,ZNF567",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1B, Tab DEGs_LAIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M40975,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGED_POST_VACCINATION_VS_UNCHALLENGED_72HR_TOP_30_DEG_UP,VIRUS,UP,CHALLENGE,CHALLENGE,H6,H,6,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGED_POST_VACCINATION_VS_UNCHALLENGED_72HR_TOP_30_DEG_UP,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes up-regulated in skin of body VZV challenged post-vaccination vs unchallenged in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 72H. Comment: Table showing the top 30 genes upregulated at 72 hours after varicella zoster virus (VZV) challenge before and after vaccination.","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"CCL5,CD2,CD8A,CLEC12A,CLEC4E,CTLA4,CXCL10,CXCL9,EOMES,FCGR1A,FCGR1BP,FPR1,GBP5,GNLY,GZMA,GZMB,IDO1,ITGAL,KLHDC7B,KLRC2,LYZ,PLAC8,PRKCQ,SELL,SERPINA1,TARP,TRGC2,TRGV9,UBD,XCL1",30,"CCL5,CD2,CD8A,CLEC12A,CLEC4E,CTLA4,CXCL10,CXCL9,EOMES,FCGR1A,FCGR1B,FPR1,GBP5,GNLY,GZMA,GZMB,IDO1,ITGAL,KLHDC7B,KLRC2,LYZ,PLAC8,PRKCQ,SELL,SERPINA1,TARP,TRGC2,TRGV9,UBD,XCL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-pDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40901,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP,VIRUS,UP,VACCINE,COMPARISON,ANY,ANY,ANY,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell post-vaccination vs pre-vaccination in adults (18-40) after exposure to APSV Wetvax , time point anyD. Comment: Significantly Modulated Genes Common to Vaccinia and Yellow Fever Vaccination","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ANXA2,APOBEC3B,XAF1,BLVRA,CD74,CEBPB,CREG1,EIF4A1,FCGR3A,FPR2,GLRX,HERC5,HSBP1,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IL1RN,ISG15,IRF9,LAP3,LGALS3BP,LMO2,LY6E,MARCKS,MT1M,MX1,MX2,OAS1,OAS2,PLSCR1,PSMA4,PSMA6,PSMB9,PSME1,PSME2,PYHIN1,SERPINA1,SERPING1,SP110,TAP1,TNFSF10,TRIM21,TRIM22,UBE2D3,USP18,VRK2",55,"ANXA2,APOBEC3B,BIRC4BP,BLVRA,CD74,CEBPB,CREG1,EIF4A1,FCGR3A,FPRL1,GLRX,HERC5,HSBP1,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IL1RN,ISG15,ISGF3G,LAP3,LGALS3BP,LMO2,LY6E,MARCKS,MT1M,MX1,MX2,OAS1,OAS2,PLSCR1,PSMA4,PSMA6,PSMB9,PSME1,PSME2,PYHIN1,SERPINA1,SERPING1,SP110,TAP1,TNFSF10,TRIM21,TRIM22,UBE2D3,USP18,VRK2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40908,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_OR_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_DN,VIRUS,DOWN,VACCINE,COMPARISON,ANY,ANY,ANY,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_OR_APSV_WETVAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell post-vaccination vs pre-vaccination in adults (18-40) after exposure to YF-Vax or APSV Wetvax (identical responses) , time point anyD. Comment: Significantly Modulated Genes Common to Vaccinia and Yellow Fever Vaccination","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ARL4C,B4GALT3,C12orf57,CBX7,CD3D,EEF1B2,ICAM3,KIF22,KLRB1,LDHB,LTB,RPL10A,RPL13,RPL23A,RPL9,RPS10,RPS15A,RPS21,RPS3A,TCF3,TMC6,TSPAN4,ZAP70",23,"ARL4C,B4GALT3,C12orf57,CBX7,CD3D,EEF1B2,ICAM3,KIF22,KLRB1,LDHB,LTB,RPL10A,RPL13,RPL23A,RPL9,RPS10,RPS15A,RPS21,RPS3A,TCF3,TMC6,TSPAN4,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133148/table/T1/,NA,NA,NA,NA
M40900,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP,VIRUS,UP,VACCINE,COMPARISON,ANY,ANY,ANY,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_AGE_18_40YO_JOINT_TO_VACCINIA_AND_YELLOW_FEVER_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell post-vaccination vs pre-vaccination in adults (18-40) after exposure to YF-Vax , time point anyD. Comment: Significantly Modulated Genes Common to Vaccinia and Yellow Fever Vaccination","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ANXA2,APOBEC3B,XAF1,BLVRA,CD74,CEBPB,CREG1,EIF4A1,FCGR3A,FPR2,GLRX,HERC5,HSBP1,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IL1RN,ISG15,IRF9,LAP3,LGALS3BP,LMO2,LY6E,MARCKS,MT1M,MX1,MX2,OAS1,OAS2,PLSCR1,PSMA4,PSMA6,PSMB9,PSME1,PSME2,PYHIN1,SERPINA1,SERPING1,SP110,TAP1,TNFSF10,TRIM21,TRIM22,UBE2D3,USP18,VRK2",55,"ANXA2,APOBEC3B,BIRC4BP,BLVRA,CD74,CEBPB,CREG1,EIF4A1,FCGR3A,FPRL1,GLRX,HERC5,HSBP1,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IL1RN,ISG15,ISGF3G,LAP3,LGALS3BP,LMO2,LY6E,MARCKS,MT1M,MX1,MX2,OAS1,OAS2,PLSCR1,PSMA4,PSMA6,PSMB9,PSME1,PSME2,PYHIN1,SERPINA1,SERPING1,SP110,TAP1,TNFSF10,TRIM21,TRIM22,UBE2D3,USP18,VRK2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40891,ATTENUVAX,LA,MEASLES,DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_DN,VIRUS,DOWN,VACCINE,COMPARISON,D14,D,14,15-25,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_DN,"Cellular immunity to measles vaccination is not fully understood at the effector response and gene expression levels. We enrolled 15 healthy individuals (15-25 years old) previously vaccinated with two doses of measles-mumps-rubella-II vaccine to characterize their cellular immunity. We detected a spectrum of lymphoproliferative response (median stimulation indices of 3.4), low precursor frequencies of interferon-gamma (median 0.11%) and interleukin-4 (median 0.05%) by Elispot, and cosecretion of Th1 and Th2 cytokines after measles virus stimulation. Further, global gene expression was examined in five subjects from this cohort after vaccination with an additional dose of measles vaccine (Attenuax, Merck) to identify the genes involved in measles immunity. Linear mixed effect models were used to identify genes significantly up or downregulated in vivo between baseline and Days 7 and 14 after measles vaccination. Measles vaccination induced upregulation of a set of 80 genes, which play a role in measles immunity, signal transduction, apoptosis, cell proliferation, and metabolic pathways. Among the 34 genes that were downregulated, only interferon-alpha is known to have a direct role in measles immunity. This study suggests that measles vaccination leads to activation of multiple cellular mechanisms that can override the immunosuppressant effects of the measles virus and induce immunity.","Genes down-regulated in peripheral blood mononuclear cell 7d or 14d vs 0d in adults (15-25) after exposure to Attenuvax , time point 7 or 14D , administered subcutaneous","Dhiman N,Ovsyannikova IG,Oberg AL,Grill DE,Jacobson RM,Poland GA",16571413,HUMAN_SEQ_ACCESSION,"SCEL,RBM6,MOXD1,CBS,XPC,APPBP2,ARHGAP11A,IFNA1,GCLM,PDK3,RBP1,ABCB4,ERBB3,RIN2,HGF,OPCML,RCVRN,DHPS,NOTCH3",19,"AF045941,AF069517,AL080058,CBS,D21089,D86981,D87717,J00210,L35546,L42452,M11433,M23234,M34309,M37190,M73239,OPCML,S43855,U26266,U97669",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-6.xlsx,NA,NA,NA,NA
M41205,ATTENUVAX,LA,MEASLES,DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_UP,VIRUS,UP,VACCINE,COMPARISON,D14,D,14,15-25,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/DHIMAN_PBMC_ATTENUVAX_AGE_15_25YO_SUBQ_7_OR_14DY_UP,"Cellular immunity to measles vaccination is not fully understood at the effector response and gene expression levels. We enrolled 15 healthy individuals (15-25 years old) previously vaccinated with two doses of measles-mumps-rubella-II vaccine to characterize their cellular immunity. We detected a spectrum of lymphoproliferative response (median stimulation indices of 3.4), low precursor frequencies of interferon-gamma (median 0.11%) and interleukin-4 (median 0.05%) by Elispot, and cosecretion of Th1 and Th2 cytokines after measles virus stimulation. Further, global gene expression was examined in five subjects from this cohort after vaccination with an additional dose of measles vaccine (Attenuax, Merck) to identify the genes involved in measles immunity. Linear mixed effect models were used to identify genes significantly up or downregulated in vivo between baseline and Days 7 and 14 after measles vaccination. Measles vaccination induced upregulation of a set of 80 genes, which play a role in measles immunity, signal transduction, apoptosis, cell proliferation, and metabolic pathways. Among the 34 genes that were downregulated, only interferon-alpha is known to have a direct role in measles immunity. This study suggests that measles vaccination leads to activation of multiple cellular mechanisms that can override the immunosuppressant effects of the measles virus and induce immunity.","Genes up-regulated in peripheral blood mononuclear cell 7d or 14d vs 0d in adults (15-25) after exposure to Attenuvax , time point 7 or 14D , administered subcutaneous","Dhiman N,Ovsyannikova IG,Oberg AL,Grill DE,Jacobson RM,Poland GA",16571413,HUMAN_SEQ_ACCESSION,"SLC11A2,FCHO1,ZSCAN12,MAGI1,KLK11,COBL,GIGYF2,PIGL,EPM2AIP1,BCAS2,SOGA1,RPGRIP1L,ITGB1BP1,SRSF8,UBE2V2,MAGEC1,UPK1A,MATN3,BBC3,PSMD3,UBE2N,NPY6R,TST,PFN1,DARS1,CKMT2,ASCL1,PROCR,EEA1,YES1,PLS3,S1PR1,F2R,HNRNPAB,ASPA,RNASE1,SPRR2A,SLC19A1,CIITA,UNC119,ADAM9,SMARCD2,ATF2,COL8A1,GATA3,ABCG1,RYR2,SPIN2A,SGK1,PLK4,ZNF710-AS1",51,"AB004857,AB006628,AB007886,AB010894,AB012917,AB014533,AB014542,AB017165,AB018309,AB020623,AB020696,AB023222,AF012024,AF031166,AF049140,AF056334,AF085807,AJ224741,BBC3,D67025,D83004,D86519,D87292,J03191,J05032,J05401,L08424,L35545,L40157,M15990,M22299,M31210,M62424,M65028,S67156,S79281,SPRR2A,U17566,U18259,U40998,U41766,U66618,X15875,X57527,X58072,X91249,X98330,Y09858,Y10032,Y13115,ZNF710-AS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M41111,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_IFN_SUBSET_UP,VIRUS,UP,SUBSET,SIGNATURE,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_IFN_SUBSET_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-50) after exposure to FluMist , time point 3D. Comment: Molecular signature induced by LAIV vaccination. (a) Interferon (IFN)-related genes differentially expressed after LAIV vaccination","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"CASP1,CD14,CD86,CIITA,CTSB,IFI35,IL10RB,IRF5,IRF7,JAK2,MX1,MX2,MYD88,OAS1,OAS2,OAS3,PECAM1,PLSCR1,PSMB10,PSMB9,SMURF2,STAT1,STAT2,TICAM2,TLR7,TLR8,TNFSF10,TNFSF13,TNFSF13B,TRIM22,UNC93B1,XAF1",32,"CASP1,CD14,CD86,CIITA,CTSB,IFI35,IL10RB,IRF5,IRF7,JAK2,MX1,MX2,MYD88,OAS1,OAS2,OAS3,PECAM1,PLSCR1,PSMB10,PSMB9,SMURF2,STAT1,STAT2,TICAM2,TLR7,TLR8,TNFSF10,TNFSF13,TNFSF13B,TRIM22,UNC93B1,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40973,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_DN,VIRUS,DOWN,SUBSET,SIGNATURE,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to FluMist , time point 7D. Comment: Molecular signature induced by LAIV vaccination. (a) Interferon (IFN)-related genes differentially expressed after LAIV vaccination","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"CDKN1B,CSNK1A1,CXCL1,ICAM1,IFITM2,CXCL8,OSM,PMAIP1,SOCS3,TRAF6",10,"CDKN1B,CSNK1A1,CXCL1,ICAM1,IFITM2,IL8,OSM,PMAIP1,SOCS3,TRAF6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 7A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962691/figure/F7/,NA,NA,NA,NA
M41050,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_UP,VIRUS,UP,SUBSET,SIGNATURE,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_IFN_SUBSET_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to FluMist , time point 7D. Comment: Molecular signature induced by LAIV vaccination. (a) Interferon (IFN)-related genes differentially expressed after LAIV vaccination","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"APOBEC3G,AZI2,BCL2,C3AR1,CD244,CREBBP,CSF1R,DNAJA3,EIF2S1,ERAP1,HDAC1,HDAC2,ICAM2,IFI16,IKBKB,IL27RA,IL6R,IRAK3,IRF3,IRF8,ITGA4,ITGAL,ITGB2,JUN,KAT2B,MAP3K7,MAVS,PTPN6,SMARCA4,STAT6,TP53,TRADD,UBA7",33,"APOBEC3G,AZI2,BCL2,C3AR1,CD244,CREBBP,CSF1R,DNAJA3,EIF2S1,ERAP1,HDAC1,HDAC2,ICAM2,IFI16,IKBKB,IL27RA,IL6R,IRAK3,IRF3,IRF8,ITGA4,ITGAL,ITGB2,JUN,KAT2B,MAP3K7,MAVS,PTPN6,SMARCA4,STAT6,TP53,TRADD,UBA7",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40936,TC-83,LA,VEEV,ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_DN,VIRUS,DOWN,SUBSET,SIGNATURE,H24,H,24,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_DN,"Venezuelan equine encephalitis virus (VEEV) is a positive-strand RNA Alphavirus endemic in Central and South America, and the causative agent of fatal encephalitis in humans. In an effort to better understand the mechanisms of infection, including differences between people who produce a neutralizing antibody response to the vaccine and those who do not, we performed whole genome transcriptional analysis in human PBMCs exposed in vitro to the live-attenuated vaccine strain of VEEV, TC-83. We compared the molecular responses in cells from three groups of individuals: naive; previously vaccinated individuals who developed a neutralizing antibody response to the vaccine (responders); and those who did not develop a neutralizing antibody response to the vaccine (nonresponders). Overall, the changes in gene expression were more intense for the naive group after TC-83 challenge and least potent in the nonresponder group. The main canonical pathways revealed the involvement of interferon and interferon-induced pathways, as well as toll-like receptors TLR- and interleukin (IL)-12-related pathways. HLA class II genotype and suppression of transcript expression for TLR2, TLR4 and TLR8 in the nonresponder group may help explain the lack of vaccine response in this study group. Because TL3 and TLR7 transcripts were elevated in all study groups, these factors may be indicators of the infection and not the immunological state of the individuals. Biomarkers were identified that differentiate between the vaccine responder and the vaccine nonresponder groups. The identified biomarkers were contrasted against transcripts that were unique to the naive population alone upon induction with TC-83. Biomarker analysis allowed for the discernment between the naive (innate) responses; the responder (recall) responses; and the nonresponder (alternative) changes to gene transcription that were caused by infection with TC-83. The study also points to the existence of HLA haplotypes that may discriminate between vaccine low- and high-responder phenotypes.","Genes down-regulated in peripheral blood mononuclear cell 24h vs 0h in adults (18-45) (non-responders (previously immunized)) after exposure to Live attenuated vaccine TC-83 , time point 24H. Comment: initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways","Erwin-Cohen R,Porter A,Pittman P,Rossi C,Dasilva L",22617845,HUMAN_GENE_SYMBOL,"C1QA,C1QB,C5AR1,CCL7,CEBPB,CLEC7A,FOS,CXCL8,ITGAX,NLRC4,RXRA,SPI1,TLR4,TLR8,TYROBP",15,"C1QA,C1QB,C5AR1,CCL7,CEBPB,CLEC7A,FOS,IL8,ITGAX,NLRC4,RXRA,SPI1,TLR4,TLR8,TYROBP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5e,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/figure/F5/,NA,NA,NA,NA
M41095,TC-83,LA,VEEV,ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,VIRUS,UP,SUBSET,SIGNATURE,H24,H,24,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,"Venezuelan equine encephalitis virus (VEEV) is a positive-strand RNA Alphavirus endemic in Central and South America, and the causative agent of fatal encephalitis in humans. In an effort to better understand the mechanisms of infection, including differences between people who produce a neutralizing antibody response to the vaccine and those who do not, we performed whole genome transcriptional analysis in human PBMCs exposed in vitro to the live-attenuated vaccine strain of VEEV, TC-83. We compared the molecular responses in cells from three groups of individuals: naive; previously vaccinated individuals who developed a neutralizing antibody response to the vaccine (responders); and those who did not develop a neutralizing antibody response to the vaccine (nonresponders). Overall, the changes in gene expression were more intense for the naive group after TC-83 challenge and least potent in the nonresponder group. The main canonical pathways revealed the involvement of interferon and interferon-induced pathways, as well as toll-like receptors TLR- and interleukin (IL)-12-related pathways. HLA class II genotype and suppression of transcript expression for TLR2, TLR4 and TLR8 in the nonresponder group may help explain the lack of vaccine response in this study group. Because TL3 and TLR7 transcripts were elevated in all study groups, these factors may be indicators of the infection and not the immunological state of the individuals. Biomarkers were identified that differentiate between the vaccine responder and the vaccine nonresponder groups. The identified biomarkers were contrasted against transcripts that were unique to the naive population alone upon induction with TC-83. Biomarker analysis allowed for the discernment between the naive (innate) responses; the responder (recall) responses; and the nonresponder (alternative) changes to gene transcription that were caused by infection with TC-83. The study also points to the existence of HLA haplotypes that may discriminate between vaccine low- and high-responder phenotypes.","Genes up-regulated in peripheral blood mononuclear cell 24h vs 0h in adults (18-45) (naive (not previously immunized)) after exposure to Live attenuated vaccine TC-83 , time point 24H. Comment: significant genes chosen for membership in canonical pathways","Erwin-Cohen R,Porter A,Pittman P,Rossi C,Dasilva L",22617845,HUMAN_GENE_SYMBOL,"CCL3,CCL7,CD38,CXCL11,RIGI,EIF2AK2,ENPP2,HSH2D,IFIH1,IFIT2,IFNA1,IFNA10,IFNA14,IFNA16,IFNA17,IFNA2,IFNA21,IFNA4,IFNA5,IFNA7,IFNA8,IFNB1,IFNE,IFNG,IL15,IL6,IRF7,LAMP3,NEXN,OAS1,OAS2,OAS3,SAMD9L,SLAMF7,STAT1,TLR3,TNF,TNFSF10,XAF1",39,"CCL3,CCL7,CD38,CXCL11,DDX58,EIF2AK2,ENPP2,HSH2D,IFIH1,IFIT2,IFNA1,IFNA10,IFNA14,IFNA16,IFNA17,IFNA2,IFNA21,IFNA4,IFNA5,IFNA7,IFNA8,IFNB1,IFNE,IFNG,IL15,IL6,IRF7,LAMP3,NEXN,OAS1,OAS2,OAS3,SAMD9L,SLAMF7,STAT1,TLR3,TNF,TNFSF10,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1B, Tab DEGs_LAIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M40980,TC-83,LA,VEEV,ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,VIRUS,UP,SUBSET,SIGNATURE,H24,H,24,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NON_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,"Venezuelan equine encephalitis virus (VEEV) is a positive-strand RNA Alphavirus endemic in Central and South America, and the causative agent of fatal encephalitis in humans. In an effort to better understand the mechanisms of infection, including differences between people who produce a neutralizing antibody response to the vaccine and those who do not, we performed whole genome transcriptional analysis in human PBMCs exposed in vitro to the live-attenuated vaccine strain of VEEV, TC-83. We compared the molecular responses in cells from three groups of individuals: naive; previously vaccinated individuals who developed a neutralizing antibody response to the vaccine (responders); and those who did not develop a neutralizing antibody response to the vaccine (nonresponders). Overall, the changes in gene expression were more intense for the naive group after TC-83 challenge and least potent in the nonresponder group. The main canonical pathways revealed the involvement of interferon and interferon-induced pathways, as well as toll-like receptors TLR- and interleukin (IL)-12-related pathways. HLA class II genotype and suppression of transcript expression for TLR2, TLR4 and TLR8 in the nonresponder group may help explain the lack of vaccine response in this study group. Because TL3 and TLR7 transcripts were elevated in all study groups, these factors may be indicators of the infection and not the immunological state of the individuals. Biomarkers were identified that differentiate between the vaccine responder and the vaccine nonresponder groups. The identified biomarkers were contrasted against transcripts that were unique to the naive population alone upon induction with TC-83. Biomarker analysis allowed for the discernment between the naive (innate) responses; the responder (recall) responses; and the nonresponder (alternative) changes to gene transcription that were caused by infection with TC-83. The study also points to the existence of HLA haplotypes that may discriminate between vaccine low- and high-responder phenotypes.","Genes up-regulated in peripheral blood mononuclear cell 24h vs 0h in adults (18-45) (non-responders (previously immunized)) after exposure to Live attenuated vaccine TC-83 , time point 24H. Comment: initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways","Erwin-Cohen R,Porter A,Pittman P,Rossi C,Dasilva L",22617845,HUMAN_GENE_SYMBOL,"ALDH8A1,ATP8A1,CD160,CD38,CXCL11,RIGI,HSH2D,IFIT2,MYH3,NEXN,PF4,RASGRP1,SAMD9L,TAF15,TLR3,TNFSF10,USF1,XAF1",18,"ALDH8A1,ATP8A1,CD160,CD38,CXCL11,DDX58,HSH2D,IFIT2,MYH3,NEXN,PF4,RASGRP1,SAMD9L,TAF15,TLR3,TNFSF10,USF1,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1B, Tab DEGs_LAIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M41094,TC-83,LA,VEEV,ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,VIRUS,UP,SUBSET,SIGNATURE,H24,H,24,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP,"Venezuelan equine encephalitis virus (VEEV) is a positive-strand RNA Alphavirus endemic in Central and South America, and the causative agent of fatal encephalitis in humans. In an effort to better understand the mechanisms of infection, including differences between people who produce a neutralizing antibody response to the vaccine and those who do not, we performed whole genome transcriptional analysis in human PBMCs exposed in vitro to the live-attenuated vaccine strain of VEEV, TC-83. We compared the molecular responses in cells from three groups of individuals: naive; previously vaccinated individuals who developed a neutralizing antibody response to the vaccine (responders); and those who did not develop a neutralizing antibody response to the vaccine (nonresponders). Overall, the changes in gene expression were more intense for the naive group after TC-83 challenge and least potent in the nonresponder group. The main canonical pathways revealed the involvement of interferon and interferon-induced pathways, as well as toll-like receptors TLR- and interleukin (IL)-12-related pathways. HLA class II genotype and suppression of transcript expression for TLR2, TLR4 and TLR8 in the nonresponder group may help explain the lack of vaccine response in this study group. Because TL3 and TLR7 transcripts were elevated in all study groups, these factors may be indicators of the infection and not the immunological state of the individuals. Biomarkers were identified that differentiate between the vaccine responder and the vaccine nonresponder groups. The identified biomarkers were contrasted against transcripts that were unique to the naive population alone upon induction with TC-83. Biomarker analysis allowed for the discernment between the naive (innate) responses; the responder (recall) responses; and the nonresponder (alternative) changes to gene transcription that were caused by infection with TC-83. The study also points to the existence of HLA haplotypes that may discriminate between vaccine low- and high-responder phenotypes.","Genes up-regulated in peripheral blood mononuclear cell 24h vs 0h in adults (18-45) (responders (previously immunized)) after exposure to Live attenuated vaccine TC-83 , time point 24H. Comment: initial exposure 2-10 months before PBMCs drawn. significant genes chosen for membership in canonical pathways","Erwin-Cohen R,Porter A,Pittman P,Rossi C,Dasilva L",22617845,HUMAN_GENE_SYMBOL,"CCR5,CCRL2,CD38,CD68,CXCL11,RIGI,EIF2AK2,EPDR1,HSH2D,IFIH1,IFIT2,IFNA1,IFNA14,IFNA16,IFNA2,IFNA21,IFNA4,IFNA7,IFNA8,IFNB1,IL15,IRF7,LYN,NEXN,NOD2,OAS1,OAS2,OAS3,SAMD9L,TCN2,TLR3,TNF,TNFSF10,XAF1",34,"CCR5,CCRL2,CD38,CD68,CXCL11,DDX58,EIF2AK2,EPDR1,HSH2D,IFIH1,IFIT2,IFNA1,IFNA14,IFNA16,IFNA2,IFNA21,IFNA4,IFNA7,IFNA8,IFNB1,IL15,IRF7,LYN,NEXN,NOD2,OAS1,OAS2,OAS3,SAMD9L,TCN2,TLR3,TNF,TNFSF10,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1A, Tab DEGs_TIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M41059,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_336HR_SUSTAINED_UP,BACTERIUM,UP,SUBSET,SIGNATURE,H336,H,336,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_336HR_SUSTAINED_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell (18 to 336)h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 18 to 336H. Comment: Pattern 3, sustained-up. These approx 9 of 42 genes in pattern linked to immune function.","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"ARRB1,ATL3,CD300A,LRP1,M6PR,MAPKAPK3,SPN,TXNIP,VAMP8",9,"ARRB1,ATL3,CD300A,LRP1,M6PR,MAPKAPK3,SPN,TXNIP,VAMP8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40960,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_DN,BACTERIUM,DOWN,SUBSET,SIGNATURE,H48,H,48,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_DN,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes down-regulated in peripheral blood mononuclear cell (18 to 48)h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 18 to 48H. Comment: Pattern 4, down early. These 21 of 56 genes in pattern linked to immune-related functions.","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"CCL5,CD28,CD37,CD3D,CD3E,CD3G,CD40,CD96,EIF3M,F11R,F2R,FASLG,GSPT1,IFNA10,IFNA17,KLF2,KLRC3,KLRK1,NACA,NAP1L1,NKG7,NKTR,NOSIP,NUMA1,PPP2R5C,PRKCH,PTPRCAP,RHOH,RORA,STAT3,STMN3,TNF,TNFRSF25,TRAF1,TRAF5,TRBV19,UBE3A,ZAP70",38,"CCL5,CD28,CD37,CD3D,CD3E,CD3G,CD40,CD96,EIF3M,F11R,F2R,FASLG,GSPT1,IFNA10,IFNA17,KLF2,KLRC3,KLRK1,NACA,NAP1L1,NKG7,NKTR,NOSIP,NUMA1,PPP2R5C,PRKCH,PTPRCAP,RHOH,RORA,STAT3,STMN3,TNF,TNFRSF25,TRAF1,TRAF5,TRBV19,UBE3A,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/bin/jiy420_suppl_supplementary_table_1.xlsx,NA,NA,NA,NA
M40968,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_UP,BACTERIUM,UP,SUBSET,SIGNATURE,H48,H,48,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_48HR_EARLY_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell (18 to 48)h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 18 to 48H. Comment: Pattern 6, up early","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"CD302,CD36,CLEC4A,CREG1,CSF2RA,CSF2RB,ENTPD1,FCGR2A,GLIPR1,IL13RA1,IL18,IRAK3,LAMP2,LILRA6,LY96,NCF2,QPCT,RNASE2,SKAP2",19,"CD302,CD36,CLEC4A,CREG1,CSF2RA,CSF2RB,ENTPD1,FCGR2A,GLIPR1,IL13RA1,IL18,IRAK3,LAMP2,LILRA6,LY96,NCF2,QPCT,RNASE2,SKAP2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40976,ZOSTAVAX,LA,VZV,PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP,VIRUS,UP,SUBSET,TOP DEGS,H6,H,6,70-93,ELDER,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PATEL_SKIN_OF_BODY_ZOSTAVAX_AGE_70_93YO_VZV_CHALLENGE_6HR_TOP_30_DEG_UP,"Background: The live attenuated vaccine Zostavax was developed to prevent varicella zoster virus (VZV) reactivation that causes herpes zoster (shingles) in older humans. However, the impact of vaccination on the cutaneous response to VZV is not known. Methods: We investigated the response to intradermal VZV antigen challenge before and after Zostavax vaccination in participants > 70 years of age by immunohistological and transcriptomic analyses of skin biopsy specimens collected from the challenge site. Results: Vaccination increased the proportion of VZV-specific CD4+ T cells in the blood and promoted the accumulation of both CD4+ and CD8+ T cells in the skin after VZV antigen challenge. However, Zostavax did not alter the proportion of resident memory T cells (CD4+ and CD8+) or CD4+Foxp3+ regulatory T cells in unchallenged skin. After vaccination, there was increased cutaneous T-cell proliferation at the challenge site and also increased recruitment of T cells from the blood, as indicated by an elevated T-cell migratory gene signature. CD8+ T-cell-associated functional genes were also highly induced in the skin after vaccination. Conclusion: Zostavax vaccination does not alter the abundance of cutaneous resident memory T cells but instead increases the recruitment of VZV-specific T cells from the blood and enhances T-cell activation, particularly cells of the CD8+ subset, in the skin after VZV antigen challenge.","Genes up-regulated in skin of body 6hr vs 0hr in adults (70-93) (VZV challenge) after exposure to Zostavax , time point 6H. Comment: A List of the top 30 genes upregulated at 6 hours post VZV challenge","Patel NP,Vukmanovic-Stejic M,Suarez-Farinas M,Chambers ES,Sandhu D,Fuentes-Duculan J,Mabbott NA,Rustin MHA,Krueger J,Akbar AN",30247603,HUMAN_GENE_SYMBOL,"ADAMTS8,BCL2A1,CCL2,CCL3,CCL8,CH25H,CXCL1,CXCL10,CXCL2,CXCL9,FCGR1A,FCGR1BP,FOSL1,FPR1,GZMB,ICAM1,IL1B,IL1RL1,IL6,CXCL8,IRF1,MMP12,OASL,PTX3,RGS16,SELE,SELL,SERPINA1,UBD",29,"ADAMTS8,BCL2A1,CCL2,CCL3,CCL8,CH25H,CXCL1,CXCL10,CXCL2,CXCL9,FCGR1A,FCGR1B,FOSL1,FPR1,GZMB,ICAM1,IL1B,IL1RL1,IL6,IL8,IRF1,MMP12,OASL,PTX3,RGS16,SELE,SELL,SERPINA1,UBD",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41076,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_13_16YO_STIMULATED_VS_UNSTIMULATED_3_TO_7YR_POST_TOP_DEG_UP,VIRUS,UP,SUBSET,TOP DEGS,Y7,W,7,13-16,ADOLESCENT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_13_16YO_STIMULATED_VS_UNSTIMULATED_3_TO_7YR_POST_TOP_DEG_UP,"Immune responses to current rubella vaccines demonstrate significant inter-individual variability. We performed mRNA-Seq profiling on PBMCs from high and low antibody responders to rubella vaccination to delineate transcriptional differences upon viral stimulation. Generalized linear models were used to assess the per gene fold change (FC) for stimulated versus unstimulated samples or the interaction between outcome and stimulation. Model results were evaluated by both FC and p-value. Pathway analysis and self-contained gene set tests were performed for assessment of gene group effects. Of 17,566 detected genes, we identified 1,080 highly significant differentially expressed genes upon viral stimulation (p < 1.00E(-15), FDR < 1.00E(-14)), including various immune function and inflammation-related genes, genes involved in cell signaling, cell regulation and transcription, and genes with unknown function. Analysis by immune outcome and stimulation status identified 27 genes (p <= 0.0006 and FDR <= 0.30) that responded differently to viral stimulation in high vs. low antibody responders, including major histocompatibility complex (MHC) class I genes (HLA-A, HLA-B and B2M with p = 0.0001, p = 0.0005 and p = 0.0002, respectively), and two genes related to innate immunity and inflammation (EMR3 and MEFV with p = 1.46E(-08) and p = 0.0004, respectively). Pathway and gene set analysis also revealed transcriptional differences in antigen presentation and innate/inflammatory gene sets and pathways between high and low responders. Using mRNA-Seq genome-wide transcriptional profiling, we identified antigen presentation and innate/inflammatory genes that may assist in explaining rubella vaccine-induced immune response variations. Such information may provide new scientific insights into vaccine-induced immunity useful in rational vaccine development and immune response monitoring.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in children (13-16) after exposure to M-M-R II , time point 3 to 7Y. Comment: top differentially expressed genes, full set of 1080 avail in Suppl Materials","Haralambieva IH,Oberg AL,Ovsyannikova IG,Kennedy RB,Grill DE,Middha S,Bot BM,Wang VW,Smith DI,Jacobson RM,Poland GA",23658707,HUMAN_GENE_SYMBOL,"AQP9,ARHGEF28,ARRDC4,B3GNT5,CCL18,CCL23,CLEC1A,CXCL6,DLC1,ENPP2,FAM135B,FAM20A,FFAR4,FGD5,FN1,GNG12,IL1B,LYVE1,MLXIPL,NRP1,OLR1,PCOLCE2,PDPN,PPIC,PPP1R14C,PROCR,S1PR3,SERPINA1,SERPINE1,SGMS2,SHROOM4,SIGLEC11,SLC39A8,SPINT1,SPRED1,TIMP4,TMEM52B,TMTC1,TNFAIP8L3,TNFRSF12A,TREM1,VSIG4",42,"AQP9,ARHGEF28,ARRDC4,B3GNT5,CCL18,CCL23,CLEC1A,CXCL6,DLC1,ENPP2,FAM135B,FAM20A,FFAR4,FGD5,FN1,GNG12,IL1B,LYVE1,MLXIPL,NRP1,OLR1,PCOLCE2,PDPN,PPIC,PPP1R14C,PROCR,S1PR3,SERPINA1,SERPINE1,SGMS2,SHROOM4,SIGLEC11,SLC39A8,SPINT1,SPRED1,TIMP4,TMEM52B,TMTC1,TNFAIP8L3,TNFRSF12A,TREM1,VSIG4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41126,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_UP,VIRUS,UP,VACCINE,VAC ONLY,ANY,ANY,ANY,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell in adults (18-40) after exposure to YF-Vax , time point anyD","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"APOD,CACNA2D2,HAND1,LIMD2,NHLH2,NRBP2,PYCR2,SYNGR3,TAGLN3,THRB",10,"APOD,CACNA2D2,HAND1,LIMD2,NHLH2,NRBP2,PYCR2,SYNGR3,TAGLN3,THRB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Additional File 2, Tab A BCG",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654906/bin/1755-8794-2-10-S2.xls,NA,NA,NA,NA
M41119,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_DN,VIRUS,DOWN,VACCINE,VAC ONLY,ANY,ANY,ANY,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_AGE_18_40YO_ANYD_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell in adults (18-40) after exposure to YF-Vax , time point anyD","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"APRT,ATP5MJ,TMEM259,BRAT1,CCNI,COL6A2,CORO1A,DPP7,EGLN2,EIF4B,FBXW5,LIF,NDUFV1,PRB3,RPS13,RPS2,RPS7,SLC25A6,VAV1",19,"APRT,C14orf2,C19orf6,C7orf27,CCNI,COL6A2,CORO1A,DPP7,EGLN2,EIF4B,FBXW5,LIF,NDUFV1,PRB3,RPS13,RPS2,RPS7,SLC25A6,VAV1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41124,ZOSTAVAX,LA,VZV,LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,25-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_1DY_UP,"Herpes zoster (shingles) causes significant morbidity in immune compromised hosts and older adults. Whereas a vaccine is available for prevention of shingles, its efficacy declines with age. To help to understand the mechanisms driving vaccinal responses, we constructed a multiscale, multifactorial response network (MMRN) of immunity in healthy young and older adults immunized with the live attenuated shingles vaccine Zostavax. Vaccination induces robust antigen-specific antibody, plasmablasts, and CD4<sup>+</sup> T cells yet limited CD8<sup>+</sup> T cell and antiviral responses. The MMRN reveals striking associations between orthogonal datasets, such as transcriptomic and metabolomics signatures, cell populations, and cytokine levels, and identifies immune and metabolic correlates of vaccine immunity. Networks associated with inositol phosphate, glycerophospholipids, and sterol metabolism are tightly coupled with immunity. Critically, the sterol regulatory binding protein 1 and its targets are key integrators of antibody and T follicular cell responses. Our approach is broadly applicable to study human immunity and can help to identify predictors of efficacy as well as mechanisms controlling immunity to vaccination.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (25-40/60-79) after exposure to Zostavax , time point 1D","Li S,Sullivan NL,Rouphael N,Yu T,Banton S,Maddur MS,McCausland M,Chiu C,Canniff J,Dubey S,Liu K,Tran V,Hagan T,Duraisingham S,Wieland A,Mehta AK,Whitaker JA,Subramaniam S,Jones DP,Sette A,Vora K,Weinberg A,Mulligan MJ,Nakaya HI,Levin M,Ahmed R,Pulendran B",28502771,HUMAN_GENE_SYMBOL,"CCL5,GZMH,MYO6,PSPH,S1PR5,SLC22A16,TARP",7,"CCL5,GZMH,MYO6,PSPH,S1PR5,SLC22A16,TARP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/bin/NIHMS871779-supplement-2.tiff,NA,NA,NA,NA
M40890,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D2-4,D,3,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell (2 to 4)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 2 to 4D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ADSL,ATP5PO,CCL5,CD3D,COL21A1,CRIP1,CSTB,DGUOK,DRG1,EIF3F,ENG,FNTA,GLIPR1,GRIA1,HMGCL,IGKC,IL15RA,KLRB1,LIMCH1,MRPL3,MRPL58,PATJ,PEX7,PLA2G1B,POLR2H,RNASE6,RPL12,RPL13A,RPL19,RPLP1,RPS21,RPS4Y1,S100A4,SLC25A20,TRO,TTK,TXNDC5,UQCR11",38,"ADSL,ATP5O,CCL5,CD3D,COL21A1,CRIP1,CSTB,DGUOK,DRG1,EIF3F,ENG,FNTA,GLIPR1,GRIA1,HMGCL,IGKC,IL15RA,KLRB1,LIMCH1,MRPL3,MRPL58,PATJ,PEX7,PLA2G1B,POLR2H,RNASE6,RPL12,RPL13A,RPL19,RPLP1,RPS21,RPS4Y1,S100A4,SLC25A20,TRO,TTK,TXNDC5,UQCR11",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-6.xlsx,NA,NA,NA,NA
M40887,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D2-4,D,3,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_2_TO_4DY_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell (2 to 4)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 2 to 4D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ADM,ANKRD22,ANXA3,AQP9,ATF3,ATG2A,BCL2A1,BCL6,C2,CD63,CEACAM1,CEBPB,CLSTN3,CXCL10,CXCR1,DNM1,DSC2,DYSF,FCGR1A,FCGR2B,FCGR3A,FGL2,FPR1,GAB2,GBP2,GCH1,HBB,HBD,HERC5,HLX,HMCES,ICAM1,IER3,IFI44,IFI44L,IFIT1,IFIT3,IGF2R,IL15,IRF1,KCNJ15,LAP3,LIMK2,MCL1,MX1,MXD1,NAMPT,NFIL3,OR2V2,PFKFB3,PTPRJ,RSAD2,SERPING1,SLC12A7,SLC35A2,SOCS3,SOD2,STAT1,TBXT,UBE2L6,VNN2,WARS1,ZNFX1",63,"ADM,ANKRD22,ANXA3,AQP9,ATF3,ATG2A,BCL2A1,BCL6,C2,CD63,CEACAM1,CEBPB,CLSTN3,CXCL10,CXCR1,DNM1,DSC2,DYSF,FCGR1A,FCGR2B,FCGR3A,FGL2,FPR1,GAB2,GBP2,GCH1,HBB,HBD,HERC5,HLX1,HMCES,ICAM1,IER3,IFI44,IFI44L,IFIT1,IFIT3,IGF2R,IL15,IRF1,KCNJ15,LAP3,LIMK2,MCL1,MX1,MXD1,NAMPT,NFIL3,OR2V2,PFKFB3,PTPRJ,RSAD2,SERPING1,SLC12A7,SLC35A2,SOCS3,SOD2,STAT1,TBXT,UBE2L6,VNN2,WARS,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T4/,NA,NA,NA,NA
M41089,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-50) after exposure to FluMist , time point 3D. Comment: Supplementary Table 1b: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA1,ABHD13,ABHD5,ADAM8,ADNP2,GRK2,AFF4,AHCTF1,AKAP8,ALKBH5,ANGEL2,ANKDD1A,ANKRD28,ANKRD33B,AP1G1,AP3M2,APPL2,ARAF,ARAP3,AREL1,ARID3B,ARID4A,ARIH1,ARIH2,ARL4C,ARMC8,ARMCX5,BMAL1,ARPP19,ASB6,ATAD2,ATG14,ATG16L1,ATL2,ATP11B,ATP2B1,ATP6V1H,ATXN1,ATXN7,B3GNT2,BACH2,BAZ2A,BBX,BCCIP,BCL7B,BCLAF1,BCR,BHLHE40,BOD1L1,BOLA2,BRAP,BRD1,BRD7,BRPF3,BRWD1,BSDC1,ABTB3,BTG3,EDRF1,C12orf29,TIGAR,RGCC,TEX30,BORA,MZT1,C14orf28,EMC7,HAPSTR1,CFAP20,RMC1,SUCO,FAM209A,FAM209B,FAM210B,HMCES,TRMO,PRXL2C,CAMK4,CAND1,CANT1,CAPZA1,CASP3,CASS4,CBX4,CCDC186,CEP95,CCDC66,CCNH,CCNL1,CCNT1,CD28,CD44,CD59,CD69,CDC37L1,CDC42,CDC73,CDK11A,CDK12,CDK17,CDK7,CDR2,CDS2,CEBPB,CEBPZ,CENPC,CGRRF1,CHD1,CHD2,CHD7,CHIC2,CHORDC1,CHST11,CIR1,CISD2,CLDND1,CLK1,CLK4,CLTB,CNOT6L,CNST,COPS8,CREBRF,CRY1,CRY2,CSNK1A1,CSNK1D,CSNK1E,CSNK1G3,CTDSP2,CUL2,CUL3,CUL4A,CWC25,CWF19L1,CWF19L2,CYLD,CYP4F3,DCP1A,DCTN4,DDA1,DDIT4,DDX20,DDX24,DENND1B,DENND4A,DERL1,ESS2,DHRS13,DHX40,DHX8,DICER1,DIP2B,DIS3,DLEU2,DNAJA1,DNAJB1,DNAJB6,DNAJC2,DNAJC27,DOCK4,DPP8,DUSP4,EBLN2,EIF2AK3,EIF3A,EIF4E,EIF4G3,ELK4,ELL2,ELOVL5,EML4,EMSY,ENC1,EP300,EPC1,SELENOI,ERMN,ERO1B,ESCO1,EXOSC9,EZH2,EZR,FAF2,RAMAC,DENND6A,HYCC2,RETREG2,FAM168B,FAM169A,TVP23B,ATOSA,SINHCAF,FAM76B,FASTKD2,FBXL3,FBXO16,FBXO21,FBXO3,FBXO45,FGFR1,FGFR1OP2,FKBP11,LINC-PINT,FNBP4,FOSL2,FOXN3,FOXO1,FOXO3,FOXP1,FRYL,FUBP1,FUBP3,FUT8,G2E3,GABARAPL1,GALC,GALNT3,GATA3,GCNT7,GGNBP2,GIGYF2,GJB6,GKAP1,GMNN,GNA13,GNAI3,GNAS,GOLGA4,GPCPD1,GPR132,GPRASP1,GPRIN3,GRPEL2,GSK3B,GTPBP1,H2AZ2,HABP4,HBP1,HERC3,HEXA,HIC1,HIC2,HIPK1,H1-2,H2BC4,H2AC18,H2AC19,HIVEP1,HMGXB4,HNRNPC,HNRNPD,HNRNPH3,HNRNPL,HOOK1,HSPA14,HSPA9,IDS,IFNGR1,IFRD1,IGF1R,IMPA1,INO80D,IRF2BP2,ISCA1,ITM2A,IVNS1ABP,JAG1,JAK1,JARID2,JMJD1C,JMY,JOSD1,JUND,KBTBD2,KCTD2,KDM3A,KDM5B,KDM5C,KDM6A,KDM6B,KIF1B,KIF25,KIF5B,KLF3,KLHL24,KLHL9,KPNA3,KPNA4,KPNA5,KRAS,IGKV1-16,PPFIBP1,LATS2,LCOR,LEPROTL1,LITAF,LMNA,,LONRF3,IRAG2,LRP10,LRPAP1,LRRC8C,LRRFIP1,LUC7L2,LYSMD3,MAF,MAFF,MAK16,MAP1LC3B,MAP3K2,MAP4K4,MAPKAPK2,MARCHF6,MARF1,MBIP,MBNL2,MCM6,MCM9,MCPH1,MCTP2,MED13,MED14,MED21,MED23,MEGF6,METAP2,METRNL,NTMT1,METTL14,METTL16,MGAT5,OGA,MIDN,MIER1,MIER3,MIS12,MKNK2,CENPU,MLF2,MME,MPZL3,MRPS22,MSI2,MSL2,MTERF4,MTFP1,MYLIP,MYNN,KAT6A,NAF1,NAP1L3,NAP1L5,NCOA1,NDE1,NDFIP1,NDUFAF5,NDUFAF7,NDUFV2,NEDD1,NET1,NFKBIB,NFKBID,NFRKB,NMD3,NOP58,NR1D2,NRBF2,NSMAF,NUFIP1,NUP153,NUP160,NUP50,NUP54,NXT1,OPA1,OSBP,OSGIN2,OTUD5,PAFAH1B2,PAIP1,TENT4B,PATL1,PBXIP1,PCIF1,PDCD4,PDE12,PDE4D,PDIA3,PDK1,PDK3,PDP1,PDS5A,PDXDC1,PDXDC2P,PDZD8,PELI2,PER1,,PGRMC2,PGS1,PHACTR1,PHC1,PHF1,PHF10,PHF20L1,PHF3,PHF5A,PI4K2A,PIGA,PIGB,PIK3C2A,PIK3CA,PIK3R1,PJA2,PKN2,PLAA,PLCL1,PLCXD2,PLK3,PMAIP1,PNISR,PNO1,PNPLA8,POLB,POLR2D,POLR3E,POM121,POM121C,PPIL4,PPM1A,PPM1B,PPM1D,PPP1CB,PPP1R16B,PPP1R3B,PPP2CA,PPP2R5C,PPP3R1,PPP4R1,PPP4R2,PPP4R3A,PPP6C,PRDM2,PRKAA1,PRKCH,PRMT9,PRPF3,PSIP1,PSME4,PSPC1,PTBP2,PTP4A1,PTS,PURB,QSOX1,RAB11FIP2,RAB18,RAB30,RAB8B,RAE1,RAF1,RALGAPA2,RANBP2,RAPGEF2,RARA,RASA2,RB1CC1,RBBP6,RBM12,SCAF8,RBM26,RBM27,RBM33,RBM38,RBM39,RC3H1,RCOR3,RELA,RELB,RELL1,RFC1,RGPD5,RGPD6,RGPD8,RHBDD2,RHOH,RICTOR,RIF1,RIOK1,RMND5A,RNF10,RNF103,RNF125,RNF19A,RNF19B,RNF38,RNMT,RORA,RPS27,RPS6KA5,RPS6KB1,RRN3,RRP12,RSBN1,RTN4,RUNX3,RYK,S1PR1,SAMD4B,SAP130,SAR1A,SC5D,SCML1,SEC22C,SECISBP2L,SENP2,SENP5,SEPSECS,SERINC1,SESN2,SF3B1,SFN,SFPQ,SREK1,SFSWAP,SFXN1,SIK3,SIPA1L1,SIRT1,SLAIN1,SLAIN2,SLC12A6,SLC25A28,SLC25A36,SLC25A37,SLC26A6,SLC35D1,SLC9A8,PRELID3B,SMAD7,SMC4,SMN1,SMN2,SNW1,SNX13,SNX9,SON,SORL1,SPAG9,SPATA13,SPATA2L,SPOCK2,SPTAN1,ST7,STAG1,STAM,STAMBPL1,STK17A,STK35,STT3B,STXBP5,SUMO1,SUPV3L1,SURF4,SVIP,SYAP1,SYS1,SYTL3,TAB3,TACC1,TAF1D,TAF9B,TBC1D15,TBC1D23,TBC1D25,TBRG1,TCP11L2,TFAM,TFB2M,TFDP2,TFG,TFIP11,TGS1,THBS1,THUMPD2,THUMPD3,TIMM23,TMCC3,TMEM135,TMEM170A,TMEM39A,TMEM41B,PIP4P1,TMF1,TMPO,TMX4,TNFAIP3,TNIK,TOP1,TP53INP2,TPCN2,TPP2,TRAPPC10,TRIM23,TRIM59,RO60,TSC22D2,TSPYL2,TTC39B,TWF1,POLR1F,TXNDC11,TXNL1,UBAP2L,UBE2B,UBL3,UBN1,UBXN6,UFM1,BLTP3B,UNK,USP16,USP36,USP38,USP42,VCP,VEGFA,VIRMA,WAC,WASL,WBP11,WDR26,WDR33,WDR48,WIPF1,WIPF2,WTAP,WWP2,XCL1,YES1,YKT6,YTHDC1,ZBTB11,ZBTB2,ZBTB44,ZC3H12A,ZC3H15,ZDBF2,ZDHHC18,ZEB1,ZFC3H1,ZFP1,ZFP36L1,ZFP91,ZFR,ZFX,ZFYVE27,ZHX1,ZNF12,ZNF131,ZNF136,ZNF184,ZNF211,ZNF24,ZNF274,ZNF292,ZNF317,ZNF395,ZNF410,ZNF430,ZNF451,ZNF507,ZNF518B,ZNF567,ZNF644,ZNF708,ZNF746,ZNF791,ZNF805,ZRANB1",682,"ABCA1,ABHD13,ABHD5,ADAM8,ADNP2,ADRBK1,AFF4,AHCTF1,AKAP8,ALKBH5,ANGEL2,ANKDD1A,ANKRD28,ANKRD33B,AP1G1,AP3M2,APPL2,ARAF,ARAP3,AREL1,ARID3B,ARID4A,ARIH1,ARIH2,ARL4C,ARMC8,ARMCX5,ARNTL,ARPP19,ASB6,ATAD2,ATG14,ATG16L1,ATL2,ATP11B,ATP2B1,ATP6V1H,ATXN1,ATXN7,B3GNT2,BACH2,BAZ2A,BBX,BCCIP,BCL7B,BCLAF1,BCR,BHLHE40,BOD1L,BOLA2,BRAP,BRD1,BRD7,BRPF3,BRWD1,BSDC1,BTBD11,BTG3,C10orf137,C12orf29,C12orf5,C13orf15,C13orf27,C13orf34,C13orf37,C14orf28,C15orf24,C16orf72,C16orf80,C18orf8,C1orf9,C20orf106,C20orf107,C20orf108,C3orf37,C9orf156,C9orf21,CAMK4,CAND1,CANT1,CAPZA1,CASP3,CASS4,CBX4,CCDC186,CCDC45,CCDC66,CCNH,CCNL1,CCNT1,CD28,CD44,CD59,CD69,CDC37L1,CDC42,CDC73,CDK11A,CDK12,CDK17,CDK7,CDR2,CDS2,CEBPB,CEBPZ,CENPC1,CGRRF1,CHD1,CHD2,CHD7,CHIC2,CHORDC1,CHST11,CIR1,CISD2,CLDND1,CLK1,CLK4,CLTB,CNOT6L,CNST,COPS8,CREBRF,CRY1,CRY2,CSNK1A1,CSNK1D,CSNK1E,CSNK1G3,CTDSP2,CUL2,CUL3,CUL4A,CWC25,CWF19L1,CWF19L2,CYLD,CYP4F3,DCP1A,DCTN4,DDA1,DDIT4,DDX20,DDX24,DENND1B,DENND4A,DERL1,DGCR14,DHRS13,DHX40,DHX8,DICER1,DIP2B,DIS3,DLEU2,DNAJA1,DNAJB1,DNAJB6,DNAJC2,DNAJC27,DOCK4,DPP8,DUSP4,EBLN2,EIF2AK3,EIF3A,EIF4E,EIF4G3,ELK4,ELL2,ELOVL5,EML4,EMSY,ENC1,EP300,EPC1,EPT1,ERMN,ERO1LB,ESCO1,EXOSC9,EZH2,EZR,FAF2,FAM103A1,FAM116A,FAM126B,FAM134A,FAM168B,FAM169A,FAM18B,FAM214A,FAM60A,FAM76B,FASTKD2,FBXL3,FBXO16,FBXO21,FBXO3,FBXO45,FGFR1,FGFR1OP2,FKBP11,FLJ43663,FNBP4,FOSL2,FOXN3,FOXO1,FOXO3,FOXP1,FRYL,FUBP1,FUBP3,FUT8,G2E3,GABARAPL1,GALC,GALNT3,GATA3,GCNT7,GGNBP2,GIGYF2,GJB6,GKAP1,GMNN,GNA13,GNAI3,GNAS,GOLGA4,GPCPD1,GPR132,GPRASP1,GPRIN3,GRPEL2,GSK3B,GTPBP1,H2AFV,HABP4,HBP1,HERC3,HEXA,HIC1,HIC2,HIPK1,HIST1H1C,HIST1H2BC,HIST2H2AA3,HIST2H2AA4,HIVEP1,HMGXB4,HNRNPC,HNRNPD,HNRNPH3,HNRNPL,HOOK1,HSPA14,HSPA9,IDS,IFNGR1,IFRD1,IGF1R,IMPA1,INO80D,IRF2BP2,ISCA1,ITM2A,IVNS1ABP,JAG1,JAK1,JARID2,JMJD1C,JMY,JOSD1,JUND,KBTBD2,KCTD2,KDM3A,KDM5B,KDM5C,KDM6A,KDM6B,KIF1B,KIF25,KIF5B,KLF3,KLHL24,KLHL9,KPNA3,KPNA4,KPNA5,KRAS,L1,L2,LATS2,LCOR,LEPROTL1,LITAF,LMNA,LOC145474,LONRF3,LRMP,LRP10,LRPAP1,LRRC8C,LRRFIP1,LUC7L2,LYSMD3,MAF,MAFF,MAK16,MAP1LC3B,MAP3K2,MAP4K4,MAPKAPK2,MARCH6,MARF1,MBIP,MBNL2,MCM6,MCM9,MCPH1,MCTP2,MED13,MED14,MED21,MED23,MEGF6,METAP2,METRNL,METTL11A,METTL14,METTL16,MGAT5,MGEA5,MIDN,MIER1,MIER3,MIS12,MKNK2,MLF1IP,MLF2,MME,MPZL3,MRPS22,MSI2,MSL2,MTERFD2,MTP18,MYLIP,MYNN,MYST3,NAF1,NAP1L3,NAP1L5,NCOA1,NDE1,NDFIP1,NDUFAF5,NDUFAF7,NDUFV2,NEDD1,NET1,NFKBIB,NFKBID,NFRKB,NMD3,NOP58,NR1D2,NRBF2,NSMAF,NUFIP1,NUP153,NUP160,NUP50,NUP54,NXT1,OPA1,OSBP,OSGIN2,OTUD5,PAFAH1B2,PAIP1,PAPD5,PATL1,PBXIP1,PCIF1,PDCD4,PDE12,PDE4D,PDIA3,PDK1,PDK3,PDP1,PDS5A,PDXDC1,PDXDC2,PDZD8,PELI2,PER1,PGBD3,PGRMC2,PGS1,PHACTR1,PHC1,PHF1,PHF10,PHF20L1,PHF3,PHF5A,PI4K2A,PIGA,PIGB,PIK3C2A,PIK3CA,PIK3R1,PJA2,PKN2,PLAA,PLCL1,PLCXD2,PLK3,PMAIP1,PNISR,PNO1,PNPLA8,POLB,POLR2D,POLR3E,POM121,POM121C,PPIL4,PPM1A,PPM1B,PPM1D,PPP1CB,PPP1R16B,PPP1R3B,PPP2CA,PPP2R5C,PPP3R1,PPP4R1,PPP4R2,PPP4R3A,PPP6C,PRDM2,PRKAA1,PRKCH,PRMT10,PRPF3,PSIP1,PSME4,PSPC1,PTBP2,PTP4A1,PTS,PURB,QSOX1,RAB11FIP2,RAB18,RAB30,RAB8B,RAE1,RAF1,RALGAPA2,RANBP2,RAPGEF2,RARA,RASA2,RB1CC1,RBBP6,RBM12,RBM16,RBM26,RBM27,RBM33,RBM38,RBM39,RC3H1,RCOR3,RELA,RELB,RELL1,RFC1,RGPD5,RGPD6,RGPD8,RHBDD2,RHOH,RICTOR,RIF1,RIOK1,RMND5A,RNF10,RNF103,RNF125,RNF19A,RNF19B,RNF38,RNMT,RORA,RPS27,RPS6KA5,RPS6KB1,RRN3,RRP12,RSBN1,RTN4,RUNX3,RYK,S1PR1,SAMD4B,SAP130,SAR1A,SC5DL,SCML1,SEC22C,SECISBP2L,SENP2,SENP5,SEPSECS,SERINC1,SESN2,SF3B1,SFN,SFPQ,SFRS12,SFRS8,SFXN1,SIK3,SIPA1L1,SIRT1,SLAIN1,SLAIN2,SLC12A6,SLC25A28,SLC25A36,SLC25A37,SLC26A6,SLC35D1,SLC9A8,SLMO2,SMAD7,SMC4,SMN1,SMN2,SNW1,SNX13,SNX9,SON,SORL1,SPAG9,SPATA13,SPATA2L,SPOCK2,SPTAN1,ST7,STAG1,STAM,STAMBPL1,STK17A,STK35,STT3B,STXBP5,SUMO1,SUPV3L1,SURF4,SVIP,SYAP1,SYS1,SYTL3,TAB3,TACC1,TAF1D,TAF9B,TBC1D15,TBC1D23,TBC1D25,TBRG1,TCP11L2,TFAM,TFB2M,TFDP2,TFG,TFIP11,TGS1,THBS1,THUMPD2,THUMPD3,TIMM23,TMCC3,TMEM135,TMEM170A,TMEM39A,TMEM41B,TMEM55B,TMF1,TMPO,TMX4,TNFAIP3,TNIK,TOP1,TP53INP2,TPCN2,TPP2,TRAPPC10,TRIM23,TRIM59,TROVE2,TSC22D2,TSPYL2,TTC39B,TWF1,TWISTNB,TXNDC11,TXNL1,UBAP2L,UBE2B,UBL3,UBN1,UBXN6,UFM1,UHRF1BP1L,UNK,USP16,USP36,USP38,USP42,VCP,VEGFA,VIRMA,WAC,WASL,WBP11,WDR26,WDR33,WDR48,WIPF1,WIPF2,WTAP,WWP2,XCL1,YES1,YKT6,YTHDC1,ZBTB11,ZBTB2,ZBTB44,ZC3H12A,ZC3H15,ZDBF2,ZDHHC18,ZEB1,ZFC3H1,ZFP1,ZFP36L1,ZFP91,ZFR,ZFX,ZFYVE27,ZHX1,ZNF12,ZNF131,ZNF136,ZNF184,ZNF211,ZNF24,ZNF274,ZNF292,ZNF317,ZNF395,ZNF410,ZNF430,ZNF451,ZNF507,ZNF518B,ZNF567,ZNF644,ZNF708,ZNF746,ZNF791,ZNF805,ZRANB1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_mnc_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41008,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_3DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-50) after exposure to FluMist , time point 3D. Comment: Supplementary Table 1b: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AAK1,AAMP,ABCF2,ADAM10,ADAP2,GRK3,AFG3L2,AGPAT3,AGPS,AGTRAP,PHYKPL,AIF1,AIMP2,AK2,AKR1A1,ALDH1A1,ALDH2,ALDH3A2,ALDH9A1,AMN1,,AOAH,AP1S2,AP2A2,AP2S1,AP3D1,APLP2,APOL3,APPL1,ARHGAP17,ARPC1B,ARPC5,ARRB1,ARSD,ASH2L,ASRGL1,ASXL2,ATIC,ATP10D,ATP5PD,ATP5MF,ATP6V0D1,ATP6V1A,ATP6V1B2,ATP6V1C1,AURKAIP1,B3GALT6,BANF1,BCKDHA,BLNK,BLVRA,BST2,BTF3L4,BTK,BZW2,ARMH3,FAM204A,AKIP1,C11orf68,SMCO4,SPTSSA,HYPK,CDIP1,CYBC1,OXLD1,SMIM7,MICOS10,TCEANC2,TMEM230,GATD3,RTCB,KIAA0930,ABHD18,SMIM14,TRIQK,CAMKK2,CARD16,CARD9,CASP1,CAST,CBL,CBR1,CCDC50,COA3,CD14,CD302,CD36,CD84,CD86,CD93,CDK13,CEBPA,ADA2,CES2,CFP,COA4,CHKB,CHMP4A,CHMP5,CHST15,CHTF8,CIITA,CITED2,CLCN3,CLEC4A,CLN5,CLPTM1,CLTA,CMTM7,CNDP2,CNP,COMMD8,COMT,CORO1C,COX5A,CPNE8,CPVL,CREBL2,CROCC,CROCCP2,CRTAP,CSK,CSNK2A1,CST3,CSTB,CTBP2,CTDSP2,CTNNA1,CTNND1,CTSB,CTSC,CTSS,CUEDC2,CYB561A3,CYBB,CYC1,CYFIP1,CYP4V2,DAPK1,DCAF7,DCTD,DCTN2,DCTPP1,DDOST,DDX18,DDX60,DDX60L,DERA,DMAC1,DMXL1,DNASE2,DNLZ,DPAGT1,DPH3,DPP8,DPYD,DRG1,DTX3L,DYNC1I2,DYNLL1,EAF2,EBNA1BP2,ECHDC1,ECHS1,EFTUD2,EHBP1L1,EIF2AK1,EMILIN2,ENO1,ENY2,EPB41L3,ERCC1,ESRP2,ETFA,EXOC4,EXOSC1,EXOSC5,FAM110A,PCED1B,RTL8C,ANTKMT,PSME3IP1,GASK1B,COX20,PIEZO1,RMDN1,CIAO2A,FASTK,FBP1,FCER1G,FCGR1BP,FCN1,FGD2,FGD4,FGL2,FGR,FKBP15,FKBP5,FUCA1,GALNT2,GAS7,GATAD1,GCNT2,GDI2,GEMIN7,GIT2,SLX1B,GLRX,GLYR1,GNS,GOLIM4,GPAA1,GPBAR1,GRN,GRSF1,GSTO1,GSTP1,GTF2H2,GTF2H2C,GTF2H2C_2,GTF3C2,HAUS7,HCG18,HCK,PUDP,HEBP1,HFE,HHEX,HIPK2,HK1,HK3,HLA-DMB,HLA-DRB1,HM13,HMGN4,HNRNPA0,HOXA7,HPSE,HTATIP2,HVCN1,ICE2,IDH2,IDH3A,IDH3G,IFI16,IFI30,IFI35,IFT80,IGHG1,IGHM,IKZF1,IKZF3,IL10RB,IL17RA,ILK,INTS7,IRF5,IRF7,ITPR2,ITPRIPL2,JAK2,KCNE3,KCTD12,KIAA0513,KLHL36,KLHL6,KRTAP2-4,KYNU,LAIR1,LARP1,LARP4B,LARS1,LBHD1,LDAH,LEPROT,LILRA1,LILRB1,LIMS1,LMO2,LSM10,LSM6,LTA4H,LY6H,MANF,MAP2K1,MAP4,MAPK1,MARCHF1,MARCO,MAT2A,MAT2B,MED16,MEF2C,MEGF9,MESD,METTL7A,METTL8,MFSD1,MFSD14B,MGST3,MKKS,MLKL,MLX,MPEG1,MRM2,MRPL16,MRPL20,MRPL24,MRPL51,MRPS11,MRPS16,MRPS18C,MS4A4A,MS4A6A,MX1,MX2,MYCBP,MYD88,MYOF,N4BP2L1,NAAA,NADK,NAGA,NAGK,NAIP,NCOA2,NDUFAF3,NDUFB10,NDUFB3,NDUFB5,NDUFS2,NDUFS7,NECAP2,NIF3L1,NIPAL3,NOLC1,NOTCH2,NSL1,NUB1,NUDT22,NUDT5,NUP214,OAS1,OAS2,OAS3,OCIAD1,OGFOD1,ORAI3,ORMDL2,OSCAR,OCA2,PAICS,PANK2,PARP1,PARP12,PARP14,PCK2,PCMT1,PCMTD1,PDCD6,PDHB,PDIA6,PDLIM5,PDXK,PEA15,PECAM1,PGD,PGLS,PGM2,PHPT1,PIGP,PIK3AP1,PIK3C3,PLAC8,PLBD1,PLOD3,PLSCR1,PLXNB2,PMVK,POLK,PPA2,PPHLN1,PPID,PPP1R11,PPP1R7,PPT1,PRAM1,PRDX4,PRELID1,PREPL,PLPBP,PRPF19,PRPF6,PRR5L,PSMB10,PSMB2,PSMB9,PTBP1,PTGER2,PUSL1,PYCARD,QKI,RAB10,RAB27A,RAB3GAP1,RAB40C,RAB4B,RAB8A,RAP1GDS1,RASSF4,RB1,RBBP4,RBM8A,RDH11,REEP4,REEP5,RGS19,RHBDD1,RNF135,RNF20,RNF5,RNFT1,RNH1,RPRD2,RPUSD3,RRP12,RRP7A,RSL1D1,RTN1,RUBCN,RUFY3,RXRA,S100Z,SAMD9L,SAMHD1,SART3,SAT2,SBNO1,SCAMP2,SCARB2,SCPEP1,SDHC,SDR39U1,SEC22B,SEC23IP,SELENOH,SERBP1,SERF2,SERPINB1,SH2D3C,SHMT2,SHTN1,SIDT2,SLC12A7,SLC22A18,SLC24A1,SLC24A4,SLC25A24,SLC27A3,SLC2A6,SLC31A1,SLC7A7,SLX1A,SMARCA4,SMURF2,SNTB2,SNX1,SNX17,SNX2,SNX27,SNX6,SP110,SPTLC1,SPTLC2,SQOR,SRD5A3,SRGAP2C,SSB,SSR1,STAT1,STAT2,STX4,STX7,SUCLG1,SULT1A1,SUMF1,SUSD1,SYK,SYNCRIP,SYNE3,SYTL3,TAF4,TANGO2,TBC1D8,TBXAS1,TCF3,TCF4,TCF7L2,TICAM2,TIMM8B,TINF2,TKT,TLR7,TLR8,TM9SF1,TM9SF4,TMBIM4,TMED7-TICAM2,TMED9,TMEM126B,TMEM19,TMEM205,TMEM209,TMEM63A,TMEM80,TMPO,TMX1,TNFSF10,TNFSF12-TNFSF13,TNFSF13,TNFSF13B,TNRC6B,TNS3,TOR1A,TOR1B,TPI1,TPST2,TRAPPC3,TREX1,TRIM14,TRIM22,TRIM34,TRIM5,TRIM6-TRIM34,TRIM69,TRIO,TRIP11,TRMT112,TSPAN31,TSPAN4,UBE2I,UBE2L3,UCP2,UEVLD,UNC50,UNC93B1,USP19,USP34,VAV1,VPS41,VRK2,WSB1,XAF1,XIAP,XRCC5,YWHAB,YWHAE,YY1AP1,ZC3H4,ZFAND5,ZNF106,ZNF143,ZNHIT1",563,"AAK1,AAMP,ABCF2,ADAM10,ADAP2,ADRBK2,AFG3L2,AGPAT3,AGPS,AGTRAP,AGXT2L2,AIF1,AIMP2,AK2,AKR1A1,ALDH1A1,ALDH2,ALDH3A2,ALDH9A1,AMN1,ANP32A-IT1,AOAH,AP1S2,AP2A2,AP2S1,AP3D1,APLP2,APOL3,APPL1,ARHGAP17,ARPC1B,ARPC5,ARRB1,ARSD,ASH2L,ASRGL1,ASXL2,ATIC,ATP10D,ATP5H,ATP5J2,ATP6V0D1,ATP6V1A,ATP6V1B2,ATP6V1C1,AURKAIP1,B3GALT6,BANF1,BCKDHA,BLNK,BLVRA,BST2,BTF3L4,BTK,BZW2,C10orf76,C10orf84,C11orf17,C11orf68,C11orf75,C14orf147,C15orf63,C16orf5,C17orf62,C17orf90,C19orf42,C1orf151,C1orf83,C20orf30,C21orf33,C22orf28,C22orf9,C4orf29,C4orf34,C8orf83,CAMKK2,CARD16,CARD9,CASP1,CAST,CBL,CBR1,CCDC50,CCDC56,CD14,CD302,CD36,CD84,CD86,CD93,CDK13,CEBPA,CECR1,CES2,CFP,CHCHD8,CHKB,CHMP4A,CHMP5,CHST15,CHTF8,CIITA,CITED2,CLCN3,CLEC4A,CLN5,CLPTM1,CLTA,CMTM7,CNDP2,CNP,COMMD8,COMT,CORO1C,COX5A,CPNE8,CPVL,CREBL2,CROCC,CROCCL1,CRTAP,CSK,CSNK2A1,CST3,CSTB,CTBP2,CTDSP2,CTNNA1,CTNND1,CTSB,CTSC,CTSS,CUEDC2,CYBASC3,CYBB,CYC1,CYFIP1,CYP4V2,DAPK1,DCAF7,DCTD,DCTN2,DCTPP1,DDOST,DDX18,DDX60,DDX60L,DERA,DMAC1,DMXL1,DNASE2,DNLZ,DPAGT1,DPH3,DPP8,DPYD,DRG1,DTX3L,DYNC1I2,DYNLL1,EAF2,EBNA1BP2,ECHDC1,ECHS1,EFTUD2,EHBP1L1,EIF2AK1,EMILIN2,ENO1,ENY2,EPB41L3,ERCC1,ESRP2,ETFA,EXOC4,EXOSC1,EXOSC5,FAM110A,FAM113B,FAM127A,FAM173A,FAM192A,FAM198B,FAM36A,FAM38A,FAM82B,FAM96A,FASTK,FBP1,FCER1G,FCGR1B,FCN1,FGD2,FGD4,FGL2,FGR,FKBP15,FKBP5,FUCA1,GALNT2,GAS7,GATAD1,GCNT2,GDI2,GEMIN7,GIT2,GIYD2,GLRX,GLYR1,GNS,GOLIM4,GPAA1,GPBAR1,GRN,GRSF1,GSTO1,GSTP1,GTF2H2,GTF2H2C,GTF2H2D,GTF3C2,HAUS7,HCG18,HCK,HDHD1A,HEBP1,HFE,HHEX,HIPK2,HK1,HK3,HLA-DMB,HLA-DRB1,HM13,HMGN4,HNRNPA0,HOXA7,HPSE,HTATIP2,HVCN1,ICE2,IDH2,IDH3A,IDH3G,IFI16,IFI30,IFI35,IFT80,IGHG1,IGHM,IKZF1,IKZF3,IL10RB,IL17RA,ILK,INTS7,IRF5,IRF7,ITPR2,ITPRIPL2,JAK2,KCNE3,KCTD12,KIAA0513,KLHL36,KLHL6,KRTAP2-4,KYNU,LAIR1,LARP1,LARP4B,LARS,LBHD1,LDAH,LEPROT,LILRA1,LILRB1,LIMS1,LMO2,LSM10,LSM6,LTA4H,LY6H,MANF,MAP2K1,MAP4,MAPK1,MARCH1,MARCO,MAT2A,MAT2B,MED16,MEF2C,MEGF9,MESDC2,METTL7A,METTL8,MFSD1,MFSD14B,MGST3,MKKS,MLKL,MLX,MPEG1,MRM2,MRPL16,MRPL20,MRPL24,MRPL51,MRPS11,MRPS16,MRPS18C,MS4A4A,MS4A6A,MX1,MX2,MYCBP,MYD88,MYOF,N4BP2L1,NAAA,NADK,NAGA,NAGK,NAIP,NCOA2,NDUFAF3,NDUFB10,NDUFB3,NDUFB5,NDUFS2,NDUFS7,NECAP2,NIF3L1,NIPAL3,NOLC1,NOTCH2,NSL1,NUB1,NUDT22,NUDT5,NUP214,OAS1,OAS2,OAS3,OCIAD1,OGFOD1,ORAI3,ORMDL2,OSCAR,P,PAICS,PANK2,PARP1,PARP12,PARP14,PCK2,PCMT1,PCMTD1,PDCD6,PDHB,PDIA6,PDLIM5,PDXK,PEA15,PECAM1,PGD,PGLS,PGM2,PHPT1,PIGP,PIK3AP1,PIK3C3,PLAC8,PLBD1,PLOD3,PLSCR1,PLXNB2,PMVK,POLK,PPA2,PPHLN1,PPID,PPP1R11,PPP1R7,PPT1,PRAM1,PRDX4,PRELID1,PREPL,PROSC,PRPF19,PRPF6,PRR5L,PSMB10,PSMB2,PSMB9,PTBP1,PTGER2,PUSL1,PYCARD,QKI,RAB10,RAB27A,RAB3GAP1,RAB40C,RAB4B,RAB8A,RAP1GDS1,RASSF4,RB1,RBBP4,RBM8A,RDH11,REEP4,REEP5,RGS19,RHBDD1,RNF135,RNF20,RNF5,RNFT1,RNH1,RPRD2,RPUSD3,RRP12,RRP7A,RSL1D1,RTN1,RUBCN,RUFY3,RXRA,S100Z,SAMD9L,SAMHD1,SART3,SAT2,SBNO1,SCAMP2,SCARB2,SCPEP1,SDHC,SDR39U1,SEC22B,SEC23IP,SELENOH,SERBP1,SERF2,SERPINB1,SH2D3C,SHMT2,SHTN1,SIDT2,SLC12A7,SLC22A18,SLC24A1,SLC24A4,SLC25A24,SLC27A3,SLC2A6,SLC31A1,SLC7A7,SLX1A,SMARCA4,SMURF2,SNTB2,SNX1,SNX17,SNX2,SNX27,SNX6,SP110,SPTLC1,SPTLC2,SQRDL,SRD5A3,SRGAP2P1,SSB,SSR1,STAT1,STAT2,STX4,STX7,SUCLG1,SULT1A1,SUMF1,SUSD1,SYK,SYNCRIP,SYNE3,SYTL3,TAF4,TANGO2,TBC1D8,TBXAS1,TCF3,TCF4,TCF7L2,TICAM2,TIMM8B,TINF2,TKT,TLR7,TLR8,TM9SF1,TM9SF4,TMBIM4,TMED7-TICAM2,TMED9,TMEM126B,TMEM19,TMEM205,TMEM209,TMEM63A,TMEM80,TMPO,TMX1,TNFSF10,TNFSF12-TNFSF13,TNFSF13,TNFSF13B,TNRC6B,TNS3,TOR1A,TOR1B,TPI1,TPST2,TRAPPC3,TREX1,TRIM14,TRIM22,TRIM34,TRIM5,TRIM6-TRIM34,TRIM69,TRIO,TRIP11,TRMT112,TSPAN31,TSPAN4,UBE2I,UBE2L3,UCP2,UEVLD,UNC50,UNC93B1,USP19,USP34,VAV1,VPS41,VRK2,WSB1,XAF1,XIAP,XRCC5,YWHAB,YWHAE,YY1AP1,ZC3H4,ZFAND5,ZNF106,ZNF143,ZNHIT1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_neu_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41084,ZOSTAVAX,LA,VZV,LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,25-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/LI_PBMC_ZOSTAVAX_AGE_25_40_AND_60_79YO_3DY_UP,"Herpes zoster (shingles) causes significant morbidity in immune compromised hosts and older adults. Whereas a vaccine is available for prevention of shingles, its efficacy declines with age. To help to understand the mechanisms driving vaccinal responses, we constructed a multiscale, multifactorial response network (MMRN) of immunity in healthy young and older adults immunized with the live attenuated shingles vaccine Zostavax. Vaccination induces robust antigen-specific antibody, plasmablasts, and CD4<sup>+</sup> T cells yet limited CD8<sup>+</sup> T cell and antiviral responses. The MMRN reveals striking associations between orthogonal datasets, such as transcriptomic and metabolomics signatures, cell populations, and cytokine levels, and identifies immune and metabolic correlates of vaccine immunity. Networks associated with inositol phosphate, glycerophospholipids, and sterol metabolism are tightly coupled with immunity. Critically, the sterol regulatory binding protein 1 and its targets are key integrators of antibody and T follicular cell responses. Our approach is broadly applicable to study human immunity and can help to identify predictors of efficacy as well as mechanisms controlling immunity to vaccination.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (25-40/60-79) after exposure to Zostavax , time point 3D","Li S,Sullivan NL,Rouphael N,Yu T,Banton S,Maddur MS,McCausland M,Chiu C,Canniff J,Dubey S,Liu K,Tran V,Hagan T,Duraisingham S,Wieland A,Mehta AK,Whitaker JA,Subramaniam S,Jones DP,Sette A,Vora K,Weinberg A,Mulligan MJ,Nakaya HI,Levin M,Ahmed R,Pulendran B",28502771,HUMAN_GENE_SYMBOL,"EGR1,ERAP2,IFI44L,KDELR2,MX1,PDP1,PSPH",7,"EGR1,ERAP2,IFI44L,KDELR2,MX1,PDP1,PSPH",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 2A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711477/bin/NIHMS871779-supplement-2.tiff,NA,NA,NA,NA
M41047,YF17D,LA,YF,QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_3DY_UP,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4-an orchestrator of the integrated stress response-that correlated with and predicted YF-17D CD8(+) T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (18-45) after exposure to YF-17D vaccine , time point 3D","Querec TD,Akondy RS,Lee EK,Cao W,Nakaya HI,Teuwen D,Pirani A,Gernert K,Deng J,Marzolf B,Kennedy K,Wu H,Bennouna S,Oluoch H,Miller J,Vencio RZ,Mulligan M,Aderem A,Ahmed R,Pulendran B",19029902,HUMAN_GENE_SYMBOL,"C3AR1,CD38,CXCL10,RIGI,DDX60,DDX60L,EIF2AK2,HERC5,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IL10,IRF7,ISG15,LAMP3,LGALS3BP,DHX58,IFIH1,MX1,MX2,MYOF,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP9,PLSCR1,PNPT1,RASA2,RGL1,RSAD2,SAMD9,SAMD9L,SERPING1,STAT1,TLR7,TMEM255A,TRIM22,TRIM5,XAF1",47,"C3AR1,CD38,CXCL10,DDX58,DDX60,DDX60L,EIF2AK2,HERC5,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IL10,IRF7,ISG15,LAMP3,LGALS3BP,LGP2,MDA-5,MX1,MX2,MYOF,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP9,PLSCR1,PNPT1,RASA2,RGL1,RSAD2,SAMD9,SAMD9L,SERPING1,STAT1,TLR7,TMEM255A,TRIM22,TRIM5,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Additional File 2, Tab A BCG",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654906/bin/1755-8794-2-10-S2.xls,NA,NA,NA,NA
M41048,YF17D,LA,YF,QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QUEREC_PBMC_YF_17D_VACCINE_AGE_18_45YO_7DY_UP,"A major challenge in vaccinology is to prospectively determine vaccine efficacy. Here we have used a systems biology approach to identify early gene 'signatures' that predicted immune responses in humans vaccinated with yellow fever vaccine YF-17D. Vaccination induced genes that regulate virus innate sensing and type I interferon production. Computational analyses identified a gene signature, including complement protein C1qB and eukaryotic translation initiation factor 2 alpha kinase 4-an orchestrator of the integrated stress response-that correlated with and predicted YF-17D CD8(+) T cell responses with up to 90% accuracy in an independent, blinded trial. A distinct signature, including B cell growth factor TNFRS17, predicted the neutralizing antibody response with up to 100% accuracy. These data highlight the utility of systems biology approaches in predicting vaccine efficacy.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-45) after exposure to YF-17D vaccine , time point 7D","Querec TD,Akondy RS,Lee EK,Cao W,Nakaya HI,Teuwen D,Pirani A,Gernert K,Deng J,Marzolf B,Kennedy K,Wu H,Bennouna S,Oluoch H,Miller J,Vencio RZ,Mulligan M,Aderem A,Ahmed R,Pulendran B",19029902,HUMAN_GENE_SYMBOL,"C3AR1,CD38,CXCL10,RIGI,DDX60,DDX60L,EIF2AK2,HERC5,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IL10,IRF7,ISG15,LAMP3,LGALS3BP,DHX58,IFIH1,MX1,MX2,MYOF,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP9,PLSCR1,PNPT1,RASA2,RGL1,RSAD2,SAMD9,SAMD9L,SERPING1,STAT1,TLR7,TMEM255A,TRIM22,TRIM5,XAF1",47,"C3AR1,CD38,CXCL10,DDX58,DDX60,DDX60L,EIF2AK2,HERC5,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IL10,IRF7,ISG15,LAMP3,LGALS3BP,LGP2,MDA-5,MX1,MX2,MYOF,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP9,PLSCR1,PNPT1,RASA2,RGL1,RSAD2,SAMD9,SAMD9L,SERPING1,STAT1,TLR7,TMEM255A,TRIM22,TRIM5,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/table/T2/,NA,NA,NA,NA
M41070,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D4-7,D,5.5,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell (4 to 7)d vs 0d in adults (18-40) after exposure to YF-Vax , time point 4 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ACAA1,ACP5,ACVRL1,ADCY9,AKAP8L,AKR7A2,ALDH16A1,AMD1,APRT,ARF5,ARFGAP1,ARHGAP27,ARHGAP4,ARL4C,ARL6IP4,ATP5MJ,AVP,B4GALT3,BANP,BCR,BPIFB2,BRAT1,BTF3,C12orf57,CACNA2D3,CBX7,CCDC88B,CCM2,CCNI,CCT3,CCT4,CCT7,CD244,CD3D,CHAT,CHCHD5,CHFR,CHGA,CHMP1A,CLPP,CLPTM1L,COL6A2,CORO1A,CTNNBIP1,CTU1,CUTA,CXXC5,CYBC1,DBP,DCBLD2,DENND4B,DHX30,DPP7,DUOXA2,DUSP15,EDARADD,EEF1B2,EEF1D,EEF1G,EEF2,EGLN2,EIF3E,EIF3F,EIF3L,EIF4B,ENO1,FAAP100,FHIP1B,FAR2,FBXL15,FBXW5,FKBP2,FLNA,FOXC1,GATD3,GJC1,GPR156,GPR78,GTPBP6,GUK1,HADHA,HCLS1,HMGB1,ICAM3,IGLV1-44,IL24,INKA1,INPPL1,IRGC,ITGA6,JMJD8,KDELR1,KIF1C,KIF22,KLRB1,KRT18,LCE1E,LDHB,LIF,LRP1,LRRC45,LTA4H,LTB,MAD2L2,MAGEA3,MAST1,MBD3,MCM7,MEGF8,MMS19,MN1,MOB2,MRPL28,MTMR14,MYO1G,NCLN,NDUFB8,NDUFV1,NEUROG1,NEUROG3,NKG7,NME3,NMRK2,NPEPL1,OTOS,OTUD7A,P4HB,PAF1,PCSK1N,PDLIM2,PLEC,PLIN1,PMEPA1,PNRC1,POLM,PPFIA4,PPP1R12C,PPP1R37,PRB3,PREB,PRPF6,PRR15,PRRC2B,CYTH4,PSMC5,PSTPIP1,PYGB,QARS1,RABL6,RACK1,RBM10,RBM38,RDH13,RGL2,RHOT2,RMND5A,RPL10,RPL10A,RPL11,RPL13,RPL15,RPL18,RPL18A,RPL22,RPL22L1,RPL23A,RPL3,RPL35A,RPL36,RPL37A,RPL39,RPL5,RPL6,RPL7A,RPL9,MAP7D1,RPS10,RPS11,RPS13,RPS14,RPS15,RPS15A,RPS17,RPS2,RPS21,RPS27A,RPS3,RPS3A,RPS4X,RPS5,RPS6,RPS7,RPSA,S100A5,SEC61A1,SESN2,SF3A2,SFI1,SRSF1,SRSF5,SGSH,SGTA,SIPA1,SLC13A5,SLC22A8,SLC25A6,SLC2A4RG,SLC4A1,SNAI3,SNHG29,SNRNP200,SPEF1,SPSB3,STK11,STX4,TBCA,TCF25,TCF3,TCOF1,TMC6,TMEM121,TMEM259,TMEM63A,TNFAIP8,TNRC6C,TOMM7,TOP2B,TRABD,TSC22D4,TSPAN4,TSSC4,TUFM,UBA52,UBXN1,VAV1,VPS28,VPS35,VPS51,VWA5B2,WDR18,ZAP70,ZC3H11A,ZNF423,ZBTB45,ZNF681",245,"ACAA1,ACP5,ACVRL1,ADCY9,AKAP8L,AKR7A2,ALDH16A1,AMD1,APRT,ARF5,ARFGAP1,ARHGAP27,ARHGAP4,ARL4C,ARL6IP4,ATP5MPL,AVP,B4GALT3,BANP,BCR,BPIFB2,BRAT1,BTF3,C12orf57,CACNA2D3,CBX7,CCDC88,CCM2,CCNI,CCT3,CCT4,CCT7,CD244,CD3D,CHAT,CHCHD5,CHFR,CHGA,CHMP1A,CLPP,CLPTM1L,COL6A2,CORO1A,CTNNBIP1,CTU1,CUTA,CXXC5,CYBC1,DBP,DCBLD2,DENND4B,DHX30,DPP7,DUOXA2,DUSP15,EDARADD,EEF1B2,EEF1D,EEF1G,EEF2,EGLN2,EIF3E,EIF3F,EIF3L,EIF4B,ENO1,FAAP100,FAM160A2,FAR2,FBXL15,FBXW5,FKBP2,FLNA,FOXC1,GATD3A,GJC1,GPR156,GPR78,GTPBP6,GUK1,HADHA,HCLS1,HMGB1,ICAM3,IGLV1-44,IL24,INKA1,INPPL1,IRGC,ITGA6,JMJD8,KDELR1,KIF1C,KIF22,KLRB1,KRT18,LCE1E,LDHB,LIF,LRP1,LRRC45,LTA4H,LTB,MAD2L2,MAGEA3,MAST1,MBD3,MCM7,MEGF8,MMS19,MN1,MOB2,MRPL28,MTMR14,MYO1G,NCLN,NDUFB8,NDUFV1,NEUROG1,NEUROG3,NKG7,NME3,NMRK2,NPEPL1,OTOS,OTUD7A,P4HB,PAF1,PCSK1N,PDLIM2,PLEC,PLIN1,PMEPA1,PNRC1,POLM,PPFIA4,PPP1R12C,PPP1R37,PRB3,PREB,PRPF6,PRR15,PRRC2B,PSCD4,PSMC5,PSTPIP1,PYGB,QARS1,RABL6,RACK1,RBM10,RBM38,RDH13,RGL2,RHOT2,RMND5A,RPL10,RPL10A,RPL11,RPL13,RPL15,RPL18,RPL18A,RPL22,RPL22L1,RPL23A,RPL3,RPL35A,RPL36,RPL37A,RPL39,RPL5,RPL6,RPL7A,RPL9,RPRC1,RPS10,RPS11,RPS13,RPS14,RPS15,RPS15A,RPS17,RPS2,RPS21,RPS27A,RPS3,RPS3A,RPS4X,RPS5,RPS6,RPS7,RPSA,S100A5,SEC61A1,SESN2,SF3A2,SFI1,SFRS1,SFRS5,SGSH,SGTA,SIPA1,SLC13A5,SLC22A8,SLC25A6,SLC2A4RG,SLC4A1,SNAI3,SNHG29,SNRNP200,SPEF1,SPSB3,STK11,STX4,TBCA,TCF25,TCF3,TCOF1,TMC6,TMEM121,TMEM259,TMEM63A,TNFAIP8,TNRC6C,TOMM7,TOP2B,TRABD,TSC22D4,TSPAN4,TSSC4,TUFM,UBA52,UBXN1,VAV1,VPS28,VPS35,VPS51,VWA5B2,WDR18,ZAP70,ZC3H11A,ZNF423,ZNF499,ZNF681",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41052,YF VAX,LA,YF,SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D4-7,D,5.5,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell (4 to 7)d vs 0d in adults (18-40) after exposure to YF-Vax , time point 4 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"A2ML1,ABCB1,ABR,ADIPOR2,AKIP1,ALAS1,ANXA2,AP3S1,APAF1,APEX2,APOBEC3A,APOBEC3B,APOD,AQP1,ARHGAP1,ASB4,ATG3,ATP6V0E1,ATP6V1G1,BCL2L14,BET1L,BEX4,BLVRA,KLHL28,CACNA2D2,CALCOCO1,CAV2,CCL25,CCL8,CCR5,CCT5,CD177,CD53,CD74,CD86,CDC45,CDKN1C,CDX4,CEACAM7,CEBPA-DT,CEBPB,CEP57,CHD5,CHMP2B,CHMP5,CHST15,CHST2,CIAO2A,CISD2,CMPK2,COP1,COX5A,CREG1,CDK12,CSDC2,CSF1R,CST4,CTBP2,CTH,CX3CR1,CYP3A43,DAZAP2,DDA1,RIGI,DEFB105A,DNAJA1,DNAJC5,DOCK10,DRAP1,DSTN,DUSP11,DYNLT1,EBNA1BP2,EGR4,EIF2AK2,EIF4A1,EIF4E,ERH,ETV6,FCGR3A,FGF6,FGR,FLVCR2,FOXN3,FOXO3,FPR2,GBP5,GDA,GLRX,GMPR,GNAS,GNPTG,GP1BA,GPR137C,GSTK1,GTF3C6,H2AZ2,H3-3A,H3-3B,H3-4,H3C1,H3C11,H3C12,H3C3,H3C7,H3C8,HAND1,HCFC1,HCN3,HERC5,HERC6,HEXIM1,HJURP,HMGN2,HMOX1,HNRNPA3P1,HNRNPC,HNRNPU,HS3ST4,HSBP1,HSH2D,HSPH1,HYPK,IER5,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNA10,IFNA17,IGSF3,IL17A,IL1RN,IL2RG,ISG15,ISG20,IRF9,ITGAM,JDP2,JUNB,JUND,KCNH2,KCNJ10,KLF14,KMT5C,KPTN,KRTAP4-11,KRTCAP2,LAP3,LARP1,LARS2,LBX2-AS1,LENG8,LGALS3BP,DHX58,LILRB2,LIMD2,LMO2,PBX3-DT,LRP5L,LRRC3B,LRRC4C,LSM6,NCAPG2,KLRA1P,LY6E,LZTS1,MAD2L1BP,MAFB,MAL2,MAN2B2,MAP3K5,MARCKS,MARK4,MBTPS1,MCM2,MDH1,MKRN3,MNT,MPEG1,MRPL10,MS4A7,MT1G,MT1M,MT1X,MT2A,MTF1,MTREX,MX1,MX2,NBN,NCBP3,NCOA1,NEK7,NF1,NFKBIA,NHLH2,NISCH,NMI,NMNAT3,NOTCH2,NOTCH3,NPHP1,NRBF2,NRBP2,NUCKS1,OAS1,OAS2,OAS3,OASL,OR1Q1,OR4K17,P2RY10,PALM2AKAP2,PARG,PARP12,PARP9,PCOLCE,PDCD10,PDHA1,PECAM1,PHF2,PIM3,PINLYP,PLAC8,PLAG1,PLEK,FERMT2,PLSCR1,PMM2,PPAN,PRR13,PSMA4,PSMA6,PSMB9,PSMD10,PSME1,PSME2,PTP4A1,PTP4A2,PTPN2,PYCR2,PYHIN1,RAB11FIP4,RABGAP1L,RABL2B,ZMIZ1,RBX1,RFPL3,RFWD3,RGS14,RHO,RMI1,RNF220,RRM2,RTP4,RWDD3,S100A11,SAMD9,SAMD9L,SARDH,DSE,SASH1,SAT1,SBF2,SCAMP2,SCFD1,SCO2,SDC3,SDK2,SEC61B,SERPINA1,SERPINB10,SERPING1,SF3B1,SHISA5,SIDT2,SIGLEC7,SLC23A3,SLC25A22,SLC26A5,SLITRK2,SMAD6,SMARCC2,SNAI2,SNRPE,SNRPG,SNX5,SOWAHA,SOX9,SP110,SPATS2L,SPRY4,SRC,SRI,SRPX,SSR1,STAB2,STARD13,STAT6,STMN4,STRN4,SYNGR3,TAF6,TAGLN3,TAP1,TAS2R5,TBX6,TDRD7,TENT5A,TFDP3,ALYREF,THRB,TMEM106A,TMPRSS11E,TNFAIP2,TNFSF10,TNFSF13B,TNK2,TRHDE,TRIM21,TRIM22,TRIM8,TRIP12,TRMT112,TSPAN9,TUBA1A,TXNDC15,TYR,TYROBP,UBE2D3,UHMK1,FERMT3,USP18,VRK2,WDR49,WFDC3,XAF1,YEATS2,ZBTB20,ZC3H4,ZCCHC2,ZCCHC8,ZFP36L2,ZHX3,ZSCAN10,ZNF24,DNAJC2",356,"A2ML1,ABCB1,ABR,ADIPOR2,AKIP1,ALAS1,ANXA2,AP3S1,APAF1,APEX2,APOBEC3A,APOBEC3B,APOD,AQP1,ARHGAP1,ASB4,ATG3,ATP6V0E,ATP6V1G1,BCL2L14,BET1L,BEX4,BLVRA,BTBD5,CACNA2D2,CALCOCO1,CAV2,CCL25,CCL8,CCR5,CCT5,CD177,CD53,CD74,CD86,CDC45,CDKN1C,CDX4,CEACAM7,CEBPA-DT,CEBPB,CEP57,CHD5,CHMP2B,CHMP5,CHST15,CHST2,CIAO2A,CISD2,CMPK2,COP1,COX5A,CREG1,CRKRS,CSDC2,CSF1R,CST4,CTBP2,CTH,CX3CR1,CYP3A43,DAZAP2,DDA1,DDX58,DEFB105A,DNAJA1,DNAJC5,DOCK10,DRAP1,DSTN,DUSP11,DYNLT1,EBNA1BP2,EGR4,EIF2AK2,EIF4A1,EIF4E,ERH,ETV6,FCGR3A,FGF6,FGR,FLVCR2,FOXN3,FOXO3,FPRL1,GBP5,GDA,GLRX,GMPR,GNAS,GNPTG,GP1BA,GPR137C,GSTK1,GTF3C6,H2AFV,H3-3A,H3-3B,H3-4,H3C1,H3C11,H3C12,H3C3,H3C7,H3C8,HAND1,HCFC1,HCN3,HERC5,HERC6,HEXIM1,HJURP,HMGN2,HMOX1,HNRPA3,HNRPC,HNRPU,HS3ST4,HSBP1,HSH2D,HSPH1,HYPK,IER5,IFI27,IFI30,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNA10,IFNA17,IGSF3,IL17A,IL1RN,IL2RG,ISG15,ISG20,ISGF3G,ITGAM,JDP2,JUNB,JUND,KCNH2,KCNJ10,KLF14,KMT5C,KPTN,KRTAP4-11,KRTCAP2,LAP3,LARP1,LARS2,LBX2-AS1,LENG8,LGALS3BP,LGP2,LILRB2,LIMD2,LMO2,LOC51145,LRP5L,LRRC3B,LRRC4C,LSM6,LUZP5,LY49L,LY6E,LZTS1,MAD2L1BP,MAFB,MAL2,MAN2B2,MAP3K5,MARCKS,MARK4,MBTPS1,MCM2,MDH1,MKRN3,MNT,MPEG1,MRPL10,MS4A7,MT1G,MT1M,MT1X,MT2A,MTF1,MTREX,MX1,MX2,NBN,NCBP3,NCOA1,NEK7,NF1,NFKBIA,NHLH2,NISCH,NMI,NMNAT3,NOTCH2,NOTCH3,NPHP1,NRBF2,NRBP2,NUCKS1,OAS1,OAS2,OAS3,OASL,OR1Q1,OR4K17,P2RY10,PALM2AKAP2,PARG,PARP12,PARP9,PCOLCE,PDCD10,PDHA1,PECAM1,PHF2,PIM3,PINLYP,PLAC8,PLAG1,PLEK,PLEKHC1,PLSCR1,PMM2,PPAN,PRR13,PSMA4,PSMA6,PSMB9,PSMD10,PSME1,PSME2,PTP4A1,PTP4A2,PTPN2,PYCR2,PYHIN1,RAB11FIP4,RABGAP1L,RABL2B,RAI17,RBX1,RFPL3,RFWD3,RGS14,RHO,RMI1,RNF220,RRM2,RTP4,RWDD3,S100A11,SAMD9,SAMD9L,SARDH,SART2,SASH1,SAT1,SBF2,SCAMP2,SCFD1,SCO2,SDC3,SDK2,SEC61B,SERPINA1,SERPINB10,SERPING1,SF3B1,SHISA5,SIDT2,SIGLEC7,SLC23A3,SLC25A22,SLC26A5,SLITRK2,SMAD6,SMARCC2,SNAI2,SNRPE,SNRPG,SNX5,SOWAHA,SOX9,SP110,SPATS2L,SPRY4,SRC,SRI,SRPX,SSR1,STAB2,STARD13,STAT6,STMN4,STRN4,SYNGR3,TAF6,TAGLN3,TAP1,TAS2R5,TBX6,TDRD7,TENT5A,TFDP3,THOC4,THRB,TMEM106A,TMPRSS11E,TNFAIP2,TNFSF10,TNFSF13B,TNK2,TRHDE,TRIM21,TRIM22,TRIM8,TRIP12,TRMT112,TSPAN9,TUBA3,TXNDC15,TYR,TYROBP,UBE2D3,UHMK1,URP2,USP18,VRK2,WDR49,WFDC3,XAF1,YEATS2,ZBTB20,ZC3H4,ZCCHC2,ZCCHC8,ZFP36L2,ZHX3,ZNF206,ZNF24,ZRF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723701/table/T1/,NA,NA,NA,NA
M40862,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D5-7,D,6,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell (5 to 7)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 5 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"A2M,ABCC5,ABLIM1,ADH5,ADSL,AKR1B1,ALDH3A1,ALOX5AP,ARL4C,ATP2B4,ATP5PO,AXIN1,B4GALT3,BIN1,XIAP,C12orf57,CBLB,CBX7,CCDC107,CCL5,CCR7,CD19,CD1C,CD2,CD3D,CD3G,CD79B,CD8A,CD8B,CD99,CDC25B,CHML,CLIC4,COL21A1,CRIP1,CYFIP2,DBF4,DCAF8,DEXI,DGKD,DGUOK,DHRS3,DLX4,ECI2,EEF1B2,EI24,EIF2S1,ESYT1,EXPH5,F11R,FBLN5,FCGBP,FLNB,FOXO1,GATA3,GRAP,GZMA,GZMB,GZMH,GZMK,GZMM,HADH,HINT1,HSPA4,HUNK,HYAL2,ICAM3,IGHG1,IGKC,,IGLL1,IL11RA,IL16,IL18,IL18R1,IL18RAP,IL24,IL7R,INPP4B,ITGAE,ITM2A,ITPKB,KCNN4,KIF22,KLRB1,KLRC2,KLRC3,KMT2A,FGFBP2,LAT,LCK,LDHB,LIMCH1,LLGL2,LTB,MAX,MDC1,MDN1,MRNIP,MRPS21,MS4A1,KAT6A,NAP1L4,NCAM1,NELL2,NR1D1,NSG1,OSER1,P2RX5,PASK,PCED1B,PDE3B,PEBP1,PELP1,PHF20,PHYHIP,POC1B,PPP6C,PRKCH,PRKCQ,PRSS1,PUF60,RAB33A,RASGRP2,RETREG3,RGS14,RHOH,RNASE6,RPA2,RPL10A,RPL12,RPL13,RPL13A,RPL14,RPL23A,RPL35,RPL37,RPL9,RPS10,RPS15A,RPS16,RPS18,RPS21,RPS27,RPS28,RPS29,RPS3A,RPS4Y1,SAE1,SKAP1,SERPINF1,SH2D1A,SLC38A1,SMPD1,SNHG32,SNRPN,SORL1,SOX10,SPIB,SPOCK2,SPTBN1,SRPK2,TACR1,TAF7,TARP,TCF3,TCF7,TCL1A,TMC6,TMEM8B,TNPO1,TOM1L1,TPD52,,TRAF3IP3,TSPAN4,TTC3,TTC9,TTK,TXK,UBB,VARS2,WDR54,XYLB,ZAP70,ZNF211,ZNF266,ZNF496,ZNF526,ZNF692",190,"A2M,ABCC5,ABLIM1,ADH5,ADSL,AKR1B1,ALDH3A1,ALOX5AP,ARL4C,ATP2B4,ATP5O,AXIN1,B4GALT3,BIN1,BIRC4,C12orf57,CBLB,CBX7,CCDC107,CCL5,CCR7,CD19,CD1C,CD2,CD3D,CD3G,CD79B,CD8A,CD8B,CD99,CDC25B,CHML,CLIC4,COL21A1,CRIP1,CYFIP2,DBF4,DCAF8,DEXI,DGKD,DGUOK,DHRS3,DLX4,ECI2,EEF1B2,EI24,EIF2S1,ESYT1,EXPH5,F11R,FBLN5,FCGBP,FLNB,FOXO1A,GATA3,GRAP,GZMA,GZMB,GZMH,GZMK,GZMM,HADH,HINT1,HSPA4,HUNK,HYAL2,ICAM3,IGHG1,IGKC,IGL,IGLL1,IL11RA,IL16,IL18,IL18R1,IL18RAP,IL24,IL7R,INPP4B,ITGAE,ITM2A,ITPKB,KCNN4,KIF22,KLRB1,KLRC2,KLRC3,KMT2A,KSP37,LAT,LCK,LDHB,LIMCH1,LLGL2,LTB,MAX,MDC1,MDN1,MRNIP,MRPS21,MS4A1,MYST3,NAP1L4,NCAM1,NELL2,NR1D1,NSG1,OSER1,P2RX5,PASK,PCED1B,PDE3B,PEBP1,PELP1,PHF20,PHYHIP,POC1B,PPP6C,PRKCH,PRKCQ,PRSS1,PUF60,RAB33A,RASGRP2,RETREG3,RGS14,RHOH,RNASE6,RPA2,RPL10A,RPL12,RPL13,RPL13A,RPL14,RPL23A,RPL35,RPL37,RPL9,RPS10,RPS15A,RPS16,RPS18,RPS21,RPS27,RPS28,RPS29,RPS3A,RPS4Y1,SAE1,SCAP1,SERPINF1,SH2D1A,SLC38A1,SMPD1,SNHG32,SNRPN,SORL1,SOX10,SPIB,SPOCK2,SPTBN1,SRPK2,TACR1,TAF7,TARP,TCF3,TCF7,TCL1A,TMC6,TMEM8B,TNPO1,TOM1L1,TPD52,TRA,TRAF3IP3,TSPAN4,TTC3,TTC9,TTK,TXK,UBB,VARS2,WDR54,XYLB,ZAP70,ZNF211,ZNF266,ZNF496,ZNF526,ZNF692",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6A (ID),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M40879,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D5-7,D,6,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_5_TO_7DY_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell (5 to 7)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 5 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ACP2,ACP3,ADAP2,ADGRE1,ADM,AIF1,AIM2,ALDH1A1,ALDH3B1,ALPK1,ANKRD22,ANXA2,ANXA4,ANXA5,AP1S2,APOBEC3B,APOL1,APOL3,AQP9,ARNT,ARPC3,ARRB1,ATF3,ATF5,ATOX1,ATP1B3,ATP6V1B2,BACH1,BAZ1A,BCL2A1,BCL6,BLVRA,BST1,C1QA,C1QB,C2,C3AR1,CALCOCO2,CAMK2D,CAPG,CASP1,CASP4,CASP5,CASP7,CAST,CCR1,CD163,CD36,CD40,CD63,CD74,CEBPB,CES1,CLSTN3,CNIH4,CPVL,CREG1,CTNNA1,CTSB,CTSL,CTSO,CTSS,CXCL10,CXCL9,CYBB,CYFIP1,CYFIP2,DHRS9,DNAJC15,DNM1,DPYD,DSC2,DSG2,DTX3L,DYSF,EFHD2,EIF4A1,ELF4,EMILIN2,EPB41L3,ETF1,ETV7,FAS,FBXL5,FCGR1A,FCGR2B,FCGR3A,FCN1,FGL2,FKBP15,FN1,FPR1,FPR2,FUBP1,GBP1,GBP2,GCA,GCH1,GCNT2,GK,GLB1,GLRX,GLS,GNB4,GNG10,GRB2,GRN,GSDMD,GSTO1,GYG1,HCK,HERC5,HLA-B,HLA-DOA,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA,HLA-DRB1,HP,ICAM1,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IGSF6,IL13,IL13RA1,IL15,IL15RA,IL1RN,IDO1,IRF1,IRF2,IRF7,IRF9,ISG15,ITM2B,JAK2,KIAA0930,KLF4,KLHL8,LAP3,LGALS3BP,LGALS9,LHFPL2,LILRA3,LILRB1,LILRB3,LIMK2,LIPA,LMO2,LPGAT1,LST1,LTBR,LY6E,LYN,MARCKS,MARCO,MCL1,MICU1,MNDA,MS4A6A,MT1F,MT1M,MTHFD2,MX1,MX2,MYD88,NANS,NAPA,NCF1,NCF2,NCKAP1L,NFX1,NIBAN1,NKG7,NLRP3,NPC2,NUP62,OAS1,OAS2,OGT,PDXK,PEA15,PFKFB3,PLSCR1,PLXNB2,PDP1,PPP1R21,PRDX2,PSAP,PSMA4,PSMA6,PSMB10,PSMB2,PSMB3,PSMB9,PSME1,PSME2,PTTG1IP,PYHIN1,RAB24,RBMS1,RCN1,RHOG,RIPK2,RNF149,RNF175,RNPEP,RSAD2,RTCB,S100A9,SCARB2,SCP2,SDF2,SEPTIN4,SERPINA1,SERPING1,SH2B3,SIRPA,SIRPB1,SLAMF8,SLC31A2,SLC35A2,SLC43A3,SLC8A1,SLC9A9,SMPDL3A,SNX10,SOCS3,SOD2,SORT1,SP110,SPTLC2,SRBD1,ST3GAL4,ST3GAL5,STAT1,STAT2,STOM,TAF9B,TAP1,TAP2,TBX19,TCF7L2,TEC,TFEC,TGOLN2,THEMIS2,TJP2,TLR1,TLR2,TLR8,TMSB15A,TNFRSF1B,TNFSF10,TNFSF13,TNNT1,TPM4,TRAFD1,TRIM21,TRIM22,TRIM34,TSPO,UBE2D3,UBE2L6,USP18,VRK2,WARS1,WDFY1,XAF1,ZNF264,ZNF671,ZNFX1",285,"ACP2,ACPP,ADAP2,ADGRE1,ADM,AIF1,AIM2,ALDH1A1,ALDH3B1,ALPK1,ANKRD22,ANXA2,ANXA4,ANXA5,AP1S2,APOBEC3B,APOL1,APOL3,AQP9,ARNT,ARPC3,ARRB1,ATF3,ATF5,ATOX1,ATP1B3,ATP6V1B2,BACH1,BAZ1A,BCL2A1,BCL6,BLVRA,BST1,C1QA,C1QB,C2,C3AR1,CALCOCO2,CAMK2D,CAPG,CASP1,CASP4,CASP5,CASP7,CAST,CCR1,CD163,CD36,CD40,CD63,CD74,CEBPB,CES1,CLSTN3,CNIH4,CPVL,CREG1,CTNNA1,CTSB,CTSL,CTSO,CTSS,CXCL10,CXCL9,CYBB,CYFIP1,CYFIP2,DHRS9,DNAJC15,DNM1,DPYD,DSC2,DSG2,DTX3L,DYSF,EFHD2,EIF4A1,ELF4,EMILIN2,EPB41L3,ETF1,ETV7,FAS,FBXL5,FCGR1A,FCGR2B,FCGR3A,FCN1,FGL2,FKBP15,FN1,FPR1,FPRL1,FUBP1,GBP1,GBP2,GCA,GCH1,GCNT2,GK,GLB1,GLRX,GLS,GNB4,GNG10,GRB2,GRN,GSDMDC1,GSTO1,GYG1,HCK,HERC5,HLA-B,HLA-DOA,HLA-DPA1,HLA-DPB1,HLA-DQB1,HLA-DRA,HLA-DRB1,HP,ICAM1,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IGSF6,IL13,IL13RA1,IL15,IL15RA,IL1RN,INDO,IRF1,IRF2,IRF7,IRF9,ISG15,ITM2B,JAK2,KIAA0930,KLF4,KLHL8,LAP3,LGALS3BP,LGALS9,LHFPL2,LILRA3,LILRB1,LILRB3,LIMK2,LIPA,LMO2,LPGAT1,LST1,LTBR,LY6E,LYN,MARCKS,MARCO,MCL1,MICU1,MNDA,MS4A6A,MT1F,MT1M,MTHFD2,MX1,MX2,MYD88,NANS,NAPA,NCF1,NCF2,NCKAP1L,NFX1,NIBAN1,NKG7,NLRP3,NPC2,NUP62,OAS1,OAS2,OGT,PDXK,PEA15,PFKFB3,PLSCR1,PLXNB2,PPM2C,PPP1R21,PRDX2,PSAP,PSMA4,PSMA6,PSMB10,PSMB2,PSMB3,PSMB9,PSME1,PSME2,PTTG1IP,PYHIN1,RAB24,RBMS1,RCN1,RHOG,RIPK2,RNF149,RNF175,RNPEP,RSAD2,RTCB,S100A9,SCARB2,SCP2,SDF2,SEPT4,SERPINA1,SERPING1,SH2B3,SIRPA,SIRPB1,SLAMF8,SLC31A2,SLC35A2,SLC43A3,SLC8A1,SLC9A9,SMPDL3A,SNX10,SOCS3,SOD2,SORT1,SP110,SPTLC2,SRBD1,ST3GAL4,ST3GAL5,STAT1,STAT2,STOM,TAF9B,TAP1,TAP2,TBX19,TCF7L2,TEC,TFEC,TGOLN2,THEMIS2,TJP2,TLR1,TLR2,TLR8,TMSL8,TNFRSF1B,TNFSF10,TNFSF13,TNNT1,TPM4,TRAFD1,TRIM21,TRIM22,TRIM34,TSPO,UBE2D3,UBE2L6,USP18,VRK2,WARS,WDFY1,XAF1,ZNF264,ZNF671,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig1 & Suppl Fig 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/bin/NIHMS593578-supplement-01.pdf|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/figure/F1/,NA,NA,NA,NA
M41163,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D5-7,D,6,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell (5 to 7)d vs 0d in adults (18-40) after exposure to APSV Wetvax , time point 5 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"OSER1,SNHG32,CBLB,CD2,CD79B,FLNB,GRAP,HYAL2,IL24,ITPKB,FGFBP2,LLGL2,MS4A1,NAP1L4,P2RX5,RPL12,SKAP1,SLC38A1,SPIB,SPOCK2,TARP",21,"C20orf111,C6orf48,CBLB,CD2,CD79B,FLNB,GRAP,HYAL2,IL24,ITPKB,KSP37,LLGL2,MS4A1,NAP1L4,P2RX5,RPL12,SCAP1,SLC38A1,SPIB,SPOCK2,TARP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6A (ID),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M41045,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D5-7,D,6,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_40YO_5_TO_7DY_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell (5 to 7)d vs 0d in adults (18-40) after exposure to APSV Wetvax , time point 5 to 7D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ALDH1A1,APOL1,ATOX1,C1QB,C3AR1,CAMK2D,CD40,CES1,FN1,GLS,HLA-DPB1,HLA-DRA,IRF1,IRF2,IRF7,LILRA2,LIMK2,NFX1,SLC8A1,SORT1,SPTLC2,TJP2,TNFRSF1B,ZNF671",24,"ALDH1A1,APOL1,ATOX1,C1QB,C3AR1,CAMK2D,CD40,CES1,FN1,GLS,HLA-DPB1,HLA-DRA,IRF1,IRF2,IRF7,LILRA2,LIMK2,NFX1,SLC8A1,SORT1,SPTLC2,TJP2,TNFRSF1B,ZNF671",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig1 & Suppl Fig 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/bin/NIHMS593578-supplement-01.pdf|https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049462/figure/F1/,NA,NA,NA,NA
M40889,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D50-60,D,55,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_DN,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes down-regulated in peripheral blood mononuclear cell (50 to 60)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 50 to 60D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ADORA2A,APOL3,ARRB1,ASGR1,ASH2L,ATP6V1B2,ATP6V1C1,ATP6V1E1,BCAP31,BCAT2,BTN3A2,BTN3A3,C3AR1,CACNA2D3,CCDC22,CCN5,CCR2,CCT3,CD1C,CD300LF,CD79B,CD8B,CEBPA,CISD3,CISH,CLU,COMT,CORO1A,CSF1R,CSNK2A1,CTSZ,CTTN,CX3CR1,CYP27A1,DAXX,DDX23,DOK2,DTX2,DYNLL1,ECHS1,EDC4,EIF2B2,EMG1,FARSA,FBP1,FES,FGL2,FGR,FKBP15,GBA1,GLB1,GOSR2,GTF2H4,HEXA,HMGCL,HSD17B4,HSPA1B,HSPA8,HYAL2,ICAM2,ING4,KAT5,KCNE3,KCNH2,KEAP1,KIAA0930,KIF3C,LAIR1,LARP4,LASP1,LAT,LMAN2,LPXN,MAPK11,MCM3,MCRS1,METTL13,MYBPH,NANS,NBR1,NFS1,NIPSNAP1,NUBP1,NUDT2,NUP62,OAS1,OPRL1,PAAF1,PDGFA,PDZK1,PHB1,PIM1,PIM3,PPP1R11,PRMT5,PRPF6,PSEN1,PTDSS1,TWF2,PTPN6,PTRH1,RAB32,RAB8A,RBM4,RGS14,RGS3,RPA2,RTCB,SASH3,ENTR1,SEPHS1,SRSF5,SH2D3C,PUF60,SLC25A20,SLC31A2,SNRNP40,SPIB,SPOP,SRCAP,STYXL1,SUPT16H,TCL1A,TICAM2,TLN1,TLR5,TLR8,TM9SF1,TNFSF10,TNFSF13,TRIM21,UROD,UTP14A,VAMP8,VCL,VGLL4,VIPAS39,VPS35,VPS45,VPS72,ZNF154,ZNF226,ZNF692",143,"ADORA2A,APOL3,ARRB1,ASGR1,ASH2L,ATP6V1B2,ATP6V1C1,ATP6V1E1,BCAP31,BCAT2,BTN3A2,BTN3A3,C3AR1,CACNA2D3,CCDC22,CCN5,CCR2,CCT3,CD1C,CD300LF,CD79B,CD8B,CEBPA,CISD3,CISH,CLU,COMT,CORO1A,CSF1R,CSNK2A1,CTSZ,CTTN,CX3CR1,CYP27A1,DAXX,DDX23,DOK2,DTX2,DYNLL1,ECHS1,EDC4,EIF2B2,EMG1,FARSA,FBP1,FES,FGL2,FGR,FKBP15,GBA,GLB1,GOSR2,GTF2H4,HEXA,HMGCL,HSD17B4,HSPA1B,HSPA8,HYAL2,ICAM2,ING4,KAT5,KCNE3,KCNH2,KEAP1,KIAA0930,KIF3C,LAIR1,LARP4,LASP1,LAT,LMAN2,LPXN,MAPK11,MCM3,MCRS1,METTL13,MYBPH,NANS,NBR1,NFS1,NIPSNAP1,NUBP1,NUDT2,NUP62,OAS1,OPRL1,PAAF1,PDGFA,PDZK1,PHB,PIM1,PIM3,PPP1R11,PRMT5,PRPF6,PSEN1,PTDSS1,PTK9L,PTPN6,PTRH1,RAB32,RAB8A,RBM4,RGS14,RGS3,RPA2,RTCB,SASH3,SDCCAG3,SEPHS1,SFRS5,SH2D3C,SIAHBP1,SLC25A20,SLC31A2,SNRNP40,SPIB,SPOP,SRCAP,STYXL1,SUPT16H,TCL1A,TICAM2,TLN1,TLR5,TLR8,TM9SF1,TNFSF10,TNFSF13,TRIM21,UROD,UTP14A,VAMP8,VCL,VGLL4,VIPAS39,VPS35,VPS45A,VPS72,ZNF154,ZNF226,ZNF692",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-6.xlsx,NA,NA,NA,NA
M40877,WETVAX,LA,SMALLPOX,SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D50-60,D,55,18-32,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/SCHERER_PBMC_APSV_WETVAX_AGE_18_32YO_50_TO_60DY_UP,"Gene expression in human peripheral blood mononuclear cells was systematically evaluated following smallpox and yellow fever vaccination, and naturally occurring upper respiratory infection (URI). All three infections were characterized by the induction of many interferon stimulated genes, as well as enhanced expression of genes involved in proteolysis and antigen presentation. Vaccinia infection was also characterized by a distinct expression signature composed of up-regulation of monocyte response genes, with repression of genes expressed by B and T-cells. In contrast, the yellow fever host response was characterized by a suppression of ribosomal and translation factors, distinguishing this infection from vaccinia and URI. No significant URI-specific signature was observed, perhaps reflecting greater heterogeneity in the study population and etiological agents. Taken together, these data suggest that specific host gene expression signatures may be identified that distinguish one or a small number of virus agents.","Genes up-regulated in peripheral blood mononuclear cell (50 to 60)d vs 0d in adults (18-32) after exposure to APSV Wetvax , time point 50 to 60D","Scherer CA,Magness CL,Steiger KV,Poitinger ND,Caputo CM,Miner DG,Winokur PL,Klinzman D,McKee J,Pilar C,Ward PA,Gillham MH,Haulman NJ,Stapleton JT,Iadonato SP",17651872,HUMAN_GENE_SYMBOL,"ACAD9,ACBD5,ADM,AFAP1,AGFG1,CRYBG1,ANKLE2,,AREG,ARID5A,ATG2A,ATM,ATP1B3,B4GALT4,BCL2A1,BTG3,CASP3,CBLB,CCNE1,CCNL1,CD47,CD55,CDC73,CDKN1B,CDKN2C,CFI,CHD1,CLEC2B,CLK1,CLSTN3,COL4A5,CREM,CRH,CRTAM,CSNK1A1,CXCR4,DCAF11,DCTN6,DLL1,DNTTIP2,DUSP12,DYRK1A,EIF1B,ELAC1,ERH,ETF1,ETS2,FN1,FNBP4,G0S2,GADD45A,GALNT3,GNG10,HBP1,LAMTOR5,HCK,HERC1,HERPUD1,HIF1A,HMCES,HNRNPA3P1,HPGD,ID2,IDS,IFNGR1,IL13,IL18,CXCL8,CXCR2,INSIG1,IRS2,JARID2,KDM6A,NDC80,LITAF,LMO4,LPIN1,LUC7L3,MAP4K5,MCL1,,MPP7,MXD1,MXI1,NDUFV2,NIBAN1,NKRF,NR4A2,OSGIN2,P2RY10,NAMPT,PDE4B,PDK4,PER1,PFKFB3,PHF12,PIK3R1,PIP5K1A,PLAT,PNN,POLR3E,PPM1A,PPM1B,SRGN,PRKCH,PRKDC,PRMT3,PRPS1,PSMC5,PTBP2,PTP4A1,PTPN22,RABGGTB,RASA2,RBBP6,TRIM13,RGPD5,RIPK2,RNF103,RSRC2,RTF1,RUNX1,S100P,SAR1A,SBDS,SC5D,SEC63,SERINC1,SESN1,SETD2,MTREX,SLC16A6,SLC7A5,SMAD3,SMNDC1,SNIP1,SNRPE,SOD2,HSPA13,STIM1,STRAP,TAF13,TAS2R5,TGFBR3,THBD,TLE1,TMED10,TNC,TNFAIP3,TNKS2,TOB1,TRIM23,TTC32,UBE2D3,UQCRFS1,USP14,USP48,UVRAG,WDR26,YES1,ZBTB1,ZFP36L2,ZFP91,ZKSCAN1,ZNF267,ZNF281,ZNF326,ZNF394,ZNF451,ADNP2,ZNF625",171,"ACAD9,ACBD5,ADM,AFAP,AGFG1,AIM1,ANKLE2,APG1,AREG,ARID5A,ATG2A,ATM,ATP1B3,B4GALT4,BCL2A1,BTG3,CASP3,CBLB,CCNE1,CCNL1,CD47,CD55,CDC73,CDKN1B,CDKN2C,CFI,CHD1,CLEC2B,CLK1,CLSTN3,COL4A5,CREM,CRH,CRTAM,CSNK1A1,CXCR4,DCAF11,DCTN6,DLL1,DNTTIP2,DUSP12,DYRK1A,EIF1B,ELAC1,ERH,ETF1,ETS2,FN1,FNBP4,G0S2,GADD45A,GALNT3,GNG10,HBP1,HBXIP,HCK,HERC1,HERPUD1,HIF1A,HMCES,HNRPA3,HPGD,ID2,IDS,IFNGR1,IL13,IL18,IL8,IL8RB,INSIG1,IRS2,JARID2,KDM6A,KNTC2,LITAF,LMO4,LPIN1,LUC7L3,MAP4K5,MCL1,MIR570HG,MPP7,MXD1,MXI1,NDUFV2,NIBAN1,NKRF,NR4A2,OSGIN2,P2RY10,PBEF1,PDE4B,PDK4,PER1,PFKFB3,PHF12,PIK3R1,PIP5K1A,PLAT,PNN,POLR3E,PPM1A,PPM1B,PRG1,PRKCH,PRKDC,PRMT3,PRPS1,PSMC5,PTBP2,PTP4A1,PTPN22,RABGGTB,RASA2,RBBP6,RFP2,RGPD5,RIPK2,RNF103,RSRC2,RTF1,RUNX1,S100P,SAR1A,SBDS,SC5DL,SEC63,SERINC1,SESN1,SETD2,SKIV2L2,SLC16A6,SLC7A5,SMAD3,SMNDC1,SNIP1,SNRPE,SOD2,STCH,STIM1,STRAP,TAF13,TAS2R5,TGFBR3,THBD,TLE1,TMED10,TNC,TNFAIP3,TNKS2,TOB1,TRIM23,TTC32,UBE2D3,UQCRFS1,USP14,USP48,UVRAG,WDR26,YES1,ZBTB1,ZFP36L2,ZFP91,ZKSCAN1,ZNF267,ZNF281,ZNF326,ZNF394,ZNF451,ZNF508,ZNF625",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T4/,NA,NA,NA,NA
M40939,FLUMIST,LA,INFLUENZA,NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in B cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ACOX1,ACOX3,ACVR1B,ACVR2A,ADNP2,ADSL,AHCYL1,AHNAK,AHR,AK2,AKAP13,ALCAM,ALDH18A1,ALOX5,ANAPC5,ANXA4,AP4E1,APAF1,API5,APIP,APOA2,APOBEC3F,APPL2,ARG2,ARIH1,ARL1,ARL4C,ATAD2,ATAD2B,ATP2B4,ATP5PO,ATP6AP2,ATP6V0D1,ATXN2L,ATXN7,AZIN1,B4GALT1,BAZ1A,BCL2L13,BCL3,BLVRA,BRCC3,BRD3OS,BABAM2,BST2,C1QBP,ADISSP,CFAP410,C2orf27A,NREP,C5orf15,C8orf44,CACNA2D3,CALM1,CAMSAP1,CAPNS1,CAPRIN1,CBLL1,CBX6,CCDC47,CD244,CD300A,POLR1G,CD44,CD58,CD59,CD84,CD86,CDC37,CDK2AP2,CDS2,CEBPD,CELF1,CENPF,CES1,CIZ1,CLEC7A,CLIC4,CLMN,CLTA,CLU,CNIH4,CNOT4,COL9A3,COQ9,COX5B,CREM,CRYBB2,CSGALNACT2,CSNK1D,CTBP2,CTNNA1,TASL,CYLD,CYP1B1,DDX21,RIGI,DNAJB6,DPP4,VPS26C,DUSP7,DYRK1A,DZIP3,EBAG9,ECE1,EIF4A3,EIF4E2,EIF4EBP2,EIF4G1,ELF2,ELF4,EMG1,ERAP1,ERCC1,NIBAN1,FARP1,FBXO9,FCN2,FEZ2,FGR,FHL3,FHOD1,FIS1,FNTB,FOSL2,FYN,GART,GAS7,GBP1,GK,GLB1,GLB1L,GLYR1,GNS,GOSR2,GPAA1,GPD2,GTF2I,GTPBP1,GYPC,H1-0,HAAO,HADHA,HDGF,HIGD1B,HIP1R,HIPK2,H1-4,H2AC8,HK2,HLA-DRB1,HLA-DRB3,HLA-DRB4,HLA-DRB5,HMGXB4,HPS1,HPSE,HSPA9,ICAM1,ICE1,ID2,ID2B,IDH3B,IFI30,IFNGR1,IGFBP7,,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHM,IL10RB,IL27RA,IL6ST,INPP1,KATNA1,KCNN3,EMC1,ATG13,KIF2A,KLF11,KLF8,KLHL11,KMT2A,KPNA1,KPNA6,KPNB1,KYNU,LANCL2,LDOC1,LGALS1,LGALS3,LGALS8,LILRA1,LILRA2,LMNA,LPCAT3,LTN1,LUC7L,LYL1,LYN,LYZ,MAP2K7,MAP4K5,MAP7D1,MAPKAP1,MAPKAPK2,MARCHF5,MARS1,MASP2,MBD4,MDM2,MED1,MED27,MFAP1,MLX,MNDA,MNT,MRC2,MRPS15,CMC4,MYCBP,MYH10,KAT7,KAT6A,KAT6B,NAMPT,NCF2,NCOA2,NCR3,NECAB3,NEO1,NFE2L1,NID1,NIPBL,NMD3,NOC3L,NPHP4,NPL,NSUN6,NUP210,OAS3,OAZ2,OPA1,P2RX1,PARP8,PCGF3,PEBP1,PECAM1,PES1,PHACTR2,PHC1,PHF3,PI4KA,PIGC,PIGH,PIK3CB,PIK3R1,PIN1,PITPNC1,PLCD1,PLEC,PLGLB1,PLGLB2,PLK3,PLXNC1,PML,POLR1C,POLR2E,PPARD,PPP1CA,PPP1R9A,PPP3R1,DESI2,PRDX1,PRKAG2,PRPF38B,PRRC1,PSD3,PSMB2,PSME3,PSMG2,PSTPIP1,PTEN,PTPN12,PTPRS,QKI,QSOX1,RAB1A,RAB4A,RABGEF1,RABGGTB,PLAAT4,RASA1,RBM19,RBM5,RBPJ,RCN1,RDX,RERE,REXO2,RHOBTB3,RIN2,RIN3,RNASEH1,RNF115,RNPEPL1,ROGDI,RPE,RRN3,RUFY3,S100A8,SCO2,SEC23B,SECISBP2L,SENP2,SENP5,SERINC5,SERPINB1,SCAF11,SGPL1,SKAP2,SLC12A7,SLC1A4,SLC24A1,SLC35A1,SLC35F5,SMARCD1,SMG6,SNIP1,SNRNP35,SNX1,SON,SPAG9,SPTLC2,SRGN,SRSF10,SSRP1,STAMBP,STX17,SULT1A2,SULT1A3,SULT1A4,SUPT6H,SWAP70,SYNE1,SYNJ2,TACC1,TAF9B,TBL1XR1,TFAM,TFB2M,TFE3,TFRC,TGFBI,TIMP1,TLE4,TLR7,TM2D1,TMEM11,TMEM135,TNFAIP3,TNFSF13,TNPO1,TOR1AIP1,TOR3A,TPK1,TRAF6,TRAM1,TRIB3,TSFM,TSG101,TTC21B,U2AF1,UBE2D1,UPF1,UPP1,USP1,USP13,UTP14A,UTP14C,UTP18,VAMP3,VPS11,WARS1,WDR41,WDR45B,WIPI2,YES1,YLPM1,YWHAH,ZFAND6,ZFYVE26,ZNF148,ZNF292,ZNF324,ZNF532,ZNF710",400,"ACOX1,ACOX3,ACVR1B,ACVR2A,ADNP2,ADSL,AHCYL1,AHNAK,AHR,AK2,AKAP13,ALCAM,ALDH18A1,ALOX5,ANAPC5,ANXA4,AP4E1,APAF1,API5,APIP,APOA2,APOBEC3F,APPL2,ARG2,ARIH1,ARL1,ARL4C,ATAD2,ATAD2B,ATP2B4,ATP5O,ATP6AP2,ATP6V0D1,ATXN2L,ATXN7,AZIN1,B4GALT1,BAZ1A,BCL2L13,BCL3,BLVRA,BRCC3,BRD3OS,BRE,BST2,C1QBP,C20orf27,C21orf2,C2orf27A,C5orf13,C5orf15,C8orf44,CACNA2D3,CALM1,CAMSAP1,CAPNS1,CAPRIN1,CBLL1,CBX6,CCDC47,CD244,CD300A,CD3EAP,CD44,CD58,CD59,CD84,CD86,CDC37,CDK2AP2,CDS2,CEBPD,CELF1,CENPF,CES1,CIZ1,CLEC7A,CLIC4,CLMN,CLTA,CLU,CNIH4,CNOT4,COL9A3,COQ9,COX5B,CREM,CRYBB2,CSGALNACT2,CSNK1D,CTBP2,CTNNA1,CXorf21,CYLD,CYP1B1,DDX21,DDX58,DNAJB6,DPP4,DSCR3,DUSP7,DYRK1A,DZIP3,EBAG9,ECE1,EIF4A3,EIF4E2,EIF4EBP2,EIF4G1,ELF2,ELF4,EMG1,ERAP1,ERCC1,FAM129A,FARP1,FBXO9,FCN2,FEZ2,FGR,FHL3,FHOD1,FIS1,FNTB,FOSL2,FYN,GART,GAS7,GBP1,GK,GLB1,GLB1L,GLYR1,GNS,GOSR2,GPAA1,GPD2,GTF2I,GTPBP1,GYPC,H1F0,HAAO,HADHA,HDGF,HIGD1B,HIP1R,HIPK2,HIST1H1E,HIST1H2AE,HK2,HLA-DRB1,HLA-DRB3,HLA-DRB4,HLA-DRB5,HMGXB4,HPS1,HPSE,HSPA9,ICAM1,ICE1,ID2,ID2B,IDH3B,IFI30,IFNGR1,IGFBP7,IGH,IGHA1,IGHA2,IGHD,IGHG1,IGHG3,IGHM,IL10RB,IL27RA,IL6ST,INPP1,KATNA1,KCNN3,KIAA0090,KIAA0652,KIF2A,KLF11,KLF8,KLHL11,KMT2A,KPNA1,KPNA6,KPNB1,KYNU,LANCL2,LDOC1,LGALS1,LGALS3,LGALS8,LILRA1,LILRA2,LMNA,LPCAT3,LTN1,LUC7L,LYL1,LYN,LYZ,MAP2K7,MAP4K5,MAP7D1,MAPKAP1,MAPKAPK2,MARCH5,MARS,MASP2,MBD4,MDM2,MED1,MED27,MFAP1,MLX,MNDA,MNT,MRC2,MRPS15,MTCP1NB,MYCBP,MYH10,MYST2,MYST3,MYST4,NAMPT,NCF2,NCOA2,NCR3,NECAB3,NEO1,NFE2L1,NID1,NIPBL,NMD3,NOC3L,NPHP4,NPL,NSUN6,NUP210,OAS3,OAZ2,OPA1,P2RX1,PARP8,PCGF3,PEBP1,PECAM1,PES1,PHACTR2,PHC1,PHF3,PI4KA,PIGC,PIGH,PIK3CB,PIK3R1,PIN1,PITPNC1,PLCD1,PLEC,PLGLB1,PLGLB2,PLK3,PLXNC1,PML,POLR1C,POLR2E,PPARD,PPP1CA,PPP1R9A,PPP3R1,PPPDE1,PRDX1,PRKAG2,PRPF38B,PRRC1,PSD3,PSMB2,PSME3,PSMG2,PSTPIP1,PTEN,PTPN12,PTPRS,QKI,QSOX1,RAB1A,RAB4A,RABGEF1,RABGGTB,RARRES3,RASA1,RBM19,RBM5,RBPJ,RCN1,RDX,RERE,REXO2,RHOBTB3,RIN2,RIN3,RNASEH1,RNF115,RNPEPL1,ROGDI,RPE,RRN3,RUFY3,S100A8,SCO2,SEC23B,SECISBP2L,SENP2,SENP5,SERINC5,SERPINB1,SFRS2IP,SGPL1,SKAP2,SLC12A7,SLC1A4,SLC24A1,SLC35A1,SLC35F5,SMARCD1,SMG6,SNIP1,SNRNP35,SNX1,SON,SPAG9,SPTLC2,SRGN,SRSF10,SSRP1,STAMBP,STX17,SULT1A2,SULT1A3,SULT1A4,SUPT6H,SWAP70,SYNE1,SYNJ2,TACC1,TAF9B,TBL1XR1,TFAM,TFB2M,TFE3,TFRC,TGFBI,TIMP1,TLE4,TLR7,TM2D1,TMEM11,TMEM135,TNFAIP3,TNFSF13,TNPO1,TOR1AIP1,TOR3A,TPK1,TRAF6,TRAM1,TRIB3,TSFM,TSG101,TTC21B,U2AF1,UBE2D1,UPF1,UPP1,USP1,USP13,UTP14A,UTP14C,UTP18,VAMP3,VPS11,WARS,WDR41,WDR45L,WIPI2,YES1,YLPM1,YWHAH,ZFAND6,ZFYVE26,ZNF148,ZNF292,ZNF324,ZNF532,ZNF710",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41075,FLUMIST,LA,INFLUENZA,NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MONOCYTE_FLUMIST_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in monocyte 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ACOT7,ACTL7A,ADCK2,ADORA3,AGER,AHCTF1,AKAP13,AMELY,AMMECR1,ANAPC5,APLP2,APOA2,ARF6,ARL4C,ATP2B1,ATP4A,BARD1,BHLHE40,BIN1,BNIP1,BRPF1,BTN2A1,TIGAR,TSR3,SMIM7,C1QA,LAMP5,C2CD3,FAXDC2,CALR,CBX6,CCDC186,CD209,CD247,CD84,CDH16,CHD1,CHD2,CHN2,CIT,CLN8,CLP1,COG5,COG7,COL1A1,COPB1,CROCCP3,CSF1,CTBP1,CYLD,DDIT4,DDX49,DHRS3,DIAPH1,DIO2,,DOK1,DSC2,EBLN2,EHD1,EIF4G1,ELF4,ELL,EMP1,ENPP4,EPHB1,EPHB2,ERAP1,ESR2,ATOSB,FAM3A,TENT5A,FBXO3,,FLNB,FLOT1,FOSL2,FTSJ1,FUT4,FUT7,GALNT10,GALNT3,GGTLC2,GK,GLS,GLYR1,GM2A,GMEB1,GNA13,GOSR1,GPX3,GSTM1,HBEGF,HBP1,HCFC1R1,HES1,HIF1A,HLA-DOB,HYMAI,ID2,ID2B,IFT122,IGFALS,IGFBP5,,IGKC,IL1RN,INVS,IQSEC1,IRF4,IRF7,ITCH,JAK3,JRK,KAZN,KDM6B,MACF1,KLHL26,KRAS,LDLR,LILRA3,LMNA,LPIN2,LY6E,LY6G5C,MAL,MAP1A,MAP3K14,MAPKAPK2,MARCHF6,MBP,MBTPS2,MCM3AP,MEF2D,MGLL,MLEC,MPZL1,MTF2,MTHFR,MTMR9,MTOR,MYO1A,NACA,NBN,NET1,NFATC1,NFKBIE,NLRP1,NUMA1,NUP50,NXN,OASL,OTUB1,PAFAH1B2,PDE4D,PDK2,PDZK1IP1,PFKFB3,PHACTR1,PHF1,PHLDA1,PHLPP2,PIGZ,PIK3CB,PIK3CG,PLAAT3,PLAGL2,PLEK,PLEKHO2,PLN,PLSCR3,PLXNA1,PLXNB2,PML,POLR2A,PPFIBP2,PPM1A,PRNP,PRPS1,PXMP4,R3HCC1,RAB20,RAB2A,RAC2,RAD1,RAP2A,RAP2B,RASSF7,RECQL5,REL,RHOC,RNF126,RNF185,RNF6,RPH3AL,RREB1,RSRC1,RUNX1,,RUNX2,SAMSN1,SEC14L1,SEC14L5,SEPTIN6,SRSF11,SH3BP2,SIRPA,SIRT7,SKIL,SLC22A4,SLC25A37,SLC29A1,SLC35D1,SLC6A6,SMAD3,SMAD7,SMARCD1,SMURF2,SNIP1,SOCS3,SPDEF,SPTBN5,STK32B,STK38,SZT2,TAPBPL,TCL1A,TFIP11,TFPT,TGFB1,THBD,THBS1,TLE3,TMCC2,TMEM158,TMPRSS15,TNFAIP2,TNNI2,TPM3,TPPP3,TRAPPC4,TSPYL2,TWF1,TYRO3,UBAP1,UBTF,UROD,UTP18,VAMP5,VEGFA,VSIG4,XPNPEP1,YES1,YOD1,ZBTB43,ZBTB7B,ZDHHC17,ZGPAT,ZNF267,ZNF3,ZNF394,ZNF589,ZRSR2P1,ZW10",264,"ACOT7,ACTL7A,ADCK2,ADORA3,AGER,AHCTF1,AKAP13,AMELY,AMMECR1,ANAPC5,APLP2,APOA2,ARF6,ARL4C,ATP2B1,ATP4A,BARD1,BHLHE40,BIN1,BNIP1,BRPF1,BTN2A1,C12orf5,C16orf42,C19orf42,C1QA,C20orf103,C2CD3,C5orf4,CALR,CBX6,CCDC186,CD209,CD247,CD84,CDH16,CHD1,CHD2,CHN2,CIT,CLN8,CLP1,COG5,COG7,COL1A1,COPB1,CROCCL2,CSF1,CTBP1,CYLD,DDIT4,DDX49,DHRS3,DIAPH1,DIO2,DKFZP586I1420,DOK1,DSC2,EBLN2,EHD1,EIF4G1,ELF4,ELL,EMP1,ENPP4,EPHB1,EPHB2,ERAP1,ESR2,FAM214B,FAM3A,FAM46A,FBXO3,FLJ42627,FLNB,FLOT1,FOSL2,FTSJ1,FUT4,FUT7,GALNT10,GALNT3,GGTLC2,GK,GLS,GLYR1,GM2A,GMEB1,GNA13,GOSR1,GPX3,GSTM1,HBEGF,HBP1,HCFC1R1,HES1,HIF1A,HLA-DOB,HYMAI,ID2,ID2B,IFT122,IGFALS,IGFBP5,IGK,IGKC,IL1RN,INVS,IQSEC1,IRF4,IRF7,ITCH,JAK3,JRK,KAZN,KDM6B,KIAA0754,KLHL26,KRAS,LDLR,LILRA3,LMNA,LPIN2,LY6E,LY6G5C,MAL,MAP1A,MAP3K14,MAPKAPK2,MARCH6,MBP,MBTPS2,MCM3AP,MEF2D,MGLL,MLEC,MPZL1,MTF2,MTHFR,MTMR9,MTOR,MYO1A,NACA,NBN,NET1,NFATC1,NFKBIE,NLRP1,NUMA1,NUP50,NXN,OASL,OTUB1,PAFAH1B2,PDE4D,PDK2,PDZK1IP1,PFKFB3,PHACTR1,PHF1,PHLDA1,PHLPP2,PIGZ,PIK3CB,PIK3CG,PLA2G16,PLAGL2,PLEK,PLEKHO2,PLN,PLSCR3,PLXNA1,PLXNB2,PML,POLR2A,PPFIBP2,PPM1A,PRNP,PRPS1,PXMP4,R3HCC1,RAB20,RAB2A,RAC2,RAD1,RAP2A,RAP2B,RASSF7,RECQL5,REL,RHOC,RNF126,RNF185,RNF6,RPH3AL,RREB1,RSRC1,RUNX1,RUNX1-IT1,RUNX2,SAMSN1,SEC14L1,SEC14L5,SEPT6,SFRS11,SH3BP2,SIRPA,SIRT7,SKIL,SLC22A4,SLC25A37,SLC29A1,SLC35D1,SLC6A6,SMAD3,SMAD7,SMARCD1,SMURF2,SNIP1,SOCS3,SPDEF,SPTBN5,STK32B,STK38,SZT2,TAPBPL,TCL1A,TFIP11,TFPT,TGFB1,THBD,THBS1,TLE3,TMCC2,TMEM158,TMPRSS15,TNFAIP2,TNNI2,TPM3,TPPP3,TRAPPC4,TSPYL2,TWF1,TYRO3,UBAP1,UBTF,UROD,UTP18,VAMP5,VEGFA,VSIG4,XPNPEP1,YES1,YOD1,ZBTB43,ZBTB7B,ZDHHC17,ZGPAT,ZNF267,ZNF3,ZNF394,ZNF589,ZRSR1,ZW10",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41130,FLUMIST,LA,INFLUENZA,NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MYELOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in myeloid dendritic cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCF2,ABL1,ACSL1,ADAMTS2,AGRN,AKAP6,ALDH6A1,AMZ2,APOBEC3F,APOBEC3G,APPL2,ARFGAP2,ARHGAP1,ARIH1,ARMC9,ASAH1,ASAP2,ATF7IP,ATP2C1,BAG3,BCAT1,BNIP1,AKIP1,CMC2,OGFOD3,SZRD1,C2orf68,C9orf78,TMEM268,CASP4,CASP9,CCDC92,CCR6,CD22,CDK10,CDK5R1,CDR1,CES2,CFAP74,CHN2,CHUK,CLCN5,CLEC11A,CLPX,COBLL1,COPB1,CPPED1,CPT1A,CRAT,CREM,CRIPT,CRTC3,CUL5,DCAF7,DDB2,DDX19A,DDX60,DGKE,VPS26C,DTNA,DUOX1,DUT,DZIP3,E2F5,EI24,ELK3,ELMO2,ENPP2,ENTPD4,EP400,ERAP1,FCMR,TCAF1,FAM120A,SLF2,CYRIB,FBXO7,FBXW7,FLOT1,FXN,G0S2,G6PC3,GBE1,GBP1,GLRX2,GNPDA1,GOT1,GPR107,H2AZ2,HEMK1,HMGN4,ICOSLG,IFI44,IFIH1,IFIT5,IGF2R,,IGKC,IL15,INSM1,JAK3,KIAA0040,KIF1C,KIZ,KLHL7,KMO,KPNA2,KPNA3,KPNA6,KRAS,KRT86,LAT,LMBR1L,LMO4,LPAR1,LY6G5C,LY75,MAL,MALT1,MAP1A,MAP7,MARCHF6,MASP2,MDM2,MID1,MMP11,MRPS10,MRS2,MSRB2,MTMR4,MTPAP,MYOF,NAA16,NAA40,NCAM1,NCAPG,NDEL1,NFKB2,NIPSNAP1,NOC3L,NPAT,NR3C1,NR4A3,NRP1,NUAK2,NUP153,NUP37,OASL,TENM1,OGT,PBX2,PCDHGC3,PCIF1,PCYOX1L,PDCD2,PDLIM5,PEX7,PIGG,PIK3C3,PIK3CA,PJA1,PLA2G7,PMS2P3,POLR2C,POLR3D,PPARD,PPM1D,PRKD1,PRKRIP1,THAP12,PSEN2,PSIP1,PTCD3,PTK2,PTRH2,PTTG1,QDPR,RAB20,RAB27A,RAB28,RALGAPB,RANBP6,RCN1,RCOR3,RGL1,RING1,RRP1B,RS1,SAE1,SAR1A,SEC31B,SENP5,SF1,SFRP1,SRSF7,SIAH1,GEMIN2,SLC25A20,SLC25A24,SLC29A1,SLC48A1,SLC7A11,SMAD4,SMAGP,SMARCA2,SMC4,SNRNP35,SNRPB,SNUPN,SOX4,SP140,SPATA2L,SPNS1,SRI,SRRD,STAT1,STAT3,SYPL1,TAF1C,TCEAL2,TCF7L1,TCF7L2,TFEC,TFF3,TFIP11,TFRC,TICAM1,TM2D1,TMCO1,TMEM106C,TMEM147,TMEM41B,TMEM50B,TNFRSF25,TOE1,TRIB2,TRIM38,TSPAN13,TTBK2,TTLL3,UBE2B,UBTF,UBXN7,VEGFA,VRK3,WAC,XPNPEP3,XPO4,XPO6,XRCC1,YAF2,ZBTB17,ZBTB40,ZC3H14,TUT4,ZFP64,ZFX,ZMIZ2,ZNF155,ZNF211,ZBTB18,ZNF264,ZNF337,ZNF589,ZNF672,ZNF706,ZNF821,ZSCAN12",268,"ABCF2,ABL1,ACSL1,ADAMTS2,AGRN,AKAP6,ALDH6A1,AMZ2,APOBEC3F,APOBEC3G,APPL2,ARFGAP2,ARHGAP1,ARIH1,ARMC9,ASAH1,ASAP2,ATF7IP,ATP2C1,BAG3,BCAT1,BNIP1,C11orf17,C16orf61,C17orf101,C1orf144,C2orf68,C9orf78,C9orf91,CASP4,CASP9,CCDC92,CCR6,CD22,CDK10,CDK5R1,CDR1,CES2,CFAP74,CHN2,CHUK,CLCN5,CLEC11A,CLPX,COBLL1,COPB1,CPPED1,CPT1A,CRAT,CREM,CRIPT,CRTC3,CUL5,DCAF7,DDB2,DDX19A,DDX60,DGKE,DSCR3,DTNA,DUOX1,DUT,DZIP3,E2F5,EI24,ELK3,ELMO2,ENPP2,ENTPD4,EP400,ERAP1,FAIM3,FAM115A,FAM120A,FAM178A,FAM49B,FBXO7,FBXW7,FLOT1,FXN,G0S2,G6PC3,GBE1,GBP1,GLRX2,GNPDA1,GOT1,GPR107,H2AFV,HEMK1,HMGN4,ICOSLG,IFI44,IFIH1,IFIT5,IGF2R,IGK,IGKC,IL15,INSM1,JAK3,KIAA0040,KIF1C,KIZ,KLHL7,KMO,KPNA2,KPNA3,KPNA6,KRAS,KRT86,LAT,LMBR1L,LMO4,LPAR1,LY6G5C,LY75,MAL,MALT1,MAP1A,MAP7,MARCH6,MASP2,MDM2,MID1,MMP11,MRPS10,MRS2,MSRB2,MTMR4,MTPAP,MYOF,NAA16,NAA40,NCAM1,NCAPG,NDEL1,NFKB2,NIPSNAP1,NOC3L,NPAT,NR3C1,NR4A3,NRP1,NUAK2,NUP153,NUP37,OASL,ODZ1,OGT,PBX2,PCDHGC3,PCIF1,PCYOX1L,PDCD2,PDLIM5,PEX7,PIGG,PIK3C3,PIK3CA,PJA1,PLA2G7,PMS2L3,POLR2C,POLR3D,PPARD,PPM1D,PRKD1,PRKRIP1,PRKRIR,PSEN2,PSIP1,PTCD3,PTK2,PTRH2,PTTG1,QDPR,RAB20,RAB27A,RAB28,RALGAPB,RANBP6,RCN1,RCOR3,RGL1,RING1,RRP1B,RS1,SAE1,SAR1A,SEC31B,SENP5,SF1,SFRP1,SFRS7,SIAH1,SIP1,SLC25A20,SLC25A24,SLC29A1,SLC48A1,SLC7A11,SMAD4,SMAGP,SMARCA2,SMC4,SNRNP35,SNRPB,SNUPN,SOX4,SP140,SPATA2L,SPNS1,SRI,SRRD,STAT1,STAT3,SYPL1,TAF1C,TCEAL2,TCF7L1,TCF7L2,TFEC,TFF3,TFIP11,TFRC,TICAM1,TM2D1,TMCO1,TMEM106C,TMEM147,TMEM41B,TMEM50B,TNFRSF25,TOE1,TRIB2,TRIM38,TSPAN13,TTBK2,TTLL3,UBE2B,UBTF,UBXN7,VEGFA,VRK3,WAC,XPNPEP3,XPO4,XPO6,XRCC1,YAF2,ZBTB17,ZBTB40,ZC3H14,ZCCHC11,ZFP64,ZFX,ZMIZ2,ZNF155,ZNF211,ZNF238,ZNF264,ZNF337,ZNF589,ZNF672,ZNF706,ZNF821,ZSCAN12",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41018,FLUMIST,LA,INFLUENZA,NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in plasmacytoid dendritic cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AAK1,ABCA11P,ABCC6,ABCF2,ABHD5,ACAN,ASIC1,ACHE,ACP5,ACVR1B,ACY1,ADAM19,ADAM8,ADARB1,ADCY3,ADCY6,ADGRG1,ADORA1,CRYBG2,AKAP13,AKAP6,AKAP8L,AKR1C4,ALAS2,ALDH4A1,ALK,ALX1,ALX3,AMHR2,ANAPC10,ANGPT1,ANK3,AP1M2,APLP1,APOC2,APOE,APOM,APPBP2,AQP2,AR,ARHGAP26,ARHGAP6,ARHGEF11,ARHGEF17,ART4,ASAP3,ASCL1,ASH1L,ASL,ASMTL-AS1,ASPHD1,ATAD2,ATF7IP,ATG2A,ATP1B1,DMAC2L,AVPR1A,AZGP1,B3GNT3,B9D1,BACH1,BBS9,BDKRB2,BEX1,BGN,BIK,BIRC5,BLVRA,BOP1,BPNT1,BRF1,BRPF1,BTNL8,BUB1B,AKIP1,SPX,TEX30,CLBA1,C15orf39,OGFOD3,TMEM259,C1S,C1orf68,SOGA1,FNDC11,AAR2,CFAP410,RTL10,CRACDL,C4A,C4B,ADTRP,SAPCD1,VWA7,PKD1L1-AS1,CACFD1,CABP1,CACNA1A,CACNA1E,CACNA1H,CACNA1I,CACNB2,CACNB3,CADM4,CALB1,CALCA,CALML5,CALR,CALY,CAMK1,CAMK2B,CAMK2G,CAPN10,CARD10,CASP4,CASQ1,EFCC1,CCDC71,CCK,CCL25,CCL5,CCNE2,CCR9,CD1E,CD24,CD28,CD300C,CD79B,CDA,CDC14B,CDC34,CDC42,CDC42EP3,CDC42EP4,CDCA4,CDH15,CDH4,CDK3,CDKN2A,CDKN2A-DT,CDSN,CEACAM1,CEACAM6,CEBPA,CEND1,CEP76,CFHR5,CFLAR,CHAD,CHAF1A,CHAT,CHD4,CHD5,CHFR,CHIA,CHKB-CPT1B,CHPF2,CHRDL1,CHRNG,CHST4,CILP,CKB,CLCN4,CLCN7,CLEC4M,CLPS,CLTA,CLTC,CNGB1,CNPY4,COL11A2,COL4A3,COL6A1,COL7A1,COMMD4,CORO1B,COTL1,CPNE6,CPT1B,CRB1,CRHR1,CRLF1,CRYBA4,CRYGD,CSF3,CSH1,CSNK1E,CSNK1G1,CSNK1G2,CTNND2,CUL7,CWC25,CXADR,CXCL1,CYB561,CYLC1,CYP2A6,CYP2A7,CYP2B6,CYP2C18,CYP2C8,CYP2C9,CYP2E1,CYP3A4,CYP4F8,NSG1,DAZ1,DAZ2,DAZ3,DAZ4,BRINP1,DCAF4,DCT,DCUN1D4,DDIT3,DDX11,DDX31,DENND2A,DFFB,DGKG,DHX34,DHX8,DIO2,DKK4,DLAT,DLEC1,DLG5,DLGAP4,DMXL2,DNAI1,DNAJC1,DNAJC4,DOCK5,DOCK6,DOK1,DPT,DPYSL4,DTNA,DTX2,DUS2,DUX4,DUX4L4,DUX4L5,DUX4L6,DUX4L7,DYRK1B,EFHD1,EHBP1L1,EHD1,ELF4,ELK1,ELN,ELOVL2,ELSPBP1,EMP1,ENGASE,ENOX1,EPB41L3,EPHA1,EPN1,EPN3,ERC1,ERG,ESR1,ETV1,ETV7,EXOC7,EXOG,EXOSC2,EXOSC4,EXPH5,EYA4,F11,F12,FABP2,FADD,FAIM2,EMC9,GAREM1,FBLN1,FBLN5,FBXL8,FBXO11,FCAR,FCGR1A,FCGR2C,FCN1,FGF12,FGF3,FGF5,FGL1,FH,FKBP6,FKBPL,FLNC,FN1,FOSL2,FOXF1,FOXN1,FOXP1,FRMD4A,FXYD6,FZD10,GABARAPL1,GABRG2,GAL,GALNT6,GART,GAS1,GAS7,GATA1,GATA2,GATAD1,GBP1,GCGR,GCHFR,GDF15,GGA1,GHRH,GHSR,GIMAP5,GLTP,GMDS,GMEB1,GNA11,GNAO1,GNB5,GOLIM4,GORASP1,GP2,GPER1,CMKLR2,GPR135,GPR137,GPR162,GPR22,GPR32,GPR68,GRAP2,GSG1,GSPT1,GUCA1A,GYPB,HAO2,HAPLN1,HBA1,HBA2,HBEGF,,HCN4,HEG1,HELLS,HES1,H1-1,H2AC15,HK1,HK2,HK3,HMGB3,HMGCL,HMOX2,HOOK1,HOXB5,HOXD13,HRK,HS3ST1,HS3ST2,HSD11B1,HSD17B8,HSPA6,HTR1D,ICOSLG,ID2,IER2,IER3,IFI30,IFT122,IGF1,IGF2,IGFALS,IGFBP5,IGHG1,IL15,IL1B,IL2,IL27RA,IL6,IL6ST,IMPDH1,IMPG1,ING2,INHBB,INO80D,INS-IGF2,INTS5,IQCC,IRF6,IRGQ,ISL1,ITGA2B,ITGA3,ITGA6,ITGB4,ITIH2,ITIH4,ITPK1,ITPKC,ITSN1,JAG2,JAK3,JMJD7,JMJD7-PLA2G4B,JRK,KAT5,KCND3,KCNIP2,KCTD14,KCTD5,POGLUT2,KDM6B,KHK,KIAA0040,KIAA1614,SHISAL1,KIF22,KIF25,KIR2DL5A,KIR3DL1,KIRREL1,KLHDC10,KLHDC3,KLHL20,KLHL22,KLHL24,KLHL35,KLK1,KLK10,KLRG1,KPTN,KRT6B,KRTAP2-4,KSR1,L1CAM,LAMA2,LAMB1,LARP6,CERS4,LAT,LCMT2,LDB3,LEFTY1,LGALS14,LGI2,LHPP,LIMCH1,LIMK1,LLGL2,LMF1,LMNA,LMTK2,LPCAT4,LRP1,LRP5L,LRRC31,LRRC61,LTBP4,LYST,MAD1L1,MAFK,MAGEA10,MAGEA3,MAP2K5,MAP3K19,MAP3K9,MAPK12,MAPKAPK5-AS1,MARCKS,MAST2,MAST4,MATN1,MB,MBP,MCM10,MCOLN3,ME1,MEAK7,MED27,MED9,MEGF6,MEGF8,METRN,METTL4,MEX3D,MFAP5,MFNG,MFSD5,MICAL2,MIF,MKI67,MLXIPL,MMP25,MOG,MPIG6B,MPZL1,MR1,MRPL2,MRPS12,MSH6,MSL3,MSRB2,MST1,MT1E,MT1G,MT3,MTF1,MTFR1,MTHFR,MTOR,MUC1,MUC13,MUC4,MXRA8,MYB,MYBPC2,MYCN,MYCNOS,MYCT1,MYL6,NAA11,NAA40,NAGLU,CIAO3,NCAM1,NCAPH2,NCLN,NCR2,NDE1,NDEL1,NDRG2,NDRG4,NEU3,NEUROG2,NINL,NKX2-2,NKX2-5,NLRP1,NMT2,NOTCH3,NPAT,NPEPL1,NPHP4,NR0B1,NR1I2,NR2E3,NRP2,NSD2,NTRK2,NUAK2,NUP98,OBSCN,OBSL1,OCA2,OGFOD2,OGN,OR12D3,OR2C1,OR2F1,OR2F2,OR5V1,OSGIN1,OSM,P2RX2,P3H3,PAEP,PAWR,PAX6,PBX2,PBXIP1,PC,PCBP3,PCCA,PCDHA10,PCDHGC3,PCGF1,PDE2A,PDE4A,PDE4D,PDGFB,PDGFRA,PDHA2,PDLIM4,PDLIM5,PDZK1IP1,PER2,PEX10,PEX19,PFKFB4,PFN2,JADE3,PHF3,PHKG1,PHLDB1,PHYHIP,PIK3CB,PIP4K2B,PKNOX2,PLA2G3,PLAUR,PLEC,PLEKHO2,PLSCR1,PLXNA1,PLXNA2,PNMA8A,PNMT,POLG,POLR2J2,POLR3D,POMC,POU3F4,PPARD,PPDPF,PPIA,PPIL2,PPP2R5A,PRAMEF11,PRAMEF12,PRDM8,PRELP,PRIM1,PRKD2,PRMT7,PLPBP,PRPF31,PRR5,PRRX2,PRSS22,PSEN2,PSRC1,PTAFR,PTGER1,PTGS1,PTGS2,PTPN3,PTPRD,PTPRH,PURA,PVR,NECTIN2,NECTIN3,PWP2,PYCR3,PYY,QTRT1,RAB20,RAB23,RAB3B,RABEP2,RAD23B,RAD51B,RAI14,RANBP1,RANBP3,RARA,RARB,RASSF4,RBBP4,RBM38,RBPMS,RC3H2,RCC1,RDX,REPS1,RFC1,RFX1,RGS4,RGS9,RHBDL1,RHD,RHEB,RIF1,RIPK4,RNASE2,RNF122,RNF126,RNFT1,RPL35A,RPS28,RPS6,RRAS2,RRP12,RRP15,RRP9,RSL1D1,RTN1,RTN2,RUNX1,RYK,SAA1,SAA2,SAMD9,SCAMP4,SCARB1,SCGB2A2,SCLY,SCN2A,SCNN1A,SDC1,SDF4,SDHB,SDK2,SEMA3F,SEMA6B,SEMA7A,SENP6,SERHL2,SERPIND1,SERPINE1,KMT5A,SEZ6L,SFI1,SFTPC,SH2D3A,SIGLEC7,SIGLEC8,SIL1,SIM1,SKAP2,SKI,SKIC2,SLC11A1,SLC12A3,SLC14A2,SLC16A5,SLC16A8,SLC17A7,SLC19A1,SLC22A18AS,SLC24A2,SLC25A22,SLC25A30,SLC25A37,SLC26A6,SLC2A14,SLC2A2,SLC2A3,SLC2A4RG,SLC35A2,SLC35C1,SLC39A4,SLC4A4,SLC6A11,SLC6A2,SLC6A8,SLC7A8,NHERF2,SLCO3A1,SLN,SMAD6,SMG7,SMR3A,SMR3B,SMTN,SNAPC2,SNAPC4,SNCA,SNRPN,SNTB1,SNTB2,SOCS1,SOD3,SOX15,SOX9,SP2,SPACA1,SPINK5,SPNS1,SPTB,SRCAP,SRF,SRGAP3,SRPX2,SSBP2,ST20,ST6GALNAC2,ST7L,STAB2,STAG3,STAP2,STARD3,STARD8,STBD1,STMN1,SULT2B1,SYNM,SYP,TAB1,TACR1,TAF6L,TAT,TBC1D1,TBCD,TBK1,TBX1,TBX3,TCEAL2,TCF25,TCN2,TCP11L1,TCTN2,TECTA,TERT,TEX11,TEX15,TF,TFCP2L1,TGM4,TGOLN2,THAP7,THTPA,TIMM17A,TIMP3,TK1,TLE4,TLL2,TLN2,TLR8,TLX2,TM9SF1,TMEM131L,TMEM63A,TMX4,TNFAIP2,TNFAIP6,TNFRSF10B,TNFRSF10C,TNFRSF25,TNFSF14,TNNC2,TNPO2,TNS1,TNXA,TNXB,TOM1L2,TP73,TPD52L1,TPSAB1,TPSB2,TRA2A,TRAFD1,TRBV10-2,TREM2,TRGV5,TRIM23,TRIM31,TRIM45,TROAP,TSC22D4,TSPAN9,TTC38,TUBA4A,TUBB1,TUBG1,TUSC2,UBA6,UBE2C,UBE2H,UCN,USP32,USP46,UST,VARS1,VASH2,VAV3,VAX2,VDR,VEGFA,VNN2,VPREB3,VPS28,WDFY3,WDR76,WFS1,WIZ,WNT6,XIAP,YBX1,YIPF6,ZBTB32,ZBTB43,ZC3HAV1,ZCCHC14,ZDHHC11,ZFAND3,ZFHX2,ZFR2,ZMIZ2,ZNF154,ZNF157,ZNF174,ZNF189,ZNF292,ZSCAN31,ZNF324,ZNF467,ZNF536,ZNF551,ZNF606,ZNF76,ZSWIM8",910,"AAK1,ABCA11P,ABCC6,ABCF2,ABHD5,ACAN,ACCN2,ACHE,ACP5,ACVR1B,ACY1,ADAM19,ADAM8,ADARB1,ADCY3,ADCY6,ADGRG1,ADORA1,AIM1L,AKAP13,AKAP6,AKAP8L,AKR1C4,ALAS2,ALDH4A1,ALK,ALX1,ALX3,AMHR2,ANAPC10,ANGPT1,ANK3,AP1M2,APLP1,APOC2,APOE,APOM,APPBP2,AQP2,AR,ARHGAP26,ARHGAP6,ARHGEF11,ARHGEF17,ART4,ASAP3,ASCL1,ASH1L,ASL,ASMTL-AS1,ASPHD1,ATAD2,ATF7IP,ATG2A,ATP1B1,ATP5S,AVPR1A,AZGP1,B3GNT3,B9D1,BACH1,BBS9,BDKRB2,BEX1,BGN,BIK,BIRC5,BLVRA,BOP1,BPNT1,BRF1,BRPF1,BTNL8,BUB1B,C11orf17,C12orf39,C13orf27,C14orf79,C15orf39,C17orf101,C19orf6,C1orf68,C1S,C20orf117,C20orf195,C20orf4,C21orf2,C22orf29,C2orf55,C4A,C4B,C6orf105,C6orf26,C6orf27,C7orf69,C9orf7,CABP1,CACNA1A,CACNA1E,CACNA1H,CACNA1I,CACNB2,CACNB3,CADM4,CALB1,CALCA,CALML5,CALR,CALY,CAMK1,CAMK2B,CAMK2G,CAPN10,CARD10,CASP4,CASQ1,CCDC48,CCDC71,CCK,CCL25,CCL5,CCNE2,CCR9,CD1E,CD24,CD28,CD300C,CD79B,CDA,CDC14B,CDC34,CDC42,CDC42EP3,CDC42EP4,CDCA4,CDH15,CDH4,CDK3,CDKN2A,CDKN2A-AS1,CDSN,CEACAM1,CEACAM6,CEBPA,CEND1,CEP76,CFHR5,CFLAR,CHAD,CHAF1A,CHAT,CHD4,CHD5,CHFR,CHIA,CHKB-CPT1B,CHPF2,CHRDL1,CHRNG,CHST4,CILP,CKB,CLCN4,CLCN7,CLEC4M,CLPS,CLTA,CLTC,CNGB1,CNPY4,COL11A2,COL4A3,COL6A1,COL7A1,COMMD4,CORO1B,COTL1,CPNE6,CPT1B,CRB1,CRHR1,CRLF1,CRYBA4,CRYGD,CSF3,CSH1,CSNK1E,CSNK1G1,CSNK1G2,CTNND2,CUL7,CWC25,CXADR,CXCL1,CYB561,CYLC1,CYP2A6,CYP2A7,CYP2B6,CYP2C18,CYP2C8,CYP2C9,CYP2E1,CYP3A4,CYP4F8,D4S234E,DAZ1,DAZ2,DAZ3,DAZ4,DBC1,DCAF4,DCT,DCUN1D4,DDIT3,DDX11,DDX31,DENND2A,DFFB,DGKG,DHX34,DHX8,DIO2,DKK4,DLAT,DLEC1,DLG5,DLGAP4,DMXL2,DNAI1,DNAJC1,DNAJC4,DOCK5,DOCK6,DOK1,DPT,DPYSL4,DTNA,DTX2,DUS2L,DUX4,DUX4L4,DUX4L5,DUX4L6,DUX4L7,DYRK1B,EFHD1,EHBP1L1,EHD1,ELF4,ELK1,ELN,ELOVL2,ELSPBP1,EMP1,ENGASE,ENOX1,EPB41L3,EPHA1,EPN1,EPN3,ERC1,ERG,ESR1,ETV1,ETV7,EXOC7,EXOG,EXOSC2,EXOSC4,EXPH5,EYA4,F11,F12,FABP2,FADD,FAIM2,FAM158A,FAM59A,FBLN1,FBLN5,FBXL8,FBXO11,FCAR,FCGR1A,FCGR2C,FCN1,FGF12,FGF3,FGF5,FGL1,FH,FKBP6,FKBPL,FLNC,FN1,FOSL2,FOXF1,FOXN1,FOXP1,FRMD4A,FXYD6,FZD10,GABARAPL1,GABRG2,GAL,GALNT6,GART,GAS1,GAS7,GATA1,GATA2,GATAD1,GBP1,GCGR,GCHFR,GDF15,GGA1,GHRH,GHSR,GIMAP5,GLTP,GMDS,GMEB1,GNA11,GNAO1,GNB5,GOLIM4,GORASP1,GP2,GPER1,GPR1,GPR135,GPR137,GPR162,GPR22,GPR32,GPR68,GRAP2,GSG1,GSPT1,GUCA1A,GYPB,HAO2,HAPLN1,HBA1,HBA2,HBEGF,HCG26,HCN4,HEG1,HELLS,HES1,HIST1H1A,HIST1H2AK,HK1,HK2,HK3,HMGB3,HMGCL,HMOX2,HOOK1,HOXB5,HOXD13,HRK,HS3ST1,HS3ST2,HSD11B1,HSD17B8,HSPA6,HTR1D,ICOSLG,ID2,IER2,IER3,IFI30,IFT122,IGF1,IGF2,IGFALS,IGFBP5,IGHG1,IL15,IL1B,IL2,IL27RA,IL6,IL6ST,IMPDH1,IMPG1,ING2,INHBB,INO80D,INS-IGF2,INTS5,IQCC,IRF6,IRGQ,ISL1,ITGA2B,ITGA3,ITGA6,ITGB4,ITIH2,ITIH4,ITPK1,ITPKC,ITSN1,JAG2,JAK3,JMJD7,JMJD7-PLA2G4B,JRK,KAT5,KCND3,KCNIP2,KCTD14,KCTD5,KDELC1,KDM6B,KHK,KIAA0040,KIAA1614,KIAA1644,KIF22,KIF25,KIR2DL5A,KIR3DL1,KIRREL,KLHDC10,KLHDC3,KLHL20,KLHL22,KLHL24,KLHL35,KLK1,KLK10,KLRG1,KPTN,KRT6B,KRTAP2-4,KSR1,L1CAM,LAMA2,LAMB1,LARP6,LASS4,LAT,LCMT2,LDB3,LEFTY1,LGALS14,LGI2,LHPP,LIMCH1,LIMK1,LLGL2,LMF1,LMNA,LMTK2,LPCAT4,LRP1,LRP5L,LRRC31,LRRC61,LTBP4,LYST,MAD1L1,MAFK,MAGEA10,MAGEA3,MAP2K5,MAP3K19,MAP3K9,MAPK12,MAPKAPK5-AS1,MARCKS,MAST2,MAST4,MATN1,MB,MBP,MCM10,MCOLN3,ME1,MEAK7,MED27,MED9,MEGF6,MEGF8,METRN,METTL4,MEX3D,MFAP5,MFNG,MFSD5,MICAL2,MIF,MKI67,MLXIPL,MMP25,MOG,MPIG6B,MPZL1,MR1,MRPL2,MRPS12,MSH6,MSL3,MSRB2,MST1,MT1E,MT1G,MT3,MTF1,MTFR1,MTHFR,MTOR,MUC1,MUC13,MUC4,MXRA8,MYB,MYBPC2,MYCN,MYCNOS,MYCT1,MYL6,NAA11,NAA40,NAGLU,NARFL,NCAM1,NCAPH2,NCLN,NCR2,NDE1,NDEL1,NDRG2,NDRG4,NEU3,NEUROG2,NINL,NKX2-2,NKX2-5,NLRP1,NMT2,NOTCH3,NPAT,NPEPL1,NPHP4,NR0B1,NR1I2,NR2E3,NRP2,NSD2,NTRK2,NUAK2,NUP98,OBSCN,OBSL1,OCA2,OGFOD2,OGN,OR12D3,OR2C1,OR2F1,OR2F2,OR5V1,OSGIN1,OSM,P2RX2,P3H3,PAEP,PAWR,PAX6,PBX2,PBXIP1,PC,PCBP3,PCCA,PCDHA10,PCDHGC3,PCGF1,PDE2A,PDE4A,PDE4D,PDGFB,PDGFRA,PDHA2,PDLIM4,PDLIM5,PDZK1IP1,PER2,PEX10,PEX19,PFKFB4,PFN2,PHF16,PHF3,PHKG1,PHLDB1,PHYHIP,PIK3CB,PIP4K2B,PKNOX2,PLA2G3,PLAUR,PLEC,PLEKHO2,PLSCR1,PLXNA1,PLXNA2,PNMAL1,PNMT,POLG,POLR2J2,POLR3D,POMC,POU3F4,PPARD,PPDPF,PPIA,PPIL2,PPP2R5A,PRAMEF11,PRAMEF12,PRDM8,PRELP,PRIM1,PRKD2,PRMT7,PROSC,PRPF31,PRR5,PRRX2,PRSS22,PSEN2,PSRC1,PTAFR,PTGER1,PTGS1,PTGS2,PTPN3,PTPRD,PTPRH,PURA,PVR,PVRL2,PVRL3,PWP2,PYCRL,PYY,QTRT1,RAB20,RAB23,RAB3B,RABEP2,RAD23B,RAD51B,RAI14,RANBP1,RANBP3,RARA,RARB,RASSF4,RBBP4,RBM38,RBPMS,RC3H2,RCC1,RDX,REPS1,RFC1,RFX1,RGS4,RGS9,RHBDL1,RHD,RHEB,RIF1,RIPK4,RNASE2,RNF122,RNF126,RNFT1,RPL35A,RPS28,RPS6,RRAS2,RRP12,RRP15,RRP9,RSL1D1,RTN1,RTN2,RUNX1,RYK,SAA1,SAA2,SAMD9,SCAMP4,SCARB1,SCGB2A2,SCLY,SCN2A,SCNN1A,SDC1,SDF4,SDHB,SDK2,SEMA3F,SEMA6B,SEMA7A,SENP6,SERHL2,SERPIND1,SERPINE1,SETD8,SEZ6L,SFI1,SFTPC,SH2D3A,SIGLEC7,SIGLEC8,SIL1,SIM1,SKAP2,SKI,SKIV2L,SLC11A1,SLC12A3,SLC14A2,SLC16A5,SLC16A8,SLC17A7,SLC19A1,SLC22A18AS,SLC24A2,SLC25A22,SLC25A30,SLC25A37,SLC26A6,SLC2A14,SLC2A2,SLC2A3,SLC2A4RG,SLC35A2,SLC35C1,SLC39A4,SLC4A4,SLC6A11,SLC6A2,SLC6A8,SLC7A8,SLC9A3R2,SLCO3A1,SLN,SMAD6,SMG7,SMR3A,SMR3B,SMTN,SNAPC2,SNAPC4,SNCA,SNRPN,SNTB1,SNTB2,SOCS1,SOD3,SOX15,SOX9,SP2,SPACA1,SPINK5,SPNS1,SPTB,SRCAP,SRF,SRGAP3,SRPX2,SSBP2,ST20,ST6GALNAC2,ST7L,STAB2,STAG3,STAP2,STARD3,STARD8,STBD1,STMN1,SULT2B1,SYNM,SYP,TAB1,TACR1,TAF6L,TAT,TBC1D1,TBCD,TBK1,TBX1,TBX3,TCEAL2,TCF25,TCN2,TCP11L1,TCTN2,TECTA,TERT,TEX11,TEX15,TF,TFCP2L1,TGM4,TGOLN2,THAP7,THTPA,TIMM17A,TIMP3,TK1,TLE4,TLL2,TLN2,TLR8,TLX2,TM9SF1,TMEM131L,TMEM63A,TMX4,TNFAIP2,TNFAIP6,TNFRSF10B,TNFRSF10C,TNFRSF25,TNFSF14,TNNC2,TNPO2,TNS1,TNXA,TNXB,TOM1L2,TP73,TPD52L1,TPSAB1,TPSB2,TRA2A,TRAFD1,TRBV10-2,TREM2,TRGV5,TRIM23,TRIM31,TRIM45,TROAP,TSC22D4,TSPAN9,TTC38,TUBA4A,TUBB1,TUBG1,TUSC2,UBA6,UBE2C,UBE2H,UCN,USP32,USP46,UST,VARS,VASH2,VAV3,VAX2,VDR,VEGFA,VNN2,VPREB3,VPS28,WDFY3,WDR76,WFS1,WIZ,WNT6,XIAP,YBX1,YIPF6,ZBTB32,ZBTB43,ZC3HAV1,ZCCHC14,ZDHHC11,ZFAND3,ZFHX2,ZFR2,ZMIZ2,ZNF154,ZNF157,ZNF174,ZNF189,ZNF292,ZNF323,ZNF324,ZNF467,ZNF536,ZNF551,ZNF606,ZNF76,ZSWIM8",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M40979,FLUMIST,LA,INFLUENZA,NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_B_CELL_FLUMIST_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in B cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA1,ABCB1,ABCB4,ABHD10,ABHD2,ABHD4,ADCY7,ADORA2A,ADRM1,AGL,AHCYL1,AIMP2,AKAP1,AKR7A2,ALDH7A1,AMACR,ANAPC13,ANGEL2,ANK3,ANKHD1,ANKHD1-EIF4EBP3,ANKRD12,ANKRD36,AP2B1,APEX1,APPBP2,AQR,ARF6,ARHGAP1,ARL17A,ARL17B,ARL5A,ARMC8,ARNT,ASF1A,ASMTL,ASTE1,ATM,ATMIN,ATP13A1,ATP6V0C,BAG1,BCL10,BIN1,BMP2K,BRCA2,BTAF1,BTG3,TWNK,ANAPC15,NKAPD1,ERG28,SPTSSA,GID4,RBFA,C1QTNF3,C1orf105,MROH7,C1orf50,C1orf56,RSRP1,CNPPD1,SMIM8,CACYBP,CAND1,CARS1,CASP3,CBX1,TRMT13,CCDC88C,CCND3,CCR7,CCT4,CD200,CD22,CD226,CD24,CD2BP2,CD300A,CDC42SE1,CDC5L,CDK2,CEACAM1,CEP170,CEP290,CEP68,CKS2,CLCC1,CLCN6,CLCNKA,CLCNKB,CNTNAP2,COL4A3,COPS5,COPS7B,CPSF6,CREBZF,CRLF3,CSE1L,CSNK2A2,CSPP1,CTNND1,CUL5,EOLA1,EOLA2,CYB5A,SPECC1L,DBP,DBT,DCAF10,DCLRE1C,DDR1,DDX11,DECR1,DENND4B,DGKD,DLG1,DLGAP4,DNAH7,DNAJB1,DNAJB12,DNAJB9,DOCK2,DSP,DTX4,DUSP12,DXO,EHBP1,EIF2S1,EIF4G2,EIF5B,ELF2,ENPP4,ENTPD1,EPM2A,ERH,ERLIN2,ERN1,ERP44,ETS1,EXOG,FAF2,FAM117A,FAM120C,ABRAXAS2,RIPOR2,FCF1,FCRL2,FIG4,FKBP14,FKBP5,FLI1,FOXM1,FOXN3,FOXO4,FRYL,FTSJ1,GALNS,GALNT2,GARRE1,GART,GBX2,GCDH,GCOM1,GFRA2,GNAI3,GOLM1,GPR89A,GPR89B,GPSM2,GRK6,GTF2H1,GTF3A,GVINP1,HACD2,HAX1,HECTD3,HEMK1,HERC4,H2AC17,HLA-DOA,HRK,RIDA,HUWE1,HYI,IDS,IFRD1,IFT57,IFT74,IGF2R,IGHA1,IGHD,IGHG1,IGHG3,IGHM,IGHV4-31,,IGLV4-60,IL16,IL27RA,IL5,ILF3,INPP4A,INTS1,INTS7,INTS9,INVS,IRS2,ITGB1BP1,ITK,ITPA,JUN,KHDRBS2,KIN,KLF9,KLHDC10,KRT14,KSR1,LARGE1,LCMT1,LETM1,LIG4,LIMK2,LIPE,LRRC1,LY75,LZTR1,MAGOH,MAP2K4,MAP4,MAPK13,MARCHF7,MARCHF8,MAST3,MAVS,MECP2,METTL2A,METTL2B,MEX3C,MFNG,MGST3,RIOX2,MRTFA,MLF2,MLH3,MLX,MPHOSPH9,MRM3,MRPS30,MST1L,MTDH,MTMR1,MTRF1L,MMUT,MYCBP,MYL6B,MYOM1,NAT9,NCOA3,NDST2,NDUFC1,NDUFS4,NF1,NFATC2IP,NGDN,NLK,NME6,NPY,NR2C1,NSUN5P1,NT5E,NUP160,OGFOD2,ORAI2,OSBPL10,OSBPL3,OSGIN2,PAIP2B,PARP2,PCDH9,PCF11,PCM1,PCMT1,PCNA,PDCL3,PDE4DIP,PDHX,PDIA4,PER2,PEX3,PHF14,PHF20,PIGG,PIK3C3,PIK3IP1,PIP5K1A,PJA1,PKNOX1,PLAGL1,PNN,POLDIP3,POLM,POLR2M,PLPP1,PPM1D,PPP1R11,PPP1R13B,PPP2R1B,PPP2R5E,PRDX6,PRIM2,PSEN2,PSMC3IP,PSMD13,PTOV1,PTPN1,PTPN11,PTPN22,PYGM,RAB9A,RABEP2,RAD51D,RALGDS,RANGRF,RAP2A,RAP2B,RASGRP3,RB1,RBBP6,RBL2,RBM15B,RBM41,REEP5,RFK,RGS1,RGS20,RHOBTB3,RIC8A,RNGTT,RPAP2,RPL28,RPL37A,RPP21,RRP1B,RUNX1,RUVBL2,RWDD3,SAMM50,SARM1,SDHAF1,SEC23B,SEC24A,SERPINB8,SETD6,SF3A3,SUGP1,SCAF4,AKAP17A,SFXN3,SH3GLB2,SH3YL1,SHMT2,SIAH2,SIGIRR,SKAP1,SKP1,SLC11A2,SLC25A11,SLC25A14,SLC25A36,SLC30A4,SLC35E2A,SMAD3,SMCHD1,SMPD1,SNRPA,SP110,SPAST,SPTLC1,SRBD1,SSPN,ST13,ST6GAL1,STK17A,STOM,STX6,SUMO3,TADA3,TARP,TAX1BP3,TAFAZZIN,TBC1D30,TBC1D5,TBCC,TCEAL1,TCL6,TFIP11,THSD1,TIMP3,TLE1,TM2D1,TM7SF3,LDAF1,CEMIP2,TMEM41B,TMOD1,TMSB15B,TMSB4Y,TMX4,TNKS,TOMM70,TOP3A,TOX4,TP53TG1,TPD52,TRAF5,TRAM2,TREML2,TRGC2,TRIM39,,TRIO,TRMT112,TRPC1,TSPYL5,TSTD2,TTC4,TTF1,TTLL12,TUBB2A,TUBB4A,TUBGCP3,TUBGCP4,TWF1,TXNRD1,UBA6,UBE2B,UBE3B,UBL3,UEVLD,UFC1,UNC50,UNG,UROD,USP46,UXS1,VAMP1,WDR12,WDR59,WDR77,WEE1,WIPF2,WSB1,WTAP,XRCC1,YEATS2,YME1L1,YPEL1,ZBED2,ZBTB10,ZBTB16,ZBTB25,ZBTB38,ZC3H14,ZKSCAN1,ZMYM5,ZNF131,ZNF133,ZNF142,ZNF155,ZNF208,ZNF318,ZNF468,ZNF480,ZNF484,ZNF573,ZNF749,ZXDB",478,"ABCA1,ABCB1,ABCB4,ABHD10,ABHD2,ABHD4,ADCY7,ADORA2A,ADRM1,AGL,AHCYL1,AIMP2,AKAP1,AKR7A2,ALDH7A1,AMACR,ANAPC13,ANGEL2,ANK3,ANKHD1,ANKHD1-EIF4EBP3,ANKRD12,ANKRD36,AP2B1,APEX1,APPBP2,AQR,ARF6,ARHGAP1,ARL17A,ARL17B,ARL5A,ARMC8,ARNT,ASF1A,ASMTL,ASTE1,ATM,ATMIN,ATP13A1,ATP6V0C,BAG1,BCL10,BIN1,BMP2K,BRCA2,BTAF1,BTG3,C10orf2,C11orf51,C11orf57,C14orf1,C14orf147,C17orf39,C18orf22,C1orf105,C1orf175,C1orf50,C1orf56,C1orf63,C1QTNF3,C2orf24,C6orf162,CACYBP,CAND1,CARS,CASP3,CBX1,CCDC76,CCDC88C,CCND3,CCR7,CCT4,CD200,CD22,CD226,CD24,CD2BP2,CD300A,CDC42SE1,CDC5L,CDK2,CEACAM1,CEP170,CEP290,CEP68,CKS2,CLCC1,CLCN6,CLCNKA,CLCNKB,CNTNAP2,COL4A3,COPS5,COPS7B,CPSF6,CREBZF,CRLF3,CSE1L,CSNK2A2,CSPP1,CTNND1,CUL5,CXorf40A,CXorf40B,CYB5A,CYTSA,DBP,DBT,DCAF10,DCLRE1C,DDR1,DDX11,DECR1,DENND4B,DGKD,DLG1,DLGAP4,DNAH7,DNAJB1,DNAJB12,DNAJB9,DOCK2,DSP,DTX4,DUSP12,DXO,EHBP1,EIF2S1,EIF4G2,EIF5B,ELF2,ENPP4,ENTPD1,EPM2A,ERH,ERLIN2,ERN1,ERP44,ETS1,EXOG,FAF2,FAM117A,FAM120C,FAM175B,FAM65B,FCF1,FCRL2,FIG4,FKBP14,FKBP5,FLI1,FOXM1,FOXN3,FOXO4,FRYL,FTSJ1,GALNS,GALNT2,GARRE1,GART,GBX2,GCDH,GCOM1,GFRA2,GNAI3,GOLM1,GPR89A,GPR89B,GPSM2,GRK6,GTF2H1,GTF3A,GVIN1,HACD2,HAX1,HECTD3,HEMK1,HERC4,HIST1H2AM,HLA-DOA,HRK,HRSP12,HUWE1,HYI,IDS,IFRD1,IFT57,IFT74,IGF2R,IGHA1,IGHD,IGHG1,IGHG3,IGHM,IGHV4-31,IGL,IGLV4-60,IL16,IL27RA,IL5,ILF3,INPP4A,INTS1,INTS7,INTS9,INVS,IRS2,ITGB1BP1,ITK,ITPA,JUN,KHDRBS2,KIN,KLF9,KLHDC10,KRT14,KSR1,LARGE1,LCMT1,LETM1,LIG4,LIMK2,LIPE,LRRC1,LY75,LZTR1,MAGOH,MAP2K4,MAP4,MAPK13,MARCH7,MARCH8,MAST3,MAVS,MECP2,METTL2A,METTL2B,MEX3C,MFNG,MGST3,MINA,MKL1,MLF2,MLH3,MLX,MPHOSPH9,MRM3,MRPS30,MST1P9,MTDH,MTMR1,MTRF1L,MUT,MYCBP,MYL6B,MYOM1,NAT9,NCOA3,NDST2,NDUFC1,NDUFS4,NF1,NFATC2IP,NGDN,NLK,NME6,NPY,NR2C1,NSUN5P1,NT5E,NUP160,OGFOD2,ORAI2,OSBPL10,OSBPL3,OSGIN2,PAIP2B,PARP2,PCDH9,PCF11,PCM1,PCMT1,PCNA,PDCL3,PDE4DIP,PDHX,PDIA4,PER2,PEX3,PHF14,PHF20,PIGG,PIK3C3,PIK3IP1,PIP5K1A,PJA1,PKNOX1,PLAGL1,PNN,POLDIP3,POLM,POLR2M,PPAP2A,PPM1D,PPP1R11,PPP1R13B,PPP2R1B,PPP2R5E,PRDX6,PRIM2,PSEN2,PSMC3IP,PSMD13,PTOV1,PTPN1,PTPN11,PTPN22,PYGM,RAB9A,RABEP2,RAD51D,RALGDS,RANGRF,RAP2A,RAP2B,RASGRP3,RB1,RBBP6,RBL2,RBM15B,RBM41,REEP5,RFK,RGS1,RGS20,RHOBTB3,RIC8A,RNGTT,RPAP2,RPL28,RPL37A,RPP21,RRP1B,RUNX1,RUVBL2,RWDD3,SAMM50,SARM1,SDHAF1,SEC23B,SEC24A,SERPINB8,SETD6,SF3A3,SF4,SFRS15,SFRS17A,SFXN3,SH3GLB2,SH3YL1,SHMT2,SIAH2,SIGIRR,SKAP1,SKP1,SLC11A2,SLC25A11,SLC25A14,SLC25A36,SLC30A4,SLC35E2,SMAD3,SMCHD1,SMPD1,SNRPA,SP110,SPAST,SPTLC1,SRBD1,SSPN,ST13,ST6GAL1,STK17A,STOM,STX6,SUMO3,TADA3,TARP,TAX1BP3,TAZ,TBC1D30,TBC1D5,TBCC,TCEAL1,TCL6,TFIP11,THSD1,TIMP3,TLE1,TM2D1,TM7SF3,TMEM159,TMEM2,TMEM41B,TMOD1,TMSB15B,TMSB4Y,TMX4,TNKS,TOMM70A,TOP3A,TOX4,TP53TG1,TPD52,TRAF5,TRAM2,TREML2,TRGC2,TRIM39,TRIM39R,TRIO,TRMT112,TRPC1,TSPYL5,TSTD2,TTC4,TTF1,TTLL12,TUBB2A,TUBB4,TUBGCP3,TUBGCP4,TWF1,TXNRD1,UBA6,UBE2B,UBE3B,UBL3,UEVLD,UFC1,UNC50,UNG,UROD,USP46,UXS1,VAMP1,WDR12,WDR59,WDR77,WEE1,WIPF2,WSB1,WTAP,XRCC1,YEATS2,YME1L1,YPEL1,ZBED2,ZBTB10,ZBTB16,ZBTB25,ZBTB38,ZC3H14,ZKSCAN1,ZMYM5,ZNF131,ZNF133,ZNF142,ZNF155,ZNF208,ZNF318,ZNF468,ZNF480,ZNF484,ZNF573,ZNF749,ZXDB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_dnc_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41173,FLUMIST,LA,INFLUENZA,NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MONOCYTE_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in monocyte 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AAK1,ALK,ANKRD36B,ARAP3,ASNS,ATF7IP,AVL9,BCL11A,BCL3,BET1,BTAF1,NPR3,CCL4,CD22,CD300A,CDC14A,CLN5,COBLL1,STEEP1,DLG5,DUSP10,EGR1,,FAM149B1,FCER1A,FKBP8,,FLT3,FUBP1,GBE1,GPR75,MACROH2A1,H1-2,HMGA1,IARS1,ID2,ID2B,IER5,INSR,ITIH2,KHDC4,MAPKAPK2,MCM3,MDFIC,MED6,RIOX2,MTMR3,MYL5,NAXD,NFX1,NRIP2,OGT,OXCT1,P2RY14,PPP1R15A,PRKCI,PRMT2,RAB3GAP1,RBM12B-AS1,RBM3,RFXANK,RNF24,S100PBP,SCAMP1,SEL1L3,SUGP2,SCAF11,SIGLEC9,SIRT3,SLC10A1,SLC38A1,SMC5,SMC6,SNAPC5,SNCA,SPIN2A,SPIN2B,SPTBN1,SRD5A1,ST20,TARDBP,TRIM37,TRMT11,UBE2H,UEVLD,UNC45A,DYNC2I1,WWP2,XPO1,ZFP64,ZNF692",91,"AAK1,ALK,ANKRD36B,ARAP3,ASNS,ATF7IP,AVL9,BCL11A,BCL3,BET1,BTAF1,C5orf23,CCL4,CD22,CD300A,CDC14A,CLN5,COBLL1,CXorf56,DLG5,DUSP10,EGR1,ERV3-2,FAM149B1,FCER1A,FKBP8,FLJ42627,FLT3,FUBP1,GBE1,GPR75,H2AFY,HIST1H1C,HMGA1,IARS,ID2,ID2B,IER5,INSR,ITIH2,KHDC4,MAPKAPK2,MCM3,MDFIC,MED6,MINA,MTMR3,MYL5,NAXD,NFX1,NRIP2,OGT,OXCT1,P2RY14,PPP1R15A,PRKCI,PRMT2,RAB3GAP1,RBM12B-AS1,RBM3,RFXANK,RNF24,S100PBP,SCAMP1,SEL1L3,SFRS14,SFRS2IP,SIGLEC9,SIRT3,SLC10A1,SLC38A1,SMC5,SMC6,SNAPC5,SNCA,SPIN2A,SPIN2B,SPTBN1,SRD5A1,ST20,TARDBP,TRIM37,TRMT11,UBE2H,UEVLD,UNC45A,WDR60,WWP2,XPO1,ZFP64,ZNF692",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_dnc_d3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41172,FLUMIST,LA,INFLUENZA,NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,OTHER,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_MYELOID_DENDRITIC_CELL_FLUARIX_FLUVIRIN_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in myeloid dendritic cell 7d vs 0d in young adults (18-50) after exposure to Fluarix/Fluvirin , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AASDHPPT,ABCC1,ACBD3,ACLY,ACOT11,ACSL1,ACTN4,ADAM19,ADAP1,AHCTF1,AHCYL2,AKAP13,AKAP9,ALG13,AMFR,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANKHD1,ANKHD1-EIF4EBP3,ARFGEF2,ARL4A,ASB13,ASXL2,ATF3,ATF5,ATF6,ATG9A,ATMIN,ATP6V1B2,ATP7A,ATP9B,ATR,BAG6,BAIAP2,BAZ2B,BCAP29,BICRAL,BRWD1,BTAF1,BTG1,BTN2A1,C10orf88,RGCC,ERG28,METTL22,LYRM9,RBFA,URI1,RSRP1,CAB39L,CALM1,CAMKK2,CBR1,CEP83,CCDC59,CCDC86,CCL3,CCL3L1,CCL3L3,CCNG2,CD226,CD72,CDC14A,CEBPB,CEP57,CEP68,CHD3,CITED2,CLPX,COPS8,COX5B,CCP110,CPD,CREB5,CREG1,CSE1L,CTNND1,EOLA1,EOLA2,CYB5A,CYB5B,CYB5R3,NSG1,DCAKD,ECI1,DEPDC5,DHDDS,DNAJC16,DPH1,DTNA,DXO,EIF2S1,ELOVL5,EML4,ERAP1,ERP44,EXOC3,EXOSC2,EXOSC9,MZT2B,FAM13B,ABRAXAS2,SLF2,TENT5A,DIPK1A,FBXO21,FDFT1,FDPS,FGR,FIP1L1,FKBP11,FKBP15,GABPB1-IT1,FLT3LG,FN3KRP,FNBP1L,FNTA,FOXP1,FPR3,CMTR1,FUS,GABBR1,GADD45B,GBP1,PAXBP1,GNAI3,GNAQ,GNAS,GOLT1B,GON4L,GPR107,HCAR3,GSK3B,GTF2H1,HIC2,H2BC12,HLA-DOB,HLA-DRB4,HNRNPA0,HPS1,HSPA9,HSPBAP1,IFFO1,IFIH1,IFITM2,IL1B,IQSEC1,IRF2,ISG20L2,ITGAX,ITGB1,ITPR1,JUN,KDELR1,ATG13,KLC2,KLF2,KPNA3,LAMP1,LANCL1,LARP4B,LAT,LDOC1,LEMD3,LILRA2,LMBR1L,LMBRD1,LONP2,LRCH4,LRP5L,LRRFIP2,LY96,LYL1,MAN2A2,MAN2C1,MAP1LC3B,MAP3K14,MAP7,MAPK14,MARCHF1,MAST2,MCTS1,MDH2,MDM2,MECP2,MED7,METAP1,MLEC,MSRB2,MTMR2,MTR,MTRR,MUTYH,MYH10,N4BP2L2,NADK,NADSYN1,NBN,NCF1,NCF1B,NCF1C,NCK1,NCK2,NECAP1,NFATC2IP,NIPBL,NLRP3,NOC3L,NOL12,NOTCH2,NTAN1,NUP43,NUP50,NUP58,NXT1,OPN3,OSBPL3,OSGIN2,OTUD4,OVCA2,P2RY13,P2RY14,PACS1,PARP4,PCGF3,PCNX2,PDE4A,PDLIM5,PELO,PFKL,PHIP,PHTF2,GSAP,PITPNA,PKD2,PKNOX1,PKP4,PLA1A,PLA2G4C,PLEKHA5,POLA1,POLR1C,POLR3K,PLPP1,PRPF39,PRPSAP1,PSME4,PTBP2,PTPN22,PTPN9,PUM2,RABAC1,RABGAP1L,RAD17,RAF1,RALGAPB,RANBP9,RAP2A,RAP2C,RASGRP1,RASSF1,RBM25,RCAN3,RCBTB1,RCHY1,RETSAT,RFX5,RHOT1,RIOK3,RNF19B,RNGTT,RPA2,RPGR,CNOT9,RRN3P1,RUNX3,SAMD4A,SAP25,SAP30,SCAPER,SECISBP2L,SENP6,SEPHS1,SETDB1,SF1,SF3A1,SFN,SCAF4,SRSF7,SGCE,SH3GL1,SIGLEC9,SLA,SLC11A2,SLC20A2,SLC30A1,SLC33A1,SLC35D2,SLC39A6,SLC4A3,SLFN12,SMAP1,SMC4,SMC5,SMYD2,SNRPA1,SNX11,SOAT1,SOCS3,SOCS6,SOD2,SP100,SPAG9,SPIN2A,SPNS1,SPPL2B,SPTLC1,SRD5A1,SRRM2,SRSF10,SSBP1,ST8SIA4,STK38,STK38L,STK39,STX12,STX18,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,TACC3,TAF10,TAF1B,TAPBP,TARBP1,TBC1D9B,TBCE,TCF20,TCF3,TCIRG1,TCP1,TFIP11,THADA,TIA1,TMED5,TMEM41B,TNFAIP8,TNIP2,TOMM34,TP53BP1,TP53TG1,TRAK2,TRAPPC11,TRIAP1,TRIB2,TRIM28,TRIM33,RO60,TSC22D2,TSEN34,TRAPPC12,TTLL5,TUBB3,TWF1,TXNL4A,UBAP2L,UBE2I,UBE2K,UBN1,UBQLN2,UPP1,USP4,USP9X,VDAC1,VPS33B,VWA5A,WASHC4,WDR59,WSB1,XRCC4,YTHDC2,ZBTB20,ZBTB22,ZCCHC10,ZDHHC6,ZFP64,ZFR,ZMYM4,ZNF225,ZNF35,ZNF410,ZNF544,ZNF557,ZNF629,ZXDB",400,"AASDHPPT,ABCC1,ACBD3,ACLY,ACOT11,ACSL1,ACTN4,ADAM19,ADAP1,AHCTF1,AHCYL2,AKAP13,AKAP9,ALG13,AMFR,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANKHD1,ANKHD1-EIF4EBP3,ARFGEF2,ARL4A,ASB13,ASXL2,ATF3,ATF5,ATF6,ATG9A,ATMIN,ATP6V1B2,ATP7A,ATP9B,ATR,BAG6,BAIAP2,BAZ2B,BCAP29,BICRAL,BRWD1,BTAF1,BTG1,BTN2A1,C10orf88,C13orf15,C14orf1,C16orf68,C17orf108,C18orf22,C19orf2,C1orf63,CAB39L,CALM1,CAMKK2,CBR1,CCDC41,CCDC59,CCDC86,CCL3,CCL3L1,CCL3L3,CCNG2,CD226,CD72,CDC14A,CEBPB,CEP57,CEP68,CHD3,CITED2,CLPX,COPS8,COX5B,CP110,CPD,CREB5,CREG1,CSE1L,CTNND1,CXorf40A,CXorf40B,CYB5A,CYB5B,CYB5R3,D4S234E,DCAKD,DCI,DEPDC5,DHDDS,DNAJC16,DPH1,DTNA,DXO,EIF2S1,ELOVL5,EML4,ERAP1,ERP44,EXOC3,EXOSC2,EXOSC9,FAM128B,FAM13B,FAM175B,FAM178A,FAM46A,FAM69A,FBXO21,FDFT1,FDPS,FGR,FIP1L1,FKBP11,FKBP15,FLJ10038,FLT3LG,FN3KRP,FNBP1L,FNTA,FOXP1,FPR3,FTSJD2,FUS,GABBR1,GADD45B,GBP1,GCFC1,GNAI3,GNAQ,GNAS,GOLT1B,GON4L,GPR107,GPR109B,GSK3B,GTF2H1,HIC2,HIST1H2BK,HLA-DOB,HLA-DRB4,HNRNPA0,HPS1,HSPA9,HSPBAP1,IFFO1,IFIH1,IFITM2,IL1B,IQSEC1,IRF2,ISG20L2,ITGAX,ITGB1,ITPR1,JUN,KDELR1,KIAA0652,KLC2,KLF2,KPNA3,LAMP1,LANCL1,LARP4B,LAT,LDOC1,LEMD3,LILRA2,LMBR1L,LMBRD1,LONP2,LRCH4,LRP5L,LRRFIP2,LY96,LYL1,MAN2A2,MAN2C1,MAP1LC3B,MAP3K14,MAP7,MAPK14,MARCH1,MAST2,MCTS1,MDH2,MDM2,MECP2,MED7,METAP1,MLEC,MSRB2,MTMR2,MTR,MTRR,MUTYH,MYH10,N4BP2L2,NADK,NADSYN1,NBN,NCF1,NCF1B,NCF1C,NCK1,NCK2,NECAP1,NFATC2IP,NIPBL,NLRP3,NOC3L,NOL12,NOTCH2,NTAN1,NUP43,NUP50,NUPL1,NXT1,OPN3,OSBPL3,OSGIN2,OTUD4,OVCA2,P2RY13,P2RY14,PACS1,PARP4,PCGF3,PCNXL2,PDE4A,PDLIM5,PELO,PFKL,PHIP,PHTF2,PION,PITPNA,PKD2,PKNOX1,PKP4,PLA1A,PLA2G4C,PLEKHA5,POLA1,POLR1C,POLR3K,PPAP2A,PRPF39,PRPSAP1,PSME4,PTBP2,PTPN22,PTPN9,PUM2,RABAC1,RABGAP1L,RAD17,RAF1,RALGAPB,RANBP9,RAP2A,RAP2C,RASGRP1,RASSF1,RBM25,RCAN3,RCBTB1,RCHY1,RETSAT,RFX5,RHOT1,RIOK3,RNF19B,RNGTT,RPA2,RPGR,RQCD1,RRN3P1,RUNX3,SAMD4A,SAP25,SAP30,SCAPER,SECISBP2L,SENP6,SEPHS1,SETDB1,SF1,SF3A1,SFN,SFRS15,SFRS7,SGCE,SH3GL1,SIGLEC9,SLA,SLC11A2,SLC20A2,SLC30A1,SLC33A1,SLC35D2,SLC39A6,SLC4A3,SLFN12,SMAP1,SMC4,SMC5,SMYD2,SNRPA1,SNX11,SOAT1,SOCS3,SOCS6,SOD2,SP100,SPAG9,SPIN2A,SPNS1,SPPL2B,SPTLC1,SRD5A1,SRRM2,SRSF10,SSBP1,ST8SIA4,STK38,STK38L,STK39,STX12,STX18,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,TACC3,TAF10,TAF1B,TAPBP,TARBP1,TBC1D9B,TBCE,TCF20,TCF3,TCIRG1,TCP1,TFIP11,THADA,TIA1,TMED5,TMEM41B,TNFAIP8,TNIP2,TOMM34,TP53BP1,TP53TG1,TRAK2,TRAPPC11,TRIAP1,TRIB2,TRIM28,TRIM33,TROVE2,TSC22D2,TSEN34,TTC15,TTLL5,TUBB3,TWF1,TXNL4A,UBAP2L,UBE2I,UBE2K,UBN1,UBQLN2,UPP1,USP4,USP9X,VDAC1,VPS33B,VWA5A,WASHC4,WDR59,WSB1,XRCC4,YTHDC2,ZBTB20,ZBTB22,ZCCHC10,ZDHHC6,ZFP64,ZFR,ZMYM4,ZNF225,ZNF35,ZNF410,ZNF544,ZNF557,ZNF629,ZXDB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_mnc_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41129,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_DN,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_DN,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to FluMist , time point 7D. Comment: Supplementary Table 1a: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"ABCA1,ABHD13,ABHD5,ABT1,ACSL1,ACTR3,ADAM22,ADAM28,ADIPOR1,ADO,ADORA2A,AEN,AHCTF1,AKAP8,AKIRIN2,ALG13,AMD1,AMFR,AMPD2,ANKHD1,ANKRD13C,ANKRD37,ANKRD9,ZFAND4,ANXA3,AP1G1,AP3M2,AQP9,AREG,ARHGAP5,ARHGEF7,ARID4A,ARID5A,ARIH2,ARL8A,ARPC5L,ARPP19,ASCC3,ASNSD1,ATAD2,ATF7IP2,ATG2A,ATP11B,ATP1B1,ATP2A3,ATP5IF1,ATXN1L,ATXN7,AZI2,AZIN1,B3GNT2,B3GNT5,B3GNT7,B4GALT1,BACH1,BAG3,BAG5,BASP1,BAZ2A,BBX,BCAS2,BCL10,BCL2A1,BCL2L11,BCL3,BCL6,BCL7A,BCLAF1,BEX2,BEX4,BEX5,BIRC3,BNIP1,BNIP2,BNIP3L,BRAF,MPC2,BTG1,BTG2,BTG3,BUD31,BZW1,CACUL1,ARMH3,AKIP1,C11orf58,KANSL2,GPATCH2L,VCPKMT,IRF2BPL,HAPSTR1,C18orf21,C18orf25,R3HDM4,C1D,C1orf52,SDE2,OSER1,MAIP1,CCDC174,C3orf38,C5AR1,CYSTM1,GFOD1,C6orf226,TMEM243,MALSU1,RBM48,CAMK2D,CASZ1,CBX4,CCDC28A,CCDC50,CCDC59,CCL28,CCNG2,CCNK,CCNT2,CD55,CD83,CDADC1,CDC40,CDC42,CDK16,CDK17,CDKN1B,CDKN2D,CFL2,CHD2,CHD7,CHMP1B,CHMP2B,CHPT1,CHSY1,CLC,CLEC2B,CLP1,CLU,CMTM2,CMTM6,CNOT6L,CNOT8,COG5,COIL,COPS2,COQ10B,COX4I1,CPEB2,CPEB4,CREBRF,CREM,YBX3,CSRNP1,CTBS,CUL1,CWC15,CXCL1,CXCL2,CXCR1,CXCR4,CXCR5,CYTIP,SPECC1L,DBF4,DCAF16,DCP1A,DCTN6,DDIT3,DDX20,DDX21,DDX27,DDX47,DDX50,DDX6,DEFA1,DEFA1B,DEFA3,DENND3,DERL1,ESS2,DHRS3,DIDO1,DIS3,DNAJB1,DNAJB9,DNAJC3,DNTTIP2,DOCK4,DPM1,DTX4,DUSP10,DUSP11,DUSP12,DUSP2,DUSP5,DUSP8,DYNLL2,DYNLT1,DYRK2,EAF1,EAPP,EGLN1,EGR2,EGR3,EHD4,EID3,EIF1,EIF1AD,EIF1AX,EIF1B,EIF5,ELAVL3,ELF1,ELF2,ELL,ELL2,EML4,ENC1,EPB41L4A-AS1,ERN1,ERO1A,,ETF1,ETNK1,ETV3,EXOC8,UBALD2,RAMAC,FAM104A,ABHD17B,FHIP2A,FAM169A,TENT5C,CYRIA,FAM53C,LRATD2,FAM8A1,FASTKD5,FBXL12,FBXO21,FBXO28,FBXO33,FBXO7,FEM1B,FEM1C,,CCDC71L,FNDC3B,FNIP1,FOSL2,FOXO3,FPR1,FPR2,TIMM10B,FYTTD1,G0S2,G3BP2,GAB2,GABARAPL1,GABARAPL3,GADD45A,GAS5,GCC1,GCOM1,GET4,GGNBP2,GIGYF2,GK,BICRA,GLUL,GMEB2,GMFB,GNA13,GNE,GNL1,GOLGA4,GOLT1B,GOSR1,GPD1,HCAR3,GPR160,GPR18,GPR183,GPR65,ADGRG3,TAMALIN,GRPEL1,GSN,GSPT1,GTF2B,GTF2IRD2,GTPBP4,GUK1,GYPC,GZF1,H2AZ2,HAUS3,HAVCR2,HBA1,HBA2,HBB,HBEGF,HBG1,HBG2,HBM,HBP1,HBQ1,HECA,HERPUD1,HIC2,HIF1A,HINT1,HIP1R,H2AC6,H3C10,HMGCS1,HMGXB4,HNRNPA0,HNRNPH2,HNRNPH3,HNRNPL,HOXA5,HP1BP3,HSF2,HSPA13,HSPA14,HSPA9,ICAM1,ICOS,ID3,IDI1,IDS,IFIT5,IFITM1,IFITM2,IFNGR1,IFRD1,IKZF5,IL1B,IL1R2,CXCL8,ILF3,ING3,INSIG1,IP6K2,IRGQ,IRS2,ISCA1,IST1,ITCH,ITPKB,ITPRIP,IVNS1ABP,JADE1,JARID2,KDM7A,JMJD1C,JMJD6,JMY,JUND,KAT8,KBTBD2,KBTBD4,KBTBD8,KCMF1,KDM2A,KDM5B,KDM6B,KHNYN,KIAA1143,KIF1B,KLF3,KLF7,KLHDC2,KLHL15,KLHL2,KLHL21,KLHL28,KMT2E,KPNA4,KRAS,KRR1,L3MBTL3,LARP7,LCOR,LEPROTL1,LIMK2,LITAF,LMTK2,MIR23AHG,LONRF1,LPAR2,PLPPR2,LRG1,LRRC8A,LRRC8B,LY9,LYPD3,MAD2L1BP,MAFK,MAP1LC3B,MAP2K3,MAP2K7,MAP3K2,MAP3K8,MAPK1IP1L,MAPK6,MAPK8,MAPKAPK2,LAMTOR3,MARCHF7,MARCHF8,MATR3,MAX,MBOAT7,MCL1,MCPH1,MED13L,MED21,MED23,MED26,MED28,MED30,MED6,MEF2D,MEOX1,MEPCE,METAP2,MEX3C,MFAP1,MFSD14A,MGAM,MGAT4A,MIER1,MIER3,MIR22HG,MKRN1,MMADHC,MMD,MME,MMP9,MNT,MOAP1,MOB4,MRM3,MRPL47,MRPS22,MTERF4,MTHFD2L,MTMR10,MTMR14,MTMR3,MTMR6,MTPAP,,AP5M1,MXD1,MXD4,MXI1,MYLIP,KAT7,NAA50,NAMPT,NCOA1,NDEL1,NSMCE3,NDST1,NDUFAF5,NECAP1,NEDD9,NET1,NFE2L2,NFIL3,NFKBID,NFYC,NGDN,NGRN,NINJ1,NIPA2,NOL11,NR1D2,NR4A2,NR4A3,NRAS,NRBF2,NRIP1,NSF,NUAK2,NUB1,NUDT15,NUDT4,NUFIP2,NUP153,NUP98,NUP58,ODC1,ORAI2,OSBPL2,OSM,OTUD1,P2RY10,PAIP1,PAIP2,PAPOLA,PAX5,PCGF5,PCIF1,PCNX1,PDCD4,PDCL,PDE12,PDE4B,PDE4D,PDRG1,PDZD8,PELI1,PELO,PER1,PET117,PEX2,PF4,PFKFB3,PHACTR1,PHC3,PHF1,PHF11,PHLDA1,PIGB,PIK3R1,PIM2,PIM3,PKD1,PKN2,PLAGL2,PLAUR,PLCL1,PLEKHF2,PMAIP1,PNO1,PNPLA2,PNPLA8,POLR1C,POLR2M,POLR3F,PPARD,PPBP,PPIF,PPM1A,PPM1B,PPP1R15B,PPP1R2,PPP1R3B,PPP2R1B,PPP2R2A,PPP4R3A,PPTC7,PRC1,PRDM2,PRDM4,PRDX6,PRKAR1A,PROK2,PRPF4B,PRRC2C,PSMD12,PTGER4,PTGS2,PTP4A1,PTPMT1,PTPN2,PTPRE,PTPRK,QKI,RAB11FIP1,RAB11FIP4,RAB18,RAB1A,RAB20,RAB21,RAB2A,RAB43,RAB8B,RABIF,RAD23B,RALGPS2,RANBP6,RAP2C,RAPGEF2,RASGEF1B,RASSF5,RBBP6,RBM15,RBM18,RBM33,RBM7,RBM8A,RBMXL1,RBSN,RC3H2,RCL1,REL,RELT,RFLNB,TRMT10C,RGS1,RGS2,RIOK3,RIPK2,RIT1,RLF,RLIM,RMND5A,RNF103,RNF11,RNF138,RNF139,RNF4,RNF6,RNMT,RORA,RPAIN,RPF1,RPRD1B,RPS24,RPS6KB1,RRAGD,RRM2B,RSL24D1,RSRC2,RUBCNL,RYBP,S100P,SAMD8,SAMSN1,SAR1A,SBDS,CAVIN2,SEC14L1,SEC31A,SELENOK,SEMA4D,SERINC5,SERPINB1,SERPINB2,SERTAD1,SERTAD2,SF3A1,,SREK1IP1,SCAF11,SFXN1,SGTB,SH3GLB1,SIAH1,SIAH2,SIK1,SIK3,SIPA1L2,SKP1,SLC12A6,SLC17A7,SLC19A2,SLC25A28,SLC25A30,SLC25A33,SLC25A36,SLC25A37,SLC2A14,SLC2A3,SLC3A2,SLC7A5,SLCO3A1,PRELID3B,SLU7,SMAD4,PPP4R3B,SMNDC1,SMPD4,SMURF1,SNCA,SNHG15,SNHG8,SNIP1,SNN,SNORD89,SNRK,SNRNP27,SNRPA1,SOCS1,SOCS3,SOD2,SP100,SP3,SPARC,SPOPL,SPTY2D1,U2SURP,SRGN,SS18L2,ITPRID2,STK17B,STK35,STRAP,STX11,SUB1,SUMO3,SUN1,SUSD6,SVIL,SYNCRIP,SYS1,SYTL3,TADA2B,TBPL1,TCP11L2,TERF2IP,TFAM,TFG,TFRC,TGIF1,TGIF2,TGS1,THBD,THBS1,THSD1,THUMPD1,TIFA,TIMM17A,TIMM23,TIPARP,TLE3,TM2D2,TM2D3,TMCC3,TMEM167B,TMEM183A,TMEM183BP,CNEP1R1,TMEM38B,TMEM68,TMEM70,TMF1,TNFAIP6,TNFRSF10C,TNIP1,TOPORS,TOX4,TP53BP2,TPM3,TPRG1L,TPSG1,TRAF6,TRAPPC4,TREM1,TRIB1,TRIM13,TRIM23,TRIM58,TSFM,TSPYL1,TSPYL4,TUBA1A,TUBA1C,TWF1,UBAP1,UBE2B,UBE2G1,UBE2J1,UBXN6,UGCG,BLTP3B,UQCRC2,USF3,USP12,USP15,USP19,USP30,USP36,USP42,USPL1,UTP23,VAPA,VAV2,VCPIP1,VNN3P,VPS18,VPS37B,VTI1A,WBP11,WDR20,WDR45B,WDR48,WHAMM,WTAP,XKR8,XRN1,YOD1,YPEL5,YTHDC1,YTHDF2,YTHDF3,ZBTB1,ZBTB10,ZBTB33,ZBTB43,ZBTB5,ZC3HAV1,ZCCHC2,ZEB1,ZFAND2A,ZFAND6,ZFP36L1,ZFX,ZFY,ZMYM2,ZNF10,ZNF134,ZNF14,ZNF18,ZBTB18,ZNF24,ZNF267,ZNF281,ZBTB21,ZNF326,ZNF331,ZNF350,ZNF394,ZNF395,ZNF529,ZNF548,ZNF552,ZNF571,ZNF586,ZNF622,ZNF639,ZNF644,ZNF655,ZNF689,ZNF766,ZNF830,ZNF844,ZNF92,ZNFX1,ZNHIT3,ZRANB1,ZXDB,ZZEF1",848,"ABCA1,ABHD13,ABHD5,ABT1,ACSL1,ACTR3,ADAM22,ADAM28,ADIPOR1,ADO,ADORA2A,AEN,AHCTF1,AKAP8,AKIRIN2,ALG13,AMD1,AMFR,AMPD2,ANKHD1,ANKRD13C,ANKRD37,ANKRD9,ANUBL1,ANXA3,AP1G1,AP3M2,AQP9,AREG,ARHGAP5,ARHGEF7,ARID4A,ARID5A,ARIH2,ARL8A,ARPC5L,ARPP19,ASCC3,ASNSD1,ATAD2,ATF7IP2,ATG2A,ATP11B,ATP1B1,ATP2A3,ATPIF1,ATXN1L,ATXN7,AZI2,AZIN1,B3GNT2,B3GNT5,B3GNT7,B4GALT1,BACH1,BAG3,BAG5,BASP1,BAZ2A,BBX,BCAS2,BCL10,BCL2A1,BCL2L11,BCL3,BCL6,BCL7A,BCLAF1,BEX2,BEX4,BEX5,BIRC3,BNIP1,BNIP2,BNIP3L,BRAF,BRP44,BTG1,BTG2,BTG3,BUD31,BZW1,C10orf46,C10orf76,C11orf17,C11orf58,C12orf41,C14orf118,C14orf138,C14orf4,C16orf72,C18orf21,C18orf25,C19orf22,C1D,C1orf52,C1orf55,C20orf111,C2orf47,C3orf19,C3orf38,C5AR1,C5orf32,C6orf114,C6orf226,C7orf23,C7orf30,C7orf64,CAMK2D,CASZ1,CBX4,CCDC28A,CCDC50,CCDC59,CCL28,CCNG2,CCNK,CCNT2,CD55,CD83,CDADC1,CDC40,CDC42,CDK16,CDK17,CDKN1B,CDKN2D,CFL2,CHD2,CHD7,CHMP1B,CHMP2B,CHPT1,CHSY1,CLC,CLEC2B,CLP1,CLU,CMTM2,CMTM6,CNOT6L,CNOT8,COG5,COIL,COPS2,COQ10B,COX4I1,CPEB2,CPEB4,CREBRF,CREM,CSDA,CSRNP1,CTBS,CUL1,CWC15,CXCL1,CXCL2,CXCR1,CXCR4,CXCR5,CYTIP,CYTSA,DBF4,DCAF16,DCP1A,DCTN6,DDIT3,DDX20,DDX21,DDX27,DDX47,DDX50,DDX6,DEFA1,DEFA1B,DEFA3,DENND3,DERL1,DGCR14,DHRS3,DIDO1,DIS3,DNAJB1,DNAJB9,DNAJC3,DNTTIP2,DOCK4,DPM1,DTX4,DUSP10,DUSP11,DUSP12,DUSP2,DUSP5,DUSP8,DYNLL2,DYNLT1,DYRK2,EAF1,EAPP,EGLN1,EGR2,EGR3,EHD4,EID3,EIF1,EIF1AD,EIF1AX,EIF1B,EIF5,ELAVL3,ELF1,ELF2,ELL,ELL2,EML4,ENC1,EPB41L4A-AS1,ERN1,ERO1L,ERV3-2,ETF1,ETNK1,ETV3,EXOC8,FAM100B,FAM103A1,FAM104A,FAM108B1,FAM160B1,FAM169A,FAM46C,FAM49A,FAM53C,FAM84B,FAM8A1,FASTKD5,FBXL12,FBXO21,FBXO28,FBXO33,FBXO7,FEM1B,FEM1C,FLJ14107,FLJ36031,FNDC3B,FNIP1,FOSL2,FOXO3,FPR1,FPR2,FXC1,FYTTD1,G0S2,G3BP2,GAB2,GABARAPL1,GABARAPL3,GADD45A,GAS5,GCC1,GCOM1,GET4,GGNBP2,GIGYF2,GK,GLTSCR1,GLUL,GMEB2,GMFB,GNA13,GNE,GNL1,GOLGA4,GOLT1B,GOSR1,GPD1,GPR109B,GPR160,GPR18,GPR183,GPR65,GPR97,GRASP,GRPEL1,GSN,GSPT1,GTF2B,GTF2IRD2,GTPBP4,GUK1,GYPC,GZF1,H2AFV,HAUS3,HAVCR2,HBA1,HBA2,HBB,HBEGF,HBG1,HBG2,HBM,HBP1,HBQ1,HECA,HERPUD1,HIC2,HIF1A,HINT1,HIP1R,HIST1H2AC,HIST1H3H,HMGCS1,HMGXB4,HNRNPA0,HNRNPH2,HNRNPH3,HNRNPL,HOXA5,HP1BP3,HSF2,HSPA13,HSPA14,HSPA9,ICAM1,ICOS,ID3,IDI1,IDS,IFIT5,IFITM1,IFITM2,IFNGR1,IFRD1,IKZF5,IL1B,IL1R2,IL8,ILF3,ING3,INSIG1,IP6K2,IRGQ,IRS2,ISCA1,IST1,ITCH,ITPKB,ITPRIP,IVNS1ABP,JADE1,JARID2,JHDM1D,JMJD1C,JMJD6,JMY,JUND,KAT8,KBTBD2,KBTBD4,KBTBD8,KCMF1,KDM2A,KDM5B,KDM6B,KHNYN,KIAA1143,KIF1B,KLF3,KLF7,KLHDC2,KLHL15,KLHL2,KLHL21,KLHL28,KMT2E,KPNA4,KRAS,KRR1,L3MBTL3,LARP7,LCOR,LEPROTL1,LIMK2,LITAF,LMTK2,LOC284454,LONRF1,LPAR2,LPPR2,LRG1,LRRC8A,LRRC8B,LY9,LYPD3,MAD2L1BP,MAFK,MAP1LC3B,MAP2K3,MAP2K7,MAP3K2,MAP3K8,MAPK1IP1L,MAPK6,MAPK8,MAPKAPK2,MAPKSP1,MARCH7,MARCH8,MATR3,MAX,MBOAT7,MCL1,MCPH1,MED13L,MED21,MED23,MED26,MED28,MED30,MED6,MEF2D,MEOX1,MEPCE,METAP2,MEX3C,MFAP1,MFSD14A,MGAM,MGAT4A,MIER1,MIER3,MIR22HG,MKRN1,MMADHC,MMD,MME,MMP9,MNT,MOAP1,MOBKL3,MRM3,MRPL47,MRPS22,MTERFD2,MTHFD2L,MTMR10,MTMR14,MTMR3,MTMR6,MTPAP,MUC8,MUDENG,MXD1,MXD4,MXI1,MYLIP,MYST2,NAA50,NAMPT,NCOA1,NDEL1,NDNL2,NDST1,NDUFAF5,NECAP1,NEDD9,NET1,NFE2L2,NFIL3,NFKBID,NFYC,NGDN,NGRN,NINJ1,NIPA2,NOL11,NR1D2,NR4A2,NR4A3,NRAS,NRBF2,NRIP1,NSF,NUAK2,NUB1,NUDT15,NUDT4,NUFIP2,NUP153,NUP98,NUPL1,ODC1,ORAI2,OSBPL2,OSM,OTUD1,P2RY10,PAIP1,PAIP2,PAPOLA,PAX5,PCGF5,PCIF1,PCNX,PDCD4,PDCL,PDE12,PDE4B,PDE4D,PDRG1,PDZD8,PELI1,PELO,PER1,PET117,PEX2,PF4,PFKFB3,PHACTR1,PHC3,PHF1,PHF11,PHLDA1,PIGB,PIK3R1,PIM2,PIM3,PKD1,PKN2,PLAGL2,PLAUR,PLCL1,PLEKHF2,PMAIP1,PNO1,PNPLA2,PNPLA8,POLR1C,POLR2M,POLR3F,PPARD,PPBP,PPIF,PPM1A,PPM1B,PPP1R15B,PPP1R2,PPP1R3B,PPP2R1B,PPP2R2A,PPP4R3A,PPTC7,PRC1,PRDM2,PRDM4,PRDX6,PRKAR1A,PROK2,PRPF4B,PRRC2C,PSMD12,PTGER4,PTGS2,PTP4A1,PTPMT1,PTPN2,PTPRE,PTPRK,QKI,RAB11FIP1,RAB11FIP4,RAB18,RAB1A,RAB20,RAB21,RAB2A,RAB43,RAB8B,RABIF,RAD23B,RALGPS2,RANBP6,RAP2C,RAPGEF2,RASGEF1B,RASSF5,RBBP6,RBM15,RBM18,RBM33,RBM7,RBM8A,RBMXL1,RBSN,RC3H2,RCL1,REL,RELT,RFLNB,RG9MTD1,RGS1,RGS2,RIOK3,RIPK2,RIT1,RLF,RLIM,RMND5A,RNF103,RNF11,RNF138,RNF139,RNF4,RNF6,RNMT,RORA,RPAIN,RPF1,RPRD1B,RPS24,RPS6KB1,RRAGD,RRM2B,RSL24D1,RSRC2,RUBCNL,RYBP,S100P,SAMD8,SAMSN1,SAR1A,SBDS,SDPR,SEC14L1,SEC31A,SELK,SEMA4D,SERINC5,SERPINB1,SERPINB2,SERTAD1,SERTAD2,SF3A1,SF3B14,SFRS12IP1,SFRS2IP,SFXN1,SGTB,SH3GLB1,SIAH1,SIAH2,SIK1,SIK3,SIPA1L2,SKP1,SLC12A6,SLC17A7,SLC19A2,SLC25A28,SLC25A30,SLC25A33,SLC25A36,SLC25A37,SLC2A14,SLC2A3,SLC3A2,SLC7A5,SLCO3A1,SLMO2,SLU7,SMAD4,SMEK2,SMNDC1,SMPD4,SMURF1,SNCA,SNHG15,SNHG8,SNIP1,SNN,SNORD89,SNRK,SNRNP27,SNRPA1,SOCS1,SOCS3,SOD2,SP100,SP3,SPARC,SPOPL,SPTY2D1,SR140,SRGN,SS18L2,SSFA2,STK17B,STK35,STRAP,STX11,SUB1,SUMO3,SUN1,SUSD6,SVIL,SYNCRIP,SYS1,SYTL3,TADA2B,TBPL1,TCP11L2,TERF2IP,TFAM,TFG,TFRC,TGIF1,TGIF2,TGS1,THBD,THBS1,THSD1,THUMPD1,TIFA,TIMM17A,TIMM23,TIPARP,TLE3,TM2D2,TM2D3,TMCC3,TMEM167B,TMEM183A,TMEM183B,TMEM188,TMEM38B,TMEM68,TMEM70,TMF1,TNFAIP6,TNFRSF10C,TNIP1,TOPORS,TOX4,TP53BP2,TPM3,TPRG1L,TPSG1,TRAF6,TRAPPC4,TREM1,TRIB1,TRIM13,TRIM23,TRIM58,TSFM,TSPYL1,TSPYL4,TUBA1A,TUBA1C,TWF1,UBAP1,UBE2B,UBE2G1,UBE2J1,UBXN6,UGCG,UHRF1BP1L,UQCRC2,USF3,USP12,USP15,USP19,USP30,USP36,USP42,USPL1,UTP23,VAPA,VAV2,VCPIP1,VNN3,VPS18,VPS37B,VTI1A,WBP11,WDR20,WDR45L,WDR48,WHAMM,WTAP,XKR8,XRN1,YOD1,YPEL5,YTHDC1,YTHDF2,YTHDF3,ZBTB1,ZBTB10,ZBTB33,ZBTB43,ZBTB5,ZC3HAV1,ZCCHC2,ZEB1,ZFAND2A,ZFAND6,ZFP36L1,ZFX,ZFY,ZMYM2,ZNF10,ZNF134,ZNF14,ZNF18,ZNF238,ZNF24,ZNF267,ZNF281,ZNF295,ZNF326,ZNF331,ZNF350,ZNF394,ZNF395,ZNF529,ZNF548,ZNF552,ZNF571,ZNF586,ZNF622,ZNF639,ZNF644,ZNF655,ZNF689,ZNF766,ZNF830,ZNF844,ZNF92,ZNFX1,ZNHIT3,ZRANB1,ZXDB,ZZEF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_neu_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41131,FLUMIST,LA,INFLUENZA,NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PBMC_FLUMIST_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in adults (18-50) after exposure to FluMist , time point 7D. Comment: Supplementary Table 1b: All the differentially expressed genes identified in PBMCs of TIV vaccinees.","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AARS1,ABCB7,ABCC10,ABCD3,ABCF2,ABI3,ACAA1,ACADM,ACAP2,ACAT1,ACER3,ACLY,ACSL5,ACTL6A,ACTR3,ADAP2,ADCY7,ADCY9,ADH5,ADHFE1,ADSL,AGAP4,AGK,AGL,AGPAT3,PHYKPL,AHCYL1,AHCYL2,AHNAK,AHSA1,AHSA2P,AIDA,AIFM1,AIMP2,AK2,AKAP10,AKAP11,AKAP13,ALDH3A2,ALDH3B1,ALG10B,ALG13,ALG6,ALG8,ALKBH3,JAML,AMMECR1,AMPD3,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANAPC1,ANAPC4,ANAPC7,ANKFY1,ANKH,ANKIB1,ANKLE2,ANKRD10,ANKRD17,ANKZF1,ANXA2,ANXA2P2,ANXA4,ANXA6,AP1AR,AP1M1,AP1S2,AP3S2,AP4B1,AP4E1,APAF1,APBB1IP,APEH,API5,APLP2,APOBEC3C,APOBEC3F,APOBEC3G,APPBP2,APPL1,APTX,AQR,ARF1,ARHGAP26,ARHGAP27,ARHGAP30,ARHGEF10L,ARID1A,ARIH2,ARL11,ARL17A,ARL17B,ARL6IP5,ARMC1,ARMC10,ARMC8,ARMT1,ARSD,ARSG,ARV1,ASB3,ASCC1,ASCL2,GET3,ASRGL1,ASXL2,ATF1,ATF7IP,ATF7IP2,ATG3,ATG7,ATL3,ATM,ATMIN,ATP13A1,ATP2B4,ATP2C1,ATP5MC1,ATP6AP1,ATP6V0A2,ATP6V0E1,ATP6V1C1,ATP6V1D,ATP8B1,ATP8B2,ATPAF1,ATRN,ATXN2,AUH,AVL9,AZI2,B3GALNT2,BATF,BAZ1A,BAZ1B,BCL2,BDP1,BFAR,BICD2,BIRC6,BIVM,BMP2K,BPTF,BRCC3,BRD3,BRD8,BRI3BP,BRWD1,BTBD7,BTN2A1,BTN2A2,BTN3A2,BTN3A3,MCMBP,WBP1L,ARMH3,AKIP1,C11orf21,C11orf54,HIKESHI,INTS13,ERG28,TMEM260,MIS18BP1,LYSET,C14orf119,DTD2,PCNX4,SPTSSA,L3HYPDH,DGLUCY,FAM219B,KATNBL1,C15orf40,MOSMO,VPS35L,ACTMAP,BABAM1,LRIF1,C1orf162,HENMT1,RSRP1,ADISSP,GATD3,CFAP298,PRR14L,KIAA0930,C2CD5,GCFC2,COA5,C2orf74,C3AR1,TIMMDC1,TCAIM,HPF1,NREP,C5orf15,C5orf22,ABRACL,SLC18B1,C6orf89,MPLKIP,CCZ1,CCZ1B,TMEM248,FMC1,C8orf44,TRIQK,TOR4A,TMEM250,C9orf72,CAB39,CABIN1,CACNA2D3,CACNA2D4,CACYBP,CALHM2,CALML4,CANX,CAPG,CAPN3,CAPRIN1,CAPRIN2,CARD8,CARNMT1,CARS1,CASP1,CASP2,CASP6,CASP8AP2,CBFA2T2,CBR4,ZNG1A,ZNG1B,ZNG1C,ZNG1E,ZNG1F,ZNG1F,CBX1,PRIMPOL,VPS50,CEP83,NSRP1,TRMT13,CCDC88A,CCM2,CCND3,CCNL2,CCR2,CCT3,CCT4,CCT5,CCT6A,CCT7,CD160,CD163,CD164,CD1C,CD1D,CD2,CD244,CD27,CD300A,CD33,CD4,CD53,CD58,CD84,CDC14A,CDC16,CDC25B,CDC7,CDK2AP2,CDK4,CDK8,HDHD5,CELF1,CENPB,CENPJ,CEP104,CNTRL,CEP164,CEP170,CEP350,CEP85,CEPT1,CES2,CFDP1,CGGBP1,CHCHD3,CHCHD4,CHD9,CHM,CHMP4A,CIAO1,CIAPIN1,CIDEB,CIRBP,CISD1,CISD3,CLCC1,CLCN3,CLEC12A,CLEC12B,CLEC2D,CLIC3,CLIP4,CLK2,CLN8,CLNS1A,CLOCK,CLPTM1L,CLPX,CLTA,CLTC,CMAS,CNOT1,CNOT4,CNOT6,CNPY2,COASY,NELFB,COG2,COMMD1,COMMD10,COMMD3,COMT,COPA,COPB2,COPS5,COPS7A,COPZ1,COQ2,COQ5,COQ9,COX10,COX15,COX18,CPM,CPNE2,CPNE3,CPOX,CPSF1,CPSF2,CPSF3,CREB1,CREB3L2,CREBBP,CREBL2,CREBZF,CRIM1,CRLS1,CROCCP2,CRTAM,CRYBG3,CRYZL1,CSF1R,CSF2RA,CSNK1A1,CSNK2A1,CTBP2,CTNNA1,CTSB,CTSC,CTSH,CUL1,CUL4A,CWC27,CX3CR1,CXorf38,CYB5B,CYBRD1,CYP20A1,CYP4V2,DAB1,DAGLB,DAPP1,DARS1,DCAF10,DCAF13,DCAF6,DCAF7,DCLRE1B,DCLRE1C,DCP1B,DCPS,DDI2,DDX17,DDX19A,DDX23,INTS6L,DDX41,DDX46,DECR1,DEF6,DELE1,DENND2D,DENND4B,DFFA,DGKZ,DHPS,DHRS4-AS1,DHX16,DHX32,DHX33,DIAPH1,DIAPH2,DICER1,DIDO1,DIP2A,DIS3L,DIS3L2,DLGAP4,DNAAF5,DNAJA3,DNAJC10,DNAJC13,DNAJC16,DNAJC17,DNAJC24,DNAJC7,DNM1L,DNMT1,DOCK10,DOCK9,DOK2,DPP3,DPY19L4,DPY30,DPYSL2,DRAM2,DTNBP1,DUSP18,DUSP22,DUSP7,DYM,ECH1,ECHDC1,ECI2,ECPAS,EDEM3,EEA1,EEF1A1,EEF2K,EFCAB14,CRACR2A,EFL1,EHBP1L1,EHMT1,EIF1,EIF2B4,EIF2S1,EIF2S2,EIF3B,EIF3J,EIF4A1,EIF4ENIF1,EIF5B,ELAVL1,ELK3,ELOVL1,ELP3,EMSY,ENGASE,EOMES,EPRS1,EPS15,ERAP1,ERI1,ESYT1,ESYT2,ETNK1,EVL,EWSR1,EXOC1,EXOC4,EXOC5,EXOSC10,EXT2,EYA3,EZH1,FADS1,FCMR,OTULINL,FAM111A,FAM114A2,FAM117A,FAM118B,HYCC1,RETREG1,RETREG3,ATPSCKMT,ABRAXAS1,SLF2,PSME3IP1,FAM200B,TASOR,PIEZO1,DENND10,SUPT20H,RIPOR2,FAM78A,FARSB,FASTKD1,FBXL20,FBH1,FBXO22,FBXO9,FBXW11,FBXW2,FCF1,FCRL3,FEZ2,FGD2,FGD4,FH,FIG4,FKBP15,FKBP5,FLAD1,FLI1,FLII,PSMA3-AS1,SLC12A2-DT,TAPT1-AS1,FLT3,FLT4,FNBP1,FNIP2,FNTA,FTSJ3,FUCA2,FUS,FYB1,FYN,FZD2,G3BP1,G6PC3,GAB3,GALM,GALNT1,GALNT7,GALT,GANAB,GAPT,GART,GATAD1,GATC,GBA2,GCDH,PAXBP1,GCN1,GEMIN6,GEMIN7,GGCT,GGPS1,GIGYF2,GIMAP1,GIMAP2,GIMAP4,GIMAP6,GIMAP8,GIN1,GLB1,GLCCI1,GLG1,GLIPR1,GLS,GLT8D1,GMIP,GMPR2,GNL2,GNPAT,GNPDA1,GOLGA3,GOLGA5,GOLPH3L,GON4L,GOPC,GOT2,GPALPP1,GPATCH2,GPATCH4,GPD1L,GPD2,GPR171,GPR75,GPR89A,GPR89B,GRSF1,GSE1,GSR,GSTK1,GTF2A1,GTF2E1,GTF2H1,GTF2H5,GTPBP10,GUSBP2,GVINP1,GZMA,MACROH2A1,HADH,HADHA,HADHB,HAUS1,HCG18,HDAC1,HDAC2,HDAC9,HDDC3,HDHD2,HDLBP,HEATR3,HECA,HELQ,HELZ,HERC2P3,HERC4,HEXA,HEXB,HEXD,HGSNAT,HIBCH,H1-3,H2BC8,HIVEP3,HLTF,HM13,HMBOX1,HMOX2,JPT2,HNMT,HNRNPAB,HNRNPF,HNRNPH2,HOOK3,HPCAL1,HPS3,HS2ST1,HSCB,HSD17B12,HSD17B4,IFT25,HSPBAP1,HUWE1,HYOU1,IARS1,IBTK,ICAM2,IDE,IDH1,IER3IP1,IFFO1,IFI16,IKBKB,IKZF1,IL17RA,IL27RA,IL6R,IL7R,IMMT,ING4,INPP4A,INSR,INTS10,INTS3,INTS7,INTS8,IP6K2,IPCEF1,IPO7,IPO8,IPO9,IQGAP1,IQGAP2,IRAK3,IRF3,IRF5,IRF8,ITGA4,ITGAL,ITGB2,ITK,ITPKB,ITPRIPL2,JRK,JUN,KANSL1L,KAT2B,KCNE3,KCNK6,KCTD12,KCTD15,KDELR1,KDELR2,KDM5A,KHDC4,KIAA0319L,KIAA2026,KIDINS220,KIZ,KLF6,KLHDC10,KLHDC3,KLHDC4,KLHL6,KLHL7,KLHL8,KLRD1,KLRG1,KMT2A,KMT5B,KRCC1,KRI1,KRIT1,KRTCAP2,KYAT3,LACTB2,LAIR1,LARP4B,LARS1,LAT,LBH,LCK,LCORL,LDAH,LDLRAP1,LETMD1,LGALS1,LGALS3,LIAS,LILRA4,LILRB1,LIMD1,LINC00324,LINC01138,LMAN2,LMAN2L,LNPEP,LNPK,ENSG00000272447,NEK2-DT,LONP1,LONP2,LPP,LPXN,LRCH3,LRIG2,LRRC37A2,LRRC47,LRRC8D,LUC7L,LUC7L2,LUC7L3,LY86,LY9,LYRM7,M6PR,MACF1,MAD1L1,MALAT1,MANBA,MAP3K7,MAP4K4,MAPK1,MAPK1IP1L,MAPKAP1,MARCHF1,MARS1,MAVS,MBNL1,MBNL2,MBOAT1,MBP,MCCC2,MCEE,MCM3,MCM3AP,MCM5,MCTS1,MDFIC,MDM1,ME2,MEAK7,MED1,MED11,MED12,MED13L,MEF2A,MEMO1,METAP1,METTL17,METTL13,METTL2A,METTL2B,METTL3,METTL5,METTL8,MEX3C,MFSD4B,MFSD8,MGA,MGAT2,MGST1,MGST2,MICA,MICAL2,MID1,RIOX2,MITD1,MKKS,MKLN1,MLEC,MLX,MLXIP,MMS19,MNDA,MOB3B,MOB1B,MON2,MORC2,MOSPD2,MPDU1,MPEG1,MPHOSPH8,MPHOSPH9,MPV17,MRE11,MRI1,MRPL57,MRPL14,MRPL15,MRPL18,MRPL30,MRPL34,MRPL36,MRPL37,MRPL38,MRPL48,MRPS14,MRPS18B,MRPS21,MRPS28,MRPS31,MRPS5,MRPS6,MRPS9,MRS2,MRTO4,MS4A14,MS4A6A,MS4A7,MSH2,MSL3,MTA1,MTCH2,MTDH,MTHFD1,MTIF2,MTIF3,MTMR11,MTO1,MTRF1,MTX2,MUS81,MYCL,MYDGF,MYO1G,MZF1,N4BP2L2,NAA25,NAA40,NAAA,NACC2,NADK,NADSYN1,NAIP,NAPB,NARS1,NASP,NBPF1,NBPF10,NBPF11,NBPF12,NBPF8,NBPF9,NBR1,NCBP1,NCBP2,NCEH1,NCOA3,NCOA6,NCOR1,FTX,JPX,NCSTN,NDC1,NDFIP1,NDUFA10,NDUFA8,NDUFAF1,NDUFS1,NDUFV3,NEAT1,NEK4,NEK7,NEK9,NFATC2,NFATC2IP,NFATC3,NFYC,NHLRC3,NID1,NIPBL,NIT1,NIT2,NLRC3,NLRC4,NLRP12,NME6,NMRAL1,NMT1,NMT2,NNT,NOTCH2,NOTCH2NLA,NPAT,NPEPPS,NPIPA1,NR2C2,NSF,NSMCE4A,NSUN5,NSUN5P1,NSUN5P2,NT5C2,NUDCD1,NUDCD3,NUDT16,NUDT7,NUDT9,NUMB,NUP210,NUP43,NUP62,NUP42,NVL,OGDH,OGFOD1,OGG1,OGT,OLIG1,OMA1,ORC2,ORMDL1,OSBPL11,OSBPL3,OSGEPL1,OSTC,OSTM1,OTUB1,OXR1,P2RX7,PAAF1,PAFAH1B1,PAK1,PALB2,PAM,TENT2,PAPSS2,PAQR8,PARN,PARP4,PARVG,PBRM1,PCCA,PCID2,PCM1,PCMT1,PCMTD1,PCYOX1,PCYOX1L,PDCD11,PDCD6IP,PDE4DIP,PDE6D,PDE7A,PDHA1,PDHB,PDHX,PDIA4,PDIA5,PDIA6,PDZD11,PEX11B,PFDN6,PFKP,PHB1,PHF14,PHF20,PHF20L1,PHF21A,PHKA2,PID1,PIGF,PIGG,PIGM,PIGV,PIH1D1,PIK3C3,PILRB,PIN4,GSAP,PITPNB,PITRM1,PLCB1,PLGLB1,PLGLB2,PLRG1,PMM2,PMS1,PMS2P1,PMS2P6,PMS2P2,PMS2P5,PNKD,PNPT1,POC5,POGLUT1,POGZ,POLI,POLK,POLR1B,POLR1D,POLR2J2,POLR3K,POP5,POT1,POU2F2,PPID,PPIE,PPM1L,PPP1R12A,PPP1R2,PPP1R21,PPP2CB,PPP3CB,PPP6R3,SLC66A3,PRDM15,PRDM2,PRDX1,PRDX3,PREB,PREP,PRF1,PRKACB,PRKAG1,PRKAG2,PRKCD,PRMT2,PLPBP,PRPF38A,PRPSAP1,PRPSAP2,PSAP,PSD4,PSEN1,PSMA7,PSMC4,PSMD1,PSMD14,PSMG1,PSPC1,PSTPIP1,PTER,PTGDR,PTPN22,PTPN6,PUM1,PURA,PUS7,PWWP2A,PYCR2,PYHIN1,QKI,QRSL1,QSER1,RAB10,RAB27A,RAB28,RAB3D,RAB3GAP1,RAB3GAP2,RAB7A,RAB29,RABGAP1,RAC2,RAD1,RAD17,RAD50,RAD51C,RAI1,RALA,RALGAPB,RAP1GDS1,RAPGEF6,RAPH1,RARS1,RASA1,RASA4,RASAL3,RASEF,RASGEF1A,RASGRP1,RASSF4,RBBP4,RBM14,RBM41,RBM42,RBM4B,RBM5,RBM6,RBM8A,RCAN1,RCBTB2,RCSD1,RDH11,RECK,RECQL,REEP3,REEP5,RER1,REV1,RFC2,RFXAP,RGS14,RGS3,RHOB,RHOT1,RMND1,RNASE2,RNASE4,RNASE6,RNASEH2C,RNF111,RNF146,RNF170,RNF213,RNPC3,LAMTOR2,ROCK2,RPA2,RPAP2,RPE,RPRD1A,RPS27A,RPS6KA1,RPS6KA3,RSBN1L,RSC1A1,RSF1,RSPRY1,RTN1,RTN4,RUFY2,RUSC1-AS1,RUVBL1,RUVBL2,S100PBP,SAE1,SAMD3,SAMD9L,SAMHD1,SAMM50,SAP30,SAP30L,SARS1,SCAMP1,SCARB2,SCFD1,SCML4,SCOC,SCPEP1,SCRIB,SDAD1,ENTR1,SDCCAG8,SDHC,SEC11A,SEC22A,SEC23B,SEC23IP,SEC31A,SEC63,SELPLG,SENP6,SEPTIN9,SERBP1,SERINC3,SESTD1,SETD3,SETD4,SETD5,SETDB1,SETDB2,SETX,SF3B3,SRSF1,SUGP2,SRSF3,SRSF7,SFT2D1,SFXN4,SGMS2,SGPL1,SH3BP5,SH3TC1,SHMT2,SHPRH,SHQ1,SIGMAR1,SIN3B,SIRPB2,SKA2,MTREX,SKP2,SLAMF1,SLAMF6,SLAMF7,SLC22A15,SLC25A11,SLC25A40,SLC25A43,SLC25A45,SLC25A46,SLC26A2,SLC30A5,SLC30A7,SLC33A1,SLC35A1,SLC35A5,SLC35B3,SLC35D2,SLC35E2A,SLC38A10,SLC38A9,SLC43A3,SLC44A1,SLC46A2,SLC46A3,SLC4A1AP,SLC7A1,SLC7A6,SLFN5,SMARCA2,SMARCA4,SMARCAD1,SMARCAL1,SMC1A,SMC5,PPP4R3B,SMG1,SNAPIN,SNHG10,SNORA28,SNRNP40,SNRPD3,SNTB2,SNUPN,SNX1,SNX19,SNX27,SNX5,SON,SOS1,SP1,SP140,SP3,SPAST,SPATA5,SPCS2,SPG11,SPART,SPG7,SPIN3,SPN,SPNS1,SPOP,SPTLC2,SRFBP1,SRGAP2,SRGAP2C,SRPRB,SS18,SSR1,SSR3,ST3GAL1,ST6GAL1,STAB1,STAG3L1,STAM2,STAMBP,STAT6,STIP1,STK17B,STK38,STRAP,STT3A,STX12,STX18,STX6,STX7,STYX,STYXL1,SUCLA2,SUGT1,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,SUPT16H,SUSD3,SYNCRIP,SYNGR2,SYNRG,SYTL1,TADA3,TAF15,TAOK1,TAOK3,TARDBP,TARP,TARS1,TARS3,TATDN1,TBC1D10C,TBC1D9B,TBCE,TBCK,TCF12,TCF7L2,TCHP,TCTN3,TDRD3,TDRD7,TERF2,TES,TET2,TEX10,TFB1M,TFCP2,TFEB,TFEC,TGFBI,TGOLN2,THEM4,THOC2,THYN1,TIA1,TIMM13,TIMP2,TIPRL,TK2,TLR5,TM2D1,TM7SF3,TM9SF4,TMCO1,TMED10,TMEM107,TMEM14C,TMEM165,TMEM168,STING1,NEMP1,PACC1,TMEM214,TMEM216,TMEM218,TMEM223,RXYLT1,TMEM50B,TMEM63A,TMEM69,TMEM80,TMEM87B,TMOD2,TMOD3,TMPO,TMX2,TMX3,TNFAIP8L2,TNFSF12-TNFSF13,TNFSF13,TNFSF8,TNIP1,TNPO3,TNRC18,TOMM5,TOR3A,TP53,TPCN1,TPP1,TRAC,TRADD,TRAF3IP3,TRAF5,TRAM2,TRAPPC11,TRAPPC3,TRAPPC6B,TRAPPC8,,TRGC2,TRIM13,TRIM27,TRIM33,TRIM4,TRIM44,TRIM52,TRIM56,TRIM66,TRIM73,TRIP4,TRIT1,TRPS1,TRPV2,TRRAP,TSC1,TSEN15,TSEN2,TSNAX,TSPAN14,TSPAN32,TTC1,TTC13,TTC14,TRAPPC12,TTC17,TTC27,SKIC3,TTC7A,TTC9C,TTL,TTYH2,TUG1,TXK,TXN2,TXNDC15,UBA1,UBA3,UBA5,UBA7,UBAP2,UBASH3A,UBE2L3,UBE2V2,UBE4A,UBN2,UBTD2,UBTF,UBXN11,UBXN8,UCHL5,UFSP2,UGGT1,UGP2,UPF3A,UQCC1,UQCR10,UQCRC1,USO1,USP21,USP28,USP33,USP34,USP48,UTP14A,UTP14C,UTP6,UVSSA,VAMP1,VAMP4,VAMP8,VBP1,VCAN,VDAC3,VIPAS39,VIPR1,VKORC1,VPS13D,VPS16,VPS35,VPS36,VPS45,VPS52,VPS72,VPS8,VRK3,VTA1,WASH3P,WASHC3,WASHC4,WASHC5,WDFY2,WDR11,WDR12,WDR33,WDR46,WDR59,SKIC8,WDR73,WDR77,WRAP73,DNAAF10,WDSUB1,WNK1,WSB1,XIAP,XPO1,XPO7,XRCC5,YEATS2,YIF1A,YIPF5,YPEL2,PTGR3,MAP3K20,ZBTB40,ZBTB48,ZC3H13,ZC3H14,ZC3H6,TUT4,ZDHHC13,ZDHHC16,ZFC3H1,ZFP64,ZFP90,ZGPAT,ZKSCAN1,ZMYM4,ZMYM6,ZNF106,ZNF146,ZNF148,ZNF207,ZNF224,ZNF248,ZNF280D,ZNF302,ZNF354A,ZNF439,ZNF512,ZNF514,ZNF518A,ZNF559,ZNF573,ZNF609,ZNF638,ZNF641,ZNF664,ZNF721,ZNF75D,ZNF767P,ZNF789,ZNF862,ZRSR2,ZSCAN29,ZSWIM6,ZW10",1577,"AARS,ABCB7,ABCC10,ABCD3,ABCF2,ABI3,ACAA1,ACADM,ACAP2,ACAT1,ACER3,ACLY,ACSL5,ACTL6A,ACTR3,ADAP2,ADCY7,ADCY9,ADH5,ADHFE1,ADSL,AGAP4,AGK,AGL,AGPAT3,AGXT2L2,AHCYL1,AHCYL2,AHNAK,AHSA1,AHSA2,AIDA,AIFM1,AIMP2,AK2,AKAP10,AKAP11,AKAP13,ALDH3A2,ALDH3B1,ALG10B,ALG13,ALG6,ALG8,ALKBH3,AMICA1,AMMECR1,AMPD3,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANAPC1,ANAPC4,ANAPC7,ANKFY1,ANKH,ANKIB1,ANKLE2,ANKRD10,ANKRD17,ANKZF1,ANXA2,ANXA2P2,ANXA4,ANXA6,AP1AR,AP1M1,AP1S2,AP3S2,AP4B1,AP4E1,APAF1,APBB1IP,APEH,API5,APLP2,APOBEC3C,APOBEC3F,APOBEC3G,APPBP2,APPL1,APTX,AQR,ARF1,ARHGAP26,ARHGAP27,ARHGAP30,ARHGEF10L,ARID1A,ARIH2,ARL11,ARL17A,ARL17B,ARL6IP5,ARMC1,ARMC10,ARMC8,ARMT1,ARSD,ARSG,ARV1,ASB3,ASCC1,ASCL2,ASNA1,ASRGL1,ASXL2,ATF1,ATF7IP,ATF7IP2,ATG3,ATG7,ATL3,ATM,ATMIN,ATP13A1,ATP2B4,ATP2C1,ATP5G1,ATP6AP1,ATP6V0A2,ATP6V0E1,ATP6V1C1,ATP6V1D,ATP8B1,ATP8B2,ATPAF1,ATRN,ATXN2,AUH,AVL9,AZI2,B3GALNT2,BATF,BAZ1A,BAZ1B,BCL2,BDP1,BFAR,BICD2,BIRC6,BIVM,BMP2K,BPTF,BRCC3,BRD3,BRD8,BRI3BP,BRWD1,BTBD7,BTN2A1,BTN2A2,BTN3A2,BTN3A3,C10orf119,C10orf26,C10orf76,C11orf17,C11orf21,C11orf54,C11orf73,C12orf11,C14orf1,C14orf101,C14orf106,C14orf109,C14orf119,C14orf126,C14orf135,C14orf147,C14orf149,C14orf159,C15orf17,C15orf29,C15orf40,C16orf52,C16orf62,C19orf54,C19orf62,C1orf103,C1orf162,C1orf59,C1orf63,C20orf27,C21orf33,C21orf59,C22orf30,C22orf9,C2CD5,C2orf3,C2orf64,C2orf74,C3AR1,C3orf1,C3orf23,C4orf27,C5orf13,C5orf15,C5orf22,C6orf115,C6orf192,C6orf89,C7orf11,C7orf28A,C7orf28B,C7orf42,C7orf55,C8orf44,C8orf83,C9orf167,C9orf69,C9orf72,CAB39,CABIN1,CACNA2D3,CACNA2D4,CACYBP,CALHM2,CALML4,CANX,CAPG,CAPN3,CAPRIN1,CAPRIN2,CARD8,CARNMT1,CARS,CASP1,CASP2,CASP6,CASP8AP2,CBFA2T2,CBR4,CBWD1,CBWD2,CBWD3,CBWD5,CBWD6,CBWD7,CBX1,CCDC111,CCDC132,CCDC41,CCDC55,CCDC76,CCDC88A,CCM2,CCND3,CCNL2,CCR2,CCT3,CCT4,CCT5,CCT6A,CCT7,CD160,CD163,CD164,CD1C,CD1D,CD2,CD244,CD27,CD300A,CD33,CD4,CD53,CD58,CD84,CDC14A,CDC16,CDC25B,CDC7,CDK2AP2,CDK4,CDK8,CECR5,CELF1,CENPB,CENPJ,CEP104,CEP110,CEP164,CEP170,CEP350,CEP85,CEPT1,CES2,CFDP1,CGGBP1,CHCHD3,CHCHD4,CHD9,CHM,CHMP4A,CIAO1,CIAPIN1,CIDEB,CIRBP,CISD1,CISD3,CLCC1,CLCN3,CLEC12A,CLEC12B,CLEC2D,CLIC3,CLIP4,CLK2,CLN8,CLNS1A,CLOCK,CLPTM1L,CLPX,CLTA,CLTC,CMAS,CNOT1,CNOT4,CNOT6,CNPY2,COASY,COBRA1,COG2,COMMD1,COMMD10,COMMD3,COMT,COPA,COPB2,COPS5,COPS7A,COPZ1,COQ2,COQ5,COQ9,COX10,COX15,COX18,CPM,CPNE2,CPNE3,CPOX,CPSF1,CPSF2,CPSF3,CREB1,CREB3L2,CREBBP,CREBL2,CREBZF,CRIM1,CRLS1,CROCCL1,CRTAM,CRYBG3,CRYZL1,CSF1R,CSF2RA,CSNK1A1,CSNK2A1,CTBP2,CTNNA1,CTSB,CTSC,CTSH,CUL1,CUL4A,CWC27,CX3CR1,CXorf38,CYB5B,CYBRD1,CYP20A1,CYP4V2,DAB1,DAGLB,DAPP1,DARS,DCAF10,DCAF13,DCAF6,DCAF7,DCLRE1B,DCLRE1C,DCP1B,DCPS,DDI2,DDX17,DDX19A,DDX23,DDX26B,DDX41,DDX46,DECR1,DEF6,DELE1,DENND2D,DENND4B,DFFA,DGKZ,DHPS,DHRS4-AS1,DHX16,DHX32,DHX33,DIAPH1,DIAPH2,DICER1,DIDO1,DIP2A,DIS3L,DIS3L2,DLGAP4,DNAAF5,DNAJA3,DNAJC10,DNAJC13,DNAJC16,DNAJC17,DNAJC24,DNAJC7,DNM1L,DNMT1,DOCK10,DOCK9,DOK2,DPP3,DPY19L4,DPY30,DPYSL2,DRAM2,DTNBP1,DUSP18,DUSP22,DUSP7,DYM,ECH1,ECHDC1,ECI2,ECPAS,EDEM3,EEA1,EEF1A1,EEF2K,EFCAB14,EFCAB4B,EFTUD1,EHBP1L1,EHMT1,EIF1,EIF2B4,EIF2S1,EIF2S2,EIF3B,EIF3J,EIF4A1,EIF4ENIF1,EIF5B,ELAVL1,ELK3,ELOVL1,ELP3,EMSY,ENGASE,EOMES,EPRS,EPS15,ERAP1,ERI1,ESYT1,ESYT2,ETNK1,EVL,EWSR1,EXOC1,EXOC4,EXOC5,EXOSC10,EXT2,EYA3,EZH1,FADS1,FAIM3,FAM105A,FAM111A,FAM114A2,FAM117A,FAM118B,FAM126A,FAM134B,FAM134C,FAM173B,FAM175A,FAM178A,FAM192A,FAM200B,FAM208A,FAM38A,FAM45A,FAM48A,FAM65B,FAM78A,FARSB,FASTKD1,FBXL20,FBXO18,FBXO22,FBXO9,FBXW11,FBXW2,FCF1,FCRL3,FEZ2,FGD2,FGD4,FH,FIG4,FKBP15,FKBP5,FLAD1,FLI1,FLII,FLJ31306,FLJ33630,FLJ39653,FLT3,FLT4,FNBP1,FNIP2,FNTA,FTSJ3,FUCA2,FUS,FYB,FYN,FZD2,G3BP1,G6PC3,GAB3,GALM,GALNT1,GALNT7,GALT,GANAB,GAPT,GART,GATAD1,GATC,GBA2,GCDH,GCFC1,GCN1,GEMIN6,GEMIN7,GGCT,GGPS1,GIGYF2,GIMAP1,GIMAP2,GIMAP4,GIMAP6,GIMAP8,GIN1,GLB1,GLCCI1,GLG1,GLIPR1,GLS,GLT8D1,GMIP,GMPR2,GNL2,GNPAT,GNPDA1,GOLGA3,GOLGA5,GOLPH3L,GON4L,GOPC,GOT2,GPALPP1,GPATCH2,GPATCH4,GPD1L,GPD2,GPR171,GPR75,GPR89A,GPR89B,GRSF1,GSE1,GSR,GSTK1,GTF2A1,GTF2E1,GTF2H1,GTF2H5,GTPBP10,GUSBL1,GVIN1,GZMA,H2AFY,HADH,HADHA,HADHB,HAUS1,HCG18,HDAC1,HDAC2,HDAC9,HDDC3,HDHD2,HDLBP,HEATR3,HECA,HELQ,HELZ,HERC2P3,HERC4,HEXA,HEXB,HEXDC,HGSNAT,HIBCH,HIST1H1D,HIST1H2BG,HIVEP3,HLTF,HM13,HMBOX1,HMOX2,HN1L,HNMT,HNRNPAB,HNRNPF,HNRNPH2,HOOK3,HPCAL1,HPS3,HS2ST1,HSCB,HSD17B12,HSD17B4,HSPB11,HSPBAP1,HUWE1,HYOU1,IARS,IBTK,ICAM2,IDE,IDH1,IER3IP1,IFFO1,IFI16,IKBKB,IKZF1,IL17RA,IL27RA,IL6R,IL7R,IMMT,ING4,INPP4A,INSR,INTS10,INTS3,INTS7,INTS8,IP6K2,IPCEF1,IPO7,IPO8,IPO9,IQGAP1,IQGAP2,IRAK3,IRF3,IRF5,IRF8,ITGA4,ITGAL,ITGB2,ITK,ITPKB,ITPRIPL2,JRK,JUN,KANSL1L,KAT2B,KCNE3,KCNK6,KCTD12,KCTD15,KDELR1,KDELR2,KDM5A,KHDC4,KIAA0319L,KIAA2026,KIDINS220,KIZ,KLF6,KLHDC10,KLHDC3,KLHDC4,KLHL6,KLHL7,KLHL8,KLRD1,KLRG1,KMT2A,KMT5B,KRCC1,KRI1,KRIT1,KRTCAP2,KYAT3,LACTB2,LAIR1,LARP4B,LARS,LAT,LBH,LCK,LCORL,LDAH,LDLRAP1,LETMD1,LGALS1,LGALS3,LIAS,LILRA4,LILRB1,LIMD1,LINC00324,LINC01138,LMAN2,LMAN2L,LNPEP,LNPK,LOC642361,LOC91548,LONP1,LONP2,LPP,LPXN,LRCH3,LRIG2,LRRC37A2,LRRC47,LRRC8D,LUC7L,LUC7L2,LUC7L3,LY86,LY9,LYRM7,M6PR,MACF1,MAD1L1,MALAT1,MANBA,MAP3K7,MAP4K4,MAPK1,MAPK1IP1L,MAPKAP1,MARCH1,MARS,MAVS,MBNL1,MBNL2,MBOAT1,MBP,MCCC2,MCEE,MCM3,MCM3AP,MCM5,MCTS1,MDFIC,MDM1,ME2,MEAK7,MED1,MED11,MED12,MED13L,MEF2A,MEMO1,METAP1,METT11D1,METTL13,METTL2A,METTL2B,METTL3,METTL5,METTL8,MEX3C,MFSD4B,MFSD8,MGA,MGAT2,MGST1,MGST2,MICA,MICAL2,MID1,MINA,MITD1,MKKS,MKLN1,MLEC,MLX,MLXIP,MMS19,MNDA,MOB3B,MOBKL1A,MON2,MORC2,MOSPD2,MPDU1,MPEG1,MPHOSPH8,MPHOSPH9,MPV17,MRE11A,MRI1,MRP63,MRPL14,MRPL15,MRPL18,MRPL30,MRPL34,MRPL36,MRPL37,MRPL38,MRPL48,MRPS14,MRPS18B,MRPS21,MRPS28,MRPS31,MRPS5,MRPS6,MRPS9,MRS2,MRTO4,MS4A14,MS4A6A,MS4A7,MSH2,MSL3,MTA1,MTCH2,MTDH,MTHFD1,MTIF2,MTIF3,MTMR11,MTO1,MTRF1,MTX2,MUS81,MYCL1,MYDGF,MYO1G,MZF1,N4BP2L2,NAA25,NAA40,NAAA,NACC2,NADK,NADSYN1,NAIP,NAPB,NARS,NASP,NBPF1,NBPF10,NBPF11,NBPF12,NBPF8,NBPF9,NBR1,NCBP1,NCBP2,NCEH1,NCOA3,NCOA6,NCOR1,NCRNA00182,NCRNA00183,NCSTN,NDC1,NDFIP1,NDUFA10,NDUFA8,NDUFAF1,NDUFS1,NDUFV3,NEAT1,NEK4,NEK7,NEK9,NFATC2,NFATC2IP,NFATC3,NFYC,NHLRC3,NID1,NIPBL,NIT1,NIT2,NLRC3,NLRC4,NLRP12,NME6,NMRAL1,NMT1,NMT2,NNT,NOTCH2,NOTCH2NL,NPAT,NPEPPS,NPIP,NR2C2,NSF,NSMCE4A,NSUN5,NSUN5P1,NSUN5P2,NT5C2,NUDCD1,NUDCD3,NUDT16,NUDT7,NUDT9,NUMB,NUP210,NUP43,NUP62,NUPL2,NVL,OGDH,OGFOD1,OGG1,OGT,OLIG1,OMA1,ORC2L,ORMDL1,OSBPL11,OSBPL3,OSGEPL1,OSTC,OSTM1,OTUB1,OXR1,P2RX7,PAAF1,PAFAH1B1,PAK1,PALB2,PAM,PAPD4,PAPSS2,PAQR8,PARN,PARP4,PARVG,PBRM1,PCCA,PCID2,PCM1,PCMT1,PCMTD1,PCYOX1,PCYOX1L,PDCD11,PDCD6IP,PDE4DIP,PDE6D,PDE7A,PDHA1,PDHB,PDHX,PDIA4,PDIA5,PDIA6,PDZD11,PEX11B,PFDN6,PFKP,PHB,PHF14,PHF20,PHF20L1,PHF21A,PHKA2,PID1,PIGF,PIGG,PIGM,PIGV,PIH1D1,PIK3C3,PILRB,PIN4,PION,PITPNB,PITRM1,PLCB1,PLGLB1,PLGLB2,PLRG1,PMM2,PMS1,PMS2L1,PMS2L14,PMS2L2,PMS2L5,PNKD,PNPT1,POC5,POGLUT1,POGZ,POLI,POLK,POLR1B,POLR1D,POLR2J2,POLR3K,POP5,POT1,POU2F2,PPID,PPIE,PPM1L,PPP1R12A,PPP1R2,PPP1R21,PPP2CB,PPP3CB,PPP6R3,PQLC3,PRDM15,PRDM2,PRDX1,PRDX3,PREB,PREP,PRF1,PRKACB,PRKAG1,PRKAG2,PRKCD,PRMT2,PROSC,PRPF38A,PRPSAP1,PRPSAP2,PSAP,PSD4,PSEN1,PSMA7,PSMC4,PSMD1,PSMD14,PSMG1,PSPC1,PSTPIP1,PTER,PTGDR,PTPN22,PTPN6,PUM1,PURA,PUS7,PWWP2A,PYCR2,PYHIN1,QKI,QRSL1,QSER1,RAB10,RAB27A,RAB28,RAB3D,RAB3GAP1,RAB3GAP2,RAB7A,RAB7L1,RABGAP1,RAC2,RAD1,RAD17,RAD50,RAD51C,RAI1,RALA,RALGAPB,RAP1GDS1,RAPGEF6,RAPH1,RARS,RASA1,RASA4,RASAL3,RASEF,RASGEF1A,RASGRP1,RASSF4,RBBP4,RBM14,RBM41,RBM42,RBM4B,RBM5,RBM6,RBM8A,RCAN1,RCBTB2,RCSD1,RDH11,RECK,RECQL,REEP3,REEP5,RER1,REV1,RFC2,RFXAP,RGS14,RGS3,RHOB,RHOT1,RMND1,RNASE2,RNASE4,RNASE6,RNASEH2C,RNF111,RNF146,RNF170,RNF213,RNPC3,ROBLD3,ROCK2,RPA2,RPAP2,RPE,RPRD1A,RPS27A,RPS6KA1,RPS6KA3,RSBN1L,RSC1A1,RSF1,RSPRY1,RTN1,RTN4,RUFY2,RUSC1-AS1,RUVBL1,RUVBL2,S100PBP,SAE1,SAMD3,SAMD9L,SAMHD1,SAMM50,SAP30,SAP30L,SARS,SCAMP1,SCARB2,SCFD1,SCML4,SCOC,SCPEP1,SCRIB,SDAD1,SDCCAG3,SDCCAG8,SDHC,SEC11A,SEC22A,SEC23B,SEC23IP,SEC31A,SEC63,SELPLG,SENP6,SEPT9,SERBP1,SERINC3,SESTD1,SETD3,SETD4,SETD5,SETDB1,SETDB2,SETX,SF3B3,SFRS1,SFRS14,SFRS3,SFRS7,SFT2D1,SFXN4,SGMS2,SGPL1,SH3BP5,SH3TC1,SHMT2,SHPRH,SHQ1,SIGMAR1,SIN3B,SIRPB2,SKA2,SKIV2L2,SKP2,SLAMF1,SLAMF6,SLAMF7,SLC22A15,SLC25A11,SLC25A40,SLC25A43,SLC25A45,SLC25A46,SLC26A2,SLC30A5,SLC30A7,SLC33A1,SLC35A1,SLC35A5,SLC35B3,SLC35D2,SLC35E2,SLC38A10,SLC38A9,SLC43A3,SLC44A1,SLC46A2,SLC46A3,SLC4A1AP,SLC7A1,SLC7A6,SLFN5,SMARCA2,SMARCA4,SMARCAD1,SMARCAL1,SMC1A,SMC5,SMEK2,SMG1,SNAPIN,SNHG10,SNORA28,SNRNP40,SNRPD3,SNTB2,SNUPN,SNX1,SNX19,SNX27,SNX5,SON,SOS1,SP1,SP140,SP3,SPAST,SPATA5,SPCS2,SPG11,SPG20,SPG7,SPIN3,SPN,SPNS1,SPOP,SPTLC2,SRFBP1,SRGAP2,SRGAP2P1,SRPRB,SS18,SSR1,SSR3,ST3GAL1,ST6GAL1,STAB1,STAG3L1,STAM2,STAMBP,STAT6,STIP1,STK17B,STK38,STRAP,STT3A,STX12,STX18,STX6,STX7,STYX,STYXL1,SUCLA2,SUGT1,SULT1A1,SULT1A2,SULT1A3,SULT1A4,SUN1,SUPT16H,SUSD3,SYNCRIP,SYNGR2,SYNRG,SYTL1,TADA3,TAF15,TAOK1,TAOK3,TARDBP,TARP,TARS,TARSL2,TATDN1,TBC1D10C,TBC1D9B,TBCE,TBCK,TCF12,TCF7L2,TCHP,TCTN3,TDRD3,TDRD7,TERF2,TES,TET2,TEX10,TFB1M,TFCP2,TFEB,TFEC,TGFBI,TGOLN2,THEM4,THOC2,THYN1,TIA1,TIMM13,TIMP2,TIPRL,TK2,TLR5,TM2D1,TM7SF3,TM9SF4,TMCO1,TMED10,TMEM107,TMEM14C,TMEM165,TMEM168,TMEM173,TMEM194A,TMEM206,TMEM214,TMEM216,TMEM218,TMEM223,TMEM5,TMEM50B,TMEM63A,TMEM69,TMEM80,TMEM87B,TMOD2,TMOD3,TMPO,TMX2,TMX3,TNFAIP8L2,TNFSF12-TNFSF13,TNFSF13,TNFSF8,TNIP1,TNPO3,TNRC18,TOMM5,TOR3A,TP53,TPCN1,TPP1,TRAC,TRADD,TRAF3IP3,TRAF5,TRAM2,TRAPPC11,TRAPPC3,TRAPPC6B,TRAPPC8,TRD,TRGC2,TRIM13,TRIM27,TRIM33,TRIM4,TRIM44,TRIM52,TRIM56,TRIM66,TRIM73,TRIP4,TRIT1,TRPS1,TRPV2,TRRAP,TSC1,TSEN15,TSEN2,TSNAX,TSPAN14,TSPAN32,TTC1,TTC13,TTC14,TTC15,TTC17,TTC27,TTC37,TTC7A,TTC9C,TTL,TTYH2,TUG1,TXK,TXN2,TXNDC15,UBA1,UBA3,UBA5,UBA7,UBAP2,UBASH3A,UBE2L3,UBE2V2,UBE4A,UBN2,UBTD2,UBTF,UBXN11,UBXN8,UCHL5,UFSP2,UGGT1,UGP2,UPF3A,UQCC1,UQCR10,UQCRC1,USO1,USP21,USP28,USP33,USP34,USP48,UTP14A,UTP14C,UTP6,UVSSA,VAMP1,VAMP4,VAMP8,VBP1,VCAN,VDAC3,VIPAR,VIPR1,VKORC1,VPS13D,VPS16,VPS35,VPS36,VPS45,VPS52,VPS72,VPS8,VRK3,VTA1,WASH3P,WASHC3,WASHC4,WASHC5,WDFY2,WDR11,WDR12,WDR33,WDR46,WDR59,WDR61,WDR73,WDR77,WDR8,WDR92,WDSUB1,WNK1,WSB1,XIAP,XPO1,XPO7,XRCC5,YEATS2,YIF1A,YIPF5,YPEL2,ZADH2,ZAK,ZBTB40,ZBTB48,ZC3H13,ZC3H14,ZC3H6,ZCCHC11,ZDHHC13,ZDHHC16,ZFC3H1,ZFP64,ZFP90,ZGPAT,ZKSCAN1,ZMYM4,ZMYM6,ZNF106,ZNF146,ZNF148,ZNF207,ZNF224,ZNF248,ZNF280D,ZNF302,ZNF354A,ZNF439,ZNF512,ZNF514,ZNF518A,ZNF559,ZNF573,ZNF609,ZNF638,ZNF641,ZNF664,ZNF721,ZNF75D,ZNF767,ZNF789,ZNF862,ZRSR2,ZSCAN29,ZSWIM6,ZW10",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_neu_d3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41122,FLUMIST,LA,INFLUENZA,NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-50,ADULT,DENDRITIC CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP,"Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons. We studied healthy adults vaccinated with trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV). TIV induced higher antibody titers and more plasmablasts than LAIV did. In subjects vaccinated with TIV, early molecular signatures correlated with and could be used to accurately predict later antibody titers in two independent trials. Notably, expression of the kinase CaMKIV at day 3 was inversely correlated with later antibody titers. Vaccination of CaMKIV-deficient mice with TIV induced enhanced antigen-specific antibody titers, which demonstrated an unappreciated role for CaMKIV in the regulation of antibody responses. Thus, systems approaches can be used to predict immunogenicity and provide new mechanistic insights about vaccines.","Genes up-regulated in plasmacytoid dendritic cell 7d vs 0d in young adults (18-50) after exposure to FluMist , time point 7D","Nakaya HI,Wrammert J,Lee EK,Racioppi L,Marie-Kunze S,Haining WN,Means AR,Kasturi SP,Khan N,Li GM,McCausland M,Kanchan V,Kokko KE,Li S,Elbein R,Mehta AK,Aderem A,Subbarao K,Ahmed R,Pulendran B",21743478,HUMAN_GENE_SYMBOL,"AACS,ABCB1,ABCB4,ABCC4,ABHD2,ACACA,ACAT1,ACSF2,ACSL3,ACSL4,ACTA2,ACTR6,ADA,ADAM10,ADAM22,ADAM9,ADCK2,ADD1,ADD3,ADI1,ADK,ADNP,ADRB2,GRK3,AFF1,AFG3L2,AGA,AGPAT5,AGTPBP1,AIMP2,AJAP1,AK1,AK2,,AKT3,ALCAM,ALDH5A1,ALG13,ALG5,AMD1,AMIGO2,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANGEL2,ANKFY1,ANKHD1,ANKHD1-EIF4EBP3,ANKMY2,ANKRD10,ANKRD17,ANKRD49,ANXA2,ANXA4,ANXA7,AP2B1,APAF1,APC,API5,APOBEC3G,APOOL,APPBP2,APPL1,AR,ARAP2,AREG,ARF3,ARF4,ARFGEF2,ARG2,ARHGAP12,ARHGAP15,ARHGAP17,ARHGAP24,ARHGEF7,ARIH1,ARL1,ARL3,ARL8B,ASCC3,ASF1A,ASMTL,ASNS,ASNSD1,ASXL2,ATAD2B,ATF1,ATF2,ATF7,ATG12,ATM,ATP10A,ATP13A3,ATP2A2,ATP2C1,ATP5F1C,DMAC2,ATP6V1A,ATP9B,ATRX,ATXN1,ATXN10,AUTS2,AVL9,AZI2,BAG6,BANK1,BAZ1A,BBS4,BCL11A,BCL2L1,BCL2L11,BEX4,BIN1,BLMH,BMP2K,BMPR2,BABAM2,BRIX1,BSPRY,BTAF1,BTBD3,BTG1,BTG2,BTK,BUB3,BUD31,BZW1,EDRF1,WBP1L,C10orf88,C11orf21,C11orf24,NKAPD1,ZFTA,C12orf43,RITA1,ERG28,GPATCH2L,RIOX1,CFAP20,CYBC1,NCBP3,C18orf25,URI1,SMIM7,C1QBP,UTP25,C1orf112,C1orf50,RSRP1,LAMP5,CFAP298,C2CD5,ATRAID,SMIM8,C7orf25,INTS15,CCZ1,CCZ1B,SPOUT1,CA8,CALCRL,CAMSAP1,CAND2,CAP1,CAPN7,CAPNS1,CAPZA1,CAPZB,CARD8,CARF,CARS1,CAT,CBX1,CCDC47,CCDC59,CCDC86,CCDC90B,CCDC91,CCDC93,YJU2,CCND2,CCND3,CCNG1,CCNG2,CCNT2,CCR1,CCR2,CCT2,CCT4,CCT6A,CD164,CD55,CDC16,CDK12,CDK13,CDK2AP1,CDK2AP2,CDK5RAP1,CDR2,CDYL,CELF1,CELF2,CENPJ,CNTRL,CEP290,CEP350,CEP57,CEP63,CEP68,CETN3,CHD9,CHST11,CHST15,CHTOP,CIAPIN1,CISD1,CITED2,CIZ1,CLCN3,CLIC3,CLIP1,CLK1,CLTA,CMAS,CMKLR1,CMPK1,CMTM6,CNDP2,CNIH1,CNOT1,CNOT4,COBLL1,COG2,COG8,COIL,COMT,COPB1,COPS2,COPS6,COPS8,COPZ1,COX11,COX15,COX16,CPD,CREB1,CREBL2,CREBZF,CRELD2,CREM,CRIM1,CSE1L,CSF2RA,CSNK1A1,CSNK1D,CSRP2,CTBP2,CTBS,CTNNA1,CTNS,CTSB,CUEDC1,CUL4A,CUL4B,CUL5,CUTC,CYFIP1,CYFIP2,DAAM1,DAB2,DAD1,DAP3,DAPK1,DARS1,DBF4,DCAF13,DCAF7,DCK,DCP2,DCTN3,DDX19A,DDX27,DDX42,DDX6,DECR1,DENND4B,DERA,DERL2,DGCR2,DGKA,DGUOK,DHDDS,DHFR,DIAPH1,DICER1,DIMT1,DLEU1,DMTF1,DMXL1,DMXL2,DNAJB9,DNAJC10,DNAJC13,DNAJC24,DNAJC8,DNAJC9,DNASE1L3,DNTTIP2,DPP3,DPP8,DPYSL2,DR1,VPS26C,DSG2,DUSP3,DUSP6,DXO,DYNC1H1,DZIP3,E2F5,EAF2,EBNA1BP2,EBP,ECH1,ECHS1,ECPAS,EDEM2,EEA1,EFCAB2,MICU2,EFHC1,EFR3A,EGLN1,EGR1,EID1,EIF1AX,EIF2B1,AGO2,EIF2S1,EIF2S2,EIF3B,EIF3G,EIF3J,EIF3M,EIF5B,ELAVL1,ELF1,ELL3,ELMO2,EML4,ENO1,ENOPH1,ENPP2,ENPP4,ENSA,ENTPD1,ENTPD6,EPHB1,EPM2A,EPRS1,EPS15,ERAP1,ERAP2,ERBIN,ERCC1,ERLIN2,ERMAP,ERO1B,ERP44,ESD,ETNK1,EVI5,EWSR1,EXOC5,EXOSC8,EZH1,F8A1,F8A2,F8A3,FAF1,FAHD2A,FCMR,OTULINL,FAM117A,RETREG2,FAM13A,ABRAXAS2,SLF2,TASOR,FAM3C,DENND10,SUPT20H,CYRIA,RIPOR2,RMDN3,RMDN1,FANCI,FAR2,FASTKD1,FASTKD2,FDFT1,FECH,FEM1B,FEZ2,FGFR2,FHL1,FIBP,FKBP5,FLI1,FLNB,FLOT1,FLOT2,FLT3,FMR1,FNDC3A,FUT4,FYN,GADD45A,GALNT1,GALNT3,GALNT7,GATB,GCOM1,GCSH,GDE1,,GGH,GK,GLCE,GLMN,GLO1,GLOD4,GLRX,GLRX3,GLS,GLUL,GMFB,GNAI3,GNAL,GNB1,GNL3L,GNPAT,GNS,GOLGA4,GOLPH3,GOSR2,GPBP1L1,GPD1L,GPR107,GPR183,GPX7,GRHPR,GRPEL1,GSPT1,GSPT2,GSTM4,GTF2A2,GTF2H5,GTF3A,GYG1,H2AZ2,HADH,HARS1,HAUS3,HECTD3,HGSNAT,HIBCH,HIC2,HIP1,HIPK3,H2AC6,H4C8,HMG20A,HMG20B,HMGCR,HMGCS1,JPT2,HNRNPDL,HS3ST1,HS3ST3B1,HSBP1,HSDL2,HSF2,HSPA13,HSPA4,HSPA5,HSPD1,HSPH1,HUS1,IARS1,IBTK,ICE2,IDI1,IDI2-AS1,IFRD1,IFT52,IFT74,IGFBP7,IGHM,IKBKB,IL13RA1,IL18RAP,IL27RA,IL4R,IL6R,INPP4A,INSIG1,INTS1,INTS6,INTS7,IPO5,IPO7,,IQCE,IQGAP1,IQSEC1,IRF2,ISCA1,ISG20,ITGA4,ITGAV,ITGB3BP,ITPR2,JAK2,KARS1,KCNA5,KCNAB1,KCTD12,KCTD20,KDELR2,KDM3B,KDM4A,KDM6A,TRAPPC8,KIF1A,KIN,KLHDC10,KLHDC2,KMO,KMT2A,KPNA1,KPNA2,KPNA5,KRBOX4,KRCC1,KRT10,KTN1,KYAT3,LAMC1,LAMP2,LAPTM4B,LARP4B,LCP2,LDLRAD4,LEPROT,LHFPL2,LILRB2,LIMS1,LIN37,LMF1,LONP2,LPCAT3,LPGAT1,LRBA,LRCH3,LRPPRC,LRRC40,LRRC8D,LRRFIP2,LSM1,LSM3,LSM5,LTN1,LUC7L3,LYRM4,M6PR,MACF1,MAD2L1,MAGEH1,MAK16,MALT1,MAN2A2,MANF,MAP1LC3B,MAP3K5,MAP3K7,MAP4K5,MAP7D3,MAPK1,MAPK14,MAPKAPK3,MARCHF6,MARCHF7,MARS1,MAT2A,MATR3,MBD1,MBD4,MBNL1,MBNL2,MCC,MCM3AP-AS1,MCM4,MCUB,MDFIC,MDN1,MEAF6,MED28,MED31,MED7,MEF2A,MEF2C,METAP1,MFN1,MGAT4A,MGAT5,MGMT,MIA3,MICB,RIOX2,MIOS,MIR22HG,MLEC,CENPU,MLX,MMRN1,MOAP1,MON2,MOXD1,MPP1,MPRIP,MPV17,MRFAP1L1,MRPL3,MRPL33,MRPL48,MRPS15,MRPS16,MRPS17,MRPS18B,MRS2,MSH3,MSL2,MSRA,MTDH,MTERF3,MTF2,MTHFD2,MTM1,MTMR1,MTR,MTRR,MTX2,BLOC1S5,MYCBP,MZB1,N4BP1,N4BP2L2,NADK,NAE1,NAGA,NAPA,NBN,NCBP2,NCF4,NCK2,NCOA6,NDST2,NECAP1,NEK9,NFAT5,NFU1,NFX1,NFYB,NFYC,NIPA2,NIPBL,NOC3L,NOD1,NOL8,NOL9,NOP56,NOTCH4,NPEPPS,NPIPB3,NPM1,NR3C1,NR4A2,NR4A3,NRP1,NSDHL,NSL1,NT5C2,NUBP1,NUDT15,NUDT3,NUMA1,NUP160,NUP210,NUP98,OAS1,OAT,STN1,OBSL1,OCRL,ODC1,OPA1,OPN3,OSBPL8,OSBPL9,OSTF1,OTUD4,OXCT1,OXR1,OXSR1,P2RY14,P3H2,P4HA1,PAFAH1B1,PAFAH2,PAIP1,PAIP2B,PAK2,PALM2AKAP2,PAPOLA,PARP2,PARVB,PAXIP1,PBX3,PBXIP1,PCM1,PCMT1,PDCD10,PDCD2,PDCL3,PDE12,PDE4DIP,PDF,PDHB,PDIA5,PDIA6,PEPD,PEX13,PFKFB2,PGAP2,PGM1,PHKB,PHTF1,PI4KA,PIK3CA,PIP4K2A,PITPNA,PJA2,PKP4,PLAAT3,PLCL2,PLEKHB2,PLIN3,PLK4,PLVAP,PLXNC1,PMP22,PNISR,PNOC,POLM,POLR2M,POLR3C,POP4,POP5,POT1,POU4F1,PPIG,PPP1CC,PPP1R10,PPP1R11,PPP1R12A,PPP1R16B,PPP2CB,PPP2R3C,PPP2R5C,PPP2R5D,PPP2R5E,PPP3CA,PPP3CB,PPP3CC,PPP3R1,PPP6C,DESI2,DESI1,PQBP1,PRDM10,PRDM2,PRDX4,PRDX6,PRKACB,PRKAG2,PRKCA,PRKCD,PRKCI,PRKDC,PRNP,PRPF38B,PRPF4,PRPF6,PRPF8,PSEN1,PSMA1,PSMA2,PSMB6,PSMB8,PSMD14,PSMD2,PSMD4,PSMG1,PTBP2,PTBP3,PTEN,PTGER4,PTP4A1,PTP4A3,PTPN11,PTPN22,PUM1,PUM2,PWP1,PYGB,PYROXD1,QKI,R3HCC1,R3HDM1,RAB33B,RAB38,RAB3GAP2,RAB40B,RAB5A,RAB6B,RAB7A,RABGAP1L,RABGGTB,RABL3,RAD17,RAD51AP1,RALBP1,RALGAPA1,RANBP1,TERF2IP,RAP2C,RAPGEF2,RASA1,RBBP6,RBCK1,RBL2,RBM10,RBM15B,RBM28,RBM41,RBM8A,RBMS1,RCAN1,RCN2,RCOR1,RCOR3,RDH11,RDH14,REST,RET,REXO2,RFK,RFWD3,RGS1,RGS10,RGS2,RGS7,RHOQ,RHOT1,RIMS3,RIT1,RMND5B,RNF11,RNF13,RNF130,RNF139,RNF14,RNF8,ROCK1,RPA2,RPA3,RPAP3,RPE,RPF1,RPL13,RPP38,RPS6KA2,RPS6KA3,RPS6KA4,CNOT9,RRBP1,RRN3,RRP1B,RSAD1,RSL1D1,RUBCN,RUFY3,,RUVBL2,RWDD2B,RXRB,RYR3,S100A10,S100PBP,SAC3D1,SACS,SAE1,MSMO1,SC5D,SCD,SCN9A,SCP2,SCUBE3,SCYL2,SCYL3,SDHAF3,SEC22B,SEC23B,SEC24A,SEC31A,SEC62,SECISBP2L,SEL1L,SEL1L3,SENP3,SENP6,SEPTIN11,SERINC3,SERINC4,SERP1,SESN1,SETD6,SETX,SUGP1,AKAP17A,SRSF6,SFSWAP,SH3BGR,SH3BGRL,SH3BP4,SH3GLB1,SHMT2,SHQ1,SIDT1,SIDT2,SIK1,GEMIN2,SLC11A2,SLC15A2,SLC16A7,SLC18A2,SLC1A4,SLC24A1,SLC25A32,SLC25A46,SLC30A9,SLC33A1,SLC35A2,SLC35A3,SLC35D1,SLC38A1,SLC39A6,SLC43A3,SLC4A3,SLC4A7,SLC5A3,SLC7A1,SLC7A6,SLC9A6,PRELID3B,SMAD3,SMAP1,SMARCA5,SMARCAL1,SMARCC1,SMG1,SMURF2,SMYD2,SNAP23,SNAPC3,SNAPC5,SNCA,SNRNP200,SNX13,SOD2,CAPN15,SOS2,SP110,SP4,SPAG9,SPAST,SPCS2,SPG7,SPIN2A,SPIN2B,SPOP,SPTBN1,U2SURP,SRPK2,SRPRB,SSX4,SSX4B,ST13,ST3GAL1,ST3GAL6,ST6GALNAC4,STAM2,STAMBP,STAT6,STIM1,STK26,STX18,STX6,SUMO1,SUN1,SUPT3H,SUZ12,SYK,SYNE2,TACC1,TAF12,TAF1B,TAF4,TANK,TAX1BP3,TBC1D1,TBC1D4,TBC1D5,TBCC,TBCCD1,TBL2,TBPL1,TCF3,TCF4,TCL1A,TCP1,TDG,TDP1,TDRD3,TEX10,TFCP2,THAP1,THBD,THOC2,THOC7,THUMPD1,TIA1,TIMELESS,TIMM17A,TLR6,TLR7,TM2D1,TMBIM6,TMCO1,TMCO6,TMED10,TMED5,TMED7,TMEM131,TMEM14A,TMEM184C,TMEM185B,TMEM33,TMEM38B,TMEM39A,TMEM50A,TMEM59,TMEM70,TMPO,TMUB2,TMX4,TNPO1,TOB2,TOP3A,TOPBP1,TOR1A,TOR1B,TPD52,TPM4,TPRKB,TRAK1,TRAM1,TRAM2,TRAPPC10,TRDMT1,TRIM14,TRIM27,TRIM33,TRIM38,TRIP11,TRMT61B,RO60,TRPS1,TRPV1,TSC1,TSC22D1,TSC22D3,TSNAX,TSPAN31,TSR1,TTC13,TTC3,EMC2,SKIC3,TTF1,TUBB,TUBB4B,TUBB3,TUBGCP4,TWF1,NME8,TXNDC5,U2AF2,UBA2,UBA3,UBAP1,UBAP2L,UBE2B,UBE2D3,UBE2E3,UBE2J1,UBE2L3,UBE3A,UBE4A,UBE4B,UBFD1,UBL3,UBR2,UBR5,UBR7,UBTF,UCHL3,UCP2,UEVLD,UPF2,UPF3A,UQCR10,UQCRB,USP1,USP15,USP4,USP6,USP9X,UTP11,VAMP1,VCL,VPS11,VPS41,VPS45,VSNL1,WAC,WAPL,WASF1,WASHC2A,WASHC2C,WASHC3,WASHC4,WBP11,WBP4,WDR1,WDR3,WDR37,WDR47,WDR59,WDR70,WIPF2,WIPI1,WSB1,WSB2,XPO1,XRCC4,XRCC5,YAF2,YKT6,YWHAE,YWHAQ,ZBTB10,ZBTB25,ZBTB33,ZC3H14,ZC3H15,ZCCHC24,ZFP36L2,ZMYM2,ZMYM4,ZMYND11,ZMYND8,ZNF106,ZNF117,ZNF124,ZNF131,ZNF148,ZNF195,ZNF202,ZNF207,ZNF224,ZNF226,ZBTB18,ZNF277,ZNF329,ZNF337,ZNF354A,ZNF544,ZNF609,ZNF7,ZNF713,ZNF814,ZNF83,ZNHIT6",1219,"AACS,ABCB1,ABCB4,ABCC4,ABHD2,ACACA,ACAT1,ACSF2,ACSL3,ACSL4,ACTA2,ACTR6,ADA,ADAM10,ADAM22,ADAM9,ADCK2,ADD1,ADD3,ADI1,ADK,ADNP,ADRB2,ADRBK2,AFF1,AFG3L2,AGA,AGPAT5,AGTPBP1,AIMP2,AJAP1,AK1,AK2,AKAP2,AKT3,ALCAM,ALDH5A1,ALG13,ALG5,AMD1,AMIGO2,AMY1A,AMY1B,AMY1C,AMY2A,AMY2B,ANGEL2,ANKFY1,ANKHD1,ANKHD1-EIF4EBP3,ANKMY2,ANKRD10,ANKRD17,ANKRD49,ANXA2,ANXA4,ANXA7,AP2B1,APAF1,APC,API5,APOBEC3G,APOOL,APPBP2,APPL1,AR,ARAP2,AREG,ARF3,ARF4,ARFGEF2,ARG2,ARHGAP12,ARHGAP15,ARHGAP17,ARHGAP24,ARHGEF7,ARIH1,ARL1,ARL3,ARL8B,ASCC3,ASF1A,ASMTL,ASNS,ASNSD1,ASXL2,ATAD2B,ATF1,ATF2,ATF7,ATG12,ATM,ATP10A,ATP13A3,ATP2A2,ATP2C1,ATP5C1,ATP5SL,ATP6V1A,ATP9B,ATRX,ATXN1,ATXN10,AUTS2,AVL9,AZI2,BAG6,BANK1,BAZ1A,BBS4,BCL11A,BCL2L1,BCL2L11,BEX4,BIN1,BLMH,BMP2K,BMPR2,BRE,BRIX1,BSPRY,BTAF1,BTBD3,BTG1,BTG2,BTK,BUB3,BUD31,BZW1,C10orf137,C10orf26,C10orf88,C11orf21,C11orf24,C11orf57,C11orf95,C12orf43,C12orf52,C14orf1,C14orf118,C14orf169,C16orf80,C17orf62,C17orf85,C18orf25,C19orf2,C19orf42,C1orf107,C1orf112,C1orf50,C1orf63,C1QBP,C20orf103,C21orf59,C2CD5,C2orf28,C6orf162,C7orf25,C7orf26,C7orf28A,C7orf28B,C9orf114,CA8,CALCRL,CAMSAP1,CAND2,CAP1,CAPN7,CAPNS1,CAPZA1,CAPZB,CARD8,CARF,CARS,CAT,CBX1,CCDC47,CCDC59,CCDC86,CCDC90B,CCDC91,CCDC93,CCDC94,CCND2,CCND3,CCNG1,CCNG2,CCNT2,CCR1,CCR2,CCT2,CCT4,CCT6A,CD164,CD55,CDC16,CDK12,CDK13,CDK2AP1,CDK2AP2,CDK5RAP1,CDR2,CDYL,CELF1,CELF2,CENPJ,CEP110,CEP290,CEP350,CEP57,CEP63,CEP68,CETN3,CHD9,CHST11,CHST15,CHTOP,CIAPIN1,CISD1,CITED2,CIZ1,CLCN3,CLIC3,CLIP1,CLK1,CLTA,CMAS,CMKLR1,CMPK1,CMTM6,CNDP2,CNIH,CNOT1,CNOT4,COBLL1,COG2,COG8,COIL,COMT,COPB1,COPS2,COPS6,COPS8,COPZ1,COX11,COX15,COX16,CPD,CREB1,CREBL2,CREBZF,CRELD2,CREM,CRIM1,CSE1L,CSF2RA,CSNK1A1,CSNK1D,CSRP2,CTBP2,CTBS,CTNNA1,CTNS,CTSB,CUEDC1,CUL4A,CUL4B,CUL5,CUTC,CYFIP1,CYFIP2,DAAM1,DAB2,DAD1,DAP3,DAPK1,DARS,DBF4,DCAF13,DCAF7,DCK,DCP2,DCTN3,DDX19A,DDX27,DDX42,DDX6,DECR1,DENND4B,DERA,DERL2,DGCR2,DGKA,DGUOK,DHDDS,DHFR,DIAPH1,DICER1,DIMT1L,DLEU1,DMTF1,DMXL1,DMXL2,DNAJB9,DNAJC10,DNAJC13,DNAJC24,DNAJC8,DNAJC9,DNASE1L3,DNTTIP2,DPP3,DPP8,DPYSL2,DR1,DSCR3,DSG2,DUSP3,DUSP6,DXO,DYNC1H1,DZIP3,E2F5,EAF2,EBNA1BP2,EBP,ECH1,ECHS1,ECPAS,EDEM2,EEA1,EFCAB2,EFHA1,EFHC1,EFR3A,EGLN1,EGR1,EID1,EIF1AX,EIF2B1,EIF2C2,EIF2S1,EIF2S2,EIF3B,EIF3G,EIF3J,EIF3M,EIF5B,ELAVL1,ELF1,ELL3,ELMO2,EML4,ENO1,ENOPH1,ENPP2,ENPP4,ENSA,ENTPD1,ENTPD6,EPHB1,EPM2A,EPRS,EPS15,ERAP1,ERAP2,ERBIN,ERCC1,ERLIN2,ERMAP,ERO1LB,ERP44,ESD,ETNK1,EVI5,EWSR1,EXOC5,EXOSC8,EZH1,F8A1,F8A2,F8A3,FAF1,FAHD2A,FAIM3,FAM105A,FAM117A,FAM134A,FAM13A,FAM175B,FAM178A,FAM208A,FAM3C,FAM45A,FAM48A,FAM49A,FAM65B,FAM82A2,FAM82B,FANCI,FAR2,FASTKD1,FASTKD2,FDFT1,FECH,FEM1B,FEZ2,FGFR2,FHL1,FIBP,FKBP5,FLI1,FLNB,FLOT1,FLOT2,FLT3,FMR1,FNDC3A,FUT4,FYN,GADD45A,GALNT1,GALNT3,GALNT7,GATB,GCOM1,GCSH,GDE1,GDS1,GGH,GK,GLCE,GLMN,GLO1,GLOD4,GLRX,GLRX3,GLS,GLUL,GMFB,GNAI3,GNAL,GNB1,GNL3L,GNPAT,GNS,GOLGA4,GOLPH3,GOSR2,GPBP1L1,GPD1L,GPR107,GPR183,GPX7,GRHPR,GRPEL1,GSPT1,GSPT2,GSTM4,GTF2A2,GTF2H5,GTF3A,GYG1,H2AFV,HADH,HARS,HAUS3,HECTD3,HGSNAT,HIBCH,HIC2,HIP1,HIPK3,HIST1H2AC,HIST1H4H,HMG20A,HMG20B,HMGCR,HMGCS1,HN1L,HNRPDL,HS3ST1,HS3ST3B1,HSBP1,HSDL2,HSF2,HSPA13,HSPA4,HSPA5,HSPD1,HSPH1,HUS1,IARS,IBTK,ICE2,IDI1,IDI2-AS1,IFRD1,IFT52,IFT74,IGFBP7,IGHM,IKBKB,IL13RA1,IL18RAP,IL27RA,IL4R,IL6R,INPP4A,INSIG1,INTS1,INTS6,INTS7,IPO5,IPO7,IPW,IQCE,IQGAP1,IQSEC1,IRF2,ISCA1,ISG20,ITGA4,ITGAV,ITGB3BP,ITPR2,JAK2,KARS,KCNA5,KCNAB1,KCTD12,KCTD20,KDELR2,KDM3B,KDM4A,KDM6A,KIAA1012,KIF1A,KIN,KLHDC10,KLHDC2,KMO,KMT2A,KPNA1,KPNA2,KPNA5,KRBOX4,KRCC1,KRT10,KTN1,KYAT3,LAMC1,LAMP2,LAPTM4B,LARP4B,LCP2,LDLRAD4,LEPROT,LHFPL2,LILRB2,LIMS1,LIN37,LMF1,LONP2,LPCAT3,LPGAT1,LRBA,LRCH3,LRPPRC,LRRC40,LRRC8D,LRRFIP2,LSM1,LSM3,LSM5,LTN1,LUC7L3,LYRM4,M6PR,MACF1,MAD2L1,MAGEH1,MAK16,MALT1,MAN2A2,MANF,MAP1LC3B,MAP3K5,MAP3K7,MAP4K5,MAP7D3,MAPK1,MAPK14,MAPKAPK3,MARCH6,MARCH7,MARS,MAT2A,MATR3,MBD1,MBD4,MBNL1,MBNL2,MCC,MCM3AP-AS1,MCM4,MCUB,MDFIC,MDN1,MEAF6,MED28,MED31,MED7,MEF2A,MEF2C,METAP1,MFN1,MGAT4A,MGAT5,MGMT,MIA3,MICB,MINA,MIOS,MIR22HG,MLEC,MLF1IP,MLX,MMRN1,MOAP1,MON2,MOXD1,MPP1,MPRIP,MPV17,MRFAP1L1,MRPL3,MRPL33,MRPL48,MRPS15,MRPS16,MRPS17,MRPS18B,MRS2,MSH3,MSL2,MSRA,MTDH,MTERFD1,MTF2,MTHFD2,MTM1,MTMR1,MTR,MTRR,MTX2,MUTED,MYCBP,MZB1,N4BP1,N4BP2L2,NADK,NAE1,NAGA,NAPA,NBN,NCBP2,NCF4,NCK2,NCOA6,NDST2,NECAP1,NEK9,NFAT5,NFU1,NFX1,NFYB,NFYC,NIPA2,NIPBL,NOC3L,NOD1,NOL8,NOL9,NOP56,NOTCH4,NPEPPS,NPIPL3,NPM1,NR3C1,NR4A2,NR4A3,NRP1,NSDHL,NSL1,NT5C2,NUBP1,NUDT15,NUDT3,NUMA1,NUP160,NUP210,NUP98,OAS1,OAT,OBFC1,OBSL1,OCRL,ODC1,OPA1,OPN3,OSBPL8,OSBPL9,OSTF1,OTUD4,OXCT1,OXR1,OXSR1,P2RY14,P3H2,P4HA1,PAFAH1B1,PAFAH2,PAIP1,PAIP2B,PAK2,PALM2-AKAP2,PAPOLA,PARP2,PARVB,PAXIP1,PBX3,PBXIP1,PCM1,PCMT1,PDCD10,PDCD2,PDCL3,PDE12,PDE4DIP,PDF,PDHB,PDIA5,PDIA6,PEPD,PEX13,PFKFB2,PGAP2,PGM1,PHKB,PHTF1,PI4KA,PIK3CA,PIP4K2A,PITPNA,PJA2,PKP4,PLA2G16,PLCL2,PLEKHB2,PLIN3,PLK4,PLVAP,PLXNC1,PMP22,PNISR,PNOC,POLM,POLR2M,POLR3C,POP4,POP5,POT1,POU4F1,PPIG,PPP1CC,PPP1R10,PPP1R11,PPP1R12A,PPP1R16B,PPP2CB,PPP2R3C,PPP2R5C,PPP2R5D,PPP2R5E,PPP3CA,PPP3CB,PPP3CC,PPP3R1,PPP6C,PPPDE1,PPPDE2,PQBP1,PRDM10,PRDM2,PRDX4,PRDX6,PRKACB,PRKAG2,PRKCA,PRKCD,PRKCI,PRKDC,PRNP,PRPF38B,PRPF4,PRPF6,PRPF8,PSEN1,PSMA1,PSMA2,PSMB6,PSMB8,PSMD14,PSMD2,PSMD4,PSMG1,PTBP2,PTBP3,PTEN,PTGER4,PTP4A1,PTP4A3,PTPN11,PTPN22,PUM1,PUM2,PWP1,PYGB,PYROXD1,QKI,R3HCC1,R3HDM1,RAB33B,RAB38,RAB3GAP2,RAB40B,RAB5A,RAB6B,RAB7A,RABGAP1L,RABGGTB,RABL3,RAD17,RAD51AP1,RALBP1,RALGAPA1,RANBP1,RAP1,RAP2C,RAPGEF2,RASA1,RBBP6,RBCK1,RBL2,RBM10,RBM15B,RBM28,RBM41,RBM8A,RBMS1,RCAN1,RCN2,RCOR1,RCOR3,RDH11,RDH14,REST,RET,REXO2,RFK,RFWD3,RGS1,RGS10,RGS2,RGS7,RHOQ,RHOT1,RIMS3,RIT1,RMND5B,RNF11,RNF13,RNF130,RNF139,RNF14,RNF8,ROCK1,RPA2,RPA3,RPAP3,RPE,RPF1,RPL13,RPP38,RPS6KA2,RPS6KA3,RPS6KA4,RQCD1,RRBP1,RRN3,RRP1B,RSAD1,RSL1D1,RUBCN,RUFY3,RUNX1-IT1,RUVBL2,RWDD2B,RXRB,RYR3,S100A10,S100PBP,SAC3D1,SACS,SAE1,SC4MOL,SC5DL,SCD,SCN9A,SCP2,SCUBE3,SCYL2,SCYL3,SDHAF3,SEC22B,SEC23B,SEC24A,SEC31A,SEC62,SECISBP2L,SEL1L,SEL1L3,SENP3,SENP6,SEPT11,SERINC3,SERINC4,SERP1,SESN1,SETD6,SETX,SF4,SFRS17A,SFRS6,SFRS8,SH3BGR,SH3BGRL,SH3BP4,SH3GLB1,SHMT2,SHQ1,SIDT1,SIDT2,SIK1,SIP1,SLC11A2,SLC15A2,SLC16A7,SLC18A2,SLC1A4,SLC24A1,SLC25A32,SLC25A46,SLC30A9,SLC33A1,SLC35A2,SLC35A3,SLC35D1,SLC38A1,SLC39A6,SLC43A3,SLC4A3,SLC4A7,SLC5A3,SLC7A1,SLC7A6,SLC9A6,SLMO2,SMAD3,SMAP1,SMARCA5,SMARCAL1,SMARCC1,SMG1,SMURF2,SMYD2,SNAP23,SNAPC3,SNAPC5,SNCA,SNRNP200,SNX13,SOD2,SOLH,SOS2,SP110,SP4,SPAG9,SPAST,SPCS2,SPG7,SPIN2A,SPIN2B,SPOP,SPTBN1,SR140,SRPK2,SRPRB,SSX4,SSX4B,ST13,ST3GAL1,ST3GAL6,ST6GALNAC4,STAM2,STAMBP,STAT6,STIM1,STK26,STX18,STX6,SUMO1,SUN1,SUPT3H,SUZ12,SYK,SYNE2,TACC1,TAF12,TAF1B,TAF4,TANK,TAX1BP3,TBC1,TBC1D4,TBC1D5,TBCC,TBCCD1,TBL2,TBPL1,TCF3,TCF4,TCL1A,TCP1,TDG,TDP1,TDRD3,TEX10,TFCP2,THAP1,THBD,THOC2,THOC7,THUMPD1,TIA1,TIMELESS,TIMM17A,TLR6,TLR7,TM2D1,TMBIM6,TMCO1,TMCO6,TMED10,TMED5,TMED7,TMEM131,TMEM14A,TMEM184C,TMEM185B,TMEM33,TMEM38B,TMEM39A,TMEM50A,TMEM59,TMEM70,TMPO,TMUB2,TMX4,TNPO1,TOB2,TOP3A,TOPBP1,TOR1A,TOR1B,TPD52,TPM4,TPRKB,TRAK1,TRAM1,TRAM2,TRAPPC10,TRDMT1,TRIM14,TRIM27,TRIM33,TRIM38,TRIP11,TRMT61B,TROVE2,TRPS1,TRPV1,TSC1,TSC22D1,TSC22D3,TSNAX,TSPAN31,TSR1,TTC13,TTC3,TTC35,TTC37,TTF1,TUBB,TUBB2C,TUBB3,TUBGCP4,TWF1,TXNDC3,TXNDC5,U2AF2,UBA2,UBA3,UBAP1,UBAP2L,UBE2B,UBE2D3,UBE2E3,UBE2J1,UBE2L3,UBE3A,UBE4A,UBE4B,UBFD1,UBL3,UBR2,UBR5,UBR7,UBTF,UCHL3,UCP2,UEVLD,UPF2,UPF3A,UQCR10,UQCRB,USP1,USP15,USP4,USP6,USP9X,UTP11,VAMP1,VCL,VPS11,VPS41,VPS45,VSNL1,WAC,WAPAL,WASF1,WASHC2A,WASHC2C,WASHC3,WASHC4,WBP11,WBP4,WDR1,WDR3,WDR37,WDR47,WDR59,WDR70,WIPF2,WIPI1,WSB1,WSB2,XPO1,XRCC4,XRCC5,YAF2,YKT6,YWHAE,YWHAQ,ZBTB10,ZBTB25,ZBTB33,ZC3H14,ZC3H15,ZCCHC24,ZFP36L2,ZMYM2,ZMYM4,ZMYND11,ZMYND8,ZNF106,ZNF117,ZNF124,ZNF131,ZNF148,ZNF195,ZNF202,ZNF207,ZNF224,ZNF226,ZNF238,ZNF277,ZNF329,ZNF337,ZNF354A,ZNF544,ZNF609,ZNF7,ZNF713,ZNF814,ZNF83,ZNHIT6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_neu_d3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41187,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_DN,BACTERIUM,DOWN,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_DN,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes down-regulated in CD4-positive, alpha-beta memory T cell 7d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 7D , administered PO (oral). Comment: top 100 most significantly altered genes comparing Day 0 and Day 7 responses directly ex vivo","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"C9orf85,EEF1A1P9,HSPE1,,NKX1-1,TMEM191A,TMSB4X",7,"C9orf85,EEF1AL7,HSPE1,LINC00260,NKX1-1,TMEM191A,TMSB4X",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6C (PO),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M41068,BCG,LA,TUBERCULOSIS,HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_UP,BACTERIUM,UP,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,T CELL,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HOFT_CD4_POSITIVE_ALPHA_BETA_MEMORY_T_CELL_BCG_VACCINE_AGE_18_45YO_7DY_UP,"Protective efficacy of Bacillus Calmette-Guerin (BCG) may be affected by the methods and routes of vaccine administration. We have studied the safety and immunogenicity of oral (PO) and/or intradermal (ID) administration of BCG in healthy human subjects. No major safety concerns were detected in the 68 healthy adults vaccinated with PO and/or ID BCG. Although both PO and ID BCG could induce systemic Th1 responses capable of IFN-gamma production, ID BCG more strongly induced systemic Th1 responses. In contrast, stronger mucosal responses (TB-specific secretory IgA and bronchoalveolar lavage T cells) were induced by PO BCG vaccination. To generate preliminary data comparing the early gene signatures induced by mucosal and systemic BCG vaccination, CD4<sup>+</sup> memory T cells were isolated from subsets of BCG vaccinated subjects pre- (Day 0) and post-vaccination (Days 7 and 56), rested or stimulated with BCG infected dendritic cells, and then studied by Illumina BeadArray transcriptomal analysis. Notably, distinct gene expression profiles were identified both on Day 7 and Day 56 comparing the PO and ID BCG vaccinated groups by GSEA analysis. Future correlation analyses between specific gene expression patterns and distinct mucosal and systemic immune responses induced will be highly informative for TB vaccine development.","Genes up-regulated in CD4-positive, alpha-beta memory T cell 7d vs 0d in adults (18-45) after exposure to BCG vaccine , time point 7D , administered PO (oral). Comment: top 100 most significantly altered genes comparing Day 0 and Day 7 responses directly ex vivo","Hoft DF,Xia M,Zhang GL,Blazevic A,Tennant J,Kaplan C,Matuschak G,Dube TJ,Hill H,Schlesinger LS,Andersen PL,Brusic V",28853442,HUMAN_GENE_SYMBOL,"ACTN1,ATP6V0A1,CES1,CLIP2,CYP27B1,DHCR24,EEF1A2,ENTPD1,FHL3,GMEB1,GNG11,HUS1B,INSIG1,KIAA0930,MATK,MED24,MITF,NDP,NOC4L,OPA3,PDGFB,PPP1R16A,PTGES2,PTGFRN,RASA2,RHBDF1,RSPH3,SAMD1,SIX5,SLC2A6,SMPD1,TBC1D22A,TBC1D24,TEDC1,TGFBRAP1,TJP2,TNFRSF8,TOP3A,ZNF264,ZNF768",40,"ACTN1,ATP6V0A1,CES1,CLIP2,CYP27B1,DHCR24,EEF1A2,ENTPD1,FHL3,GMEB1,GNG11,HUS1B,INSIG1,KIAA0930,MATK,MED24,MITF,NDP,NOC4L,OPA3,PDGFB,PPP1R16A,PTGES2,PTGFRN,RASA2,RHBDF1,RSPH3,SAMD1,SIX5,SLC2A6,SMPD1,TBC1D22A,TBC1D24,TEDC1,TGFBRAP1,TJP2,TNFRSF8,TOP3A,ZNF264,ZNF768",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table IV,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Suplementary_t.doc,NA,NA,NA,NA
M41123,ZOSTAVAX,LA,VZV,QI_PBMC_ZOSTAVAX_AGE_50_75YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,52-75,"ADULT, ELDER",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QI_PBMC_ZOSTAVAX_AGE_50_75YO_1DY_UP,"Vaccination with attenuated live varicella zoster virus (VZV) can prevent zoster reactivation, but protection is incomplete especially in an older population. To decipher the molecular mechanisms underlying variable vaccine responses, T- and B-cell responses to VZV vaccination were examined in individuals of different ages including identical twin pairs. Contrary to the induction of VZV-specific antibodies, antigen-specific T cell responses were significantly influenced by inherited factors. Diminished generation of long-lived memory T cells in older individuals was mainly caused by increased T cell loss after the peak response while the expansion of antigen-specific T cells was not affected by age. Gene expression in activated CD4 T cells at the time of the peak response identified gene modules related to cell cycle regulation and DNA repair that correlated with the contraction phase of the T cell response and consequently the generation of long-lived memory cells. These data identify cell cycle regulatory mechanisms as targets to reduce T cell attrition in a vaccine response and to improve the generation of antigen-specific T cell memory, in particular in an older population.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in seniors (50-75) after exposure to Zostavax , time point 1D. Comment: S2 Table has Illumina probe IDs","Qi Q,Cavanagh MM,Le Saux S,Wagar LE,Mackey S,Hu J,Maecker H,Swan GE,Davis MM,Dekker CL,Tian L,Weyand CM,Goronzy JJ",27764254,HUMAN_GENE_SYMBOL,"DUSP11,EXOSC10,FAF2,PPIAL4A,PSMG2,TCAF1,TOX3",7,"DUSP11,EXOSC10,FAF2,PPIAL4A,PSMG2,TCAF1,TOX3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S2 Table,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/bin/pone.0160970.s002.docx,NA,NA,NA,NA
M41083,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 1d vs 0d in children (0.5-14y) after exposure to FluMist , time point 1D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"ATP9B,MFSD12,MSRB3,MTCH2,PCGF3,PRDM10,RORA,SASS6",8,"ATP9B,MFSD12,MSRB3,MTCH2,PCGF3,PRDM10,RORA,SASS6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/table/JIU079TB3/,NA,NA,NA,NA
M41170,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_1DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 1d vs 0d in children (0.5-14y) after exposure to FluMist , time point 1D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"CHTF8,CPT1A,DSCC1,FLVCR1,STK40,TRAPPC6B,URB1",7,"CHTF8,CPT1A,DSCC1,FLVCR1,STK40,TRAPPC6B,URB1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40903,FLUENZ,LA,INFLUENZA,PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_3DY_4DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3-4,D,3.5,03-17,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_3DY_4DY_DN,"Live attenuated influenza vaccines (LAIV) can prevent influenza illness and death in children. The absence of known correlates of protection induced by LAIV requires human studies of underlying mechanisms of vaccine-induced immunity, to further elucidate the immunological processes occurring. In this study, children scheduled for elective tonsillectomy were enrolled in a clinical trial to evaluate the immune response to LAIV, in order to compare T and B cell gene expression profiles. Twenty-three children (aged 3-17 years) were divided into 4 groups; unvaccinated controls, or vaccinated intranasally with LAIV at days 3-4, 6-7, and 12-15 before tonsillectomy. Total RNA extraction was performed on tonsillar tissue and high RNA quality was assured. The samples were then analyzed using a validated RT2 Profiler PCR Array containing 84 gene-specific primers involved in B and T cell activation, proliferation, differentiation, regulation and polarization. The gene expression after LAIV vaccination was subsequently compared to the controls. We observed that at d 3-4 post vaccination, 6 genes were down-regulated, namely APC, CD3G, FASLG, IL7, CD8A and TLR1. Meanwhile at 6-7 days post vaccination, 9 genes were significantly up-regulated, including RIPK2, TGFB1, MICB, SOCS1, IL2RA, MS4A1, PTPRC, IL2 and IL8. By days 12-15 the genes RIPK2, IL4, IL12B and TLR2 were overexpressed. RIPK2 was upregulated at all 3 time points. Our data suggests an overall proliferation, differentiation and regulation of B and T cells in the tonsils following LAIV, where the majority of genes were up-regulated at days 6-7 and normalized by days 12-15. These findings may provide a first step into defining future biomarkers or correlates of protection after LAIV immunization.","Genes down-regulated in blood 3d and 4d vs 0d in children (3-17) after exposure to Fluenz (LAIV) , time point 3D and 4D (merged) , administered i.n.","Panapasa JA,Cox RJ,Mohn KG,Aqrawi LA,Brokstad KA",26148331,HUMAN_GENE_SYMBOL,"APC,CD3G,CD8A,FASLG,IL7,TLR1",6,"APC,CD3G,CD8A,FASLG,IL7,TLR1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table III,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Supplemetary_t.doc,NA,NA,NA,NA
M41071,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D30,D,30,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 30d vs 0d in children (0.5-14y) after exposure to FluMist , time point 30D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"CBR1,HEMGN,LSMEM1,MGAM2,,SERPINA1,VPS41,WASHC2A,XCR1",9,"CBR1,HEMGN,LSMEM1,MGAM2,NFTA5,SERPINA1,VPS41,WASHC2A,XCR1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/table/JIU079TB3/,NA,NA,NA,NA
M41175,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D30,D,30,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_30DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 30d vs 0d in children (0.5-14y) after exposure to FluMist , time point 30D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"DSCC1,FLVCR1,IL3RA,PPP1R3F,PSMG3-AS1,TERF1",6,"DSCC1,FLVCR1,IL3RA,PPP1R3F,PSMG3-AS1,TERF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41134,FLUENZ,LA,INFLUENZA,PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_6DY_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D6-7,D,6.5,03-17,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/PANAPASA_BLOOD_FLUENZ_AGE_03_17YO_6DY_7DY_UP,"Live attenuated influenza vaccines (LAIV) can prevent influenza illness and death in children. The absence of known correlates of protection induced by LAIV requires human studies of underlying mechanisms of vaccine-induced immunity, to further elucidate the immunological processes occurring. In this study, children scheduled for elective tonsillectomy were enrolled in a clinical trial to evaluate the immune response to LAIV, in order to compare T and B cell gene expression profiles. Twenty-three children (aged 3-17 years) were divided into 4 groups; unvaccinated controls, or vaccinated intranasally with LAIV at days 3-4, 6-7, and 12-15 before tonsillectomy. Total RNA extraction was performed on tonsillar tissue and high RNA quality was assured. The samples were then analyzed using a validated RT2 Profiler PCR Array containing 84 gene-specific primers involved in B and T cell activation, proliferation, differentiation, regulation and polarization. The gene expression after LAIV vaccination was subsequently compared to the controls. We observed that at d 3-4 post vaccination, 6 genes were down-regulated, namely APC, CD3G, FASLG, IL7, CD8A and TLR1. Meanwhile at 6-7 days post vaccination, 9 genes were significantly up-regulated, including RIPK2, TGFB1, MICB, SOCS1, IL2RA, MS4A1, PTPRC, IL2 and IL8. By days 12-15 the genes RIPK2, IL4, IL12B and TLR2 were overexpressed. RIPK2 was upregulated at all 3 time points. Our data suggests an overall proliferation, differentiation and regulation of B and T cells in the tonsils following LAIV, where the majority of genes were up-regulated at days 6-7 and normalized by days 12-15. These findings may provide a first step into defining future biomarkers or correlates of protection after LAIV immunization.","Genes up-regulated in blood 6d/7d vs 0d in children (3-17) after exposure to Fluenz (LAIV) , time point 6D and 7D combined (identical signature) , administered i.n.","Panapasa JA,Cox RJ,Mohn KG,Aqrawi LA,Brokstad KA",26148331,HUMAN_GENE_SYMBOL,"IL2,IL2RA,CXCL8,MICB,MS4A1,PTPRC,RIPK2,SOCS1,TGFB1",9,"IL2,IL2RA,IL8,MICB,MS4A1,PTPRC,RIPK2,SOCS1,TGFB1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41026,FLUMIST,LA,INFLUENZA,COLE_BLOOD_FLUMIST_QUADRIVALENT_AGE_03_17YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,03-17,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/COLE_BLOOD_FLUMIST_QUADRIVALENT_AGE_03_17YO_7DY_UP,"BACKGROUND: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV). To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV. METHODS: Children 3-17years of age receiving quadrivalent influenza vaccine were enrolled. Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10days) following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log<sub>2</sub> transformed and compared between the two vaccine groups. RESULTS: Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in both groups. CONCLUSIONS: Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients. These results help to elucidate the immune response to influenza vaccines and may be related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.","Genes up-regulated in blood 7d vs 0d in children (3-17) after exposure to Flumist Quadrivalent (LAIV) , time point 7D. Comment: LAIV (live attenuated influenza vaccine)","Cole KS,Martin JM,Horne WT,Lin CJ,Nowalk MP,Alcorn JF,Zimmerman RK",29132989,HUMAN_GENE_SYMBOL,"CXCL10,IFI6,IFIT3,MX1,TNFSF10",5,"CXCL10,IFI6,IFIT3,MX1,TNFSF10",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_dnc_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41117,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_DN,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes down-regulated in blood 7d vs 0d in children (0.5-14y) after exposure to FluMist , time point 7D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"ASB16-AS1,BMF,FGFBP3,MYBPH,PPP1R8,RASGRP4,RSC1A1,TBC1D17",8,"ASB16-AS1,BMF,FGFBP3,MYBPH,PPP1R8,RASGRP4,RSC1A1,TBC1D17",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl File 1, Table 3",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713456/bin/elife-00299-supp1.xlsx,NA,NA,NA,NA
M41096,FLUMIST,LA,INFLUENZA,CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,05-14,"INFANT, ADOLESCENT",WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/CAO_BLOOD_FLUMIST_AGE_05_14YO_7DY_UP,"BACKGROUND: Live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) are effective for prevention of influenza virus infection in children, but the mechanisms associated with protection are not well defined. METHODS: We analyzed the differences in B-cell responses and transcriptional profiles in children aged 6 months to 14 years immunized with these 2 vaccines. RESULTS: LAIV elicited a significant increase in naive, memory, and transitional B cells on day 30 after vaccination, whereas TIV elicited an increased number of plasmablasts on day 7. Antibody titers against the 3 vaccine strains (H1N1, H3N2, and B) were significantly higher in the TIV group and correlated with number of antibody-secreting cells. Both vaccines induced overexpression of interferon (IFN)-signaling genes but with different kinetics. TIV induced expression of IFN genes on day 1 after vaccination in all age groups, and LAIV induced expression of IFN genes on day 7 after vaccination but only in children < 5 years old. IFN-related genes overexpressed in both vaccinated groups correlated with H3N2 antibody titers. CONCLUSIONS: These results suggest that LAIV and TIV induced significantly different B-cell responses in vaccinated children. Early induction of IFN appears to be important for development of antibody responses.","Genes up-regulated in blood 7d vs 0d in children (0.5-14y) after exposure to FluMist , time point 7D. Comment: ~80% of cohort were white, ~50/50 Female:male","Cao RG,Suarez NM,Obermoser G,Lopez SM,Flano E,Mertz SE,Albrecht RA,Garca-Sastre A,Mejias A,Xu H,Qin H,Blankenship D,Palucka K,Pascual V,Ramilo O",24495909,HUMAN_GENE_SYMBOL,"BCAS2,C11orf24,DSCC1,FASLG,ICA1,MASTL,OAS2",7,"BCAS2,C11orf24,DSCC1,FASLG,ICA1,MASTL,OAS2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,s4_bcl_d1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242433/bin/pone.0167488.s005.xlsx,NA,NA,NA,NA
M41161,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D10,D,10,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 10d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 10D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCC5,ABHD5,ABTB1,ADGRE3,ALKBH7,ALPL,APMAP,ARAP3,ARHGAP24,BTF3,GUCD1,FAXDC2,CA4,CAMK1D,CD46,CDK19,CPPED1,CYP27A1,DCAF12,DCAF6,DDX3X,EEF2,EIF3F,EIF3L,EIF4B,ELAPOR1,EPB42,ERGIC1,NIBAN1,FAM210B,FBXO7,FCER1A,FOXO1,GLS,GNG7,GPR162,H1-2,HECA,HSD17B11,ICAM3,IL1R2,IMPA2,IRS2,KBTBD7,LGALS3,LINC00265,,LMBRD1,LST1,MED25,MEF2D,MKRN1,MPP1,MPZL1,MYADM,NPL,ORM1,OSBP2,PABPC1,PABPC4,PACS1,PANX2,PCBP2,PDZK1IP1,PHOSPHO1,PI3,PINK1,PIP4K2A,PITHD1,PLVAP,PPM1F,PRDX2,PRKDC,PTOV1,PYGL,RFLNB,RPL22,RPL37A,RPS3,RPS4X,RPS6KA5,RUBCNL,SELENBP1,SERF2,SIGLEC10,SNCA,SNRPG,SORL1,SRRD,STAT5B,STMN3,TAGLN2,TBC1D14,TBL1X,TGM3,TMCO3,TNS1,TOPORS,TP53INP2,TSPAN5,TXNDC12,TMX4,UBE2H,USP10,VNN2,WLS,ZNF217",107,"ABCC5,ABHD5,ABTB1,ADGRE3,ALKBH7,ALPL,APMAP,ARAP3,ARHGAP24,BTF3,C22orf13,C5orf4,CA4,CAMK1D,CD46,CDK19,CPPED1,CYP27A1,DCAF12,DCAF6,DDX3X,EEF2,EIF3F,EIF3L,EIF4B,ELAPOR1,EPB42,ERGIC1,FAM129A,FAM210B,FBXO7,FCER1A,FOXO1,GLS,GNG7,GPR162,H1-2,HECA,HSD17B11,ICAM3,IL1R2,IMPA2,IRS2,KBTBD7,LGALS3,LINC00265,LINC00999,LMBRD1,LST1,MED25,MEF2D,MKRN1,MPP1,MPZL1,MYADM,NPL,ORM1,OSBP2,PABPC1,PABPC4,PACS1,PANX2,PCBP2,PDZK1IP1,PHOSPHO1,PI3,PINK1,PIP4K2A,PITHD1,PLVAP,PPM1F,PRDX2,PRKDC,PTOV1,PYGL,RFLNB,RPL22,RPL37A,RPS3,RPS4X,RPS6KA5,RUBCNL,SELENBP1,SERF2,SIGLEC10,SNCA,SNRPG,SORL1,SRRD,STAT5B,STMN3,TAGLN2,TBC1D14,TBL1X,TGM3,TMCO3,TNS1,TOPORS,TP53INP2,TSPAN5,TXNDC12,TXNDC13,UBE2H,USP10,VNN2,WLS,ZNF217",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6C (PO),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M41141,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D10,D,10,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_10DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 10d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 10D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCA1,ABI3,ACOT7,ACOT9,ACTA2,ADA,ADAP2,ADAR,AIM2,ANKRD22,AP5B1,APOBEC3F,APOL3,ASCL2,ASPRV1,ATF3,BATF2,BLVRA,BST2,BTN3A1,CALHM6,CASP1,CCNB2,CCR1,CD38,CDC20,CDCA5,CDCA7,CEACAM1,CENPM,CHMP5,CTSL,CUL1,CX3CR1,CYBB,CYSLTR1,RIGI,DDX60,DHRS9,DHX58,DRAP1,DUSP5,EIF2AK2,EPB41L3,EPSTI1,FAM8A1,FBXO6,FLVCR2,FRMD3,GADD45B,GALM,GBP1,GBP2,GBP5,GCH1,GNGT2,GPBAR1,HAVCR2,HELZ2,HERC5,HERC6,HES4,HLA-A,IDH2,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,JCHAIN,IL15,IL1RN,IRF7,IRF9,ISG15,LAP3,LGALS3BP,LGALS9,LHFPL2,LMO2,LY6E,MAD2L1BP,MCM4,MICB,MOV10,MT1A,MT1F,MT2A,MX1,MYL6B,MYOF,NAGA,NAGK,NAPA,NCOA7,NEXN,NME1,NMI,NPC2,NTNG2,NUB1,NUSAP1,OAS1,OAS2,OAS3,OASL,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PCK2,PHF11,PHGDH,PLAC8,PLSCR1,PML,PRF1,PSME2,PTTG1,RAB8A,REC8,RGL1,RGS12,RIN2,RIPK3,RNF135,RRAS,RSAD2,RTP4,SAMD4A,SAMD9L,SAT1,SCARB2,SCO2,SDF2L1,SEPTIN4,SERPING1,SHFL,SHISA5,SIL1,SLC27A3,SLC31A2,SNTB1,SOCS1,SP110,SP140,SPATS2L,SRBD1,SRC,STAT1,STAT2,STMN1,SUSD1,TAP1,TAP2,TDRD7,TENT5A,TIMM10,TK1,TLR7,TMEM123,TMEM140,TMEM268,TMEM62,TNFSF10,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM38,TRIM5,TUBG1,TXNDC11,TXNDC5,TYMS,UBA7,UBE2C,UBE2L6,UBE2S,UHRF1,VAMP5,WARS1,XAF1,ZBP1,ZC3HAV1",196,"ABCA1,ABI3,ACOT7,ACOT9,ACTA2,ADA,ADAP2,ADAR,AIM2,ANKRD22,AP5B1,APOBEC3F,APOL3,ASCL2,ASPRV1,ATF3,BATF2,BLVRA,BST2,BTN3A1,CALHM6,CASP1,CCNB2,CCR1,CD38,CDC20,CDCA5,CDCA7,CEACAM1,CENPM,CHMP5,CTSL,CUL1,CX3CR1,CYBB,CYSLTR1,DDX58,DDX60,DHRS9,DHX58,DRAP1,DUSP5,EIF2AK2,EPB41L3,EPSTI1,FAM8A1,FBXO6,FLVCR2,FRMD3,GADD45B,GALM,GBP1,GBP2,GBP5,GCH1,GNGT2,GPBAR1,HAVCR2,HELZ2,HERC5,HERC6,HES4,HLA-A,IDH2,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IGJ,IL15,IL1RN,IRF7,IRF9,ISG15,LAP3,LGALS3BP,LGALS9,LHFPL2,LMO2,LY6E,MAD2L1BP,MCM4,MICB,MOV10,MT1A,MT1F,MT2A,MX1,MYL6B,MYOF,NAGA,NAGK,NAPA,NCOA7,NEXN,NME1,NMI,NPC2,NTNG2,NUB1,NUSAP1,OAS1,OAS2,OAS3,OASL,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PCK2,PHF11,PHGDH,PLAC8,PLSCR1,PML,PRF1,PSME2,PTTG1,RAB8A,REC8,RGL1,RGS12,RIN2,RIPK3,RNF135,RRAS,RSAD2,RTP4,SAMD4A,SAMD9L,SAT1,SCARB2,SCO2,SDF2L1,SEPT4,SERPING1,SHFL,SHISA5,SIL1,SLC27A3,SLC31A2,SNTB1,SOCS1,SP110,SP140,SPATS2L,SRBD1,SRC,STAT1,STAT2,STMN1,SUSD1,TAP1,TAP2,TDRD7,TENT5A,TIMM10,TK1,TLR7,TMEM123,TMEM140,TMEM268,TMEM62,TNFSF10,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM38,TRIM5,TUBG1,TXNDC11,TXNDC5,TYMS,UBA7,UBE2C,UBE2L6,UBE2S,UHRF1,VAMP5,WARS,XAF1,ZBP1,ZC3HAV1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S2 Table,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987012/bin/pone.0160970.s002.docx,NA,NA,NA,NA
M41057,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D14,D,14,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 14d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 14D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ANAPC16,ATM,CD46,CMPK1,FIS1,HSD17B11,LMO2,NAP1L1,OSBPL8,P2RY13,RBM47,ZNF217",12,"ANAPC16,ATM,CD46,CMPK1,FIS1,HSD17B11,LMO2,NAP1L1,OSBPL8,P2RY13,RBM47,ZNF217",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6C (ID),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M40954,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D14,D,14,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_14DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 14d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 14D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ACOT7,ADA,MANF,CCNB2,CD19,CD38,CDC20,CDCA5,CDCA7,CDK12,CENPM,COBLL1,CRELD2,CXCR3,DUSP5,FAM30A,FCRL5,FKBP11,GLDC,HSP90B1,IDH2,ITM2C,JCHAIN,MAGED1,MCM4,MYDGF,MYL6B,MYO1F,MZB1,NME1,NUSAP1,PDIA4,PHGDH,POU2AF1,PPIB,PRDX4,PTTG1,RTCB,SDF2L1,SEC11C,SEL1L3,SIL1,SLC7A5,SP140,SRM,STMN1,TENT5C,TK1,TNFRSF13B,TNFRSF17,TRIM26,TUBG1,TXNDC11,TXNDC5,UBE2C,UBE2S,UHRF1,XBP1",58,"ACOT7,ADA,ARMET,CCNB2,CD19,CD38,CDC20,CDCA5,CDCA7,CDK12,CENPM,COBLL1,CRELD2,CXCR3,DUSP5,FAM30A,FCRL5,FKBP11,GLDC,HSP90B1,IDH2,ITM2C,JCHAIN,MAGED1,MCM4,MYDGF,MYL6B,MYO1F,MZB1,NME1,NUSAP1,PDIA4,PHGDH,POU2AF1,PPIB,PRDX4,PTTG1,RTCB,SDF2L1,SEC11C,SEL1L3,SIL1,SLC7A5,SP140,SRM,STMN1,TENT5C,TK1,TNFRSF13B,TNFRSF17,TRIM26,TUBG1,TXNDC11,TXNDC5,UBE2C,UBE2S,UHRF1,XBP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 1 (type b),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146700/bin/mmc1.doc,NA,NA,NA,NA
M40915,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D28,D,28,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 28d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 28D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ANAPC16,ATM,CMPK1,EIF3F,IL7R,ITM2A,NAP1L1,PABPC4,RPL22,RPLP0,SNRPN,SNURF,STMN3",13,"ANAPC16,ATM,CMPK1,EIF3F,IL7R,ITM2A,NAP1L1,PABPC4,RPL22,RPLP0,SNRPN,SNURF,STMN3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6C (ID),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832504/figure/F6/,NA,NA,NA,NA
M41063,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D28,D,28,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_28DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 28D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ANPEP,AP5B1,ASPRV1,TMEM121B,CSRNP1,EPSTI1,FCER1G,HK3,IL1RN,IRF9,LGALS9,LY6E,MX1,MYD88,MYO1F,NAGA,NTNG2,OASL,OGFR,P2RX1,PRAM1,RIPK3,RNF135,RNF31,SHISA5,SIGLEC5,SIL1",27,"ANPEP,AP5B1,ASPRV1,CECR6,CSRNP1,EPSTI1,FCER1G,HK3,IL1RN,IRF9,LGALS9,LY6E,MX1,MYD88,MYO1F,NAGA,NTNG2,OASL,OGFR,P2RX1,PRAM1,RIPK3,RNF135,RNF31,SHISA5,SIGLEC5,SIL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,NA,NA,NA,NA,NA,NA
M41147,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 3D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCC5,ABHD5,ADGRE3,ALKBH7,ALPL,ARAP3,BANK1,BCL6,C12orf57,CAMK1D,CBX7,CD46,CDK19,CPD,CPPED1,CREB5,DDX3X,EEF1A1,EEF1B2,EEF2,EIF3F,EIF3L,EIF4B,ELAPOR1,ERGIC1,HYCC2,ATOSA,FAU,FBL,FCRLA,FOXO1,GLS,GMCL1,GNG7,GPR162,GPR183,H1-2,H4C3,ICAM3,IMPA2,IRS2,KBTBD7,KLHDC2,KLHL2,LMBRD1,MPZL1,MYADM,NAMPT,NARF,NFXL1,NIBAN1,ORM1,OSBPL8,PABPC4,PI3,PPM1F,PRKDC,PTOV1,PYGL,RBM47,RFLNB,RPL13A,RPL18,RPL22,RPL27,RPL3,RPL30,RPL35A,RPL37A,RPL4,RPL5,RPLP0,RPS13,RPS14,RPS18,RPS20,RPS25,RPS27A,RPS29,RPS3,RPS4X,RPS5,RPS6,RPS6KA5,RPS8,RUBCNL,SEL1L3,SNHG29,SORL1,STAT5B,STMN3,TBC1D14,TBL1X,TMCO3,TOMM7,TOPORS,TP53INP2,TPT1,TXNDC12,TMX4,VNN2,WLS,ZNF217,ZNF281",104,"ABCC5,ABHD5,ADGRE3,ALKBH7,ALPL,ARAP3,BANK1,BCL6,C12orf57,CAMK1D,CBX7,CD46,CDK19,CPD,CPPED1,CREB5,DDX3X,EEF1A1,EEF1B2,EEF2,EIF3F,EIF3L,EIF4B,ELAPOR1,ERGIC1,FAM126B,FAM214A,FAU,FBL,FCRLA,FOXO1,GLS,GMCL1,GNG7,GPR162,GPR183,H1-2,H4C3,ICAM3,IMPA2,IRS2,KBTBD7,KLHDC2,KLHL2,LMBRD1,MPZL1,MYADM,NAMPT,NARF,NFXL1,NIBAN1,ORM1,OSBPL8,PABPC4,PI3,PPM1F,PRKDC,PTOV1,PYGL,RBM47,RFLNB,RPL13A,RPL18,RPL22,RPL27,RPL3,RPL30,RPL35A,RPL37A,RPL4,RPL5,RPLP0,RPS13,RPS14,RPS18,RPS20,RPS25,RPS27A,RPS29,RPS3,RPS4X,RPS5,RPS6,RPS6KA5,RPS8,RUBCNL,SEL1L3,SNHG29,SORL1,STAT5B,STMN3,TBC1D14,TBL1X,TMCO3,TOMM7,TOPORS,TP53INP2,TPT1,TXNDC12,TXNDC13,VNN2,WLS,ZNF217,ZNF281",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41142,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_3DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 3D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCA1,ABI3,ACOT9,ADA,ADA2,ADAP2,ADAR,AIM2,ALDH3B1,ANKFY1,AP5B1,APOBEC3A,APOBEC3F,ASCL2,ASPRV1,ATF5,BLVRA,BST2,BTN3A1,C1QA,C1QB,C3AR1,CAMK1,CASP1,CCR1,CD300C,CD68,CD86,CDKN1A,CDKN1C,CEACAM1,CNDP2,CSF1R,CSRNP1,CST3,CTSL,CX3CR1,CYBB,CYSLTR1,RIGI,DDX60,DHRS9,DHX58,DPYSL2,DRAP1,DUSP5,EIF2AK2,EPB41L3,EPSTI1,FBXO6,FCER1G,FCN1,FFAR2,FLVCR2,FRMPD1,GADD45B,GALM,GBP1,GIMAP8,GLMP,GNA15,GNGT2,GORASP1,GPBAR1,GRN,HAVCR2,HELZ2,HERC5,HERC6,HES4,HK3,HLA-A,HMOX1,IDH2,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IL1RN,IRF7,IRF9,ISG15,JUP,KCNMB1,KIAA0319L,LAP3,LGALS3BP,LGALS9,LHFPL2,LILRB1,LMO2,LY6E,LYPD2,MAD2L1BP,MAFB,MARCO,MICB,MOV10,MS4A7,MT1A,MT1F,MT2A,MX1,MX2,MYD88,MYOF,NAGA,NAGK,NAPA,NPC2,NRROS,NTNG2,NUB1,OAS1,OAS2,OAS3,OASL,OGFR,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PCK2,PHF11,PLAC8,PLAGL2,PLSCR1,PRAM1,PSME1,PSME2,PTGDS,RAB8A,RBCK1,REC8,RGL1,RGS12,RHBDF2,RIN2,RIPK3,RNF135,RNF31,RNH1,RRAS,RSAD2,RTP4,SAMD4A,SAMD9L,SCARB2,SCIMP,SCO2,SEPTIN4,SERPING1,SERTAD1,SHFL,SHISA5,SIDT2,SIGLEC5,SIL1,SLC27A3,SLC2A6,SLC37A2,SLC3A2,SMCO4,SNTB1,SORT1,SP110,SP140,SPATS2L,SRBD1,SRC,STAT1,STAT2,SUSD1,TAGLN,TAP1,TAP2,TCN2,TDRD7,TENT5A,TICAM1,TIMM10,TLR7,TMEM123,TMEM140,TMEM268,TMEM62,TNFSF10,TNFSF13B,TNS3,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM26,TRIM38,TRIM5,TTC38,TTYH3,TYMP,UBA7,UBE2L6,WARS1,XAF1,ZBP1,ZC3HAV1,ZFYVE26,ZNFX1",219,"ABCA1,ABI3,ACOT9,ADA,ADA2,ADAP2,ADAR,AIM2,ALDH3B1,ANKFY1,AP5B1,APOBEC3A,APOBEC3F,ASCL2,ASPRV1,ATF5,BLVRA,BST2,BTN3A1,C1QA,C1QB,C3AR1,CAMK1,CASP1,CCR1,CD300C,CD68,CD86,CDKN1A,CDKN1C,CEACAM1,CNDP2,CSF1R,CSRNP1,CST3,CTSL,CX3CR1,CYBB,CYSLTR1,DDX58,DDX60,DHRS9,DHX58,DPYSL2,DRAP1,DUSP5,EIF2AK2,EPB41L3,EPSTI1,FBXO6,FCER1G,FCN1,FFAR2,FLVCR2,FRMD2,GADD45B,GALM,GBP1,GIMAP8,GLMP,GNA15,GNGT2,GORASP1,GPBAR1,GRN,HAVCR2,HELZ2,HERC5,HERC6,HES4,HK3,HLA-A,HMOX1,IDH2,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IL1RN,IRF7,IRF9,ISG15,JUP,KCNMB1,KIAA0319L,LAP3,LGALS3BP,LGALS9,LHFPL2,LILRB1,LMO2,LY6E,LYPD2,MAD2L1BP,MAFB,MARCO,MICB,MOV10,MS4A7,MT1A,MT1F,MT2A,MX1,MX2,MYD88,MYOF,NAGA,NAGK,NAPA,NPC2,NRROS,NTNG2,NUB1,OAS1,OAS2,OAS3,OASL,OGFR,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PCK2,PHF11,PLAC8,PLAGL2,PLSCR1,PRAM1,PSME1,PSME2,PTGDS,RAB8A,RBCK1,REC8,RGL1,RGS12,RHBDF2,RIN2,RIPK3,RNF135,RNF31,RNH1,RRAS,RSAD2,RTP4,SAMD4A,SAMD9L,SCARB2,SCIMP,SCO2,SEPT4,SERPING1,SERTAD1,SHFL,SHISA5,SIDT2,SIGLEC5,SIL1,SLC27A3,SLC2A6,SLC37A2,SLC3A2,SMCO4,SNTB1,SORT1,SP110,SP140,SPATS2L,SRBD1,SRC,STAT1,STAT2,SUSD1,TAGLN,TAP1,TAP2,TCN2,TDRD7,TENT5A,TICAM1,TIMM10,TLR7,TMEM123,TMEM140,TMEM268,TMEM62,TNFSF10,TNFSF13B,TNS3,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM26,TRIM38,TRIM5,TTC38,TTYH3,TYMP,UBA7,UBE2L6,WARS,XAF1,ZBP1,ZC3HAV1,ZFYVE26,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 1 (type c),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146700/bin/mmc1.doc,NA,NA,NA,NA
M41001,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D60,D,60,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 60d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 60D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ADIPOR1,GUCD1,CDC14B,DCAF6,DMTN,DNAJB2,DPM2,FBXO7,FIS1,FKBP8,GUK1,GYPC,HAGH,HBQ1,MARCHF2,MBNL3,MYL4,OR2T35,PDZK1IP1,PHOSPHO1,PLEK2,PRDX2,PRDX5,ROPN1B,SERF2,SESN3,SRRD,ST6GALNAC4,STMN3,TGM2,TPRA1,TSPAN5,UBXN6,YBX3",34,"ADIPOR1,C22orf13,CDC14B,DCAF6,DMTN,DNAJB2,DPM2,FBXO7,FIS1,FKBP8,GUK1,GYPC,HAGH,HBQ1,MARCHF2,MBNL3,MYL4,OR2T35,PDZK1IP1,PHOSPHO1,PLEK2,PRDX2,PRDX5,ROPN1B,SERF2,SESN3,SRRD,ST6GALNAC4,STMN3,TGM2,TPRA1,TSPAN5,UBXN6,YBX3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M40985,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D60,D,60,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_60DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 60d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 60D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ADA2,ADAP2,ANKRD22,APOL3,BLVRA,CD163,CD74,CD86,CNDP2,CYBB,DHX58,EMILIN2,EPB41L3,FCN1,FLVCR2,HAVCR2,HK2,IFI30,IL15,KCNMB1,KYNU,LGALS9,LHFPL2,MICB,MS4A3,MYOF,NAGA,NAGK,NLRP3,NOD2,NPC2,NUB1,PLAGL2,RGS12,RTCB,SCARB2,SCIMP,SIL1,SLC37A2,SMCO4,SNTB1,SORT1,STAT2,SUSD1,TAP1,TLR7,TMEM268,TNS3,TTYH3,WARS1",50,"ADA2,ADAP2,ANKRD22,APOL3,BLVRA,CD163,CD74,CD86,CNDP2,CYBB,DHX58,EMILIN2,EPB41L3,FCN1,FLVCR2,HAVCR2,HK2,IFI30,IL15,KCNMB1,KYNU,LGALS9,LHFPL2,MICB,MS4A3,MYOF,NAGA,NAGK,NLRP3,NOD2,NPC2,NUB1,PLAGL2,RGS12,RTCB,SCARB2,SCIMP,SIL1,SLC37A2,SMCO4,SNTB1,SORT1,STAT2,SUSD1,TAP1,TLR7,TMEM268,TNS3,TTYH3,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475634/table/JIS546TB2/,NA,NA,NA,NA
M41086,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_DN,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes down-regulated in peripheral blood mononuclear cell 7d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 7D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCC5,ABHD5,ABTB1,ALKBH7,ALPL,ANAPC16,APMAP,ARAP3,ATM,BANK1,BCL6,BSG,BTF3,C12orf57,CA4,CAMK1D,CBX7,CD46,CDC34,CDK19,CMTM2,CPD,CPPED1,CREB5,CYP27A1,CYP4F3,DCAF12,DCAF6,DDX3X,DSC2,EEF1A1,EEF1B2,EEF2,EIF2S3,EIF3F,EIF3L,EIF4B,ELAPOR1,ADGRE3,AHSP,ERGIC1,HYCC2,NIBAN1,FAM210B,ATOSA,FAU,FBL,FBXO7,FCRLA,FIS1,FOXO1,GLRX5,GLS,GMCL1,GNG10,GNG7,GPR183,H1-2,H4C3,HECA,HINT1,HSD17B11,ICAM3,IL1R2,IL7R,IMPA2,IRS2,ITM2A,KBTBD7,KLHDC2,KLHL2,KLRB1,LDHB,LINC00265,,LMBRD1,LRRN3,MBP,MED25,MEF2D,MGAM,MKRN1,MME,MPZL1,MTURN,MYADM,NAP1L1,NARF,NELL2,NFXL1,NPL,ORM1,OSBP2,OSBPL8,PABPC1,PABPC4,PANX2,NAMPT,PCBP2,PDZK1IP1,PGLYRP1,PHOSPHO1,PI3,PINK1,PITHD1,PLEK2,PPBP,PPM1F,PRDX2,PRDX5,PRKDC,PTOV1,PYGL,QPCT,RFLNB,RGCC,RNF11,RPL10A,RPL11,RPL13,RPL13A,RPL14,RPL18,RPL22,RPL23,RPL27,RPL3,RPL30,RPL31,RPL35,RPL35A,RPL37A,RPL39,RPL4,RPL5,RPL7,RPL7A,RPL9,RPLP0,RPLP1,RPS10,RPS13,RPS14,RPS15A,RPS17,RPS18,RPS20,RPS23,RPS24,RPS25,RPS27A,RPS29,RPS3,RPS3A,RPS4X,RPS5,RPS6,RPS6KA5,RPS8,RUBCNL,S100A12,SERF2,SESN3,SGK1,SLC25A37,SLC4A1,SNHG29,SNRPN,SNURF,SORL1,SRRD,STAT5B,STMN3,TAGLN2,TBC1D14,TBL1X,TGM3,TMCO3,TOMM7,TOPORS,TP53INP2,TPT1,TSPAN5,TXNDC12,TMX4,UBE2H,USP10,VNN2,WLS,ZNF217,ZNF281",191,"ABCC5,ABHD5,ABTB1,ALKBH7,ALPL,ANAPC16,APMAP,ARAP3,ATM,BANK1,BCL6,BSG,BTF3,C12orf57,CA4,CAMK1D,CBX7,CD46,CDC34,CDK19,CMTM2,CPD,CPPED1,CREB5,CYP27A1,CYP4F3,DCAF12,DCAF6,DDX3X,DSC2,EEF1A1,EEF1B2,EEF2,EIF2S3,EIF3F,EIF3L,EIF4B,ELAPOR1,EMR3,ERAF,ERGIC1,FAM126B,FAM129A,FAM210B,FAM214A,FAU,FBL,FBXO7,FCRLA,FIS1,FOXO1,GLRX5,GLS,GMCL1,GNG10,GNG7,GPR183,H1-2,H4C3,HECA,HINT1,HSD17B11,ICAM3,IL1R2,IL7R,IMPA2,IRS2,ITM2A,KBTBD7,KLHDC2,KLHL2,KLRB1,LDHB,LINC00265,LINC00999,LMBRD1,LRRN3,MBP,MED25,MEF2D,MGAM,MKRN1,MME,MPZL1,MTURN,MYADM,NAP1L1,NARF,NELL2,NFXL1,NPL,ORM1,OSBP2,OSBPL8,PABPC1,PABPC4,PANX2,PBEF1,PCBP2,PDZK1IP1,PGLYRP1,PHOSPHO1,PI3,PINK1,PITHD1,PLEK2,PPBP,PPM1F,PRDX2,PRDX5,PRKDC,PTOV1,PYGL,QPCT,RFLNB,RGCC,RNF11,RPL10A,RPL11,RPL13,RPL13A,RPL14,RPL18,RPL22,RPL23,RPL27,RPL3,RPL30,RPL31,RPL35,RPL35A,RPL37A,RPL39,RPL4,RPL5,RPL7,RPL7A,RPL9,RPLP0,RPLP1,RPS10,RPS13,RPS14,RPS15A,RPS17,RPS18,RPS20,RPS23,RPS24,RPS25,RPS27A,RPS29,RPS3,RPS3A,RPS4X,RPS5,RPS6,RPS6KA5,RPS8,RUBCNL,S100A12,SERF2,SESN3,SGK1,SLC25A37,SLC4A1,SNHG29,SNRPN,SNURF,SORL1,SRRD,STAT5B,STMN3,TAGLN2,TBC1D14,TBL1X,TGM3,TMCO3,TOMM7,TOPORS,TP53INP2,TPT1,TSPAN5,TXNDC12,TXNDC13,UBE2H,USP10,VNN2,WLS,ZNF217,ZNF281",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41140,STAMARIL,LA,YF,GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GAUCHER_PBMC_YF_VAX_STAMARIL_UNKNOWN_AGE_7DY_UP,"Correlates of immune-mediated protection to most viral and cancer vaccines are still unknown. This impedes the development of novel vaccines to incurable diseases such as HIV and cancer. In this study, we have used functional genomics and polychromatic flow cytometry to define the signature of the immune response to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector arms of innate immunity, including complement, the inflammasome, and interferons, as well as adaptive immunity as shown by an early T cell response followed by a brisk and variable B cell response. Development of these responses is preceded, as demonstrated in three independent vaccination trials and in a novel in vitro system of primary immune responses (modular immune in vitro construct [MIMIC] system), by the coordinated up-regulation of transcripts for specific transcription factors, including STAT1, IRF7, and ETS2, which are upstream of the different effector arms of the immune response. These results clearly show that the immune response to a strong vaccine is preceded by coordinated induction of master transcription factors that lead to the development of a broad, polyfunctional, and persistent immune response that integrates all effector cells of the immune system.","Genes up-regulated in peripheral blood mononuclear cell 7d vs 0d in unknown after exposure to YF-Vax/Stamaril , time point 7D","Gaucher D,Therrien R,Kettaf N,Angermann BR,Boucher G,Filali-Mouhim A,Moser JM,Mehta RS,Drake DR 3rd,Castro E,Akondy R,Rinfret A,Yassine-Diab B,Said EA,Chouikh Y,Cameron MJ,Clum R,Kelvin D,Somogyi R,Greller LD,Balderas RS,Wilkinson P,Pantaleo G,Tartaglia J,Haddad EK,Skaly RP",19047440,HUMAN_GENE_SYMBOL,"ABCA1,ABI3,ACOT7,ACOT9,ACTA2,ADA,ADA2,ADAP2,ADAR,AIM2,ALDH3B1,ANKFY1,ANKRD22,AP5B1,APOBEC3A,APOBEC3F,APOL3,ASCL2,ASPRV1,ATF3,ATF5,CSRNP1,BATF2,BLVRA,BST2,BTN3A1,C1QA,C1QB,C3AR1,CAMK1,CAP1,CASP5,CCL8,CCNB2,CCR1,CD163,CD300C,CD36,CD38,CD68,CD74,CD86,CDC20,CDCA5,CDCA7,CDKN1A,CDKN1C,CEACAM1,CENPM,CHMP5,CMPK2,CNDP2,CSF1R,CST3,CTSL,CUL1,CX3CR1,CXCL10,CYBB,CYSLTR1,RIGI,DDX60,DHRS9,DHX58,DPYSL2,DRAP1,DUSP5,DYNLT1,EIF2AK2,EMILIN2,EPB41L3,EPSTI1,FAM8A1,FBXO6,FCER1G,FCN1,FFAR2,FLVCR2,FRMD3,GADD45B,GALM,GBP1,GBP2,GBP4,GBP5,GCH1,GIMAP8,GLMP,GNA15,GNGT2,GNLY,GORASP1,GPBAR1,GRN,GZMB,HAVCR2,HELZ2,HERC5,HERC6,HES4,HK3,HLA-A,HLA-DRB4,HMOX1,HSH2D,IDH2,IDO1,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IL15,IL1RN,IRF7,IRF9,ISG15,ISG20,JUP,KCNMB1,KIAA0319L,KIR2DL3,KIR2DL4,KYNU,LAG3,LAMP3,LAP3,LDLR,LGALS3BP,LGALS9,LHFPL2,LILRB1,LMO2,LY6E,MAD2L1BP,MAFB,MARCKS,MARCO,MCM4,MICB,MOB3C,MOV10,MS4A7,MT1A,MT1F,MT2A,MX1,MX2,MYD88,MYDGF,MYOF,NAGA,NAGK,NAPA,NCOA7,NEXN,NLRP3,NMI,NOD2,NPC2,NRROS,NT5C,NTNG2,NUB1,NUSAP1,OAS1,OAS2,OAS3,OASL,OGFR,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PATL1,PCK2,PHACTR2,PHF11,PIK3AP1,PLAC8,PLAGL2,PLSCR1,PML,PPM1K,PRAM1,PRF1,PSME1,PSME2,PTGDS,RAB8A,RBCK1,REC8,RGL1,RGS12,RHBDF2,RIN2,RIPK3,RNF135,RNF31,RNH1,RRAS,RSAD2,RTCB,RTP4,SAMD4A,SAMD9L,SAT1,SCARB2,SCIMP,SCO2,SDF2L1,SEPTIN4,SERPING1,SERTAD1,SHFL,SHISA5,SIDT2,SIGLEC5,SIL1,SLC27A3,SLC2A6,SLC37A2,SLC3A2,SLFN12,SMCO4,SNTB1,SOCS1,SORT1,SP110,SP140,SPATS2L,SQOR,SRBD1,SRC,SRM,STAB1,STAT1,STAT2,SUSD1,TAGLN,TAP1,TAP2,TCN2,TDRD7,TENT5A,TICAM1,TIMM10,TLR7,TMEM123,TMEM140,TMEM268,TMEM51,TMEM62,TNFAIP6,TNFSF10,TNFSF13B,TNS3,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM26,TRIM38,TRIM5,TTC21A,TTC38,TTYH3,TUBG1,TXNDC11,TYMP,UBA7,UBE2L6,UBE2S,UNC93B1,VAMP5,WARS1,XAF1,ZBP1,ZC3HAV1,ZFYVE26,ZNFX1",292,"ABCA1,ABI3,ACOT7,ACOT9,ACTA2,ADA,ADA2,ADAP2,ADAR,AIM2,ALDH3B1,ANKFY1,ANKRD22,AP5B1,APOBEC3A,APOBEC3F,APOL3,ASCL2,ASPRV1,ATF3,ATF5,AXUD1,BATF2,BLVRA,BST2,BTN3A1,C1QA,C1QB,C3AR1,CAMK1,CAP1,CASP5,CCL8,CCNB2,CCR1,CD163,CD300C,CD36,CD38,CD68,CD74,CD86,CDC20,CDCA5,CDCA7,CDKN1A,CDKN1C,CEACAM1,CENPM,CHMP5,CMPK2,CNDP2,CSF1R,CST3,CTSL,CUL1,CX3CR1,CXCL10,CYBB,CYSLTR1,DDX58,DDX60,DHRS9,DHX58,DPYSL2,DRAP1,DUSP5,DYNLT1,EIF2AK2,EMILIN2,EPB41L3,EPSTI1,FAM8A1,FBXO6,FCER1G,FCN1,FFAR2,FLVCR2,FRMD3,GADD45B,GALM,GBP1,GBP2,GBP4,GBP5,GCH1,GIMAP8,GLMP,GNA15,GNGT2,GNLY,GORASP1,GPBAR1,GRN,GZMB,HAVCR2,HELZ2,HERC5,HERC6,HES4,HK3,HLA-A,HLA-DRB4,HMOX1,HSH2D,IDH2,IDO1,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM3,IL15,IL1RN,IRF7,IRF9,ISG15,ISG20,JUP,KCNMB1,KIAA0319L,KIR2DL3,KIR2DL4,KYNU,LAG3,LAMP3,LAP3,LDLR,LGALS3BP,LGALS9,LHFPL2,LILRB1,LMO2,LY6E,MAD2L1BP,MAFB,MARCKS,MARCO,MCM4,MICB,MOB3C,MOV10,MS4A7,MT1A,MT1F,MT2A,MX1,MX2,MYD88,MYDGF,MYOF,NAGA,NAGK,NAPA,NCOA7,NEXN,NLRP3,NMI,NOD2,NPC2,NRROS,NT5C,NTNG2,NUB1,NUSAP1,OAS1,OAS2,OAS3,OASL,OGFR,OSBPL5,OTOF,PARP10,PARP12,PARP14,PARP9,PATL1,PCK2,PHACTR2,PHF11,PIK3AP1,PLAC8,PLAGL2,PLSCR1,PML,PPM1K,PRAM1,PRF1,PSME1,PSME2,PTGDS,RAB8A,RBCK1,REC8,RGL1,RGS12,RHBDF2,RIN2,RIPK3,RNF135,RNF31,RNH1,RRAS,RSAD2,RTCB,RTP4,SAMD4A,SAMD9L,SAT1,SCARB2,SCIMP,SCO2,SDF2L1,SEPTIN4,SERPING1,SERTAD1,SHFL,SHISA5,SIDT2,SIGLEC5,SIL1,SLC27A3,SLC2A6,SLC37A2,SLC3A2,SLFN12,SMCO4,SNTB1,SOCS1,SORT1,SP110,SP140,SPATS2L,SQOR,SRBD1,SRC,SRM,STAB1,STAT1,STAT2,SUSD1,TAGLN,TAP1,TAP2,TCN2,TDRD7,TENT5A,TICAM1,TIMM10,TLR7,TMEM123,TMEM140,TMEM268,TMEM51,TMEM62,TNFAIP6,TNFSF10,TNFSF13B,TNS3,TOR1B,TRAFD1,TRIM21,TRIM22,TRIM26,TRIM38,TRIM5,TTC21A,TTC38,TTYH3,TUBG1,TXNDC11,TYMP,UBA7,UBE2L6,UBE2S,UNC93B1,VAMP5,WARS,XAF1,ZBP1,ZC3HAV1,ZFYVE26,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723701/table/T1/,NA,NA,NA,NA
M40919,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_DN,PARASITE,DOWN,VACCINE,VAC ONLY,H18,H,18,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_DN,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes down-regulated in peripheral blood mononuclear cell 18hr vs 0hr in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 18H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"B2M,CARD10,CARD9,CCL18,CCL19,CCL20,CCL21,CCR4,CCR6,CCR7,CD83,FCGR3A,ICAM1,ICOS,IRAK1,IRAK1BP1,LAMP3,NOD1,PYCARD,TAP2,TICAM1",21,"B2M,CARD10,CARD9,CCL18,CCL19,CCL20,CCL21,CCR4,CCR6,CCR7,CD83,FCGR3A,ICAM1,ICOS,IRAK1,IRAK1BP1,LAMP3,NOD1,PYCARD,TAP2,TICAM1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5B,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962691/figure/F5/,NA,NA,NA,NA
M40884,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_UP,PARASITE,UP,VACCINE,VAC ONLY,H18,H,18,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell 18hr vs 0hr in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 18H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"ADAM11,ADAMDEC1,CARD14,CARD8,CCL17,CCL22,CCR1,CCR2,CCR3,CCR5,CD1A,CD1B,CD1C,CD1D,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD86,CDC42,DCP1B,DCSTAMP,DCTN2,FAS,FCER1A,FCER1G,FCGR1A,FCGR2A,FCGR2B,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,HSP90B1,ICAM2,IRAK2,IRAK4,LILRB4,MYD88,NOD2,RBMS1,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",57,"ADAM11,ADAMDEC1,CARD14,CARD8,CCL17,CCL22,CCR1,CCR2,CCR3,CCR5,CD1A,CD1B,CD1C,CD1D,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD86,CDC42,DCP1B,DCSTAMP,DCTN2,FAS,FCER1A,FCER1G,FCGR1A,FCGR2A,FCGR2B,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,HSP90B1,ICAM2,IRAK2,IRAK4,LILRB4,MYD88,NOD2,RBMS1,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40917,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_DN,PARASITE,DOWN,VACCINE,VAC ONLY,H192,H,192,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_DN,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes down-regulated in peripheral blood mononuclear cell 192h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 192H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"B2M,CCL17,CCL18,CCL19,CCL20,CCR1,CCR3,CCR6,CCR7,CD209,CD44,CD58,CD68,CD74,CD80,CD83,CDC42,DCSTAMP,FAS,FCER1A,FCER1G,FCGR2A,FCGR2B,FCGR3A,HSP90B1,ICAM1,ICOS,IRAK1,LAMP3,PYCARD,SOD2,TAP2,TICAM1",33,"B2M,CCL17,CCL18,CCL19,CCL20,CCR1,CCR3,CCR6,CCR7,CD209,CD44,CD58,CD68,CD74,CD80,CD83,CDC42,DCSTAMP,FAS,FCER1A,FCER1G,FCGR2A,FCGR2B,FCGR3A,HSP90B1,ICAM1,ICOS,IRAK1,LAMP3,PYCARD,SOD2,TAP2,TICAM1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig S7b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/sfig07/,NA,NA,NA,NA
M40886,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_UP,PARASITE,UP,VACCINE,VAC ONLY,H192,H,192,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_192HR_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell 192h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 192H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"ADAM11,ADAMDEC1,CARD10,CARD14,CARD8,CARD9,CCL16,CCL21,CCL22,CCR2,CCR4,CCR5,CD1A,CD1B,CD1C,CD1D,CD81,CD86,DCP1B,DCTN2,FCGR1A,HLA-DMA,HLA-DQB1,HLA-DRB1,ICAM2,IRAK1BP1,IRAK2,IRAK4,LILRB4,MYD88,NOD1,NOD2,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",45,"ADAM11,ADAMDEC1,CARD10,CARD14,CARD8,CARD9,CCL16,CCL21,CCL22,CCR2,CCR4,CCR5,CD1A,CD1B,CD1C,CD1D,CD81,CD86,DCP1B,DCTN2,FCGR1A,HLA-DMA,HLA-DQB1,HLA-DRB1,ICAM2,IRAK1BP1,IRAK2,IRAK4,LILRB4,MYD88,NOD1,NOD2,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40918,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_DN,PARASITE,DOWN,VACCINE,VAC ONLY,H336,H,336,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_DN,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes down-regulated in peripheral blood mononuclear cell 336h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 336H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"B2M,CARD14,CCL16,CCL18,CCL19,CCL20,CCL22,CCR3,CCR6,CCR7,CD1A,CD1B,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD83,DCSTAMP,FCGR2B,HSP90B1,ICAM1,ICOS,IRAK1,IRAK1BP1,LAMP3,PYCARD,SOD2,TAP2,TICAM1",32,"B2M,CARD14,CCL16,CCL18,CCL19,CCL20,CCL22,CCR3,CCR6,CCR7,CD1A,CD1B,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD83,DCSTAMP,FCGR2B,HSP90B1,ICAM1,ICOS,IRAK1,IRAK1BP1,LAMP3,PYCARD,SOD2,TAP2,TICAM1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139290/figure/F7/,NA,NA,NA,NA
M40885,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_UP,PARASITE,UP,VACCINE,VAC ONLY,H336,H,336,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_336HR_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell 336h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 336H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"ADAMDEC1,CARD10,CARD8,CARD9,CCL17,CCL21,CCR1,CCR2,CCR4,CCR5,CD1C,CD1D,CD86,CDC42,DCP1B,DCTN2,FAS,FCER1A,FCER1G,FCGR1A,FCGR2A,FCGR3A,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,ICAM2,IRAK2,IRAK4,LILRB4,MYD88,NOD1,NOD2,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",46,"ADAMDEC1,CARD10,CARD8,CARD9,CCL17,CCL21,CCR1,CCR2,CCR4,CCR5,CD1C,CD1D,CD86,CDC42,DCP1B,DCTN2,FAS,FCER1A,FCER1G,FCGR1A,FCGR2A,FCGR3A,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,ICAM2,IRAK2,IRAK4,LILRB4,MYD88,NOD1,NOD2,TAP1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40948,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_DN,PARASITE,DOWN,VACCINE,VAC ONLY,H48,H,48,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_DN,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes down-regulated in peripheral blood mononuclear cell 48h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 48H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"CARD10,CARD14,CARD9,CCL18,CCL19,CCR4,CCR6,CCR7,CD83,FCGR1A,ICOS,IRAK1,IRAK1BP1,IRAK4,LAMP3,PYCARD,TAP2,HSP90B1",18,"CARD10,CARD14,CARD9,CCL18,CCL19,CCR4,CCR6,CCR7,CD83,FCGR1A,ICOS,IRAK1,IRAK1BP1,IRAK4,LAMP3,PYCARD,TAP2,TRA1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485475/bin/NIHMS65741-supplement-2.pdf,NA,NA,NA,NA
M40883,LVS F TULARENSIS,LA,F TULARENSIS,FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_UP,PARASITE,UP,VACCINE,VAC ONLY,H48,H,48,22-54,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_48HR_UP,"The live vaccine strain (LVS) of Francisella tularensis is the only vaccine against tularemia available for humans, yet its mechanism of protection remains unclear. We probed human immunological responses to LVS vaccination with transcriptome analysis using PBMC samples from volunteers at time points pre- and post-vaccination. Gene modulation was highly uniform across all time points, implying commonality of vaccine responses. Principal components analysis revealed three highly distinct principal groupings: pre-vaccination (-144 h), early (+18 and +48 h), and late post-vaccination (+192 and +336 h). The most significant changes in gene expression occurred at early post-vaccination time points (<=48h), specifically in the induction of pro-inflammatory and innate immunity-related genes. Evidence supporting modulation of innate effector function, specifically antigen processing and presentation by dendritic cells, was especially apparent. Our data indicate that the LVS strain of F. tularensis invokes a strong early response upon vaccination. This pattern of gene regulation may provide insightful information regarding both vaccine efficacy and immunopathogenesis that may provide insight into infection with virulent strains of F. tularensis. Additionally, we obtained valuable information that should prove useful in evaluation of vaccine lots as well as efficacy testing of new anti-F. tularensis vaccines.","Genes up-regulated in peripheral blood mononuclear cell 48h vs 0h in adults (22-54) after exposure to F. tularensis vaccine LVS , time point 48H","Fuller CL,Brittingham KC,Porter MW,Hepburn MJ,Petitt PL,Pittman PR,Bavari S",17349694,HUMAN_GENE_SYMBOL,"ADAMDEC1,B2M,CARD8,CCL16,CCL17,CCL20,CCL21,CCL22,CCR1,CCR2,CCR3,CCR5,CD1A,CD1B,CD1C,CD1D,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD86,CDC42,DCP1B,DCSTAMP,DCTN2,FAS,FCER1A,FCER1G,FCGR2A,FCGR2B,FCGR3A,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,ICAM1,ICAM2,IRAK2,LILRB4,MYD88,NOD1,NOD2,SOD2,TAP1,TICAM1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",60,"ADAMDEC1,B2M,CARD8,CCL16,CCL17,CCL20,CCL21,CCL22,CCR1,CCR2,CCR3,CCR5,CD1A,CD1B,CD1C,CD1D,CD209,CD44,CD58,CD68,CD74,CD80,CD81,CD86,CDC42,DCP1B,DCSTAMP,DCTN2,FAS,FCER1A,FCER1G,FCGR2A,FCGR2B,FCGR3A,HLA-DMA,HLA-DMB,HLA-DQB1,HLA-DRB1,ICAM1,ICAM2,IRAK2,LILRB4,MYD88,NOD1,NOD2,SOD2,TAP1,TICAM1,TIRAP,TLR1,TLR10,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,TRAF6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41148,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_DN,VIRUS,DOWN,VACCINE,VAC VS CTRL,D14,D,14,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_DN,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes down-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 14D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"EPB42,LINC01002,OR2W3,PI3,SELENBP1,SLC4A1,TNS1",7,"EPB42,LINC01002,OR2W3,PI3,SELENBP1,SLC4A1,TNS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946173/bin/mmc1.docx,NA,NA,NA,NA
M41022,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_LIVE_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_UP,VIRUS,UP,VACCINE,VAC VS CTRL,D14,D,14,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_LIVE_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_14DY_UP,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes up-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 14D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"AASDHPPT,ABCB10,ABCD3,ABCE1,ACADM,ACTR6,ADD3,AEBP2,AGL,AGPAT5,AIMP1,AK3,,AKAP7,ALG13,AMIGO2,ANK3,ANKRD13C,ANKRD28,ANKRD36,ANKRD36B,ANP32E,AP5M1,API5,AQP3,ARAP2,ARFGEF2,ARGLU1,ARHGAP5,ARHGEF3,ARID4B,ARL5A,ARMC1,ARMCX3,ARMT1,ARPP19,ASF1A,ASNS,ATAD1,ATF1,ATF2,ATM,ATP11C,ATP5PO,ATP5PF,ATP8A1,ATR,B3GNT2,BAG4,BCL11B,BCLAF1,BDP1,BIRC2,BIRC3,BMI1,BORCS7,BTAF1,BTN3A3,BUB3,BZW1,C11orf58,C12orf29,KICS2,C12orf75,C21orf91,C2CD5,C2orf69,C3orf38,C4orf46,C5orf24,CAAP1,CACYBP,CAMK4,CAND1,CASP8AP2,CBLB,ZNG1A,ZNG1B,ZNG1C,ZNG1F,CBX3,CCAR1,CCDC117,CCDC14,CCDC91,CCNC,CCNG1,CCT2,CD28,CD2AP,CD3D,CD47,CD52,CD69,CDK17,CDKN2AIP,CEBPZ,CENPK,CEP120,CEP20,CEP57,CETN3,CFAP97,CHD2,CHML,CHMP2B,CHMP5,CHORDC1,CKS2,CLDND1,CLEC2B,CLEC2D,CLIP4,CLK1,CLK4,CLNS1A,CMC1,CMPK1,CMPK2,CMTR2,CNIH4,COG6,COMMD8,COPS2,COPS4,COX11,COX16,COX6C,COX7A2,COX7B,CPEB2,CPOX,CPSF6,CRBN,CREBL2,CREBZF,CRTAM,CRY1,CSE1L,CSGALNACT2,CUL4A,CUL5,CYCS,DAB1,DARS1,DBF4,DBI,DCAF13,DCK,DDHD1,DDHD2,DDX18,DDX3Y,DDX60,DEK,DENND1B,DENND4C,DENR,DERL1,DIPK1A,DIS3,DMXL1,DNAJB9,DNAJC10,DNAJC15,DNTTIP2,DOCK10,DPM1,DR1,DUT,EDRF1,EEA1,EED,EEF1B2,MICU2,EFR3A,EIF1AX,EIF1AY,EIF2AK3,EIF3E,EIF4A2,EIF4E,ELK3,ELL2,EPSTI1,ERAP1,ERAP2,ERH,ERLEC1,ESF1,ETNK1,EXOC5,EXOSC8,FABP5,PABIR2,FAM169A,FAM20B,FAM3C,FAM98B,FASTKD1,FBXO3,FBXW7,FDX1,FGFR1OP2,FIGNL1,FKBP11,FKBP3,FRA10AC1,FUBP1,FUBP3,FYN,G3BP1,GBP1,GBP3,GCH1,GCOM1,GET4,GIMAP2,GIMAP6,GLCCI1,GLOD4,GLS,GOLGA4,GOLGA6L9,GOLGA8A,GOLT1B,GORAB,GPBP1,GRPEL2,GSKIP,GZMA,GZMH,GZMK,HAT1,HAUS1,HDDC2,HERC5,HIBCH,HINT1,HLTF,HMGB1,HMGB2,HMGN3,HNRNPA2B1,HNRNPA3,HNRNPU,HS3ST3B1,HSP90AA1,HSP90B1,HSPA13,IFT25,HSPD1,HSPE1,HSPH1,IBTK,ICE1,ICE2,IER3IP1,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT5,IFT80,,IGHA1,IGHA2,IGHG1,IGHG2,IGHM,IGHV4-31,,IGKC,IGKV1-5,IGKV1D-33,IGKV3-20,IGKV3D-11,IGKV3D-15,IGKV4-1,,IGLJ3,IGLV1-44,IGLV2-18,IGLV2-23,IKZF5,IL6ST,IL7R,IMPA1,INTS13,ISG15,ITGA4,ITGAV,ITGB1,ITK,JCHAIN,JMY,BLTP1,KIF2A,KLF12,KLHL14,KLHL28,KLRC1,KLRC2,KLRC3,KLRF1,KLRK1,KPNA5,KRCC1,KRR1,KTN1,LANCL1,LDHB,LEF1,LEPROTL1,LMAN1,LRPPRC,LRRC40,LRRC8C,LSM14A,LSM5,LSM7,LTN1,LUC7L3,LY6E,LYZ,MAF,MALT1,MAN2A1,MANEA,MAP4K5,MATR3,MBNL2,MDFIC,MESD,METAP2,METTL5,MEX3C,MFSD6,MGAT2,MGAT4A,MIB1,MITD1,MOB1B,MOB4,MRFAP1L1,MRPL3,MRPL47,MRPS31,MS4A1,MTDH,MTHFD2,MTO1,MTR,MTREX,MTX3,MYBL1,MYSM1,MZB1,N4BP2,N4BP2L1,N4BP2L2,NAA15,NAA16,NAE1,NDUFA5,NDUFA6,NEMF,NFU1,NIFK,NIPSNAP3A,NME1,NME1-NME2,NME2,NOC3L,NOP58,NPM1,NR1D2,NR2C1,NRAS,NRIP1,NSA2,NSMCE4A,NUCB2,NUDCD2,NUDT21,NUP54,OAS1,OAS2,OAS3,OASL,OMA1,OSTC,OTUD6B,OXR1,PALM2AKAP2,PCGF5,PCLAF,PCMT1,PCMTD1,PCMTD2,PCNA,PCNP,PDHX,PDP1,PEX3,PGGT1B,PHC3,PHF10,PHF14,PHTF2,PIGK,PIGY,PIK3C2A,PLEKHA1,PM20D2,PMS1,PNISR,PNN,PNPT1,PNRC2,POLR2K,POLR2M,POU2AF1,PPA1,PPA2,PPIB,PPIG,PPIL3,PPIP5K2,PPP4R2,PPP4R3B,PPWD1,PRDX4,PREPL,PRKACB,PRKCI,PRNP,PRPF39,PRPF40A,PRPF4B,PRPS2,PRRC1,PSIP1,PSMA2,PSMA3,PSMA4,PSMC2,PSMC6,PSMD14,PTAR1,PTCH1,PXYLP1,PYROXD1,RAB11A,RABGAP1L,RABGGTB,RACGAP1,RALGAPA1,RAN,RANBP2,RANBP6,RAP1B,RAP2A,RAP2C,RASGRP1,RBAK,RBIS,RBM15,RBM25,RBM34,RBMX,RCBTB1,RCN2,RECQL,RFX7,RIOX2,RNF138,RNF6,RNFT1,RORA,RPAP3,RPL17,RPL22L1,RPL23,RPL24,RPL26,RPL34,RPL35,RPL36A,RPS17,RPS24,RPS27L,RPS6KB1,RPS7,RRAS2,RRM1,RRM2,RSAD2,RSL24D1,RTCA,RTP4,RWDD1,SACS,SAMD3,SAMD9,SAMD9L,SAR1B,SARNP,SBDS,SCOC,SDAD1,SEC11C,SEC23A,SEC24A,SEC31A,SEC61G,SEC63,SENP6,SERP1,SETDB2,SRSF1,SRSF11,SREK1,SREK1IP1,SRSF3,SGPP1,SGTB,SH2D1A,SHLD2,SHPRH,SLAMF7,SLC18B1,SLC25A32,SLC25A46,SLC30A1,SLC33A1,SLC35A3,SLC35B3,SLC38A1,SLC39A10,SLC39A6,SLC39A8,SLC44A1,SLC5A3,SLIRP,PRELID3B,SMARCA5,SMC3,SMC4,SMIM15,SNHG5,SNRPD2,SNRPE,SNRPG,SPIN1,SRP19,SRP72,SRP9,SRSF10,SSB,STAMBPL1,STK39,STT3B,SUB1,SUCLA2,SUCLG2,SUCO,SUN1,SYNCRIP,TAF1D,TAF9,TASOR,TASOR2,TBC1D4,TBL1XR1,TCERG1,TCF12,TDG,TENT2,TENT4B,TFAM,TFRC,TGFBR3,THAP5,THEMIS,THUMPD1,TIA1,TIFA,TIMM17A,TLK1,TM9SF3,TMED5,TMEM106B,TMEM123,TMEM126A,TMEM126B,TMEM135,TMEM161B,TMEM168,TMEM181,TMEM209,TMEM243,TMEM263,TMEM64,TMEM87B,TMF1,TMX1,TMX3,TNFAIP8,TNFRSF17,TOMM5,TOMM7,TPD52,TPP2,TRA2B,TRAM1,TRAT1,TRIM22,TRMT11,TRMT13,TSNAX,TTC14,EMC2,SKIC3,TWF1,TXNDC15,TXNDC5,TYMS,U2SURP,UAP1,UBA2,UBA6,UBE2Q2,UBE3A,UBR1,UBR3,UBXN4,UFL1,UPF3A,UQCRB,UQCRH,UQCRQ,URI1,USO1,USP1,USP16,USP47,USP53,UTP23,VBP1,VEZT,VPS54,VTA1,WWP1,XAF1,XPOT,YTHDC2,YWHAQ,ZBTB1,ZBTB11,ZBTB38,ZBTB41,ZBTB8OS,ZC3H15,ZCCHC10,ZCCHC7,ZDHHC20,ZFP62,ZMYM2,ZMYM6,ZNF107,ZNF146,ZNF207,ZNF22,ZBTB21,ZNF451,ZNF518A,ZNF600,ZNF639,ZNF644,ZNF655,ZNF721,ZNF770,ZNF83,ZNHIT3,ZNHIT6,ZRANB2,ZWINT,ZZZ3",691,"AASDHPPT,ABCB10,ABCD3,ABCE1,ACADM,ACTR6,ADD3,AEBP2,AGL,AGPAT5,AIMP1,AK3,AKAP2,AKAP7,ALG13,AMIGO2,ANK3,ANKRD13C,ANKRD28,ANKRD36,ANKRD36B,ANP32E,AP5M1,API5,AQP3,ARAP2,ARFGEF2,ARGLU1,ARHGAP5,ARHGEF3,ARID4B,ARL5A,ARMC1,ARMCX3,ARMT1,ARPP19,ASF1A,ASNS,ATAD1,ATF1,ATF2,ATM,ATP11C,ATP5O,ATP5PF,ATP8A1,ATR,B3GNT2,BAG4,BCL11B,BCLAF1,BDP1,BIRC2,BIRC3,BMI1,BORCS7,BTAF1,BTN3A3,BUB3,BZW1,C11orf58,C12orf29,C12orf66,C12orf75,C21orf91,C2CD5,C2orf69,C3orf38,C4orf46,C5orf24,CAAP1,CACYBP,CAMK4,CAND1,CASP8AP2,CBLB,CBWD1,CBWD2,CBWD3,CBWD6,CBX3,CCAR1,CCDC117,CCDC14,CCDC91,CCNC,CCNG1,CCT2,CD28,CD2AP,CD3D,CD47,CD52,CD69,CDK17,CDKN2AIP,CEBPZ,CENPK,CEP120,CEP20,CEP57,CETN3,CFAP97,CHD2,CHML,CHMP2B,CHMP5,CHORDC1,CKS2,CLDND1,CLEC2B,CLEC2D,CLIP4,CLK1,CLK4,CLNS1A,CMC1,CMPK1,CMPK2,CMTR2,CNIH4,COG6,COMMD8,COPS2,COPS4,COX11,COX16,COX6C,COX7A2,COX7B,CPEB2,CPOX,CPSF6,CRBN,CREBL2,CREBZF,CRTAM,CRY1,CSE1L,CSGALNACT2,CUL4A,CUL5,CYCS,DAB1,DARS1,DBF4,DBI,DCAF13,DCK,DDHD1,DDHD2,DDX18,DDX3Y,DDX60,DEK,DENND1B,DENND4C,DENR,DERL1,DIPK1A,DIS3,DMXL1,DNAJB9,DNAJC10,DNAJC15,DNTTIP2,DOCK10,DPM1,DR1,DUT,EDRF1,EEA1,EED,EEF1B2,EFHA1,EFR3A,EIF1AX,EIF1AY,EIF2AK3,EIF3E,EIF4A2,EIF4E,ELK3,ELL2,EPSTI1,ERAP1,ERAP2,ERH,ERLEC1,ESF1,ETNK1,EXOC5,EXOSC8,FABP5,FAM122B,FAM169A,FAM20B,FAM3C,FAM98B,FASTKD1,FBXO3,FBXW7,FDX1,FGFR1OP2,FIGNL1,FKBP11,FKBP3,FRA10AC1,FUBP1,FUBP3,FYN,G3BP1,GBP1,GBP3,GCH1,GCOM1,GET4,GIMAP2,GIMAP6,GLCCI1,GLOD4,GLS,GOLGA4,GOLGA6L9,GOLGA8A,GOLT1B,GORAB,GPBP1,GRPEL2,GSKIP,GZMA,GZMH,GZMK,HAT1,HAUS1,HDDC2,HERC5,HIBCH,HINT1,HLTF,HMGB1,HMGB2,HMGN3,HNRNPA2B1,HNRNPA3,HNRNPU,HS3ST3B1,HSP90AA1,HSP90B1,HSPA13,HSPB11,HSPD1,HSPE1,HSPH1,IBTK,ICE1,ICE2,IER3IP1,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT5,IFT80,IGH,IGHA1,IGHA2,IGHG1,IGHG2,IGHM,IGHV4-31,IGK,IGKC,IGKV1-5,IGKV1D-33,IGKV3-20,IGKV3D-11,IGKV3D-15,IGKV4-1,IGL,IGLJ3,IGLV1-44,IGLV2-18,IGLV2-23,IKZF5,IL6ST,IL7R,IMPA1,INTS13,ISG15,ITGA4,ITGAV,ITGB1,ITK,JCHAIN,JMY,KIAA1109,KIF2A,KLF12,KLHL14,KLHL28,KLRC1,KLRC2,KLRC3,KLRF1,KLRK1,KPNA5,KRCC1,KRR1,KTN1,LANCL1,LDHB,LEF1,LEPROTL1,LMAN1,LRPPRC,LRRC40,LRRC8C,LSM14A,LSM5,LSM7,LTN1,LUC7L3,LY6E,LYZ,MAF,MALT1,MAN2A1,MANEA,MAP4K5,MATR3,MBNL2,MDFIC,MESD,METAP2,METTL5,MEX3C,MFSD6,MGAT2,MGAT4A,MIB1,MITD1,MOB1B,MOB4,MRFAP1L1,MRPL3,MRPL47,MRPS31,MS4A1,MTDH,MTHFD2,MTO1,MTR,MTREX,MTX3,MYBL1,MYSM1,MZB1,N4BP2,N4BP2L1,N4BP2L2,NAA15,NAA16,NAE1,NDUFA5,NDUFA6,NEMF,NFU1,NIFK,NIPSNAP3A,NME1,NME1-NME2,NME2,NOC3L,NOP58,NPM1,NR1D2,NR2C1,NRAS,NRIP1,NSA2,NSMCE4A,NUCB2,NUDCD2,NUDT21,NUP54,OAS1,OAS2,OAS3,OASL,OMA1,OSTC,OTUD6B,OXR1,PALM2AKAP2,PCGF5,PCLAF,PCMT1,PCMTD1,PCMTD2,PCNA,PCNP,PDHX,PDP1,PEX3,PGGT1B,PHC3,PHF10,PHF14,PHTF2,PIGK,PIGY,PIK3C2A,PLEKHA1,PM20D2,PMS1,PNISR,PNN,PNPT1,PNRC2,POLR2K,POLR2M,POU2AF1,PPA1,PPA2,PPIB,PPIG,PPIL3,PPIP5K2,PPP4R2,PPP4R3B,PPWD1,PRDX4,PREPL,PRKACB,PRKCI,PRNP,PRPF39,PRPF40A,PRPF4B,PRPS2,PRRC1,PSIP1,PSMA2,PSMA3,PSMA4,PSMC2,PSMC6,PSMD14,PTAR1,PTCH1,PXYLP1,PYROXD1,RAB11A,RABGAP1L,RABGGTB,RACGAP1,RALGAPA1,RAN,RANBP2,RANBP6,RAP1B,RAP2A,RAP2C,RASGRP1,RBAK,RBIS,RBM15,RBM25,RBM34,RBMX,RCBTB1,RCN2,RECQL,RFX7,RIOX2,RNF138,RNF6,RNFT1,RORA,RPAP3,RPL17,RPL22L1,RPL23,RPL24,RPL26,RPL34,RPL35,RPL36A,RPS17,RPS24,RPS27L,RPS6KB1,RPS7,RRAS2,RRM1,RRM2,RSAD2,RSL24D1,RTCA,RTP4,RWDD1,SACS,SAMD3,SAMD9,SAMD9L,SAR1B,SARNP,SBDS,SCOC,SDAD1,SEC11C,SEC23A,SEC24A,SEC31A,SEC61G,SEC63,SENP6,SERP1,SETDB2,SFRS1,SFRS11,SFRS12,SFRS12IP1,SFRS3,SGPP1,SGTB,SH2D1A,SHLD2,SHPRH,SLAMF7,SLC18B1,SLC25A32,SLC25A46,SLC30A1,SLC33A1,SLC35A3,SLC35B3,SLC38A1,SLC39A10,SLC39A6,SLC39A8,SLC44A1,SLC5A3,SLIRP,SLMO2,SMARCA5,SMC3,SMC4,SMIM15,SNHG5,SNRPD2,SNRPE,SNRPG,SPIN1,SRP19,SRP72,SRP9,SRSF10,SSB,STAMBPL1,STK39,STT3B,SUB1,SUCLA2,SUCLG2,SUCO,SUN1,SYNCRIP,TAF1D,TAF9,TASOR,TASOR2,TBC1D4,TBL1XR1,TCERG1,TCF12,TDG,TENT2,TENT4B,TFAM,TFRC,TGFBR3,THAP5,THEMIS,THUMPD1,TIA1,TIFA,TIMM17A,TLK1,TM9SF3,TMED5,TMEM106B,TMEM123,TMEM126A,TMEM126B,TMEM135,TMEM161B,TMEM168,TMEM181,TMEM209,TMEM243,TMEM263,TMEM64,TMEM87B,TMF1,TMX1,TMX3,TNFAIP8,TNFRSF17,TOMM5,TOMM7,TPD52,TPP2,TRA2B,TRAM1,TRAT1,TRIM22,TRMT11,TRMT13,TSNAX,TTC14,TTC35,TTC37,TWF1,TXNDC15,TXNDC5,TYMS,U2SURP,UAP1,UBA2,UBA6,UBE2Q2,UBE3A,UBR1,UBR3,UBXN4,UFL1,UPF3A,UQCRB,UQCRH,UQCRQ,URI1,USO1,USP1,USP16,USP47,USP53,UTP23,VBP1,VEZT,VPS54,VTA1,WWP1,XAF1,XPOT,YTHDC2,YWHAQ,ZBTB1,ZBTB11,ZBTB38,ZBTB41,ZBTB8OS,ZC3H15,ZCCHC10,ZCCHC7,ZDHHC20,ZFP62,ZMYM2,ZMYM6,ZNF107,ZNF146,ZNF207,ZNF22,ZNF295,ZNF451,ZNF518A,ZNF600,ZNF639,ZNF644,ZNF655,ZNF721,ZNF770,ZNF83,ZNHIT3,ZNHIT6,ZRANB2,ZWINT,ZZZ3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table S3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/bin/NIHMS784868-supplement-Supplemental_Text_and_Figures.pdf,NA,NA,NA,NA
M40951,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_DN,VIRUS,DOWN,VACCINE,VAC VS CTRL,D2,D,2,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_DN,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes down-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 2D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"ABAT,BRI3BP,CAMK1D,CD24,CEP68,CXCL8,DIP2A,DPY19L3,FCER1A,FCHO2,FRY,GPR27,GRAMD1C,H2AZ2,IGF1R,IRS2,ITM2A,KBTBD7,LINC01215,PDZD8,PIGX,RFLNB,RNF141,RRAGD,RUNX2,SGK1,SH3YL1,STEAP4,STXBP5,THBD,TMCC3,TP53INP1",32,"ABAT,BRI3BP,CAMK1D,CD24,CEP68,CXCL8,DIP2A,DPY19L3,FCER1A,FCHO2,FRY,GPR27,GRAMD1C,H2AZ2,IGF1R,IRS2,ITM2A,KBTBD7,LINC01215,PDZD8,PIGX,RFLNB,RNF141,RRAGD,RUNX2,SGK1,SH3YL1,STEAP4,STXBP5,THBD,TMCC3,TP53INP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946173/bin/mmc1.docx,NA,NA,NA,NA
M41139,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP,VIRUS,UP,VACCINE,VAC VS CTRL,D2,D,2,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_2DY_UP,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes up-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 2D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"ANKRD22,APOBEC3A,,APOL6,ATRIP,BATF2,BLVRA,BST2,CALHM6,CCL2,CCL8,CD274,CEACAM1,CMTR1,CXCL10,RIGI,DDX60,DDX60L,DOCK4,DRAP1,EIF2AK2,EPSTI1,ETV7,FBXO6,FRMD3,GALM,GBP1,GBP4,GBP5,GCH1,HELZ2,HERC5,HERC6,HES4,IFI16,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IL1RN,IRF1-AS1,IRF7,ISG15,ISG20,KIAA0319L,LAMP3,LAP3,LGALS9,LIPA,,LY6E,MAFB,MOV10,MS4A4A,MT1H,MT1HL1,MT1X,MT2A,MVB12A,MX1,MX2,NCOA7,NEXN,NTNG2,NUB1,OAS1,OAS2,OAS3,OASL,PARP12,PARP14,PARP9,PLSCR1,PML,PNPT1,RIN2,RNF213,RSAD2,RTP4,SAMD4A,SAMD9,SAMD9L,SCO2,SERPING1,SHFL,SIGLEC1,SOCS1,SP140,SPATS2L,SRGAP2,SRGAP2B,SRGAP2C,STAT1,STAT2,TDRD7,TENT5A,TFEC,TMEM268,TNFAIP6,TNFSF10,TNFSF13B,TOR1B,TREX1,TRIM22,TRIM5,TTC21A,UBE2L6,USP18,WARS1,XAF1,ZBP1,ZC3HAV1,ZCCHC2",121,"ANKRD22,APOBEC3A,APOBEC3A_B,APOL6,ATRIP,BATF2,BLVRA,BST2,CALHM6,CCL2,CCL8,CD274,CEACAM1,CMTR1,CXCL10,DDX58,DDX60,DDX60L,DOCK4,DRAP1,EIF2AK2,EPSTI1,ETV7,FBXO6,FRMD3,GALM,GBP1,GBP4,GBP5,GCH1,HELZ2,HERC5,HERC6,HES4,IFI16,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IL1RN,IRF1-AS1,IRF7,ISG15,ISG20,KIAA0319L,LAMP3,LAP3,LGALS9,LIPA,LOC101926887,LY6E,MAFB,MOV10,MS4A4A,MT1H,MT1HL1,MT1X,MT2A,MVB12A,MX1,MX2,NCOA7,NEXN,NTNG2,NUB1,OAS1,OAS2,OAS3,OASL,PARP12,PARP14,PARP9,PLSCR1,PML,PNPT1,RIN2,RNF213,RSAD2,RTP4,SAMD4A,SAMD9,SAMD9L,SCO2,SERPING1,SHFL,SIGLEC1,SOCS1,SP140,SPATS2L,SRGAP2,SRGAP2B,SRGAP2C,STAT1,STAT2,TDRD7,TENT5A,TFEC,TMEM268,TNFAIP6,TNFSF10,TNFSF13B,TOR1B,TREX1,TRIM22,TRIM5,TTC21A,UBE2L6,USP18,WARS,XAF1,ZBP1,ZC3HAV1,ZCCHC2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table S3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/bin/NIHMS784868-supplement-Supplemental_Text_and_Figures.pdf,NA,NA,NA,NA
M41029,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_DN,VIRUS,DOWN,VACCINE,VAC VS CTRL,D7,D,7,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_DN,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes down-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 7D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"CPA3,EPB42,IGF1R,MARCHF8,PI3,RFLNB,SLC4A1",7,"CPA3,EPB42,IGF1R,MARCHF8,PI3,RFLNB,SLC4A1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946173/bin/mmc1.docx,NA,NA,NA,NA
M41023,TC-83,LA,VEEV,ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP,VIRUS,UP,VACCINE,VAC VS CTRL,D7,D,7,23-48,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ERWIN_COHEN_BLOOD_VACCINE_TC_83_AGE_23_48YO_VACCINATED_VS_CONTROL_7DY_UP,"Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naive individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.","Genes up-regulated in blood vaccinated vs control in adults (23-48) after exposure to Live attenuated vaccine TC-83 , time point 7D","Erwin-Cohen RA,Porter AI,Pittman PR,Rossi CA,DaSilva L",27870591,HUMAN_GENE_SYMBOL,"APOL6,BLVRA,CCR1,CMPK2,CXCL10,RIGI,DDX60,DDX60L,EIF2AK2,EPSTI1,ETV7,FBXO6,GBP1,HERC5,HERC6,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IL1RN,IRF7,ISG15,LAMP3,LAP3,LY6E,MAFB,MS4A4A,MT2A,MX1,MX2,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP14,PARP9,PLSCR1,PNPT1,PPM1K,RIN2,RNF213,RSAD2,RTP4,SAMD9,SAMD9L,SCO2,SERPING1,SHISA5,SIGLEC1,SPATS2L,STAT2,TNFAIP6,TNFSF10,TOR1B,TRIM14,TRIM22,TRIM5,UBE2L6,USP18,XAF1,ZBP1,ZCCHC2",72,"APOL6,BLVRA,CCR1,CMPK2,CXCL10,DDX58,DDX60,DDX60L,EIF2AK2,EPSTI1,ETV7,FBXO6,GBP1,HERC5,HERC6,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IL1RN,IRF7,ISG15,LAMP3,LAP3,LY6E,MAFB,MS4A4A,MT2A,MX1,MX2,NEXN,OAS1,OAS2,OAS3,OASL,PARP12,PARP14,PARP9,PLSCR1,PNPT1,PPM1K,RIN2,RNF213,RSAD2,RTP4,SAMD9,SAMD9L,SCO2,SERPING1,SHISA5,SIGLEC1,SPATS2L,STAT2,TNFAIP6,TNFSF10,TOR1B,TRIM14,TRIM22,TRIM5,UBE2L6,USP18,XAF1,ZBP1,ZCCHC2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5b,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946932/figure/F5/,NA,NA,NA,NA
M40977,DRYVAX,LA,SMALLPOX,KENNEDY_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_DN,VIRUS,UP,VACCINE,VAC VS CTRL,M48,M,48,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KENNEDY_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_DN,"Despite its eradication over 30 years ago, smallpox (as well as other orthopox viruses) remains a pathogen of interest both in terms of biodefense and for its use as a vector for vaccines and immunotherapies. Here we describe the application of mRNA-Seq transcriptome profiling to understanding immune responses in smallpox vaccine recipients. Contrary to other studies examining gene expression in virally infected cell lines, we utilized a mixed population of peripheral blood mononuclear cells in order to capture the essential intercellular interactions that occur in vivo, and would otherwise be lost, using single cell lines or isolated primary cell subsets. In this mixed cell population we were able to detect expression of all annotated vaccinia genes. On the host side, a number of genes encoding cytokines, chemokines, complement factors and intracellular signaling molecules were downregulated upon viral infection, whereas genes encoding histone proteins and the interferon response were upregulated. We also identified a small number of genes that exhibited significantly different expression profiles in subjects with robust humoral immunity compared with those with weaker humoral responses. Our results provide evidence that differential gene regulation patterns may be at work in individuals with robust humoral immunity compared with those with weaker humoral immune responses.","Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (18-40) after exposure to Dryvax , time point 1 to 48M. Comment: top differentially expressed genes, more avail in Suppl Materials","Kennedy RB,Oberg AL,Ovsyannikova IG,Haralambieva IH,Grill D,Poland GA",23594957,HUMAN_GENE_SYMBOL,"ADORA3,APOC2,ARNT2,ARPIN,BMP3,C4BPB,CD14,CHST6,CXCL6,DCANP1,GPBAR1,GPR84,HAMP,HNMT,IL18,KCNJ10,LAMP5,MFAP5,MPEG1,MYEOV,NDP,OPRL1,PDCD1LG2,PDPN,PRSS50,PTGES,S100A8,S100A9,SEMA3A,SIRPB2,SIRPD,SYT15,THBS1,TREML4,XCR1",35,"ADORA3,APOC2,ARNT2,ARPIN,BMP3,C4BPB,CD14,CHST6,CXCL6,DCANP1,GPBAR1,GPR84,HAMP,HNMT,IL18,KCNJ10,LAMP5,MFAP5,MPEG1,MYEOV,NDP,ORL1,PDCD1LG2,PDPN,PRSS50,PTGES,S100A8,S100A9,SEMA3A,SIRPB2,SIRPD,SYT15,THBS1,TREML4,XCR1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Additional File 2, Tab B PPD",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654906/bin/1755-8794-2-10-S2.xls,NA,NA,NA,NA
M41188,DRYVAX,LA,SMALLPOX,KENNEDY_PBMC_DRYVAX_AGE_18_50YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_UP,VIRUS,UP,VACCINE,VAC VS CTRL,M48,M,48,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KENNEDY_PBMC_DRYVAX_AGE_18_50YO_STIMULATED_VS_UNSTIMULATED_1_TO_48MO_TOP_DEG_UP,"Despite its eradication over 30 years ago, smallpox (as well as other orthopox viruses) remains a pathogen of interest both in terms of biodefense and for its use as a vector for vaccines and immunotherapies. Here we describe the application of mRNA-Seq transcriptome profiling to understanding immune responses in smallpox vaccine recipients. Contrary to other studies examining gene expression in virally infected cell lines, we utilized a mixed population of peripheral blood mononuclear cells in order to capture the essential intercellular interactions that occur in vivo, and would otherwise be lost, using single cell lines or isolated primary cell subsets. In this mixed cell population we were able to detect expression of all annotated vaccinia genes. On the host side, a number of genes encoding cytokines, chemokines, complement factors and intracellular signaling molecules were downregulated upon viral infection, whereas genes encoding histone proteins and the interferon response were upregulated. We also identified a small number of genes that exhibited significantly different expression profiles in subjects with robust humoral immunity compared with those with weaker humoral responses. Our results provide evidence that differential gene regulation patterns may be at work in individuals with robust humoral immunity compared with those with weaker humoral immune responses.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (18-40) after exposure to Dryvax , time point 1 to 48M. Comment: top differentially expressed genes, more avail in Suppl Materials","Kennedy RB,Oberg AL,Ovsyannikova IG,Haralambieva IH,Grill D,Poland GA",23594957,HUMAN_GENE_SYMBOL,"CH25H,EPHB3,H1-3,H1-4,H2AC17,H2AC20,H2AC8,H2BC15,H2BC8,H4C16,H4C3,H4C5,H4C8,HSPA4L,HSPA6,IFNB1,IFNG,IL3,LVRN,RNF152,TNFRSF10D,WFIKKN1",22,"CH25H,EPHB3,H1-3,H1-4,H2AC17,H2AC20,H2AC8,H2BC15,H2BC8,H4-16,H4C3,H4C5,H4C8,HSPA4L,HSPA6,IFNB1,IFNG,IL3,LVRN,RNF152,TNFRSF10D,WFIKKN1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA
M41189,DRYVAX,LA,SMALLPOX,HARALAMBIEVA_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_9_TO_34MO_UP,VIRUS,UP,VACCINE,VAC VS CTRL,M9-M34,M,NA,18-40,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_DRYVAX_AGE_18_40YO_STIMULATED_VS_UNSTIMULATED_9_TO_34MO_UP,"BACKGROUND: The mechanisms underlying smallpox vaccine-induced variations in immune responses are not well understood, but are of considerable interest to a deeper understanding of poxvirus immunity and correlates of protection. METHODS: We assessed transcriptional messenger RNA expression changes in 197 recipients of primary smallpox vaccination representing the extremes of humoral and cellular immune responses. RESULTS: The 20 most significant differentially expressed genes include a tumor necrosis factor-receptor superfamily member, an interferon (IFN) gene, a chemokine gene, zinc finger protein genes, nuclear factors, and histones (P <= 1.06E(-20), q <= 2.64E(-17)). A pathway analysis identified 4 enriched pathways with cytokine production by the T-helper 17 subset of CD4+ T cells being the most significant pathway (P = 3.42E(-05)). Two pathways (antiviral actions of IFNs, P = 8.95E(-05); and IFN-alpha/beta signaling pathway, P = 2.92E(-04)), integral to innate immunity, were enriched when comparing high with low antibody responders (false discovery rate, < 0.05). Genes related to immune function and transcription (TLR8, P =.0002; DAPP1, P =.0003; LAMP3, P = 9.96E(-05); NR4A2, P <= .0002; EGR3, P = 4.52E(-05)), and other genes with a possible impact on immunity (LNPEP, P = 3.72E(-05); CAPRIN1, P =.0001; XRN1, P =.0001), were found to be expressed differentially in high versus low antibody responders. CONCLUSION: We identified novel and known immunity-related genes and pathways that may account for differences in immune response to smallpox vaccination.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (18-40) after exposure to Dryvax , time point 9 to 34M. Comment: Original exposure within previous 4 years","Haralambieva IH,Oberg AL,Dhiman N,Ovsyannikova IG,Kennedy RB,Grill DE,Jacobson RM,Poland GA",22949304,HUMAN_GENE_SYMBOL,"CCAR2,CD160,GARIN3,H4C5,HERC5,IFNA1,IKZF1,IKZF2,NEXN,NFE2L3,NR4A2,POLR2C,RSRC1,SOBP,TNFRSF10D,TNK2,XCL1",17,"CCAR2,CD160,FAM71B,H4C5,HERC5,IFNA1,IKZF1,IKZF2,NEXN,NFE2L3,NR4A2,POLR2C,RSRC1,SOBP,TNFRSF10D,TNK2,XCL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Additional File 2, Tab B PPD",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654906/bin/1755-8794-2-10-S2.xls,NA,NA,NA,NA
M41202,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_DN,VIRUS,DOWN,VACCINE,VAC VS CTRL,Y7,W,7,11-22,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_DN,"BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.","Genes down-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) after exposure to M-M-R II , time point 7Y","Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA",27529750,HUMAN_GENE_SYMBOL,"A2M,A2M-AS1,AATK,ABCC3,ABCC5,ABHD2,ACADVL,ACOT11,ACP3,ACP5,ADAM12,ADAM15,ADAM22,ADAMTS10,ADAMTS7,ADGRA2,ADI1,ADK,ADORA2B,ADORA3,AGAP1,AHNAK,AIF1,AKR7A2,ALDH1A1,ALDH2,ALDH3A2,ALDH7A1,ALK,ALOX5,ALPK2,AMPD2,ANGPT1,ANKRD18A,ANKRD34A,ANOS1,,ANTXRL,ANXA9,AOC1,AP1S2,AP2S1,APBA1,APBB1IP,APLP2,APMAP,APOC1,APOE,AQP3,ARAP3,ARHGAP18,ARHGAP20,ARHGAP4,ARHGAP6,ARHGDIB,ARHGEF4,ARPIN,ARRB1,ARRB2,ARRDC2,ASB13,ASGR1,ASIC1,ASRGL1,ATP2B1,ATP5PB,ATP6AP2,ATP6V0A1,ATP6V0D2,ATP9A,ATPSCKMT,AVPR2,BAIAP2-DT,BHLHE41,BLVRB,BMF,BMP2,BNC2,BRI3BP,BST1,C10orf55,C11orf21,KCNJ5-AS1,C12orf57,C14orf132,C16orf74,C19orf84,C1QA,C1QC,C1orf162,FAXDC2,LINC02908,CACHD1,CACNA1D,CACNA2D4,CALM2,CALU,CAMK1,CARD9,CASS4,CAT,CATSPER1,CBX7,CCDC149,CCDC170,CCDC68,CCDC9B,CCL22,CCL24,CCN3,CCR2,CD101,CD14,CD163L1,CD1C,CD207,CD209,CD27,CD300C,CD300LB,CD300LF,CD33,CD36,CD4,CD40LG,CD52,CD9,CD93,CDA,CDHR1,CDHR2,CDR2L,CEACAM19,CEACAM3,CEBPA,CEBPA-DT,CELSR1,CENPK,CERK,CFAP44,CHI3L1,CHL1,CHN2,CHST13,CLCN4,CLCN5,CLDN7,CLEC10A,CLEC11A,CLEC4A,CLEC5A,CLEC7A,CLMN,CMTM4,CNN2,CNRIP1,COL18A1,COL19A1,COL23A1,COL6A3,COLEC12,COLGALT1,COTL1,CPAMD8,CPM,CPNE9,CPVL,CR1,CREB5,CREBL2,CRIP3,CRISPLD2,CRTAP,CRYL1,CSF1R,CSTA,CTDSPL,CTNNBIP1,CTSA,CTSF,CTTNBP2,CXCL1,CXCL5,CXCL6,CYBB,CYBRD1,CYFIP1,CYP1B1,CYP1B1-AS1,CYP27A1,DAB2,DAD1,DBH,DBNL,DBP,DCANP1,DEF8,DEPDC7,DEPTOR,DHRS9,DLEU7,DLG4,DNAJB13,DNER,DNM1,DOC2A,DOCK3,DOK2,DPCD,DPEP2,DPEP3,DPYD,DSC1,DSC2,DSCAML1,DSG2,DTNA,DTX1,DYNC2H1,EDNRB,EEF2K,EIF3F,EIF3L,EIF4B,EIF4EBP1,EPB41L1,EPHB3,EPHX4,EPPK1,EPS8,EPX,ERBB3,ERP27,ESCO2,ESYT1,EVI2B,F13A1,FABP3,FADS1,FAH,FAM110C,FAM13A,FAM153A,,FAM171B,FAM210B,FAT4,FBP1,FCER1A,FCER2,FCGR1A,FCGR2A,FCGR2B,FCGR2C,FCGRT,FCN1,FCRL6,FCRLB,FES,FFAR4,FGD4,FGF9,FGFBP2,FKBP1A,LINC03033,NHSL2,NHSL1-AS1,FN1,FNDC10,FOLR2,FOLR3,FOS,FOXRED2,FPR1,FRMD4B,FTCDNL1,FUCA1,FXYD7,GAPT,GAS1,GAS2L3,GAS7,GASK1B,GATM,GCOM1,GDPD3,GFRA2,GGTA1,GIPC3,GLB1L,GLIPR1,GNAQ,GNB3,GP1BA,GPAT3,GPC4,GPNMB,GPR34,GPR82,GPRASP2,GPRC5B,GPX3,GRAMD4,GSN,GSTA4,GSTM2,GUCY2C,GZMA,HAAO,HAL,HAMP,HCST,HEXA-AS1,HGF,HHEX,HIP1,HLA-DMA,HLA-DMB,HLF,HNMT,HOPX,HRH2,HSD11B1,HSD17B4,HSPA7,HTR3A,HTR7,HTRA1,ICAM4,ICAM5,IER5L,IFNGR1,IGSF22,IL16,IL18BP,IL1A,IL1R1,IMPA2,INSR,,IQCD,IQCK,ITFG2-AS1,ITGA11,ITGAM,ITGB2,ITGB2-AS1,ITGB5,JAML,KANK2,KCNAB2,KCNC3,KCNJ15,KCNJ5,KCNMB4,KCNQ1,KCTD15,KIAA0930,KIF5A,KISS1R,KLF2,KLF3-AS1,KLF7,KLHL14,KLHL3,KLHL41,KLRB1,KRT1,KRT72,KRT73,LAMB3,LAT2,LDHD,LDLRAD3,LDLRAP1,LEP,LGALS3,LGR4,LGR6,LILRA1,LILRA2,LILRB5,LIM2,LIME1,LINC00304,LINC00622,LINC00926,LINC01094,LINC01281,LINC01547,LINC01963,LINC02035,LINGO3,LIPA,,,POU2F2-AS1,ENSG00000284954,ENSG00000255240,LOXL3,LPL,LRMDA,LRP1,LRP3,LRP5,LRRC25,DNAAF11,LRRC70,LST1,LTA4H,LTBP2,LY86,LY96,LYZ,M1AP,MACROH2A1,MAML3,MAN2B1,MARVELD1,MATK,MCEMP1,ME1,METTL7A,MGAM,MGST2,MICAL2,MINDY1,MIR4712,MIR548AN,MLEC,MMP28,MMP7,MMP9,MMRN1,MPEG1,MPZL2,MRC1,MRC2,MROH6,MS4A6A,MYCL,MYO7A,NAIP,NAT8L,NCEH1,NEFL,NEFM,NEK6,NEXMIF,NFAM1,NFIA,NFXL1,NHS,NHSL2,NINJ2,NLRC4,NLRP1,NLRP12,NMUR1,NOG,NOTCH3,NOXA1,NRCAM,NRG1,NRGN,NT5DC2,NTN4,NUDT6,OLFM1,OLFM2,OPLAH,OPRL1,OTOA,OXER1,OXNAD1,P2RY13,P2RY2,PADI2,PALD1,PAPSS2,PARM1,PC,PCDH1,PCSK6,PCYOX1,PDGFC,PDK4,PDZD4,PECAM1,PFDN5,PGLYRP2,PHETA1,PI16,PID1,PKDREJ,PKIB,PLAC9,PLB1,PLBD1,PLCB2,PLIN2,PLLP,PLPPR2,PLXDC1,PLXDC2,PLXNA1,PMFBP1,PNPLA7,PPARG,PPBP,PPFIA4,PPM1H,PPM1M,PPT1,PRADC1,PRAM1,PRKAG3,PRKAR2A,PROC,PROS1,PRSS23,PRSS36,PRXL2B,PSRC1,PSTPIP1,PTGDR,PTGDR2,PTGFRN,PTGS1,PTPRN2-AS1,PYGL,QPCT,QSOX1,RAB37,RAB3A,RAB3D,RAB3IL1,RAI14,RAPH1,RARRES1,RASA4,RASAL1,RASGRF1,RASGRP2,RASGRP4,RASL10A,RASSF2,RBL2,RBP1,RCN3,REPS2,RFLNB,RGCC,RGS12,RGS14,RGS18,RNASE1,RNASE6,RNF125,RNF130,RORC,RPGRIP1,RPL10,RPL17,RPL22,RPL4,RPS3A,RTL8B,RTN4R,RXRA,S100A12,S100A4,S100A8,S100A9,S1PR1,SAMD1,SATB2,SCARB1,SCNN1A,SDC2,SDK2,SELENOP,SEMA3A,SEMA4C,SEMA6C,SERPINE1,SETD7,SFRP5,SGCD,SGMS2,SH3BGRL,SH3BGRL3,SH3RF3,SH3RF3-AS1,SH3TC1,SHISA8,SIAH3,SIGIRR,SIGLEC10,SIGLEC12,SIGLEC15,SIGLEC7,SIGLEC9,SIRPB2,SIRPD,SIRPG,SKAP2,SLAMF8,SLAMF9,SLC11A1,SLC16A10,SLC16A6,SLC17A7,SLC1A5,SLC24A4,SLC27A1,SLC29A3,SLC2A9,SLC37A2,SLC40A1,SLC46A1,SLC46A2,SLC46A3,SLC47A1,SLC47A2,SLC48A1,SLC4A7,SLCO2B1,SLITRK4,SMAD6,SMIM10L2A,SNCA,SNHG28,SNX18,SNX29,SNX30,SORL1,SORT1,SOWAHD,SPAG8,SPARC,SPATA6,SPECC1,SPINT2,SPIRE1,SPON1,SRD5A3,SSC4D,SSPN,ST14,ST18,STAB1,STAC,STARD13,STEAP3,STEAP4,STK32B,STK32C,STXBP1,STXBP5-AS1,SULT1B1,SUMF1,SYK,TBC1D10C,TBC1D14,TBC1D30,TBXAS1,TDRD6,TENM1,TENM4,TESC,TFCP2L1,TFRC,TGFBI,TGFBR1,THBD,TIMP2,TIMP3,TK2,TLN2,TLR5,TLR6,TM6SF1,TMC8,TMCC2,TMED10,TMEM107,TMEM144,TMEM14C,TMEM170B,TMEM273,TMEM45B,TMEM71,TMEM86A,TNFAIP8L2,TNFRSF10C,TNFRSF8,TNFSF11,TNFSF12-TNFSF13,TNNI2,TOMM7,TOP2B,TPBGL,TPCN1,TREM2,TRERF1,TRIM2,TRIM47,TRIQK,TRPC1,TSPAN18,TSPAN32,TSPAN4,TSPAN7,TSPO,TTC3,TTLL2,TXLNB,UACA,UBXN11,UCP2,UNC5B,VAMP8,VASH1,VAT1,VCAN,VENTX,VIPR1,VNN1,VSIG1,VSIG4,VSIG8,VSIR,VWF,WDR17,WNT1,WNT10B,WNT7A,XYLB,YPEL3,ZBED3-AS1,ZDHHC7,ZFHX3,ZMYND10,ZNF185,ZNF704",746,"A2M,A2M-AS1,AATK,ABCC3,ABCC5,ABHD2,ACADVL,ACOT11,ACP3,ACP5,ADAM12,ADAM15,ADAM22,ADAMTS10,ADAMTS7,ADGRA2,ADI1,ADK,ADORA2B,ADORA3,AGAP1,AHNAK,AIF1,AKR7A2,ALDH1A1,ALDH2,ALDH3A2,ALDH7A1,ALK,ALOX5,ALPK2,AMPD2,ANGPT1,ANKRD18A,ANKRD34A,ANOS1,ANP32A-IT1,ANTXRL,ANXA9,AOC1,AP1S2,AP2S1,APBA1,APBB1IP,APLP2,APMAP,APOC1,APOE,AQP3,ARAP3,ARHGAP18,ARHGAP20,ARHGAP4,ARHGAP6,ARHGDIB,ARHGEF4,ARPIN,ARRB1,ARRB2,ARRDC2,ASB13,ASGR1,ASIC1,ASRGL1,ATP2B1,ATP5PB,ATP6AP2,ATP6V0A1,ATP6V0D2,ATP9A,ATPSCKMT,AVPR2,BAIAP2-DT,BHLHE41,BLVRB,BMF,BMP2,BNC2,BRI3BP,BST1,C10orf55,C11orf21,C11orf45,C12orf57,C14orf132,C16orf74,C19orf84,C1orf162,C1QA,C1QC,C5orf4,C9orf139,CACHD1,CACNA1D,CACNA2D4,CALM2,CALU,CAMK1,CARD9,CASS4,CAT,CATSPER1,CBX7,CCDC149,CCDC170,CCDC68,CCDC9B,CCL22,CCL24,CCN3,CCR2,CD101,CD14,CD163L1,CD1C,CD207,CD209,CD27,CD300C,CD300LB,CD300LF,CD33,CD36,CD4,CD40LG,CD52,CD9,CD93,CDA,CDHR1,CDHR2,CDR2L,CEACAM19,CEACAM3,CEBPA,CEBPA-DT,CELSR1,CENPK,CERK,CFAP44,CHI3L1,CHL1,CHN2,CHST13,CLCN4,CLCN5,CLDN7,CLEC10A,CLEC11A,CLEC4A,CLEC5A,CLEC7A,CLMN,CMTM4,CNN2,CNRIP1,COL18A1,COL19A1,COL23A1,COL6A3,COLEC12,COLGALT1,COTL1,CPAMD8,CPM,CPNE9,CPVL,CR1,CREB5,CREBL2,CRIP3,CRISPLD2,CRTAP,CRYL1,CSF1R,CSTA,CTDSPL,CTNNBIP1,CTSA,CTSF,CTTNBP2,CXCL1,CXCL5,CXCL6,CYBB,CYBRD1,CYFIP1,CYP1B1,CYP1B1-AS1,CYP27A1,DAB2,DAD1,DBH,DBNL,DBP,DCANP1,DEF8,DEPDC7,DEPTOR,DHRS9,DLEU7,DLG4,DNAJB13,DNER,DNM1,DOC2A,DOCK3,DOK2,DPCD,DPEP2,DPEP3,DPYD,DSC1,DSC2,DSCAML1,DSG2,DTNA,DTX1,DYNC2H1,EDNRB,EEF2K,EIF3F,EIF3L,EIF4B,EIF4EBP1,EPB41L1,EPHB3,EPHX4,EPPK1,EPS8,EPX,ERBB3,ERP27,ESCO2,ESYT1,EVI2B,F13A1,FABP3,FADS1,FAH,FAM110C,FAM13A,FAM153A,FAM153B,FAM171B,FAM210B,FAT4,FBP1,FCER1A,FCER2,FCGR1A,FCGR2A,FCGR2B,FCGR2C,FCGRT,FCN1,FCRL6,FCRLB,FES,FFAR4,FGD4,FGF9,FGFBP2,FKBP1A,FLJ22447,FLJ44635,FLJ46906,FN1,FNDC10,FOLR2,FOLR3,FOS,FOXRED2,FPR1,FRMD4B,FTCDNL1,FUCA1,FXYD7,GAPT,GAS1,GAS2L3,GAS7,GASK1B,GATM,GCOM1,GDPD3,GFRA2,GGTA1,GIPC3,GLB1L,GLIPR1,GNAQ,GNB3,GP1BA,GPAT3,GPC4,GPNMB,GPR34,GPR82,GPRASP2,GPRC5B,GPX3,GRAMD4,GSN,GSTA4,GSTM2,GUCY2C,GZMA,HAAO,HAL,HAMP,HCST,HEXA-AS1,HGF,HHEX,HIP1,HLA-DMA,HLA-DMB,HLF,HNMT,HOPX,HRH2,HSD11B1,HSD17B4,HSPA7,HTR3A,HTR7,HTRA1,ICAM4,ICAM5,IER5L,IFNGR1,IGSF22,IL16,IL18BP,IL1A,IL1R1,IMPA2,INSR,IPW,IQCD,IQCK,ITFG2-AS1,ITGA11,ITGAM,ITGB2,ITGB2-AS1,ITGB5,JAML,KANK2,KCNAB2,KCNC3,KCNJ15,KCNJ5,KCNMB4,KCNQ1,KCTD15,KIAA0930,KIF5A,KISS1R,KLF2,KLF3-AS1,KLF7,KLHL14,KLHL3,KLHL41,KLRB1,KRT1,KRT72,KRT73,LAMB3,LAT2,LDHD,LDLRAD3,LDLRAP1,LEP,LGALS3,LGR4,LGR6,LILRA1,LILRA2,LILRB5,LIM2,LIME1,LINC00304,LINC00622,LINC00926,LINC01094,LINC01281,LINC01547,LINC01963,LINC02035,LINGO3,LIPA,LOC100129034,LOC100130987,LOC100505622,LOC100507547,LOC283194,LOXL3,LPL,LRMDA,LRP1,LRP3,LRP5,LRRC25,LRRC6,LRRC70,LST1,LTA4H,LTBP2,LY86,LY96,LYZ,M1AP,MACROH2A1,MAML3,MAN2B1,MARVELD1,MATK,MCEMP1,ME1,METTL7A,MGAM,MGST2,MICALCL,MINDY1,MIR4712,MIR548AN,MLEC,MMP28,MMP7,MMP9,MMRN1,MPEG1,MPZL2,MRC1,MRC2,MROH6,MS4A6A,MYCL,MYO7A,NAIP,NAT8L,NCEH1,NEFL,NEFM,NEK6,NEXMIF,NFAM1,NFIA,NFXL1,NHS,NHSL2,NINJ2,NLRC4,NLRP1,NLRP12,NMUR1,NOG,NOTCH3,NOXA1,NRCAM,NRG1,NRGN,NT5DC2,NTN4,NUDT6,OLFM1,OLFM2,OPLAH,OPRL1,OTOA,OXER1,OXNAD1,P2RY13,P2RY2,PADI2,PALD1,PAPSS2,PARM1,PC,PCDH1,PCSK6,PCYOX1,PDGFC,PDK4,PDZD4,PECAM1,PFDN5,PGLYRP2,PHETA1,PI16,PID1,PKDREJ,PKIB,PLAC9,PLB1,PLBD1,PLCB2,PLIN2,PLLP,PLPPR2,PLXDC1,PLXDC2,PLXNA1,PMFBP1,PNPLA7,PPARG,PPBP,PPFIA4,PPM1H,PPM1M,PPT1,PRADC1,PRAM1,PRKAG3,PRKAR2A,PROC,PROS1,PRSS23,PRSS36,PRXL2B,PSRC1,PSTPIP1,PTGDR,PTGDR2,PTGFRN,PTGS1,PTPRN2-AS1,PYGL,QPCT,QSOX1,RAB37,RAB3A,RAB3D,RAB3IL1,RAI14,RAPH1,RARRES1,RASA4,RASAL1,RASGRF1,RASGRP2,RASGRP4,RASL10A,RASSF2,RBL2,RBP1,RCN3,REPS2,RFLNB,RGCC,RGS12,RGS14,RGS18,RNASE1,RNASE6,RNF125,RNF130,RORC,RPGRIP1,RPL10,RPL17,RPL22,RPL4,RPS3A,RTL8B,RTN4R,RXRA,S100A12,S100A4,S100A8,S100A9,S1PR1,SAMD1,SATB2,SCARB1,SCNN1A,SDC2,SDK2,SELENOP,SEMA3A,SEMA4C,SEMA6C,SERPINE1,SETD7,SFRP5,SGCD,SGMS2,SH3BGRL,SH3BGRL3,SH3RF3,SH3RF3-AS1,SH3TC1,SHISA8,SIAH3,SIGIRR,SIGLEC10,SIGLEC12,SIGLEC15,SIGLEC7,SIGLEC9,SIRPB2,SIRPD,SIRPG,SKAP2,SLAMF8,SLAMF9,SLC11A1,SLC16A10,SLC16A6,SLC17A7,SLC1A5,SLC24A4,SLC27A1,SLC29A3,SLC2A9,SLC37A2,SLC40A1,SLC46A1,SLC46A2,SLC46A3,SLC47A1,SLC47A2,SLC48A1,SLC4A7,SLCO2B1,SLITRK4,SMAD6,SMIM10L2A,SNCA,SNHG28,SNX18,SNX29,SNX30,SORL1,SORT1,SOWAHD,SPAG8,SPARC,SPATA6,SPECC1,SPINT2,SPIRE1,SPON1,SRD5A3,SSC4D,SSPN,ST14,ST18,STAB1,STAC,STARD13,STEAP3,STEAP4,STK32B,STK32C,STXBP1,STXBP5-AS1,SULT1B1,SUMF1,SYK,TBC1D10C,TBC1D14,TBC1D30,TBXAS1,TDRD6,TENM1,TENM4,TESC,TFCP2L1,TFRC,TGFBI,TGFBR1,THBD,TIMP2,TIMP3,TK2,TLN2,TLR5,TLR6,TM6SF1,TMC8,TMCC2,TMED10,TMEM107,TMEM144,TMEM14C,TMEM170B,TMEM273,TMEM45B,TMEM71,TMEM86A,TNFAIP8L2,TNFRSF10C,TNFRSF8,TNFSF11,TNFSF12-TNFSF13,TNNI2,TOMM7,TOP2B,TPBGL,TPCN1,TREM2,TRERF1,TRIM2,TRIM47,TRIQK,TRPC1,TSPAN18,TSPAN32,TSPAN4,TSPAN7,TSPO,TTC3,TTLL2,TXLNB,UACA,UBXN11,UCP2,UNC5B,VAMP8,VASH1,VAT1,VCAN,VENTX,VIPR1,VNN1,VSIG1,VSIG4,VSIG8,VSIR,VWF,WDR17,WNT1,WNT10B,WNT7A,XYLB,YPEL3,ZBED3-AS1,ZDHHC7,ZFHX3,ZMYND10,ZNF185,ZNF704",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/,NA,NA,NA,NA
M41080,MMR II,LA,MMR,HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_UP,VIRUS,UP,VACCINE,VAC VS CTRL,Y7,W,7,11-22,"ADOLESCENT, ADULT",PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/HARALAMBIEVA_PBMC_M_M_R_II_AGE_11_22YO_VACCINATED_VS_UNVACCINATED_7YR_UP,"BACKGROUND: There are insufficient system-wide transcriptomic (or other) data that help explain the observed inter-individual variability in antibody titers after measles vaccination in otherwise healthy individuals. METHODS: We performed a transcriptome(mRNA-Seq)-profiling study after in vitro viral stimulation of PBMCs from 30 measles vaccine recipients, selected from a cohort of 764 schoolchildren, based on the highest and lowest antibody titers. We used regression and network biology modeling to define markers associated with neutralizing antibody response. RESULTS: We identified 39 differentially expressed genes that demonstrate significant differences between the high and low antibody responder groups (p-value <= 0.0002, q-value <= 0.092), including the top gene CD93 (p < 1.0E-13, q < 1.0E-09), encoding a receptor required for antigen-driven B-cell differentiation, maintenance of immunoglobulin production and preservation of plasma cells in the bone marrow. Network biology modeling highlighted plasma cell survival (CD93, IL6, CXCL12), chemokine/cytokine activity and cell-cell communication/adhesion/migration as biological processes associated with the observed differential response in the two responder groups. CONCLUSION: We identified genes and pathways that explain in part, and are associated with, neutralizing antibody titers after measles vaccination. This new knowledge could assist in the identification of biomarkers and predictive signatures of protective immunity that may be useful in the design of new vaccine candidates and in clinical studies.","Genes up-regulated in peripheral blood mononuclear cell vaccinated vs unvaccinated in adolescent/young adults (11-22) after exposure to M-M-R II , time point 7Y","Haralambieva IH,Zimmermann MT,Ovsyannikova IG,Grill DE,Oberg AL,Kennedy RB,Poland GA",27529750,HUMAN_GENE_SYMBOL,"AANAT,ABCD1,ABHD16B,ABHD17C,ABTB2,ACAN,ACHE,ACOT9,ACP2,ACSBG1,ACSL1,ACSM1,ACSM5,ACTA2,ADAM19,ADAMDEC1,ADAMTS14,ADAMTS2,ADCY4,ADGRB1,ADGRE1,ADGRF3,ADM,ADM2,ADORA2A,ADPGK-AS1,ADPRH,ADPRS,,AGRN,AIFM2,AIM2,AK4,AK8,,AKT1S1,AMBRA1,AMER1,AMOTL2,ANK3,ANKRD1,ANKRD22,ANKRD29,ANKRD33B,ANKRD45,ANKRD53,ANXA10,AP5B1,APOBEC3A,APOBEC3B,APOBEC3F,APOBEC3G,APOL1,APOL2,APOL3,APOL6,ARHGAP23,ARHGEF10L,ARHGEF11,ARHGEF3,ARID5A,ARID5B,ARL5B,ARMCX1,ARNT2,BMAL2,ASCL2,ASPHD2,ATF3,ATF5,ATP10A,ATP13A2,AXL,B3GNT2,B4GALT5,BAALC,BAALC-AS2,BACE2,BAG1,BAK1,BAMBI,BARD1,BATF2,BATF3,BAZ1A,BBS12,BCL2L13,BCL2L14,BIRC5,BLZF1,BPGM,BRCA2,BRIP1,BRSK1,BSPRY,BST2,BTG3,BUB1,C15orf48,C17orf67,C1GALT1,C1QTNF1,C1R,C1S,C1orf226,C2,C3orf52,C4orf36,C5,LINC03040,CACNA1A,CALD1,CALHM6,CARD17P,CASP1,CASP10,CASP3,CASP4,CASP5,CASP7,CASZ1,CAVIN3,CBLN3,CBR1,ZNG1A,ZNG1B,CCDC146,CCDC42,CCDC80,CCDC9,CCL18,CCL19,CCL2,CCL3,CCL3L3,CCL4,,CCL7,CCL8,CCN2,CCNA1,CCR1,CCR10,CCR5,CCRL2,CD109,CD200,CD274,CD2AP,CD38,CD40,CD69,CD70,CD72,CD80,CD83,CDC42EP1,CDC42EP2,CDC45,CDH1,CDK1,CDK18,CDKN1A,CDKN1C,CDKN2A,CDKN2B,CEACAM1,CECR2,CEMIP,CENPJ,CES1,CETP,CFB,CFLAR-AS1,CGAS,CH25H,CHAC1,CHI3L2,CHODL,CHRNA6,CHRNB2,CHST12,CHST7,CHSY1,CIB2,CIR1,CKAP4,CKB,CLDN14,CLDN23,CLEC12B,CLEC4C,CLEC4F,CLECL1P,CLLU1-AS1,CLMP,CMPK2,CMTR1,CMYA5,CNP,COBL,COL24A1,COL4A2,CORO2B,CPEB2,CPEB3,CPNE5,CR1L,CREM,CSF1,CSRNP1,CTNND2,CTSL,CUX2,CXCL10,CXCL11,CXCL12,CXCL13,CXCL9,CYP1A1,CYP27B1,CYP2J2,CYP4F11,CYP7B1,CYSTM1,DACT3-AS1,DAPP1,DBF4B,DCDC1,DCSTAMP,DCUN1D3,DDIT3,RIGI,DDX60,DDX60L,DENND1B,DHX58,DIP2C,DIRC3,DLGAP1,DLL1,DLL4,DMD,DNAAF1,DNAH12,DNAH8,DNAI3,DNAJB4,DNAJC5B,DNAJC6,DNASE1L3,DOP1A,DPYS,DRAM1,DRAP1,DSP,DTX3L,DUSP1,DUSP5,DUSP6,DYNLT1,DYRK3,DYSF,E2F7,ECE1,EDARADD,EDN1,EEF1A2,EGR2,EHD4,EIF2AK2,EIF4E3,ELF4,ELFN1,ELL3,ELMO2,ELOVL3,ELOVL7,EMP1,ENDOD1,ENDOU,ENPP2,ENTHD1,EPHA2,EPHB1,EPOP,EPSTI1,ERICH3,ESPNL,ETV7,EXOC3L1,PABIR3,FAM225A,FAM3B,FAM47E,FAM53A,FAM72A,FAM72B,FAM72D,FANCA,FAR2,FAS,,FASLG,FBXO39,FBXO6,FCRL4,FERMT2,FFAR2,FFAR3,FGD2,FIRRE,FKBP1B,FLT3,FMNL2,FNDC11,FNDC3B,FNIP2,FOSL1,FOXC1,FRMD3,FRRS1,FSCN1,FUT4,FXYD6,FZD4,GALNT8,GAREM1,GBP1,GBP2,GBP3,GBP4,GBP5,GBP6,GBP7,GCH1,GCNT1,GCNT2,GJA3,GJB2,GLI3,GLP1R,GMPR,GPBAR1,GPD2,GPR141,GPR15,GPR155,GPR161,GPR180,GPRIN1,GREM1,GRHL1,GRIN3A,GRIP1,GTPBP1,GTPBP2,GUCY1A1,GUCY1B1,H2AC6,H2AC7,H2BC11,H2BC18,H2BC4,H2BC5,H3-5,H3C13,H3C4,H4C12,H4C8,HAPLN3,HBD,HCAR2,HCAR3,HCG4,HDAC9,HDC,HDX,HELB,HELZ2,HERC5,HERC6,HES4,HESX1,HIRA,HK2,HLA-DOB,HLA-G,HLA-L,HLX,HMMR,HPSE,HRH1,HS3ST3A1,HSH2D,ICAM1,IDO1,IDO2,IER5,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNG,IGF2BP2,IGF2BP3,IGFBP3,IGFBP4,IL12A,IL12RB2,IL15,IL15RA,IL1RN,IL27,IL2RA,IL36RN,IL3RA,IL4I1,IL6,IL7,ILDR1,INAFM1,INHBA,IPCEF1,IRAK2,IRF1,IRF1-AS1,IRF2,IRF4,IRF7,IRS1,ISG15,ISG20,ITGA2,ITGA7,ITGB8,ITIH1,ITIH4,ITPKA,JADE3,JAG1,JAK2,JMJD1C-AS1,JUP,KAT14,KCNA2,KCNE1,KCNE5,KCNJ10,KCNJ2,KCNK5,KCNMB1,KCNN1,KCNS3,KCTD19,KDM6A,KIAA0040,KIAA0408,KIAA1217,KIAA1522,KIF19,KIR2DL4,KITLG,KLF5,KLF6,KLHDC7B,KPTN,KRT5,KY,L3MBTL4,LAG3,LAMB1,LAMP3,LAMP5,LAP3,LDHAL6B,LGALS2,LGALS3BP,LGALS9,LGALS9B,LHFPL6,LHFPL1,LHFPL2,LIF,LILRA3,LILRA4,LILRA5,LILRA6,LILRB2,LILRB4,LIMCH1,LINC-PINT,LINC00161,LINC00173,LINC00189,LINC00487,LINC00960,LINC00996,LINC01260,LINC01531,TMEM277P,LINC02363,LMNB1,LPAR1,LPAR3,LPIN2,LRP12,LRRC3,LRRC32,LRRN2,LSS,LTA,LY6E,LY6E-DT,LYN,LYPD5,LYSMD2,MACROD2,MAFF,MAML2,MAMLD1,MAP1A,MAP2,MAPK11,MAPK8IP2,MASTL,MCM10,MCOLN2,MDGA1,MDK,MEFV,MEIS3,MELK,MELTF,MEP1A,MGAT3,MGC16275,MICALL1,MICB,MIR155HG,MIR320E,MIR3945HG,MIR4645,MIR4750,MIR9-1HG,MMP19,MOB3C,MOCOS,MOV10,MOXD1,MROCKI,MRPL44,MSC,MSR1,MST1R,MT1E,MT1M,MT2A,MTHFD1L,MUC1,MVB12B,MX1,MX2,MXD1,MYBL2,MYO10,MYO16,MYO1E,MYO1G,MYO7B,MZB1,N4BP1,NAA25,NACAD,NADK,NAPA,NBN,NBPF7P,NCAM1,NCF1,NCOA7,NDC80,NDUFC2-KCTD14,NECTIN2,NECTIN3,NEURL1,NEURL3,NEXN,NFE2L3,NFIX,NGFR,NINJ1,NIPAL4,NKAPL,NKX3-1,NLRP7,NMI,NOD1,NOD2,NR1H3,NR4A3,NRIP3,NRSN2,NRXN2,NSUN7,NTN1,NUB1,NUPR1,OAS1,OAS2,OAS3,OASL,ODF2L,OLIG1,OLIG2,OPTN,OR52B6,OR52K2,OSBPL1A,OSBPL5,OSBPL6,OSM,OTOF,P2RX4,P2RX7,P4HA2,PACSIN3,PANX1,PANX2,PAPLN,PARP10,PARP11,PARP12,PARP14,PARP3,PARP9,PAX5,PAX8,PAX8-AS1,PCGF5,PDCD1,PDCD1LG2,PDE4B,PDGFRL,PERM1,PFKP,PGAP1,PHEX,PHF11,PHGDH,PHLDA2,PI4K2B,PILRA,PIWIL4,PKMYT1,PLA2G4C,PLEKHA4,PLEKHA7,PLEKHD1,PLEKHG7,PLEKHH1,PLEKHN1,PLS3,PLSCR1,PLSCR2,PLSCR4,PLVAP,PMAIP1,PML,PNOC,PNPT1,POGLUT3,POU5F1B,PPM1J,PPM1K,PPP1R15A,PPP2R2A,PRDM16,PRECSIT,PRG2,PRG4,PRICKLE1,PRKD2,PRLR,PROB1,PROCR,PRR16,PRR5,PRR5-ARHGAP8,PRRG1,PRRG4,PRRT2,PRUNE2,PSAT1,PSEN2,PSMB9,PTGDS,PTGER2,PTOV1-AS1,PTPRS,PTPRU,PTTG2,PXDC1,PYCR1,RAB19,RAB20,RAB39A,RAPGEF2,RAPGEF3,RAPGEF5,RASGEF1B,RASGRP3,RBCK1,RBM11,RBM43,RELB,RET,RFPL3,RGMA,RGS1,RGS13,RGS20,RHBDF2,RHEBL1,RHOC,RILP,RIN2,RIPK2,RNASE2,RNF122,RNF165,RNF19B,RNF213,RNF43,RSAD2,RSPH9,RTCB,RTP4,RUBCN,RUFY4,RUNX2,SAMD4A,SAMD9,SAMD9L,SAMSN1,SASH1,SBK1,SCAMP5,SCARB2,SCG3,SCIN,SCLT1,SCML4,SCO2,SCT,SDC3,SDS,SECTM1,SELENOO,SEMA4A,SERPINB9,SERPING1,SERPINH1,SERTAD1,SH2B2,SHFL,SHOX2,SIDT1,SIGLEC1,SIGLEC14,SLAMF7,SLC12A3,SLC1A4,SLC22A16,SLC22A4,SLC24A3,SLC25A28,SLC27A2,SLC2A12,SLC2A6,SLC30A4,SLC31A2,SLC35F3,SLC37A1,SLC38A5,SLC39A8,SLC41A2,SLC52A1,SLC6A8,SLC6A9,SLC7A5,SLC8A1,SLCO5A1,SLFN12,SLFN12L,SLFN13,SMAGP,SMCHD1,SMIM3,SMPD3,SMTNL1,SNX10,SOAT1,SOBP,SOCS1,SOCS2,SOGA3,SORBS1,SOX8,SP100,SP110,SP140,SPATS2L,SPHK1,SPSB1,SPTA1,SQOR,SRC,SRD5A1,SRGAP2,SRGAP2B,SSTR2,SSTR3,ST3GAL5,ST8SIA4,STAP1,STAT1,STAT2,STBD1,STIMATE,STIMATE-MUSTN1,STOM,STOML1,STON2,STRIP2,STX11,SUPT3H,SUSD1,SYNPO,SYNPO2,SYPL2,SYTL3,TANK,TAP1,TAP2,TBC1D17,TCAF2,TCHH,TCN2,TDO2,TDRD7,TENT4A,TENT5A,TFEC,TGFA,TGM1,TIAM2,TICAM1,TICAM2,TJP1,TJP2,TLNRD1,TLR2,TLR3,TMEM106A,TMEM139,TMEM140,TMEM150B,LDAF1,TMEM171,TMEM178B,TMEM187,TMEM200A,TMEM217,TMEM229B,TMEM244,TMEM255A,TMEM26,TMEM268,TMEM62,TMOD1,TMPRSS13,TMPRSS3,TMTC1,TNF,TNFAIP6,TNFRSF13B,TNFSF10,TNFSF13B,TNFSF4,TNK2,TOR1B,TP53INP2,TPSAB1,TPX2,TRADD,TRAF1,TRAF2,TRAFD1,TRANK1,TREX1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM36,TRIM38,TRIM5,TRIM56,TRIM6,TRIM69,TRIP6,TRPM4,TSC22D1,TSPAN13,TSPAN5,TTC21A,TTC39A,TTC39B,TTC7B,TUBA1C,TUBB2A,TUBB2B,TUBB3,TUFT1,UBE2C,UBE2L6,UBE2QL1,UBE2S,UBE2Z,UBQLNL,UPB1,USP18,USP30-AS1,USP42,USP6NL,VAMP5,VAV3,VRK2,VWA5B1,WARS1,WDFY1,WHRN,WNK2,WNT10A,WNT5A,XAF1,XCR1,XRN1,YEATS2,ZBP1,ZBTB32,ZBTB42,ZC3HAV1L,ZCCHC2,ZNF107,ZNF267,ZNF365,ZNF366,ZNF462,ZNF618,ZNF620,ZNF684,ZNFX1,ZNRF2,ZSWIM4,ZSWIM5",977,"AANAT,ABCD1,ABHD16B,ABHD17C,ABTB2,ACAN,ACHE,ACOT9,ACP2,ACSBG1,ACSL1,ACSM1,ACSM5,ACTA2,ADAM19,ADAMDEC1,ADAMTS14,ADAMTS2,ADCY4,ADGRB1,ADGRE1,ADGRF3,ADM,ADM2,ADORA2A,ADPGK-AS1,ADPRH,ADPRS,AFF1-AS1,AGRN,AIFM2,AIM2,AK4,AK8,AKAP2,AKT1S1,AMBRA1,AMER1,AMOTL2,ANK3,ANKRD1,ANKRD22,ANKRD29,ANKRD33B,ANKRD45,ANKRD53,ANXA10,AP5B1,APOBEC3A,APOBEC3B,APOBEC3F,APOBEC3G,APOL1,APOL2,APOL3,APOL6,ARHGAP23,ARHGEF10L,ARHGEF11,ARHGEF3,ARID5A,ARID5B,ARL5B,ARMCX1,ARNT2,ARNTL2,ASCL2,ASPHD2,ATF3,ATF5,ATP10A,ATP13A2,AXL,B3GNT2,B4GALT5,BAALC,BAALC-AS2,BACE2,BAG1,BAK1,BAMBI,BARD1,BATF2,BATF3,BAZ1A,BBS12,BCL2L13,BCL2L14,BIRC5,BLZF1,BPGM,BRCA2,BRIP1,BRSK1,BSPRY,BST2,BTG3,BUB1,C15orf48,C17orf67,C1GALT1,C1orf226,C1QTNF1,C1R,C1S,C2,C3orf52,C4orf36,C5,C6orf223,CACNA1A,CALD1,CALHM6,CARD17,CASP1,CASP10,CASP3,CASP4,CASP5,CASP7,CASZ1,CAVIN3,CBLN3,CBR1,CBWD1,CBWD2,CCDC146,CCDC42,CCDC80,CCDC9,CCL18,CCL19,CCL2,CCL3,CCL3L3,CCL4,CCL4L1,CCL7,CCL8,CCN2,CCNA1,CCR1,CCR10,CCR5,CCRL2,CD109,CD200,CD274,CD2AP,CD38,CD40,CD69,CD70,CD72,CD80,CD83,CDC42EP1,CDC42EP2,CDC45,CDH1,CDK1,CDK18,CDKN1A,CDKN1C,CDKN2A,CDKN2B,CEACAM1,CECR2,CEMIP,CENPJ,CES1,CETP,CFB,CFLAR-AS1,CGAS,CH25H,CHAC1,CHI3L2,CHODL,CHRNA6,CHRNB2,CHST12,CHST7,CHSY1,CIB2,CIR1,CKAP4,CKB,CLDN14,CLDN23,CLEC12B,CLEC4C,CLEC4F,CLECL1,CLLU1-AS1,CLMP,CMPK2,CMTR1,CMYA5,CNP,COBL,COL24A1,COL4A2,CORO2B,CPEB2,CPEB3,CPNE5,CR1L,CREM,CSF1,CSRNP1,CTNND2,CTSL,CUX2,CXCL10,CXCL11,CXCL12,CXCL13,CXCL9,CYP1A1,CYP27B1,CYP2J2,CYP4F11,CYP7B1,CYSTM1,DACT3-AS1,DAPP1,DBF4B,DCDC1,DCSTAMP,DCUN1D3,DDIT3,DDX58,DDX60,DDX60L,DENND1B,DHX58,DIP2C,DIRC3,DLGAP1,DLL1,DLL4,DMD,DNAAF1,DNAH12,DNAH8,DNAI3,DNAJB4,DNAJC5B,DNAJC6,DNASE1L3,DOP1A,DPYS,DRAM1,DRAP1,DSP,DTX3L,DUSP1,DUSP5,DUSP6,DYNLT1,DYRK3,DYSF,E2F7,ECE1,EDARADD,EDN1,EEF1A2,EGR2,EHD4,EIF2AK2,EIF4E3,ELF4,ELFN1,ELL3,ELMO2,ELOVL3,ELOVL7,EMP1,ENDOD1,ENDOU,ENPP2,ENTHD1,EPHA2,EPHB1,EPOP,EPSTI1,ERICH3,ESPNL,ETV7,EXOC3L1,FAM122C,FAM225A,FAM3B,FAM47E,FAM53A,FAM72A,FAM72B,FAM72D,FANCA,FAR2,FAS,FAS-AS1,FASLG,FBXO39,FBXO6,FCRL4,FERMT2,FFAR2,FFAR3,FGD2,FIRRE,FKBP1B,FLT3,FMNL2,FNDC11,FNDC3B,FNIP2,FOSL1,FOXC1,FRMD3,FRRS1,FSCN1,FUT4,FXYD6,FZD4,GALNT8,GAREM1,GBP1,GBP2,GBP3,GBP4,GBP5,GBP6,GBP7,GCH1,GCNT1,GCNT2,GJA3,GJB2,GLI3,GLP1R,GMPR,GPBAR1,GPD2,GPR141,GPR15,GPR155,GPR161,GPR180,GPRIN1,GREM1,GRHL1,GRIN3A,GRIP1,GTPBP1,GTPBP2,GUCY1A1,GUCY1B1,H2AC6,H2AC7,H2BC11,H2BC18,H2BC4,H2BC5,H3-5,H3C13,H3C4,H4C12,H4C8,HAPLN3,HBD,HCAR2,HCAR3,HCG4,HDAC9,HDC,HDX,HELB,HELZ2,HERC5,HERC6,HES4,HESX1,HIRA,HK2,HLA-DOB,HLA-G,HLA-L,HLX,HMMR,HPSE,HRH1,HS3ST3A1,HSH2D,ICAM1,IDO1,IDO2,IER5,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNG,IGF2BP2,IGF2BP3,IGFBP3,IGFBP4,IL12A,IL12RB2,IL15,IL15RA,IL1RN,IL27,IL2RA,IL36RN,IL3RA,IL4I1,IL6,IL7,ILDR1,INAFM1,INHBA,IPCEF1,IRAK2,IRF1,IRF1-AS1,IRF2,IRF4,IRF7,IRS1,ISG15,ISG20,ITGA2,ITGA7,ITGB8,ITIH1,ITIH4,ITPKA,JADE3,JAG1,JAK2,JMJD1C-AS1,JUP,KAT14,KCNA2,KCNE1,KCNE5,KCNJ10,KCNJ2,KCNK5,KCNMB1,KCNN1,KCNS3,KCTD19,KDM6A,KIAA0040,KIAA0408,KIAA1217,KIAA1522,KIF19,KIR2DL4,KITLG,KLF5,KLF6,KLHDC7B,KPTN,KRT5,KY,L3MBTL4,LAG3,LAMB1,LAMP3,LAMP5,LAP3,LDHAL6B,LGALS2,LGALS3BP,LGALS9,LGALS9B,LHFP,LHFPL1,LHFPL2,LIF,LILRA3,LILRA4,LILRA5,LILRA6,LILRB2,LILRB4,LIMCH1,LINC-PINT,LINC00161,LINC00173,LINC00189,LINC00487,LINC00960,LINC00996,LINC01260,LINC01531,LINC01869,LINC02363,LMNB1,LPAR1,LPAR3,LPIN2,LRP12,LRRC3,LRRC32,LRRN2,LSS,LTA,LY6E,LY6E-DT,LYN,LYPD5,LYSMD2,MACROD2,MAFF,MAML2,MAMLD1,MAP1A,MAP2,MAPK11,MAPK8IP2,MASTL,MCM10,MCOLN2,MDGA1,MDK,MEFV,MEIS3,MELK,MELTF,MEP1A,MGAT3,MGC16275,MICALL1,MICB,MIR155HG,MIR320E,MIR3945HG,MIR4645,MIR4750,MIR9-1HG,MMP19,MOB3C,MOCOS,MOV10,MOXD1,MROCKI,MRPL44,MSC,MSR1,MST1R,MT1E,MT1M,MT2A,MTHFD1L,MUC1,MVB12B,MX1,MX2,MXD1,MYBL2,MYO10,MYO16,MYO1E,MYO1G,MYO7B,MZB1,N4BP1,NAA25,NACAD,NADK,NAPA,NBN,NBPF7,NCAM1,NCF1,NCOA7,NDC80,NDUFC2-KCTD14,NECTIN2,NECTIN3,NEURL1,NEURL3,NEXN,NFE2L3,NFIX,NGFR,NINJ1,NIPAL4,NKAPL,NKX3-1,NLRP7,NMI,NOD1,NOD2,NR1H3,NR4A3,NRIP3,NRSN2,NRXN2,NSUN7,NTN1,NUB1,NUPR1,OAS1,OAS2,OAS3,OASL,ODF2L,OLIG1,OLIG2,OPTN,OR52B6,OR52K2,OSBPL1A,OSBPL5,OSBPL6,OSM,OTOF,P2RX4,P2RX7,P4HA2,PACSIN3,PANX1,PANX2,PAPLN,PARP10,PARP11,PARP12,PARP14,PARP3,PARP9,PAX5,PAX8,PAX8-AS1,PCGF5,PDCD1,PDCD1LG2,PDE4B,PDGFRL,PERM1,PFKP,PGAP1,PHEX,PHF11,PHGDH,PHLDA2,PI4K2B,PILRA,PIWIL4,PKMYT1,PLA2G4C,PLEKHA4,PLEKHA7,PLEKHD1,PLEKHG7,PLEKHH1,PLEKHN1,PLS3,PLSCR1,PLSCR2,PLSCR4,PLVAP,PMAIP1,PML,PNOC,PNPT1,POGLUT3,POU5F1B,PPM1J,PPM1K,PPP1R15A,PPP2R2A,PRDM16,PRECSIT,PRG2,PRG4,PRICKLE1,PRKD2,PRLR,PROB1,PROCR,PRR16,PRR5,PRR5-ARHGAP8,PRRG1,PRRG4,PRRT2,PRUNE2,PSAT1,PSEN2,PSMB9,PTGDS,PTGER2,PTOV1-AS1,PTPRS,PTPRU,PTTG2,PXDC1,PYCR1,RAB19,RAB20,RAB39A,RAPGEF2,RAPGEF3,RAPGEF5,RASGEF1B,RASGRP3,RBCK1,RBM11,RBM43,RELB,RET,RFPL3,RGMA,RGS1,RGS13,RGS20,RHBDF2,RHEBL1,RHOC,RILP,RIN2,RIPK2,RNASE2,RNF122,RNF165,RNF19B,RNF213,RNF43,RSAD2,RSPH9,RTCB,RTP4,RUBCN,RUFY4,RUNX2,SAMD4A,SAMD9,SAMD9L,SAMSN1,SASH1,SBK1,SCAMP5,SCARB2,SCG3,SCIN,SCLT1,SCML4,SCO2,SCT,SDC3,SDS,SECTM1,SELENOO,SEMA4A,SERPINB9,SERPING1,SERPINH1,SERTAD1,SH2B2,SHFL,SHOX2,SIDT1,SIGLEC1,SIGLEC14,SLAMF7,SLC12A3,SLC1A4,SLC22A16,SLC22A4,SLC24A3,SLC25A28,SLC27A2,SLC2A12,SLC2A6,SLC30A4,SLC31A2,SLC35F3,SLC37A1,SLC38A5,SLC39A8,SLC41A2,SLC52A1,SLC6A8,SLC6A9,SLC7A5,SLC8A1,SLCO5A1,SLFN12,SLFN12L,SLFN13,SMAGP,SMCHD1,SMIM3,SMPD3,SMTNL1,SNX10,SOAT1,SOBP,SOCS1,SOCS2,SOGA3,SORBS1,SOX8,SP100,SP110,SP140,SPATS2L,SPHK1,SPSB1,SPTA1,SQOR,SRC,SRD5A1,SRGAP2,SRGAP2P2,SSTR2,SSTR3,ST3GAL5,ST8SIA4,STAP1,STAT1,STAT2,STBD1,STIMATE,STIMATE-MUSTN1,STOM,STOML1,STON2,STRIP2,STX11,SUPT3H,SUSD1,SYNPO,SYNPO2,SYPL2,SYTL3,TANK,TAP1,TAP2,TBC1D17,TCAF2,TCHH,TCN2,TDO2,TDRD7,TENT4A,TENT5A,TFEC,TGFA,TGM1,TIAM2,TICAM1,TICAM2,TJP1,TJP2,TLNRD1,TLR2,TLR3,TMEM106A,TMEM139,TMEM140,TMEM150B,TMEM159,TMEM171,TMEM178B,TMEM187,TMEM200A,TMEM217,TMEM229B,TMEM244,TMEM255A,TMEM26,TMEM268,TMEM62,TMOD1,TMPRSS13,TMPRSS3,TMTC1,TNF,TNFAIP6,TNFRSF13B,TNFSF10,TNFSF13B,TNFSF4,TNK2,TOR1B,TP53INP2,TPSAB1,TPX2,TRADD,TRAF1,TRAF2,TRAFD1,TRANK1,TREX1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM36,TRIM38,TRIM5,TRIM56,TRIM6,TRIM69,TRIP6,TRPM4,TSC22D1,TSPAN13,TSPAN5,TTC21A,TTC39A,TTC39B,TTC7B,TUBA1C,TUBB2A,TUBB2B,TUBB3,TUFT1,UBE2C,UBE2L6,UBE2QL1,UBE2S,UBE2Z,UBQLNL,UPB1,USP18,USP30-AS1,USP42,USP6NL,VAMP5,VAV3,VRK2,VWA5B1,WARS,WDFY1,WHRN,WNK2,WNT10A,WNT5A,XAF1,XCR1,XRN1,YEATS2,ZBP1,ZBTB32,ZBTB42,ZC3HAV1L,ZCCHC2,ZNF107,ZNF267,ZNF365,ZNF366,ZNF462,ZNF618,ZNF620,ZNF684,ZNFX1,ZNRF2,ZSWIM4,ZSWIM5",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table S1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700883/bin/pone.0067922.s004.docx,NA,NA,NA,NA
M41152,BCG,LA,TUBERCULOSIS,FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_DN,BACTERIUM,DOWN,VACCINE,VAC VS CTRL,W10,W,10,INFANT,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_DN,"BACKGROUND: Novel tuberculosis (TB) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, Mycobacterium bovis Bacille Calmette-Guerin (BCG). Because BCG vaccination is used extensively in infants, this population group is likely to be the first in which efficacy trials of new vaccines will be conducted. However, our understanding of the complexity of immunity to BCG in infants is inadequate, making interpretation of vaccine-induced immune responses difficult. METHODS: To better understand BCG-induced immunity, we performed gene expression profiling in five 10-week old infants routinely vaccinated with BCG at birth. RNA was extracted from 12 hour BCG-stimulated or purified protein derivative of tuberculin (PPD)-stimulated PBMC, isolated from neonatal blood collected 10 weeks after vaccination. RNA was hybridised to the Sentrix(R) HumanRef-8 Expression BeadChip (Illumina) to measure expression of > 16,000 genes. RESULTS: We found that ex vivo stimulation of PBMC with PPD and BCG induced largely similar gene expression profiles, except that BCG induced greater macrophage activation. The peroxisome proliferator-activated receptor (PPAR) signaling pathway, including PPAR-gamma, involved in activation of the alternative, anti-inflammatory macrophage response was down-regulated following stimulation with both antigens. In contrast, up-regulation of genes associated with the classic, pro-inflammatory macrophage response was noted. Further analysis revealed a decrease in the expression of cell adhesion molecules (CAMs), including integrin alpha M (ITGAM), which is known to be important for entry of mycobacteria into the macrophage. Interestingly, more leukocyte genes were down-regulated than up-regulated. CONCLUSION: Our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to TB induced by vaccination with BCG.","Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (10w) after exposure to BCG (Danish strain BCG Statens Serum Institut, Denmark) , time point 10W. Comment: PBMCs drawn at 10 weeks following immunization at birth","Fletcher HA,Keyser A,Bowmaker M,Sayles PC,Kaplan G,Hussey G,Hill AV,Hanekom WA",19239680,HUMAN_GENE_SYMBOL,"ABCA1,ABCC3,ABCG1,ADAP2,AIF1,ALCAM,ALDH1A2,ALDH3B1,ANXA1,ANXA11,ANXA2,ANXA4,ANXA5,APOC1,APOE,ARAP3,ARHGAP18,ASPHD1,ATP6AP2,ATP6V1A,AVPI1,C1orf54,C3,C3AR1,C5AR2,C5AR1,CA2,CAMK1,CAMSAP2,CAPG,CAPN2,CARD9,CCR1,CCR5,CD151,CD300C,CD300LB,CD33,CD36,CD52,CD63,CD84,CD86,CD9,CEBPA,CEBPB,CHST13,CLDN23,CLEC12A,CLEC4A,CLEC5A,CLIP2,CORO1C,CPQ,CREG1,CSF1R,CST3,CST6,CTSB,CTSD,CTSS,CXCL16,CYBB,CYFIP1,CYP1B1,CYP27A1,CYTH4,DAB2,DAGLA,DCSTAMP,DHRS9,DPYSL2,EEF1AKMT3,EGR2,EMP1,ENG,EVA1B,FABP4,FAM20C,FBP1,FCGRT,FGL2,FGR,FKBP1A,FLRT2,FLVCR2,FOS,FPR3,FTL,FUCA2,G6PD,GCLC,GLA,GLIPR1,GLIPR2,GLMP,GLUL,GPC2,GPC4,GPNMB,GPR35,GREM1,GSN,HAVCR2,HCST,HEBP1,HEXB,HK3,HMOX1,HSD3B7,HTRA1,ICAM5,IFI30,IGF2BP2,IGF2R,IGSF6,IL17RA,IL1R2,IL1RN,IL3RA,INF2,ITGAM,ITGAX,KCNE3,KCNN4,KCTD12,KIAA0930,KIFC3,LGALS1,LGALS3,LHFPL2,LILRA2,LIMS1,LINC00520,LINC01010,LMNA,LPL,LRP1,LRP3,LTBR,LYZ,MAPKAPK3,ME1,METTL7B,MFSD12,MGST1,MITF,MMP19,MMP9,MNDA,MPP1,MRAS,MYOF,NCEH1,NEK6,NIBAN2,NLRC4,NPC2,NPL,NRROS,NT5E,NUMB,OTOA,PACSIN2,PAPSS1,PDE4A,PDGFRB,PDLIM7,PDXK,PFKFB4,PI4K2A,PIEZO1,PKM,PLA2G7,PLBD1,PLEKHO2,PLIN2,PLXDC2,PNKD,PPARG,PPM1M,PTGR1,PTGS1,PTPN6,PTPRE,RAI14,RASSF4,RGCC,RGL1,RHOC,RNF122,RNF130,RPS6KA1,RXRA,S100A10,S100A11,S100A4,S100A6,SCARB2,SCG5,SDCBP,SDSL,SERPINE1,SH3BGRL3,SHTN1,SIGLEC9,SIPA1L2,SIRPA,SLAMF8,SLC16A3,SLC17A5,SLC1A3,SLC26A11,SLC27A3,SLC31A1,SLC31A2,SLC35E4,SLC37A2,SLC38A6,SLC44A1,SLC49A3,SLC7A8,SLCO3A1,SMCO4,SNAI3,SPHK1,SPI1,SPINT1,SPP1,SPRED1,SRXN1,STAB1,STARD8,TBXAS1,TGFBI,THEMIS2,TIMP2,TKTL1,TM4SF19,TMBIM1,TMEM158,TNFRSF21,TNS3,TPM4,TPST1,TSPO,TYROBP,VIM,VIPR1,VWA5A,VWF,ZEB2,ZMIZ1,ZMYND15,ZNF366,ZYX",256,"ABCA1,ABCC3,ABCG1,ADAP2,AIF1,ALCAM,ALDH1A2,ALDH3B1,ANXA1,ANXA11,ANXA2,ANXA4,ANXA5,APOC1,APOE,ARAP3,ARHGAP18,ASPHD1,ATP6AP2,ATP6V1A,AVPI1,C1orf54,C3,C3AR1,C5AR2,C5R1,CA2,CAMK1,CAMSAP2,CAPG,CAPN2,CARD9,CCR1,CCR5,CD151,CD300C,CD300LB,CD33,CD36,CD52,CD63,CD84,CD86,CD9,CEBPA,CEBPB,CHST13,CLDN23,CLEC12A,CLEC4A,CLEC5A,CLIP2,CORO1C,CPQ,CREG1,CSF1R,CST3,CST6,CTSB,CTSD,CTSS,CXCL16,CYBB,CYFIP1,CYP1B1,CYP27A1,CYTH4,DAB2,DAGLA,DCSTAMP,DHRS9,DPYSL2,EEF1AKMT3,EGR2,EMP1,ENG,EVA1B,FABP4,FAM20C,FBP1,FCGRT,FGL2,FGR,FKBP1A,FLRT2,FLVCR2,FOS,FPR3,FTL,FUCA2,G6PD,GCLC,GLA,GLIPR1,GLIPR2,GLMP,GLUL,GPC2,GPC4,GPNMB,GPR35,GREM1,GSN,HAVCR2,HCST,HEBP1,HEXB,HK3,HMOX1,HSD3B7,HTRA1,ICAM5,IFI30,IGF2BP2,IGF2R,IGSF6,IL17RA,IL1R2,IL1RN,IL3RA,INF2,ITGAM,ITGAX,KCNE3,KCNN4,KCTD12,KIAA0930,KIFC3,LGALS1,LGALS3,LHFPL2,LILRA2,LIMS1,LINC00520,LINC01010,LMNA,LPL,LRP1,LRP3,LTBR,LYZ,MAPKAPK3,ME1,METTL7B,MFSD12,MGST1,MITF,MMP19,MMP9,MNDA,MPP1,MRAS,MYOF,NCEH1,NEK6,NIBAN2,NLRC4,NPC2,NPL,NRROS,NT5E,NUMB,OTOA,PACSIN2,PAPSS1,PDE4A,PDGFRB,PDLIM7,PDXK,PFKFB4,PI4K2A,PIEZO1,PKM,PLA2G7,PLBD1,PLEKHO2,PLIN2,PLXDC2,PNKD,PPARG,PPM1M,PTGR1,PTGS1,PTPN6,PTPRE,RAI14,RASSF4,RGCC,RGL1,RHOC,RNF122,RNF130,RPS6KA1,RXRA,S100A10,S100A11,S100A4,S100A6,SCARB2,SCG5,SDCBP,SDSL,SERPINE1,SH3BGRL3,SHTN1,SIGLEC9,SIPA1L2,SIRPA,SLAMF8,SLC16A3,SLC17A5,SLC1A3,SLC26A11,SLC27A3,SLC31A1,SLC31A2,SLC35E4,SLC37A2,SLC38A6,SLC44A1,SLC49A3,SLC7A8,SLCO3A1,SMCO4,SNAI3,SPHK1,SPI1,SPINT1,SPP1,SPRED1,SRXN1,STAB1,STARD8,TBXAS1,TGFBI,THEMIS2,TIMP2,TKTL1,TM4SF19,TMBIM1,TMEM158,TNFRSF21,TNS3,TPM4,TPST1,TSPO,TYROBP,VIM,VIPR1,VWA5A,VWF,ZEB2,ZMIZ1,ZMYND15,ZNF366,ZYX",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/,NA,NA,NA,NA
M41041,BCG,LA,TUBERCULOSIS,FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,W10,W,10,INFANT,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FLETCHER_PBMC_BCG_10W_INFANT_BCG_STIMULATED_VS_UNSTIMULATED_10W_UP,"BACKGROUND: Novel tuberculosis (TB) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, Mycobacterium bovis Bacille Calmette-Guerin (BCG). Because BCG vaccination is used extensively in infants, this population group is likely to be the first in which efficacy trials of new vaccines will be conducted. However, our understanding of the complexity of immunity to BCG in infants is inadequate, making interpretation of vaccine-induced immune responses difficult. METHODS: To better understand BCG-induced immunity, we performed gene expression profiling in five 10-week old infants routinely vaccinated with BCG at birth. RNA was extracted from 12 hour BCG-stimulated or purified protein derivative of tuberculin (PPD)-stimulated PBMC, isolated from neonatal blood collected 10 weeks after vaccination. RNA was hybridised to the Sentrix(R) HumanRef-8 Expression BeadChip (Illumina) to measure expression of > 16,000 genes. RESULTS: We found that ex vivo stimulation of PBMC with PPD and BCG induced largely similar gene expression profiles, except that BCG induced greater macrophage activation. The peroxisome proliferator-activated receptor (PPAR) signaling pathway, including PPAR-gamma, involved in activation of the alternative, anti-inflammatory macrophage response was down-regulated following stimulation with both antigens. In contrast, up-regulation of genes associated with the classic, pro-inflammatory macrophage response was noted. Further analysis revealed a decrease in the expression of cell adhesion molecules (CAMs), including integrin alpha M (ITGAM), which is known to be important for entry of mycobacteria into the macrophage. Interestingly, more leukocyte genes were down-regulated than up-regulated. CONCLUSION: Our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to TB induced by vaccination with BCG.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (10w) after exposure to BCG (Danish strain BCG Statens Serum Institut, Denmark) , time point 10W. Comment: PBMCs drawn at 10 weeks following immunization at birth","Fletcher HA,Keyser A,Bowmaker M,Sayles PC,Kaplan G,Hussey G,Hill AV,Hanekom WA",19239680,HUMAN_GENE_SYMBOL,"AARS1,ABTB2,ACOT7,ADA,ADORA2A,AKR1C2,APOL1,APOL3,AQP9,ASNS,ASPHD2,BATF,BATF3,BCL2A1,C2CD4B,CCL1,CCL20,CCL22,CCL3,CCL3L1,CCL4,CD38,CD93,CHAC1,CITED4,CKB,CSF2,CSF3,CXCL1,CXCL10,CXCL2,CXCL3,CXCL8,CXCR5,D2HGDH,DDIT4,DUSP5,EBI3,EDN1,EML2,EPSTI1,F3,FERMT2,FEZ1,G0S2,GADD45B,GBP1,GBP2,GBP4,GBP5,GNG8,HDGFL3,HECW2,IDO1,IER3,IFI44L,IFIH1,IFIT3,IL12B,IL1A,IL1B,IL36G,IL6,IRF1,IRF4,IRF9,ISG15,LAMP3,LIF,LTA,MAP3K8,MARS1,MMP1,MMP10,MMP14,MT2A,MTHFD1L,MX1,NAMPT,NEU4,NFKB1,NFKBIZ,NME2,OAS3,OSM,PARP9,PHGDH,PHLDA2,PIM1,PIM2,PLAAT4,PMAIP1,PSAT1,PSMB9,PSME2,PTGS2,PTX3,PYCR1,RGS3,RIPK2,RNF144B,RUNX3,SERPINA1,SERPINB1,SERPINB2,SERPINB7,SESN2,SLC22A1,SLC7A5,SLC7A7,SOCS1,SOD2,STAT1,TFPI2,TNF,TNFAIP6,TNFSF4,TRAF4,TRIB3,TRIM22,UBE2L6,VNN1,VNN3P,VPREB3,WARS1,XCL2,ZMIZ2",127,"AARS1,ABTB2,ACOT7,ADA,ADORA2A,AKR1C2,APOL1,APOL3,AQP9,ASNS,ASPHD2,BATF,BATF3,BCL2A1,C2CD4B,CCL1,CCL20,CCL22,CCL3,CCL3L1,CCL4,CD38,CD93,CHAC1,CITED4,CKB,CSF2,CSF3,CXCL1,CXCL10,CXCL2,CXCL3,CXCL8,CXCR5,D2HGDH,DDIT4,DUSP5,EBI3,EDN1,EML2,EPSTI1,F3,FERMT2,FEZ1,G0S2,GADD45B,GBP1,GBP2,GBP4,GBP5,GNG8,HDGFL3,HECW2,IDO1,IER3,IFI44L,IFIH1,IFIT3,IL12B,IL1A,IL1B,IL36G,IL6,IRF1,IRF4,IRF9,ISG15,LAMP3,LIF,LTA,MAP3K8,MARS,MMP1,MMP10,MMP14,MT2A,MTHFD1L,MX1,NAMPT,NEU4,NFKB1,NFKBIZ,NME2,OAS3,OSM,PARP9,PHGDH,PHLDA2,PIM1,PIM2,PLAAT4,PMAIP1,PSAT1,PSMB9,PSME2,PTGS2,PTX3,PYCR1,RGS3,RIPK2,RNF144B,RUNX3,SERPINA1,SERPINB1,SERPINB2,SERPINB7,SESN2,SLC22A1,SLC7A5,SLC7A7,SOCS1,SOD2,STAT1,TFPI2,TNF,TNFAIP6,TNFSF4,TRAF4,TRIB3,TRIM22,UBE2L6,VNN1,VNN3,VPREB3,WARS,XCL2,ZMIZ2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA
M41082,HIV LIPO 5,SU,HIV,RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_0W_14W_METALLOTHIONEIN_SUBSET_UP,VIRUS,UP,SUBSET,SIGNATURE,D1,D,1,37-48,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_0W_14W_METALLOTHIONEIN_SUBSET_UP,"OBJECTIVE: To dissect the biological mechanisms involved in the cellular responses to a candidate vaccine containing 5 HIV peptides coupled to a palmytoil tail (HIV-LIPO-5) in healthy volunteers, by using extensive immunogenicity assessments with different stimulation durations. DESIGN: Immunogenicity substudy of a randomized phase II prophylactic HIV vaccine trial (ANRS VAC 18). METHODS: HIV-LIPO-5 or placebo was administered at W0, W4, W12 and W24. Peripheral blood mononuclear cells from a subset of participants at W0 and W14 were stimulated with HIV-LIPO-5, Gag peptides contained in the vaccine and control peptides. ELISpot, lymphoproliferation, intracellular cytokine staining (ICS), cytokine multiplex and transcriptomic analyses were performed. Different time points and stimulation conditions were compared, controlling for test multiplicity. RESULTS: Cultured ELISpot and lymphoproliferation responses were detected at W14. Ex-vivo ICS showed mainly interleukin (IL)-2-producing cells. Secretion of interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, IL-5 and IL-13 increased significantly after culture and Gag stimulation at W14 compared to W0. Metallothionein genes were consistently overexpressed after HIV-LIPO-5 stimulation at W0 and W14. At W14, significant probes increased substantially, including IFN-gamma, CXCL9, IL2RA, TNFAIP6, CCL3L1 and IL-6. Canonical pathway analyses indicated a role of interferon signalling genes in response to HIV-LIPO-5. CONCLUSION: HIV-LIPO-5 vaccination elicited Th1 and Th2 memory precursor responses and a consistent modulation in gene expression. The response profile before vaccination suggests an adjuvant effect of the lipid tail of HIV-LIPO-5. Our combined immunogenicity analyses allowed to identify a specific signature profile of HIV-LIPO-5 and indicate that HIV-LIPO-5 could be further developed as a prime in heterologous prime-boost strategies.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (37-48) after exposure to HIV-LIPO-5 , time point 0W and 14 W. Comment: metallothionein genes, 0W and 14W combined (identical signatures)","Richert L,Hue S,Hocini H,Raimbault M,Lacabaratz C,Surenaud M,Wiedemann A,Tisserand P,Durier C,Salmon D,Lelivre JD,Chne G,Thibaut R,Lvy Y,ANRS Vaccine Network/Vaccine Research Institute",23759749,HUMAN_GENE_SYMBOL,"MT1A,MT1E,MT1F,MT1G,MT1H,MT1M,MT1X,MT2A",8,"MT1A,MT1E,MT1F,MT1G,MT1H,MT1M,MT1X,MT2A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Abstract,NA,NA,NA,NA,NA
M41028,HIV LIPO 5,SU,HIV,RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_INTERFERON_SUBSET_UP,VIRUS,UP,SUBSET,SIGNATURE,W14,W,14,37-48,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_INTERFERON_SUBSET_UP,"OBJECTIVE: To dissect the biological mechanisms involved in the cellular responses to a candidate vaccine containing 5 HIV peptides coupled to a palmytoil tail (HIV-LIPO-5) in healthy volunteers, by using extensive immunogenicity assessments with different stimulation durations. DESIGN: Immunogenicity substudy of a randomized phase II prophylactic HIV vaccine trial (ANRS VAC 18). METHODS: HIV-LIPO-5 or placebo was administered at W0, W4, W12 and W24. Peripheral blood mononuclear cells from a subset of participants at W0 and W14 were stimulated with HIV-LIPO-5, Gag peptides contained in the vaccine and control peptides. ELISpot, lymphoproliferation, intracellular cytokine staining (ICS), cytokine multiplex and transcriptomic analyses were performed. Different time points and stimulation conditions were compared, controlling for test multiplicity. RESULTS: Cultured ELISpot and lymphoproliferation responses were detected at W14. Ex-vivo ICS showed mainly interleukin (IL)-2-producing cells. Secretion of interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, IL-5 and IL-13 increased significantly after culture and Gag stimulation at W14 compared to W0. Metallothionein genes were consistently overexpressed after HIV-LIPO-5 stimulation at W0 and W14. At W14, significant probes increased substantially, including IFN-gamma, CXCL9, IL2RA, TNFAIP6, CCL3L1 and IL-6. Canonical pathway analyses indicated a role of interferon signalling genes in response to HIV-LIPO-5. CONCLUSION: HIV-LIPO-5 vaccination elicited Th1 and Th2 memory precursor responses and a consistent modulation in gene expression. The response profile before vaccination suggests an adjuvant effect of the lipid tail of HIV-LIPO-5. Our combined immunogenicity analyses allowed to identify a specific signature profile of HIV-LIPO-5 and indicate that HIV-LIPO-5 could be further developed as a prime in heterologous prime-boost strategies.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (37-48) after exposure to HIV-LIPO-5 , time point 14W. Comment: Genes that act in the interferon pathway","Richert L,Hue S,Hocini H,Raimbault M,Lacabaratz C,Surenaud M,Wiedemann A,Tisserand P,Durier C,Salmon D,Lelivre JD,Chne G,Thibaut R,Lvy Y,ANRS Vaccine Network/Vaccine Research Institute",23759749,HUMAN_GENE_SYMBOL,"IFI35,IFNG,SOCS1,STAT1,TAP1",5,"IFI35,IFNG,SOCS1,STAT1,TAP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41035,HIV LIPO 5,SU,HIV,RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_TOP_FUNCTIONAL_NETWORK_UP,VIRUS,UP,SUBSET,TOP DEGS,W14,W,14,37-48,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_TOP_FUNCTIONAL_NETWORK_UP,"OBJECTIVE: To dissect the biological mechanisms involved in the cellular responses to a candidate vaccine containing 5 HIV peptides coupled to a palmytoil tail (HIV-LIPO-5) in healthy volunteers, by using extensive immunogenicity assessments with different stimulation durations. DESIGN: Immunogenicity substudy of a randomized phase II prophylactic HIV vaccine trial (ANRS VAC 18). METHODS: HIV-LIPO-5 or placebo was administered at W0, W4, W12 and W24. Peripheral blood mononuclear cells from a subset of participants at W0 and W14 were stimulated with HIV-LIPO-5, Gag peptides contained in the vaccine and control peptides. ELISpot, lymphoproliferation, intracellular cytokine staining (ICS), cytokine multiplex and transcriptomic analyses were performed. Different time points and stimulation conditions were compared, controlling for test multiplicity. RESULTS: Cultured ELISpot and lymphoproliferation responses were detected at W14. Ex-vivo ICS showed mainly interleukin (IL)-2-producing cells. Secretion of interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, IL-5 and IL-13 increased significantly after culture and Gag stimulation at W14 compared to W0. Metallothionein genes were consistently overexpressed after HIV-LIPO-5 stimulation at W0 and W14. At W14, significant probes increased substantially, including IFN-gamma, CXCL9, IL2RA, TNFAIP6, CCL3L1 and IL-6. Canonical pathway analyses indicated a role of interferon signalling genes in response to HIV-LIPO-5. CONCLUSION: HIV-LIPO-5 vaccination elicited Th1 and Th2 memory precursor responses and a consistent modulation in gene expression. The response profile before vaccination suggests an adjuvant effect of the lipid tail of HIV-LIPO-5. Our combined immunogenicity analyses allowed to identify a specific signature profile of HIV-LIPO-5 and indicate that HIV-LIPO-5 could be further developed as a prime in heterologous prime-boost strategies.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (37-48) after exposure to HIV-LIPO-5 , time point 14W. Comment: top functional network of up-regulated genes","Richert L,Hue S,Hocini H,Raimbault M,Lacabaratz C,Surenaud M,Wiedemann A,Tisserand P,Durier C,Salmon D,Lelivre JD,Chne G,Thibaut R,Lvy Y,ANRS Vaccine Network/Vaccine Research Institute",23759749,HUMAN_GENE_SYMBOL,"CCL1,CCL3L1,CD69,CXCL6,CXCL9,EBI3,GBP1,IDO1,IFNB1,IFNG,IL15RA,IL1A,IL24,IL36G,PSMB9,RIPK2,SOCS1,SOCS2,STAT1,TAP1,TAP2,TFPI2,TLR10,TNFRSF18,TNFRSF4,UBD,UHMK1",27,"CCL1,CCL3L1,CD69,CXCL6,CXCL9,EBI3,GBP1,IDO1,IFNB1,IFNG,IL15RA,IL1A,IL24,IL36G,PSMB9,RIPK2,SOCS1,SOCS2,STAT1,TAP1,TAP2,TFPI2,TLR10,TNFRSF18,TNFRSF4,UBD,UHMK1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M41027,HIV LIPO 5,SU,HIV,RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_SIGNIFICANT_VARIATION_UP,VIRUS,UP,SUBSET,TOP DEGS,W14,W,14,37-48,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/RICHERT_PBMC_HIV_LIPO_5_AGE_37_48YO_STIMULATED_VS_UNSTIMULATED_14W_SIGNIFICANT_VARIATION_UP,"OBJECTIVE: To dissect the biological mechanisms involved in the cellular responses to a candidate vaccine containing 5 HIV peptides coupled to a palmytoil tail (HIV-LIPO-5) in healthy volunteers, by using extensive immunogenicity assessments with different stimulation durations. DESIGN: Immunogenicity substudy of a randomized phase II prophylactic HIV vaccine trial (ANRS VAC 18). METHODS: HIV-LIPO-5 or placebo was administered at W0, W4, W12 and W24. Peripheral blood mononuclear cells from a subset of participants at W0 and W14 were stimulated with HIV-LIPO-5, Gag peptides contained in the vaccine and control peptides. ELISpot, lymphoproliferation, intracellular cytokine staining (ICS), cytokine multiplex and transcriptomic analyses were performed. Different time points and stimulation conditions were compared, controlling for test multiplicity. RESULTS: Cultured ELISpot and lymphoproliferation responses were detected at W14. Ex-vivo ICS showed mainly interleukin (IL)-2-producing cells. Secretion of interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, IL-5 and IL-13 increased significantly after culture and Gag stimulation at W14 compared to W0. Metallothionein genes were consistently overexpressed after HIV-LIPO-5 stimulation at W0 and W14. At W14, significant probes increased substantially, including IFN-gamma, CXCL9, IL2RA, TNFAIP6, CCL3L1 and IL-6. Canonical pathway analyses indicated a role of interferon signalling genes in response to HIV-LIPO-5. CONCLUSION: HIV-LIPO-5 vaccination elicited Th1 and Th2 memory precursor responses and a consistent modulation in gene expression. The response profile before vaccination suggests an adjuvant effect of the lipid tail of HIV-LIPO-5. Our combined immunogenicity analyses allowed to identify a specific signature profile of HIV-LIPO-5 and indicate that HIV-LIPO-5 could be further developed as a prime in heterologous prime-boost strategies.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in adults (37-48) after exposure to HIV-LIPO-5 , time point 14W. Comment: genes with a significant variation at W14 after 24-h HIV-LIPO-5 stimulation, IFN-gamma, CXCL9, IL2RA, TNFAIP6, CCL3L1 and IL-6 were overexpressed with a fold change |FC| >1.8","Richert L,Hue S,Hocini H,Raimbault M,Lacabaratz C,Surenaud M,Wiedemann A,Tisserand P,Durier C,Salmon D,Lelivre JD,Chne G,Thibaut R,Lvy Y,ANRS Vaccine Network/Vaccine Research Institute",23759749,HUMAN_GENE_SYMBOL,"CCL3L1,CXCL9,IFNG,IL2RA,IL6,TNFAIP6",6,"CCL3L1,CXCL9,IFNG,IL2RA,IL6,TNFAIP6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40969,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D0,D,0,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0DY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 0D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"ABCA13,ARG1,BPI,CAMP,CEACAM8,CPA3,CRISP3,DEFA1B,DEFA4,DNM1P46,FOLR3,LTF,MMP8,MS4A3,OLR1,RNASE3,SLPI,TCN1,TKTL1",19,"ABCA13,ARG1,BPI,CAMP,CEACAM8,CPA3,CRISP3,DEFA1B,DEFA4,DNM1P46,FOLR3,LTF,MMP8,MS4A3,OLR1,RNASE3,SLPI,TCN1,TKTL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41136,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,D28,D,28,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_DN,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes down-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 28D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"ALAS2,DCAF12,FAM210B,GYPA,MBNL3,RPS26,RPS26P11,SLC25A37,SLC4A1,SNCA,STRADB",11,"ALAS2,DCAF12,FAM210B,GYPA,MBNL3,RPS26,RPS26P11,SLC25A37,SLC4A1,SNCA,STRADB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/bin/jiy420_suppl_supplementary_table_1.xlsx,NA,NA,NA,NA
M40981,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D28,D,28,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_28DY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 28D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"ANXA3,ARG1,DLX4,CAMP,CCL4,CEACAM8,CRISP3,DEFA1B,DEFA4,DOCK4,FOLR3,LTF,MMP8,MS4A3,OLR1,TCN1,TKTL1",17,"ANXA3,ARG1,BP1,CAMP,CCL4,CEACAM8,CRISP3,DEFA1B,DEFA4,DOCK4,FOLR3,LTF,MMP8,MS4A3,OLR1,TCN1,TKTL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40984,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_7DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D3,D,3,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_7DY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 7D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"ANXA3,ARG1,,DLX4,CCL4,,CEACAM8,CRISP3,CXCL8,DEFA1B,DEFA4,F3,FOLR3,KISS1R,IFNG,IL1RN,IL23A,IRAK2,KCNJ2,KCNJ2-AS1,KMO,LACC1,LTF,MIR3945HG,MMP8,MS4A3,RIN2,RNASE3,SERPINB2,TCN1,TKTL1,TNF,TNFAIP6,ZC3H12C",34,"ANXA3,ARG1,BABAM2-AS1,BP1,CCL4,CCL4L1,CEACAM8,CRISP3,CXCL8,DEFA1B,DEFA4,F3,FOLR3,GPR54,IFNG,IL1RN,IL23A,IRAK2,KCNJ2,KCNJ2-AS1,KMO,LACC1,LTF,MIR3945HG,MMP8,MS4A3,RIN2,RNASE3,SERPINB2,TCN1,TKTL1,TNF,TNFAIP6,ZC3H12C",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40982,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_35DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D35,D,35,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_35DY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 35D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,",DLX4,CCL4,CEACAM8,CRISP3,CXCL10,DEFA1B,DEFA4,FCGR1A,FCGR1BP,IFNG,LTF,MMP8,SERPING1,TCN1,TKTL1",16,"APOBEC3A_B,BP1,CCL4,CEACAM8,CRISP3,CXCL10,DEFA1B,DEFA4,FCGR1A,FCGR1B,IFNG,LTF,MMP8,SERPING1,TCN1,TKTL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40924,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_3DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D35,D,35,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_3DY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 3D","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"ABCA13,ANXA3,ARG1,BPI,CEACAM1,CEACAM8,DEFA1B,DEFA4,FOLR3,IFNG,LTF,MMP8,MS4A3,TCN1,TKTL1",15,"ABCA13,ANXA3,ARG1,BPI,CEACAM1,CEACAM8,DEFA1B,DEFA4,FOLR3,IFNG,LTF,MMP8,MS4A3,TCN1,TKTL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41053,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_HIGH_IGM_RESPONDERS_3DY_7D_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_HIGH_IGM_RESPONDERS_3DY_7D_DN,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes down-regulated in blood 3d and 7d vs 0hr in adults (18-45) (high IgM responders) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 3D, 7D combined (identical signatures) , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"IL2RB,KLRB1,KLRD1,NKG7,SLAMF7,TBX21",6,"IL2RB,KLRB1,KLRD1,NKG7,SLAMF7,TBX21",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/bin/jiy420_suppl_supplementary_table_1.xlsx,NA,NA,NA,NA
M41155,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_LOW_IGM_RESPONDERS_6HY_1DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,H6,H,6,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_LOW_IGM_RESPONDERS_6HY_1DY_UP,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes up-regulated in blood 6hr/1DY vs 0hr in adults (18-45) (low IgM responders) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 6H/1DY combined (identical signature) , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"CAV1,KCNH1,KRTCAP2,SLC44A1,TXNDC15",5,"CAV1,KCNH1,KRTCAP2,SLC44A1,TXNDC15",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41021,PFALCIPARUM RTSS,SU,MALARIA,KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP,PARASITE,UP,VACCINE,COMPARISON,D1,D,1,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_UNKN_AGE_IMM_WITH_ARR_VS_IMM_BY_RRR_PRIMARY_IMMUNIZ_WITH_RECOMB_ADENOVIRUS_35_1DY_UP,"RTS,S is an advanced malaria vaccine candidate and confers significant protection against <i>Plasmodium falciparum</i> infection in humans. Little is known about the molecular mechanisms driving vaccine immunity. Here, we applied a systems biology approach to study immune responses in subjects receiving three consecutive immunizations with RTS,S (RRR), or in those receiving two immunizations of RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) (ARR) vector expressing circumsporozoite protein. Subsequent controlled human malaria challenge (CHMI) of the vaccinees with <i>Plasmodium</i>-infected mosquitoes, 3 wk after the final immunization, resulted in ~50% protection in both groups of vaccinees. Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with protection in the RRR group. In contrast, ARR-induced lower antibody responses, and protection was associated with polyfunctional CD4<sup>+</sup> T-cell responses 2 wk after priming with Ad35. Molecular signatures of B and plasma cells detected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR cohort. In contrast, early signatures of innate immunity and dendritic cell activation were highly associated with protection in the ARR cohort. For both vaccine regimens, natural killer (NK) cell signatures negatively correlated with and predicted protection. These results suggest that protective immunity against <i>P. falciparum</i> can be achieved via multiple mechanisms and highlight the utility of systems approaches in defining molecular correlates of protection to vaccination.","Genes up-regulated in peripheral blood mononuclear cell immunized with ARR vs immunized by RRR in unknown (primary immunization with recombinant adenovirus 35 (Ad35)) after exposure to P. falciparum RTS,S/AS01 , time point 1D","Kazmin D,Nakaya HI,Lee EK,Johnson MJ,van der Most R,van den Berg RA,Ballou WR,Jongert E,Wille-Reece U,Ockenhouse C,Aderem A,Zak DE,Sadoff J,Hendriks J,Wrammert J,Ahmed R,Pulendran B",28193898,HUMAN_GENE_SYMBOL,"EPHB2,HESX1,IFI27,IFI44L,IFI6,LGALS3BP,LINC00487,LY6E,SERPING1,SIGLEC1",10,"EPHB2,HESX1,IFI27,IFI44L,IFI6,LGALS3BP,LINC00487,LY6E,SERPING1,SIGLEC1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528489/bin/1208972109_sd01.xlsx,NA,NA,NA,NA
M40909,PFALCIPARUM RTSS,SU,MALARIA,KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_NEGATIVE,PARASITE,NEGATIVE,CORRELATION,PROTECTION,D56,D,56,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_NEGATIVE,"RTS,S is an advanced malaria vaccine candidate and confers significant protection against <i>Plasmodium falciparum</i> infection in humans. Little is known about the molecular mechanisms driving vaccine immunity. Here, we applied a systems biology approach to study immune responses in subjects receiving three consecutive immunizations with RTS,S (RRR), or in those receiving two immunizations of RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) (ARR) vector expressing circumsporozoite protein. Subsequent controlled human malaria challenge (CHMI) of the vaccinees with <i>Plasmodium</i>-infected mosquitoes, 3 wk after the final immunization, resulted in ~50% protection in both groups of vaccinees. Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with protection in the RRR group. In contrast, ARR-induced lower antibody responses, and protection was associated with polyfunctional CD4<sup>+</sup> T-cell responses 2 wk after priming with Ad35. Molecular signatures of B and plasma cells detected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR cohort. In contrast, early signatures of innate immunity and dendritic cell activation were highly associated with protection in the ARR cohort. For both vaccine regimens, natural killer (NK) cell signatures negatively correlated with and predicted protection. These results suggest that protective immunity against <i>P. falciparum</i> can be achieved via multiple mechanisms and highlight the utility of systems approaches in defining molecular correlates of protection to vaccination.","Genes negatively correlated with protection in peripheral blood mononuclear cell in unknown after exposure to P. falciparum RTS,S/AS01 , time point 56D","Kazmin D,Nakaya HI,Lee EK,Johnson MJ,van der Most R,van den Berg RA,Ballou WR,Jongert E,Wille-Reece U,Ockenhouse C,Aderem A,Zak DE,Sadoff J,Hendriks J,Wrammert J,Ahmed R,Pulendran B",28193898,HUMAN_GENE_SYMBOL,"ADGRG1,ARL4C,CCL5,CD244,CD247,CD7,CD96,CLIC3,CST7,GIMAP7,GNLY,GZMA,GZMB,GZMH,GZMM,HOPX,IL18RAP,IL2RB,KIR2DL1,KIR2DL2,KIR2DL3,KIR2DL4,KIR2DL5A,KIR2DS1,KIR2DS2,KIR2DS3,KIR2DS5,KIR3DL1,KIR3DL3,KLRB1,KLRC1,KLRD1,KLRF1,KLRK1,MYBL1,NKG7,PRF1,PRKCQ,PTGDR,PVRIG,RORA,S1PR5,SAMD3,SH2D2A,STAT4,TBX21,TGFBR3,,,XCL2,ZAP70",51,"ADGRG1,ARL4C,CCL5,CD244,CD247,CD7,CD96,CLIC3,CST7,GIMAP7,GNLY,GZMA,GZMB,GZMH,GZMM,HOPX,IL18RAP,IL2RB,KIR2DL1,KIR2DL2,KIR2DL3,KIR2DL4,KIR2DL5A,KIR2DS1,KIR2DS2,KIR2DS3,KIR2DS5,KIR3DL1,KIR3DL3,KLRB1,KLRC1,KLRD1,KLRF1,KLRK1,MYBL1,NKG7,PRF1,PRKCQ,PTGDR,PVRIG,RORA,S1PR5,SAMD3,SH2D2A,STAT4,TBX21,TGFBR3,TRA,TRD,XCL2,ZAP70",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M41120,PFALCIPARUM RTSS,SU,MALARIA,KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_POSITIVE,PARASITE,POSITIVE,CORRELATION,PROTECTION,D56,D,56,UNK,UNKNOWN,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KAZMIN_PBMC_P_FALCIPARUM_RTSS_AS01_AGE_UNKNOWN_CORRELATED_WITH_PROTECTION_56DY_POSITIVE,"RTS,S is an advanced malaria vaccine candidate and confers significant protection against <i>Plasmodium falciparum</i> infection in humans. Little is known about the molecular mechanisms driving vaccine immunity. Here, we applied a systems biology approach to study immune responses in subjects receiving three consecutive immunizations with RTS,S (RRR), or in those receiving two immunizations of RTS,S/AS01 following a primary immunization with adenovirus 35 (Ad35) (ARR) vector expressing circumsporozoite protein. Subsequent controlled human malaria challenge (CHMI) of the vaccinees with <i>Plasmodium</i>-infected mosquitoes, 3 wk after the final immunization, resulted in ~50% protection in both groups of vaccinees. Circumsporozoite protein (CSP)-specific antibody titers, prechallenge, were associated with protection in the RRR group. In contrast, ARR-induced lower antibody responses, and protection was associated with polyfunctional CD4<sup>+</sup> T-cell responses 2 wk after priming with Ad35. Molecular signatures of B and plasma cells detected in PBMCs were highly correlated with antibody titers prechallenge and protection in the RRR cohort. In contrast, early signatures of innate immunity and dendritic cell activation were highly associated with protection in the ARR cohort. For both vaccine regimens, natural killer (NK) cell signatures negatively correlated with and predicted protection. These results suggest that protective immunity against <i>P. falciparum</i> can be achieved via multiple mechanisms and highlight the utility of systems approaches in defining molecular correlates of protection to vaccination.","Genes positively correlated with protection in peripheral blood mononuclear cell in unknown after exposure to P. falciparum RTS,S/AS01 , time point 56D","Kazmin D,Nakaya HI,Lee EK,Johnson MJ,van der Most R,van den Berg RA,Ballou WR,Jongert E,Wille-Reece U,Ockenhouse C,Aderem A,Zak DE,Sadoff J,Hendriks J,Wrammert J,Ahmed R,Pulendran B",28193898,HUMAN_GENE_SYMBOL,"CARD11,FASLG,FCGR3B,PLEKHF1,PRKCH,TARP",6,"CARD11,FASLG,FCGR3B,PLEKHF1,PRKCH,TARP",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M40925,HEPATITIS B SURFACE ANTIGEN,SU,HBV,QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0_TO_35DY_JOINTLY_UP,VIRUS,UP,SUBSET,TOP DEGS,D35,D,35,<50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/QIU_PBMC_HEPTATITIS_B_SURFACE_ANTIGEN_AGE_UNDER50_NON_RESPONDERS_VS_RESPONDERS_0_TO_35DY_JOINTLY_UP,"Individuals fail to elicit protective antibody after hepatitis B vaccination remain at risk for hepatitis B virus infection. Analysis of the transcriptome of peripheral blood mononuclear cells (PBMCs) is essential to elucidate the characteristics of gene expression in non-responders. In this study, we enrolled seven responders who had received three injections and seven non-responders who had six injections of hepatitis B vaccine before. All the participants were then vaccinated with a three-dose boost regimen. Microarray analysis and Luminex assay were applied to examine mRNA expression and Th1/Th2/Th9/Th17/Th22/Treg cytokine and chemokine profiles in non-responders and responders. Differentially expressed genes in PBMCs of non-responders at 5 time points, i.e. pre-vaccination, 3<sup>rd</sup>, 7<sup>th</sup>, 28<sup>th</sup> day post the first dose vaccination and 7<sup>th</sup> day post the second dose vaccination indicated a dense network trend. Compared with responders, nine coding genes (BPI, DEFA1B, DEFA4, CEACAM8, MMP8, FOLR3, LTF, TCN1 and TKTL1) were significantly up-regulated in non-responders at all 5 time points, which could probably be the characteristic genes in hepatitis B vaccine non-responsiveness. Gene ontology analysis revealed that most of the DEGs were related with immune responses. Validation results of these 9 genes using quantitative real-time polymerase chain reaction were mostly consistent with the results of microarray. Cytokine analysis demonstrated that IL-27 and CXCL12 concentrations in responders were significantly higher than non-responders on the 3<sup>rd</sup> day after the first dose and 7<sup>th</sup> day after the second dose of vaccination, respectively. No significant difference was observed in other cytokine and chemokine signatures between the two groups. In conclusion, our results revealed characteristic transcriptome and cytokine changes in hepatitis B vaccine non-responders after boost immunization.","Genes up-regulated in peripheral blood mononuclear cell non-responders vs responders in adults (<50) after exposure to Heptatitis B surface antigen vaccine (HBsAg) , time point 0, 3, 7, 28 and 35 jointly. Comment: these genes were upregulated at all five timepoints","Qiu S,He P,Fang X,Tong H,Lv J,Liu J,Zhang L,Zhai X,Wang L,Hu Z,Yu Y",29580160,HUMAN_GENE_SYMBOL,"BPI,CEACAM8,DEFA1B,DEFA4,FOLR3,LTF,MMP8,TCN1,TKTL1",9,"BPI,CEACAM8,DEFA1B,DEFA4,FOLR3,LTF,MMP8,TCN1,TKTL1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 3: Non-adjuvanted,https://www.sciencedirect.com/science/article/pii/S0166354217300098?via%3Dihub#fig3,NA,NA,NA,NA
M41135,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_UP,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes up-regulated in blood 1d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 1D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"ADRA2C,AMY1B,ARTN,ATAD1,ATP11C,BANF2,BMP8B,BOLA2,BRIX1,C4orf3,C9orf64,CAMK1G,CAMK2A,CAPZA1,CASTOR1,CD48,CRB3,CSNK1G1,EID3,ENSA,NALF2,FAM162A,FAM89A,FSTL4,FUT8-AS1,GCLM,GIMAP2,GOLGA6L7,GUCA2A,HBE1,HCN2,H3-4,HLA-C,HS3ST6,IER3IP1,IGFBP1,IL17REL,ING3,ITM2B,KCTD7,KRT75,KRTAP10-2,LINC01618,MAPK8IP2,MIR488,MRPL15,MTX2,NR2F2,NRSN2,OR52D1,PCYOX1,PHLDB1,PKP2,PLA2G3,PRDX4,PRKACG,RASSF6,RBMX2,RFX4,RNASEH2B,RNF7,RPS18,RUNX1T1,RXRG,SCGN,SIGLEC6,SMIM30,SNORD13,SNORD3D,SNTA1,SNX14,SOD2-OT1,SPINK2,SRGAP2C,STAR,SUMO1,SYP,TAFAZZIN,TMEM106B,TMEM191A,TMEM70,TMSB4X,TTC30A,ZNF160,ZNF320,ZNF93",86,"ADRA2C,AMY1B,ARTN,ATAD1,ATP11C,BANF2,BMP8B,BOLA2,BRIX1,C4orf3,C9orf64,CAMK1G,CAMK2A,CAPZA1,CASTOR1,CD48,CRB3,CSNK1G1,EID3,ENSA,FAM155B,FAM162A,FAM89A,FSTL4,FUT8-AS1,GCLM,GIMAP2,GOLGA6L7,GUCA2A,HBE1,HCN2,HIST3H3,HLA-C,HS3ST6,IER3IP1,IGFBP1,IL17REL,ING3,ITM2B,KCTD7,KRT75,KRTAP10-2,LINC01618,MAPK8IP2,MIR488,MRPL15,MTX2,NR2F2,NRSN2,OR52D1,PCYOX1,PHLDB1,PKP2,PLA2G3,PRDX4,PRKACG,RASSF6,RBMX2,RFX4,RNASEH2B,RNF7,RPS18,RUNX1T1,RXRG,SCGN,SIGLEC6,SMIM30,SNORD13,SNORD3D,SNTA1,SNX14,SOD2-OT1,SPINK2,SRGAP2C,STAR,SUMO1,SYP,TAZ,TMEM106B,TMEM191A,TMEM70,TMSB4X,TTC30A,ZNF160,ZNF320,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41085,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_1DY_DN,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes down-regulated in blood 1d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 1D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"ACD,ACLY,ACO2,ACTB,ADD1,GRK2,AFF4,ANTXR2,ARAP1,ARF1,ARF3,ARHGAP1,ARHGAP30,ARID3A,ARPC4,ATP6AP1,ATP6V1B2,BANP,BABAM2,MIDEAS,CACNA1S,CAP1,CBL,CLASP1,CREBBP,CTCF,DPEP2,DPF2,DPP8,DVL3,FBXL18,FLII,FOXJ3,FRA10AC1,GALNT10,GBA1,WLS,GRK6,HARS2,,HGS,HNRNPK,IDH3B,LAMP1,LAPTM5,LASP1,,MAST3,KMT2D,MSN,MTMR3,MYH9,KAT6A,NDRG3,PGD,PPP1CA,PRRC2C,RAB5B,RABGEF1,RALY,RASSF5,RCSD1,RIC8A,MAP7D1,SAP130,SEC16A,SEC23B,SF3B2,SH2D3C,SON,SORL1,SPEN,SRRM1,STK24,STK4,STX2,TAF4,TBC1D22A,UBA1,UBA1,UPF1,VPS8,WAS,WDR1,YWHAZ,ZAN,ZNF106,ZNF341",88,"ACD,ACLY,ACO2,ACTB,ADD1,ADRBK1,AFF4,ANTXR2,ARAP1,ARF1,ARF3,ARHGAP1,ARHGAP30,ARID3A,ARPC4,ATP6AP1,ATP6V1B2,BANP,BRE,C14orf43,CACNA1S,CAP1,CBL,CLASP1,CREBBP,CTCF,DPEP2,DPF2,DPP8,DVL3,FBXL18,FLII,FOXJ3,FRA10AC1,GALNT10,GBA,GPR177,GRK6,HARS2,HDGF2,HGS,HNRNPK,IDH3B,LAMP1,LAPTM5,LASP1,LOC728533,MAST3,MLL4,MSN,MTMR3,MYH9,MYST3,NDRG3,PGD,PPP1CA,PRRC2C,RAB5B,RABGEF1,RALY,RASSF5,RCSD1,RIC8A,RPRC1,SAP130,SEC16A,SEC23B,SF3B2,SH2D3C,SON,SORL1,SPEN,SRRM1,STK24,STK4,STX2,TAF4,TBC1D22A,UBA1,UBE1,UPF1,VPS8,WAS,WDR1,YWHAZ,ZAN,ZFP106,ZNF341",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 7A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909487/figure/f0035/,NA,NA,NA,NA
M40965,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_DN,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes down-regulated in blood 3d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 3D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"ACTG1,AFF4,AMDHD2,ARAP3,ARPC1B,ATG4B,ATP6V1A,TTI2,ZNG1F,CHMP2A,CORO1A,DNAJB12,DNTTIP1,DPEP2,WLS,HBP1,KCTD2,MAEA,MAPRE1,NUDT5,OSTF1,PARN,PGAM1,PPP1CA,PSMC1,PSMD13,RAB7A,RAI2,S100A4,SCAND1,TMLHE,TRIM63,WAS,ZAN",34,"ACTG1,AFF4,AMDHD2,ARAP3,ARPC1B,ATG4B,ATP6V1A,C8orf41,CBWD6,CHMP2A,CORO1A,DNAJB12,DNTTIP1,DPEP2,GPR177,HBP1,KCTD2,MAEA,MAPRE1,NUDT5,OSTF1,PARN,PGAM1,PPP1CA,PSMC1,PSMD13,RAB7A,RAI2,S100A4,SCAND1,TMLHE,TRIM63,WAS,ZAN",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 7B,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/figure/ppat.1005892.g007/,NA,NA,NA,NA
M41005,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_3DY_UP,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes up-regulated in blood 3d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 3D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"AMY1B,ARTN,BCAN,BMP8B,MROH8,CAMK1G,CASTOR1,SPICE1,COL6A3,EML2,RTL8B,FRMPD2B,G6PC1,GCK,GDF1,HBE1,IGFBP1,ING3,CLUH,LINC01618,MIR7-3HG,MPI,EEF1AKMT1,NECAP2,OR11A1,OR2A20P,PCYOX1,PKP2,RFX4,RNU4-1,RNU4-2,SCX,STAR,TMEM191A,TMEM70,TMSB4X,TTC30A,XRCC3,ZNF320,ZNF93",40,"AMY1B,ARTN,BCAN,BMP8B,C20orf132,CAMK1G,CASTOR1,CCDC52,COL6A3,EML2,FAM127C,FRMPD2L1,G6PC,GCK,GDF1,HBE1,IGFBP1,ING3,KIAA0664,LINC01618,MIR7-3HG,MPI,N6AMT2,NECAP2,OR11A1,OR2A20P,PCYOX1,PKP2,RFX4,RNU4-1,RNU4-2,SCXA,STAR,TMEM191A,TMEM70,TMSB4X,TTC30A,XRCC3,ZNF320,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41121,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_DN,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes down-regulated in blood 7d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 7D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"IDH3B,NUDT16L1,PAX2,PDXDC1,PRKCZ,SMPD2,UQCR10",7,"IDH3B,NUDT16L1,PAX2,PDXDC1,PRKCZ,SMPD2,UCRC",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s003.docx,NA,NA,NA,NA
M41209,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_7DY_UP,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes up-regulated in blood 7d vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 7D , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"ALDH8A1,ICA1L,AMY1B,BMP8B,C9orf64,CAMK2A,CDK6,EXO5,DTNA,RTL8B,FRMPD2B,GGT2P,GOLGA6L7,HBE1,HECA,HSP90AA2P,HTR2A,IGFBP1,ING3,ITM2B,KCTD7,NME2,PCYOX1,RAD51,RASSF6,RFX4,RPS6KA3,SCX,SIGLEC6,SLC26A4-AS1,SOD2-OT1,STAR,TAOK3,TMEM156,TMEM191A,TMEM70,TMSB4X,TTC30A,ZNF160,ZNF320,ZNF568,ZNF93",42,"ALDH8A1,ALS2CR14,AMY1B,BMP8B,C9orf64,CAMK2A,CDK6,DEM1,DTNA,FAM127C,FRMPD2L1,GGT2,GOLGA6L7,HBE1,HECA,HSP90AA2P,HTR2A,IGFBP1,ING3,ITM2B,KCTD7,NME2,PCYOX1,RAD51,RASSF6,RFX4,RPS6KA3,SCXA,SIGLEC6,SLC26A4-AS1,SOD2-OT1,STAR,TAOK3,TMEM156,TMEM191A,TMEM70,TMSB4X,TTC30A,ZNF160,ZNF320,ZNF568,ZNF93",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41065,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_DN,VIRUS,DOWN,VACCINE,VAC ONLY,H6,H,6,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_DN,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes down-regulated in blood 6hr vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 6H , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"ACTRT1,SLC35G6,ART1,ATP1A3,ATP6AP1L,B4GALT3,BDNF,MYG1,R3HDM4,C1QTNF2,HMCES,CMTM3,CRLF2,DDIT4,DDX19A,DNA2,DPF1,EXOG,ST13P4,FCGR3A,FGF23,FKBP5,FRA10AC1,GFRA4,GMPPB,GOLGA8M,TPRA1,GUK1,HOXB6,HRH1,IDH3B,IGHMBP2,IRF3,ITPRIPL1,KCNJ10,LSP1,LYL1,MED1,MEGF10,MEGF8,OR51D1,PDRG1,PMEPA1,PRDM9,PRR5,PSENEN,PTK6,PTPN7,RELL1,RFX5,RGS10,SAP30,SEPTIN5,SGCA,SLC25A39,SLC39A13,SPRYD3,TBC1D21,TSC22D3,UBB,UBL4A,UBXN6,ZNF580",63,"ACTRT1,AMAC1L3,ART1,ATP1A3,ATP6AP1L,B4GALT3,BDNF,C12orf10,C19orf22,C1QTNF2,C3orf37,CMTM3,CRLF2,DDIT4,DDX19A,DNA2,DPF1,EXOG,FAM10A4,FCGR3A,FGF23,FKBP5,FRA10AC1,GFRA4,GMPPB,GOLGA8M,GPR175,GUK1,HOXB6,HRH1,IDH3B,IGHMBP2,IRF3,ITPRIPL1,KCNJ10,LSP1,LYL1,MED1,MEGF10,MEGF8,OR51D1,PDRG1,PMEPA1,PRDM9,PRR5,PSENEN,PTK6,PTPN7,RELL1,RFX5,RGS10,SAP30,SEPT5,SGCA,SLC25A39,SLC39A13,SPRYD3,TBC1D21,TSC22D3,UBB,UBL4A,UBXN6,ZNF580",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s003.docx,NA,NA,NA,NA
M41003,CN54GP140,SU,HIV,ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_UP,VIRUS,UP,VACCINE,VAC ONLY,H6,H,6,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ANDERSON_BLOOD_CN54GP140_ADJUVANTED_WITH_GLA_AF_AGE_18_45YO_6HR_UP,"Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a recombinant HIV-1 envelope glycoprotein subunit CN54gp140 adjuvanted with the TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) and correlated signatures to CN54gp140-specific serum antibody responses. Fourteen healthy volunteers aged 18-45 years were immunized intramuscularly three times at 1-month intervals and whole blood samples were collected at baseline, 6 h, and 1, 3, and 7 days post first immunization. Subtle changes in the transcriptomic profiles were observed following immunization, ranging from over 300 differentially expressed genes (DEGs) at day 1 to nearly 100 DEGs at day 7 following immunization. Functional pathway analysis revealed blood transcription modules (BTMs) related to general cell cycle activation, and innate immune cell activation at early time points, as well as BTMs related to T cells and B cell activation at the later time points post-immunization. Diverse CN54gp140-specific serum antibody responses of the subjects enabled their categorization into high or low responders, at early ( < 1 month) and late (up to 6 months) time points post vaccination. BTM analyses revealed repression of modules enriched in NK cells, and the mitochondrial electron chain, in individuals with high or sustained antigen-specific antibody responses. However, low responders showed an enhancement of BTMs associated with enrichment in myeloid cells and monocytes as well as integrin cell surface interactions. Flow cytometry analysis of peripheral blood mononuclear cells obtained from the subjects revealed an enhanced frequency of CD56<sup>dim</sup> NK cells in the majority of vaccines 14 days after vaccination as compared with the baseline. These results emphasize the utility of a systems biology approach to enhance our understanding on the mechanisms of action of TLR4 adjuvanted human vaccines.","Genes up-regulated in blood 6hr vs 0hr in adults (18-45) after exposure to CN54gp140 adjuvanted with GLA-AF , time point 6H , administered i.m.","Anderson J,Olafsdottir TA,Kratochvil S,McKay PF,stensson M,Persson J,Shattock RJ,Harandi AM",29535712,HUMAN_GENE_SYMBOL,"AP1M2,ATG3,C4orf3,FAM200A,CCR2,CD1C,CIAO1,CREB1,NALF2,FUT6,FUT8-AS1,ING3,IPP,KIAA2026,KRR1,LYPLAL1,SLC25A51,MIR25,MYOF,NFKBIZ,OTP,PCYOX1,PHAX,PTGR2,PTPRO,RAB18,RAPSN,RASSF6,RPN2,SEM1,SLC4A4,SLU7,SPTY2D1,TAF15,TMSB4X,UFSP2,ZFYVE27",37,"AP1M2,ATG3,C4orf3,C7orf38,CCR2,CD1C,CIAO1,CREB1,FAM155B,FUT6,FUT8-AS1,ING3,IPP,KIAA2026,KRR1,LYPLAL1,MCART1,MIR25,MYOF,NFKBIZ,OTP,PCYOX1,PHAX,PTGR2,PTPRO,RAB18,RAPSN,RASSF6,RPN2,SHFM1,SLC4A4,SLU7,SPTY2D1,TAF15,TMSB4X,UFSP2,ZFYVE27",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40912,PPD,SU,TUBERCULOSIS,FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_DN,BACTERIUM,DOWN,VACCINE,VAC VS CTRL,W10,W,10,INFANT,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_DN,"BACKGROUND: Novel tuberculosis (TB) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, Mycobacterium bovis Bacille Calmette-Guerin (BCG). Because BCG vaccination is used extensively in infants, this population group is likely to be the first in which efficacy trials of new vaccines will be conducted. However, our understanding of the complexity of immunity to BCG in infants is inadequate, making interpretation of vaccine-induced immune responses difficult. METHODS: To better understand BCG-induced immunity, we performed gene expression profiling in five 10-week old infants routinely vaccinated with BCG at birth. RNA was extracted from 12 hour BCG-stimulated or purified protein derivative of tuberculin (PPD)-stimulated PBMC, isolated from neonatal blood collected 10 weeks after vaccination. RNA was hybridised to the Sentrix(R) HumanRef-8 Expression BeadChip (Illumina) to measure expression of > 16,000 genes. RESULTS: We found that ex vivo stimulation of PBMC with PPD and BCG induced largely similar gene expression profiles, except that BCG induced greater macrophage activation. The peroxisome proliferator-activated receptor (PPAR) signaling pathway, including PPAR-gamma, involved in activation of the alternative, anti-inflammatory macrophage response was down-regulated following stimulation with both antigens. In contrast, up-regulation of genes associated with the classic, pro-inflammatory macrophage response was noted. Further analysis revealed a decrease in the expression of cell adhesion molecules (CAMs), including integrin alpha M (ITGAM), which is known to be important for entry of mycobacteria into the macrophage. Interestingly, more leukocyte genes were down-regulated than up-regulated. CONCLUSION: Our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to TB induced by vaccination with BCG.","Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (10w) after exposure to BCG (Danish strain BCG Statens Serum Institut, Denmark) , time point 10W. Comment: PBMCs drawn at 10 weeks following immunization at birth","Fletcher HA,Keyser A,Bowmaker M,Sayles PC,Kaplan G,Hussey G,Hill AV,Hanekom WA",19239680,HUMAN_GENE_SYMBOL,"ABCC3,ABCG1,AIF1,ALCAM,ALDH1A2,ALDH3B1,ANXA1,ANXA11,ANXA4,APOC1,APOE,ASAH1,ASPHD1,ATP6AP2,ATP6V1A,AVPI1,C1orf54,C5AR1,CA2,CAMK1,CAPN2,CARD9,CCR1,CCR5,CD151,CD33,CD36,CD52,CD63,CD86,CD9,CEBPA,CLIP2,CORO1C,CSF1R,CST3,CST6,CTSB,CTSD,CTSS,CYB5R4,CYFIP1,DAB2,DAGLA,DCSTAMP,DHRS9,DPYSL2,EEF1AKMT3,EGR2,EMP1,ENG,FABP4,FAM20C,FBP1,FCGRT,FCN1,FGL2,FHL3,FKBP1A,FLRT2,FLVCR2,FPR3,FTL,G6PD,GCLC,GLA,GLIPR1,GLIPR2,GLMP,GPC4,GPNMB,GREM1,GRN,GSN,HAVCR2,HCST,HEXB,HK3,HMOX1,HSD3B7,HTRA1,ICAM5,IFI30,IGF2BP2,IGF2R,IGSF6,IL13RA1,IL1R2,IL1RN,INF2,ITGAM,KCNE3,KIAA0930,KLF9,LGALS3,LHFPL2,LIMS1,LINC00520,LINC01010,LMNA,LPL,LRP1,LRP3,LYZ,ME1,METTL7B,MFSD12,MGST1,MITF,MMP19,MNDA,MPP1,MRAS,MYOF,NCEH1,NEK6,NIBAN2,NLRC4,NPL,NRROS,OTOA,PACSIN2,PAPSS1,PDGFRB,PI4K2A,PLBD1,PLBD2,PLIN2,PLXDC2,PPARG,PTGS1,RAB34,RGCC,RHOC,RNASE1,RNF130,RPS6KA1,S100A10,S100A4,S100A6,SCARB2,SDCBP,SDSL,SERPINE1,SHTN1,SIRPA,SLAMF8,SLC17A5,SLC1A3,SLC1A4,SLC27A3,SLC31A1,SLC31A2,SLC37A2,SLC38A6,SLC44A1,SLC49A3,SLC7A8,SLCO3A1,SMCO4,SPHK1,SPINK1,SPINT1,SPP1,SPRED1,SPRY2,STAB1,TGFBI,THEMIS2,TIMP2,TKTL1,TM4SF19,TMBIM1,TNFRSF21,TNS3,TSPO,VIM,VWA5A,VWF,ZMIZ1,ZNF366",181,"ABCC3,ABCG1,AIF1,ALCAM,ALDH1A2,ALDH3B1,ANXA1,ANXA11,ANXA4,APOC1,APOE,ASAH1,ASPHD1,ATP6AP2,ATP6V1A,AVPI1,C1orf54,C5R1,CA2,CAMK1,CAPN2,CARD9,CCR1,CCR5,CD151,CD33,CD36,CD52,CD63,CD86,CD9,CEBPA,CLIP2,CORO1C,CSF1R,CST3,CST6,CTSB,CTSD,CTSS,CYB5R4,CYFIP1,DAB2,DAGLA,DCSTAMP,DHRS9,DPYSL2,EEF1AKMT3,EGR2,EMP1,ENG,FABP4,FAM20C,FBP1,FCGRT,FCN1,FGL2,FHL3,FKBP1A,FLRT2,FLVCR2,FPR3,FTL,G6PD,GCLC,GLA,GLIPR1,GLIPR2,GLMP,GPC4,GPNMB,GREM1,GRN,GSN,HAVCR2,HCST,HEXB,HK3,HMOX1,HSD3B7,HTRA1,ICAM5,IFI30,IGF2BP2,IGF2R,IGSF6,IL13RA1,IL1R2,IL1RN,INF2,ITGAM,KCNE3,KIAA0930,KLF9,LGALS3,LHFPL2,LIMS1,LINC00520,LINC01010,LMNA,LPL,LRP1,LRP3,LYZ,ME1,METTL7B,MFSD12,MGST1,MITF,MMP19,MNDA,MPP1,MRAS,MYOF,NCEH1,NEK6,NIBAN2,NLRC4,NPL,NRROS,OTOA,PACSIN2,PAPSS1,PDGFRB,PI4K2A,PLBD1,PLBD2,PLIN2,PLXDC2,PPARG,PTGS1,RAB34,RGCC,RHOC,RNASE1,RNF130,RPS6KA1,S100A10,S100A4,S100A6,SCARB2,SDCBP,SDSL,SERPINE1,SHTN1,SIRPA,SLAMF8,SLC17A5,SLC1A3,SLC1A4,SLC27A3,SLC31A1,SLC31A2,SLC37A2,SLC38A6,SLC44A1,SLC49A3,SLC7A8,SLCO3A1,SMCO4,SPHK1,SPINK1,SPINT1,SPP1,SPRED1,SPRY2,STAB1,TGFBI,THEMIS2,TIMP2,TKTL1,TM4SF19,TMBIM1,TNFRSF21,TNS3,TSPO,VIM,VWA5A,VWF,ZMIZ1,ZNF366",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946173/bin/mmc1.docx,NA,NA,NA,NA
M41042,PPD,SU,TUBERCULOSIS,FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,W10,W,10,INFANT,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FLETCHER_PBMC_BCG_10W_INFANT_PPD_STIMULATED_VS_UNSTIMULATED_10W_UP,"BACKGROUND: Novel tuberculosis (TB) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, Mycobacterium bovis Bacille Calmette-Guerin (BCG). Because BCG vaccination is used extensively in infants, this population group is likely to be the first in which efficacy trials of new vaccines will be conducted. However, our understanding of the complexity of immunity to BCG in infants is inadequate, making interpretation of vaccine-induced immune responses difficult. METHODS: To better understand BCG-induced immunity, we performed gene expression profiling in five 10-week old infants routinely vaccinated with BCG at birth. RNA was extracted from 12 hour BCG-stimulated or purified protein derivative of tuberculin (PPD)-stimulated PBMC, isolated from neonatal blood collected 10 weeks after vaccination. RNA was hybridised to the Sentrix(R) HumanRef-8 Expression BeadChip (Illumina) to measure expression of > 16,000 genes. RESULTS: We found that ex vivo stimulation of PBMC with PPD and BCG induced largely similar gene expression profiles, except that BCG induced greater macrophage activation. The peroxisome proliferator-activated receptor (PPAR) signaling pathway, including PPAR-gamma, involved in activation of the alternative, anti-inflammatory macrophage response was down-regulated following stimulation with both antigens. In contrast, up-regulation of genes associated with the classic, pro-inflammatory macrophage response was noted. Further analysis revealed a decrease in the expression of cell adhesion molecules (CAMs), including integrin alpha M (ITGAM), which is known to be important for entry of mycobacteria into the macrophage. Interestingly, more leukocyte genes were down-regulated than up-regulated. CONCLUSION: Our results suggest that a combination of suppressed and up-regulated genes may be key in determining development of protective immunity to TB induced by vaccination with BCG.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in infants (10w) after exposure to BCG (Danish strain BCG Statens Serum Institut, Denmark) , time point 10W. Comment: PBMCs drawn at 10 weeks following immunization at birth","Fletcher HA,Keyser A,Bowmaker M,Sayles PC,Kaplan G,Hussey G,Hill AV,Hanekom WA",19239680,HUMAN_GENE_SYMBOL,"ABTB2,ACSL1,ADORA2A,AKR1C2,AQP9,ATP2B1,BATF,BCL2A1,C15orf48,C2CD4B,CCL1,CCL20,CCL22,CCL3,CCL3L1,CCL4,CD93,CEMIP,CHAC1,CKB,CSF2,CSF3,CXCL1,CXCL2,CXCL3,CXCL5,CXCL8,CXCR5,DDIT4,DUSP5,EBI3,EDN1,EPB41L3,ACSL1,FEZ1,G0S2,GBP1,GBP2,GBP4,GBP5,GLYR1,GNG11,GNG8,HCAR3,IDO1,IER3,IL1A,IL1B,IL36G,IL6,INHBA,LAMP3,LTA,MAP3K8,MARCKS,MMP1,MMP10,MMP14,MT1G,MT1M,MT2A,MTHFD1L,NAMPT,NEU4,NFKBIZ,OSM,PARP9,PHGDH,PHLDA2,PIM1,PIM2,PTGS2,PTX3,PYCR1,RGS16,RIPK2,RNF144B,SERPINA1,SERPINB2,SERPINB7,SESN2,SLC7A5,SLC7A7,SOD2,TFPI2,THBD,THBS1,TNF,TNFAIP6,TRAF4,TRIB3,VNN3P,VPREB3",93,"ABTB2,ACSL1,ADORA2A,AKR1C2,AQP9,ATP2B1,BATF,BCL2A1,C15orf48,C2CD4B,CCL1,CCL20,CCL22,CCL3,CCL3L1,CCL4,CD93,CEMIP,CHAC1,CKB,CSF2,CSF3,CXCL1,CXCL2,CXCL3,CXCL5,CXCL8,CXCR5,DDIT4,DUSP5,EBI3,EDN1,EPB41L3,FACL2,FEZ1,G0S2,GBP1,GBP2,GBP4,GBP5,GLYR1,GNG11,GNG8,HCAR3,IDO1,IER3,IL1A,IL1B,IL36G,IL6,INHBA,LAMP3,LTA,MAP3K8,MARCKS,MMP1,MMP10,MMP14,MT1G,MT1M,MT2A,MTHFD1L,NAMPT,NEU4,NFKBIZ,OSM,PARP9,PHGDH,PHLDA2,PIM1,PIM2,PTGS2,PTX3,PYCR1,RGS16,RIPK2,RNF144B,SERPINA1,SERPINB2,SERPINB7,SESN2,SLC7A5,SLC7A7,SOD2,TFPI2,THBD,THBS1,TNF,TNFAIP6,TRAF4,TRIB3,VNN3,VPREB3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table S3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878824/bin/NIHMS784868-supplement-Supplemental_Text_and_Figures.pdf,NA,NA,NA,NA
M40863,TWINRIX,VLP,"HBV, HAV",FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,D0,D,0,25-83,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_DN,"Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three vaccines, including one against HBV. Here we show, using transcriptional and cytometric profiling of whole blood collected before vaccination, that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlate with stronger responses to HBV vaccine. In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlate with weaker responses to this vaccine. Increased numbers of erythrocytes and the haem-induced response also correlate with poor response to the HBV vaccine. A transcriptomics-based pre-vaccination predictor of response to HBV vaccine is built and validated in distinct sets of older adults. This moderately accurate (area under the curve ~65%) but robust signature is supported by flow cytometry and cytokine profiling. This study is the first that identifies baseline predictors and mechanisms of response to the HBV vaccine.","Genes down-regulated in blood responders vs poor responders in adults (25-83) (responders) after exposure to Twinrix , time point 0D","Fourati S,Cristescu R,Loboda A,Talla A,Filali A,Railkar R,Schaeffer AK,Favre D,Gagnon D,Peretz Y,Wang IM,Beals CR,Casimiro DR,Carayannopoulos LN,Skaly RP",26742691,HUMAN_GENE_SYMBOL,"AADACL3,AAMDC,ABCB5,ABCC6,ABHD2,ABL2,ACADS,ADAM12,ADAM17,ADAMTSL2,ADAP2,ADCY9,ADGRE2,ADGRF3,ADORA3,AFDN,AFF1,AFF2,AFMID,AGBL1,AGFG1,AGMO,AGPAT4,AGPS,AGRN,AGTPBP1,AIF1,AKR1B15,AKR7A3,ALDH3B1,ALYREF,ANAPC11,ANGPT1,ANKRD11,ANKRD50,ANO10,ANOS1,ANXA5,ANXA8,ANXA8L1,APLP2,APOA1,APOL6,APP,ARF5,ARHGEF10L,ARHGEF37,ARL11,ARPC4-TTLL3,ARSA,ART1,ASCL2,ASRGL1,ATF6,ATF7,ATP11A-AS1,ATP5MF,ATP5MF-PTCD1,ATP8A2,ATP8B3,AZU1,B4GALNT2,BAHCC1,BAK1,BAZ2A,BAZ2B,BBS7,BEAN1,BEND7,BOD1L1,BPESC1,BPI,BRD7,BTN3A1,BUB1B,C22orf23,C3AR1,C6orf136,C7orf50,LINC02913,CA14,CABIN1,CACUL1,CAD,CALML4,CAMP,CAPG,CAPN1,CARD16,CASP10,CASQ1,CAVIN3,CBS,CBX2,CC2D2B,CCDC149,CFAP119,CCNB2,CD101,CD109,CD14,CD163,CD177,CD300E,CD63,CDC42BPA,CDC42EP4,CDCA8,CDH17,CDT1,CDX1,CEACAM21,CEACAM6,CEACAM8,CENPE,CEP63,CFAP46,CFAP73,CGAS,,CHCHD2,CHD7,CHIT1,CILK1,CLEC7A,CLPS,CLTCL1,CMIP,CNRIP1,COG4,COL11A2,COL2A1,COL4A1,COL6A2,CORO2A,CPLANE1,CRCP,CRHBP,CRISP3,CSNK1D,CTNNA1,CTNNBIP1,CTSB,CTSG,CTTNBP2NL,CUX1,CYBB,CYP2C8,CYRIA,DAGLB,DCLRE1C,DDI1,DDX3Y,DDX6,DEFA1,DEFA1B,DEFA3,DEFA4,DENND1A,DGKG,DHRS4L2,DISP3,,DLEU2,DLEU7,DLG4,DLG5,DLGAP5,DMXL2,DNAH12,DUSP3,DUSP7,DYNLT2B,EGF,EIF1AY,EIF2B3,ELANE,ELOVL3,EMC9,ENKD1,EPB41L3,EPB41L4A,EPHB2,EPS8L1,ERBB2,ERMAP,ESS2,ETV6,EVX1,EXOSC3,FAH,FAM114A1,FAM3B,FAM95B1,FCAR,FCER1G,FCHSD1,FCN1,FGD4,FGD6,FGF1,FGF18,FGG,FKBP9,NHSL1-AS1,FLYWCH2,FOLR2,FRMD7,FSTL3,FUCA2,FUOM,FXYD6,FYTTD1,GAB1,GBA1,GCM1,GCNT2,GFER,GLB1L,GLB1L3,GLMP,GM2A,GNA11,GNA14,GNAT1,GNG4,GPD2,GPN2,GPR107,GPR151,GPR84,GRK3,GSEC,GTF3C2,H2AZ2,H2BW1,H3C13,H3C14,H3C15,H4C1,H4C9,HAND2-AS1,HAUS2,HAUS6,HBZ,HCN2,HCN3,HEATR1,HEATR3,HEATR5A,HELZ2,HGF,HLA-A,HLA-DQA1,HLA-DRB4,HNMT,HOXB-AS3,HP,HPGDS,HPR,HPX,HS2ST1,HS3ST5,HSPA1B,HTRA1,IFI16,IFI27,IFI44,IFI44L,IFI6,IFIT3,IFITM3,IGF1R,IGSF21,IKBKG,IL34,IL5RA,INF2,INO80,INPPL1,INSR,IRF7,IRF9,ISG15,ITGA2B,ITGA9,ITGB3,ITIH3,JDP2,JPH4,KAAG1,KAT6A,KCNJ2,KCNQ1,KCNQ2,KCTD20,KDM5D,KIAA0319L,KIAA0825,KIAA2013,KIF18B,KIF5B,KIF9,KIR3DL1,KISS1R,KLHDC9,KLHL10,KLK10,KLK15,KPNA6,KPNB1,KRT37,KRT73,KTN1,KXD1,LACC1,LARP4B,LAS1L,LATS2,LAYN,LCN2,LDLRAD3,LFNG,LGALS12,LGALS3BP,LILRA6,LILRB1,LILRB4,CYTOR,LINC00301,LINC00588,LINC00900,LINC00901,RNF32-DT,LINC01168,LINC01270,LINC01305,LINC01503,LINC01686,LINC02649,LINC02724,LINGO2,LMOD3,EPB41L1-AS1,,,,FMNL1-DT,NUDT16-DT,,,LOXL3,LOXL4,LRATD1,LRMDA,LRP1,LRRC71,LRRC75B,LRRK1,LRSAM1,LTF,LYPD4,LZTS3,MAD2L1,MAFG,TRAPPC14,MAP2K6,MAP3K20,MAP3K6,MAPK14,MBOAT2,MEAK7,MED29,MEG3,MET,MEX3C,MICAL2,MIR4435-2HG,MKI67,MKKS,MMP11,MMP19,MMP8,MND1,MPO,MRE11,MROH7,MROH7-TTC4,MRPS12,MT1E,MT2A,MTCL1,MTNR1A,MVB12B,MX1,MX2,MYB,MYBPC3,MYCL,MYO10,NAAA,NAGK,NBPF10,NBPF14,NBPF15,NBR1,NCBP3,NCKAP1L,NCLN,NDUFA4L2,NECAB1,NECTIN1,NEK3,NETO1,NEURL1,NEXN-AS1,NFIC,NIBAN1,NISCH,NLN,NLRP3,NMB,NMNAT2,NOTCH2,NOTCH2NLA,NPRL3,NR0B1,NR2F2,NR6A1,NRARP,NSD3,NT5DC4,NTNG2,NUBP2,NUDT12,NUDT3,NUMA1,NUMBL,NUP93,OAS1,OAS3,OASL,ODF3B,OLAH,OLFM4,OLFML2B,OPLAH,OR51T1,OR52E8,OR6C1,OSGIN1,OTUD4,OTX1,P2RY2,PALLD,PAQR5,PAQR6,PARP9,PAWR,PCA3,PCBD2,PCLO,PDE12,PFKFB3,PGA3,PGA4,PGA5,PGBD2,PGPEP1,PIK3AP1,PIK3R3,PIK3R6,PINLYP,PIP4K2B,PIWIL2,PLAAT5,PLB1,PLCB3,PLCE1,PLIN5,PLSCR1,PLTP,PLXNB3,PML,PNPLA1,POLR3K,POMC,PPARA,PPARG,PPFIA1,PPP4R2,PRDM7,PRKD1,PROB1,PRPS1L1,PRR11,PRR27,PRRC2C,PRSS36,PRTN3,PSAP,PSORS1C3,PTN,PTPN14,PTPRZ1,PTX3,PYGB,RAB20,RABL6,RAD51,RAD51C,RALGPS2-AS1,RBM12B-AS1,RBM47,RBMY1A1,RBMY1B,RBMY1D,RBMY1E,RBP7,RBPJ,RCOR3,REC8,RECK,REEP3,RELL1,RERE,RETN,RFTN1,RHOU,RIN1,RING1,RNASE3,RNF112,RNF20,RNF208,RO60,ROCK2,RPL7L1,RPS10-NUDT3,RPS4Y1,RPS4Y2,RRAGD,RRBP1,RREB1,RSAD2,RSPH3,RSPH9,RTL5,RUBCN,RUSC2,S100A13,S100A4,SAMD4A,SAP30,SART1,SCARB2,SCCPDH,SCD,SCG3,SCRG1,SCRT1,SELENOS,SENP5,SEPTIN3,SERINC2,SERPINB2,SERPINB6,SF3B1,SFXN5,SH3RF1,SHROOM3,SIGLEC1,SIN3B,SIRT6,SKA1,SLC17A5,SLC20A2,SLC22A18,SLC22A18AS,SLC25A18,SLC26A3,SLC27A3,SLC27A4,SLC2A14,SLC32A1,SLC35A2,SLC36A1,SLC39A7,SLC46A1,SLC5A12,SLC6A5,SLC6A8,SLC9B1,SLPI,SMG5,SNAP23,SNORD62A,SNORD62B,SNORD9,SNX27,SORT1,SOS2,SP110,SPATA2L,SPATA31C1,SPATA31C2,SPATA41,SPECC1,SPINK7,SPIRE2,SPNS1,SPNS3,SRRM2,SSH3,ST6GALNAC4,ST8SIA5,STAC3,STAT1,STBD1,STK11IP,STK36,STMN1,STRIP2,SULT4A1,SUPT6H,SYDE2,SYN2,SYNE4,SYT5,SZT2,TADA2A,,TAOK2,TARM1,TBC1D16,TBCD,TCERG1,TCERG1L,TCN1,TCN2,TDRD9,TENT5A,TEP1,TFIP11,TGIF2LX,TGIF2LY,THBS1,THRA,TIMP3,TIRAP,TJP2,TK2,TKT,TLE4,TLE6,TLK2,TM7SF3,TMED6,TMEM44,TMEM53,TMEM8B,TMEM91,TMSB4Y,TNFAIP2,TNFSF10,TNFSF13B,TNNI2,TNNT3,TNPO1,TNPO3,TNRC18,TONSL,TOP2A,TP53I3,TPCN2,TPM1,TPMT,TPP1,TPPP,TPSAB1,TPSB2,TPSD1,TRIM14,TRIM21,TRIM50,TRIM66,TRIP10,TROAP,TRPM2,TSBP1,TSHZ3,TTLL3,TTTY1,TTTY10,TTTY14,TTTY1B,TTTY2,TTTY20,TTTY21,TTTY21B,TTTY2B,TTTY3,TTTY3B,TTTY7,TTTY7B,TTTY8,TTTY8B,TXLNGY,TYMP,UBE2C,UBE2L3,UBR4,UCP3,UNC45A,UNC5A,UNC93B1,UNKL,UQCRQ,URB1,USF1,USP24,USP9Y,UTY,VCAN,VCX,VCX3A,VCX3B,VEGFC,VHL,VPS53,VWC2,WBP2NL,WNT5B,WRAP53,WWC2,XKRY,XKRYP7,XPR1,YIPF1,YWHAE,ZBP1,ZBTB47,ZC3H13,ZEB2,ZFHX3,ZFP91,ZFP91-CNTF,ZFY,ZFY-AS1,ZFYVE1,ZMYND10,ZNF106,ZNF516,ZNF562,ZNF704,ZNF829",756,"AADACL3,AAMDC,ABCB5,ABCC6,ABHD2,ABL2,ACADS,ADAM12,ADAM17,ADAMTSL2,ADAP2,ADCY9,ADGRE2,ADGRF3,ADORA3,AFDN,AFF1,AFF2,AFMID,AGBL1,AGFG1,AGMO,AGPAT4,AGPS,AGRN,AGTPBP1,AIF1,AKR1B15,AKR7A3,ALDH3B1,ALYREF,ANAPC11,ANGPT1,ANKRD11,ANKRD50,ANO10,ANOS1,ANXA5,ANXA8,ANXA8L1,APLP2,APOA1,APOL6,APP,ARF5,ARHGEF10L,ARHGEF37,ARL11,ARPC4-TTLL3,ARSA,ART1,ASCL2,ASRGL1,ATF6,ATF7,ATP11A-AS1,ATP5MF,ATP5MF-PTCD1,ATP8A2,ATP8B3,AZU1,B4GALNT2,BAHCC1,BAK1,BAZ2A,BAZ2B,BBS7,BEAN1,BEND7,BOD1L,BPESC1,BPI,BRD7,BTN3A1,BUB1B,C22orf23,C3AR1,C6orf136,C7orf50,C9orf106,CA14,CABIN1,CACUL1,CAD,CALML4,CAMP,CAPG,CAPN1,CARD16,CASP10,CASQ1,CAVIN3,CBS,CBX2,CC2D2B,CCDC149,CCDC189,CCNB2,CD101,CD109,CD14,CD163,CD177,CD300E,CD63,CDC42BPA,CDC42EP4,CDCA8,CDH17,CDT1,CDX1,CEACAM21,CEACAM6,CEACAM8,CENPE,CEP63,CFAP46,CFAP73,CGAS,CH17-340M24.3,CHCHD2,CHD7,CHIT1,CILK1,CLEC7A,CLPS,CLTCL1,CMIP,CNRIP1,COG4,COL11A2,COL2A1,COL4A1,COL6A2,CORO2A,CPLANE1,CRCP,CRHBP,CRISP3,CSNK1D,CTNNA1,CTNNBIP1,CTSB,CTSG,CTTNBP2NL,CUX1,CYBB,CYP2C8,CYRIA,DAGLB,DCLRE1C,DDI1,DDX3Y,DDX6,DEFA1,DEFA1B,DEFA3,DEFA4,DENND1A,DGKG,DHRS4L2,DISP3,DKFZp434L192,DLEU2,DLEU7,DLG4,DLG5,DLGAP5,DMXL2,DNAH12,DUSP3,DUSP7,DYNLT2B,EGF,EIF1AY,EIF2B3,ELANE,ELOVL3,EMC9,ENKD1,EPB41L3,EPB41L4A,EPHB2,EPS8L1,ERBB2,ERMAP,ESS2,ETV6,EVX1,EXOSC3,FAH,FAM114A1,FAM3B,FAM95B1,FCAR,FCER1G,FCHSD1,FCN1,FGD4,FGD6,FGF1,FGF18,FGG,FKBP9,FLJ46906,FLYWCH2,FOLR2,FRMD7,FSTL3,FUCA2,FUOM,FXYD6,FYTTD1,GAB1,GBA,GCM1,GCNT2,GFER,GLB1L,GLB1L3,GLMP,GM2A,GNA11,GNA14,GNAT1,GNG4,GPD2,GPN2,GPR107,GPR151,GPR84,GRK3,GSEC,GTF3C2,H2AZ2,H2BW1,H3C13,H3C14,H3C15,H4C1,H4C9,HAND2-AS1,HAUS2,HAUS6,HBZ,HCN2,HCN3,HEATR1,HEATR3,HEATR5A,HELZ2,HGF,HLA-A,HLA-DQA1,HLA-DRB4,HNMT,HOXB-AS3,HP,HPGDS,HPR,HPX,HS2ST1,HS3ST5,HSPA1B,HTRA1,IFI16,IFI27,IFI44,IFI44L,IFI6,IFIT3,IFITM3,IGF1R,IGSF21,IKBKG,IL34,IL5RA,INF2,INO80,INPPL1,INSR,IRF7,IRF9,ISG15,ITGA2B,ITGA9,ITGB3,ITIH3,JDP2,JPH4,KAAG1,KAT6A,KCNJ2,KCNQ1,KCNQ2,KCTD20,KDM5D,KIAA0319L,KIAA0825,KIAA2013,KIF18B,KIF5B,KIF9,KIR3DL1,KISS1R,KLHDC9,KLHL10,KLK10,KLK15,KPNA6,KPNB1,KRT37,KRT73,KTN1,KXD1,LACC1,LARP4B,LAS1L,LATS2,LAYN,LCN2,LDLRAD3,LFNG,LGALS12,LGALS3BP,LILRA6,LILRB1,LILRB4,LINC00152,LINC00301,LINC00588,LINC00900,LINC00901,LINC01006,LINC01168,LINC01270,LINC01305,LINC01503,LINC01686,LINC02649,LINC02724,LINGO2,LMOD3,LOC100130373,LOC100272217,LOC100507703,LOC143666,LOC339192,LOC339874,LOC642696,LOC644277,LOXL3,LOXL4,LRATD1,LRMDA,LRP1,LRRC71,LRRC75B,LRRK1,LRSAM1,LTF,LYPD4,LZTS3,MAD2L1,MAFG,MAP11,MAP2K6,MAP3K20,MAP3K6,MAPK14,MBOAT2,MEAK7,MED29,MEG3,MET,MEX3C,MICAL2,MIR4435-2HG,MKI67,MKKS,MMP11,MMP19,MMP8,MND1,MPO,MRE11,MROH7,MROH7-TTC4,MRPS12,MT1E,MT2A,MTCL1,MTNR1A,MVB12B,MX1,MX2,MYB,MYBPC3,MYCL,MYO10,NAAA,NAGK,NBPF10,NBPF14,NBPF15,NBR1,NCBP3,NCKAP1L,NCLN,NDUFA4L2,NECAB1,NECTIN1,NEK3,NETO1,NEURL1,NEXN-AS1,NFIC,NIBAN1,NISCH,NLN,NLRP3,NMB,NMNAT2,NOTCH2,NOTCH2NLA,NPRL3,NR0B1,NR2F2,NR6A1,NRARP,NSD3,NT5DC4,NTNG2,NUBP2,NUDT12,NUDT3,NUMA1,NUMBL,NUP93,OAS1,OAS3,OASL,ODF3B,OLAH,OLFM4,OLFML2B,OPLAH,OR51T1,OR52E8,OR6C1,OSGIN1,OTUD4,OTX1,P2RY2,PALLD,PAQR5,PAQR6,PARP9,PAWR,PCA3,PCBD2,PCLO,PDE12,PFKFB3,PGA3,PGA4,PGA5,PGBD2,PGPEP1,PIK3AP1,PIK3R3,PIK3R6,PINLYP,PIP4K2B,PIWIL2,PLAAT5,PLB1,PLCB3,PLCE1,PLIN5,PLSCR1,PLTP,PLXNB3,PML,PNPLA1,POLR3K,POMC,PPARA,PPARG,PPFIA1,PPP4R2,PRDM7,PRKD1,PROB1,PRPS1L1,PRR11,PRR27,PRRC2C,PRSS36,PRTN3,PSAP,PSORS1C3,PTN,PTPN14,PTPRZ1,PTX3,PYGB,RAB20,RABL6,RAD51,RAD51C,RALGPS2-AS1,RBM12B-AS1,RBM47,RBMY1A1,RBMY1B,RBMY1D,RBMY1E,RBP7,RBPJ,RCOR3,REC8,RECK,REEP3,RELL1,RERE,RETN,RFTN1,RHOU,RIN1,RING1,RNASE3,RNF112,RNF20,RNF208,RO60,ROCK2,RPL7L1,RPS10-NUDT3,RPS4Y1,RPS4Y2,RRAGD,RRBP1,RREB1,RSAD2,RSPH3,RSPH9,RTL5,RUBCN,RUSC2,S100A13,S100A4,SAMD4A,SAP30,SART1,SCARB2,SCCPDH,SCD,SCG3,SCRG1,SCRT1,SELENOS,SENP5,SEPTIN3,SERINC2,SERPINB2,SERPINB6,SF3B1,SFXN5,SH3RF1,SHROOM3,SIGLEC1,SIN3B,SIRT6,SKA1,SLC17A5,SLC20A2,SLC22A18,SLC22A18AS,SLC25A18,SLC26A3,SLC27A3,SLC27A4,SLC2A14,SLC32A1,SLC35A2,SLC36A1,SLC39A7,SLC46A1,SLC5A12,SLC6A5,SLC6A8,SLC9B1,SLPI,SMG5,SNAP23,SNORD62A,SNORD62B,SNORD9,SNX27,SORT1,SOS2,SP110,SPATA2L,SPATA31C1,SPATA31C2,SPATA41,SPECC1,SPINK7,SPIRE2,SPNS1,SPNS3,SRRM2,SSH3,ST6GALNAC4,ST8SIA5,STAC3,STAT1,STBD1,STK11IP,STK36,STMN1,STRIP2,SULT4A1,SUPT6H,SYDE2,SYN2,SYNE4,SYT5,SZT2,TADA2A,TAMALIN-AS1,TAOK2,TARM1,TBC1D16,TBCD,TCERG1,TCERG1L,TCN1,TCN2,TDRD9,TENT5A,TEP1,TFIP11,TGIF2LX,TGIF2LY,THBS1,THRA,TIMP3,TIRAP,TJP2,TK2,TKT,TLE4,TLE6,TLK2,TM7SF3,TMED6,TMEM44,TMEM53,TMEM8B,TMEM91,TMSB4Y,TNFAIP2,TNFSF10,TNFSF13B,TNNI2,TNNT3,TNPO1,TNPO3,TNRC18,TONSL,TOP2A,TP53I3,TPCN2,TPM1,TPMT,TPP1,TPPP,TPSAB1,TPSB2,TPSD1,TRIM14,TRIM21,TRIM50,TRIM66,TRIP10,TROAP,TRPM2,TSBP1,TSHZ3,TTLL3,TTTY1,TTTY10,TTTY14,TTTY1B,TTTY2,TTTY20,TTTY21,TTTY21B,TTTY2B,TTTY3,TTTY3B,TTTY7,TTTY7B,TTTY8,TTTY8B,TXLNGY,TYMP,UBE2C,UBE2L3,UBR4,UCP3,UNC45A,UNC5A,UNC93B1,UNKL,UQCRQ,URB1,USF1,USP24,USP9Y,UTY,VCAN,VCX,VCX3A,VCX3B,VEGFC,VHL,VPS53,VWC2,WBP2NL,WNT5B,WRAP53,WWC2,XKRY,XKRY2,XPR1,YIPF1,YWHAE,ZBP1,ZBTB47,ZC3H13,ZEB2,ZFHX3,ZFP91,ZFP91-CNTF,ZFY,ZFY-AS1,ZFYVE1,ZMYND10,ZNF106,ZNF516,ZNF562,ZNF704,ZNF829",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/bin/jiy420_suppl_supplementary_table_1.xlsx,NA,NA,NA,NA
M40869,TWINRIX,VLP,"HBV, HAV",FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D0,D,0,25-83,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FOURATI_BLOOD_TWINRIX_AGE_25_83YO_RESPONDERS_VS_POOR_RESPONDERS_0DY_UP,"Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three vaccines, including one against HBV. Here we show, using transcriptional and cytometric profiling of whole blood collected before vaccination, that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlate with stronger responses to HBV vaccine. In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlate with weaker responses to this vaccine. Increased numbers of erythrocytes and the haem-induced response also correlate with poor response to the HBV vaccine. A transcriptomics-based pre-vaccination predictor of response to HBV vaccine is built and validated in distinct sets of older adults. This moderately accurate (area under the curve ~65%) but robust signature is supported by flow cytometry and cytokine profiling. This study is the first that identifies baseline predictors and mechanisms of response to the HBV vaccine.","Genes up-regulated in blood responders vs poor responders in adults (25-83) (responders) after exposure to Twinrix , time point 0D","Fourati S,Cristescu R,Loboda A,Talla A,Filali A,Railkar R,Schaeffer AK,Favre D,Gagnon D,Peretz Y,Wang IM,Beals CR,Casimiro DR,Carayannopoulos LN,Skaly RP",26742691,HUMAN_GENE_SYMBOL,"ABCB11,ABCB4,ABLIM1,ACSM1,ADAM21,ADAM22,ADAM28,ADAM30,ADD3,ADGRG4,AFF3,AGPAT5,AHR,AIDA,ALDH1A3,ALDOB,AMMECR1,AMOTL1,ANAPC1,ANAPC16,ANGPTL1,ANK3,ANKRD36,ANKRD36B,ANKRD36C,ANP32E,AP4S1,API5,APOO,AR,ARHGAP42,ARHGEF3,ARL14EP,ARL6IP5,ARMC1,ASNS,ATF1,ATM,ATP11C,ATP1B4,ATP2B3,ATRX,AXIN2,BACH2,BANK1,BCAS2,BCL11A,BCL2,BCL7A,BCLAF1,BCLAF3,BDH2,GPRASP3,BHLHE41,BIRC3,BLK,BLNK,BMI1,BPNT1,BTLA,BTNL9,BUB3,C12orf29,KICS2,C14orf28,C19orf12,C1orf220,CASK,CATSPERB,CBLL1,CCDC160,CCDC91,CCNG1,CCR6,CD160,CD180,MS4A1,CD200,CD22,CD27,CD40,CD72,CD79A,CD79B,CDC42SE2,CDK17,CDR1,CELSR1,CFAP44,CFAP47,CFAP97,CGGBP1,CHIC1,CHM,CHML,CHN1,CLCN5,CLEC2D,CLIC4,CLN8,CLU,CNR2,CNTNAP1,COBLL1,COCH,COL4A4,COMMD3-BMI1,CPO,CR2,CT47A1,CT47A10,CT47A11,CT47A2,CT55,CTAGE15,CTAGE4,CTAGE6,CTAGE9,CTH,CWC22,CXCR5,CXorf58,CYP2E1,DACT1,DCK,DCX,DDX21,DDX3X,DLAT,DLG5,DMD,DNAAF6,DNAH12,DNAH3,DNAJC30,DNM1L,DOCK10,DOCK9,DPP4,DSP,DTD2,DYRK1A,EBF1,EDA2R,EDARADD,EEF1G,EFHC2,EFR3A,EGFL6,EGLN3,EIF1AX,EIF2S3,EIF3L,EIF4B,EIF5,EMC3-AS1,EML4,EML6,ENAM,ENPP5,EPM2A,ERP44,EXOG,FAHD1,EEIG1,FAM104B,FAM107B,FAM120C,PABIR2,FAM13A,FAM13B,FHIP1A,FAM172A,FAM177B,FAM199X,,FAM226B,FAM30A,FAM3C,FAM9A,FAM9B,FAM9C,FANCB,FBXL16,FBXW11,FCER2,FCGR2B,FCMR,FCRL1,FCRL2,FCRLA,FGA,FHOD3,FMR1NB,FOXE1,FOXO1,FOXP1,FRA10AC1,FRMPD4,FSD1L,FXR1,G3BP2,GABPA,GAGE1,GCSAM,GDPD1,GEMIN8,GNG13,GNG7,GOLGA8T,GPM6B,GPR18,GPR183,GPR82,GRIA3,GRPEL2,GSTM3,GTDC1,HECA,HEPH,HEPHL1,HHLA3,HIVEP2,HLA-DOB,HLA-DQB1,HLA-DRB1,HLA-DRB3,HLF,HMGB1,HNRNPA0,HNRNPC,HNRNPR,HSP90AB1,HSPA8,HSPD1,ICE1,ID3,IFT43,IGFBP5,IGHD,IGHG1,IGHG2,IGHM,IGLC1,IKZF1,IL24,IL7,IL7R,INSIG1,IRAK1BP1,IRF4,IRF8,ITGA6,ITM2A,ITPR1,KAT6B,KBTBD8,KCNE2,KCNH8,KDM5C,KDM6A,KHDRBS1,KLF12,KLHL14,KLHL4,LARGE1,LARGE2,LDHB,LEF1,LEKR1,LHX6,LINC00879,LINC00891,LINC00926,LINC01550,LINC02397,LIX1,,ENSG00000289047,AGA-DT,LPAR4,LRCH1,LRRN3,MAGEA3,MAGEA5P,MAGEA6,MAGT1,MALT1,MAP7D2,MATR3,MBNL1,MBTPS2,MDFIC,MECOM,MED14,METAP1D,METTL4,METTL8,MFSD4A,MID2,MIPOL1,MIR507,MLLT3,MORF4L2,MOSPD2,MOXD1,MROH2A,MRPL39,MRPS35,MRTFB,MTMR2,MTR,MTRR,MUC20,MXRA5,MYO5B,MYOT,NAP1L1,NAP1L2,NARS2,NBDY,NBEA,NBPF11,NCBP2,NDP,NEMP1,NETO1,NEXMIF,NHLRC2,NIBAN3,NIPAL3,NLGN1,NLGN4X,NOX1,NPHP1,NR3C2,NT5E,NUBPL,NUDT10,NUDT11,NUDT7,NUFIP1,NUP62CL,OCIAD1,OFD1,OGT,OPHN1,OR2A1,OR2A42,OR2L2,OR6C3,OSBPL10,P2RX5,PAIP2B,PAK3,PARM1,PAWR,PCDH19,PCDH9,PDGFB,PDK2,PEG10,PHC3,PHF10,PHF6,PHLDA1,PJA1,PKHD1L1,PKIG,PLEKHB1,PLEKHF2,PLEKHG1,PLP1,PLPP5,PLS3,PM20D2,PMEPA1,PODXL,POFUT1,POLA1,POM121,POM121C,POU2AF1,POU2F3,PPP1R21,PPP2R1B,PPP6C,PRDM2,PREX2,PRICKLE1,PRKACB,PRKCQ-AS1,PRPS2,PRRG1,PRSS1,PSG11,PSIP1,PTER,PTGES3,PTHLH,PTPRK,PURA,QRSL1,RAB30,RABGAP1L,RABL3,RAD54B,RALGPS2,RAP2C,RASGRP1,RASGRP3,RASL11B,RBM12,RBMX,REEP5,RERG,RNF185,RNFT2,RORA,RPL22,RPS4X,RPS6KA6,RRAS2,RSPRY1,RYK,S1PR1,SARAF,SCN3A,SEL1L3,SELENOI,,SEPTIN6,SEPTIN7,SERBP1,SERPINB11,SERPINE3,SET,SGCE,SH3BGR,SHISAL2A,SKP1,SLC16A10,SLC25A32,SLC25A4,SLC25A6,SLC2A12,SLC35G1,SLC38A1,SLC38A11,SLC4A5,SLC7A6OS,SLC9A7,SLITRK2,SLITRK4,SMAD3,SMARCA1,SMARCE1,SMC6,SMIM10,SMIM11,SMPX,SMURF2,SNAPC3,SNORD45B,SNORD61,SNX22,SPART,SPIB,SPICE1,SPON1,SPRR2B,SPRY1,SPTBN1,SSPN,SSX2,ST6GAL1,STAMBPL1,STAP1,STK17A,STRBP,SWAP70,SYPL1,SYTL5,TAB2,TAF1,TAF4B,TAF7,TAGAP,TBC1D4,TBC1D8B,TBC1D9,TBX20,TCEA1,TCEANC,TCERG1,TCF7,TCL6,TCTN1,TENM1,TENM3,TFDP3,THEM4,TLK1,TMEM220,TMEM230,TMEM263,TMEM35A,TMEM47,TMPO,TMSB15B,TNFRSF13C,TNFRSF25,TP73-AS1,TPD52,TPD52L1,TRAF5,TRAM1,TRAPPC2,TRIB2,TRIM2,TRIM67,TRPC5,TSEN15,TSEN2,TSPAN13,TSPYL1,TTC3,SKIC3,TTC39C,TXLNG,UBQLN1,UGT8,USP27X,USP27X-DT,USP51,USP6,USP9X,VEGFD,VPREB3,VPS4B,WDR3,WDR44,WDR6,WFDC10A,WNK3,WWP1,XIST,XPO1,YWHAQ,ZBTB33,ZBTB6,ZCCHC7,ZDHHC23,ZFR,ZFX,ZMAT1,ZNF107,ZNF135,ZNF140,ZNF141,ZNF251,ZNF253,ZNF268,ZNF280C,ZNF320,ZNF331,ZNF382,ZNF418,ZNF420,ZNF44,ZNF442,ZNF470,ZNF507,ZNF518B,ZNF519,ZNF525,ZNF529,ZNF548,ZNF550,ZNF566,ZNF582-DT,ZNF614,ZNF615,ZNF626,ZNF667,ZNF711,ZNF837,ZNF92,ZXDA,ZXDB",590,"ABCB11,ABCB4,ABLIM1,ACSM1,ADAM21,ADAM22,ADAM28,ADAM30,ADD3,ADGRG4,AFF3,AGPAT5,AHR,AIDA,ALDH1A3,ALDOB,AMMECR1,AMOTL1,ANAPC1,ANAPC16,ANGPTL1,ANK3,ANKRD36,ANKRD36B,ANKRD36C,ANP32E,AP4S1,API5,APOO,AR,ARHGAP42,ARHGEF3,ARL14EP,ARL6IP5,ARMC1,ASNS,ATF1,ATM,ATP11C,ATP1B4,ATP2B3,ATRX,AXIN2,BACH2,BANK1,BCAS2,BCL11A,BCL2,BCL7A,BCLAF1,BCLAF3,BDH2,BHLHB9,BHLHE41,BIRC3,BLK,BLNK,BMI1,BPNT1,BTLA,BTNL9,BUB3,C12orf29,C12orf66,C14orf28,C19orf12,C1orf220,CASK,CATSPERB,CBLL1,CCDC160,CCDC91,CCNG1,CCR6,CD160,CD180,CD20,CD200,CD22,CD27,CD40,CD72,CD79A,CD79B,CDC42SE2,CDK17,CDR1,CELSR1,CFAP44,CFAP47,CFAP97,CGGBP1,CHIC1,CHM,CHML,CHN1,CLCN5,CLEC2D,CLIC4,CLN8,CLU,CNR2,CNTNAP1,COBLL1,COCH,COL4A4,COMMD3-BMI1,CPO,CR2,CT47A1,CT47A10,CT47A11,CT47A2,CT55,CTAGE15,CTAGE4,CTAGE6,CTAGE9,CTH,CWC22,CXCR5,CXorf58,CYP2E1,DACT1,DCK,DCX,DDX21,DDX3X,DLAT,DLG5,DMD,DNAAF6,DNAH12,DNAH3,DNAJC30,DNM1L,DOCK10,DOCK9,DPP4,DSP,DTD2,DYRK1A,EBF1,EDA2R,EDARADD,EEF1G,EFHC2,EFR3A,EGFL6,EGLN3,EIF1AX,EIF2S3,EIF3L,EIF4B,EIF5,EMC3-AS1,EML4,EML6,ENAM,ENPP5,EPM2A,ERP44,EXOG,FAHD1,FAM102A,FAM104B,FAM107B,FAM120C,FAM122B,FAM13A,FAM13B,FAM160A1,FAM172A,FAM177B,FAM199X,FAM226A,FAM226B,FAM30A,FAM3C,FAM9A,FAM9B,FAM9C,FANCB,FBXL16,FBXW11,FCER2,FCGR2B,FCMR,FCRL1,FCRL2,FCRLA,FGA,FHOD3,FMR1NB,FOXE1,FOXO1,FOXP1,FRA10AC1,FRMPD4,FSD1L,FXR1,G3BP2,GABPA,GAGE1,GCSAM,GDPD1,GEMIN8,GNG13,GNG7,GOLGA8T,GPM6B,GPR18,GPR183,GPR82,GRIA3,GRPEL2,GSTM3,GTDC1,HECA,HEPH,HEPHL1,HHLA3,HIVEP2,HLA-DOB,HLA-DQB1,HLA-DRB1,HLA-DRB3,HLF,HMGB1,HNRNPA0,HNRNPC,HNRNPR,HSP90AB1,HSPA8,HSPD1,ICE1,ID3,IFT43,IGFBP5,IGHD,IGHG1,IGHG2,IGHM,IGLC1,IKZF1,IL24,IL7,IL7R,INSIG1,IRAK1BP1,IRF4,IRF8,ITGA6,ITM2A,ITPR1,KAT6B,KBTBD8,KCNE2,KCNH8,KDM5C,KDM6A,KHDRBS1,KLF12,KLHL14,KLHL4,LARGE1,LARGE2,LDHB,LEF1,LEKR1,LHX6,LINC00879,LINC00891,LINC00926,LINC01550,LINC02397,LIX1,LOC100132741,LOC100294145,LOC285500,LPAR4,LRCH1,LRRN3,MAGEA3,MAGEA5,MAGEA6,MAGT1,MALT1,MAP7D2,MATR3,MBNL1,MBTPS2,MDFIC,MECOM,MED14,METAP1D,METTL4,METTL8,MFSD4A,MID2,MIPOL1,MIR507,MLLT3,MORF4L2,MOSPD2,MOXD1,MROH2A,MRPL39,MRPS35,MRTFB,MTMR2,MTR,MTRR,MUC20,MXRA5,MYO5B,MYOT,NAP1L1,NAP1L2,NARS2,NBDY,NBEA,NBPF11,NCBP2,NDP,NEMP1,NETO1,NEXMIF,NHLRC2,NIBAN3,NIPAL3,NLGN1,NLGN4X,NOX1,NPHP1,NR3C2,NT5E,NUBPL,NUDT10,NUDT11,NUDT7,NUFIP1,NUP62CL,OCIAD1,OFD1,OGT,OPHN1,OR2A1,OR2A42,OR2L2,OR6C3,OSBPL10,P2RX5,PAIP2B,PAK3,PARM1,PAWR,PCDH19,PCDH9,PDGFB,PDK2,PEG10,PHC3,PHF10,PHF6,PHLDA1,PJA1,PKHD1L1,PKIG,PLEKHB1,PLEKHF2,PLEKHG1,PLP1,PLPP5,PLS3,PM20D2,PMEPA1,PODXL,POFUT1,POLA1,POM121,POM121C,POU2AF1,POU2F3,PPP1R21,PPP2R1B,PPP6C,PRDM2,PREX2,PRICKLE1,PRKACB,PRKCQ-AS1,PRPS2,PRRG1,PRSS1,PSG11,PSIP1,PTER,PTGES3,PTHLH,PTPRK,PURA,QRSL1,RAB30,RABGAP1L,RABL3,RAD54B,RALGPS2,RAP2C,RASGRP1,RASGRP3,RASL11B,RBM12,RBMX,REEP5,RERG,RNF185,RNFT2,RORA,RPL22,RPS4X,RPS6KA6,RRAS2,RSPRY1,RYK,S1PR1,SARAF,SCN3A,SEL1L3,SELENOI,SEPT15,SEPTIN6,SEPTIN7,SERBP1,SERPINB11,SERPINE3,SET,SGCE,SH3BGR,SHISAL2A,SKP1,SLC16A10,SLC25A32,SLC25A4,SLC25A6,SLC2A12,SLC35G1,SLC38A1,SLC38A11,SLC4A5,SLC7A6OS,SLC9A7,SLITRK2,SLITRK4,SMAD3,SMARCA1,SMARCE1,SMC6,SMIM10,SMIM11A,SMPX,SMURF2,SNAPC3,SNORD45B,SNORD61,SNX22,SPG20,SPIB,SPICE1,SPON1,SPRR2B,SPRY1,SPTBN1,SSPN,SSX2,ST6GAL1,STAMBPL1,STAP1,STK17A,STRBP,SWAP70,SYPL1,SYTL5,TAB2,TAF1,TAF4B,TAF7,TAGAP,TBC1D4,TBC1D8B,TBC1D9,TBX20,TCEA1,TCEANC,TCERG1,TCF7,TCL6,TCTN1,TENM1,TENM3,TFDP3,THEM4,TLK1,TMEM220,TMEM230,TMEM263,TMEM35A,TMEM47,TMPO,TMSB15B,TNFRSF13C,TNFRSF25,TP73-AS1,TPD52,TPD52L1,TRAF5,TRAM1,TRAPPC2,TRIB2,TRIM2,TRIM67,TRPC5,TSEN15,TSEN2,TSPAN13,TSPYL1,TTC3,TTC37,TTC39C,TXLNG,UBQLN1,UGT8,USP27X,USP27X-AS1,USP51,USP6,USP9X,VEGFD,VPREB3,VPS4B,WDR3,WDR44,WDR6,WFDC10A,WNK3,WWP1,XIST,XPO1,YWHAQ,ZBTB33,ZBTB6,ZCCHC7,ZDHHC23,ZFR,ZFX,ZMAT1,ZNF107,ZNF135,ZNF140,ZNF141,ZNF251,ZNF253,ZNF268,ZNF280C,ZNF320,ZNF331,ZNF382,ZNF418,ZNF420,ZNF44,ZNF442,ZNF470,ZNF507,ZNF518B,ZNF519,ZNF525,ZNF529,ZNF548,ZNF550,ZNF566,ZNF582-AS1,ZNF614,ZNF615,ZNF626,ZNF667,ZNF711,ZNF837,ZNF92,ZXDA,ZXDB",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41162,TWINRIX,VLP,"HBV, HAV",WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_ANTI_HBS_CONC_PRIMARY_VACC_1DY_SIGNIFICANT,VIRUS,SIGNIFICANT,CORRELATION,ANTIBODY,D1,D,1,20-40 vs 60-84,ADULT VS ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_ANTI_HBS_CONC_PRIMARY_VACC_1DY_SIGNIFICANT,"Many current vaccines are less immunogenic and less effective in elderly compared to younger adults due to age-related changes of the immune system. Most vaccines utilized in the elderly contain antigens, which the target population has had previous contact with due to previous vaccination or infection. Therefore, most studies investigating vaccine-induced immune responses in the elderly do not analyze responses to neo-antigens but rather booster responses. However, age-related differences in the immune response could differentially affect primary versus recall responses. We therefore investigated the impact of age on primary and recall antibody responses following hepatitis B vaccination in young and older adults. Focused gene expression profiling was performed before and 1 day after the vaccination in order to identify gene signatures predicting antibody responses. Young (20-40 years; <i>n</i> = 24) and elderly ( > 60 years; <i>n</i> = 17) healthy volunteers received either a primary series (no prior vaccination) or a single booster shot (documented primary vaccination more than 10 years ago). Antibody titers were determined at days 0, 7, and 28, as well as 6 months after the vaccination. After primary vaccination, antibody responses were lower and delayed in the elderly compared to young adults. Non-responders after the three-dose primary series were only observed in the elderly group. Maximum antibody concentrations after booster vaccination were similar in both age groups. Focused gene expression profiling identified 29 transcripts that correlated with age at baseline and clustered in a network centered around type I interferons and pro-inflammatory cytokines. In addition, smaller 8- and 6-gene signatures were identified at baseline that associated with vaccine responsiveness during primary and booster vaccination, respectively. When evaluating the kinetic changes in gene expression profiles before and after primary vaccination, a 33-gene signature, dominated by IFN-signaling, pro-inflammatory cytokines, inflammasome components, and immune cell subset markers, was uncovered that was associated with vaccine responsiveness. By contrast, no such transcripts were identified during booster vaccination. Our results document that primary differs from booster vaccination in old age, in regard to antibody responses as well as at the level of gene signatures. Clinical: www.clinicaltrialsregister.eu, this trial was registered at the EU Clinical Trial Register (EU-CTR) with the EUDRACT-Nr. 2013-002589-38.","Genes significantly correlated with anti-HBs concentration in blood in young/old adults (20-40)/(60-84) (primary vaccination) after exposure to Twinrix , time point 1D. Comment: transcripts that were differentially regulated between individuals with anti-HBs concentrations of >= 10,000 and < 10,000 IU/l","Weinberger B,Haks MC,de Paus RA,Ottenhoff THM,Bauer T,Grubeck-Loebenstein B",29868000,HUMAN_GENE_SYMBOL,"BPI,CCL19,CD14,CD19,CD3E,CXCL9,GATA3,GZMA,IFI35,IFI44L,IFI6,IFIT5,IL2,IL22RA1,IL6,IL7R,IL9,MARCO,NLRP1,NLRP12,NLRP2,NLRP4,RAB33A,SLAMF7,CISH,STAT1,TGFB1,TLR3,TLR9,TNF,TNFRSF1A,TNFRSF1B,TNIP1",33,"BPI,CCL19,CD14,CD19,CD3E,CXCL9,GATA3,GZMA,IFI35,IFI44L,IFI6,IFIT5,IL2,IL22RA1,IL6,IL7R,IL9,MARCO,NLRP1,NLRP12,NLRP2,NLRP4,RAB33A,SLAMF7,SOCS,STAT1,TGFB1,TLR3,TLR9,TNF,TNFRSF1A,TNFRSF1B,TNIP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41044,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,M12,M,12,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes negatively correlated with antibody response in peripheral blood mononuclear cell in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 12M. Comment: Spearman Correlation of Gene Expression with Neutralizing Antibody Levels","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ADD3,CFD,CHRNA7,CXCL2,FUCA1,HPCAL1,HS3ST1,HS3ST2,IMPA2,KRT5,LEF1,MZF1,PLIN2,RBMS2,SLC43A1,SNCA,SORL1,SPAG8,SRRM2,TNS1",20,"ADD3,CFD,CHRNA7,CXCL2,FUCA1,HPCAL1,HS3ST1,HS3ST2,IMPA2,KRT5,LEF1,MZF1,PLIN2,RBMS2,SLC43A1,SNCA,SORL1,SPAG8,SRRM2,TNS1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M40945,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,M12,M,12,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_12MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes positively correlated with antibody response in peripheral blood mononuclear cell in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 12M. Comment: Spearman Correlation of Gene Expression with Neutralizing Antibody Levels","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ADGRB3,,ALAS1,ALDH1A2,AURKA,CCND2,CD180,CD1B,CYTH2,FANCG,GAPDH,HIRIP3,IFNG,IL1RN,LGALS2,MT2A,POLR3K,QPCT,RNASEL,RTN3,SLAMF1,SLC25A40",22,"ADGRB3,AKAP2,ALAS1,ALDH1A2,AURKA,CCND2,CD180,CD1B,CYTH2,FANCG,GAPDH,HIRIP3,IFNG,IL1RN,LGALS2,MT2A,POLR3K,QPCT,RNASEL,RTN3,SLAMF1,SLC25A40",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M41043,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,M7,M,7,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_NEGATIVE,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes negatively correlated with antibody response in peripheral blood mononuclear cell in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 7M. Comment: Spearman Correlation of Gene Expression with Neutralizing Antibody Levels","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ADD3,BMAL2,CXCL2,FUCA1,GMEB1,HPCAL1,HS3ST2,IMPA2,KRT5,LEF1,PMP22,RBMS2,SLC43A1",13,"ADD3,ARNTL2,CXCL2,FUCA1,GMEB1,HPCAL1,HS3ST2,IMPA2,KRT5,LEF1,PMP22,RBMS2,SLC43A1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M40944,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,M7,M,7,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_7MO_CORRELATED_WITH_ANTIBODY_RESPONSE_POSITIVE,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes positively correlated with antibody response in peripheral blood mononuclear cell in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 7M. Comment: Spearman Correlation of Gene Expression with Neutralizing Antibody Levels","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ADGRB3,ALAS1,ARHGAP29,AURKA,CCND2,CD180,CD1B,FANCG,GGT5,GML,HIRIP3,IL1RN,IL6,INHBA,LGALS2,NTN1,PFKP,RNASEL,SLAMF1,TNF,TPI1",21,"ADGRB3,ALAS1,ARHGAP29,AURKA,CCND2,CD180,CD1B,FANCG,GGT5,GML,HIRIP3,IL1RN,IL6,INHBA,LGALS2,NTN1,PFKP,RNASEL,SLAMF1,TNF,TPI1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067885/bin/khvi-14-07-1450122-s001.xlsx,NA,NA,NA,NA
M40923,TWINRIX,VLP,"HBV, HAV",WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,W2,W,2,20-40 vs 60-84,ADULT VS ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_4_POST_BOOSTER_VACC_1DY_POSITIVE,"Many current vaccines are less immunogenic and less effective in elderly compared to younger adults due to age-related changes of the immune system. Most vaccines utilized in the elderly contain antigens, which the target population has had previous contact with due to previous vaccination or infection. Therefore, most studies investigating vaccine-induced immune responses in the elderly do not analyze responses to neo-antigens but rather booster responses. However, age-related differences in the immune response could differentially affect primary versus recall responses. We therefore investigated the impact of age on primary and recall antibody responses following hepatitis B vaccination in young and older adults. Focused gene expression profiling was performed before and 1 day after the vaccination in order to identify gene signatures predicting antibody responses. Young (20-40 years; <i>n</i> = 24) and elderly ( > 60 years; <i>n</i> = 17) healthy volunteers received either a primary series (no prior vaccination) or a single booster shot (documented primary vaccination more than 10 years ago). Antibody titers were determined at days 0, 7, and 28, as well as 6 months after the vaccination. After primary vaccination, antibody responses were lower and delayed in the elderly compared to young adults. Non-responders after the three-dose primary series were only observed in the elderly group. Maximum antibody concentrations after booster vaccination were similar in both age groups. Focused gene expression profiling identified 29 transcripts that correlated with age at baseline and clustered in a network centered around type I interferons and pro-inflammatory cytokines. In addition, smaller 8- and 6-gene signatures were identified at baseline that associated with vaccine responsiveness during primary and booster vaccination, respectively. When evaluating the kinetic changes in gene expression profiles before and after primary vaccination, a 33-gene signature, dominated by IFN-signaling, pro-inflammatory cytokines, inflammasome components, and immune cell subset markers, was uncovered that was associated with vaccine responsiveness. By contrast, no such transcripts were identified during booster vaccination. Our results document that primary differs from booster vaccination in old age, in regard to antibody responses as well as at the level of gene signatures. Clinical: www.clinicaltrialsregister.eu, this trial was registered at the EU Clinical Trial Register (EU-CTR) with the EUDRACT-Nr. 2013-002589-38.","Genes positively correlated with high anti-HBs concentration at week 4 post-boost in blood in young/old adults (20-38)/(62-74) (booster vaccination) after exposure to Twinrix , time point 1D. Comment: Correlation between pre-immunization expression levels of single genes (log2-transformed) and anti-HBs concentrations (log10-transformed) at week 4 after booster vaccination","Weinberger B,Haks MC,de Paus RA,Ottenhoff THM,Bauer T,Grubeck-Loebenstein B",29868000,HUMAN_GENE_SYMBOL,"CXCR5,CCR7,CD19,CD274,CTLA4,IL6",6,"BLR1,CCR7,CD19,CD274,CTLA4,IL6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M40957,TWINRIX,VLP,"HBV, HAV",WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_30_PRIMARY_VACC_1DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,W3,W,3,20-40 vs 60-84,ADULT VS ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/WEINBERGER_BLOOD_TWINRIX_AGE_20_40_AND_60_84YO_CORRELATED_WITH_HIGH_ANTI_HBS_CONC_AT_WEEK_30_PRIMARY_VACC_1DY_POSITIVE,"Many current vaccines are less immunogenic and less effective in elderly compared to younger adults due to age-related changes of the immune system. Most vaccines utilized in the elderly contain antigens, which the target population has had previous contact with due to previous vaccination or infection. Therefore, most studies investigating vaccine-induced immune responses in the elderly do not analyze responses to neo-antigens but rather booster responses. However, age-related differences in the immune response could differentially affect primary versus recall responses. We therefore investigated the impact of age on primary and recall antibody responses following hepatitis B vaccination in young and older adults. Focused gene expression profiling was performed before and 1 day after the vaccination in order to identify gene signatures predicting antibody responses. Young (20-40 years; <i>n</i> = 24) and elderly ( > 60 years; <i>n</i> = 17) healthy volunteers received either a primary series (no prior vaccination) or a single booster shot (documented primary vaccination more than 10 years ago). Antibody titers were determined at days 0, 7, and 28, as well as 6 months after the vaccination. After primary vaccination, antibody responses were lower and delayed in the elderly compared to young adults. Non-responders after the three-dose primary series were only observed in the elderly group. Maximum antibody concentrations after booster vaccination were similar in both age groups. Focused gene expression profiling identified 29 transcripts that correlated with age at baseline and clustered in a network centered around type I interferons and pro-inflammatory cytokines. In addition, smaller 8- and 6-gene signatures were identified at baseline that associated with vaccine responsiveness during primary and booster vaccination, respectively. When evaluating the kinetic changes in gene expression profiles before and after primary vaccination, a 33-gene signature, dominated by IFN-signaling, pro-inflammatory cytokines, inflammasome components, and immune cell subset markers, was uncovered that was associated with vaccine responsiveness. By contrast, no such transcripts were identified during booster vaccination. Our results document that primary differs from booster vaccination in old age, in regard to antibody responses as well as at the level of gene signatures. Clinical: www.clinicaltrialsregister.eu, this trial was registered at the EU Clinical Trial Register (EU-CTR) with the EUDRACT-Nr. 2013-002589-38.","Genes positively correlated with high anti-HBs concentration at week 30 in blood in young/old adults (20-40)/(60-84) (primary vaccination) after exposure to Twinrix , time point 1D. Comment: Correlation between pre-immunization expression levels of single genes (log2-transformed) and anti-HBs concentrations (log10-transformed) at week 30 post-primary vaccination","Weinberger B,Haks MC,de Paus RA,Ottenhoff THM,Bauer T,Grubeck-Loebenstein B",29868000,HUMAN_GENE_SYMBOL,"CD14,CD8A,IFITM1,IFITM3,LYN,SEC14L1,TNIP1",7,"CD14,CD8A,IFITM1,IFITM3,LYN,SEC14L1,TNIP1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41062,TIV INFLUENZA,VLP,INFLUENZA,KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MOS_DN,VIRUS,DOWN,VACCINE,BOOSTER,M12-13,M,12.5,65+,ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MOS_DN,"We tested antibody responses to the trivalent inactivated influenza vaccine (TIV) in 34 aged individuals ( > 65 yrs) during the 2012/13 vaccination seasons. Nearly all had been vaccinated the previous year although the time interval between the two vaccine doses differed. One subgroup was re-vaccinated in 2012/13 within 6-9 months of their 2011/12 vaccination, the other received the two doses of vaccine in the typical ~12 month interval. Unexpectedly the sub-cohort with early revaccination exhibited significantly increased response rates and antibody titers to TIV compared to their normally re-vaccinated aged counter parts. Microarray analyses of gene expression in whole blood RNA taken at the day of the 2012/13 re-vaccination revealed statistically significant differences in expression of 754 genes between the individuals with early re-vaccination compared to subjects vaccinated in a normal 12 month interval. These observations suggest that TIV has long-lasting effects on the immune system affecting B cell responses as well as the transcriptome of peripheral blood mononuclear cells and this residual effect may augment vaccination response in patients where the effect of the previous vaccination has not yet diminished.","Genes down-regulated in blood cohort 1 (re-vaccinated in 6-9 months) vs cohort 2 (re-vaccinated in 12-13 months) in adults (65+) after exposure to 2012-2013 seasonal trivalent inactivated influenza vaccine (TIV) , time point N/A. Comment: Cohort 1 (re-vaccinated in 6-9 months) vs Cohort 2 (re-vaccinated in 12-13 months)","Kannan S,Kossenkov A,Kurupati RK,Xiang JZ,Doyle SA,Schmader KE,Schowe L,Ertl HC",26637961,HUMAN_GENE_SYMBOL,"AAMDC,ABAT,ABCG1,ACP2,ADAT1,ADSS2,AGAP6,AGO3,AKAP13,ALDH2,ALDOA,AMY1B,ANKZF1,,ANXA11,ANXA2P1,AP1B1,APLP2,APOBR,ARHGAP30,ARHGAP9,ARNT,ARPIN,ARRDC3,ASH2L,ASTN2-AS1,ATF1,ATG13,ATG4B,ATP6V0B,ATP6V0D1,,BCL7B,BCLAF1,BICRAL,BIN2,BIN3,BRD1,BRD7,BST2,BTK,C2orf68,CALCOCO1,CALHM2,CAPG,CAPNS1,CAPRIN1,CARS1,CARS2,CAST,CATSPER2,CBX4,CCS,CCT6A,CCT7,CD14,CD163,CD63,CD99L2,CDC123,CDK5RAP3,CDKN1C,CDYL,CEP19,CFP,CNPY3,COL4A2,COMT,CORO1C,CPPED1,CPVL,CSF2RA,CSGALNACT2,CSNK1D,CTBP1,CTDP1,CTNNA1,CXCL16,CYP51A1,DCAF6,DDX19A,DDX19B,DHX9,DIP2A,DMC1,DNTTIP1,DTWD2,DTX2,DUSP22,ECHDC3,EGLN2,EIF4G2,EPB41L3,ERGIC1,EWSR1,FAM193A,FAM238B,FAM86KP,FAR2,FBXO38,FBXO44,FCGR2B,FCGR3A,FCGR3B,FKTN,FRA10AC1,FTH1,FYN,GALNT10,GALNT3,GAPDH,GBA2,GIT2,GLE1,GNAI2,GNB2,GRIPAP1,GRN,GTF2H1,MACROH2A1,H3-5,H3C13,H6PD,HADHB,HAL,HERPUD2,HIF1A,HLA-F,HNRNPA3,HNRNPAB,HNRNPCL3,HNRNPK,HPSE,HSF1,HSPA1A,HSPA4,HTRA2,IDS,IFFO1,IL10RB,IL16,IL18,ILK,IQSEC1,ITGB1BP1,ITPK1,KDELR1,KEAP1,BLTP2,KIAA0319L,KIAA2026,KIR2DL3,KLF4,KLF6,KLHL18,KRT23,LAPTM5,LILRB3,LINC01018,LINC01720,LLPH,LMAN2,LMO4,LMOD3,LRRC25,LRRK1,LRTOMT,LSM6,LSP1,MACO1,MAPK14,MARCO,MARS1,MAZ,MCMDC2,ME2,MED8,MFF,MGAM,MGAM2,MIGA1,MILR1,MINDY2,MPLKIP,MTMR3,MTMR4,,NBPF3,NCF4,NCOA1,NDRG3,NDUFA10,NDUFB9,NDUFS2,NFYA,NFYC,NLRP1,NLRP12,NPLOC4,NUBPL,NUDT22,NUP62,ORAI2,ORAI3,OS9,OTX1,PABPC3,PATE2,PATL2,PBXIP1,,PGAM1,PGAM4,PHAX,PHC3,PHRF1,PI4KAP1,PID1,PIGS,PKM,PLAUR,PMS2CL,PNPT1,POLR2J3,POTEF,POTEM,PPFIBP2,PPP1CA,PPP1R12B,PRAM1,PRCP,PRKCB,PRKCZ,PRKD2,PRKDC,PRR5,PRXL2A,PSEN1,PSMB8,PSMC4,PSPC1,PTPRA,PXN,QKI,R3HDM1,RABL6,RAD51,RAE1,RANGRF,RASSF5,RBM4,RBP2,RDH10,REL,RELA,RERE,RGL2,RMC1,RNF130,RNF135,RNF180,RNF213,RPN2,RPP38,RTN3,RTN4,SCN11A,SEC13,SEC23B,SEC24D,SERPINA1,SETD3,SF1,SLBP,SLC25A20,SLC25A51,SLC2A14,SLC35E1,SLC7A7,SLC9A8,SMAP1,SNORD22,SNRNP35,SORD,SP110,SPG11,SPG21,SPPL3,SPTLC1,SQOR,SRPK2,STAB1,STAT3,STK32B,STX5,STYXL1,SULF2,SULT1A2,SULT1A3,SUOX,SYAP1,SYK,TADA2A,,TCHP,TCP1,TDRD1,TECPR2,TERF2IP,TFEB,TIMM23,TLR1,TM9SF1,TMEM69,TNFAIP2,TNFRSF8,TOB2,TOR3A,TP53INP2,TRGV5,TRIM27,TRO,TSPAN14,TTC9C,TTF1,TUBA1A,TUBA1C,TXNL1,U2AF1,UBE4B,UGGT1,UIMC1,USP4,USP48,USP49,VAC14,VKORC1,VPS18,VPS41,WASF2,WDR1,WDR5,WDR82,WNK1,ZC3H7A,ZMYND15,ZNF557",347,"AAMDC,ABAT,ABCG1,ACP2,ADAT1,ADSS,AGAP6,AGO3,AKAP13,ALDH2,ALDOA,AMY1B,ANKZF1,ANP32A-IT1,ANXA11,ANXA2P1,AP1B1,APLP2,APOBR,ARHGAP30,ARHGAP9,ARNT,ARPIN,ARRDC3,ASH2L,ASTN2-AS1,ATF1,ATG13,ATG4B,ATP6V0B,ATP6V0D1,BAGE4,BCL7B,BCLAF1,BICRAL,BIN2,BIN3,BRD1,BRD7,BST2,BTK,C2orf68,CALCOCO1,CALHM2,CAPG,CAPNS1,CAPRIN1,CARS,CARS2,CAST,CATSPER2,CBX4,CCS,CCT6A,CCT7,CD14,CD163,CD63,CD99L2,CDC123,CDK5RAP3,CDKN1C,CDYL,CEP19,CFP,CNPY3,COL4A2,COMT,CORO1C,CPPED1,CPVL,CSF2RA,CSGALNACT2,CSNK1D,CTBP1,CTDP1,CTNNA1,CXCL16,CYP51A1,DCAF6,DDX19A,DDX19B,DHX9,DIP2A,DMC1,DNTTIP1,DTWD2,DTX2,DUSP22,ECHDC3,EGLN2,EIF4G2,EPB41L3,ERGIC1,EWSR1,FAM193A,FAM238B,FAM86KP,FAR2,FBXO38,FBXO44,FCGR2B,FCGR3A,FCGR3B,FKTN,FRA10AC1,FTH1,FYN,GALNT10,GALNT3,GAPDH,GBA2,GIT2,GLE1,GNAI2,GNB2,GRIPAP1,GRN,GTF2H1,H2AFY,H3-5,H3C13,H6PD,HADHB,HAL,HERPUD2,HIF1A,HLA-F,HNRNPA3,HNRNPAB,HNRNPCL3,HNRNPK,HPSE,HSF1,HSPA1A,HSPA4,HTRA2,IDS,IFFO1,IL10RB,IL16,IL18,ILK,IQSEC1,ITGB1BP1,ITPK1,KDELR1,KEAP1,KIAA0100,KIAA0319L,KIAA2026,KIR2DL3,KLF4,KLF6,KLHL18,KRT23,LAPTM5,LILRB3,LINC01018,LINC01720,LLPH,LMAN2,LMO4,LMOD3,LRRC25,LRRK1,LRTOMT,LSM6,LSP1,MACO1,MAPK14,MARCO,MARS,MAZ,MCMDC2,ME2,MED8,MFF,MGAM,MGAM2,MIGA1,MILR1,MINDY2,MPLKIP,MTMR3,MTMR4,MTRNR2L1,NBPF3,NCF4,NCOA1,NDRG3,NDUFA10,NDUFB9,NDUFS2,NFYA,NFYC,NLRP1,NLRP12,NPLOC4,NUBPL,NUDT22,NUP62,ORAI2,ORAI3,OS9,OTX1,PABPC3,PATE2,PATL2,PBXIP1,PDPK2,PGAM1,PGAM4,PHAX,PHC3,PHRF1,PI4KAP1,PID1,PIGS,PKM,PLAUR,PMS2CL,PNPT1,POLR2J3,POTEF,POTEM,PPFIBP2,PPP1CA,PPP1R12B,PRAM1,PRCP,PRKCB,PRKCZ,PRKD2,PRKDC,PRR5,PRXL2A,PSEN1,PSMB8,PSMC4,PSPC1,PTPRA,PXN,QKI,R3HDM1,RABL6,RAD51,RAE1,RANGRF,RASSF5,RBM4,RBP2,RDH10,REL,RELA,RERE,RGL2,RMC1,RNF130,RNF135,RNF180,RNF213,RPN2,RPP38,RTN3,RTN4,SCN11A,SEC13,SEC23B,SEC24D,SERPINA1,SETD3,SF1,SLBP,SLC25A20,SLC25A51,SLC2A14,SLC35E1,SLC7A7,SLC9A8,SMAP1,SNORD22,SNRNP35,SORD,SP110,SPG11,SPG21,SPPL3,SPTLC1,SQOR,SRPK2,STAB1,STAT3,STK32B,STX5,STYXL1,SULF2,SULT1A2,SULT1A3,SUOX,SYAP1,SYK,TADA2A,TAF11L1,TCHP,TCP1,TDRD1,TECPR2,TERF2IP,TFEB,TIMM23,TLR1,TM9SF1,TMEM69,TNFAIP2,TNFRSF8,TOB2,TOR3A,TP53INP2,TRGV5,TRIM27,TRO,TSPAN14,TTC9C,TTF1,TUBA1A,TUBA1C,TXNL1,U2AF1,UBE4B,UGGT1,UIMC1,USP4,USP48,USP49,VAC14,VKORC1,VPS18,VPS41,WASF2,WDR1,WDR5,WDR82,WNK1,ZC3H7A,ZMYND15,ZNF557",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211276/table/T2/,NA,NA,NA,NA
M40962,TIV INFLUENZA,VLP,INFLUENZA,KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MO_UP,VIRUS,UP,VACCINE,BOOSTER,M12-13,M,12.5,65+,ELDER,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/KANNAN_BLOOD_2012_2013_TIV_AGE_65PLS_REVACCINATED_IN_6_9_MO_VS_REVACCINATED_IN_12_13_MO_UP,"We tested antibody responses to the trivalent inactivated influenza vaccine (TIV) in 34 aged individuals ( > 65 yrs) during the 2012/13 vaccination seasons. Nearly all had been vaccinated the previous year although the time interval between the two vaccine doses differed. One subgroup was re-vaccinated in 2012/13 within 6-9 months of their 2011/12 vaccination, the other received the two doses of vaccine in the typical ~12 month interval. Unexpectedly the sub-cohort with early revaccination exhibited significantly increased response rates and antibody titers to TIV compared to their normally re-vaccinated aged counter parts. Microarray analyses of gene expression in whole blood RNA taken at the day of the 2012/13 re-vaccination revealed statistically significant differences in expression of 754 genes between the individuals with early re-vaccination compared to subjects vaccinated in a normal 12 month interval. These observations suggest that TIV has long-lasting effects on the immune system affecting B cell responses as well as the transcriptome of peripheral blood mononuclear cells and this residual effect may augment vaccination response in patients where the effect of the previous vaccination has not yet diminished.","Genes up-regulated in blood cohort 1 (re-vaccinated in 6-9 months) vs cohort 2 (re-vaccinated in 12-13 months) in adults (65+) after exposure to 2012-2013 seasonal trivalent inactivated influenza vaccine (TIV) , time point N/A. Comment: Cohort 1 (re-vaccinated in 6-9 months) vs Cohort 2 (re-vaccinated in 12-13 months)","Kannan S,Kossenkov A,Kurupati RK,Xiang JZ,Doyle SA,Schmader KE,Schowe L,Ertl HC",26637961,HUMAN_GENE_SYMBOL,"ADM2,ADO,AHNAK2,AK3,ARHGEF6,ARMC8,ATP5PD,ATP6AP1L,ATXN10,ATXN1L,BCL11B,C11orf96,C12orf57,C19orf53,C1orf54,C5orf47,CAMKMT,CAMLG,CAPS,CCDC59,CD28,CDC40,CEBPZ,CENPX,CEP41,CFAP74,CLDND1,CLTCL1,CNGA3,CNKSR1,COIL,COMMD3,COX6C,CPM,CRB3,CSE1L,CSNK1A1,CT55,CUL2,CYP4X1,DENND1B,DENND4C,DGCR6,DHCR7,DIRAS2,DLX4,DMAC1,DNAJC15,DOCK10,DPH5,DPP7,DYNC1LI2,EEF1B2,EIF2S1,EIF3E,EIF3H,ELOVL4,FAM86B2,FBXO5,FCGR3A,FEM1C,FIBCD1,FKBP10,FOXD4,GNAT1,GOLGA8B,GPR183,GRPEL2,GTF3A,HACD3,HCAR3,H1-1,H1-3,HMGCS1,HNRNPU,HOXD3,HS6ST3,HSPE1,HSPG2,ICOS,IFT46,IL11RA,IL17C,IMPG2,INTS6,IPO11,IQCM,ITK,ITM2A,KCTD3,KLHL5,KRTAP10-11,KRTAP5-1,KSR2,LEPROTL1,LINC01554,LINC01931,LINC02346,LINC02538,LSM3,LSM7,LYRM7,MAT2A,MICOS13,MIS12,MMGT1,MOB2,MOSPD3,MRPL3,MTERF3,MTFR2,NAE1,NAIP,NAP1L1,NAPEPLD,NDUFAF2,NENF,NNAT,NOSIP,NOTO,NRG3,NSG2,NUDT6,NUP155,OR2W5P,OR51M1,OXLD1,PAICS,PATE1,PBX4,PCSK1N,PER2,PLD6,PLEKHA1,PLPP6,POLR2H,PPIL3,PRKAA1,PRRT1,PTGR2,RALA,RASGRP1,RBM12,RBM15,RD3,RGS12,RND2,RO60,RPL10A,RPL17,RPL18A,RPL24,RPL3,RPL35A,RPL38,RPL6,RPLP0,RPP40,RPS3,RPS3A,RPS6,RSBN1,SC5D,SCN11A,SCNN1B,SECISBP2L,SERBP1,SLC13A3,SLC16A2,SLC30A3,SLC30A7,SLC7A6,SMIM11,SNHG29,SNHG32,SNHG6,SNORA49,SOX8,SPDYE3,SRP72,SRSF6,SRSF7,STMN3,STYX,SULT2B1,SUZ12,TARDBP,TDG,TMEM126B,TMEM145,TMEM256,TMEM41B,TMEM67,TMEM80,TOP3B,TRAT1,TRIB2,TRIM4,TRIM73,TRIML1,UBE2E1,UBE2G2,UBE2Q2,UBP1,UMODL1-AS1,USP16,USP24,USP37,UXT,VSX2,WDR36,WDR75,XPO4,ZBTB33,ZFAND2A,ZFC3H1,ZFP91,ZMYND11,ZNF26,ZNF484,ZNF491,ZNF512B,ZNF566,ZNF816,ZSWIM7,ZZZ3",226,"ADM2,ADO,AHNAK2,AK3,ARHGEF6,ARMC8,ATP5PD,ATP6AP1L,ATXN10,ATXN1L,BCL11B,C11orf96,C12orf57,C19orf53,C1orf54,C5orf47,CAMKMT,CAMLG,CAPS,CCDC59,CD28,CDC40,CEBPZ,CENPX,CEP41,CFAP74,CLDND1,CLTCL1,CNGA3,CNKSR1,COIL,COMMD3,COX6C,CPM,CRB3,CSE1L,CSNK1A1,CT55,CUL2,CYP4X1,DENND1B,DENND4C,DGCR6,DHCR7,DIRAS2,DLX4,DMAC1,DNAJC15,DOCK10,DPH5,DPP7,DYNC1LI2,EEF1B2,EIF2S1,EIF3E,EIF3H,ELOVL4,FAM86B2,FBXO5,FCGR3A,FEM1C,FIBCD1,FKBP10,FOXD4,GNAT1,GOLGA8B,GPR183,GRPEL2,GTF3A,HACD3,HCAR3,HIST1H1A,HIST1H1D,HMGCS1,HNRNPU,HOXD3,HS6ST3,HSPE1,HSPG2,ICOS,IFT46,IL11RA,IL17C,IMPG2,INTS6,IPO11,IQCM,ITK,ITM2A,KCTD3,KLHL5,KRTAP10-11,KRTAP5-1,KSR2,LEPROTL1,LINC01554,LINC01931,LINC02346,LINC02538,LSM3,LSM7,LYRM7,MAT2A,MICOS13,MIS12,MMGT1,MOB2,MOSPD3,MRPL3,MTERF3,MTFR2,NAE1,NAIP,NAP1L1,NAPEPLD,NDUFAF2,NENF,NNAT,NOSIP,NOTO,NRG3,NSG2,NUDT6,NUP155,OR2W5,OR51M1,OXLD1,PAICS,PATE1,PBX4,PCSK1N,PER2,PLD6,PLEKHA1,PLPP6,POLR2H,PPIL3,PRKAA1,PRRT1,PTGR2,RALA,RASGRP1,RBM12,RBM15,RD3,RGS12,RND2,RO60,RPL10A,RPL17,RPL18A,RPL24,RPL3,RPL35A,RPL38,RPL6,RPLP0,RPP40,RPS3,RPS3A,RPS6,RSBN1,SC5D,SCN11A,SCNN1B,SECISBP2L,SERBP1,SLC13A3,SLC16A2,SLC30A3,SLC30A7,SLC7A6,SMIM11A,SNHG29,SNHG32,SNHG6,SNORA49,SOX8,SPDYE3,SRP72,SRSF6,SRSF7,STMN3,STYX,SULT2B1,SUZ12,TARDBP,TDG,TMEM126B,TMEM145,TMEM256,TMEM41B,TMEM67,TMEM80,TOP3B,TRAT1,TRIB2,TRIM4,TRIM73,TRIML1,UBE2E1,UBE2G2,UBE2Q2,UBP1,UMODL1-AS1,USP16,USP24,USP37,UXT,VSX2,WDR36,WDR75,XPO4,ZBTB33,ZFAND2A,ZFC3H1,ZFP91,ZMYND11,ZNF26,ZNF484,ZNF491,ZNF512B,ZNF566,ZNF816,ZSWIM7,ZZZ3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1A, Tab DEGs_TIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M41046,TWINRIX,VLP,"HBV, HAV",FOURATI_BLOOD_TWINRIX_AGE_65_83YO_POOR_RESPONDERS_VS_RESPONDERS_0DY_NETWORK_INFERENCE_UP,VIRUS,UP,SUBSET,SIGNATURE,D0,D,0,65-83,ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FOURATI_BLOOD_TWINRIX_AGE_65_83YO_POOR_RESPONDERS_VS_RESPONDERS_0DY_NETWORK_INFERENCE_UP,"Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three vaccines, including one against HBV. Here we show, using transcriptional and cytometric profiling of whole blood collected before vaccination, that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlate with stronger responses to HBV vaccine. In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlate with weaker responses to this vaccine. Increased numbers of erythrocytes and the haem-induced response also correlate with poor response to the HBV vaccine. A transcriptomics-based pre-vaccination predictor of response to HBV vaccine is built and validated in distinct sets of older adults. This moderately accurate (area under the curve ~65%) but robust signature is supported by flow cytometry and cytokine profiling. This study is the first that identifies baseline predictors and mechanisms of response to the HBV vaccine.","Genes up-regulated in blood poor responders vs responders in seniors (65-83) (poor responders) after exposure to Twinrix , time point 0D. Comment: Networks were inferred for the BioAge module 1 combined to the 15-gene signature and the BioAge module 16 combined to the 15-gene signature, respectively.","Fourati S,Cristescu R,Loboda A,Talla A,Filali A,Railkar R,Schaeffer AK,Favre D,Gagnon D,Peretz Y,Wang IM,Beals CR,Casimiro DR,Carayannopoulos LN,Skaly RP",26742691,HUMAN_GENE_SYMBOL,"IL15,IRF7,IRF9,,OAS1,TRGC1",6,"IL15,IRF7,IRF9,NFkB,OAS1,TRGC1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M41017,TWINRIX,VLP,"HBV, HAV",FOURATI_BLOOD_TWINRIX_AGE_65_81YO_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_DN,VIRUS,DOWN,SUBSET,TRAINING SET,D0,D,0,65-81,ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FOURATI_BLOOD_TWINRIX_AGE_65_81YO_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_DN,"Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three vaccines, including one against HBV. Here we show, using transcriptional and cytometric profiling of whole blood collected before vaccination, that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlate with stronger responses to HBV vaccine. In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlate with weaker responses to this vaccine. Increased numbers of erythrocytes and the haem-induced response also correlate with poor response to the HBV vaccine. A transcriptomics-based pre-vaccination predictor of response to HBV vaccine is built and validated in distinct sets of older adults. This moderately accurate (area under the curve ~65%) but robust signature is supported by flow cytometry and cytokine profiling. This study is the first that identifies baseline predictors and mechanisms of response to the HBV vaccine.","Genes down-regulated in blood responders vs poor responders in seniors (65-81) (responders (training set)) after exposure to Twinrix , time point 0D. Comment: Network inference based on the 15 markers identified as predictors of the response to the HBV vaccine.","Fourati S,Cristescu R,Loboda A,Talla A,Filali A,Railkar R,Schaeffer AK,Favre D,Gagnon D,Peretz Y,Wang IM,Beals CR,Casimiro DR,Carayannopoulos LN,Skaly RP",26742691,HUMAN_GENE_SYMBOL,"HP,HPR,KIF18B,SYDE2,TOP3A",5,"HP,HPR,KIF18B,SYDE2,TOP3A",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 6A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151076/figure/F6/,NA,NA,NA,NA
M41164,TWINRIX,VLP,"HBV, HAV",FOURATI_BLOOD_TWINRIX_AGE_65_81Y0_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_UP,VIRUS,UP,SUBSET,TRAINING SET,D0,D,0,65-81,ELDER,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FOURATI_BLOOD_TWINRIX_AGE_65_81Y0_RESPONDERS_VS_POOR_RESPONDERS_TRAINING_SET_0DY_NETWORK_INFERENCE_UP,"Aging is associated with hyporesponse to vaccination, whose mechanisms remain unclear. In this study hepatitis B virus (HBV)-naive older adults received three vaccines, including one against HBV. Here we show, using transcriptional and cytometric profiling of whole blood collected before vaccination, that heightened expression of genes that augment B-cell responses and higher memory B-cell frequencies correlate with stronger responses to HBV vaccine. In contrast, higher levels of inflammatory response transcripts and increased frequencies of pro-inflammatory innate cells correlate with weaker responses to this vaccine. Increased numbers of erythrocytes and the haem-induced response also correlate with poor response to the HBV vaccine. A transcriptomics-based pre-vaccination predictor of response to HBV vaccine is built and validated in distinct sets of older adults. This moderately accurate (area under the curve ~65%) but robust signature is supported by flow cytometry and cytokine profiling. This study is the first that identifies baseline predictors and mechanisms of response to the HBV vaccine.","Genes up-regulated in blood responders vs poor responders in seniors (65-81) (responders (training set)) after exposure to Twinrix , time point 0D. Comment: Network inference based on the 15 markers identified as predictors of the response to the HBV vaccine.","Fourati S,Cristescu R,Loboda A,Talla A,Filali A,Railkar R,Schaeffer AK,Favre D,Gagnon D,Peretz Y,Wang IM,Beals CR,Casimiro DR,Carayannopoulos LN,Skaly RP",26742691,HUMAN_GENE_SYMBOL,"AMMECR1,BANK1,EFHC2,IGHG1,MS4A1,SPTBN1,TSPAN13",7,"AMMECR1,BANK1,EFHC2,IGHG1,MS4A1,SPTBN1,TSPAN13",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40958,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_DN,VIRUS,DOWN,VACCINE,VAC ONLY,M2,M,2,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_DN,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes down-regulated in peripheral blood mononuclear cell 2m vs 0m in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 2M. Comment: Gene Expression with Neutralizing Antibody Levels","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ABLIM1,ACADVL,ACP5,ACRV1,ADD3,ADGRB3,ADORA2B,ADORA3,AGPAT2,ALDH3A2,ALOX5,ANAPC2,ANOS1,APLNR,APOC1,APOC2,APOE,AR,ARHGAP29,ARHGEF1,ASAH1,ASCL1,ATP5F1C,AVPR1A,B3GALT4,BASP1,BEX3,BICRA,BLVRB,CA5A,CA6,CACFD1,CACNA2D2,CACNA2D3,CADM1,CALCB,CAMKK2,CARTPT,CD14,CD180,CD2BP2,CD9,CD99,CDC25B,CEBPD,CELSR1,CER1,CES1,CFAP410,CFD,CHGA,CHPT1,CHRNA7,CHST3,CHST8,CLDN7,CLEC11A,CLEC3B,CNR1,CPLX2,CSF3R,CTSD,CTSK,CUX1,CXCL2,CYBA,CYP27A1,CYTH2,DAB2,DBP,DGCR2,DHRS3,DHRS9,DIDO1,DLG4,DNAJB2,DNASE2,DOC2A,DPEP2,DPP4,DRD2,DUSP13,DXO,EEF1D,EHHADH,EMP3,ENDOG,ENTR1,EPAS1,ERF,EVX1,F11,F13A1,FABP4,FAIM2,FARP1,FCGRT,FCMR,FGF9,FLRT2,FOXO3,FRAT1,FST,FUCA1,FXYD1,GAA,GABBR2,GADD45B,GAGE1,GAK,GAS7,GCHFR,GDF11,GHR,GLTP,GML,GNB1L,GPNMB,GPRC5C,GRB10,GRID2,GRN,GRPR,GSDME,HAMP,HBA1,HBA2,HMOX1,HOMER3,HOXC5,HPCAL1,HPSE,HS3ST1,HS3ST2,HSD17B14,HSF2,HTRA1,ICAM3,ID3,IFNA21,IGF1,IKZF4,IMPA2,INTS6,IRF3,IRS2,ISYNA1,ITGA6,KCNJ14,KCNK10,KIF13A,KIFC3,KLF2,KLK12,KRT5,LCK,LEF1,LGMN,LPA,LRP1,LRPAP1,LTBP3,LY86,MAD1L1,MAEA,MAGI2,MAPK12,MAPK8IP2,MCOLN1,MERTK,MFSD10,MGAT4B,MIF,MMD,MS4A4A,MXD4,MYO9B,MZF1,NAGLU,NAGPA,NAP1L3,NEB,NISCH,NME3,NOD2,NOP53,NPL,NR0B1,NUDT3,OCA2,PABPC4,PCYOX1,PDCL,PDE2A,PDE6A,PDGFC,PDK4,PECAM1,PEPD,PHLDA1,PIK3R2,PKD2L1,PLA2G4B,PLCB2,PLD3,PLIN2,PLPP3,PLXNC1,PMP22,POLD1,PON2,PPAN,PPP2R3B,PPP2R5A,PRKCZ,PTDSS2,PTH1R,PYCARD,RABAC1,RAI2,RAP2A,RARRES1,RASAL1,RASGRP2,RBM17,RNASE1,RNASEL,RNASET2,RNF130,RPGRIP1,RPL13,RPS6KA2,RTN3,RUNDC3A,RXRA,S100A8,SCAND1,SCARB1,SDS,SELENOP,SGSH,SIGIRR,SLC11A1,SLC23A2,SLC43A1,SLC7A8,SNCA,SORL1,SP2,SPAG1,SPAG8,SPARC,SRPX,SRRM2,STC1,TAS2R1,TBXAS1,TCEAL9,TENM1,TESK2,TIMP2,TM6SF1,TMEM8B,TNFRSF14,TNFRSF1A,TNS1,TP53TG5,TPBG,TPRA1,TPSAB1,TPST2,TSC1,TSPAN4,TUBGCP2,USF2,VAT1,VLDLR,VNN1,VNN3P,VPREB3,VPS51,WASF3,ZBTB18,ZNF117,ZNF324,ZNF395,ZNF74",287,"ABLIM1,ACADVL,ACP5,ACRV1,ADD3,ADGRB3,ADORA2B,ADORA3,AGPAT2,ALDH3A2,ALOX5,ANAPC2,ANOS1,APLNR,APOC1,APOC2,APOE,AR,ARHGAP29,ARHGEF1,ASAH1,ASCL1,ATP5F1C,AVPR1A,B3GALT4,BASP1,BEX3,BICRA,BLVRB,CA5A,CA6,CACFD1,CACNA2D2,CACNA2D3,CADM1,CALCB,CAMKK2,CARTPT,CD14,CD180,CD2BP2,CD9,CD99,CDC25B,CEBPD,CELSR1,CER1,CES1,CFAP410,CFD,CHGA,CHPT1,CHRNA7,CHST3,CHST8,CLDN7,CLEC11A,CLEC3B,CNR1,CPLX2,CSF3R,CTSD,CTSK,CUX1,CXCL2,CYBA,CYP27A1,CYTH2,DAB2,DBP,DGCR2,DHRS3,DHRS9,DIDO1,DLG4,DNAJB2,DNASE2,DOC2A,DPEP2,DPP4,DRD2,DUSP13,DXO,EEF1D,EHHADH,EMP3,ENDOG,ENTR1,EPAS1,ERF,EVX1,F11,F13A1,FABP4,FAIM2,FARP1,FCGRT,FCMR,FGF9,FLRT2,FOXO3,FRAT1,FST,FUCA1,FXYD1,GAA,GABBR2,GADD45B,GAGE1,GAK,GAS7,GCHFR,GDF11,GHR,GLTP,GML,GNB1L,GPNMB,GPRC5C,GRB10,GRID2,GRN,GRPR,GSDME,HAMP,HBA1,HBA2,HMOX1,HOMER3,HOXC5,HPCAL1,HPSE,HS3ST1,HS3ST2,HSD17B14,HSF2,HTRA1,ICAM3,ID3,IFNA21,IGF1,IKZF4,IMPA2,INTS6,IRF3,IRS2,ISYNA1,ITGA6,KCNJ14,KCNK10,KIF13A,KIFC3,KLF2,KLK12,KRT5,LCK,LEF1,LGMN,LPA,LRP1,LRPAP1,LTBP3,LY86,MAD1L1,MAEA,MAGI2,MAPK12,MAPK8IP2,MCOLN1,MERTK,MFSD10,MGAT4B,MIF,MMD,MS4A4A,MXD4,MYO9B,MZF1,NAGLU,NAGPA,NAP1L3,NEB,NISCH,NME3,NOD2,NOP53,NPL,NR0B1,NUDT3,OCA2,PABPC4,PCYOX1,PDCL,PDE2A,PDE6A,PDGFC,PDK4,PECAM1,PEPD,PHLDA1,PIK3R2,PKD2L1,PLA2G4B,PLCB2,PLD3,PLIN2,PLPP3,PLXNC1,PMP22,POLD1,PON2,PPAN,PPP2R3B,PPP2R5A,PRKCZ,PTDSS2,PTHR1,PYCARD,RABAC1,RAI2,RAP2A,RARRES1,RASAL1,RASGRP2,RBM17,RNASE1,RNASEL,RNASET2,RNF130,RPGRIP1,RPL13,RPS6KA2,RTN3,RUNDC3A,RXRA,S100A8,SCAND1,SCARB1,SDS,SELENOP,SGSH,SIGIRR,SLC11A1,SLC23A2,SLC43A1,SLC7A8,SNCA,SORL1,SP2,SPAG1,SPAG8,SPARC,SRPX,SRRM2,STC1,TAS2R1,TBXAS1,TCEAL9,TENM1,TESK2,TIMP2,TM6SF1,TMEM8B,TNFRSF14,TNFRSF1A,TNS1,TP53TG5,TPBG,TPRA1,TPSAB1,TPST2,TSC1,TSPAN4,TUBGCP2,USF2,VAT1,VLDLR,VNN1,VNN3,VPREB3,VPS51,WASF3,ZBTB18,ZNF117,ZNF324,ZNF395,ZNF74",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Fig 2B,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s008.docx,NA,NA,NA,NA
M41138,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_UP,VIRUS,UP,VACCINE,VAC ONLY,M2,M,2,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_2MO_UP,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes up-regulated in peripheral blood mononuclear cell 2m vs 0m in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 2M. Comment: List of DE Genes After Vaccination Using p<0.05 as Cutoff","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ACO2,ACOT7,ACSL1,ADAM19,ADAR,AFF4,AICDA,AIM2,,AKR1B10,ALAS1,ALDH1A2,ANAPC10,AP1G1,APEX2,APOBEC3B,APOBEC3G,APOL1,BMAL2,ATF5,ATF6,ATOX1,AURKA,BATF3,BAX,BCL7B,BHLHE40,BIRC3,BPGM,BRCA1,BUB1,C1QB,C2,C5,CA11,CACNA1A,CASP1,CASP5,CASQ1,CAV3,CCL11,CCL13,CCL17,CCL18,CCL19,CCL20,CCL23,CCL24,CCL4,CCL7,CCNB2,CCND2,CD1B,CD1E,CD209,CD38,CD40,CD70,CD83,CDC40,CDC45,CDC6,CDK6,CDK7,CDKN1A,CDKN3,CENPA,CFB,CFH,CH25H,CHAF1A,CKS1B,CKS2,CLEC10A,CLEC1A,CLIC2,CLIC5,COL1A2,COL2A1,CSF2,CSF2RB,CTAGE1,CTLA4,CTSC,CXCL11,CXCL13,CXCL9,CYP27B1,DDB2,RIGI,DMD,DNAJC7,DNM1L,DSE,DUSP4,DUSP6,EBI3,EBNA1BP2,EFCAB2,EGF,EML4,ENPP2,ESR1,ETS2,FANCA,FANCG,FASLG,FEN1,FKBPL,FPR2,FSTL3,GABBR1,GABPB2,GAPDH,GART,GCH1,GCNT1,GGT5,GINS2,GMEB1,GMNN,GNB5,GNL2,GNLY,GOLM1,GPD2,GPR63,GTPBP4,GZMA,GZMB,HBEGF,HCAR3,HIRIP3,HIVEP3,HLA-DQA1,HOXC11,HP1BP3,HRH4,HSD11B1,HSPH1,ICAM1,IDH3A,IDI1,IDO1,IFITM1,IFITM2,IFNG,IGSF3,IL12RB2,IL15,IL17RB,IL1B,IL1R2,IL1RN,IL2,IL21R,IL2RA,IL3,IL5,IL6,IL6ST,INHBA,INSIG1,IRF2,ISG20,JAG1,KCNJ15,KCNJ2,KCNN4,KIF11,KIF20A,KIR2DS5,KMO,LAD1,LAMC2,LAMP3,LANCL2,LDLR,LGALS2,LIF,LIMA1,LMNB1,LNPEP,LTA,LUZP4,MAD2L1,MAL,MAP2,MAPK11,MARCHF6,MICB,MKI67,MLN,MMP12,MMP8,MNDA,MPO,MPZ,MSMO1,MT1H,MT1X,MT2A,MTHFD2,MTRR,MYBL2,NAMPT,NAPG,NCAPG,NDC80,NDRG2,NDUFV2,NEFH,NMD3,NMT1,NTN1,NUSAP1,OTOR,OXCT1,P2RY1,PAICS,PALM,PARP11,PCK2,PCNA,PDGFA,PDK4,PDSS1,PFDN1,PFKP,PGAM1,PHKA1,PHLDA2,PIK3C3,PIK3R3,PIP4K2A,PKIG,PLA2G4C,PLAAT4,PLEK,PLK1,PMS2,POLA1,POLD1,POLR3K,PPA1,PPEF1,PRC1,PREP,PROM1,PSMA2,PSMA5,PSMB2,PSMB5,PSMB9,PSMD12,PTAFR,PTGES,PTGS2,QPCT,RAB13,RAB17,RAB8B,RAD50,RAPGEF2,RBMS2,RBX1,RFC3,RFC4,RGS1,RNF24,RRM2,RUVBL1,SDHB,SERPINA6,SERPINE1,SERPING1,SHH,SLAMF1,SLC1A4,SLC1A5,SLC22A17,SLC25A17,SLC25A40,SLC2A3,SLC2A6,SLC39A8,SOCS1,SRI,ST3GAL5,STAP1,STX2,SUB1,TAP2,TARS1,TBX1,TEX13B,THRAP3,TIMM17A,TLR1,TLR2,TMSB15A,TNF,TNFSF10,TNPO2,TOP2A,TPI1,TRAIP,TRIM15,TRIP13,TSPAN13,TSPAN5,TXN,TYMS,UCHL5,UCK2,VAMP5,VDR,VRK2,WARS1,XCL1,ZNF222,ZNF267,ZNF35,ZPR1,ZWINT",325,"ACO2,ACOT7,ACSL1,ADAM19,ADAR,AFF4,AICDA,AIM2,AKAP2,AKR1B10,ALAS1,ALDH1A2,ANAPC10,AP1G1,APEX2,APOBEC3B,APOBEC3G,APOL1,ARNTL2,ATF5,ATF6,ATOX1,AURKA,BATF3,BAX,BCL7B,BHLHE40,BIRC3,BPGM,BRCA1,BUB1,C1QB,C2,C5,CA11,CACNA1A,CASP1,CASP5,CASQ1,CAV3,CCL11,CCL13,CCL17,CCL18,CCL19,CCL20,CCL23,CCL24,CCL4,CCL7,CCNB2,CCND2,CD1B,CD1E,CD209,CD38,CD40,CD70,CD83,CDC40,CDC45,CDC6,CDK6,CDK7,CDKN1A,CDKN3,CENPA,CFB,CFH,CH25H,CHAF1A,CKS1B,CKS2,CLEC10A,CLEC1A,CLIC2,CLIC5,COL1A2,COL2A1,CSF2,CSF2RB,CTAGE1,CTLA4,CTSC,CXCL11,CXCL13,CXCL9,CYP27B1,DDB2,DDX58,DMD,DNAJC7,DNM1L,DSE,DUSP4,DUSP6,EBI3,EBNA1BP2,EFCAB2,EGF,EML4,ENPP2,ESR1,ETS2,FANCA,FANCG,FASLG,FEN1,FKBPL,FPR2,FSTL3,GABBR1,GABPB2,GAPDH,GART,GCH1,GCNT1,GGT5,GINS2,GMEB1,GMNN,GNB5,GNL2,GNLY,GOLM1,GPD2,GPR63,GTPBP4,GZMA,GZMB,HBEGF,HCAR3,HIRIP3,HIVEP3,HLA-DQA1,HOXC11,HP1BP3,HRH4,HSD11B1,HSPH1,ICAM1,IDH3A,IDI1,IDO1,IFITM1,IFITM2,IFNG,IGSF3,IL12RB2,IL15,IL17RB,IL1B,IL1R2,IL1RN,IL2,IL21R,IL2RA,IL3,IL5,IL6,IL6ST,INHBA,INSIG1,IRF2,ISG20,JAG1,KCNJ15,KCNJ2,KCNN4,KIF11,KIF20A,KIR2DS5,KMO,LAD1,LAMC2,LAMP3,LANCL2,LDLR,LGALS2,LIF,LIMA1,LMNB1,LNPEP,LTA,LUZP4,MAD2L1,MAL,MAP2,MAPK11,MARCHF6,MICB,MKI67,MLN,MMP12,MMP8,MNDA,MPO,MPZ,MSMO1,MT1H,MT1X,MT2A,MTHFD2,MTRR,MYBL2,NAMPT,NAPG,NCAPG,NDC80,NDRG2,NDUFV2,NEFH,NMD3,NMT1,NTN1,NUSAP1,OTOR,OXCT1,P2RY1,PAICS,PALM,PARP11,PCK2,PCNA,PDGFA,PDK4,PDSS1,PFDN1,PFKP,PGAM1,PHKA1,PHLDA2,PIK3C3,PIK3R3,PIP4K2A,PKIG,PLA2G4C,PLAAT4,PLEK,PLK1,PMS2,POLA1,POLD1,POLR3K,PPA1,PPEF1,PRC1,PREP,PROM1,PSMA2,PSMA5,PSMB2,PSMB5,PSMB9,PSMD12,PTAFR,PTGES,PTGS2,QPCT,RAB13,RAB17,RAB8B,RAD50,RAPGEF2,RBMS2,RBX1,RFC3,RFC4,RGS1,RNF24,RRM2,RUVBL1,SDHB,SERPINA6,SERPINE1,SERPING1,SHH,SLAMF1,SLC1A4,SLC1A5,SLC22A17,SLC25A17,SLC25A40,SLC2A3,SLC2A6,SLC39A8,SOCS1,SRI,ST3GAL5,STAP1,STX2,SUB1,TAP2,TARS1,TBX1,TEX13B,THRAP3,TIMM17A,TLR1,TLR2,TMSB15A,TNF,TNFSF10,TNPO2,TOP2A,TPI1,TRAIP,TRIM15,TRIP13,TSPAN13,TSPAN5,TXN,TYMS,UCHL5,UCK2,VAMP5,VDR,VRK2,WARS,XCL1,ZNF222,ZNF267,ZNF35,ZPR1,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M41157,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_DN,VIRUS,DOWN,VACCINE,VAC VS CTRL,D0,D,0,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_DN,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes down-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 0D. Comment: List of Genes induced by VLP directly, independently of vaccination (p<0.05 and FC>1.30)","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"A2M,ABCC3,ABO,AK1,AKR1B10,ALDH1A1,ALDH3A2,ALDH7A1,APOC1,APOC2,APOE,ATXN1,BCL11B,BEX3,C5,CADM1,CASP8AP2,CAV3,CD8B,CD9,CD96,CDK6,CELSR1,CEP250,CHIT1,CHRM4,CHRNA1,CHRNG,CLCA1,CLIC5,COL1A2,CPM,CRHBP,CRYGD,CTSG,CXXC4,CYP27A1,CYP2C18,DPEP2,DTWD1,EDA2R,EFNA5,EIF1AX,ENC1,ENOSF1,EPAS1,F13A1,FABP3,FABP4,FGF9,FOLR2,GCM1,GLIPR1,GLT8D2,GPRC5B,GPX3,GSDME,HAMP,HOXC11,HOXD11,HPCAL4,HS3ST2,HSD17B4,HTR2C,HTT,IL5RA,IMPA2,INSR,IRS2,ITGAE,ITGAV,ITIH3,KCNMA1,KDELR2,KEL,KIR2DS5,LAMC2,LEP,LMO1,MARCHF6,MARCO,MMP2,MMP8,MRC2,NDRG2,NEO1,NINJ2,NPFFR1,NPL,NQO1,NRCAM,OAT,OSGEPL1,PAPSS2,PDPN,PELI2,PFKFB1,PLEK2,PLIN2,PLTP,PLXNA1,PLXNC1,PMS2,PRKG2,PTGES,RARG,RARRES1,RCAN3,RNASE4,SCD,SCML1,SDS,SELENOP,SERPINF1,SH3BP4,SHH,SLC26A2,SLC2A11,SMAD6,SNCA,SORL1,SSR3,STEAP1,STXBP1,TFCP2L1,TG,TNNI2,TNS1,TRAIP,TREM2,TRIM16,TSPAN5,UBASH3A,WNT7A,ZFYVE9,ZNF124",136,"A2M,ABCC3,ABO,AK1,AKR1B10,ALDH1A1,ALDH3A2,ALDH7A1,APOC1,APOC2,APOE,ATXN1,BCL11B,BEX3,C5,CADM1,CASP8AP2,CAV3,CD8B,CD9,CD96,CDK6,CELSR1,CEP250,CHIT1,CHRM4,CHRNA1,CHRNG,CLCA1,CLIC5,COL1A2,CPM,CRHBP,CRYGD,CTSG,CXXC4,CYP27A1,CYP2C18,DPEP2,DTWD1,EDA2R,EFNA5,EIF1AX,ENC1,ENOSF1,EPAS1,F13A1,FABP3,FABP4,FGF9,FOLR2,GCM1,GLIPR1,GLT8D2,GPRC5B,GPX3,GSDME,HAMP,HOXC11,HOXD11,HPCAL4,HS3ST2,HSD17B4,HTR2C,HTT,IL5RA,IMPA2,INSR,IRS2,ITGAE,ITGAV,ITIH3,KCNMA1,KDELR2,KEL,KIR2DS5,LAMC2,LEP,LMO1,MARCHF6,MARCO,MMP2,MMP8,MRC2,NDRG2,NEO1,NINJ2,NPFFR1,NPL,NQO1,NRCAM,OAT,OSGEPL1,PAPSS2,PDPN,PELI2,PFKFB1,PLEK2,PLIN2,PLTP,PLXNA1,PLXNC1,PMS2,PRKG2,PTGES,RARG,RARRES1,RCAN3,RNASE4,SCD,SCML1,SDS,SELENOP,SERPINF1,SH3BP4,SHH,SLC26A2,SLC2A11,SMAD6,SNCA,SORL1,SSR3,STEAP1,STXBP1,TFCP2L1,TG,TNNI2,TNS1,TRAIP,TREM2,TRIM16,TSPAN5,UBASH3A,WNT7A,ZFYVE9,ZNF124",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356402/#SD1,NA,NA,NA,NA
M41025,HPV-VLP,VLP,HPV,GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_UP,VIRUS,UP,VACCINE,VAC VS CTRL,D0,D,0,18-25,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/GARCIA_PINERES_PBMC_HPV_16_L1_VLP_AGE_18_25YO_STIMULATED_VS_UNSTIMULATED_0DY_VACCINATION_INDEPENDENT_UP,"Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMCs from 17 vaccine and 4 placebo recipients before vaccination and 1 mo after receiving the second immunization. Vaccination with a monovalent HPV-16 L1 VLP vaccine was associated with modulation of genes involved in the inflammatory/defense response, cytokine, IFN, and cell cycle pathways in VLP-stimulated PBMCs. Additionally, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing Ab titers were found for cyclin D2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with microarray data was seen for more than two-thirds of these probesets. Up-regulation of immune/defense response genes by HPV-16 L1 VLP, in particular, IFN-induced genes, was observed in PBMCs collected before vaccination, with many of these genes being further induced following vaccination. In conclusion, we identified important innate and adaptive response-related genes induced by vaccination with HPV-16 L1 VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials.","Genes up-regulated in peripheral blood mononuclear cell stimulated vs unstimulated in young adults (18-25) after exposure to HPV-16 L1 VLP , time point 0D. Comment: List of Genes induced by VLP directly, independently of vaccination (p<0.05 and FC>1.30)","Garca-Pieres AJ,Hildesheim A,Dodd L,Kemp TJ,Yang J,Fullmer B,Harro C,Lowy DR,Lempicki RA,Pinto LA",19155521,HUMAN_GENE_SYMBOL,"ACOT9,ADAMDEC1,ADGRE5,,ALAS1,APBA1,APOBEC3B,APOL1,APOL3,APOL6,AR,BMAL2,ATF5,AURKA,AURKB,AVPR1A,AXL,BATF3,BAZ1A,BCL2L14,BIRC5,BMPR1B,BST2,C1QA,C1RL,C1S,C2,CACNA1A,CBR1,CCL13,CCL17,CCL18,CCL19,CCL2,CCL3,CCL7,CCL8,CCNA2,CCND1,CCR8,CD19,CD38,CD72,CDC45,CDKN1A,CFB,CHST12,CHST3,CHST8,CKS2,CLCNKA,CLDN7,CLEC11A,CLEC4A,CSF2RB,CXCL1,CXCL10,CXCL11,CXCL9,CYP27B1,RIGI,DUSP5,DUSP6,DYNLT1,EBI3,EGR2,EIF2AK2,ENPP2,ESPL1,ESRRG,ETV7,EZH2,F3,FA2H,ENTREP3,FAS,FCGR1A,FFAR2,FGL2,FHL2,FPR2,FSCN1,FSHB,FST,G0S2,GABBR2,GBP1,GCH1,GDF11,GGT5,GINS2,GMPR,GPALPP1,GPRC5C,GRID2,GRM7,GUCY1A2,GZMB,H1-0,H2AC18,H6PD,HCAR3,HERC5,HESX1,HLX,HMMR,HOXC5,HSD11B1,HSPB1,HSPBP1,IDO1,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNA6,IFNG,IGF2BP3,IGFALS,IGFBP1,IL15,IL15RA,IL36A,IL3RA,IL6,IL9,INHBA,INSM1,IRF1,IRF7,ISG15,ISG20,JAK2,JUP,KCNJ14,KCNJ2,KCNK5,KIF13A,KIFC3,L1CAM,LAG3,LAMB3,LAMP3,LAMP5,LAP3,LGALS3BP,LIF,LIMK2,LMO2,LY6E,LYPD1,MAFF,MAP3K7CL,MMP14,MMP25,MMP9,MNDA,MT1H,MT1X,MT2A,MUC1,MX1,MX2,MXD1,MYOF,MYRF,NAMPT,NCAPG,NECTIN2,NFE2L3,NMI,NR0B1,NRG1,OAS1,OAS2,OAS3,OASL,P2RY13,PAK6,PARP11,PARP3,PBK,PCBP3,PHF11,PHLDA2,PLAC1,PLSCR1,PML,POLR3D,PROCR,PRRG4,PSMA2,PSMB9,PSME2,PTGER3,PTGIR,PTH1R,RBCK1,RELB,RGS1,RNASEL,RRM2,RTP4,SCNN1G,SCO2,SEMA4A,SEPTIN4,SERPINE1,SERPING1,SIGLEC1,SIK1,SLC2A6,SLC31A2,SLC4A2,SLC6A12,SLCO4A1,SLURP1,SOCS1,SOCS2,SP110,SP140,SPAG1,SPHK1,SRC,TAP2,TFEC,TK1,TMEM176A,TNFAIP6,TNFSF10,TNNT1,TPX2,TRAF2,TRAF4,TRAFD1,TRIM21,TYMP,TYMS,UBE2C,UBE2L6,UBE2S,USP18,VAMP5,VCAM1,VPREB3,VRK2,WARS1,XAF1,ZBP1,ZBTB32,ZWINT",258,"ACOT9,ADAMDEC1,ADGRE5,AKAP2,ALAS1,APBA1,APOBEC3B,APOL1,APOL3,APOL6,AR,ARNTL2,ATF5,AURKA,AURKB,AVPR1A,AXL,BATF3,BAZ1A,BCL2L14,BIRC5,BMPR1B,BST2,C1QA,C1RL,C1S,C2,CACNA1A,CBR1,CCL13,CCL17,CCL18,CCL19,CCL2,CCL3,CCL7,CCL8,CCNA2,CCND1,CCR8,CD19,CD38,CD72,CDC45,CDKN1A,CFB,CHST12,CHST3,CHST8,CKS2,CLCNKA,CLDN7,CLEC11A,CLEC4A,CSF2RB,CXCL1,CXCL10,CXCL11,CXCL9,CYP27B1,DDX58,DUSP5,DUSP6,DYNLT1,EBI3,EGR2,EIF2AK2,ENPP2,ESPL1,ESRRG,ETV7,EZH2,F3,FA2H,FAM189B,FAS,FCGR1A,FFAR2,FGL2,FHL2,FPR2,FSCN1,FSHB,FST,G0S2,GABBR2,GBP1,GCH1,GDF11,GGT5,GINS2,GMPR,GPALPP1,GPRC5C,GRID2,GRM7,GUCY1A2,GZMB,H1-0,H2AC18,H6PD,HCAR3,HERC5,HESX1,HLX1,HMMR,HOXC5,HSD11B1,HSPB1,HSPBP1,IDO1,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNA6,IFNG,IGF2BP3,IGFALS,IGFBP1,IL15,IL15RA,IL1F6,IL3RA,IL6,IL9,INHBA,INSM1,IRF1,IRF7,ISG15,ISG20,JAK2,JUP,KCNJ14,KCNJ2,KCNK5,KIF13A,KIFC3,L1CAM,LAG3,LAMB3,LAMP3,LAMP5,LAP3,LGALS3BP,LIF,LIMK2,LMO2,LY6E,LYPD1,MAFF,MAP3K7CL,MMP14,MMP25,MMP9,MNDA,MT1H,MT1X,MT2A,MUC1,MX1,MX2,MXD1,MYOF,MYRF,NAMPT,NCAPG,NECTIN2,NFE2L3,NMI,NR0B1,NRG1,OAS1,OAS2,OAS3,OASL,P2RY13,PAK6,PARP11,PARP3,PBK,PCBP3,PHF11,PHLDA2,PLAC1,PLSCR1,PML,POLR3D,PROCR,PRRG4,PSMA2,PSMB9,PSME2,PTGER3,PTGIR,PTH1R,RBCK1,RELB,RGS1,RNASEL,RRM2,RTP4,SCNN1G,SCO2,SEMA4A,SEPTIN4,SERPINE1,SERPING1,SIGLEC1,SIK1,SLC2A6,SLC31A2,SLC4A2,SLC6A12,SLCO4A1,SLURP1,SOCS1,SOCS2,SP110,SP140,SPAG1,SPHK1,SRC,TAP2,TFEC,TK1,TMEM176A,TNFAIP6,TNFSF10,TNNT1,TPX2,TRAF2,TRAF4,TRAFD1,TRIM21,TYMP,TYMS,UBE2C,UBE2L6,UBE2S,USP18,VAMP5,VCAM1,VPREB3,VRK2,WARS,XAF1,ZBP1,ZBTB32,ZWINT",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/table/T2/,NA,NA,NA,NA
M40953,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_HIGH_RESPONDERS_VS_LOW_RESPONDERS_0DY_UP,BACTERIUM,UP,CORRELATION,ANTIBODY,D0,D,0,18-55,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_HIGH_RESPONDERS_VS_LOW_RESPONDERS_0DY_UP,"A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-gamma (IFN-gamma) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Ralpha two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.","Genes up-regulated in peripheral blood mononuclear cell high responders vs low responders in adult (18-55) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 0D. Comment: genes part of classifier","Matsumiya M,Stylianou E,Griffiths K,Lang Z,Meyer J,Harris SA,Rowland R,Minassian AM,Pathan AA,Fletcher H,McShane H",23844129,HUMAN_GENE_SYMBOL,"CD14,CD300LF,FPR3,GAPT,MGST1,NPL,TICAM2,TLR1,ZMYND15",9,"CD14,CD300LF,FPR3,GAPT,MGST1,NPL,TICAM2,TLR1,ZMYND15",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092249/bin/supp_jiu079_jiu079supp_table1.doc,NA,NA,NA,NA
M40876,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GT_200_VS_LTE_200_1DY_DN,VIRUS,DOWN,CORRELATION,ANTIBODY,D1,D,1,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GT_200_VS_LTE_200_1DY_DN,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes down-regulated in peripheral blood mononuclear cell Ad5 nAb titers > 200 vs Ad5 nAb titers <= 200 in adults (20-50) (Ad5 nAb titers > 200) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 1D. Comment: Impaired up-regulation. Genes with MRKAd5/HIV-induced expression responses significantly impacted by Ad5 nAbs (24hrs). Table includes specific cell types.","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ABI3,ADM,AKR1A1,ANXA4,ASCL2,ASGR2,ATF3,ATF5,AXL,BLVRA,C1QB,C1QC,C2,C3AR1,C5AR1,CALML4,CAMK1,CASP5,CBR1,CCDC180,CCL8,CCRL2,CD300C,CD300E,CDKN1A,CES1,CES1P1,CFB,CFD,CLEC12A,CLEC6A,CMKLR1,CNIH4,CXCL10,CXCL11,CYGB,CYRIA,DDAH2,DHRS7B,EPHB2,FAM225A,FAM25A,FCAR,GPBAR1,GPR141,GPR35,GPR84,HAVCR2,HBEGF,HK3,ID1,IFI27,IGLV10-54,KCTD14,KIAA1958,KLHDC8B,KMO,KRTAP5-10,LGALS1,LILRA3,LILRB1,LINC00092,LINC00315,LOC401442,LTF,MAFB,MARCO,MERTK,METRNL,SLC49A3,MIR1250,MIR185,MS4A4A,MTHFD2,NFKBIA,NGFR,NLRP3,NOTCH2NLA,NR4A1,NSUN5P2,OR3A3,P2RY12,P2RY2,PER1,PILRA,PTPRO,RGL1,RRAS,RTP4,SAMD4A,SDC3,SDHB,SEMA4A,SERTAD1,SLC11A1,SLC27A3,SLC6A12,SMCO4,SNORA5B,SNORA80A,SPRR2F,TCN2,TLR7,TMEM150B,TMEM255A,TNFSF10,TP53I3,TRIB1,TSPEAR-AS2,VSTM1,ZBTB21",111,"ABI3,ADM,AKR1A1,ANXA4,ASCL2,ASGR2,ATF3,ATF5,AXL,BLVRA,C1QB,C1QC,C2,C3AR1,C5AR1,CALML4,CAMK1,CASP5,CBR1,CCDC180,CCL8,CCRL2,CD300C,CD300E,CDKN1A,CES1,CES1P1,CFB,CFD,CLEC12A,CLEC6A,CMKLR1,CNIH4,CXCL10,CXCL11,CYGB,CYRIA,DDAH2,DHRS7B,EPHB2,FAM225A,FAM25A,FCAR,GPBAR1,GPR141,GPR35,GPR84,HAVCR2,HBEGF,HK3,ID1,IFI27,IGLV10-54,KCTD14,KIAA1958,KLHDC8B,KMO,KRTAP5-10,LGALS1,LILRA3,LILRB1,LINC00092,LINC00315,LOC401442,LTF,MAFB,MARCO,MERTK,METRNL,MFSD7,MIR1250,MIR185,MS4A4A,MTHFD2,NFKBIA,NGFR,NLRP3,NOTCH2NL,NR4A1,NSUN5P2,OR3A3,P2RY12,P2RY2,PER1,PILRA,PTPRO,RGL1,RRAS,RTP4,SAMD4A,SDC3,SDHB,SEMA4A,SERTAD1,SLC11A1,SLC27A3,SLC6A12,SMCO4,SNORA5B,SNORA80A,SPRR2F,TCN2,TLR7,TMEM150B,TMEM255A,TNFSF10,TP53I3,TRIB1,TSPEAR-AS2,VSTM1,ZNF295",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplementary Table 2a: TIV-pDC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-3.xlsx,NA,NA,NA,NA
M40872,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GTE_200_VS_LTE_200_1DY_UP,VIRUS,UP,CORRELATION,ANTIBODY,D1,D,1,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_AD5_NAB_TITERS_GTE_200_VS_LTE_200_1DY_UP,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes up-regulated in peripheral blood mononuclear cell Ad5 nAb titers >= 200Ad5 nAb titers <= 200 in adults (20-50) (Ad5 nAb titers > 200) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 1D. Comment: Impaired down-regulation. Genes with MRKAd5/HIV-induced expression responses significantly impacted by Ad5 nAbs (24hrs). Table includes specific cell types.","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ABCD2,ABLIM1,ACADSB,AGL,AHCTF1,AHNAK,AK5,AKR1C3,APBA2,ARHGAP15,BANK1,BCL2,BMI1,BNIP3,C12orf57,TRABD2A,CAMK4,CCR7,CD1C,CD22,CD27,CD3D,CD96,CDCA7L,CLEC2D,CRIPT,CRTAM,CSE1L,CYP27A1,DENND4C,DLEU1,DOCK9,DPH5,DPP4,DSC1,EIF3E,EIF3L,ERGIC2,ETS1,ATPSCKMT,FCRL1,DLGAP1-AS1,FOXP1,FXR1,G0S2,GCC2,GPR174,GTF2H3,GZMK,H2AC8,HLTF,HTATSF1,IGF1R,IGHV3-21,IGLV1-40,PATJ,INPP4B,IP6K1,IPP,ITGA6,ITGB3BP,ITK,KLF12,KLHDC2,KLRB1,KLRD1,KLRF1,KLRK1,KPNA4,LDHB,LRIF1,LUC7L3,MAML2,MGAT4A,MID2,MPHOSPH9,MPRIP,MS4A1,N4BP2,NAA16,NAE1,NAP1L1,NDUFS5,NELL2,NPAT,NSA2,NT5E,NUCB2,PAIP2B,PDE3B,PLCB1,PNN,POLR1E,PPIL3,PRKACB,PSIP1,PTGDR,PWAR5,,RASGRP1,RBL2,RCAN3,RNF125,RNF157,RORA,RPL15,RPL17,RPS13,SATB1,SCARNA5,SESN1,SESN3,SFPQ,SH2D1A,SKAP1,SLC38A1,SLC4A7,SNORD116-14,SNORD4A,SNORD4B,SNORD5,SNORD6,SNORD8,STEAP4,TC2N,TCL1A,THEMIS,TLR10,TMEM204,TRAJ10,TRAJ13,TRAJ18,TRAJ20,TRAJ29,TRAJ3,TRAJ32,TRAJ33,TRAJ36,TRAJ37,TRAJ38,TRAJ40,TRAJ41,TRAJ45,TRAJ48,TRAJ5,TRAJ6,TRAJ9,TRAV13-2,TRAV17,TRAV19,TRAV20,TRAV22,TRAV23DV6,TRAV29DV5,TRAV3,TRAV41,TRAV8-2,TRBV19,TRBV27,TRBV4-2,TRGJP1,TRGV3,TTC3,USP34,USP53,TBC1D31,ZNF143,ZKSCAN8,ZNF506,ZNF770,ZNF84",171,"ABCD2,ABLIM1,ACADSB,AGL,AHCTF1,AHNAK,AK5,AKR1C3,APBA2,ARHGAP15,BANK1,BCL2,BMI1,BNIP3,C12orf57,C2orf89,CAMK4,CCR7,CD1C,CD22,CD27,CD3D,CD96,CDCA7L,CLEC2D,CRIPT,CRTAM,CSE1L,CYP27A1,DENND4C,DLEU1,DOCK9,DPH5,DPP4,DSC1,EIF3E,EIF3L,ERGIC2,ETS1,FAM173B,FCRL1,FLJ35776,FOXP1,FXR1,G0S2,GCC2,GPR174,GTF2H3,GZMK,HIST1H2AE,HLTF,HTATSF1,IGF1R,IGHV3-21,IGLV1-40,INADL,INPP4B,IP6K1,IPP,ITGA6,ITGB3BP,ITK,KLF12,KLHDC2,KLRB1,KLRD1,KLRF1,KLRK1,KPNA4,LDHB,LRIF1,LUC7L3,MAML2,MGAT4A,MID2,MPHOSPH9,MPRIP,MS4A1,N4BP2,NAA16,NAE1,NAP1L1,NDUFS5,NELL2,NPAT,NSA2,NT5E,NUCB2,PAIP2B,PDE3B,PLCB1,PNN,POLR1E,PPIL3,PRKACB,PSIP1,PTGDR,PWAR5,PWARSN,RASGRP1,RBL2,RCAN3,RNF125,RNF157,RORA,RPL15,RPL17,RPS13,SATB1,SCARNA5,SESN1,SESN3,SFPQ,SH2D1A,SKAP1,SLC38A1,SLC4A7,SNORD116-14,SNORD4A,SNORD4B,SNORD5,SNORD6,SNORD8,STEAP4,TC2N,TCL1A,THEMIS,TLR10,TMEM204,TRAJ10,TRAJ13,TRAJ18,TRAJ20,TRAJ29,TRAJ3,TRAJ32,TRAJ33,TRAJ36,TRAJ37,TRAJ38,TRAJ40,TRAJ41,TRAJ45,TRAJ48,TRAJ5,TRAJ6,TRAJ9,TRAV13-2,TRAV17,TRAV19,TRAV20,TRAV22,TRAV23DV6,TRAV29DV5,TRAV3,TRAV41,TRAV8-2,TRBV19,TRBV27,TRBV4-2,TRGJP1,TRGV3,TTC3,USP34,USP53,WDR67,ZNF143,ZNF192,ZNF506,ZNF770,ZNF84",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Abstract,NA,NA,NA,NA,NA
M40972,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_LOW_VS_HIGH_RESPONDERS_2DY_GO_T_CELL_ACTIV_AND_CO_STIM_UP,BACTERIUM,UP,CORRELATION,ANTIBODY,D2,D,2,18-55,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_LOW_VS_HIGH_RESPONDERS_2DY_GO_T_CELL_ACTIV_AND_CO_STIM_UP,"A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-gamma (IFN-gamma) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Ralpha two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.","Genes up-regulated in peripheral blood mononuclear cell low responders vs high responders in adults (18-55) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 2D. Comment: Enriched for GO terms associated with regulation of T-cell activation and co-stimulation signal (DAVID, fdr<0.05), from 176 DE genes","Matsumiya M,Stylianou E,Griffiths K,Lang Z,Meyer J,Harris SA,Rowland R,Minassian AM,Pathan AA,Fletcher H,McShane H",23844129,HUMAN_GENE_SYMBOL,"CD2,CD28,CD3D,CD5,CTLA4,DNAJA3,IL2RA,ITK,STAT5B,TRAT1",10,"CD2,CD28,CD3D,CD5,CTLA4,DNAJA3,IL2RA,ITK,STAT5B,TRAT1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711596/figure/F1/,NA,NA,NA,NA
M40881,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_NEGATIVE,VIRUS,NEGATIVE,CORRELATION,ANTIBODY,D3,D,3,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_NEGATIVE,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes negatively correlated with CD8+ T-cell response in peripheral blood mononuclear cell in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 3D","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ACTL9,ANKRD63,ANXA8L1,ARC,ARTN,ASS1,AZU1,BHLHA9,CCDC180,CCDC188,CENPM,CHKB,CLCNKA,CLDN19,CRIP3,CRYBB3,CSRP2,CTRB1,DEFB132,DLX1,DUSP15,DUSP9,EFNA2,ELFN1,FAM153A,FLJ20021,FOXH1,GJA4,GNG8,GPIHBP1,GPR152,GPR37L1,GUCA2B,,KCNF1,KCNG2,KRTAP10-1,KRTAP10-12,KRTAP10-3,KRTAP10-4,KRTAP12-4,LCE1F,LCE3A,LHFPL4,LINC01144,,,LRRC30,LRRC3C,LURAP1,LY6D,LY6H,LYPD2,MALL,MIR1225,MIR1250,MIR132,MIR1909,MIR219A1,MIR598,MIR636,MOGAT3,MRPL23-AS1,NKX6-1,NPAP1,NPB,NPPC,NUTM2A-AS1,OLMALINC,PCDHA13,PIP5KL1,PPP3R2,PRAP1,PROP1,PRR29,PRRT2,PRSS3,PSCA,PSORS1C2,PTGER1,RBAK-RBAKDN,RNU12,RPL7A,SFTPD,SLC35G6,SLC38A8,SNORA80B,SOX15,SPSB4,SSTR5,TCEAL3,TEX28,TGFBR3L,TIFAB,TMEM210,TMEM92,TPSD1,TTC6,UBAP1L,UPK3B,CCN5",101,"ACTL9,ANKRD63,ANXA8L1,ARC,ARTN,ASS1,AZU1,BHLHA9,CCDC180,CCDC188,CENPM,CHKB,CLCNKA,CLDN19,CRIP3,CRYBB3,CSRP2,CTRB1,DEFB132,DLX1,DUSP15,DUSP9,EFNA2,ELFN1,FAM153A,FLJ20021,FOXH1,GJA4,GNG8,GPIHBP1,GPR152,GPR37L1,GUCA2B,HGC6.3,KCNF1,KCNG2,KRTAP10-1,KRTAP10-12,KRTAP10-3,KRTAP10-4,KRTAP12-4,LCE1F,LCE3A,LHFPL4,LINC01144,LOC100289580,LOC401357,LRRC30,LRRC3C,LURAP1,LY6D,LY6H,LYPD2,MALL,MIR1225,MIR1250,MIR132,MIR1909,MIR219A1,MIR598,MIR636,MOGAT3,MRPL23-AS1,NKX6-1,NPAP1,NPB,NPPC,NUTM2A-AS1,OLMALINC,PCDHA13,PIP5KL1,PPP3R2,PRAP1,PROP1,PRR29,PRRT2,PRSS3,PSCA,PSORS1C2,PTGER1,RBAK-RBAKDN,RNU12,RPL7A,SFTPD,SLC35G6,SLC38A8,SNORA80B,SOX15,SPSB4,SSTR5,TCEAL3,TEX28,TGFBR3L,TIFAB,TMEM210,TMEM92,TPSD1,TTC6,UBAP1L,UPK3B,WISP2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M40895,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_POSITIVE,VIRUS,POSITIVE,CORRELATION,ANTIBODY,D3,D,3,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_CORRELATED_WITH_CD8_T_CELL_RESPONSE_3DY_POSITIVE,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes positively correlated with CD8+ T-cell response in peripheral blood mononuclear cell in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 3D","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ANKRD10-IT1,ANKRD12,ARHGAP12,ARID4A,ATRX,GOLM2,CCDC186,CCNT1,CDK8,CEBPZOS,CLEC2D,CTDSPL2,DENND4C,DHFR,ESCO1,ESF1,FAM172A,ATOSA,FBXO11,FYTTD1,GARS1-DT,GCC2,GNG11,GOLGA4,GTF2H3,HAUS3,HAUS6,HNRNPA3,HOOK3,KDM3A,KIF2A,KIN,KIR2DL1,KTN1,LCOR,LMAN1,LRRC37B,MAP4K5,MGAT4A,MIER3,MIS12,PCGF5,PCNP,PDGFD,PIGK,PIK3R1,PLEKHA1,PRKAR2B,PTPN22,RAMAC,RASA2,COP1,SBDS,SH2D1B,SINHCAF,SLC16A6,SLC25A40,SLC30A9,SMURF2,SNRNP27,THAP9-AS1,TRAJ40,TRAV13-1,TRGC2,TRGJP1,TRPM7,SNORD28,WASHC2C,ZBTB44,ZNF131,ZNF134,ZNF280D,ZNF431,ZNF484,ZNF486,ZNF507,ZNF510,ZNF518A,ZNF654,ZNF721,ZNF761,ZNF765,ZNF845,ZNHIT6",84,"ANKRD10-IT1,ANKRD12,ARHGAP12,ARID4A,ATRX,CASC4,CCDC186,CCNT1,CDK8,CEBPZOS,CLEC2D,CTDSPL2,DENND4C,DHFR,ESCO1,ESF1,FAM172A,FAM214A,FBXO11,FYTTD1,GARS1-DT,GCC2,GNG11,GOLGA4,GTF2H3,HAUS3,HAUS6,HNRNPA3,HOOK3,KDM3A,KIF2A,KIN,KIR2DL1,KTN1,LCOR,LMAN1,LRRC37B,MAP4K5,MGAT4A,MIER3,MIS12,PCGF5,PCNP,PDGFD,PIGK,PIK3R1,PLEKHA1,PRKAR2B,PTPN22,RAMAC,RASA2,RFWD2,SBDS,SH2D1B,SINHCAF,SLC16A6,SLC25A40,SLC30A9,SMURF2,SNRNP27,THAP9-AS1,TRAJ40,TRAV13-1,TRGC2,TRGJP1,TRPM7,U28,WASHC2C,ZBTB44,ZNF131,ZNF134,ZNF280D,ZNF431,ZNF484,ZNF486,ZNF507,ZNF510,ZNF518A,ZNF654,ZNF721,ZNF761,ZNF765,ZNF845,ZNHIT6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M41004,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_BCG_PRIMED_28DY_UP,BACTERIUM,UP,VACCINE,BOOSTER,H6,H,6,4-6 MO,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_BCG_PRIMED_28DY_UP,"BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. METHODS: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-gamma ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis of microarrays (SAM) statistical package and gene set enrichment analysis. RESULTS: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples. Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher IFN-gamma ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in how T cell responses develop in these two populations following vaccination with MVA85A. CONCLUSION: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of an adaptive immune response in South African infants but induction of regulatory pathways may be more important in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an important aspect of developing successful vaccines and vaccination strategies. TRIAL: ClinicalTrials.gov number NCT00953927.","Genes up-regulated in peripheral blood mononuclear cell 28d vs 7d in infants (4-6m) (BCG-primed) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 28D","Matsumiya M,Harris SA,Satti I,Stockdale L,Tanner R,O'Shea MK,Tameris M,Mahomed H,Hatherill M,Scriba TJ,Hanekom WA,McShane H,Fletcher HA",24912498,HUMAN_GENE_SYMBOL,"AIM2,ANKRD22,CXCL9,GBP1,GBP4,GBP5,PSME2,STAT1,TAP1,WARS1",10,"AIM2,ANKRD22,CXCL9,GBP1,GBP4,GBP5,PSME2,STAT1,TAP1,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl Table 1A, Tab DEGs_TIV",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140559/bin/NIHMS301940-supplement-2.xlsx,NA,NA,NA,NA
M41072,RVSV EBOV,VV,EBOV,FISCHER_BLOOD_PLASMA_RVSV_EBOV_AGE_18_55YO_HIGH_DOSE_3DY_DN,VIRUS,DOWN,VACCINE,DOSE,D3,D,3,18-55,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/FISCHER_BLOOD_PLASMA_RVSV_EBOV_AGE_18_55YO_HIGH_DOSE_3DY_DN,"VSV-EBOV is a replication-competent Ebola virus (EBOV) vaccine, which was tested in clinical trials as response to the Ebola virus disease (EVD) outbreak 2013-2016. It is the most advanced EBOV candidate currently in the licensure process. The experimental vaccine was again administered as response to outbreaks in the Democratic Republic of Congo. However, underlying molecular mechanisms that convey protection remain incompletely understood. MicroRNAs (miRNAs) are known key regulators that influence gene expression on a post-transcriptional level. The miRNA-mediated control has emerged as a critical regulatory principle in the immune system, which strongly influences the balance of innate and adaptive immune responses by modulation of signaling pathways critical for differentiation of immune cells. We investigated expression levels of circulating miRNAs (c-miRNAs) in plasma from healthy vaccinees, as they may reflect cellular dynamics following VSV-EBOV immunization and additionally may serve as potential biomarkers for vaccine efficacy. As part of the WHO-led VEBCON consortium, we investigated safety and immunogenicity of VSV-EBOV in a phase I trial. A comprehensive analysis of expression levels on c-miRNAs from plasma samples following VSV-EBOV immunization (day 0, 1, 3 post vaccination) was conducted using RT-qPCR assays. Potential biological relevance was assessed using in silico analyses. Additionally, we correlated dynamics of miRNA expressions with our previously reported data on vaccine-induced antibody and cytokine responses and finally evaluated the prognostic power by generating ROC curves. We identified four promising miRNAs (hsa-miR-146a, hsa-miR-126, hsa-miR-199a, hsa-miR-484), showing a strong association with adaptive immune responses, exhibited favourable prognostic performance and are implicated in immunology-related functions. Our results provide evidence that miRNAs may serve as useful biomarkers for prediction of vaccine-induced immunogenicity. Furthermore, our unique data set provides insight into molecular mechanisms that underlie VSV-EBOV-mediated protective immune responses, which may help to decipher VSV-EBOV immune signature and accelerate strategic vaccine design or personalized approaches.","Genes down-regulated in blood plasma 3d vs 0d in adults (18-55) (high dose) after exposure to rVSV-EBOV , time point 3D","Fischer T,Spohn M,Olearo F,Zinser ME,Kasonta R,Stubbe HC,Rechtien A,Ly ML,Schmiedel S,Lohse AW,Grundhoff A,VEBCON (VSV-Ebola Consortium),Addo MM,Dahlke C",30244872,HUMAN_GENE_SYMBOL,"MIR126,MIR199A2,MIR221,MIR23A,MIR24-1,MIR30D",6,"MIR126,MIR199A2,MIR221,MIR23A,MIR24-1,MIR30D",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 5A,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962691/figure/F5/,NA,NA,NA,NA
M41081,CHAD63-KH,VV,LEISHMANIA,OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_UP,PARASITE,UP,VACCINE,DOSE,H24,H,24,18-50,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_UP,"BACKGROUND: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or appropriately targeted cell mediated immunity, including CD8+ T cell responses, underlies the progression of VL and progression to PKDL, and can limit the therapeutic efficacy of anti-leishmanial drugs. Hence, in addition to the need for prophylactic vaccines against leishmaniasis, the development of therapeutic vaccines for use alone or in combined immuno-chemotherapy has been identified as an unmet clinical need. Here, we report the first clinical trial of a third-generation leishmaniasis vaccine, developed intentionally to induce Leishmania-specific CD8+ T cells. METHODS: We conducted a first-in-human dose escalation Phase I trial in 20 healthy volunteers to assess the safety, tolerability and immunogenicity of a prime-only adenoviral vaccine for human VL and PKDL. ChAd63-KH is a replication defective simian adenovirus expressing a novel synthetic gene (KH) encoding two Leishmania proteins KMP-11 and HASPB. Uniquely, the latter was engineered to reflect repeat domain polymorphisms and arrangements identified from clinical isolates. We monitored innate immune responses by whole blood RNA-Seq and antigen specific CD8+ T cell responses by IFN-gamma ELISPOT and intracellular flow cytometry. FINDINGS: ChAd63-KH was safe at intramuscular doses of 1x1010 and 7.5x1010 vp. Whole blood transcriptomic profiling indicated that ChAd63-KH induced innate immune responses characterized by an interferon signature and the presence of activated dendritic cells. Broad and quantitatively robust CD8+ T cell responses were induced by vaccination in 100% (20/20) of vaccinated subjects. CONCLUSION: The results of this study support the further development of ChAd63-KH as a novel third generation vaccine for VL and PKDL. TRIAL: This clinical trial (LEISH1) was registered at EudraCT (2012-005596-14) and ISRCTN (07766359).","Genes up-regulated in blood 24hr vs 0hr in adults (18-50) (high dose subjects) after exposure to ChAd63-KH , time point 24H , administered Intramuscular injection. Comment: DE gene list for high dose subjects.","Osman M,Mistry A,Keding A,Gabe R,Cook E,Forrester S,Wiggins R,Di Marco S,Colloca S,Siani L,Cortese R,Smith DF,Aebischer T,Kaye PM,Lacey CJ",28498840,HUMAN_GENE_SYMBOL,"AAMP,ABCA1,ABCD1,ABHD16A,ABHD3,ABI1,ABTB2,ACER3,ACLY,ACO1,ACOT9,ACP2,ACSL1,ACSL3,ACSL4,ACSL5,ACSM1,ACTA2,ACTR1A,ACTR3,ADAMTSL4,ADAMTSL4-AS1,ADAP2,ADAR,ADCY4,ADCY7,ADM,ADPGK,ADPGK-AS1,ADPRH,ADPRS,GRK3,AFF1,AFF2,AGBL5,AGPAT3,AGPAT5,AGRN,AIDA,AIF1,AIG1,AIM2,AK4,AKAP13,AKIRIN2,AKR1A1,ALDH1A1,ALDH2,ALPK1,AMBRA1,AMER1,ANKFY1,ANKRD13A,ANKRD22,ANKRD36BP1,ANKUB1,ANO5,ANXA10,ANXA2,ANXA2P2,ANXA3,ANXA4,ANXA5,AOAH,AOAH-IT1,AP1M2,AP1S2,AP1S3,AP2S1,AP3B1,AP3D1,AP5B1,APH1A,APLP1,APOBEC3A,APOBEC3B,APOBEC3B-AS1,APOBEC3C,APOBEC3F,APOBEC3G,APOBR,APOL1,APOL2,APOL3,APOL4,APOL6,ARAP1-AS1,ARAP2,ARCN1,ARF1,ARFIP1,ARHGAP25,ARHGAP26,ARHGAP27,ARHGAP31,ARHGEF10L,ARHGEF3,ARID4B,ARL11,ARL5B,ARL8B,ARMCX3-AS1,BMAL2,ARPC1B,ARPC3,ARPC4,ARPC5,ARR3,ARRB2,ARSB,ARSD,ARSL,ASCL2,ASGR1,ASGR2,ASPHD2,ASPRV1,ATF3,ATF5,ATF6,ATG16L2,ATG3,ATP10D,ATP1A4,ATP1B1,ATP1B3,ATP5F1B,ATP6V0D1,ATP6V0E1,ATP6V1B2,ATP6V1C2,ATP6V1E1,ATP6V1G1,ATP8A2P2,ATXN7,ATXN7L3,AURKAIP1,AZI2,B2M,B4GALT5,BACH1,BACH1-AS1,BACH1-IT2,BAK1,BAK1P1,BATF2,BATF3,BAZ1A,BAZ2A,BBX,BCL10,BCL2L14,BCL3,BECN1,BID,BIN2,BIN3,BIRC6-AS1,BLVRA,BLZF1,BMPR2,BRCA2,BRD7,BRI3,BRMS1,BROX,BST2,BTK,BTN2A1,BTN2A2,BTN2A3P,BTN3A1,BTN3A2,BTN3A3,VSIR,PLET1,NDUFV1-DT,DDIAS,TIGAR,DGLUCY,C14orf93,C15orf39,CYBC1,PRR29,C18orf25,RMC1,C19orf12,C19orf38,SHFL,C1GALT1,C1GALT1C1,C1QA,C1QB,C1orf162,ERICH3,C2,C21orf91,C2orf66,C2orf80,C3,C3AR1,C3orf14,C3orf38,DIPK2A,C4orf3,FAM241A,C4orf33,C5,C5orf15,IRF1-AS1,C5orf58,ILRUN,BNIP5,C6orf62,FAM120A2P,DOCK8-AS1,C9orf72,TMEM268,CACNA1A,CACNA1E,CADM4,CALCOCO2,CALM2P2,CALM3,CALR,CAMK2D,CAPG,CAPN2,CAPNS2,CAPZA1,CAPZA2,CARD16,CARD17P,CARD6,CARD8,CARS1,CARS2,CASP1,CASP10,CASP1P2,CASP4,CASP5,CASP7,CAST,CATSPERG,CBR1,ZNG1A,ZNG1B,ZNG1C,ZNG1E,ZNG1F,CBX1P4,CCDC146,CCDC149,CCDC154,CCDC170,MIX23P1,CCDC73,CCDC9,CCDC97,CCL1,CCL13,CCL2,CCL25,CCL7,CCL8,CCNA1,CCNL1,CCR1,CCR2,CCRL2,CCSER1,CD14,CD163,CD164,CD1D,CD209,CD274,CD2AP,CD300A,CD300C,CD300E,CD300LF,CD33,CD36,CD38,CD40,CD46,CD53,CD59,CD68,CD74,CD86,ADGRE5,CDC42EP2,CDC42EP4,CDC73,CDH23,CDH6,CDHR5,CDK17,CDKL5,CDKN1A,CDKN1C,CDKN2D,CEACAM1,CEBPB,ADA2,TMEM121B,CELF2-AS1,CENPCP1,CENPN,CEP164,CERKL,CERS6-AS1,CES1,CES1P1,CFAP58,CFAP58-DT,CFB,CFLAR,CFLAR-AS1,CFP,CHD1,CHGA,CHMP1A,CHMP2A,CHMP2B,CHMP4B,CHMP5,CHN2,CHRNA6,CHRNB1,CHRNB2,CHST7,CHSY1,CICP19,CICP3,CIITA,CIR1,CLASRP,CLCN4,CLCN5,CLCN7,CLDN18,CLEC1A,CLEC2B,CLEC4D,CLEC4E,CLEC5A,CLEC6A,CLEC7A,CLIC1,CLIC4,CLK3,CMAHP,CMC2,CMKLR1,CMPK2,CMTM6,CNDP2,CNIH4,CNP,CNTD1,CNTLN,CNTRL,COA6,COL8A2,COL9A1,COMMD9,COPE,COPG1,COPZ1,COQ10B,CORO1B,COTL1,COX5B,COX6B1,CPB1,CPEB2,CPEB3,CPED1,CPPED1,CPVL,CREBRF,CREG1,CREM,CSF1R,CSF2RB,CSF3R,CSNK1G2,CSRNP1,CST3,CTBS,CTCFL,CTNNA1,CTRL,CTSA,CTSB,CTSH,CTSL,CTSO,CTSS,CTSZ,CUL1,CXCL10,CXCL11,CXCL16,CXCL9,CXCR1,CXCR2P1,TASL,CXorf38,CYB561,CYB5R4,CYBA,CYBB,CYC1,CYFIP1,CYLD,CYP2J2,CYP4A22-AS1,CYSLTR1,CYSTM1,CYTH4,CYTOR,DAPP1,DAZAP2,DBF4B,DCAF11,DCBLD1,DCLRE1C,DCLRE1CP1,DCP1A,DCUN1D3,DDAH2,DDO,DDX10P1,DDX21,DDX3X,RIGI,DDX60,DDX60L,DECR1,DEDD2,DEFB1,DEGS1,DEK,DENND1A,DENND5A,DERL1,DESI1,DHRS12,DHRS9,DHRSX,DHTKD1,DHX58,DHX8,DIAPH2,DIP2B,DISC1,DISC1-IT1,DLC1,DLEU2,DLEU7,DMXL2,DNAAF1,DNAJA1,DNAJB11,DNAJB12,DNAJC1,DNAJC13,DNAJC15,DNAJC7,DNM1P33,DNM1P34,DNPEP,DNTTIP1,DOCK4,DOCK8,DOK1,DPF2,DPP3,DPRXP2,DPYD,DPYD-AS1,DPYD-AS2,DPYS,DPYSL2,DRAM1,DRAP1,DTNBP1,DTX3L,DUSP1,DUSP10,DUSP3,DUSP5,DUSP6,DYNLT1,DYSF,DZIP1L,ECE1,ECPAS,EDEM1,EDEM2,EFCAB2,EFHD2,EFR3A,EGLN1,EHBP1L1,EHD4,EIF2AK2,EIF4A1P2,EIF4A1P7,EIF4E3,EIF4G3,EIF4H,EIF5A,ELF1,ELF4,ELMO2,ELOVL5,EMILIN2,EMP1,EMP3,ENDOU,ENPP2,EPAS1,EPB41L3,EPG5,EPHB1,EPHB2,EPS15,EPSTI1,ERAP1,ERAP2,ERI1,ERP29,ERP44,ERV3-1,ESRRA,ETV6,ETV7,EVI2B,EWSR1,EXOC3L1,EXOC3L4,EXOC6,EXOSC9,EXT1,EYA1,FAM111A,TCAF2,FAM120A,FAM120AOS,PABIR3,NIBAN2,FAM135A,FHIP2A,ERICH6B,GASK1B,TAFA2,FAM20A,FAM20C,ATOSB,WASHC2A,WASHC2C,FAM225A,FAM225B,CALHM6,TENT5A,CYRIB,RIPOR2,GARIN4,FAM72A,FAM72B,FAM72C,FAM72D,FAM8A1,FAM91A1,CIBAR1,FANCA,FANCL,FAP,FAR2,FARP2,FAS,FBXL5,FBXO39,FBXO6,FCER1G,FCGR1A,FCGR1BP,FCGR2A,FCGR2B,FCGR2C,FCGR3A,FCGR3B,FCN1,FCN2,FEM1C,FFAR2,FFAR3,FGD2,FGD6,FGF13,FGL2,FGR,FIBP,FIG4,FKBP15,FLI1,FLOT1,FLVCR1,FLVCR2,FMNL2,FMR1,FMR1-IT1,FNDC3A,FNIP2,FOLR2,FOXC1,FOXD4L4,FOXD4L5,FOXL2,FOXN2,FOXN3-AS1,FPR2,FRMD3,FRMD4B,FTL,CMTR1,FUCA2,FUNDC2P4,FUOM,FUT4,FYB1,FYTTD1,FZD2,FZD5,GAB1,GAB2,GABARAP,GADD45B,GAK,GALM,GALNT3,GAPDHP14,GART,GAS6,GAS8,GBA1,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GBP6,GBP7,GCA,GCH1,GCNT1,GCNT2,GDI2,GIMAP2,GIMAP4,GIMAP6,GIMAP8,GK,GK-AS1,GK-IT1,GK3,GLA,GLIPR2,GLRX,GLUL,GM2A,GMFBP1,GMPR2,GNA13,GNA15,GNB1,GNB2,GNB4,GNG5,GNS,GOLGA5P1,GOLM1,GORASP1,GPBAR1,GPBP1,GPD2,GPR141,GPR155,GPR42,GPR65,GPR84,GPS2,GPX1,GRAMD1B,GRB2,GRIN3A,GRIPAP1,GRN,GSDMC,GSDMD,GSN,GSTK1,GSTO1,GTF2B,GTF2F1,GTPBP1,GTPBP2,GUCY1A1,GUCY2F,GVINP1,GYG1,H3-3A,H3P6,H3-3B,H3P36,H3-5,HADHB,HAPLN3,HAUS4,HAVCR2,HBEGF,HBG2,HBP1,HCAR2,HCAR3,HCG27,HCK,HCP5,HDX,HEBP1,HELB,HELZ2,HERC5,HERC6,HERPUD2,HES4,HESX1,HEXD,HHEX,MFSD14A,HIF1A,HIF1A-AS1,,HIGD2A,OTUD4P1,HINT3,HIRA,H1-6,H2AC6,H2BP1,H2BC21,H2BC18,H4C14,H4C15,HIVEP1,HIVEP2,HK1,HK3,HLA-A,HLA-B,HLA-C,HLA-DMA,HLA-DMB,HLA-DPA1,HLA-DPB1,HLA-DRA,HLA-DRB1,HLA-E,HLA-F,HLA-G,HLA-H,HLA-J,HLA-K,HLX,HMGB1P3,HMOX1,HNRNPA1P53,HNRNPF,HNRNPH2,HNRNPLL,HORMAD1,HPS5,HPSE,HSD17B11,HSH2D,HSPA1A,HSPA1B,HSPA5,HSPA6,HSPA7,HSPA8,HSPA8P5,HSPB9,HSPD1P6,HTATIP2,HTR4,ICAM1,ICAM2,IDH1,IDH2,IDH3A,IDH3G,IDO1,IDO2,IER2,IER5,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT1P1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IFNK,IGF2BP3,IGHE,IGHEP2,IGSF6,IL12A,IL12RB1,IL13RA1,IL15,IL15RA,IL17RC,IL17RD,IL1B,IL1RN,IL27,IL2RG,IL31RA,IL4I1,ILK,IMPDH1P10,INAFM1,INMT,INTS3,IRAK2,IREB2,IRF1,IRF2,IRF5,IRF7,IRF8,IRF9,ACOD1,ISG15,ISG20,ISOC2,ITGA4,ITM2B,ITPK1,ITPK1-AS1,ITPRIP,ITPRIPL2,JAK2,JAK3,JMJD1C,JPX,JSRP1,JUNB,JUND,JUP,KANSL1L,KARS1,KAT5,KBTBD2,KCNE3,KCNE5,KCNH7,KCNJ15,KCNJ2,KCNJ2-AS1,KCNMA1,KCNMB1,KCNS2,KCTD12,KCTD14,KCTD5,KDM1B,KDM2A,KIAA0040,KIAA0319L,MATCAP1,KIAA0930,CEP162,WASHC4,BLTP1,RIC1,RESF1,SHTN1,KIAA1958,KIF13A,KIF1B,KIF1C,KIF5B,KIF9-AS1,KLF4,KLF5,KLHDC7B,KLHDC8B,KLHL6,KMO,KPNB1,KPTN,KREMEN1,KRT18P4,KY,KYNU,LACC1,LACTB,LAG3,LAMP2,LAMP3,LAP3,LAP3P2,LAPTM4A,LARP1,LARP4B,LAT2,LATS2,LCP1,LCP2,LDLR,LGALS1,LGALS17A,LGALS3BP,LGALS8,LGALS9,LGALSL,LGSN,LHFPL2,LHFPL3-AS1,LIF,LIFR,LILRA1,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LILRB5,LIMK1,LIMK2,LINC00189,LINC00487,LINC00528,LINC00534,LINC00582,LINC00623,CCDC200,LINC00877,LINC00937,LINC00968,LIPA,LIPK,LIPM,LLPH,LMF2,LMNB1,LMO2,LMO4,LMTK2,LONRF1,LOXHD1,LOXL3,LPCAT2,LPIN2,LPP,LRRC59,LRRCC1,LRRK2,LSM10,LSP1,LTBR,LY6E,LYN,LYPD5,LYRM1,LYSMD2,LYZ,MAD2L1BP,MAFB,MAGT1,MAN1A1,MANBAL,MAP2K6,MAP3K11,MAP3K13,MAP3K5,MAP3K7CL,MAP3K8,MAPK14,MAPKAPK3,MARCKS,MARCO,MARS1,MASTL,MAT2B,MAX,CGAS,MBD2,MBOAT1,MCL1,MCTP1,MDK,ME2,MED12L,MED13,MED28,MEF2A,MEFV,MEGF11,METTL4,MFSD14B,MFSD2A,MFSD5,SLC49A3,MGAT1,MIA3,MICA,MICALL1,MICB,MICU1,MIDN,MIER1,MIIP,MILR1,MIR103A2,MIR142,MIR1827,MIR3145,MIR3150B,MIR320E,MIR3671,MIR4433A,MIR4435-2HG,MIR4477A,MIR4511,MIR4632,MIR4645,MIR4679-2,MIR4773-1,MIR5685,MIR601,MITD1,MLKL,MNDA,MOB1A,MOB3C,MORC3,MOV10,MPDU1,MPEG1,MPV17L2,MPZL1,MPZL2,MR1,MRPL16,MRPL17,MRPL44,MRPS18A,MRPS21P2,MS4A14,MS4A4A,MS4A6A,MS4A7,MSL3,MSR1,MSRB1,MSRB2,MT-TS1,MT2A,MTF1,MTG2,MTHFD1,MTHFD2,MTMR11,MTMR14,MTMR4,MTMR6,MTND1P11,MTND4P14,MTND4P26,MTND5P14,MTND5P28,MTND6P5,MTPN,MUC1,MVB12A,MVP,MX1,MX2,MXD1,MXD3,MYCBP2,MYCBP2-AS1,MYD88,MYL12A,MYOF,N4BP1,N4BP2L1,N4BP2L2,NAB1,NABP1,NADK,NAGA,NAGK,NAMPT,NANS,NAPA,NAPSB,NASP,NAT8,NBN,NBR1,NCEH1,NCF1,NCF1B,NCF1C,NCF2,NCKAP1L,NCOA2,NCOA3,NCOA7,NCSTN,NDC80,NDUFA9,NDUFB6,NECAP1,NECAP2,NETO2,NEU1,NEXN,NFAM1,NFE2L3,NFIL3,NFKB2,NFKBIA,NFKBIE,NFKBIZ,NGFR,NHLRC3,NHSL1,NINJ1,NINJ2,NIPA2,NIPSNAP3A,NIT1,NKIRAS2,NLK,NLN,NLRC4,NLRC5,NLRP3,NME8,NMI,NMT1,NOD1,NOD2,NOP10,NPC2,NPTN,NR1I3,NRAS,NRBF2,NRBF2P3,NRBF2P4,NRDC,NRIP1,NRN1,NSF,NSL1,NT5C2,NT5C3A,NT5C3AP1,NTNG2,NUB1,NUCB1,NUCB1-AS1,NUDT16,NUP205,NUP62,NUP58,NXT2,OAS1,OAS2,OAS3,OASL,STN1,ODF3B,OGFR,OOSP1,OR10AA1P,OR2W6P,OR51R1P,OR52B4,OR52H1,OR52K1,OR52K2,OR52K3P,OR52P2P,OR52T1P,OR52U1P,OR52V1P,OR56B1,OR7E100P,ORAI2,ORMDL2,OS9,OSBPL5,OSM,OSMR,OSTM1,OTOF,OTUD5,P2RX4,P2RX7,P2RY12,P2RY13,P2RY14,P2RY6,PADI6,PAEP,PAIP1P1,PAK1,PANK2,PANX1,PARP10,PARP11,PARP12,PARP14,PARP4,PARP4P2,PARP9,PATL1,PBLD,PBX2,PCBP1-AS1,PCGF5,PCK2,PDCD1LG2,PDE4B,PDIA3,PDIA6,PDK3,PDLIM5,PEA15,PEF1,PELI1,PFKFB4,PFKP,PGAP1,PHACTR2,PHC2,PHF11,PHF23,PHLPP1,PI4K2B,PIGB,PIK3AP1,PIK3CD-AS1,PIM2,PIP5K1A,PIPSL,PISD,PIWIL4,PKD2L1,PKN2,PLA2G4A,PLA2G4C,PLA2G7,PLAC8,PLAGL1,PLAGL2,PLAUR,PLCL2-AS1,PLEK,PLEKHA2,PLEKHB2,PLEKHM2,PLEKHN1,PLEKHO1,PLEKHO2,PLIN3,PLS3,PLSCR1,PLSCR2,PLSCR4,PLXDC2,PLXNB2,PMAIP1,PML,PNPT1,POLA2,POLB,POLDIP3,POMP,PPARGC1B,PPCDC,PPL,PPM1K,PPP1R11,PPP2R2A,PTPA,PPP4C,PPTC7,PRCP,PRDM1,PRDM5,PRDX1,PRELID1,PRELID1P1,PRICKLE1,PRKAG2,PRKAR1A,PRKCD,PRKCE,PRKD2,PRLR,PRMT5,PRMT5-AS1,PLPBP,PRPF4,PRPF40A,PRPS2,PRR11,PRR16,PRRG1,PRRG4,PRTG,PRUNE2,PSAP,PSEN1,PSEN2,PSENEN,PSMA2,PSMA3,PSMA4,PSMA5,PSMA6,PSMB10,PSMB2,PSMB3,PSMB4,PSMB8,PSMB9,PSMC1P4,PSMD3,PSMD6-AS2,PSME1,PSME2,PSTPIP2,PTGES3P1,PTGR1,PTGS2,PTK2B,PTP4A1,PTPN1,PTPN6,PTPRC,PTPRE,PTPRO,PTPRU,PTTG1IP,PUS3,PYCARD,QKI,RAB10,RAB11FIP4,RAB12,RAB1A,RAB20,RAB24,RAB31,RAB33B,RAB39A,RAB3GAP1,RAB43,RAB43P1,RAB5A,RAB5C,RAB8A,RAB8B,RAC1,RAC1P2,RALB,RALY,RANGAP1,RAP1AP,RAP2C,RARA,PLAAT4,RASGEF1B,RASGRP3,RASSF5,RB1,RBBP6,RBBP8,RBCK1,RBM23,RBM43,RBM47,RBM7,RBMS2,RCBTB2P1,RCC2,RCN1,RCN1P2,RCSD1,REC8,REEP3,REL,RELB,RELT,RERE,COP1,RFX5,RGL1,RGS1,RGS19,RHBDF2,RHBDL2,RHOG,RHOQ,RHOQP3,RHOT1,RICTOR,RIF1,RILPL2,RIN2,RIPK1,RIPK2,RIPK3,RMI2,RN7SKP17,RN7SKP26,RN7SL105P,RN7SL124P,RN7SL168P,RN7SL364P,RN7SL368P,RN7SL382P,RN7SL435P,RN7SL440P,RN7SL473P,RN7SL587P,RN7SL600P,RN7SL834P,RNA5SP201,RNA5SP237,RNA5SP39,RNA5SP449,RNASE2,RNASEH2B,RNASEH2B-AS1,RNASEL,RNF114,RNF13,RNF135,RNF138,RNF144A,RNF149,RNF169,RNF185,RNF185-AS1,RNF19B,RNF213,RNF217,RNF24,RNF31,RNH1,RNU1-100P,RNU4-24P,RNU4-41P,RNU5A-5P,RNU6-1082P,RNU6-1294P,RNU6-147P,RNU6-613P,RNU6-748P,RNU6-810P,RNU6-890P,RNU7-40P,RNU7-45P,RNVU1-1,RNY4P18,RO60,ROGDI,RP1L1,RP2,RPAP3,RPL28,RPL37P1,RPL3P6,RPL5P23,RPL7P53,RPS19P3,RPS2P44,RPS6KA4,RPS6KA5,RPS6KC1,RRAS,RRM2B,RSAD2,RSPH3,RSPH9,RTCB,RTEL1P1,RTF2,RTL5,RTN1,RTN2,RTP4,RUBCN,RUFY3,RUFY4,RXFP1,SAMD15,SAMD4A,SAMD9,SAMD9L,SAMHD1,SAP18,SART1,SASH1,SASH3,SAT1,SAT2,SBF2,SBNO2,SCAF11,SCAMP2,SCARB2,SCARF1,SCARNA22,SCG3,SCIMP,SCIN,SCLT1,SCML1,SCO1,SCO2,SCPEP1,SCRN3,SCUBE2,SCYL2,SCYL3,SDC3,SDE2,SDHB,SDSL,SEC24D,SECTM1,SELL,SEMA4A,SERPINA1,SERPINB1,SERPINB9,SERPING1,SERTAD1,SERTAD3,SESTD1,SETD7,SETP11,SETX,SFRP1,SFT2D1,SFT2D2,SH2B2,SH2B3,SH2D3C,SH3BGRL,SH3BP2,SH3GLB1,SH3RF1,SH3TC1,SHISA5,SHOC2,SHOX2,SIAH2-AS1,SIGLEC1,SIGLEC11,SIGLEC14,SIGLEC16,SIGLEC5,SIK1,SIK3,SIL1,SIPA1L1,SIPA1L2,SIRPD,SLA,SLAMF7,SLAMF8,SLC12A8,SLC15A3,SLC16A3,SLC17A8,SLC1A3,SLC20A1,SLC22A1,SLC22A15,SLC22A16,SLC22A4,SLC25A24,SLC25A28,SLC25A30,SLC26A8,SLC27A3,SLC2A3P2,SLC2A6,SLC31A1,SLC31A2,SLC35A4,SLC35A5,SLC37A1,SLC37A2,SLC39A1,SLC43A2,SLC43A3,SLC44A2,SLC44A4,SLC51A,SLC52A2,SLC5A9,SLC6A12,SLC6A13,SLC7A7,SLC8A1,SLC9A8,SLFN11,SLFN12,SLFN5,SLIT2,SLITRK4,SLK,SLU7,SMAD1,SMAP2,SMARCD3,SMCHD1,SMCO4,SMG7-AS1,SMIM10,SMIM14,SMTNL1,SNAPIN,SNF8,SNN,SNORA11B,SNORA51,SNORD56B,SNTB1,SNX10,SNX11,SNX17,SNX2,SNX20,SNX6,SOBP,SOCS1,SOD2,SORT1,SOWAHD,SP1,SP100,SP110,SP140,SP140L,SPAG6,SPATA1,SPATA13,SPATS2L,SPG11,SPART,SPG21,SPHK1,SPPL2A,SPSB1,SPTLC2,SQLE,SQOR,SQSTM1,SRA1,SRBD1,SRC,SRD5A1,SRGAP2,SRGAP2-AS1,SRGAP2B,SRGAP2C,SRGN,SRP54,SSB,ITPRID2,SSTR3,ST3GAL2,ST3GAL5,ST8SIA3,ST8SIA4,STAB1,STAC3,STAM2,STARD3,STARD4,STARD8,STAT1,STAT2,STAT3,STAT5A,STAU1,STK24,STK24-AS1,STK3,STK32B,STK40,STOM,STOML1,STS,STX10,STX11,STX12,STX17,STX3,STX4,STYXL1,SUCNR1,SUMO1P4,SUPT4H1,SUSD1,SYCE3,SYNGR2,SYNPO2,SYT9,SZRD1,TAB3-AS2,TAF10,TAF8,TAGAP,TANK,TAP1,TAP2,TAPBP,TAPBPL,TATDN2P2,TATDN3,TBC1D1,TBC1D20,TBC1D22A,TBC1D2B,TBC1D8,TBK1,TCF7L2,TCIRG1,TCN2,TDRD7,TEP1,TESK2,TFE3,TFEC,TFG,TGIF2,TGM1,TGM2,THA1P,THEMIS2,THOC7,TICAM2,TIFA,TIMELESS,TIMM10,TIMM17B,TINF2,TIPARP,TIPRL,TJP2,TLDC2,TLE4,TLR1,TLR2,TLR3,TLR4,TLR7,TLR8,TM9SF2,TM9SF4,TMED7,TMEM106A,STIMATE,TMEM123,TMEM131,TMEM140,TMEM144,TMEM150B,TMEM154,TMEM164,TMEM165,TMEM179B,MFSD13A,TMEM185B,TMEM199,TMEM219,TMEM229B,TMEM252,TMEM255A,TMEM30A,TMEM33,TMEM50A,TMEM51,TMEM59,TMEM60,TMEM62,TMOD2,TMOD3,TMSB10,TMUB2,TMX1,TNF,TNFAIP2,TNFAIP3,TNFAIP6,TNFRSF14,TNFRSF1A,TNFRSF1B,TNFSF10,TNFSF13B,TNFSF15,TNK2,TNS3,TOMM40L,TOP1,TOPORS,TOR1A,TOR1AIP1,TOR1B,TOX4,TOX4P1,TPM3,TPM4P1,TPMT,TPP1,TRAFD1,TRANK1,TRAPPC3,TREX1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM27,TRIM34,TRIM38,TRIM44,TRIM5,TRIM56,TRIM6,TRIM64EP,TRIM69,TRIP12,TRPC4AP,TRPV4,TSPAN17,TSPAN2,TTC21A,TTC26,TTC38,TUBA1A,TUBA1B,TXLNB,TXN2,TXNIP,TXNL4B,TYMP,TYROBP,UBA7,UBE2CP1,UBE2D1,UBE2D3,UBE2E1,UBE2F,UBE2J1,UBE2L3,UBE2L6,UBE2S,UBE2SP1,UBE2V1P6,UBE2Z,UBFD1,UBN1,UBQLN4P1,UBQLNL,UBR2,UBTFL3,UNC93B1,UNC93B2,UNC93B7,UNC93B8,UPF3AP3,UQCRC1,USF1,USP15,USP18,USP19,USP2,USP25,USP30,USP30-AS1,USP33,USP41,USP42,USP6NL,USPL1,UTRN,VAMP3,VAMP5,VASP,VAV1,VCAN-AS1,VCPIP1,VDR,VMP1,VPS9D1,VRK2,VRK3,VWA3B,WARS1,WASHC2A,WDFY1,WDFY3,WDFY3-AS1,WDR41,WDR45,WDR64,WSB1,WSB2,XAF1,XIAP,XPNPEP1,XRN1,XXYLT1-AS2,YIPF1,YKT6,YME1L1,ZBED1,ZBP1,ZBTB7B,ZC3H12A,ZC3HAV1,ZCCHC2,TUT7,ZDHHC18,ZDHHC19,ZDHHC4P1,ZDHHC5,ZEB2,ZEB2-AS1,ZFP36,ZFYVE26,ZMYM4-AS1,ZNF117,ZNF200,ZNF267,ZNF366,ZNF438,ZNF496,ZNF618,ZNF672,ZNF684,ZNF702P,ZNF710,ZNF804A,ZNFX1,ZNRF2,ZSCAN16,ZSWIM6",1994,"AAMP,ABCA1,ABCD1,ABHD16A,ABHD3,ABI1,ABTB2,ACER3,ACLY,ACO1,ACOT9,ACP2,ACSL1,ACSL3,ACSL4,ACSL5,ACSM1,ACTA2,ACTR1A,ACTR3,ADAMTSL4,ADAMTSL4-AS1,ADAP2,ADAR,ADCY4,ADCY7,ADM,ADPGK,ADPGK-AS1,ADPRH,ADPRHL2,ADRBK2,AFF1,AFF2,AGBL5,AGPAT3,AGPAT5,AGRN,AIDA,AIF1,AIG1,AIM2,AK4,AKAP13,AKIRIN2,AKR1A1,ALDH1A1,ALDH2,ALPK1,AMBRA1,AMER1,ANKFY1,ANKRD13A,ANKRD22,ANKRD36BP1,ANKUB1,ANO5,ANXA10,ANXA2,ANXA2P2,ANXA3,ANXA4,ANXA5,AOAH,AOAH-IT1,AP1M2,AP1S2,AP1S3,AP2S1,AP3B1,AP3D1,AP5B1,APH1A,APLP1,APOBEC3A,APOBEC3B,APOBEC3B-AS1,APOBEC3C,APOBEC3F,APOBEC3G,APOBR,APOL1,APOL2,APOL3,APOL4,APOL6,ARAP1-AS1,ARAP2,ARCN1,ARF1,ARFIP1,ARHGAP25,ARHGAP26,ARHGAP27,ARHGAP31,ARHGEF10L,ARHGEF3,ARID4B,ARL11,ARL5B,ARL8B,ARMCX3-AS1,ARNTL2,ARPC1B,ARPC3,ARPC4,ARPC5,ARR3,ARRB2,ARSB,ARSD,ARSE,ASCL2,ASGR1,ASGR2,ASPHD2,ASPRV1,ATF3,ATF5,ATF6,ATG16L2,ATG3,ATP10D,ATP1A4,ATP1B1,ATP1B3,ATP5B,ATP6V0D1,ATP6V0E1,ATP6V1B2,ATP6V1C2,ATP6V1E1,ATP6V1G1,ATP8A2P2,ATXN7,ATXN7L3,AURKAIP1,AZI2,B2M,B4GALT5,BACH1,BACH1-AS1,BACH1-IT2,BAK1,BAK1P1,BATF2,BATF3,BAZ1A,BAZ2A,BBX,BCL10,BCL2L14,BCL3,BECN1,BID,BIN2,BIN3,BIRC6-AS1,BLVRA,BLZF1,BMPR2,BRCA2,BRD7,BRI3,BRMS1,BROX,BST2,BTK,BTN2A1,BTN2A2,BTN2A3P,BTN3A1,BTN3A2,BTN3A3,C10orf54,C11orf34,C11orf72,C11orf82,C12orf5,C14orf159,C14orf93,C15orf39,C17orf62,C17orf72,C18orf25,C18orf8,C19orf12,C19orf38,C19orf66,C1GALT1,C1GALT1C1,C1orf162,C1orf173,C1QA,C1QB,C2,C21orf91,C2orf66,C2orf80,C3,C3AR1,C3orf14,C3orf38,C3orf58,C4orf3,C4orf32,C4orf33,C5,C5orf15,C5orf56,C5orf58,C6orf106,C6orf222,C6orf62,C9orf129,C9orf66,C9orf72,C9orf91,CACNA1A,CACNA1E,CADM4,CALCOCO2,CALM2P2,CALM3,CALR,CAMK2D,CAPG,CAPN2,CAPNS2,CAPZA1,CAPZA2,CARD16,CARD17,CARD6,CARD8,CARS,CARS2,CASP1,CASP10,CASP1P2,CASP4,CASP5,CASP7,CAST,CATSPERG,CBR1,CBWD1,CBWD2,CBWD3,CBWD5,CBWD6,CBX1P4,CCDC146,CCDC149,CCDC154,CCDC170,CCDC58P1,CCDC73,CCDC9,CCDC97,CCL1,CCL13,CCL2,CCL25,CCL7,CCL8,CCNA1,CCNL1,CCR1,CCR2,CCRL2,CCSER1,CD14,CD163,CD164,CD1D,CD209,CD274,CD2AP,CD300A,CD300C,CD300E,CD300LF,CD33,CD36,CD38,CD40,CD46,CD53,CD59,CD68,CD74,CD86,CD97,CDC42EP2,CDC42EP4,CDC73,CDH23,CDH6,CDHR5,CDK17,CDKL5,CDKN1A,CDKN1C,CDKN2D,CEACAM1,CEBPB,CECR1,CECR6,CELF2-AS1,CENPCP1,CENPN,CEP164,CERKL,CERS6-AS1,CES1,CES1P1,CFAP58,CFAP58-DT,CFB,CFLAR,CFLAR-AS1,CFP,CHD1,CHGA,CHMP1A,CHMP2A,CHMP2B,CHMP4B,CHMP5,CHN2,CHRNA6,CHRNB1,CHRNB2,CHST7,CHSY1,CICP19,CICP3,CIITA,CIR1,CLASRP,CLCN4,CLCN5,CLCN7,CLDN18,CLEC1A,CLEC2B,CLEC4D,CLEC4E,CLEC5A,CLEC6A,CLEC7A,CLIC1,CLIC4,CLK3,CMAHP,CMC2,CMKLR1,CMPK2,CMTM6,CNDP2,CNIH4,CNP,CNTD1,CNTLN,CNTRL,COA6,COL8A2,COL9A1,COMMD9,COPE,COPG1,COPZ1,COQ10B,CORO1B,COTL1,COX5B,COX6B1,CPB1,CPEB2,CPEB3,CPED1,CPPED1,CPVL,CREBRF,CREG1,CREM,CSF1R,CSF2RB,CSF3R,CSNK1G2,CSRNP1,CST3,CTBS,CTCFL,CTNNA1,CTRL,CTSA,CTSB,CTSH,CTSL,CTSO,CTSS,CTSZ,CUL1,CXCL10,CXCL11,CXCL16,CXCL9,CXCR1,CXCR2P1,CXorf21,CXorf38,CYB561,CYB5R4,CYBA,CYBB,CYC1,CYFIP1,CYLD,CYP2J2,CYP4A22-AS1,CYSLTR1,CYSTM1,CYTH4,CYTOR,DAPP1,DAZAP2,DBF4B,DCAF11,DCBLD1,DCLRE1C,DCLRE1CP1,DCP1A,DCUN1D3,DDAH2,DDO,DDX10P1,DDX21,DDX3X,DDX58,DDX60,DDX60L,DECR1,DEDD2,DEFB1,DEGS1,DEK,DENND1A,DENND5A,DERL1,DESI1,DHRS12,DHRS9,DHRSX,DHTKD1,DHX58,DHX8,DIAPH2,DIP2B,DISC1,DISC1-IT1,DLC1,DLEU2,DLEU7,DMXL2,DNAAF1,DNAJA1,DNAJB11,DNAJB12,DNAJC1,DNAJC13,DNAJC15,DNAJC7,DNM1P33,DNM1P34,DNPEP,DNTTIP1,DOCK4,DOCK8,DOK1,DPF2,DPP3,DPRXP2,DPYD,DPYD-AS1,DPYD-AS2,DPYS,DPYSL2,DRAM1,DRAP1,DTNBP1,DTX3L,DUSP1,DUSP10,DUSP3,DUSP5,DUSP6,DYNLT1,DYSF,DZIP1L,ECE1,ECPAS,EDEM1,EDEM2,EFCAB2,EFHD2,EFR3A,EGLN1,EHBP1L1,EHD4,EIF2AK2,EIF4A1P2,EIF4A1P7,EIF4E3,EIF4G3,EIF4H,EIF5A,ELF1,ELF4,ELMO2,ELOVL5,EMILIN2,EMP1,EMP3,ENDOU,ENPP2,EPAS1,EPB41L3,EPG5,EPHB1,EPHB2,EPS15,EPSTI1,ERAP1,ERAP2,ERI1,ERP29,ERP44,ERV3-1,ESRRA,ETV6,ETV7,EVI2B,EWSR1,EXOC3L1,EXOC3L4,EXOC6,EXOSC9,EXT1,EYA1,FAM111A,FAM115C,FAM120A,FAM120AOS,FAM122C,FAM129B,FAM135A,FAM160B1,FAM194B,FAM198B,FAM19A2,FAM20A,FAM20C,FAM214B,FAM21A,FAM21C,FAM225A,FAM225B,FAM26F,FAM46A,FAM49B,FAM65B,FAM71A,FAM72A,FAM72B,FAM72C,FAM72D,FAM8A1,FAM91A1,FAM92A1,FANCA,FANCL,FAP,FAR2,FARP2,FAS,FBXL5,FBXO39,FBXO6,FCER1G,FCGR1A,FCGR1B,FCGR2A,FCGR2B,FCGR2C,FCGR3A,FCGR3B,FCN1,FCN2,FEM1C,FFAR2,FFAR3,FGD2,FGD6,FGF13,FGL2,FGR,FIBP,FIG4,FKBP15,FLI1,FLOT1,FLVCR1,FLVCR2,FMNL2,FMR1,FMR1-IT1,FNDC3A,FNIP2,FOLR2,FOXC1,FOXD4L4,FOXD4L5,FOXL2,FOXN2,FOXN3-AS1,FPR2,FRMD3,FRMD4B,FTL,FTSJD2,FUCA2,FUNDC2P4,FUOM,FUT4,FYB,FYTTD1,FZD2,FZD5,GAB1,GAB2,GABARAP,GADD45B,GAK,GALM,GALNT3,GAPDHP14,GART,GAS6,GAS8,GBA,GBP1,GBP1P1,GBP2,GBP3,GBP4,GBP5,GBP6,GBP7,GCA,GCH1,GCNT1,GCNT2,GDI2,GIMAP2,GIMAP4,GIMAP6,GIMAP8,GK,GK-AS1,GK-IT1,GK3P,GLA,GLIPR2,GLRX,GLUL,GM2A,GMFBP1,GMPR2,GNA13,GNA15,GNB1,GNB2,GNB4,GNG5,GNS,GOLGA5P1,GOLM1,GORASP1,GPBAR1,GPBP1,GPD2,GPR141,GPR155,GPR42,GPR65,GPR84,GPS2,GPX1,GRAMD1B,GRB2,GRIN3A,GRIPAP1,GRN,GSDMC,GSDMD,GSN,GSTK1,GSTO1,GTF2B,GTF2F1,GTPBP1,GTPBP2,GUCY1A3,GUCY2F,GVINP1,GYG1,H3F3A,H3F3AP4,H3F3B,H3F3BP1,H3F3C,HADHB,HAPLN3,HAUS4,HAVCR2,HBEGF,HBG2,HBP1,HCAR2,HCAR3,HCG27,HCK,HCP5,HDX,HEBP1,HELB,HELZ2,HERC5,HERC6,HERPUD2,HES4,HESX1,HEXDC,HHEX,HIAT1,HIF1A,HIF1A-AS1,HIF1A-AS2,HIGD2A,HIN1L,HINT3,HIRA,HIST1H1T,HIST1H2AC,HIST2H2BA,HIST2H2BE,HIST2H2BF,HIST2H4A,HIST2H4B,HIVEP1,HIVEP2,HK1,HK3,HLA-A,HLA-B,HLA-C,HLA-DMA,HLA-DMB,HLA-DPA1,HLA-DPB1,HLA-DRA,HLA-DRB1,HLA-E,HLA-F,HLA-G,HLA-H,HLA-J,HLA-K,HLX,HMGB1P3,HMOX1,HNRNPA1P53,HNRNPF,HNRNPH2,HNRNPLL,HORMAD1,HPS5,HPSE,HSD17B11,HSH2D,HSPA1A,HSPA1B,HSPA5,HSPA6,HSPA7,HSPA8,HSPA8P5,HSPB9,HSPD1P6,HTATIP2,HTR4,ICAM1,ICAM2,IDH1,IDH2,IDH3A,IDH3G,IDO1,IDO2,IER2,IER5,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT1P1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IFNK,IGF2BP3,IGHE,IGHEP2,IGSF6,IL12A,IL12RB1,IL13RA1,IL15,IL15RA,IL17RC,IL17RD,IL1B,IL1RN,IL27,IL2RG,IL31RA,IL4I1,ILK,IMPDH1P10,INAFM1,INMT,INTS3,IRAK2,IREB2,IRF1,IRF2,IRF5,IRF7,IRF8,IRF9,IRG1,ISG15,ISG20,ISOC2,ITGA4,ITM2B,ITPK1,ITPK1-AS1,ITPRIP,ITPRIPL2,JAK2,JAK3,JMJD1C,JPX,JSRP1,JUNB,JUND,JUP,KANSL1L,KARS,KAT5,KBTBD2,KCNE3,KCNE5,KCNH7,KCNJ15,KCNJ2,KCNJ2-AS1,KCNMA1,KCNMB1,KCNS2,KCTD12,KCTD14,KCTD5,KDM1B,KDM2A,KIAA0040,KIAA0319L,KIAA0895L,KIAA0930,KIAA1009,KIAA1033,KIAA1109,KIAA1432,KIAA1551,KIAA1598,KIAA1958,KIF13A,KIF1B,KIF1C,KIF5B,KIF9-AS1,KLF4,KLF5,KLHDC7B,KLHDC8B,KLHL6,KMO,KPNB1,KPTN,KREMEN1,KRT18P4,KY,KYNU,LACC1,LACTB,LAG3,LAMP2,LAMP3,LAP3,LAP3P2,LAPTM4A,LARP1,LARP4B,LAT2,LATS2,LCP1,LCP2,LDLR,LGALS1,LGALS17A,LGALS3BP,LGALS8,LGALS9,LGALSL,LGSN,LHFPL2,LHFPL3-AS1,LIF,LIFR,LILRA1,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LILRB5,LIMK1,LIMK2,LINC00189,LINC00487,LINC00528,LINC00534,LINC00582,LINC00623,LINC00854,LINC00877,LINC00937,LINC00968,LIPA,LIPK,LIPM,LLPH,LMF2,LMNB1,LMO2,LMO4,LMTK2,LONRF1,LOXHD1,LOXL3,LPCAT2,LPIN2,LPP,LRRC59,LRRCC1,LRRK2,LSM10,LSP1,LTBR,LY6E,LYN,LYPD5,LYRM1,LYSMD2,LYZ,MAD2L1BP,MAFB,MAGT1,MAN1A1,MANBAL,MAP2K6,MAP3K11,MAP3K13,MAP3K5,MAP3K7CL,MAP3K8,MAPK14,MAPKAPK3,MARCKS,MARCO,MARS,MASTL,MAT2B,MAX,MB21D1,MBD2,MBOAT1,MCL1,MCTP1,MDK,ME2,MED12L,MED13,MED28,MEF2A,MEFV,MEGF11,METTL4,MFSD14B,MFSD2A,MFSD5,MFSD7,MGAT1,MIA3,MICA,MICALL1,MICB,MICU1,MIDN,MIER1,MIIP,MILR1,MIR103A2,MIR142,MIR1827,MIR3145,MIR3150B,MIR320E,MIR3671,MIR4433A,MIR4435-2HG,MIR4477A,MIR4511,MIR4632,MIR4645,MIR4679-2,MIR4773-1,MIR5685,MIR601,MITD1,MLKL,MNDA,MOB1A,MOB3C,MORC3,MOV10,MPDU1,MPEG1,MPV17L2,MPZL1,MPZL2,MR1,MRPL16,MRPL17,MRPL44,MRPS18A,MRPS21P2,MS4A14,MS4A4A,MS4A6A,MS4A7,MSL3,MSR1,MSRB1,MSRB2,MT-TS1,MT2A,MTF1,MTG2,MTHFD1,MTHFD2,MTMR11,MTMR14,MTMR4,MTMR6,MTND1P11,MTND4P14,MTND4P26,MTND5P14,MTND5P28,MTND6P5,MTPN,MUC1,MVB12A,MVP,MX1,MX2,MXD1,MXD3,MYCBP2,MYCBP2-AS1,MYD88,MYL12A,MYOF,N4BP1,N4BP2L1,N4BP2L2,NAB1,NABP1,NADK,NAGA,NAGK,NAMPT,NANS,NAPA,NAPSB,NASP,NAT8,NBN,NBR1,NCEH1,NCF1,NCF1B,NCF1C,NCF2,NCKAP1L,NCOA2,NCOA3,NCOA7,NCSTN,NDC80,NDUFA9,NDUFB6,NECAP1,NECAP2,NETO2,NEU1,NEXN,NFAM1,NFE2L3,NFIL3,NFKB2,NFKBIA,NFKBIE,NFKBIZ,NGFR,NHLRC3,NHSL1,NINJ1,NINJ2,NIPA2,NIPSNAP3A,NIT1,NKIRAS2,NLK,NLN,NLRC4,NLRC5,NLRP3,NME8,NMI,NMT1,NOD1,NOD2,NOP10,NPC2,NPTN,NR1I3,NRAS,NRBF2,NRBF2P3,NRBF2P4,NRD1,NRIP1,NRN1,NSF,NSL1,NT5C2,NT5C3A,NT5C3AP1,NTNG2,NUB1,NUCB1,NUCB1-AS1,NUDT16,NUP205,NUP62,NUPL1,NXT2,OAS1,OAS2,OAS3,OASL,OBFC1,ODF3B,OGFR,OOSP1,OR10AA1P,OR2W6P,OR51R1P,OR52B4,OR52H1,OR52K1,OR52K2,OR52K3P,OR52P2P,OR52T1P,OR52U1P,OR52V1P,OR56B1,OR7E100P,ORAI2,ORMDL2,OS9,OSBPL5,OSM,OSMR,OSTM1,OTOF,OTUD5,P2RX4,P2RX7,P2RY12,P2RY13,P2RY14,P2RY6,PADI6,PAEP,PAIP1P1,PAK1,PANK2,PANX1,PARP10,PARP11,PARP12,PARP14,PARP4,PARP4P2,PARP9,PATL1,PBLD,PBX2,PCBP1-AS1,PCGF5,PCK2,PDCD1LG2,PDE4B,PDIA3,PDIA6,PDK3,PDLIM5,PEA15,PEF1,PELI1,PFKFB4,PFKP,PGAP1,PHACTR2,PHC2,PHF11,PHF23,PHLPP1,PI4K2B,PIGB,PIK3AP1,PIK3CD-AS1,PIM2,PIP5K1A,PIPSL,PISD,PIWIL4,PKD2L1,PKN2,PLA2G4A,PLA2G4C,PLA2G7,PLAC8,PLAGL1,PLAGL2,PLAUR,PLCL2-AS1,PLEK,PLEKHA2,PLEKHB2,PLEKHM2,PLEKHN1,PLEKHO1,PLEKHO2,PLIN3,PLS3,PLSCR1,PLSCR2,PLSCR4,PLXDC2,PLXNB2,PMAIP1,PML,PNPT1,POLA2,POLB,POLDIP3,POMP,PPARGC1B,PPCDC,PPL,PPM1K,PPP1R11,PPP2R2A,PPP2R4,PPP4C,PPTC7,PRCP,PRDM1,PRDM5,PRDX1,PRELID1,PRELID1P1,PRICKLE1,PRKAG2,PRKAR1A,PRKCD,PRKCE,PRKD2,PRLR,PRMT5,PRMT5-AS1,PROSC,PRPF4,PRPF40A,PRPS2,PRR11,PRR16,PRRG1,PRRG4,PRTG,PRUNE2,PSAP,PSEN1,PSEN2,PSENEN,PSMA2,PSMA3,PSMA4,PSMA5,PSMA6,PSMB10,PSMB2,PSMB3,PSMB4,PSMB8,PSMB9,PSMC1P4,PSMD3,PSMD6-AS2,PSME1,PSME2,PSTPIP2,PTGES3P1,PTGR1,PTGS2,PTK2B,PTP4A1,PTPN1,PTPN6,PTPRC,PTPRE,PTPRO,PTPRU,PTTG1IP,PUS3,PYCARD,QKI,RAB10,RAB11FIP4,RAB12,RAB1A,RAB20,RAB24,RAB31,RAB33B,RAB39A,RAB3GAP1,RAB43,RAB43P1,RAB5A,RAB5C,RAB8A,RAB8B,RAC1,RAC1P2,RALB,RALY,RANGAP1,RAP1AP,RAP2C,RARA,RARRES3,RASGEF1B,RASGRP3,RASSF5,RB1,RBBP6,RBBP8,RBCK1,RBM23,RBM43,RBM47,RBM7,RBMS2,RCBTB2P1,RCC2,RCN1,RCN1P2,RCSD1,REC8,REEP3,REL,RELB,RELT,RERE,RFWD2,RFX5,RGL1,RGS1,RGS19,RHBDF2,RHBDL2,RHOG,RHOQ,RHOQP3,RHOT1,RICTOR,RIF1,RILPL2,RIN2,RIPK1,RIPK2,RIPK3,RMI2,RN7SKP17,RN7SKP26,RN7SL105P,RN7SL124P,RN7SL168P,RN7SL364P,RN7SL368P,RN7SL382P,RN7SL435P,RN7SL440P,RN7SL473P,RN7SL587P,RN7SL600P,RN7SL834P,RNA5SP201,RNA5SP237,RNA5SP39,RNA5SP449,RNASE2,RNASEH2B,RNASEH2B-AS1,RNASEL,RNF114,RNF13,RNF135,RNF138,RNF144A,RNF149,RNF169,RNF185,RNF185-AS1,RNF19B,RNF213,RNF217,RNF24,RNF31,RNH1,RNU1-100P,RNU4-24P,RNU4-41P,RNU5A-5P,RNU6-1082P,RNU6-1294P,RNU6-147P,RNU6-613P,RNU6-748P,RNU6-810P,RNU6-890P,RNU7-40P,RNU7-45P,RNVU1-1,RNY4P18,RO60,ROGDI,RP1L1,RP2,RPAP3,RPL28,RPL37P1,RPL3P6,RPL5P23,RPL7P53,RPS19P3,RPS2P44,RPS6KA4,RPS6KA5,RPS6KC1,RRAS,RRM2B,RSAD2,RSPH3,RSPH9,RTCB,RTEL1P1,RTFDC1,RTL5,RTN1,RTN2,RTP4,RUBCN,RUFY3,RUFY4,RXFP1,SAMD15,SAMD4A,SAMD9,SAMD9L,SAMHD1,SAP18,SART1,SASH1,SASH3,SAT1,SAT2,SBF2,SBNO2,SCAF11,SCAMP2,SCARB2,SCARF1,SCARNA22,SCG3,SCIMP,SCIN,SCLT1,SCML1,SCO1,SCO2,SCPEP1,SCRN3,SCUBE2,SCYL2,SCYL3,SDC3,SDE2,SDHB,SDSL,SEC24D,SECTM1,SELL,SEMA4A,SERPINA1,SERPINB1,SERPINB9,SERPING1,SERTAD1,SERTAD3,SESTD1,SETD7,SETP11,SETX,SFRP1,SFT2D1,SFT2D2,SH2B2,SH2B3,SH2D3C,SH3BGRL,SH3BP2,SH3GLB1,SH3RF1,SH3TC1,SHISA5,SHOC2,SHOX2,SIAH2-AS1,SIGLEC1,SIGLEC11,SIGLEC14,SIGLEC16,SIGLEC5,SIK1,SIK3,SIL1,SIPA1L1,SIPA1L2,SIRPD,SLA,SLAMF7,SLAMF8,SLC12A8,SLC15A3,SLC16A3,SLC17A8,SLC1A3,SLC20A1,SLC22A1,SLC22A15,SLC22A16,SLC22A4,SLC25A24,SLC25A28,SLC25A30,SLC26A8,SLC27A3,SLC2A3P2,SLC2A6,SLC31A1,SLC31A2,SLC35A4,SLC35A5,SLC37A1,SLC37A2,SLC39A1,SLC43A2,SLC43A3,SLC44A2,SLC44A4,SLC51A,SLC52A2,SLC5A9,SLC6A12,SLC6A13,SLC7A7,SLC8A1,SLC9A8,SLFN11,SLFN12,SLFN5,SLIT2,SLITRK4,SLK,SLU7,SMAD1,SMAP2,SMARCD3,SMCHD1,SMCO4,SMG7-AS1,SMIM10,SMIM14,SMTNL1,SNAPIN,SNF8,SNN,SNORA11B,SNORA51,SNORD56B,SNTB1,SNX10,SNX11,SNX17,SNX2,SNX20,SNX6,SOBP,SOCS1,SOD2,SORT1,SOWAHD,SP1,SP100,SP110,SP140,SP140L,SPAG6,SPATA1,SPATA13,SPATS2L,SPG11,SPG20,SPG21,SPHK1,SPPL2A,SPSB1,SPTLC2,SQLE,SQRDL,SQSTM1,SRA1,SRBD1,SRC,SRD5A1,SRGAP2,SRGAP2-AS1,SRGAP2B,SRGAP2C,SRGN,SRP54,SSB,SSFA2,SSTR3,ST3GAL2,ST3GAL5,ST8SIA3,ST8SIA4,STAB1,STAC3,STAM2,STARD3,STARD4,STARD8,STAT1,STAT2,STAT3,STAT5A,STAU1,STK24,STK24-AS1,STK3,STK32B,STK40,STOM,STOML1,STS,STX10,STX11,STX12,STX17,STX3,STX4,STYXL1,SUCNR1,SUMO1P4,SUPT4H1,SUSD1,SYCE3,SYNGR2,SYNPO2,SYT9,SZRD1,TAB3-AS2,TAF10,TAF8,TAGAP,TANK,TAP1,TAP2,TAPBP,TAPBPL,TATDN2P2,TATDN3,TBC1D1,TBC1D20,TBC1D22A,TBC1D2B,TBC1D8,TBK1,TCF7L2,TCIRG1,TCN2,TDRD7,TEP1,TESK2,TFE3,TFEC,TFG,TGIF2,TGM1,TGM2,THA1P,THEMIS2,THOC7,TICAM2,TIFA,TIMELESS,TIMM10,TIMM17B,TINF2,TIPARP,TIPRL,TJP2,TLDC2,TLE4,TLR1,TLR2,TLR3,TLR4,TLR7,TLR8,TM9SF2,TM9SF4,TMED7,TMEM106A,TMEM110,TMEM123,TMEM131,TMEM140,TMEM144,TMEM150B,TMEM154,TMEM164,TMEM165,TMEM179B,TMEM180,TMEM185B,TMEM199,TMEM219,TMEM229B,TMEM252,TMEM255A,TMEM30A,TMEM33,TMEM50A,TMEM51,TMEM59,TMEM60,TMEM62,TMOD2,TMOD3,TMSB10,TMUB2,TMX1,TNF,TNFAIP2,TNFAIP3,TNFAIP6,TNFRSF14,TNFRSF1A,TNFRSF1B,TNFSF10,TNFSF13B,TNFSF15,TNK2,TNS3,TOMM40L,TOP1,TOPORS,TOR1A,TOR1AIP1,TOR1B,TOX4,TOX4P1,TPM3,TPM4P1,TPMT,TPP1,TRAFD1,TRANK1,TRAPPC3,TREX1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM27,TRIM34,TRIM38,TRIM44,TRIM5,TRIM56,TRIM6,TRIM64EP,TRIM69,TRIP12,TRPC4AP,TRPV4,TSPAN17,TSPAN2,TTC21A,TTC26,TTC38,TUBA1A,TUBA1B,TXLNB,TXN2,TXNIP,TXNL4B,TYMP,TYROBP,UBA7,UBE2CP1,UBE2D1,UBE2D3,UBE2E1,UBE2F,UBE2J1,UBE2L3,UBE2L6,UBE2S,UBE2SP1,UBE2V1P6,UBE2Z,UBFD1,UBN1,UBQLN4P1,UBQLNL,UBR2,UBTFL3,UNC93B1,UNC93B2,UNC93B7,UNC93B8,UPF3AP3,UQCRC1,USF1,USP15,USP18,USP19,USP2,USP25,USP30,USP30-AS1,USP33,USP41,USP42,USP6NL,USPL1,UTRN,VAMP3,VAMP5,VASP,VAV1,VCAN-AS1,VCPIP1,VDR,VMP1,VPS9D1,VRK2,VRK3,VWA3B,WARS,WASHC2A,WDFY1,WDFY3,WDFY3-AS1,WDR41,WDR45,WDR64,WSB1,WSB2,XAF1,XIAP,XPNPEP1,XRN1,XXYLT1-AS2,YIPF1,YKT6,YME1L1,ZBED1,ZBP1,ZBTB7B,ZC3H12A,ZC3HAV1,ZCCHC2,ZCCHC6,ZDHHC18,ZDHHC19,ZDHHC4P1,ZDHHC5,ZEB2,ZEB2-AS1,ZFP36,ZFYVE26,ZMYM4-AS1,ZNF117,ZNF200,ZNF267,ZNF366,ZNF438,ZNF496,ZNF618,ZNF672,ZNF684,ZNF702P,ZNF710,ZNF804A,ZNFX1,ZNRF2,ZSCAN16,ZSWIM6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Supplemental Document 1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605227/bin/jem.20082292_1.pdf,NA,NA,NA,NA
M40937,CHAD63-KH,VV,LEISHMANIA,OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_DN,PARASITE,DOWN,VACCINE,DOSE,H24,H,24,18-50,ADULT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/OSMAN_BLOOD_CHAD63_KH_AGE_18_50YO_HIGH_DOSE_SUBJECTS_24HR_DN,"BACKGROUND: Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or appropriately targeted cell mediated immunity, including CD8+ T cell responses, underlies the progression of VL and progression to PKDL, and can limit the therapeutic efficacy of anti-leishmanial drugs. Hence, in addition to the need for prophylactic vaccines against leishmaniasis, the development of therapeutic vaccines for use alone or in combined immuno-chemotherapy has been identified as an unmet clinical need. Here, we report the first clinical trial of a third-generation leishmaniasis vaccine, developed intentionally to induce Leishmania-specific CD8+ T cells. METHODS: We conducted a first-in-human dose escalation Phase I trial in 20 healthy volunteers to assess the safety, tolerability and immunogenicity of a prime-only adenoviral vaccine for human VL and PKDL. ChAd63-KH is a replication defective simian adenovirus expressing a novel synthetic gene (KH) encoding two Leishmania proteins KMP-11 and HASPB. Uniquely, the latter was engineered to reflect repeat domain polymorphisms and arrangements identified from clinical isolates. We monitored innate immune responses by whole blood RNA-Seq and antigen specific CD8+ T cell responses by IFN-gamma ELISPOT and intracellular flow cytometry. FINDINGS: ChAd63-KH was safe at intramuscular doses of 1x1010 and 7.5x1010 vp. Whole blood transcriptomic profiling indicated that ChAd63-KH induced innate immune responses characterized by an interferon signature and the presence of activated dendritic cells. Broad and quantitatively robust CD8+ T cell responses were induced by vaccination in 100% (20/20) of vaccinated subjects. CONCLUSION: The results of this study support the further development of ChAd63-KH as a novel third generation vaccine for VL and PKDL. TRIAL: This clinical trial (LEISH1) was registered at EudraCT (2012-005596-14) and ISRCTN (07766359).","Genes down-regulated in blood 24hr vs 0hr in adults (18-50) (high dose subjects) after exposure to ChAd63-KH , time point 24H , administered Intramuscular injection. Comment: DE gene list for high dose subjects.","Osman M,Mistry A,Keding A,Gabe R,Cook E,Forrester S,Wiggins R,Di Marco S,Colloca S,Siani L,Cortese R,Smith DF,Aebischer T,Kaye PM,Lacey CJ",28498840,HUMAN_GENE_SYMBOL,"A2M-AS1,AAK1,AASDH,ABAT,ABCA10,ABCA17P,ABCA3,ABCA5,ABCA6,ABCB1,ABCC5,ABCD2,ABCG1,ABHD17C,ABI2,ABLIM1,ACACB,ACAD11,ACAD8,ACADSB,ACBD6,ACP6,PXYLP1,ACVR2A,ACVR2B,ACYP1,ADAM19,ADAM1A,ADAM22,ADAM23,ADAMTS1,ADAMTS10,ADAMTS5,ADAT2,COQ8A,ADCY9,ADD3,ADHFE1,ADK,ADNP,ADSS1,AEBP2,AGAP1,AGAP12P,AGFG2,AGL,AGO1,AGO2,AGO3,AGTPBP1,AHCTF1,AHI1,AJAP1,AK3,AK5,AKAP11,AKR1B1,AKT3,AKTIP,ALDH6A1,ALDH7A1,ALG10,ALG13,ALG1L13P,ALG6,ALMS1-IT1,ALOX12B,ALOX12P2,ALS2,AMDHD1,AMIGO1,AMOT,AMPD3,AMY2B,ANAPC1,ANGPT1,ANKAR,ANKEF1,ANKLE2,ANKRD18A,ANKRD20A5P,ANKRD26,ANKRD26P4,ANKRD28,ANKRD31,ANKRD36,ANKRD36B,ANKRD36C,ANKRD46,ANKRD55,ANKRD6,ANKS6,ANKZF1,ANO10,ANTXRLP1,AP3M2,APBA2,APBB1,APCDD1,APMAP,APPL2,ARGLU1,ARHGAP10,ARHGAP12,ARHGAP15,ARHGAP35,ARHGEF7,ARHGEF9,ARID2,ARL10,ARL14EP,ARL3,ARL4C,ARL5A,ARL6,ARMC2,ARMCX4,ARMCX5,ARSG,ARSK,ASAH2B,ASB1,ASF1A,ASF1B,ASPH,ASTE1,ATE1,ATF7IP,ATF7IP2,ATG16L1,ATG2B,ATG9B,ATL2,ATM,ATP2B4,ATP6V0A2,ATP6V0E2-AS1,ATP8A1,ATP8A2,ATP8B2,ATP5IF1,ATXN1,AUH,AUTS2,AXIN1,B3GALT2,B3GLCT,B3GNT2,B4GALT6,BAAT,BACH2,BAG2,BBS1,BBS10,BBS2,BBS4,BBS9,BCKDHB,BCL11B,BCL2,BCR,BDH2,BDNF-AS,BEND7,BFSP1,GPRASP3,BHLHE40-AS1,BICD1,BIN1,BIVM,BLM,BMS1P4,BNC2,BOK-AS1,BRD1,BRI3BP,BRICD5,BRPF3,BRWD1,BTBD7,BTBD8,BTG1,KCNJ5-AS1,TMEM263,C12orf42,C12orf57,MTRFR,C14orf132,C14orf28,CDIN1,MOSMO,C16orf74,C18orf54,BRME1,C1QTNF3,C1orf21,C1orf35,LINC02910,RTL10,C22orf39,C3orf33,HMCES,CTBP1-DT,C5orf34,C5orf63,C6orf163,ERMARD,SUGCT,C7orf25,CYREN,FMC1-LUC7L2,DMAC1,TRMO,CA4,CA5B,CABIN1,CACHD1,CALCB,CALM1,CAMK2G,CAMK4,CAMSAP1,CAMTA1,CAPN14,CAPN7,CARF,CASD1,CASK,CASP2,CASS4,CATSPERB,CBLB,CBR4,CBX1,CBX7,CBX8,CBY1,CCDC102A,CCDC102B,CFAP36,CCDC125,CCDC136,CCDC14,CCDC141,CCDC152,CCDC153,CCDC171,CEP83,CCDC57,MIX23P5,CCDC65,CCDC7,CCDC89,CCDC92,CCL5,CCNB1IP1,CCNJL,CCSER2,CD160,CD1C,CD1E,CD2,CD200R1,CD244,CD247,CD27,CD28,CD3E,CD3G,CD40LG,CD44,CD6,CD8B,CD96,CD99,CDC14A,CDC42BPG,CDH2,CDH26,CDHR3,CDK5R1,CDKN2B,CDNF,CDON,CDR2,CDRT4,CEACAM19,CENPC,CENPV,CEP120,CEP170,CEP170P1,CEP250,CEP290,CEP44,CEP57,CEP68,CEP70,CEP78,CEP85L,CEP95,CERK,CERS4,CFAP70,CFL2,CHCHD6,CHD1L,CHD3,CHD6,CHIC1,CHMP7,CILP,CLDN12,CLEC2D,CLYBL,CMC1,CMSS1,CMTM4,CNIH1,CNKSR2,CNNM3,CNOT6,CNPY4,CNTNAP3,CNTNAP3B,COG6,COL13A1,COL5A2,COL6A2,COL9A3,COLEC12,COLGALT2,COPS8,COQ10A,COX10-DT,COX11,COX19,CPAMD8,CPNE2,CPSF6,CR1,CREB3L4,CREBZF,CRIM1,CROCCP3,CROT,CRTAM,CRY1,CRYGS,CRYZL1,CSGALNACT1,KAT14,CST7,CTNNBIP1,CTPS2,CTSF,CUBN,CUTC,CXCL1,CXCL6,CXCR6,RADX,CYBRD1,CYCSP32,CYCSP34,CYFIP2,CYP27A1,CYP2D8P,CYP4F12,CYTH3,DAAM1,DACH1,DANCR,DAPK2,DBF4,DBP,DCAF17,DCHS1,DCP1B,DCUN1D2,DDHD2,DDIT4,DDX12P,DDX20,DDX31,DDX42,DEF6,DEF8,DENND11,DENND2D,DENND4C,DEPDC7,DEPTOR,DGKA,DGKD,DGKE,DGKG,DHRS3,DHRS7,DIP2A,SLC49A4,DIS3L,DIXDC1,DKK3,DLEC1,DLEU2L,DLG1,DLG2,DLGAP1-AS1,DLGAP1-AS2,DMAP1,DMKN,DNAH6,DNAJC19,DNAJC21,DNAJC24,DNAJC3-DT,DNAJC9,DNM1P47,DNMBP,DOCK3,DOK4,DPEP2,DPEP3,DPH5,DPH6,DPH7,DPP4,DPY19L2,DPY19L2P1,DPY19L2P2,DPY19L2P4,DPY19L3,DPY19L4,DSC1,DSEL,DSTN,DSTYK,DTD1,DTHD1,DUS2,DYNC2H1,DYRK2,DZANK1,DZIP3,EDAR,EEF2K,EEPD1,EFCAB5,EFCAB7,EFHC1,EFHC2,EHBP1,EIF3EP1,EIF3F,EIF3J-DT,EIF3L,EIF4B,EIF4BP6,ELAPOR2,ELOVL4,ELP2,EML5,ADGRE3,ADGRE4P,ENDOV,ENO2,ENOSF1,ENPP4,ENPP5,EOMES,EPB41L4A-AS1,EPHA4,EPHX2,EPM2AIP1,EPN2,ERBB2,ERCC6,ERMN,ERMP1,ERN1,ERP27,ESPNL,ESYT2,ETS1,EXD2,EXOSC2,EXOSC7,EXOSC8,EXTL2,EZH1,FABP7P1,FAF1,FAHD2A,FCMR,FALEC,RFLNB,EEIG1,FAM107B,FAM110C,RETREG1,FAM153A,FAM161A,FAM162A,FAM168B,FAM169A,FAM171B,ATPSCKMT,TOGARAM1,FAM184A,FAM185A,ATOSA,FAM216A,FAM217B,FAM218A,FAM219B,FAM3D,FAM43A,MINDY2,FAM66B,FAM66C,DIPK1A,FAM98B,FAN1,FANCD2,FANCG,FAT4,FAUP1,FBXL13,FBXL17,FBXL20,FBXL4,FBXO25,FBXO3,FBXO32,FBXO47,FBXW2,FCGBP,FCHO1,FEZ1,FGF7,FGF9,FGFBP2,FGFBP3,CEP43,FGGY,FIGNL1,FILIP1L,FITM2,FKBP14,FKTN,FLNB,FNBP1P1,FOCAD,FOXO1,FOXP1,FRA10AC1,FRMPD3,FSBP,FTX,FUT8,FYN,FZD3,GAB3,GABPB1-AS1,GALNT12,GALNT14,GALNT7,GAN,GAS5,GATA3,GCFC2,GCHFR,GCNT4,GDF11,GEMIN8,GFI1,GGT8P,GINS4,GJB6,GK5,GKN2,GLCCI1,GLIS3,GLMN,GLS2,NOP53,GMCL1,GNG2,GNPDA2,GOLGA2P5,GOLGA6L9,GOLGA7B,GOLGA8A,GOLGA8B,GOLGA8O,GOLGA8Q,GOLGA8R,GOLGA8S,GPA33,GPAM,GPATCH11,GPCPD1,GPD1L,ADGRA3,ADGRD1,GPR174,GPR183,GPR27,GPR34,ADGRG1,GPRASP1,GPRASP2,GPRIN3,GRAMD1C,GRAMD2B,GRAP,GRIK3,GRPEL2,GSTA4,GSTM2,GTDC1,GTF2IRD2B,GTPBP8,GUF1,GUSBP9,GZMA,GZMK,H1-10-AS1,H2AZ2,HABP4,HACD3,HACE1,HADH,HAGHL,HAVCR1,HCG18,HDAC2,HEATR5A,HELLS,HENMT1,HGSNAT,HIBCH,HIP1R,H1-2,H1-3,H4C5,ZNF875,HLCS,HLF,HLTF,HMOX2,HNRNPA1P5,HNRNPCP1,HNRNPDL,HNRNPH1,HNRNPU,HOOK1,HOPX,HOXB-AS3,HPCAL4,HPGD,HS2ST1,HS3ST3B1,HSF2,HSPBAP1,HSPD1P11,HTRA1,ICA1L,CILK1,ICOS,ID2,IDS,IER5L,IFFO2,IFNG-AS1,IFT172,IFT27,IFT57,IFT80,IFT88,IGHV1OR15-1,IGHVII-28-1,IGIP,IGLV3-9,ELP1,IKZF2,IKZF5,IL16,IL1RL1,IL23A,IL32,IL7R,CXCL8,IL9R,IMMP2L,IMP3,IMPA2,IMPDH2,IMPG2,PATJ,ING2,INPP4A,INPP4B,INPP5A,INPP5B,INSC,INTS2,IPO11,IPP,IQCC,IQCH-AS1,IRGM,IRS2,ISM1,ITGA6,ITGB4,ITK,ITM2A,ITPKB,IVD,IVNS1ABP,JAKMIP2,JMY,JUN,KAT6B,KATNAL1,KAZN,KBTBD11,KBTBD6,KCNQ5,,KCTD7,POGLUT2P1,KDM3A,KDM5B,KHK,KIAA0319,KIAA0586,KIAA0753,MACF1,MATCAP2,MINAR1,PHF24,BTBD8,CEP126,CCDC191,CFAP97,GPALPP1,MFSD4B,KIF21A,KIF22,KIF27,KIF2A,KIF3A,KIF5C,KIFAP3,KIT,KLF12,KLF3,KLF7-IT1,KLF8,KLF8P1,KLHDC1,KLHDC2,KLHL13,KLHL22,KLHL3,KLHL31,KLHL32,KLHL36,KLHL42,KLHL7,KLRA1P,KLRB1,KLRC1,KLRC2,KLRC3,KLRC4-KLRK1,KLRD1,KLRF1,KLRG1,KLRK1,KPNA1,KRT18P37,KRT36,KRT72,KRT73,KRT8P33,KRT8P34,KRT8P42,LAMA2,LANCL1,LARP4P,LAX1,LCK,LCN12,LDHB,LDLRAD4,LDLRAP1,LEF1,LEF1-AS1,LEKR1,LEP,P3H4,LGR6,LIAS,LIMA1,LINC00205,PIRAT1,LINC00243,LINC00299,LINC00342,LINC00402,LINC00426,LINC00469,ERCC6L2-AS1,SWINGN,LINC00662,LINC00671,LINC00680,LINC00683,LINC00861,LINC00920,LINC00987,LINC01550,LINC01619,LINC02210,LIPT2,LIX1L,LLGL2,LMLN,LMO7,BORCS5,LONP2,LPCAT1,LRBA,LRCH1,LRIG1,LRP1B,LRP2BP,LRP6,LRRC7,LRRN3,LSM11,LTK,LUC7L,LUC7L3,LY9,LYPLAL1,LYRM7,LYVE1,LZTFL1,LZTS2,MACF1,MAGEE1,MAGEF1,MAGEH1,MAL,MANSC1,MAP3K2,MAP3K4,MAP9,MAPK13,MAPK8,MAST4,MATK,MBIP,MBLAC2,MBNL2,MBTD1,MCEE,MCM3AP-AS1,MCM6,MCM8,ME1,MED28P1,MEGF6,METAP1,METTL24,MEX3C,MFGE8,MGAT4A,MGAT5,MIAT,MICU3,MID2,MIR146A,MIR17HG,MIR181A2HG,MIR202,MIR4473,MIR4637,MIR4720,MIR4779,MIR491,MIR598,MRTFB,MKRN2,MLH3,MLLT3,MME,MMP23B,MMP9,MMS22L,MNAT1,MOAP1,MORN3,MORN4,MPHOSPH9,MPPE1,MPRIP,MPZL3,MRE11,MRI1,MRPL46,MRPS31,MRPS6,MRS2,IRAG1,IRAG1-AS1,MSANTD2,MSH2,MSH3,MSI2,MST1P2,MTA3,MTAP,MTBP,MTERF4,MTERF2,TESMIN,MTMR2,MTUS2,MTX3,MYB,MYBL1,MYC,MYO16-AS1,MYO5A,MYO9A,MZT2A,N4BP2,N4BP3,N6AMT1,NAA16,NAA30,NAA35,NADK2,NAE1,NAF1,NAP1L1,NAP1L2,NAP1L3,NAPEPLD,ICE2,NARS2,NBEA,NBPF1,NBPF15,NBPF3,NCALD,NCR1,NCR3LG1,NDRG2,NDRG3,NDUFAF6,NDUFAF7,NECAB2,NEK11,NEK6,NELL2,NEO1,NEXMIF,NFATC2,NIPA1,NIPSNAP3B,NISCH,NKTR,NLRC3,NLRP12,NME6,NMT2,NMUR1,NOG,CCN3,NPAS2,NPAT,NPHP3,NPM1P9,NPRL2,NR1D2,NR2C1,NR3C2,NRCAM,NRXN1,NSG1,NSUN5P1,NSUN5P2,NSUN7,NT5DC1,NUBPL,NUCB2,NUCKS1,NUDT13,NUDT3,NUDT6,NUMA1,OCIAD2,OCM,ODF2L,OFD1,OGT,OR10J2P,OR2A9P,OR2L5,OR9A3P,ORMDL1,OSBPL3,OSGEPL1,OSGEPL1-AS1,OSTCP8,OTUD3,OVGP1,OXCT1,OXNAD1,PA2G4P4,PABPC1,PABPC4,PACS1,PADI4,PAFAH2,PAIP2B,PANK1,PANX2,PARD6A,PARD6B,PRKN,PARP16,PARP2,PASK,PAXBP1,PCBP4,PCED1B,PCID2,PCM1,PCMTD2,PCNX1,PCNX2,PCNX4,PCYOX1,PDE3B,PDE4D,PDE4DIP,PDE7A,PDGFD,PDP2,NHERF4,PDZD8,PEBP1,PECR,PEG10,PEX1,PEX5,PGAP2,PGM2,PGM2L1,PGM3,PGPEP1,PHACTR1,PHF10,PHF14,JADE1,PHLDA1,PHLDB2,PHOSPHO2,PIAS2,PIBF1,PIGK,PIGL,PIGP,PIK3IP1,PIK3R1,PITPNC1,PKIA,PKIB,PLAG1,PLAU,PLB1,PLCB1,PLCD1,PLCH2,PLCL1,PLCXD2,PLD1,PLEKHA1,PLEKHA5,PLEKHB1,PLEKHF1,PLEKHM3,KIZ,PLXND1,PM20D2,PMFBP1,PMS1,PNMA1,PODXL2,POLG2,POLH,POLR1E,POLR3B,POMT1,PON2,POU6F1,PPARA,PPARGC1A,PPIAL4A,PPIAL4D,PPIAL4G,PPIAP30,PPIP5K1,PPM1H,PPP1R12B,PPP1R13B,PPP2R2B,PPP3CA,PPP3CC,PPP4R4,PPWD1,PREPL,PRKAB2,PRKACB,PRKCA,PRKCH,PRKCQ,PRKCQ-AS1,PRKCZ,PRKDC,PRKG2,PRMT9,PRMT7,PROCR,PROK2,PROX2,PRPF38B,PRPF39,PRPSAP1,PRSS23,PRSS30P,PSIP1,PSMG3-AS1,PTBP2,PTCH1,PTDSS2,PTGDR,PTGFRN,PTPDC1,HACD2,PTPN22,PTPN4,PTS,PURA,PXK,PYHIN1,PYROXD2,RAB33A,RAB39B,RAB40B,RAD1,RAD23BP1,RAD51-AS1,RAD54B,RALA,RALGAPA1,RANBP2,RANP8,RAP1GDS1,RAPGEF6,RARS2,RASA2,RASA3,RASGRF2,RASGRP1,RASSF1,RBBP4P1,RBFADN,RBFOX2,RBKS,RBL2,RBM26,RBM28,RCAN3,RCN2,RCOR3,RDH16,RECK,REPS1,REST,REV1,REV3L,RFC4,RFX3,RFX7,RFXAP,RGPD3,RGPD5,RGPD6,RGPD8,RGS14,RHOT1P1,RIC3,RIC8B,RLN1,RLN2,RN7SKP110,RN7SKP198,RN7SKP97,RNF103,RNF125,RNF141,RNF157,RNF157-AS1,RNF216,RNF216P1,RNF43,RNGTT,RNU1-109P,RNU1-16P,RNU1-22P,RNU4ATAC16P,RNU6-1,RNU6-1005P,RNU6-1240P,RNU6-1284P,RNU6-1305P,RNU6-202P,RNU6-414P,RNU6-759P,RNU6-820P,RNU6-821P,RNU6-838P,RNU6-878P,RNU7-113P,RNU7-130P,RNU7-90P,RNVU1-15,RO60,RORA,RP9,RPAIN,RPAP2,RPGRIP1,RPGRIP1L,RPH3A,RPL13,RPL13A,RPL13AP20,RPL13AP25,RPL13AP5,RPL14,RPL23A,RPL23AP53,RPL3,RPL34-DT,RPL35AP19,RPL35AP26,RPL37,RPL3P4,RPL4,RPL4P1,RPL5,RPRD2,RPS20,RPS3,RPS3AP34,RPS6,RPS6KA3,RRAS2,RRH,RRM1,RRM2P3,RRN3P1,RRP8,RSBN1,RTL6,RTTN,RUBCNL,RUFY2,RUNX2,RWDD2A,RWDD3,RYK,S100A2,S100PBP,S1PR1,S1PR4,S1PR5,SACS,SAMD10,SAMD12,SAMD13,SAMD3,SATB1,SBDSP1,SBNO1,SCAI,SCAND2P,SCARNA11,SCARNA17,SCARNA6,SCRN2,SDC2,SDHAP3,SDR42E1,SEC22C,SEC61A2,SEC63,SEL1L3,SEMA4C,SEMA4F,SEPTIN7P2,SERF1A,SERF1B,SERGEF,SERINC5,SERTAD2,SESN1,SETD6,SETP16,SETP20,SFI1,SFMBT1,SFT2D3,SFXN1,SFXN5,SGK1,,SGSM2,SH2D1A,SH3BP5,SH3RF3,SH3YL1,SHF,SHPRH,SIAH1,SIM1,SIRPG,SKAP1,SKI,SKP2,SLAIN1,SLAMF6,SLC12A2,SLC16A1,SLC16A10,SLC16A14,SLC16A7,SLC19A2,SLC25A29,SLC25A36,SLC25A40,SLC25A53,SLC26A11,SLC35B4,SLC35D1,SLC35E2B,SLC35G1,SLC38A1,SLC39A10,SLC41A1,SLC4A10,SLC4A4,SLC4A7,SLC5A3,SLC7A6,SLC9B2,SLCO4C1,SMARCA2,MIEF2,SMIM8,SMKR1,SMURF2,SMYD3,SMYD4,SNCG,SNHG1,SNHG10,SNHG14,SNHG6,SNORA31,SNORA17B,SNORD108,SNORD109A,SNORD116-21,SNORD11B,SNORD64,,SNORD91B,SNRNP48,SNRPFP1,SNRPN,SNTB2,SNURF,SNX18,SNX25,SNX9,SOCS5,SOX4,SPAG16,SPATA41,SPATA5,SPATA6L,SPATA7,SPEF2,SPG7,SPICE1,SPIN1,SPINT1,SPOCK1,SPOCK2,SPON1,SPP1,SPRED1,SPTAN1,SPTBN1,SPTSSB,SREK1,SRGAP3,SRPK2,SRSF11,SSBP2,SSH1,ST18,ST6GALNAC6,ST8SIA1,STAG1,STAG3L1,STAG3L2,STAG3L3,STARD13,STARD9,STAT4,STAU2,STK39,STMN3,STRBP,STXBP1,STXBP4,STXBP5,STXBP5-AS1,SUGP2,SUGT1P3,SULT1A2,SULT1B1,SUN1,SUN2,SUPT3H,KMT5B,SYCP2,SYDE2,SYNE1,SYTL1,SYTL2,TACC3,TADA2B,TANC2,TARBP1,TARS3,TAS2R10,,TAS2R30,TAS2R40,TASP1,TBC1D10C,TBC1D19,TBC1D32,TBC1D4,TBC1D7,TBCD,TBL1XR1,TBX21,TC2N,TCEA3,TCF19,TCF7,TCFL5,DYNLT2,TDP1,TDRD15,TDRD3,TDRKH,TEF,TENM1,TESPA1,TET1,TEX30,TGDS,TGFA,TGFBR3,TGIF1,TGM3,THADA,THBD,THEM4,THEMIS,THNSL1,THOC1,THOC3,THRA,TIAL1,TIGIT,TIMD4,TJP3,TKTL1,TLE1,TM6SF1,TM7SF3,TMC2,TMC8,TMCO3,TMEM107,TMEM116,TMEM117,TMEM14A,TMEM161B,TMEM161B-DT,TMEM168,TMEM181,TMEM185A,NEMP1,NEMP2,TMEM204,TMEM245,TMEM25,TMEM41B,TMEM45B,TMEM67,TMEM91,TMIGD1,TMIGD2,TMSB15B,TMX4,TNNC1,TNPO1P1,TNRC6C,TMC6,TOB1,TOM1L2,TOP2B,TOX,TP53INP1,TP73-AS1,TPD52,TPP2,TPRG1,TRABD2A,TRAF1,TRAF3IP3,TRAF5,TRAJ1,TRAJ10,TRAJ12,TRAJ14,TRAJ16,TRAJ17,TRAJ18,TRAJ19,TRAJ20,TRAJ21,TRAJ22,TRAJ23,TRAJ24,TRAJ26,TRAJ27,TRAJ29,TRAJ31,TRAJ33,TRAJ38,TRAJ39,TRAJ4,TRAJ40,TRAJ47,TRAJ48,TRAJ5,TRAJ50,TRAJ51,TRAJ52,TRAJ55,TRAJ56,TRAJ57,TRAJ6,TRAJ8,TRAJ9,TRAT1,TRAV12-1,TRAV12-3,TRAV16,TRAV18,TRAV22,TRAV3,TRAV38-2DV8,TRAV4,TRAV5,TRBV23-1,TRBV5-3,TRBV6-1,TRBV7-1,TRDD3,TRDMT1,TRGJ2,TRGJP,TRGJP1,TRGJP2,TRGV10,TRIM16,TRIM32,TRIM37,TRIM52,TRIM59,TRIM60P18,TRIM9,TRIT1,TRMT13,TRMT61B,TRPC1,TRPM6,TSEN2,TSGA10,TSHZ1,TSPAN6,TSPYL2,TSPYL4,TSTD1,TSTD3,TTC12,TTC13,TTC23L,TTC28,TTC28-AS1,TTC3,TTC5,TTC8,TTC9,TTLL5,TUBE1,TUBGCP3,TUBGCP4,TUBGCP5,TULP4,TXK,TXNRD3,TYW5,UAP1,UBA5,UBE2Q2P1,UBE2Q2P2,UBE3D,UBR3,UBTF,UBXN7,UFSP2,ULK4,UNC119B,UNC45B,UNG,UPB1,UPF3A,URGCP,URI1,USP12-DT,USP13,USP44,USP45,USP47,USP48,USP53,UXS1,VAMP4,VAPB,VEZT,VIPR1,VN1R82P,VNN1,VPS13A,VPS26AP1,VPS26B,VPS51,VSIG1,VWA8,WDR19,WDR27,WDR3,WDR33,WDR35,CFAP44,WDR54,WDR76,WDR86-AS1,WDR91,WEE1,WNT7A,WWOX,WWP1,XCR1,XKR6,XKRX,XPA,XPC,XYLT1,YAE1,YAF2,YAP1P1,YES1,YLPM1,YPEL1,PTGR3,ZAP70,ZBED4,ZBTB1,ZBTB10,ZBTB14,ZBTB16,ZBTB20,ZBTB25,ZBTB38,ZBTB4,ZBTB40,ZBTB44,ZBTB5,ZC3H6,ZC3H8,TUT4,ZCCHC14,ZCCHC18,ZDBF2,ZDHHC20P1,ZEB1,ZFAND1,ZFP14,ZFP2,ZFP28,ZFP30,ZFP62,ZFYVE9,ZHX3,ZKSCAN7,ZMAT1,ZMAT3,ZMYM2,ZMYND11,ZNF10,ZNF101P2,ZNF138,ZNF154,ZNF157,ZNF17,ZNF182,ZNF204P,ZNF232,ZNF234,ZNF235,ZNF248,ZNF250,ZNF251,ZNF253,ZNF254,ZNF256,ZNF26,ZNF264,ZNF266,ZNF280D,ZNF285,ZNF286A,ZNF286B,ZNF30,ZNF304,ZNF318,ZNF326,ZNF329,ZNF331,ZNF337,ZNF33B,ZNF343,ZNF345,ZNF354B,ZNF354C,ZNF37BP,ZNF382,ZNF398,ZNF416,ZNF420,ZNF425,ZNF426,ZNF43,ZNF433,ZNF439,ZNF44,ZNF443,ZNF445,ZNF449,ZNF461,ZNF483,ZNF484,ZNF497,ZNF502,ZNF506,ZNF507,ZNF510,ZNF514,ZNF519,ZNF527,ZNF528,ZNF529,ZNF530,ZNF540,ZNF544,ZNF546,ZNF548,ZNF549,ZNF550,ZNF551,ZNF554,ZNF558,ZNF559,ZNF561,ZNF566,ZNF567,ZNF568,ZNF569,ZNF570,ZNF571,ZNF573,ZNF577,ZNF584,ZNF585B,ZNF589,ZNF599,ZNF600,ZNF605,ZNF607,ZNF608,ZNF615,ZNF616,ZNF623,ZNF630,ZNF649,ZNF660,ZNF662,ZNF671,ZNF681,ZNF69,ZNF699,ZNF7,ZNF71,ZNF718,ZNF721,ZNF737,ZNF746,ZNF767P,ZNF780A,ZNF780B,ZNF781,ZNF786,ZNF789,ZNF792,ZNF793,ZNF799,ZNF805,ZNF815P,ZNF823,ZNF827,ZNF829,ZNF831,ZNF835,ZNF839,ZNF84,ZNF846,ZNF85,ZNF850,ZNF852,ZNF862,ZNF891,ZNF90,ZNHIT6,POLR1HASP,ZNRF3,ZSCAN18,ZSCAN2,ZSCAN30,ZXDC,ZYG11B,ZZZ3",1892,"A2M-AS1,AAK1,AASDH,ABAT,ABCA10,ABCA17P,ABCA3,ABCA5,ABCA6,ABCB1,ABCC5,ABCD2,ABCG1,ABHD17C,ABI2,ABLIM1,ACACB,ACAD11,ACAD8,ACADSB,ACBD6,ACP6,ACPL2,ACVR2A,ACVR2B,ACYP1,ADAM19,ADAM1A,ADAM22,ADAM23,ADAMTS1,ADAMTS10,ADAMTS5,ADAT2,ADCK3,ADCY9,ADD3,ADHFE1,ADK,ADNP,ADSSL1,AEBP2,AGAP1,AGAP12P,AGFG2,AGL,AGO1,AGO2,AGO3,AGTPBP1,AHCTF1,AHI1,AJAP1,AK3,AK5,AKAP11,AKR1B1,AKT3,AKTIP,ALDH6A1,ALDH7A1,ALG10,ALG13,ALG1L13P,ALG6,ALMS1-IT1,ALOX12B,ALOX12P2,ALS2,AMDHD1,AMIGO1,AMOT,AMPD3,AMY2B,ANAPC1,ANGPT1,ANKAR,ANKEF1,ANKLE2,ANKRD18A,ANKRD20A5P,ANKRD26,ANKRD26P4,ANKRD28,ANKRD31,ANKRD36,ANKRD36B,ANKRD36C,ANKRD46,ANKRD55,ANKRD6,ANKS6,ANKZF1,ANO10,ANTXRLP1,AP3M2,APBA2,APBB1,APCDD1,APMAP,APPL2,ARGLU1,ARHGAP10,ARHGAP12,ARHGAP15,ARHGAP35,ARHGEF7,ARHGEF9,ARID2,ARL10,ARL14EP,ARL3,ARL4C,ARL5A,ARL6,ARMC2,ARMCX4,ARMCX5,ARSG,ARSK,ASAH2B,ASB1,ASF1A,ASF1B,ASPH,ASTE1,ATE1,ATF7IP,ATF7IP2,ATG16L1,ATG2B,ATG9B,ATL2,ATM,ATP2B4,ATP6V0A2,ATP6V0E2-AS1,ATP8A1,ATP8A2,ATP8B2,ATPIF1,ATXN1,AUH,AUTS2,AXIN1,B3GALT2,B3GALTL,B3GNT1,B4GALT6,BAAT,BACH2,BAG2,BBS1,BBS10,BBS2,BBS4,BBS9,BCKDHB,BCL11B,BCL2,BCR,BDH2,BDNF-AS,BEND7,BFSP1,BHLHB9,BHLHE40-AS1,BICD1,BIN1,BIVM,BLM,BMS1P4,BNC2,BOK-AS1,BRD1,BRI3BP,BRICD5,BRPF3,BRWD1,BTBD7,BTBD8,BTG1,C11orf45,C12orf23,C12orf42,C12orf57,C12orf65,C14orf132,C14orf28,C15orf41,C16orf52,C16orf74,C18orf54,C19orf57,C1orf21,C1orf35,C1QTNF3,C20orf197,C22orf29,C22orf39,C3orf33,C3orf37,C4orf42,C5orf34,C5orf63,C6orf163,C6orf70,C7orf10,C7orf25,C7orf49,C7orf55-LUC7L2,C9orf123,C9orf156,CA4,CA5B,CABIN1,CACHD1,CALCB,CALM1,CAMK2G,CAMK4,CAMSAP1,CAMTA1,CAPN14,CAPN7,CARF,CASD1,CASK,CASP2,CASS4,CATSPERB,CBLB,CBR4,CBX1,CBX7,CBX8,CBY1,CCDC102A,CCDC102B,CCDC104,CCDC125,CCDC136,CCDC14,CCDC141,CCDC152,CCDC153,CCDC171,CCDC41,CCDC57,CCDC58P5,CCDC65,CCDC7,CCDC89,CCDC92,CCL5,CCNB1IP1,CCNJL,CCSER2,CD160,CD1C,CD1E,CD2,CD200R1,CD244,CD247,CD27,CD28,CD3E,CD3G,CD40LG,CD44,CD6,CD8B,CD96,CD99,CDC14A,CDC42BPG,CDH2,CDH26,CDHR3,CDK5R1,CDKN2B,CDNF,CDON,CDR2,CDRT4,CEACAM19,CENPC,CENPV,CEP120,CEP170,CEP170P1,CEP250,CEP290,CEP44,CEP57,CEP68,CEP70,CEP78,CEP85L,CEP95,CERK,CERS4,CFAP70,CFL2,CHCHD6,CHD1L,CHD3,CHD6,CHIC1,CHMP7,CILP,CLDN12,CLEC2D,CLYBL,CMC1,CMSS1,CMTM4,CNIH,CNKSR2,CNNM3,CNOT6,CNPY4,CNTNAP3,CNTNAP3B,COG6,COL13A1,COL5A2,COL6A2,COL9A3,COLEC12,COLGALT2,COPS8,COQ10A,COX10-AS1,COX11,COX19,CPAMD8,CPNE2,CPSF6,CR1,CREB3L4,CREBZF,CRIM1,CROCCP3,CROT,CRTAM,CRY1,CRYGS,CRYZL1,CSGALNACT1,CSRP2BP,CST7,CTNNBIP1,CTPS2,CTSF,CUBN,CUTC,CXCL1,CXCL6,CXCR6,CXorf57,CYBRD1,CYCSP32,CYCSP34,CYFIP2,CYP27A1,CYP2D8P,CYP4F12,CYTH3,DAAM1,DACH1,DANCR,DAPK2,DBF4,DBP,DCAF17,DCHS1,DCP1B,DCUN1D2,DDHD2,DDIT4,DDX12P,DDX20,DDX31,DDX42,DEF6,DEF8,DENND11,DENND2D,DENND4C,DEPDC7,DEPTOR,DGKA,DGKD,DGKE,DGKG,DHRS3,DHRS7,DIP2A,DIRC2,DIS3L,DIXDC1,DKK3,DLEC1,DLEU2L,DLG1,DLG2,DLGAP1-AS1,DLGAP1-AS2,DMAP1,DMKN,DNAH6,DNAJC19,DNAJC21,DNAJC24,DNAJC3-DT,DNAJC9,DNM1P47,DNMBP,DOCK3,DOK4,DPEP2,DPEP3,DPH5,DPH6,DPH7,DPP4,DPY19L2,DPY19L2P1,DPY19L2P2,DPY19L2P4,DPY19L3,DPY19L4,DSC1,DSEL,DSTN,DSTYK,DTD1,DTHD1,DUS2L,DYNC2H1,DYRK2,DZANK1,DZIP3,EDAR,EEF2K,EEPD1,EFCAB5,EFCAB7,EFHC1,EFHC2,EHBP1,EIF3EP1,EIF3F,EIF3J-DT,EIF3L,EIF4B,EIF4BP6,ELAPOR2,ELOVL4,ELP2,EML5,EMR3,EMR4P,ENDOV,ENO2,ENOSF1,ENPP4,ENPP5,EOMES,EPB41L4A-AS1,EPHA4,EPHX2,EPM2AIP1,EPN2,ERBB2,ERCC6,ERMN,ERMP1,ERN1,ERP27,ESPNL,ESYT2,ETS1,EXD2,EXOSC2,EXOSC7,EXOSC8,EXTL2,EZH1,FABP7P1,FAF1,FAHD2A,FAIM3,FALEC,FAM101B,FAM102A,FAM107B,FAM110C,FAM134B,FAM153A,FAM161A,FAM162A,FAM168B,FAM169A,FAM171B,FAM173B,FAM179B,FAM184A,FAM185A,FAM214A,FAM216A,FAM217B,FAM218A,FAM219B,FAM3D,FAM43A,FAM63B,FAM66B,FAM66C,FAM69A,FAM98B,FAN1,FANCD2,FANCG,FAT4,FAUP1,FBXL13,FBXL17,FBXL20,FBXL4,FBXO25,FBXO3,FBXO32,FBXO47,FBXW2,FCGBP,FCHO1,FEZ1,FGF7,FGF9,FGFBP2,FGFBP3,FGFR1OP,FGGY,FIGNL1,FILIP1L,FITM2,FKBP14,FKTN,FLNB,FNBP1P1,FOCAD,FOXO1,FOXP1,FRA10AC1,FRMPD3,FSBP,FTX,FUT8,FYN,FZD3,GAB3,GABPB1-AS1,GALNT12,GALNT14,GALNT7,GAN,GAS5,GATA3,GCFC2,GCHFR,GCNT4,GDF11,GEMIN8,GFI1,GGT8P,GINS4,GJB6,GK5,GKN2,GLCCI1,GLIS3,GLMN,GLS2,GLTSCR2,GMCL1,GNG2,GNPDA2,GOLGA2P5,GOLGA6L9,GOLGA7B,GOLGA8A,GOLGA8B,GOLGA8O,GOLGA8Q,GOLGA8R,GOLGA8S,GPA33,GPAM,GPATCH11,GPCPD1,GPD1L,GPR125,GPR133,GPR174,GPR183,GPR27,GPR34,GPR56,GPRASP1,GPRASP2,GPRIN3,GRAMD1C,GRAMD3,GRAP,GRIK3,GRPEL2,GSTA4,GSTM2,GTDC1,GTF2IRD2B,GTPBP8,GUF1,GUSBP9,GZMA,GZMK,H1FX-AS1,H2AFV,HABP4,HACD3,HACE1,HADH,HAGHL,HAVCR1,HCG18,HDAC2,HEATR5A,HELLS,HENMT1,HGSNAT,HIBCH,HIP1R,HIST1H1C,HIST1H1D,HIST1H4E,HKR1,HLCS,HLF,HLTF,HMOX2,HNRNPA1P5,HNRNPCP1,HNRNPDL,HNRNPH1,HNRNPU,HOOK1,HOPX,HOXB-AS3,HPCAL4,HPGD,HS2ST1,HS3ST3B1,HSF2,HSPBAP1,HSPD1P11,HTRA1,ICA1L,ICK,ICOS,ID2,IDS,IER5L,IFFO2,IFNG-AS1,IFT172,IFT27,IFT57,IFT80,IFT88,IGHV1OR15-1,IGHVII-28-1,IGIP,IGLV3-9,IKBKAP,IKZF2,IKZF5,IL16,IL1RL1,IL23A,IL32,IL7R,IL8,IL9R,IMMP2L,IMP3,IMPA2,IMPDH2,IMPG2,INADL,ING2,INPP4A,INPP4B,INPP5A,INPP5B,INSC,INTS2,IPO11,IPP,IQCC,IQCH-AS1,IRGM,IRS2,ISM1,ITGA6,ITGB4,ITK,ITM2A,ITPKB,IVD,IVNS1ABP,JAKMIP2,JMY,JUN,KAT6B,KATNAL1,KAZN,KBTBD11,KBTBD6,KCNQ5,KCNQ5-IT1,KCTD7,KDELC1P1,KDM3A,KDM5B,KHK,KIAA0319,KIAA0586,KIAA0753,KIAA0754,KIAA0895,KIAA1024,KIAA1045,KIAA1107,KIAA1377,KIAA1407,KIAA1430,KIAA1704,KIAA1919,KIF21A,KIF22,KIF27,KIF2A,KIF3A,KIF5C,KIFAP3,KIT,KLF12,KLF3,KLF7-IT1,KLF8,KLF8P1,KLHDC1,KLHDC2,KLHL13,KLHL22,KLHL3,KLHL31,KLHL32,KLHL36,KLHL42,KLHL7,KLRAP1,KLRB1,KLRC1,KLRC2,KLRC3,KLRC4-KLRK1,KLRD1,KLRF1,KLRG1,KLRK1,KPNA1,KRT18P37,KRT36,KRT72,KRT73,KRT8P33,KRT8P34,KRT8P42,LAMA2,LANCL1,LARP4P,LAX1,LCK,LCN12,LDHB,LDLRAD4,LDLRAP1,LEF1,LEF1-AS1,LEKR1,LEP,LEPREL4,LGR6,LIAS,LIMA1,LINC00205,LINC00211,LINC00243,LINC00299,LINC00342,LINC00402,LINC00426,LINC00469,LINC00476,LINC00565,LINC00662,LINC00671,LINC00680,LINC00683,LINC00861,LINC00920,LINC00987,LINC01550,LINC01619,LINC02210,LIPT2,LIX1L,LLGL2,LMLN,LMO7,LOH12CR1,LONP2,LPCAT1,LRBA,LRCH1,LRIG1,LRP1B,LRP2BP,LRP6,LRRC7,LRRN3,LSM11,LTK,LUC7L,LUC7L3,LY9,LYPLAL1,LYRM7,LYVE1,LZTFL1,LZTS2,MACF1,MAGEE1,MAGEF1,MAGEH1,MAL,MANSC1,MAP3K2,MAP3K4,MAP9,MAPK13,MAPK8,MAST4,MATK,MBIP,MBLAC2,MBNL2,MBTD1,MCEE,MCM3AP-AS1,MCM6,MCM8,ME1,MED28P1,MEGF6,METAP1,METTL24,MEX3C,MFGE8,MGAT4A,MGAT5,MIAT,MICU3,MID2,MIR146A,MIR17HG,MIR181A2HG,MIR202,MIR4473,MIR4637,MIR4720,MIR4779,MIR491,MIR598,MKL2,MKRN2,MLH3,MLLT3,MME,MMP23B,MMP9,MMS22L,MNAT1,MOAP1,MORN3,MORN4,MPHOSPH9,MPPE1,MPRIP,MPZL3,MRE11A,MRI1,MRPL46,MRPS31,MRPS6,MRS2,MRVI1,MRVI1-AS1,MSANTD2,MSH2,MSH3,MSI2,MST1P2,MTA3,MTAP,MTBP,MTERFD2,MTERFD3,MTL5,MTMR2,MTUS2,MTX3,MYB,MYBL1,MYC,MYO16-AS1,MYO5A,MYO9A,MZT2A,N4BP2,N4BP3,N6AMT1,NAA16,NAA30,NAA35,NADK2,NAE1,NAF1,NAP1L1,NAP1L2,NAP1L3,NAPEPLD,NARG2,NARS2,NBEA,NBPF1,NBPF15,NBPF3,NCALD,NCR1,NCR3LG1,NDRG2,NDRG3,NDUFAF6,NDUFAF7,NECAB2,NEK11,NEK6,NELL2,NEO1,NEXMIF,NFATC2,NIPA1,NIPSNAP3B,NISCH,NKTR,NLRC3,NLRP12,NME6,NMT2,NMUR1,NOG,NOV,NPAS2,NPAT,NPHP3,NPM1P9,NPRL2,NR1D2,NR2C1,NR3C2,NRCAM,NRXN1,NSG1,NSUN5P1,NSUN5P2,NSUN7,NT5DC1,NUBPL,NUCB2,NUCKS1,NUDT13,NUDT3,NUDT6,NUMA1,OCIAD2,OCM,ODF2L,OFD1,OGT,OR10J2P,OR2A9P,OR2L5,OR9A3P,ORMDL1,OSBPL3,OSGEPL1,OSGEPL1-AS1,OSTCP8,OTUD3,OVGP1,OXCT1,OXNAD1,PA2G4P4,PABPC1,PABPC4,PACS1,PADI4,PAFAH2,PAIP2B,PANK1,PANX2,PARD6A,PARD6B,PARK2,PARP16,PARP2,PASK,PAXBP1,PCBP4,PCED1B,PCID2,PCM1,PCMTD2,PCNX,PCNXL2,PCNXL4,PCYOX1,PDE3B,PDE4D,PDE4DIP,PDE7A,PDGFD,PDP2,PDZD3,PDZD8,PEBP1,PECR,PEG10,PEX1,PEX5,PGAP2,PGM2,PGM2L1,PGM3,PGPEP1,PHACTR1,PHF10,PHF14,PHF17,PHLDA1,PHLDB2,PHOSPHO2,PIAS2,PIBF1,PIGK,PIGL,PIGP,PIK3IP1,PIK3R1,PITPNC1,PKIA,PKIB,PLAG1,PLAU,PLB1,PLCB1,PLCD1,PLCH2,PLCL1,PLCXD2,PLD1,PLEKHA1,PLEKHA5,PLEKHB1,PLEKHF1,PLEKHM3,PLK1S1,PLXND1,PM20D2,PMFBP1,PMS1,PNMA1,PODXL2,POLG2,POLH,POLR1E,POLR3B,POMT1,PON2,POU6F1,PPARA,PPARGC1A,PPIAL4A,PPIAL4D,PPIAL4G,PPIAP30,PPIP5K1,PPM1H,PPP1R12B,PPP1R13B,PPP2R2B,PPP3CA,PPP3CC,PPP4R4,PPWD1,PREPL,PRKAB2,PRKACB,PRKCA,PRKCH,PRKCQ,PRKCQ-AS1,PRKCZ,PRKDC,PRKG2,PRMT10,PRMT7,PROCR,PROK2,PROX2,PRPF38B,PRPF39,PRPSAP1,PRSS23,PRSS30P,PSIP1,PSMG3-AS1,PTBP2,PTCH1,PTDSS2,PTGDR,PTGFRN,PTPDC1,PTPLB,PTPN22,PTPN4,PTS,PURA,PXK,PYHIN1,PYROXD2,RAB33A,RAB39B,RAB40B,RAD1,RAD23BP1,RAD51-AS1,RAD54B,RALA,RALGAPA1,RANBP2,RANP8,RAP1GDS1,RAPGEF6,RARS2,RASA2,RASA3,RASGRF2,RASGRP1,RASSF1,RBBP4P1,RBFADN,RBFOX2,RBKS,RBL2,RBM26,RBM28,RCAN3,RCN2,RCOR3,RDH16,RECK,REPS1,REST,REV1,REV3L,RFC4,RFX3,RFX7,RFXAP,RGPD3,RGPD5,RGPD6,RGPD8,RGS14,RHOT1P1,RIC3,RIC8B,RLN1,RLN2,RN7SKP110,RN7SKP198,RN7SKP97,RNF103,RNF125,RNF141,RNF157,RNF157-AS1,RNF216,RNF216P1,RNF43,RNGTT,RNU1-109P,RNU1-16P,RNU1-22P,RNU4ATAC16P,RNU6-1,RNU6-1005P,RNU6-1240P,RNU6-1284P,RNU6-1305P,RNU6-202P,RNU6-414P,RNU6-759P,RNU6-820P,RNU6-821P,RNU6-838P,RNU6-878P,RNU7-113P,RNU7-130P,RNU7-90P,RNVU1-15,RO60,RORA,RP9,RPAIN,RPAP2,RPGRIP1,RPGRIP1L,RPH3A,RPL13,RPL13A,RPL13AP20,RPL13AP25,RPL13AP5,RPL14,RPL23A,RPL23AP53,RPL3,RPL34-AS1,RPL35AP19,RPL35AP26,RPL37,RPL3P4,RPL4,RPL4P1,RPL5,RPRD2,RPS20,RPS3,RPS3AP34,RPS6,RPS6KA3,RRAS2,RRH,RRM1,RRM2P3,RRN3P1,RRP8,RSBN1,RTL6,RTTN,RUBCNL,RUFY2,RUNX2,RWDD2A,RWDD3,RYK,S100A2,S100PBP,S1PR1,S1PR4,S1PR5,SACS,SAMD10,SAMD12,SAMD13,SAMD3,SATB1,SBDSP1,SBNO1,SCAI,SCAND2P,SCARNA11,SCARNA17,SCARNA6,SCRN2,SDC2,SDHAP3,SDR42E1,SEC22C,SEC61A2,SEC63,SEL1L3,SEMA4C,SEMA4F,SEPT7P2,SERF1A,SERF1B,SERGEF,SERINC5,SERTAD2,SESN1,SETD6,SETP16,SETP20,SFI1,SFMBT1,SFT2D3,SFXN1,SFXN5,SGK1,SGK223,SGSM2,SH2D1A,SH3BP5,SH3RF3,SH3YL1,SHF,SHPRH,SIAH1,SIM1,SIRPG,SKAP1,SKI,SKP2,SLAIN1,SLAMF6,SLC12A2,SLC16A1,SLC16A10,SLC16A14,SLC16A7,SLC19A2,SLC25A29,SLC25A36,SLC25A40,SLC25A53,SLC26A11,SLC35B4,SLC35D1,SLC35E2B,SLC35G1,SLC38A1,SLC39A10,SLC41A1,SLC4A10,SLC4A4,SLC4A7,SLC5A3,SLC7A6,SLC9B2,SLCO4C1,SMARCA2,SMCR7,SMIM8,SMKR1,SMURF2,SMYD3,SMYD4,SNCG,SNHG1,SNHG10,SNHG14,SNHG6,SNORA31,SNORA43,SNORD108,SNORD109A,SNORD116-21,SNORD11B,SNORD64,SNORD74,SNORD91B,SNRNP48,SNRPFP1,SNRPN,SNTB2,SNURF,SNX18,SNX25,SNX9,SOCS5,SOX4,SPAG16,SPATA41,SPATA5,SPATA6L,SPATA7,SPEF2,SPG7,SPICE1,SPIN1,SPINT1,SPOCK1,SPOCK2,SPON1,SPP1,SPRED1,SPTAN1,SPTBN1,SPTSSB,SREK1,SRGAP3,SRPK2,SRSF11,SSBP2,SSH1,ST18,ST6GALNAC6,ST8SIA1,STAG1,STAG3L1,STAG3L2,STAG3L3,STARD13,STARD9,STAT4,STAU2,STK39,STMN3,STRBP,STXBP1,STXBP4,STXBP5,STXBP5-AS1,SUGP2,SUGT1P3,SULT1A2,SULT1B1,SUN1,SUN2,SUPT3H,SUV420H1,SYCP2,SYDE2,SYNE1,SYTL1,SYTL2,TACC3,TADA2B,TANC2,TARBP1,TARSL2,TAS2R10,TAS2R12,TAS2R30,TAS2R40,TASP1,TBC1D10C,TBC1D19,TBC1D32,TBC1D4,TBC1D7,TBCD,TBL1XR1,TBX21,TC2N,TCEA3,TCF19,TCF7,TCFL5,TCTE3,TDP1,TDRD15,TDRD3,TDRKH,TEF,TENM1,TESPA1,TET1,TEX30,TGDS,TGFA,TGFBR3,TGIF1,TGM3,THADA,THBD,THEM4,THEMIS,THNSL1,THOC1,THOC3,THRA,TIAL1,TIGIT,TIMD4,TJP3,TKTL1,TLE1,TM6SF1,TM7SF3,TMC2,TMC8,TMCO3,TMEM107,TMEM116,TMEM117,TMEM14A,TMEM161B,TMEM161B-AS1,TMEM168,TMEM181,TMEM185A,TMEM194A,TMEM194B,TMEM204,TMEM245,TMEM25,TMEM41B,TMEM45B,TMEM67,TMEM91,TMIGD1,TMIGD2,TMSB15B,TMX4,TNNC1,TNPO1P1,TNRC6C,TNRC6C-AS1,TOB1,TOM1L2,TOP2B,TOX,TP53INP1,TP73-AS1,TPD52,TPP2,TPRG1,TRABD2A,TRAF1,TRAF3IP3,TRAF5,TRAJ1,TRAJ10,TRAJ12,TRAJ14,TRAJ16,TRAJ17,TRAJ18,TRAJ19,TRAJ20,TRAJ21,TRAJ22,TRAJ23,TRAJ24,TRAJ26,TRAJ27,TRAJ29,TRAJ31,TRAJ33,TRAJ38,TRAJ39,TRAJ4,TRAJ40,TRAJ47,TRAJ48,TRAJ5,TRAJ50,TRAJ51,TRAJ52,TRAJ55,TRAJ56,TRAJ57,TRAJ6,TRAJ8,TRAJ9,TRAT1,TRAV12-1,TRAV12-3,TRAV16,TRAV18,TRAV22,TRAV3,TRAV38-2DV8,TRAV4,TRAV5,TRBV23-1,TRBV5-3,TRBV6-1,TRBV7-1,TRDD3,TRDMT1,TRGJ2,TRGJP,TRGJP1,TRGJP2,TRGV10,TRIM16,TRIM32,TRIM37,TRIM52,TRIM59,TRIM60P18,TRIM9,TRIT1,TRMT13,TRMT61B,TRPC1,TRPM6,TSEN2,TSGA10,TSHZ1,TSPAN6,TSPYL2,TSPYL4,TSTD1,TSTD3,TTC12,TTC13,TTC23L,TTC28,TTC28-AS1,TTC3,TTC5,TTC8,TTC9,TTLL5,TUBE1,TUBGCP3,TUBGCP4,TUBGCP5,TULP4,TXK,TXNRD3,TYW5,UAP1,UBA5,UBE2Q2P1,UBE2Q2P2,UBE3D,UBR3,UBTF,UBXN7,UFSP2,ULK4,UNC119B,UNC45B,UNG,UPB1,UPF3A,URGCP,URI1,USP12-AS2,USP13,USP44,USP45,USP47,USP48,USP53,UXS1,VAMP4,VAPB,VEZT,VIPR1,VN1R82P,VNN1,VPS13A,VPS26AP1,VPS26B,VPS51,VSIG1,VWA8,WDR19,WDR27,WDR3,WDR33,WDR35,WDR52,WDR54,WDR76,WDR86-AS1,WDR91,WEE1,WNT7A,WWOX,WWP1,XCR1,XKR6,XKRX,XPA,XPC,XYLT1,YAE1D1,YAF2,YAP1P1,YES1,YLPM1,YPEL1,ZADH2,ZAP70,ZBED4,ZBTB1,ZBTB10,ZBTB14,ZBTB16,ZBTB20,ZBTB25,ZBTB38,ZBTB4,ZBTB40,ZBTB44,ZBTB5,ZC3H6,ZC3H8,ZCCHC11,ZCCHC14,ZCCHC18,ZDBF2,ZDHHC20P1,ZEB1,ZFAND1,ZFP14,ZFP2,ZFP28,ZFP30,ZFP62,ZFYVE9,ZHX3,ZKSCAN7,ZMAT1,ZMAT3,ZMYM2,ZMYND11,ZNF10,ZNF101P2,ZNF138,ZNF154,ZNF157,ZNF17,ZNF182,ZNF204P,ZNF232,ZNF234,ZNF235,ZNF248,ZNF250,ZNF251,ZNF253,ZNF254,ZNF256,ZNF26,ZNF264,ZNF266,ZNF280D,ZNF285,ZNF286A,ZNF286B,ZNF30,ZNF304,ZNF318,ZNF326,ZNF329,ZNF331,ZNF337,ZNF33B,ZNF343,ZNF345,ZNF354B,ZNF354C,ZNF37BP,ZNF382,ZNF398,ZNF416,ZNF420,ZNF425,ZNF426,ZNF43,ZNF433,ZNF439,ZNF44,ZNF443,ZNF445,ZNF449,ZNF461,ZNF483,ZNF484,ZNF497,ZNF502,ZNF506,ZNF507,ZNF510,ZNF514,ZNF519,ZNF527,ZNF528,ZNF529,ZNF530,ZNF540,ZNF544,ZNF546,ZNF548,ZNF549,ZNF550,ZNF551,ZNF554,ZNF558,ZNF559,ZNF561,ZNF566,ZNF567,ZNF568,ZNF569,ZNF570,ZNF571,ZNF573,ZNF577,ZNF584,ZNF585B,ZNF589,ZNF599,ZNF600,ZNF605,ZNF607,ZNF608,ZNF615,ZNF616,ZNF623,ZNF630,ZNF649,ZNF660,ZNF662,ZNF671,ZNF681,ZNF69,ZNF699,ZNF7,ZNF71,ZNF718,ZNF721,ZNF737,ZNF746,ZNF767,ZNF780A,ZNF780B,ZNF781,ZNF786,ZNF789,ZNF792,ZNF793,ZNF799,ZNF805,ZNF815P,ZNF823,ZNF827,ZNF829,ZNF831,ZNF835,ZNF839,ZNF84,ZNF846,ZNF85,ZNF850,ZNF852,ZNF862,ZNF891,ZNF90,ZNHIT6,ZNRD1ASP,ZNRF3,ZSCAN18,ZSCAN2,ZSCAN30,ZXDC,ZYG11B,ZZZ3",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Fig 4C-D,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763735/figure/fig04/,NA,NA,NA,NA
M40880,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_ADDNL_EXON_LVL_UP,VIRUS,UP,OTHER,EXON ANALYSIS,D1,D,1,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_ADDNL_EXON_LVL_UP,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 1D. Comment: Additional genes induced by MRKAd5 in vivo and in vitro, identified by exon-level analysis","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ACSL5,APOBEC3F,APOBEC3G,ARAP2,ARHGEF3,BMAL2,ATP10A,ATP10D,ATXN7,BCL2L14,BRCA2,C1GALT1,CARM1,CARS1,CASZ1,CCR5,CD74,CDK18,CHI3L1,CLIC4,CPEB2,CSF1,DENND1B,DESI1,DGLUCY,DISC1,DOCK8,ENPP2,PABIR3,FANCA,FARP2,FMR1,FNDC3A,GART,GBP6,GBP7,GCNT2,GIMAP5,GRIN3A,GRIPAP1,HDX,HESX1,HEXD,HIRA,HPS5,HSD3B7,IL31RA,LATS2,LCP2,LONRF1,LRRCC1,LYNX1,MCL1,MTMR11,N4BP2L1,NCOA7,NFIX,NIBAN1,NLRC5,P2RY14,PANK2,PANX1,PCGF5,PFKP,PGAP1,PLAA,PPP2R2A,PRICKLE1,PRKAG2,PRLR,PTK2B,RABGAP1L,RANGAP1,RAP1GAP2,RELB,RERE,RIPK1,RRBP1,SETX,SLC25A22,SPATA13,SRBD1,TEP1,TLR3,TMTC1,TNK2,TRIM34,TRIM6,TRPC4AP,UBE2Z,UVRAG,YEATS2,ZNF618,ZNRF2",94,"ACSL5,APOBEC3F,APOBEC3G,ARAP2,ARHGEF3,ARNTL2,ATP10A,ATP10D,ATXN7,BCL2L14,BRCA2,C1GALT1,CARM1,CARS1,CASZ1,CCR5,CD74,CDK18,CHI3L1,CLIC4,CPEB2,CSF1,DENND1B,DESI1,DGLUCY,DISC1,DOCK8,ENPP2,FAM122C,FANCA,FARP2,FMR1,FNDC3A,GART,GBP6,GBP7,GCNT2,GIMAP5,GRIN3A,GRIPAP1,HDX,HESX1,HEXDC,HIRA,HPS5,HSD3B7,IL31RA,LATS2,LCP2,LONRF1,LRRCC1,LYNX1,MCL1,MTMR11,N4BP2L1,NCOA7,NFIX,NIBAN1,NLRC5,P2RY14,PANK2,PANX1,PCGF5,PFKP,PGAP1,PLAA,PPP2R2A,PRICKLE1,PRKAG2,PRLR,PTK2B,RABGAP1L,RANGAP1,RAP1GAP2,RELB,RERE,RIPK1,RRBP1,SETX,SLC25A22,SPATA13,SRBD1,TEP1,TLR3,TMTC1,TNK2,TRIM34,TRIM6,TRPC4AP,UBE2Z,UVRAG,YEATS2,ZNF618,ZNRF2",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834766/bin/Table_2.XLSX,NA,NA,NA,NA
M40864,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D1,D,1,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_DN,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes down-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 1D. Comment: Table includes specific cell types","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"AAK1,ABCB1,ABCC5,ABCD2,ABHD14A,ABHD14B,ABI2,ABLIM1,ACADSB,ACO1,ACP6,ACSL6,ACVR2A,ACVR2B,ADAM28,ADGRE3,ADGRG1,ADK,ADNP,ADPRM,AFF3,AGL,AGMAT,AGTPBP1,AHCTF1,AHNAK,AK5,AKR1B1,AKR1C3,AKT3,ALDH18A1,ALDOC,AMY2B,ANAPC1,ANAPC15,ANAPC16,ANKH,ANKRD36B,ANKRD36C,ANP32B,ANXA6,AP3M2,APBA2,APBB1,APEX1,AQP3,ARHGAP12,ARHGAP15,ARHGAP5,ARHGEF9,ARID2,ARL4C,ATF7IP2,ATL2,ATM,ATP2B4,ATP8A1,ATP8B2,ATPSCKMT,AXIN2,BACH2,BAG2,BANK1,BBS2,BBS9,BCKDHB,BCL11B,BCL2,BCL7A,BDH1,BIN1,BLK,BMI1,BPTF,BRWD1,BTG1,BTLA,CFAP68,C12orf57,C12orf75,C14orf28,C16orf74,C1orf21,CA5B,CAD,CAMK1D,CAMK4,CAMLG,CARD11,CASD1,CASK,CASP6,CASP8AP2,CASS4,CBLB,CBX5,CBX7,CCDC7,CCL28,CCL5,CCNB1IP1,CCND2,CCNG1,CCNT1,CCR4,CCR6,CCR7,CCSER2,CD160,CD1C,CD2,CD200,CD200R1,CD22,CD244,CD247,CD248,CD27,CD28,CD3D,CD3E,CD3G,CD40LG,CD44,CD5,CD52,CD6,CD7,CD79A,CD79B,CD8A,CD8B,CD96,CDC14A,CDC14B,CDC25B,CDC42SE2,CDCA7L,CDK6,CDKN2AIP,CDR2,CENPV,CEP120,CEP128,CEP57,CEP68,CEP78,CEP95,CERK,CFAP36,CFAP97,CHD3,CHMP7,CHRM3-AS2,CLEC2D,CLK4,CLSTN3,CMPK1,CNOT6L,CNR2,COBLL1,COMMD6,COQ10A,COX11,CPSF6,CREBZF,CRIM1,CRIPT,CRTAM,CRTC3,CRY1,CRYL1,CSDE1,CSGALNACT1,CSNK1E,CST7,CTC1,CTSF,CTSW,CXCR4,CXCR5,CXXC5,CYFIP2,CYP27A1,CYP2R1,CYREN,DANCR,DCUN1D4,DDHD2,DDX3X,DDX6,DENND11,DENND2D,DENND4C,DGKA,DHRS3,DIPK1A,DIS3L,DLEU1,DLG1,DLGAP1-AS1,DNAJB1,DNAJC24,DOCK9,DPEP2,DPH5,DPP4,DSC1,DTD2,DTHD1,DUSP16,DYRK2,EBF1,EEF1A1,EEF1G,EEF2,EIF2D,EIF2S3,EIF3D,EIF3E,EIF3F,EIF3H,EIF3J-DT,EIF3K,EIF3L,EIF3M,EIF4A2,EIF4B,EIF4EBP2,ELAC1,ELAPOR1,ELP1,ELP2,EMB,ENO2,EOMES,EPB41L4A-AS1,EPHA4,EPHX2,EPRS1,ERGIC3,ERMP1,ERN1,ESYT1,ESYT2,ETS1,EVL,EXOC6B,EXOSC8,EZH1,FAHD2B,EEIG1,FAM107B,FAM168B,FAM169A,FAM172A,ATOSA,FAM219B,FBL,FBXL20,FBXO32,FCER1A,FCGBP,FCMR,FCRL1,FCRL3,FCRL6,FCRLA,FGFBP2,FHIT,FITM2,FLNB,FMNL3,FOCAD,FOXO1,FOXP1,FUT10,FYN,GABPB2,GALNT12,GARRE1,GAS5,GCSAM,GCNT4,GGTA1,GID8,GLCCI1,GNG2,GNG7,GNLY,GNPDA2,GOLPH3L,GPA33,GPATCH11,GPR171,GPR174,GPX7,GRAP,GSTM2,GSTM3,GYPC,GZMA,GZMK,H1-1,H1-2,H1-3,H1-5,H2AC11,H2AC15,H2AC17,H2AC20,H2AC21,H2AC6,H2AC8,H2BC10,H2BC14,H2BC15,H2BC7,H2BC8,H3C1,H3C11,H3C4,H4C1,H4C13,H4C2,H4C3,H4C5,H4C6,H4C8,H4C9,HABP4,HACD3,HADH,HEATR5B,HECTD1,HERC1,HIBADH,HINT1,HIVEP2,HLA-DOA,HLA-DOB,HLA-DQA1,HLTF,HMGB1,HNRNPA3,HPCAL4,HS3ST3B1,HSF2,IARS1,IFFO2,IFT46,IGF1R,IGHD,IGHM,IGHV3-53,IGHV4-34,IKZF2,IKZF3,IL16,IL18RAP,IL23A,IL2RB,IL32,IL7R,IMPDH2,PATJ,INPP4B,INTS6-AS1,IP6K1,IPO5,IPP,ITGA6,ITGB3BP,ITK,ITM2A,ITPKB,KCNA3,KCTD7,KDM3A,KIAA0586,KLF12,KLHDC2,KLHL28,KLRB1,KLRC2,KLRD1,KLRF1,KLRG1,KLRK1,KMT2A,KPNA4,LANCL1,CERS4,LAT,LAX1,LBH,LCK,LCLAT1,LDHB,LDLRAP1,LDOC1,LEF1,LEF1-AS1,LIAS,LIMA1,LINC00402,LINC00649,LINC00861,LINC00920,LINC00921,LINC00938,LINC01128,SLC12A2-DT,LINC01278,LINC01550,LINC02210,LINC02397,LRBA,LRIG1,LRPPRC,LRRN3,LTA4H,LTB,LUC7L3,LY9,LYRM7,MACF1,MAGED1,MAGEH1,MAL,MALAT1,MAML2,MAN1A2,MAP2K5,MAP3K14-AS1,MAP4K1,MAPK13,MARCHF9,MATK,MBLAC2,MBNL2,MDN1,METTL16,MFGE8,MFHAS1,MGAT4A,MGAT5,MIB1,MID2,MRTFB,MPHOSPH9,PALS2,MPRIP,MRPL45,MRPL48,MRPS27,MRPS6,MS4A1,MSH2,MSI2,MTFMT,MYBL1,MYO1D,KAT6B,MZT2A,N4BP2,NAA16,NAA40,NAE1,NAP1L1,NCALD,NCAPD2,NCAPD3,NCK2,NCR1,NDRG2,NDRG3,NDUFAF4,NELL2,NEO1,NEPRO,NET1,NFATC2,NFATC3,NIBAN3,NIPAL3,NKG7,NLRC3,NMT2,NMUR1,NOA1,NOG,NOL4L,NOL9,NOP53,NPAT,NPM1,NR1D1,NR1D2,NR3C2,NSA2,NSG1,NT5DC1,NT5E,NUCB2,NUCKS1,NUP88,OCIAD2,OFD1,OGT,OSBPL10,OTUD3,OXNAD1,P2RX5,P2RY10,PABPC1,PABPC4,PACS1,PAFAH2,PAIP2B,PARP16,PAX5,PBXIP1,PCED1B,PCED1B-AS1,PCID2,PCMTD2,PCNX1,PCNX2,PCYOX1,PDCD4,PDCD4-AS1,PDE3B,PDE4DIP,PDE7A,PDGFC,PDGFD,PDK1,PDZD4,PEBP1,PECR,PET117,PFDN5,PGM2L1,PHB2,PHLPP2,PIAS2,PIGK,PIK3C2B,PIK3IP1,PITPNC1,PLCB1,PLCG1,PLCL1,PLEKHA1,PLEKHB1,PLEKHF1,PLXDC1,PM20D2,PNRC1,POLA1,POLR1E,POLR2B,PP7080,PPIA,PPWD1,PRDX2,PREPL,PRKACB,PRKCA,PRKCH,PRKCQ,PRKCQ-AS1,PRKDC,PRORP,PRPF8,PRPS1,PRRC2B,PRSS23,PSIP1,PTCH1,PTGDR,PTPN22,PTPN4,PWAR5,,PYHIN1,EPRS1,RAB30,RAB39B,RACK1,RALGAPA1,RALGPS2,RAPGEF6,RASA2,RASA3,RASGRF2,RASGRP1,RBBP7,RBL1,RBL2,RBMX,RCAN3,RCL1,RCN2,RECK,REST,RETREG1,RFLNB,RFX7,RGCC,RGMB,RHOF,RHOH,RMRP,RNF125,RNF144A,RNF157,RORA,RPA1,RPL11,RPL12,RPL13,RPL15,RPL17,RPL18,RPL22,RPL23,RPL24,RPL26,RPL27A,RPL29,RPL3,RPL30,RPL32,RPL35,RPL35A,RPL37,RPL37A,RPL4,RPL5,RPL6,RPL8,RPLP0,RPLP1,RPLP2,RPPH1,RPS13,RPS14,RPS15,RPS15A,RPS16,RPS18,RPS19,RPS20,RPS21,RPS23,RPS29,RPS3,RPS4X,RPS4Y1,RPS5,RPS6,RPS6KA3,RRM1,RSL1D1,RSL24D1,S1PR1,SACS,SAMD3,SATB1,SBNO1,SCAI,SCARNA17,SCARNA2,SCARNA5,SCARNA6,SCARNA7,SCML4,SEL1L3,SEMA4C,SEPTIN1,SEPTIN11,SERINC5,SESN1,SESN3,SFMBT1,SFXN1,SH2D1A,SH2D1B,SH3YL1,SIDT1,SIRPG,SIT1,SKAP1,SLA2,SLAIN1,SLAMF6,SLC12A2,SLC16A1,SLC16A10,SLC16A7,SLC25A23,SLC25A29,SLC35E2A,SLC38A1,SLC41A1,SLC4A10,SLC4A7,SLC5A3,SLC7A6,SLC7A8,SLC9A7,SLFN13,SMIM8,SMYD3,SNHG1,SNHG29,SNHG3,SNHG5,SNHG8,SNORA16A,SNORA18,SNORA27,SNORA40,SNORA5A,SNORA6,SNORA61,SNORA68,SNORD101,SNORD104,SNORD116-14,SNORD15A,SNORD15B,SNORD26,,SNORD30,SNORD33,SNORD36C,SNORD4A,SNORD4B,,SNORD57,SNORD59A,SNORD6,SNORD79,SNORD97,SNRNP200,SNX25,SOD1,SORL1,SP4,SPATA5,SPECC1L,SPOCK2,SPTAN1,SPTBN1,SRPK2,SRSF5,SRSF8,SSBP2,ST13,ST3GAL1,ST6GAL1,ST6GALNAC6,STAT4,STK17A,STK39,STXBP5,SUN2,SVIP,SYNE1,SYNRG,TAF9B,TARBP1,TBC1D10A,TBL1XR1,TC2N,TCEA3,TCEAL8,TCF7,TCL1A,TCP11L2,TRBV28,TDP1,TESPA1,TFAP4,TFDP2,TGFBR3,THEM4,THEMIS,THRA,TIGD1,TIGIT,TIMM8A,TKTL1,TLE1,TLR10,TMEM106C,TMEM116,TMEM14A,TMEM156,TMEM168,TMEM181,TMEM204,TMEM97,TNIK,TNRC6C,TOB1,TOP1MT,TOP2B,TOX,TRABD2A,TRAC,TRAF1,TRAF5,TRAJ10,TRAJ11,TRAJ12,TRAJ13,TRAJ14,TRAJ16,TRAJ17,TRAJ18,TRAJ20,TRAJ21,TRAJ22,TRAJ24,TRAJ26,TRAJ27,TRAJ29,TRAJ3,TRAJ30,TRAJ32,TRAJ33,TRAJ34,TRAJ36,TRAJ37,TRAJ38,TRAJ4,TRAJ40,TRAJ41,TRAJ42,TRAJ43,TRAJ45,TRAJ47,TRAJ48,TRAJ5,TRAJ52,TRAJ56,TRAJ57,TRAJ6,TRAJ8,TRAJ9,TRAPPC2,TRAT1,TRAV1-2,TRAV12-1,TRAV12-2,TRAV12-3,TRAV13-1,TRAV13-2,TRAV14DV4,TRAV16,TRAV17,TRAV19,TRAV2,TRAV20,TRAV21,TRAV22,TRAV23DV6,TRAV24,TRAV25,TRAV26-1,TRAV26-2,TRAV27,TRAV29DV5,TRAV3,TRAV35,TRAV38-1,TRAV38-2DV8,TRAV4,TRAV41,TRAV5,TRAV8-1,TRAV8-2,TRAV8-6,TRAV9-2,TRBC2,TRBJ2-1,TRBJ2-2,TRBJ2-4,TRBJ2-5,TRBV10-1,TRBV11-2,TRBV19,TRBV2,TRBV20-1,TRBV24-1,TRBV27,TRBV3-1,TRBV4-2,TRBV5-1,TRBV5-4,TRBV5-6,TRBV6-1,TRBV6-4,TRBV6-5,TRBV9,TRDC,TRDV1,TRDV2,TRG-AS1,TRGC2,TRGJP1,TRGJP2,TRGV2,TRGV3,TRGV8,TRGV9,TRIB2,TRIM32,TRIM52-AS1,TRMT2B,TRMT61B,TSEN54,TSHZ1,TSPAN18,TSPAN3,TSPYL2,TSTD1,TTC3,TTC39C,TXK,UBA2,UBA52,UBASH3A,UBE4B,UBR5,UBTF,UNC119B,URI1,USE1,USP13,USP20,USP34,USP53,UXT,VASH1-AS1,VEGFB,VNN1,VPS13A,VPS51,VSIG1,VWA8,WDCP,WDR54,TBC1D31,WDR89,WEE1,WWP1,XPOT,YAE1,YEATS4,YPEL1,ZAP70,ZBED5-AS1,ZBTB16,ZBTB25,ZBTB44,ZC3H6,TUT4,ZDBF2,ZEB1,ZFAND1,ZFAS1,ZFP1,ZFP36L2,ZFP62,ZFP82,ZFP90,ZIK1,ZKSCAN3,ZMAT3,ZMYND11,ZNF101,ZNF181,ZKSCAN8,ZNF254,ZNF266,ZNF280D,ZNF286A,ZNF292,ZNF32,ZNF329,ZNF337,ZNF33B,ZNF383,ZNF395,ZNF420,ZNF43,ZNF486,ZNF506,ZNF507,ZNF559,ZNF585B,ZNF600,ZNF609,ZNF639,ZNF721,ZNF792,ZNF827,ZNF831,ZNF836,ZNF84,ZNF91,ZNHIT6",1017,"AAK1,ABCB1,ABCC5,ABCD2,ABHD14A,ABHD14B,ABI2,ABLIM1,ACADSB,ACO1,ACP6,ACSL6,ACVR2A,ACVR2B,ADAM28,ADGRE3,ADGRG1,ADK,ADNP,ADPRM,AFF3,AGL,AGMAT,AGTPBP1,AHCTF1,AHNAK,AK5,AKR1B1,AKR1C3,AKT3,ALDH18A1,ALDOC,AMY2B,ANAPC1,ANAPC15,ANAPC16,ANKH,ANKRD36B,ANKRD36C,ANP32B,ANXA6,AP3M2,APBA2,APBB1,APEX1,AQP3,ARHGAP12,ARHGAP15,ARHGAP5,ARHGEF9,ARID2,ARL4C,ATF7IP2,ATL2,ATM,ATP2B4,ATP8A1,ATP8B2,ATPSCKMT,AXIN2,BACH2,BAG2,BANK1,BBS2,BBS9,BCKDHB,BCL11B,BCL2,BCL7A,BDH1,BIN1,BLK,BMI1,BPTF,BRWD1,BTG1,BTLA,C11orf1,C12orf57,C12orf75,C14orf28,C16orf74,C1orf21,CA5B,CAD,CAMK1D,CAMK4,CAMLG,CARD11,CASD1,CASK,CASP6,CASP8AP2,CASS4,CBLB,CBX5,CBX7,CCDC7,CCL28,CCL5,CCNB1IP1,CCND2,CCNG1,CCNT1,CCR4,CCR6,CCR7,CCSER2,CD160,CD1C,CD2,CD200,CD200R1,CD22,CD244,CD247,CD248,CD27,CD28,CD3D,CD3E,CD3G,CD40LG,CD44,CD5,CD52,CD6,CD7,CD79A,CD79B,CD8A,CD8B,CD96,CDC14A,CDC14B,CDC25B,CDC42SE2,CDCA7L,CDK6,CDKN2AIP,CDR2,CENPV,CEP120,CEP128,CEP57,CEP68,CEP78,CEP95,CERK,CFAP36,CFAP97,CHD3,CHMP7,CHRM3-AS2,CLEC2D,CLK4,CLSTN3,CMPK1,CNOT6L,CNR2,COBLL1,COMMD6,COQ10A,COX11,CPSF6,CREBZF,CRIM1,CRIPT,CRTAM,CRTC3,CRY1,CRYL1,CSDE1,CSGALNACT1,CSNK1E,CST7,CTC1,CTSF,CTSW,CXCR4,CXCR5,CXXC5,CYFIP2,CYP27A1,CYP2R1,CYREN,DANCR,DCUN1D4,DDHD2,DDX3X,DDX6,DENND11,DENND2D,DENND4C,DGKA,DHRS3,DIPK1A,DIS3L,DLEU1,DLG1,DLGAP1-AS1,DNAJB1,DNAJC24,DOCK9,DPEP2,DPH5,DPP4,DSC1,DTD2,DTHD1,DUSP16,DYRK2,EBF1,EEF1A1,EEF1G,EEF2,EIF2D,EIF2S3,EIF3D,EIF3E,EIF3F,EIF3H,EIF3J-DT,EIF3K,EIF3L,EIF3M,EIF4A2,EIF4B,EIF4EBP2,ELAC1,ELAPOR1,ELP1,ELP2,EMB,ENO2,EOMES,EPB41L4A-AS1,EPHA4,EPHX2,EPRS1,ERGIC3,ERMP1,ERN1,ESYT1,ESYT2,ETS1,EVL,EXOC6B,EXOSC8,EZH1,FAHD2B,FAM102A,FAM107B,FAM168B,FAM169A,FAM172A,FAM214A,FAM219B,FBL,FBXL20,FBXO32,FCER1A,FCGBP,FCMR,FCRL1,FCRL3,FCRL6,FCRLA,FGFBP2,FHIT,FITM2,FLNB,FMNL3,FOCAD,FOXO1,FOXP1,FUT10,FYN,GABPB2,GALNT12,GARRE1,GAS5,GCET2,GCNT4,GGTA1,GID8,GLCCI1,GNG2,GNG7,GNLY,GNPDA2,GOLPH3L,GPA33,GPATCH11,GPR171,GPR174,GPX7,GRAP,GSTM2,GSTM3,GYPC,GZMA,GZMK,H1-1,H1-2,H1-3,H1-5,H2AC11,H2AC15,H2AC17,H2AC20,H2AC21,H2AC6,H2AC8,H2BC10,H2BC14,H2BC15,H2BC7,H2BC8,H3C1,H3C11,H3C4,H4C1,H4C13,H4C2,H4C3,H4C5,H4C6,H4C8,H4C9,HABP4,HACD3,HADH,HEATR5B,HECTD1,HERC1,HIBADH,HINT1,HIVEP2,HLA-DOA,HLA-DOB,HLA-DQA1,HLTF,HMGB1,HNRNPA3,HPCAL4,HS3ST3B1,HSF2,IARS,IFFO2,IFT46,IGF1R,IGHD,IGHM,IGHV3-53,IGHV4-34,IKZF2,IKZF3,IL16,IL18RAP,IL23A,IL2RB,IL32,IL7R,IMPDH2,INADL,INPP4B,INTS6-AS1,IP6K1,IPO5,IPP,ITGA6,ITGB3BP,ITK,ITM2A,ITPKB,KCNA3,KCTD7,KDM3A,KIAA0586,KLF12,KLHDC2,KLHL28,KLRB1,KLRC2,KLRD1,KLRF1,KLRG1,KLRK1,KMT2A,KPNA4,LANCL1,LASS4,LAT,LAX1,LBH,LCK,LCLAT1,LDHB,LDLRAP1,LDOC1,LEF1,LEF1-AS1,LIAS,LIMA1,LINC00402,LINC00649,LINC00861,LINC00920,LINC00921,LINC00938,LINC01128,LINC01184,LINC01278,LINC01550,LINC02210,LINC02397,LRBA,LRIG1,LRPPRC,LRRN3,LTA4H,LTB,LUC7L3,LY9,LYRM7,MACF1,MAGED1,MAGEH1,MAL,MALAT1,MAML2,MAN1A2,MAP2K5,MAP3K14-AS1,MAP4K1,MAPK13,MARCH9,MATK,MBLAC2,MBNL2,MDN1,METTL16,MFGE8,MFHAS1,MGAT4A,MGAT5,MIB1,MID2,MKL2,MPHOSPH9,MPP6,MPRIP,MRPL45,MRPL48,MRPS27,MRPS6,MS4A1,MSH2,MSI2,MTFMT,MYBL1,MYO1D,MYST4,MZT2A,N4BP2,NAA16,NAA40,NAE1,NAP1L1,NCALD,NCAPD2,NCAPD3,NCK2,NCR1,NDRG2,NDRG3,NDUFAF4,NELL2,NEO1,NEPRO,NET1,NFATC2,NFATC3,NIBAN3,NIPAL3,NKG7,NLRC3,NMT2,NMUR1,NOA1,NOG,NOL4L,NOL9,NOP53,NPAT,NPM1,NR1D1,NR1D2,NR3C2,NSA2,NSG1,NT5DC1,NT5E,NUCB2,NUCKS1,NUP88,OCIAD2,OFD1,OGT,OSBPL10,OTUD3,OXNAD1,P2RX5,P2RY10,PABPC1,PABPC4,PACS1,PAFAH2,PAIP2B,PARP16,PAX5,PBXIP1,PCED1B,PCED1B-AS1,PCID2,PCMTD2,PCNX,PCNXL2,PCYOX1,PDCD4,PDCD4-AS1,PDE3B,PDE4DIP,PDE7A,PDGFC,PDGFD,PDK1,PDZD4,PEBP1,PECR,PET117,PFDN5,PGM2L1,PHB2,PHLPP2,PIAS2,PIGK,PIK3C2B,PIK3IP1,PITPNC1,PLCB1,PLCG1,PLCL1,PLEKHA1,PLEKHB1,PLEKHF1,PLXDC1,PM20D2,PNRC1,POLA1,POLR1E,POLR2B,PP7080,PPIA,PPWD1,PRDX2,PREPL,PRKACB,PRKCA,PRKCH,PRKCQ,PRKCQ-AS1,PRKDC,PRORP,PRPF8,PRPS1,PRRC2B,PRSS23,PSIP1,PTCH1,PTGDR,PTPN22,PTPN4,PWAR5,PWARSN,PYHIN1,QARS,RAB30,RAB39B,RACK1,RALGAPA1,RALGPS2,RAPGEF6,RASA2,RASA3,RASGRF2,RASGRP1,RBBP7,RBL1,RBL2,RBMX,RCAN3,RCL1,RCN2,RECK,REST,RETREG1,RFLNB,RFX7,RGCC,RGMB,RHOF,RHOH,RMRP,RNF125,RNF144A,RNF157,RORA,RPA1,RPL11,RPL12,RPL13,RPL15,RPL17,RPL18,RPL22,RPL23,RPL24,RPL26,RPL27A,RPL29,RPL3,RPL30,RPL32,RPL35,RPL35A,RPL37,RPL37A,RPL4,RPL5,RPL6,RPL8,RPLP0,RPLP1,RPLP2,RPPH1,RPS13,RPS14,RPS15,RPS15A,RPS16,RPS18,RPS19,RPS20,RPS21,RPS23,RPS29,RPS3,RPS4X,RPS4Y1,RPS5,RPS6,RPS6KA3,RRM1,RSL1D1,RSL24D1,S1PR1,SACS,SAMD3,SATB1,SBNO1,SCAI,SCARNA17,SCARNA2,SCARNA5,SCARNA6,SCARNA7,SCML4,SEL1L3,SEMA4C,SEPTIN1,SEPTIN11,SERINC5,SESN1,SESN3,SFMBT1,SFXN1,SH2D1A,SH2D1B,SH3YL1,SIDT1,SIRPG,SIT1,SKAP1,SLA2,SLAIN1,SLAMF6,SLC12A2,SLC16A1,SLC16A10,SLC16A7,SLC25A23,SLC25A29,SLC35E2A,SLC38A1,SLC41A1,SLC4A10,SLC4A7,SLC5A3,SLC7A6,SLC7A8,SLC9A7,SLFN13,SMIM8,SMYD3,SNHG1,SNHG29,SNHG3,SNHG5,SNHG8,SNORA16A,SNORA18,SNORA27,SNORA40,SNORA5A,SNORA6,SNORA61,SNORA68,SNORD101,SNORD104,SNORD116-14,SNORD15A,SNORD15B,SNORD26,SNORD29,SNORD30,SNORD33,SNORD36C,SNORD4A,SNORD4B,SNORD50A,SNORD57,SNORD59A,SNORD6,SNORD79,SNORD97,SNRNP200,SNX25,SOD1,SORL1,SP4,SPATA5,SPECC1L,SPOCK2,SPTAN1,SPTBN1,SRPK2,SRSF5,SRSF8,SSBP2,ST13,ST3GAL1,ST6GAL1,ST6GALNAC6,STAT4,STK17A,STK39,STXBP5,SUN2,SVIP,SYNE1,SYNRG,TAF9B,TARBP1,TBC1D10A,TBL1XR1,TC2N,TCEA3,TCEAL8,TCF7,TCL1A,TCP11L2,TCRBV3S1,TDP1,TESPA1,TFAP4,TFDP2,TGFBR3,THEM4,THEMIS,THRA,TIGD1,TIGIT,TIMM8A,TKTL1,TLE1,TLR10,TMEM106C,TMEM116,TMEM14A,TMEM156,TMEM168,TMEM181,TMEM204,TMEM97,TNIK,TNRC6C,TOB1,TOP1MT,TOP2B,TOX,TRABD2A,TRAC,TRAF1,TRAF5,TRAJ10,TRAJ11,TRAJ12,TRAJ13,TRAJ14,TRAJ16,TRAJ17,TRAJ18,TRAJ20,TRAJ21,TRAJ22,TRAJ24,TRAJ26,TRAJ27,TRAJ29,TRAJ3,TRAJ30,TRAJ32,TRAJ33,TRAJ34,TRAJ36,TRAJ37,TRAJ38,TRAJ4,TRAJ40,TRAJ41,TRAJ42,TRAJ43,TRAJ45,TRAJ47,TRAJ48,TRAJ5,TRAJ52,TRAJ56,TRAJ57,TRAJ6,TRAJ8,TRAJ9,TRAPPC2,TRAT1,TRAV1-2,TRAV12-1,TRAV12-2,TRAV12-3,TRAV13-1,TRAV13-2,TRAV14DV4,TRAV16,TRAV17,TRAV19,TRAV2,TRAV20,TRAV21,TRAV22,TRAV23DV6,TRAV24,TRAV25,TRAV26-1,TRAV26-2,TRAV27,TRAV29DV5,TRAV3,TRAV35,TRAV38-1,TRAV38-2DV8,TRAV4,TRAV41,TRAV5,TRAV8-1,TRAV8-2,TRAV8-6,TRAV9-2,TRBC2,TRBJ2-1,TRBJ2-2,TRBJ2-4,TRBJ2-5,TRBV10-1,TRBV11-2,TRBV19,TRBV2,TRBV20-1,TRBV24-1,TRBV27,TRBV3-1,TRBV4-2,TRBV5-1,TRBV5-4,TRBV5-6,TRBV6-1,TRBV6-4,TRBV6-5,TRBV9,TRDC,TRDV1,TRDV2,TRG-AS1,TRGC2,TRGJP1,TRGJP2,TRGV2,TRGV3,TRGV8,TRGV9,TRIB2,TRIM32,TRIM52-AS1,TRMT2B,TRMT61B,TSEN54,TSHZ1,TSPAN18,TSPAN3,TSPYL2,TSTD1,TTC3,TTC39C,TXK,UBA2,UBA52,UBASH3A,UBE4B,UBR5,UBTF,UNC119B,URI1,USE1,USP13,USP20,USP34,USP53,UXT,VASH1-AS1,VEGFB,VNN1,VPS13A,VPS51,VSIG1,VWA8,WDCP,WDR54,WDR67,WDR89,WEE1,WWP1,XPOT,YAE1,YEATS4,YPEL1,ZAP70,ZBED5-AS1,ZBTB16,ZBTB25,ZBTB44,ZC3H6,ZCCHC11,ZDBF2,ZEB1,ZFAND1,ZFAS1,ZFP1,ZFP36L2,ZFP62,ZFP82,ZFP90,ZIK1,ZKSCAN3,ZMAT3,ZMYND11,ZNF101,ZNF181,ZNF192,ZNF254,ZNF266,ZNF280D,ZNF286A,ZNF292,ZNF32,ZNF329,ZNF337,ZNF33B,ZNF383,ZNF395,ZNF420,ZNF43,ZNF486,ZNF506,ZNF507,ZNF559,ZNF585B,ZNF600,ZNF609,ZNF639,ZNF721,ZNF792,ZNF827,ZNF831,ZNF836,ZNF84,ZNF91,ZNHIT6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s003.docx,NA,NA,NA,NA
M40868,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D1,D,1,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_UP,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 1D. Comment: Table includes specific cell types","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"AATBC,ABCA1,ABCD1,ABHD16A,ABI3,ABTB2,ACER3,ACOT9,ACP2,ACP3,ACSL1,ACSL3,ACSL4,ACSS2,ACTA2,ADA2,ADAM17,ADAM9,ADAMTSL4,ADAP2,ADAR,ADGRE2,ADGRE5,ADM,ADPGK,ADPRH,ADPRS,AGPAT3,AGRN,AGTRAP,AIM2,AKIRIN2,AKR1A1,ALAS1,ALOX5,ALPK1,ANKFY1,ANKRD22,ANKRD34C-AS1,ANXA2,ANXA4,ANXA5,AOAH,AP5B1,APOBR,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,ARHGAP17,ARHGAP27,ARHGAP31,ARHGEF11,ARL8A,ARSA,ARSB,ARSD,ASCL2,ASGR2,ASPHD2,ATF3,ATF5,ATG3,ATG7,ATOX1,ATP11A,ATP13A1,ATP1B1,ATP1B3,ATP2A2,ATP6V0D1,ATP6V1B2,ATP6V1C1,ATP8B4,AXL,AZI2,B4GALT5,BACH1,BAG1,BAK1,BATF2,BATF3,BAZ1A,BCKDK,BCL2A1,BCL6,BEST1,BID,BLOC1S1,BLVRA,BLZF1,BST1,BST2,BTK,C11orf24,C15orf39,C1QB,C1QC,C1orf162,C2,C3AR1,C3orf38,C4orf33,C5AR1,C5orf15,C9orf72,CALCOCO2,CALHM6,CALML4,CAMK1,CAMK2D,CAPG,CAPZA2,CARD16,CARD6,CARS2,CASP1,CASP10,CASP3,CASP4,CASP5,CASP7,CBR1,CCL2,CCL3,CCL8,CCR1,CCR2,CCRL2,CD14,CD151,CD163,CD274,CD2AP,CD300A,CD300C,CD300E,CD300LB,CD300LF,CD33,CD36,CD38,CD40,CD63,CD68,CD86,CDC42EP2,CDKN1A,CDKN1C,CEACAM1,CEACAM3,CEBPB,CES1,CFB,CFD,CFP,CGAS,CHD1,CHMP2A,CHMP5,CHST12,CHST15,CIR1,CLCN7,CLEC12A,CLEC4D,CLEC5A,CLEC6A,CLEC7A,CLIC1,CLP1,CMIP,CMKLR1,CMPK2,CMTR1,CNDP2,CNIH4,CNP,CORO1B,CPEB3,CPED1,CPNE8,CPPED1,CREB5,CREG1,CSF1R,CSF2RB,CSF3R,CSRNP1,CSRP1,CST3,CTBS,CTNNA1,CTNND1,CTSB,CTSD,CTSL,CTSZ,CUL1,CXCL10,CXCL11,CXCL16,CYBA,CYBB,CYFIP1,CYP51A1,CYRIA,CYSLTR2,CYSTM1,DAPP1,DCBLD1,DCUN1D3,DDB2,RIGI,DDX60,DDX60L,DECR1,DENND1A,DENND5A,DHRS7B,DHRS9,DHX58,DIAPH2,DICER1,DIPK2A,DMXL2,DNAJA1,DNAJC13,DNASE1L1,DNPEP,DOCK5,DOK1,DOK3,DPYSL2,DRAM1,DRAP1,DSE,DTX3L,DUSP18,DUSP3,DUSP5,DUSP6,DYNLT1,DYSF,E2F2,ECE1,EDEM2,EFHD2,EFR3A,EHBP1L1,EHD4,EIF2AK2,EIF4E2,EIF4E3,ELF4,ELMO2,EMILIN2,EMP3,EPB41L3,EPHB2,EPSTI1,ERLIN1,ETFDH,ETV6,ETV7,EXOC1,EXOC6,EXT1,FAM111A,FAM151B,ATOSB,FAM225A,FAM91A1,FAR2,FAS,FBXO6,FCAR,FCER1G,FCGR2A,FCN1,FERMT3,FES,FFAR2,FGD2,FGD4,FGD6,FGL2,FGR,FKBP15,FLVCR2,FMNL2,FNDC3B,FNIP2,FOLR2,FPR1,FPR2,FPR3,FRMD3,FUCA2,FUOM,FXYD6,G6PD,GAA,GADD45B,GALNS,GALNT3,GAS6,GASK1B,GBA1,GBP1,GBP2,GBP3,GBP4,GBP5,GCA,GCH1,GCNT1,GDAP1,GDPD5,GIMAP4,GIMAP6,GIMAP8,GK,GK3,GLB1,GLIPR2,GLMP,GLRX,GLT1D1,GLUL,GM2A,GMPPA,GMPR,GNA15,GNB2,GNB4,GNG5,GNS,GOLM1,GORASP1,GPAT3,GPBAR1,GPD2,GPR141,GPR35,GPR84,GRAMD1B,GRINA,GRK3,GRN,GSDMD,GSTO1,GTPBP1,GTPBP2,GUCY1A1,GYG1,H1-0,H2BC21,HAPLN3,HAVCR2,HCAR2,HCAR3,HCK,HEG1,HERC5,HERC6,HGF,HHEX,HK2,HK3,HLA-DMA,HLA-DMB,HLA-DPA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HLX,HMGCS1,HMOX1,HP,HPSE,HRH2,HSH2D,HSPA6,ICAM1,IDH1,IDO1,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IGF2BP2,IGF2BP3,IGFLR1,IGLV4-69,IGSF6,IL10,IL12RB1,IL15,IL15RA,IL1RN,IL27,IL4I1,IRF1,IRF1-AS1,IRF2,IRF5,IRF7,IRF9,ISG15,ISG20,ITPK1,ITPRIPL2,JAK2,JUP,KCNJ15,KCNJ2,KCNMB1,KCTD12,KCTD14,KDM1B,KDM7A,KIAA0040,KIAA0319L,KIAA0513,KIAA0930,KIAA1958,KIR2DL4,KLF4,KLHDC7B,KMO,KPTN,KRTAP4-7,KSR1,KYNU,LACTB,LAIR1,LAMP2,LAMP3,LAP3,LARP7,LAT2,LDLR,LGALS3BP,LGALS9,LGALS9B,LHFPL2,LILRA1,LILRA2,LILRA3,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LIMK1,LIMK2,LINC01504,LMF2,LMNB1,LMO2,LOXL3,LPAR1,LPCAT2,LPCAT3,LRRC25,LRRC4,LRRC59,LRRK1,LRRK2,LST1,LTBR,LTF,LY6E,LYN,LYSMD2,LYST,MAFB,MAP3K11,MAP3K7CL,MARCKS,MARCO,MASTL,MBOAT1,MBOAT7,MCEMP1,MCOLN1,MCTP1,MED20,MEFV,MERTK,METRNL,MFSD12,MFSD13A,MFSD14B,MFSD2A,SLC49A3,MIA3,MICAL1,MICB,MICU1,MIDN,MIIP,MILR1,MIR21,MIR221,MIR223,MIR22HG,MIRLET7D,MLKL,MMP8,MNDA,MOSPD2,MOV10,MPDU1,MPZL2,MR1,MRPL27,MRPL28,MRPL44,MS4A14,MS4A4A,MS4A6A,MS4A7,MSR1,MSRB2,MT1B,MT1E,MT2A,MTF1,MTHFD2,MVB12A,MVP,MX1,MX2,MXD1,MYD88,MYOF,N4BP1,NAAA,NADK,NAGA,NAGK,NAIP,NAMPT,NANS,NAPA,NAPRT,NAT8B,NBN,NCF2,NCF4,NCSTN,NECAP1,NETO2,NEU1,NEXN,NFAM1,NFE2,NFE2L3,NFIL3,NFKBIE,NHLRC3,NHSL2,NID1,NINJ1,NLN,NLRC4,NLRP3,NMI,NOD1,NOD2,NOP10,NOTCH2,NPC2,NPL,NQO2,NR1H2,NR1H3,NRIP1,NRROS,NT5C2,NT5C3A,NTNG2,NUB1,NUBP1,NUCB1,NUP62,OAS1,OAS2,OAS3,OASL,ODF3B,OGFR,OLFM4,ORMDL2,OSCAR,OTOF,P2RX4,P2RX7,P2RY12,P2RY13,P2RY2,P2RY6,PACSIN2,PAK1,PAM,PARP10,PARP11,PARP12,PARP14,PARP9,PATL1,PCMT1,PCTP,PDCD1LG2,PDLIM5,PEA15,PEAK3,PELATON,PELI1,PFKFB3,PFKFB4,PGK1,PHF11,PI4K2B,PIGS,PIK3AP1,PILRA,PIM3,PLA2G15,PLA2G7,PLAAT4,PLAC8,PLAGL2,PLAUR,PLEK,PLEKHO1,PLEKHO2,PLIN3,PLSCR1,PLXDC2,PLXNB2,PLXNC1,PML,PMVK,PNPT1,POLB,POLK,POMP,PPIF,PPM1K,PTPA,PRDX3,PRELID1,HELZ2,PRKCD,PRKCE,PRRG4,PRXL2C,PSEN2,PSENEN,PSMA4,PSMA6,PSMB10,PSMB8,PSMB9,PSME1,PSME2,PSTPIP2,PTGIR,PTPRE,PTPRO,PTTG1IP,NECTIN2,PYCARD,QSOX1,RAB10,RAB12,RAB1A,RAB20,RAB24,RAB31,RAB39A,RAB4B,RAB8A,RABGGTA,RALB,RAPGEF2,RARA,RASGEF1B,RASGRP3,RASGRP4,RASSF4,RB1,RBBP8,RBCK1,RBM47,RCBTB2,REEP4,RELT,RENBP,RTL5,RGL1,RHBDF2,RHOB,RIC1,RILPL2,RIN1,RIN2,RIPK2,RIPK3,RNASE2,RNASEL,RNASET2,RNF114,RNF13,RNF135,RNF149,RNF19B,RNF213,RNF217,RNF31,RNFT1,RNH1,RNPEP,ROGDI,RP2,RPS6KC1,RRAGC,RRAS,RSAD2,RTCB,RTP4,RUBCN,RUFY3,RUFY4,RXRA,S100A11,S100A9,SAMD4A,SAMD9,SAMD9L,SASH1,SAT1,SAT2,SBF2,SBNO2,SCARB2,SCIMP,SCLT1,SCO2,SCPEP1,SDC3,SDHB,SDSL,SEC14L1,SEC24D,SECTM1,SEMA4A,MSRB1,SERPINA1,SERPINB8,SERPINB9,SERPING1,SH2B2,SH2B3,SH3BP2,SH3RF1,SHFL,SHISA5,SHKBP1,SHTN1,SIDT2,SIGLEC1,SIGLEC14,SIGLEC5,SIGLEC7,SIGLEC9,SIL1,SIPA1L1,SIPA1L2,SIRPA,SIRPB1,SIRPB2,SIRPD,SKAP2,SLAMF7,SLAMF8,SLC11A1,SLC15A3,SLC15A4,SLC16A3,SLC16A6,SLC1A5,SLC20A1,SLC22A15,SLC22A4,SLC24A4,SLC25A24,SLC25A28,SLC27A3,SLC29A1,SLC2A6,SLC31A1,SLC31A2,SLC35A5,SLC35F6,SLC37A1,SLC37A2,SLC38A5,SLC38A7,SLC39A1,SLC39A11,SLC43A2,SLC43A3,SLC6A12,SLC7A7,SLC8A1,SLC9A9,SLFN11,SLFN12,SMAD1,SMCHD1,SMCO4,SNCA,SNTB1,SNX10,SNX11,SNX2,SNX20,SNX27,SOCS1,SOCS3,SORT1,SP100,SP110,SP140,SPATS2L,SPI1,SPOPL,SPPL2A,SPTLC2,SQLE,SQOR,SRA1,SRC,SRGAP2,SRGAP2B,SSB,ST14,ST3GAL5,ST8SIA4,STAB1,STAC3,STAM2,STARD4,STARD8,STAT1,STAT2,STAT3,STAT5A,STIMATE,STING1,STK3,STOM,STS,STX11,STX12,STX3,STXBP2,STYXL1,SUOX,SUSD1,TAGLN,TANK,TAP1,TAP2,TAPBP,TAPBPL,TASL,TATDN3,TBC1D2,TBC1D8,TBK1,TCF7L2,TCIRG1,TCN2,TDRD7,TENT5A,TET3,TFE3,TFEC,TGM2,THEMIS2,ALYREF,TIFA,TIGAR,TIMP1,TIMP2,TJP2,TLR1,TLR2,TLR4,TLR6,TLR7,TLR8,TMEM106A,TMEM131L,TMEM140,TMEM150B,TMEM175,TMEM176A,TMEM176B,TMEM179B,TMEM229B,TMEM255A,TMEM268,TMPPE,TNFAIP2,TNFAIP6,TNFAIP8L2,TNFRSF14,TNFRSF1B,TNFSF10,TNFSF13,TNFSF13B,TNS1,TNS3,TOP1,TOR1B,TOR4A,TP53I3,TPMT,TRAFD1,TRANK1,TREX1,TRIB1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM38,TRIM5,TRPV4,EMC2,TTC7A,TTYH3,TUBA1A,TYMP,TYROBP,UBA3,UBA7,UBC,UBE2D1,UBE2L6,UNC93B1,USF1,USP15,USP18,USP25,USP30-AS1,USP32,USP41,USP6NL,UTRN,VAMP3,VAMP5,VCPIP1,VDR,VRK2,VTA1,WARS1,WAS,WDFY1,WDFY3,WDR41,WIPI1,WSB1,XAF1,XKR8,XRCC4,XRN1,YIPF1,ZBP1,ZCCHC2,TUT7,ZDHHC11B,ZEB2,ZFP36,ZFYVE26,ZMIZ1,ZNF267,ZNF438,ZNFX1,ZSWIM6",1012,"AATBC,ABCA1,ABCD1,ABHD16A,ABI3,ABTB2,ACER3,ACOT9,ACP2,ACPP,ACSL1,ACSL3,ACSL4,ACSS2,ACTA2,ADA2,ADAM17,ADAM9,ADAMTSL4,ADAP2,ADAR,ADGRE2,ADGRE5,ADM,ADPGK,ADPRH,ADPRS,AGPAT3,AGRN,AGTRAP,AIM2,AKIRIN2,AKR1A1,ALAS1,ALOX5,ALPK1,ANKFY1,ANKRD22,ANKRD34C-AS1,ANXA2,ANXA4,ANXA5,AOAH,AP5B1,APOBR,APOL1,APOL2,APOL3,APOL4,APOL6,AQP9,ARHGAP17,ARHGAP27,ARHGAP31,ARHGEF11,ARL8A,ARSA,ARSB,ARSD,ASCL2,ASGR2,ASPHD2,ATF3,ATF5,ATG3,ATG7,ATOX1,ATP11A,ATP13A1,ATP1B1,ATP1B3,ATP2A2,ATP6V0D1,ATP6V1B2,ATP6V1C1,ATP8B4,AXL,AZI2,B4GALT5,BACH1,BAG1,BAK1,BATF2,BATF3,BAZ1A,BCKDK,BCL2A1,BCL6,BEST1,BID,BLOC1S1,BLVRA,BLZF1,BST1,BST2,BTK,C11orf24,C15orf39,C1orf162,C1QB,C1QC,C2,C3AR1,C3orf38,C4orf33,C5AR1,C5orf15,C9orf72,CALCOCO2,CALHM6,CALML4,CAMK1,CAMK2D,CAPG,CAPZA2,CARD16,CARD6,CARS2,CASP1,CASP10,CASP3,CASP4,CASP5,CASP7,CBR1,CCL2,CCL3,CCL8,CCR1,CCR2,CCRL2,CD14,CD151,CD163,CD274,CD2AP,CD300A,CD300C,CD300E,CD300LB,CD300LF,CD33,CD36,CD38,CD40,CD63,CD68,CD86,CDC42EP2,CDKN1A,CDKN1C,CEACAM1,CEACAM3,CEBPB,CES1,CFB,CFD,CFP,CGAS,CHD1,CHMP2A,CHMP5,CHST12,CHST15,CIR1,CLCN7,CLEC12A,CLEC4D,CLEC5A,CLEC6A,CLEC7A,CLIC1,CLP1,CMIP,CMKLR1,CMPK2,CMTR1,CNDP2,CNIH4,CNP,CORO1B,CPEB3,CPED1,CPNE8,CPPED1,CREB5,CREG1,CSF1R,CSF2RB,CSF3R,CSRNP1,CSRP1,CST3,CTBS,CTNNA1,CTNND1,CTSB,CTSD,CTSL,CTSZ,CUL1,CXCL10,CXCL11,CXCL16,CYBA,CYBB,CYFIP1,CYP51A1,CYRIA,CYSLTR2,CYSTM1,DAPP1,DCBLD1,DCUN1D3,DDB2,DDX58,DDX60,DDX60L,DECR1,DENND1A,DENND5A,DHRS7B,DHRS9,DHX58,DIAPH2,DICER1,DIPK2A,DMXL2,DNAJA1,DNAJC13,DNASE1L1,DNPEP,DOCK5,DOK1,DOK3,DPYSL2,DRAM1,DRAP1,DSE,DTX3L,DUSP18,DUSP3,DUSP5,DUSP6,DYNLT1,DYSF,E2F2,ECE1,EDEM2,EFHD2,EFR3A,EHBP1L1,EHD4,EIF2AK2,EIF4E2,EIF4E3,ELF4,ELMO2,EMILIN2,EMP3,EPB41L3,EPHB2,EPSTI1,ERLIN1,ETFDH,ETV6,ETV7,EXOC1,EXOC6,EXT1,FAM111A,FAM151B,FAM214B,FAM225A,FAM91A1,FAR2,FAS,FBXO6,FCAR,FCER1G,FCGR2A,FCN1,FERMT3,FES,FFAR2,FGD2,FGD4,FGD6,FGL2,FGR,FKBP15,FLVCR2,FMNL2,FNDC3B,FNIP2,FOLR2,FPR1,FPR2,FPR3,FRMD3,FUCA2,FUOM,FXYD6,G6PD,GAA,GADD45B,GALNS,GALNT3,GAS6,GASK1B,GBA,GBP1,GBP2,GBP3,GBP4,GBP5,GCA,GCH1,GCNT1,GDAP1,GDPD5,GIMAP4,GIMAP6,GIMAP8,GK,GK3P,GLB1,GLIPR2,GLMP,GLRX,GLT1D1,GLUL,GM2A,GMPPA,GMPR,GNA15,GNB2,GNB4,GNG5,GNS,GOLM1,GORASP1,GPAT3,GPBAR1,GPD2,GPR141,GPR35,GPR84,GRAMD1B,GRINA,GRK3,GRN,GSDMD,GSTO1,GTPBP1,GTPBP2,GUCY1A3,GYG1,H1-0,H2BC21,HAPLN3,HAVCR2,HCAR2,HCAR3,HCK,HEG1,HERC5,HERC6,HGF,HHEX,HK2,HK3,HLA-DMA,HLA-DMB,HLA-DPA1,HLA-DRA,HLA-DRB1,HLA-DRB5,HLX,HMGCS1,HMOX1,HP,HPSE,HRH2,HSH2D,HSPA6,ICAM1,IDH1,IDO1,IFI16,IFI27,IFI30,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFIT5,IFITM1,IFITM2,IFITM3,IFNGR2,IGF2BP2,IGF2BP3,IGFLR1,IGLV4-69,IGSF6,IL10,IL12RB1,IL15,IL15RA,IL1RN,IL27,IL4I1,IRF1,IRF1-AS1,IRF2,IRF5,IRF7,IRF9,ISG15,ISG20,ITPK1,ITPRIPL2,JAK2,JUP,KCNJ15,KCNJ2,KCNMB1,KCTD12,KCTD14,KDM1B,KDM7A,KIAA0040,KIAA0319L,KIAA0513,KIAA0930,KIAA1958,KIR2DL4,KLF4,KLHDC7B,KMO,KPTN,KRTAP4-7,KSR1,KYNU,LACTB,LAIR1,LAMP2,LAMP3,LAP3,LARP7,LAT2,LDLR,LGALS3BP,LGALS9,LGALS9B,LHFPL2,LILRA1,LILRA2,LILRA3,LILRA5,LILRA6,LILRB1,LILRB2,LILRB3,LILRB4,LIMK1,LIMK2,LINC01504,LMF2,LMNB1,LMO2,LOXL3,LPAR1,LPCAT2,LPCAT3,LRRC25,LRRC4,LRRC59,LRRK1,LRRK2,LST1,LTBR,LTF,LY6E,LYN,LYSMD2,LYST,MAFB,MAP3K11,MAP3K7CL,MARCKS,MARCO,MASTL,MBOAT1,MBOAT7,MCEMP1,MCOLN1,MCTP1,MED20,MEFV,MERTK,METRNL,MFSD12,MFSD13A,MFSD14B,MFSD2A,MFSD7,MIA3,MICAL1,MICB,MICU1,MIDN,MIIP,MILR1,MIR21,MIR221,MIR223,MIR22HG,MIRLET7D,MLKL,MMP8,MNDA,MOSPD2,MOV10,MPDU1,MPZL2,MR1,MRPL27,MRPL28,MRPL44,MS4A14,MS4A4A,MS4A6A,MS4A7,MSR1,MSRB2,MT1B,MT1E,MT2A,MTF1,MTHFD2,MVB12A,MVP,MX1,MX2,MXD1,MYD88,MYOF,N4BP1,NAAA,NADK,NAGA,NAGK,NAIP,NAMPT,NANS,NAPA,NAPRT1,NAT8B,NBN,NCF2,NCF4,NCSTN,NECAP1,NETO2,NEU1,NEXN,NFAM1,NFE2,NFE2L3,NFIL3,NFKBIE,NHLRC3,NHSL2,NID1,NINJ1,NLN,NLRC4,NLRP3,NMI,NOD1,NOD2,NOP10,NOTCH2,NPC2,NPL,NQO2,NR1H2,NR1H3,NRIP1,NRROS,NT5C2,NT5C3A,NTNG2,NUB1,NUBP1,NUCB1,NUP62,OAS1,OAS2,OAS3,OASL,ODF3B,OGFR,OLFM4,ORMDL2,OSCAR,OTOF,P2RX4,P2RX7,P2RY12,P2RY13,P2RY2,P2RY6,PACSIN2,PAK1,PAM,PARP10,PARP11,PARP12,PARP14,PARP9,PATL1,PCMT1,PCTP,PDCD1LG2,PDLIM5,PEA15,PEAK3,PELATON,PELI1,PFKFB3,PFKFB4,PGK1,PHF11,PI4K2B,PIGS,PIK3AP1,PILRA,PIM3,PLA2G15,PLA2G7,PLAAT4,PLAC8,PLAGL2,PLAUR,PLEK,PLEKHO1,PLEKHO2,PLIN3,PLSCR1,PLXDC2,PLXNB2,PLXNC1,PML,PMVK,PNPT1,POLB,POLK,POMP,PPIF,PPM1K,PPP2R4,PRDX3,PRELID1,PRIC285,PRKCD,PRKCE,PRRG4,PRXL2C,PSEN2,PSENEN,PSMA4,PSMA6,PSMB10,PSMB8,PSMB9,PSME1,PSME2,PSTPIP2,PTGIR,PTPRE,PTPRO,PTTG1IP,PVRL2,PYCARD,QSOX1,RAB10,RAB12,RAB1A,RAB20,RAB24,RAB31,RAB39,RAB4B,RAB8A,RABGGTA,RALB,RAPGEF2,RARA,RASGEF1B,RASGRP3,RASGRP4,RASSF4,RB1,RBBP8,RBCK1,RBM47,RCBTB2,REEP4,RELT,RENBP,RGAG4,RGL1,RHBDF2,RHOB,RIC1,RILPL2,RIN1,RIN2,RIPK2,RIPK3,RNASE2,RNASEL,RNASET2,RNF114,RNF13,RNF135,RNF149,RNF19B,RNF213,RNF217,RNF31,RNFT1,RNH1,RNPEP,ROGDI,RP2,RPS6KC1,RRAGC,RRAS,RSAD2,RTCB,RTP4,RUBCN,RUFY3,RUFY4,RXRA,S100A11,S100A9,SAMD4A,SAMD9,SAMD9L,SASH1,SAT1,SAT2,SBF2,SBNO2,SCARB2,SCIMP,SCLT1,SCO2,SCPEP1,SDC3,SDHB,SDSL,SEC14L1,SEC24D,SECTM1,SEMA4A,SEPX1,SERPINA1,SERPINB8,SERPINB9,SERPING1,SH2B2,SH2B3,SH3BP2,SH3RF1,SHFL,SHISA5,SHKBP1,SHTN1,SIDT2,SIGLEC1,SIGLEC14,SIGLEC5,SIGLEC7,SIGLEC9,SIL1,SIPA1L1,SIPA1L2,SIRPA,SIRPB1,SIRPB2,SIRPD,SKAP2,SLAMF7,SLAMF8,SLC11A1,SLC15A3,SLC15A4,SLC16A3,SLC16A6,SLC1A5,SLC20A1,SLC22A15,SLC22A4,SLC24A4,SLC25A24,SLC25A28,SLC27A3,SLC29A1,SLC2A6,SLC31A1,SLC31A2,SLC35A5,SLC35F6,SLC37A1,SLC37A2,SLC38A5,SLC38A7,SLC39A1,SLC39A11,SLC43A2,SLC43A3,SLC6A12,SLC7A7,SLC8A1,SLC9A9,SLFN11,SLFN12,SMAD1,SMCHD1,SMCO4,SNCA,SNTB1,SNX10,SNX11,SNX2,SNX20,SNX27,SOCS1,SOCS3,SORT1,SP100,SP110,SP140,SPATS2L,SPI1,SPOPL,SPPL2A,SPTLC2,SQLE,SQOR,SRA1,SRC,SRGAP2,SRGAP2B,SSB,ST14,ST3GAL5,ST8SIA4,STAB1,STAC3,STAM2,STARD4,STARD8,STAT1,STAT2,STAT3,STAT5A,STIMATE,STING1,STK3,STOM,STS,STX11,STX12,STX3,STXBP2,STYXL1,SUOX,SUSD1,TAGLN,TANK,TAP1,TAP2,TAPBP,TAPBPL,TASL,TATDN3,TBC1D2,TBC1D8,TBK1,TCF7L2,TCIRG1,TCN2,TDRD7,TENT5A,TET3,TFE3,TFEC,TGM2,THEMIS2,THOC4,TIFA,TIGAR,TIMP1,TIMP2,TJP2,TLR1,TLR2,TLR4,TLR6,TLR7,TLR8,TMEM106A,TMEM131L,TMEM140,TMEM150B,TMEM175,TMEM176A,TMEM176B,TMEM179B,TMEM229B,TMEM255A,TMEM268,TMPPE,TNFAIP2,TNFAIP6,TNFAIP8L2,TNFRSF14,TNFRSF1B,TNFSF10,TNFSF13,TNFSF13B,TNS1,TNS3,TOP1,TOR1B,TOR4A,TP53I3,TPMT,TRAFD1,TRANK1,TREX1,TRIB1,TRIM14,TRIM21,TRIM22,TRIM25,TRIM26,TRIM38,TRIM5,TRPV4,TTC35,TTC7A,TTYH3,TUBA1A,TYMP,TYROBP,UBA3,UBA7,UBC,UBE2D1,UBE2L6,UNC93B1,USF1,USP15,USP18,USP25,USP30-AS1,USP32,USP41,USP6NL,UTRN,VAMP3,VAMP5,VCPIP1,VDR,VRK2,VTA1,WARS,WAS,WDFY1,WDFY3,WDR41,WIPI1,WSB1,XAF1,XKR8,XRCC4,XRN1,YIPF1,ZBP1,ZCCHC2,ZCCHC6,ZDHHC11B,ZEB2,ZFP36,ZFYVE26,ZMIZ1,ZNF267,ZNF438,ZNFX1,ZSWIM6",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S7 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s007.xlsx,NA,NA,NA,NA
M40927,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_2DY_UP,BACTERIUM,UP,VACCINE,VAC ONLY,D2,D,2,18-55,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_2DY_UP,"A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-gamma (IFN-gamma) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Ralpha two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.","Genes up-regulated in peripheral blood mononuclear cell 2d vs 0d in adult (18-55) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 2D","Matsumiya M,Stylianou E,Griffiths K,Lang Z,Meyer J,Harris SA,Rowland R,Minassian AM,Pathan AA,Fletcher H,McShane H",23844129,HUMAN_GENE_SYMBOL,"ACP2,APOBEC3A,BCL2A1,BID,BST2,C3AR1,CARD16,CASP1,CCL2,CCL3,CCL3L1,CCL4,,CCL7,CCL8,CD68,CFD,CTSL,CXCL10,DNASE2,DRAM1,EIF2AK2,FCGR1A,FCGR1BP,FPR2,FPR3,GLMP,ICAM1,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM2,IFITM3,IL1A,IL4I1,IL6,IRF9,ISG15,LGALS9,MARCO,MX1,PARP9,PILRA,PSMB9,PYCARD,RNASE2,RSAD2,S100A8,S100A9,SERPING1,SLC15A3,SRC,STAT1,TICAM2,TLR1,TLR6,TLR8,TNF,TNFSF10,TYMP,XAF1",67,"ACP2,APOBEC3A,BCL2A1,BID,BST2,C3AR1,CARD16,CASP1,CCL2,CCL3,CCL3L1,CCL4,CCL4L1,CCL7,CCL8,CD68,CFD,CTSL1,CXCL10,DNASE2,DRAM1,EIF2AK2,FCGR1A,FCGR1B,FPR2,FPR3,GLMP,ICAM1,IFI27,IFI35,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM2,IFITM3,IL1A,IL4I1,IL6,IRF9,ISG15,LGALS9,MARCO,MX1,PARP9,PILRA,PSMB9,PYCARD,RNASE2,RSAD2,S100A8,S100A9,SERPING1,SLC15A3,SRC,STAT1,TICAM2,TLR1,TLR6,TLR8,TNF,TNFSF10,TYMP,XAF1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table IV,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701477/bin/NIHMS83712-supplement-Suplementary_t.doc,NA,NA,NA,NA
M40922,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_DN,VIRUS,DOWN,VACCINE,VAC ONLY,D3,D,3,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_DN,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes down-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 3D. Comment: Table includes specific cell types","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"BLK,CNR2,CXCR5,EIF4B,IL1R2,NIBAN3,OSBPL10,RFLNB,SCARNA6,SLC45A3,TRBV6-4",11,"BLK,CNR2,CXCR5,EIF4B,IL1R2,NIBAN3,OSBPL10,RFLNB,SCARNA6,SLC45A3,TRBV6-4",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Suppl Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072604/bin/ppat.1005892.s003.docx,NA,NA,NA,NA
M40875,HIV-1 GAG-POL NEF,VV,HIV,ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D3,D,3,20-50,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_3DY_UP,"To better understand how innate immune responses to vaccination can lead to lasting protective immunity, we used a systems approach to define immune signatures in humans over 1 wk following MRKAd5/HIV vaccination that predicted subsequent HIV-specific T-cell responses. Within 24 h, striking increases in peripheral blood mononuclear cell gene expression associated with inflammation, IFN response, and myeloid cell trafficking occurred, and lymphocyte-specific transcripts decreased. These alterations were corroborated by marked serum inflammatory cytokine elevations and egress of circulating lymphocytes. Responses of vaccinees with preexisting adenovirus serotype 5 (Ad5) neutralizing antibodies were strongly attenuated, suggesting that enhanced HIV acquisition in Ad5-seropositive subgroups in the Step Study may relate to the lack of appropriate innate activation rather than to increased systemic immune activation. Importantly, patterns of chemoattractant cytokine responses at 24 h and alterations in 209 peripheral blood mononuclear cell transcripts at 72 h were predictive of subsequent induction and magnitude of HIV-specific CD8(+) T-cell responses. This systems approach provides a framework to compare innate responses induced by vectors, as shown here by contrasting the more rapid, robust response to MRKAd5/HIV with that to yellow fever vaccine. When applied iteratively, the findings may permit selection of HIV vaccine candidates eliciting innate immune response profiles more likely to drive HIV protective immunity.","Genes up-regulated in peripheral blood mononuclear cell 3d vs 0d in adults (20-50) after exposure to MRKAd5 HIV-1 gag/pol/nef , time point 3D. Comment: Table includes specific cell types","Zak DE,Andersen-Nissen E,Peterson ER,Sato A,Hamilton MK,Borgerding J,Krishnamurty AT,Chang JT,Adams DJ,Hensley TR,Salter AI,Morgan CA,Duerr AC,De Rosa SC,Aderem A,McElrath MJ",23151505,HUMAN_GENE_SYMBOL,"ABI3,ACP2,AIM2,ALPK1,ANKFY1,C1QB,C3AR1,CALML4,CARD6,CASP10,CASP5,CCR1,CD101,CD300E,CLEC7A,CMKLR1,CMPK2,CSF1R,CTSL,CX3CR1,CXCL10,CYSLTR1,RIGI,DDX60,DHX58,DUSP6,EIF2AK2,EPSTI1,FCGR3A,FFAR2,FGD2,FGD6,FLVCR2,FPGT,FPR2,FPR3,CMTR1,GBP1,GCH1,GIMAP8,GPBAR1,GRN,H1-0,HAVCR2,HERC5,HERC6,HSH2D,HSPA6,IFI16,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM1,IFITM3,IGSF6,IL1RN,IRF9,JUP,KCNJ2,KMO,LAP3,LGALS3BP,LGALS9,LGALS9B,LRRC25,LST1,LY6E,MAFB,MARCKS,MBOAT1,MERTK,MOV10,MS4A4A,MTSS1,MX1,MX2,MYOF,NLRC4,NMI,OAS1,OAS2,OAS3,OASL,P2RX7,PARP12,PARP9,PLSCR1,PML,RSAD2,SAMD9,SAMD9L,SCARB2,SECTM1,SERPING1,SHISA5,SIDT2,SIGLEC1,SIGLEC7,SLC20A1,SLC38A9,SP110,SQLE,STAT1,SUOX,TAP1,TASL,TCF7L2,TDRD7,TFEC,TLR1,TLR2,TLR6,TNFSF10,TNFSF13B,TOR1B,TRIM21,TRIM22,TRIM38,TRIM5,UBE2L6,USP18,WARS1,WSB1,XAF1,ZBP1,ZNFX1",131,"ABI3,ACP2,AIM2,ALPK1,ANKFY1,C1QB,C3AR1,CALML4,CARD6,CASP10,CASP5,CCR1,CD101,CD300E,CLEC7A,CMKLR1,CMPK2,CSF1R,CTSL1,CX3CR1,CXCL10,CYSLTR1,DDX58,DDX60,DHX58,DUSP6,EIF2AK2,EPSTI1,FCGR3A,FFAR2,FGD2,FGD6,FLVCR2,FPGT,FPR2,FPR3,FTSJD2,GBP1,GCH1,GIMAP8,GPBAR1,GRN,H1F0,HAVCR2,HERC5,HERC6,HSH2D,HSPA6,IFI16,IFI27,IFI44,IFI44L,IFI6,IFIH1,IFIT1,IFIT2,IFIT3,IFITM1,IFITM3,IGSF6,IL1RN,IRF9,JUP,KCNJ2,KMO,LAP3,LGALS3BP,LGALS9,LGALS9B,LRRC25,LST1,LY6E,MAFB,MARCKS,MBOAT1,MERTK,MOV10,MS4A4A,MTSS1,MX1,MX2,MYOF,NLRC4,NMI,OAS1,OAS2,OAS3,OASL,P2RX7,PARP12,PARP9,PLSCR1,PML,RSAD2,SAMD9,SAMD9L,SCARB2,SECTM1,SERPING1,SHISA5,SIDT2,SIGLEC1,SIGLEC7,SLC20A1,SLC38A9,SP110,SQLE,STAT1,SUOX,TAP1,TASL,TCF7L2,TDRD7,TFEC,TLR1,TLR2,TLR6,TNFSF10,TNFSF13B,TOR1B,TRIM21,TRIM22,TRIM38,TRIM5,UBE2L6,USP18,WARS,WSB1,XAF1,ZBP1,ZNFX1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40942,RVSV ZEBOV,VV,EBOV,RECHTIEN_PBMC_RVSV_ZEBOV_AGE_18_55YO_1DY_UP,VIRUS,UP,VACCINE,VAC ONLY,D7,D,7,18-45,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/RECHTIEN_PBMC_RVSV_ZEBOV_AGE_18_55YO_1DY_UP,"Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.","Genes up-regulated in peripheral blood mononuclear cell 1d vs 0d in adults (18-55) after exposure to rVSV-ZEBOV , time point 1D","Rechtien A,Richert L,Lorenzo H,Martrus G,Hejblum B,Dahlke C,Kasonta R,Zinser M,Stubbe H,Matschl U,Lohse A,Krhling V,Eickmann M,Becker S,VEBCON Consortium,Thibaut R,Altfeld M,Addo MM",28854372,HUMAN_GENE_SYMBOL,"CCL2,CXCL10,HERC5,IFIT1,ISG15,LAMP3,NFKB1,NFKB2,RSAD2,USP18",10,"CCL2,CXCL10,HERC5,IFIT1,ISG15,LAMP3,NFKB1,NFKB2,RSAD2,USP18",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,S6 Dataset,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338067/bin/pone.0118528.s006.xlsx,NA,NA,NA,NA
M40941,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,H6,H,6,18-55,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_MVA85A_6HR_UP,"A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-gamma (IFN-gamma) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Ralpha two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.","Genes up-regulated in peripheral blood mononuclear cell vaccinated vs control in adults (18-55) (treated in vitro with MVA85A) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 6H","Matsumiya M,Stylianou E,Griffiths K,Lang Z,Meyer J,Harris SA,Rowland R,Minassian AM,Pathan AA,Fletcher H,McShane H",23844129,HUMAN_GENE_SYMBOL,"ABCG4,ADAP1,ADM,AGFG2,AK4,ANP32C,ANPEP,ANXA5,AP2B1,AQP9,ARMCX1,BAG3,BCL11A,IRF2BPL,C15orf48,SLX9,GET4,CCL2,CCL3L1,CD14,CD200,CD63,CD8B,CDK14,COL11A2,CTSL,CUX1,CXCL1,CYP1B1,DDR1,DNAJB5,DTNBP1,EXT1,EZH2,FAM170B,FCGRT,FGR,FTL,HAX1,H4C4,HLX,IER3,IFNB1,IL1RN,IL4I1,SLC7A5P2,ITGAX,ITPRIPL2,URB2,KLF4,KYNU,,LSM12,LYL1,LYN,MASP2,MFSD2A,MRTFA,MTMR11,NCF2,NOTCH2NLA,NR4A3,NUTF2,OR12D3,OR2A14,OSGEP,P2RX4,PLAUR,PLEK,PLEKHA4,PMS2CL,PPP3R1,PREP,NECTIN2,RANBP3L,RBM47,RHOU,RMRP,RPP14,RRAD,RSPRY1,SDC4,SLC2A1,SLC43A3,SOD2,SPRYD3,SRC,STAT3,TAGLN,TBC1D10A,TGFBI,THBS1,TP73-AS1,ZC3H12C,ZNF395",95,"ABCG4,ADAP1,ADM,AGFG2,AK3L1,ANP32C,ANPEP,ANXA5,AP2B1,AQP9,ARMCX1,BAG3,BCL11A,C14orf4,C15orf48,C21orf70,C7orf20,CCL2,CCL3L1,CD14,CD200,CD63,CD8B,CDK14,COL11A2,CTSL1,CUX1,CXCL1,CYP1B1,DDR1,DNAJB5,DTNBP1,EXT1,EZH2,FAM170B,FCGRT,FGR,FTL,HAX1,HIST1H4D,HLX,IER3,IFNB1,IL1RN,IL4I1,IMAA,ITGAX,ITPRIPL2,KIAA0133,KLF4,KYNU,LINCR,LSM12,LYL1,LYN,MASP2,MFSD2,MKL1,MTMR11,NCF2,NOTCH2NL,NR4A3,NUTF2,OR12D3,OR2A14,OSGEP,P2RX4,PLAUR,PLEK,PLEKHA4,PMS2CL,PPP3R1,PREP,PVRL2,RANBP3L,RBM47,RHOU,RMRP,RPP14,RRAD,RSPRY1,SDC4,SLC2A1,SLC43A3,SOD2,SPRYD3,SRC,STAT3,TAGLN,TBC1D10A,TGFBI,THBS1,TP73-AS1,ZC3H12C,ZNF395",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA
M41195,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_WILD_TYPE_MVA_6HR_UP,BACTERIUM,UP,VACCINE,VAC VS CTRL,H6,H,6,18-55,ADULT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_18_55YO_VACCINATED_VS_CONTROL_TREATED_IN_VITRO_WITH_WILD_TYPE_MVA_6HR_UP,"A better understanding of the relationships between vaccine, immunogenicity and protection from disease would greatly facilitate vaccine development. Modified vaccinia virus Ankara expressing antigen 85A (MVA85A) is a novel tuberculosis vaccine candidate designed to enhance responses induced by BCG. Antigen-specific interferon-gamma (IFN-gamma) production is greatly enhanced by MVA85A, however the variability between healthy individuals is extensive. In this study we have sought to characterize the early changes in gene expression in humans following vaccination with MVA85A and relate these to long-term immunogenicity. Two days post-vaccination, MVA85A induces a strong interferon and inflammatory response. Separating volunteers into high and low responders on the basis of T cell responses to 85A peptides measured during the trial, an expansion of circulating CD4+ CD25+ Foxp3+ cells is seen in low but not high responders. Additionally, high levels of Toll-like Receptor (TLR) 1 on day of vaccination are associated with an increased response to antigen 85A. In a classification model, combined expression levels of TLR1, TICAM2 and CD14 on day of vaccination and CTLA4 and IL2Ralpha two days post-vaccination can classify high and low responders with over 80% accuracy. Furthermore, administering MVA85A in mice with anti-TLR2 antibodies may abrogate high responses, and neutralising antibodies to TLRs 1, 2 or 6 or HMGB1 decrease CXCL2 production during in vitro stimulation with MVA85A. HMGB1 is released into the supernatant following atimulation with MVA85A and we propose this signal may be the trigger activating the TLR pathway. This study suggests an important role for an endogenous ligand in innate sensing of MVA and demonstrates the importance of pattern recognition receptors and regulatory T cell responses in determining the magnitude of the antigen specific immune response to vaccination with MVA85A in humans.","Genes up-regulated in peripheral blood mononuclear cell vaccinated vs control in adults (18-55) (treated in vitro with wild-type MVA) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 6H","Matsumiya M,Stylianou E,Griffiths K,Lang Z,Meyer J,Harris SA,Rowland R,Minassian AM,Pathan AA,Fletcher H,McShane H",23844129,HUMAN_GENE_SYMBOL,"APPBP2,AQP12B,BMX,MPLKIP,FAM220A,CCAR1,CEP41,CTH,DNAL1,C2orf69,GRB7,HELT,ICE1,ICE2,KREMEN2,LMTK2,,TEDC2-AS1,MBLAC2,MEI1,MIR574,NACA4P,BRD3OS,NOC4L,OR14C36,OR4K15,PRIM2,RANBP2,RNASEH2B,RNY3,SS18,TAF8,TGM5,TROAP,ZNF385D",35,"APPBP2,AQP12B,BMX,C7orf11,C7orf70,CCAR1,CEP41,CTH,DNAL1,FLJ38973,GRB7,HELT,ICE1,ICE2,KREMEN2,LMTK2,LOC100288254,LOC729652,MBLAC2,MEI1,MIR574,NACAP1,NCRNA00094,NOC4L,OR14C36,OR4K15,PRIM2,RANBP2,RNASEH2B,RNY3,SS18,TAF8,TGM5,TROAP,ZNF385D",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA
M40990,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_DN,BACTERIUM,DOWN,VACCINE,VAC VS OTHER,D1,D,1,4-6 MO,INFANT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_DN,"BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. METHODS: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-gamma ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis of microarrays (SAM) statistical package and gene set enrichment analysis. RESULTS: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples. Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher IFN-gamma ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in how T cell responses develop in these two populations following vaccination with MVA85A. CONCLUSION: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of an adaptive immune response in South African infants but induction of regulatory pathways may be more important in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an important aspect of developing successful vaccines and vaccination strategies. TRIAL: ClinicalTrials.gov number NCT00953927.","Genes down-regulated in blood vaccinated vs candin placebo in infants (4-6m) (BCG-primed) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 1D","Matsumiya M,Harris SA,Satti I,Stockdale L,Tanner R,O'Shea MK,Tameris M,Mahomed H,Hatherill M,Scriba TJ,Hanekom WA,McShane H,Fletcher HA",24912498,HUMAN_GENE_SYMBOL,"ARAP3,BBS2,BRI3BP,COQ8A,ESYT1,FCMR,LINC00926,,PCBP2,SGK1,VEZT,ZNF395",12,"ARAP3,BBS2,BRI3BP,COQ8A,ESYT1,FCMR,LINC00926,LOC100129034,PCBP2,SGK1,VEZT,ZNF395",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,Table 3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551876/table/T3/,NA,NA,NA,NA
M40974,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_UP,BACTERIUM,UP,VACCINE,VAC VS OTHER,D1,D,1,4-6 MO,INFANT,WHOLE BLOOD,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_BLOOD_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_1DY_UP,"BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. METHODS: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-gamma ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis of microarrays (SAM) statistical package and gene set enrichment analysis. RESULTS: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples. Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher IFN-gamma ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in how T cell responses develop in these two populations following vaccination with MVA85A. CONCLUSION: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of an adaptive immune response in South African infants but induction of regulatory pathways may be more important in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an important aspect of developing successful vaccines and vaccination strategies. TRIAL: ClinicalTrials.gov number NCT00953927.","Genes up-regulated in blood vaccinated vs candin placebo in infants (4-6m) (BCG-primed) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 1D","Matsumiya M,Harris SA,Satti I,Stockdale L,Tanner R,O'Shea MK,Tameris M,Mahomed H,Hatherill M,Scriba TJ,Hanekom WA,McShane H,Fletcher HA",24912498,HUMAN_GENE_SYMBOL,"ANKRD22,CALHM6,CARD17P,CASP1,CASP4,CXCL10,ETV7,GBP5,IDO1,MRPL44,MT1G,PARP9,POMP,UBE2L6,XRN1",15,"ANKRD22,CALHM6,CARD17,CASP1,CASP4,CXCL10,ETV7,GBP5,IDO1,MRPL44,MT1G,PARP9,POMP,UBE2L6,XRN1",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA
M41165,MVA85A,VV,TUBERCULOSIS,MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_28DY_UP,BACTERIUM,UP,VACCINE,VAC VS OTHER,D28,D,28,4-6 MO,INFANT,PBMC,https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_VACCINATED_VS_CANDIN_PLACEBO_BCG_PRIMED_28DY_UP,"BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. METHODS: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-gamma ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis of microarrays (SAM) statistical package and gene set enrichment analysis. RESULTS: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples. Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher IFN-gamma ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in how T cell responses develop in these two populations following vaccination with MVA85A. CONCLUSION: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of an adaptive immune response in South African infants but induction of regulatory pathways may be more important in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an important aspect of developing successful vaccines and vaccination strategies. TRIAL: ClinicalTrials.gov number NCT00953927.","Genes up-regulated in peripheral blood mononuclear cell vaccinated vs candin placebo in infants (4-6m) (BCG-primed) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 28D","Matsumiya M,Harris SA,Satti I,Stockdale L,Tanner R,O'Shea MK,Tameris M,Mahomed H,Hatherill M,Scriba TJ,Hanekom WA,McShane H,Fletcher HA",24912498,HUMAN_GENE_SYMBOL,"CCL8,CXCL10,CXCL9,FBXO6,GBP1,GBP4,IFI35,PARP9,STAT1,WARS1",10,"CCL8,CXCL10,CXCL9,FBXO6,GBP1,GBP4,IFI35,PARP9,STAT1,WARS",C7:VAX,HIPC SIGNATURES,NIAID/HIPC SIGNATURES,"Suppl mat, 2016HV0244R-s01.xlsx",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287313/bin/khvi-13-01-1227900-s001.zip,NA,NA,NA,NA